<SEC-DOCUMENT>0001558370-21-009246.txt : 20210726
<SEC-HEADER>0001558370-21-009246.hdr.sgml : 20210726
<ACCEPTANCE-DATETIME>20210726160405
ACCESSION NUMBER:		0001558370-21-009246
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210726
DATE AS OF CHANGE:		20210726

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			uniQure N.V.
		CENTRAL INDEX KEY:			0001590560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36294
		FILM NUMBER:		211114135

	BUSINESS ADDRESS:	
		STREET 1:		PAASHEUVELWEG 25A
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1105 BP
		BUSINESS PHONE:		1-339-970-7000

	MAIL ADDRESS:	
		STREET 1:		PAASHEUVELWEG 25A
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1105 BP

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	uniQure B.V.
		DATE OF NAME CHANGE:	20131030
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>qure-20210630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7811.37134 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 7/26/2021 8:02:24 PM -->
      <!-- iXBRL Library version: 1.0.7811.37150 -->
      <!-- iXBRL Service Job ID: 28a932e3-2c56-44ce-905f-7ba02b48c5d9 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:qure="http://www.uniqure.com/20210630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" xs:nil="true" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_PPGYK1QCz0i7-ys18eOOgQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" xs:nil="true" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_kVIVJMbKMUWyKwndLGdReQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_V30FJAMs5kyHjXPHAKDwBg">44777799</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntityCentralIndexKey" id="Tc_xsybA4rD7kSBbCAyBuMJvA_2_1">0001590560</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:CurrentFiscalYearEndDate" id="Tc_r3LHYjZWWU-xKGSC35PGQQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:DocumentFiscalYearFocus" id="Tc_MkQoYul5qEeDAM5rblI4hg_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:DocumentFiscalPeriodFocus" id="Tc_OEEgs8fJf0emzoRmZ6IjEg_5_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:AmendmentFlag" id="Tc_Ef6trLJfJU696mbP67NjdA_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_yEL8uzvfzEuzep8u6-oSHg" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_MCRGihcaXES2tnUHXX0Fgg">P1Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_iWDWSf8eDkasc3ZZLMhv3w">46050250</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="qure-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_3_1_2021_To_3_1_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_orachVcrO0W16h4VtfgGfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_4_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_OssqgnSTskC6WxJuHZafpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyu1S0cqWU2xIkIh3ub-aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LAamd-jnaESPNk8ZipEekg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S1XNLHXDj0CmAF9NqjS7Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NCAjWMQk0EWYAF5NG6CWtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2hvGL0bx6EimerX1R8EITw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HOv4QC1gA0CfyEdcEjfcYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DsFKGwOurUui9rgpsgd2zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_L4tV3PEQJkC8fL3FzxLwNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_iSci5KSdxkuiCG7kJ4B7Rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OjQYcvlwLk6FKuTEnO6ixQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AJilnv7U0UKS6Pd__e9ntw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5Zz24Wjw0WmLw7GH5paxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0D6WZbsJ9EyfBMQ5KfZThg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tqrT9yrb-06NxeDkwo4JTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_98hRD2QNWkGhe45TCCi4eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nPdO4wtnvEWlpbuGGdBg-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B-LJE5DhoUS75c9QtNuw-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_w6u8-eqmkEiHOgU-Dd9xOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_kg7c_qm1bEy7UDtpE53ICA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XjeHbyUls0C0C2A5C4oucw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FiR-EdjoaE-NUqcozk-aQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8TmbfDxKjUKS_aB_XtU_QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_PuxofUyxYUyj1pHnYLQF2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_5Wm51a7LMUeByYsBhPlv-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_081a5t6cXUS5Pm3ISOEjBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_uJk1n3G3b0G2SAKAIt-9xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">qure:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_KP_4t1AgiEGnBsb8mhLMhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_YA8vUlYvg0e7cBJmuUUNoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_hyffprjeyUC_wzIZA8RTnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_5NV54NsdkEinwOnU-elbdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_YNaFty5MakKmr7kgK48vHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_Fwx05CDlmUWbLjlZZ48Tqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_yEL8uzvfzEuzep8u6-oSHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_l15cALnFH0u_MOExc4K0wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_hgABeo6nI0Sn_Cc_DbsdkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9_e4JUkm00245rwV5zhg_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2017_To_3_31_2017_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_7i4FeprKyk6MfKmRuuYBJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_PlanIn2014Member_-Uv1a7oNgUKp-nwzRoa6rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:PlanIn2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_jB8MZBGsWEasEDd9-gnQoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseMember_jHZhFitLrEOQNQKYgI7ZBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_7HYeLAkKd06-2u6h39LYwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_0j8VHpWGtkqyg1Eoh_-56w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_qure_CollaborativeArrangementLicenseRevenueMember_hIrNE1yg2EeFUIy3Z5A96A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:CollaborativeArrangementLicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseMember_9-058g41FkiUfUyhdRdA8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_iR-v-TBnd0evOoVwhDOfvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_9iY6fqOrEE6pUHvNw-CSpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_-pQINOMXokKJREGZdwpa4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_LicenseRevenueFromRelatedPartyMember_Ktoe6WsNfUut5PLrxfJPGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:LicenseRevenueFromRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_CollaborativeRevenueFromRelatedPartyMember_cprlgbYMcECa1gZndoHMVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueFromRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_J6tdEUumu0qt9JK5Mqjr8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_LicenseRevenueFromRelatedPartyMember_R4VI051DiE205Dp9r8_D5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:LicenseRevenueFromRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_CollaborativeRevenueFromRelatedPartyMember_qHipUZ-S2kSLqtPAsxvUgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueFromRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30Oj847Y4U66T9RvHLydUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v04H0tAAR0aK-7lS6pBkDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MUECXMXIDUq79H4NmTlzIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FyQ6c103BEGWytFVswbKFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9yyiJreoCU29ZtH9tBKNqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rsNhF5HivUKK-feAZQNJXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qLQ5mvZzJUqhD9QUU80N6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XYYm-Buu4ECheKCzyils-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_MJTl_-uIN0WiFf9AUkk7rQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_YpwOrDxTvEiUCcfw64tNMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Hb9YyYVIVki_vUupPUugtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1_tWzno1-kmrzxYDHva6OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2016Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_931tErLp7EuUinvtjRhPIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_OAjMTWyJ8E-817Ww2pMKxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">qure:VectoryB.vMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_rsKxoYBI-UKgNQ9ydk4pHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_su0H_LmbCk-jIOvLYq58hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_CeTx4ptjcEaRDCkpZ_Y8fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_WvP6wlihOUS6tnrgQEZHWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_1sldxuu9EUKBKyfO334l3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_hv6WtwS-cEGRKyupdp3QwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_4CW_DXp0Ok6hoLPlu21sQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_q56A2rcme0OqndPdj4St-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9DvuX5iTKkaxcG2y02MZyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_VhK3MGv9eEWEY7B8EG-TcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">qure:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_qdkOPyY6VkGQRdYO2alqaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1TMDu79eQ0e28WbVBlbIAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_JOuPA4_0AkS3D-CstJPyIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_dtZW9N0cZUGKCdQgqHQtOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_4uX4YOxCI0Ku1yrWU3Qr-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_CfO51mljJ0eWh8ZOXwfRNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_29_2021_To_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_1Xb1Y17A2U231__SZnvguA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-29</xbrli:startDate><xbrli:endDate>2021-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2018_To_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_jJzGBF12x0arzA2m_P93oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-06</xbrli:startDate><xbrli:endDate>2018-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_mgfIVNyUyFz4VtwWRMFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K-wgrSYcl0aXW5Oo0TuS1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_12u06vcwokqbZ_3H5sstHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v-LvwFQXTU-mEhIgrrFYHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_j3iYYSYmcUedzDpmYFlnzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cZati_nTb0C-UhhIBOUNCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_VrVcTXdK_ka4cFP6BumMkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7OFIcgQjGUKozaeCn_JOaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wAnsudVWJ0eStn1YOEaRPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fJtKgxuUvkyrzU-RtzqAcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kImN7dQ-PUeOCHGKL1wPsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_7LQNKgj-qUKqmDaRdvBRmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:ShareOption2012PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_sDADOxy2gkuHqUBfnjTovQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_aitVdVnE4k67WD71TFPNZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">qure:RestrictedShareUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_1bGUyXjk5Ee1HL6K4PJVRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:ShareOption2012PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_qf3KA5AywE6IX9nX9Nuxmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_Qy8ygST_9k-q-6WvPt0QgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">qure:RestrictedShareUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_Hg1BxwkRVUyQ6vANQg5uvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:ShareOption2012PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_2y8V3lT85USL1EXFTeWauA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_BmsWarrantsMember_lc-W0vqpCUOjhIwUvmVlTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">qure:BmsWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_bIi4GQHMx0e79d3ltjcbDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">qure:RestrictedShareUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_9iYRZ8CW1k-TSh8NdyAR5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:ShareOption2012PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_g9VXfgfnr0G-HOsXC6wp3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_BmsWarrantsMember_AuiBBwndmkigvQN248BGAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">qure:BmsWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_oT74WQam8EeTmP8aiGGhow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">qure:RestrictedShareUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_VqOyaS-XX0WhG4INMVMxnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_jQQMIKMldkWohZCXDVcmdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_2QyWUqSll0SvgxvLV-w2Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_J1hFmEl5jE2V8o1LwylINA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">qure:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_YS6DOwKX1k6x5P_vJL_MIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_Mt0t04auPESNygM01bISbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_Y_O-r5G3Y0WsfXY0g7W7Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_AG5JI3Sjjk21nqVDyvBZNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_2zEJuHZdn0KJM5hi1tu5YQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_UovYXxgpLUq_6ozAyB8paA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lLWpawwVD0SS1ZQfITt7dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">qure:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_qure_The2014PlanMember_YbJyX63qJUCF1-xqxcPn-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_ESty22Jv-0Sxj10FO4p7bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_Ew8hAizqJU-URTHYHt1zAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lwLmmaw8u0StuP6cZ9EnJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_fHzfNFAetEOpeFa4wvX2DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9G_kAneeM0SgziGdwfsbMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">qure:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_qure_The2014PlanMember_GDX-daUVNkiz9HBqranRrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_qure_DirectIncrementalLaborMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_MtE5A0KG6067RmXlMj46FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">qure:DirectIncrementalLaborMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_qure_DirectIncrementalLaborMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_H4D4ClXlxkaceIkX1aMBWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">qure:DirectIncrementalLaborMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eRp_lKNL2EODSNZA9eiuHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dR853wdTkmYUidJM4e8Yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_igOZK4wZWEOra8bKTcWHwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_eXzdB_wPDkSlyzIUnaikng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_24_2020_To_6_24_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_Ll8fzwuH2kqanQly9paw0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-24</xbrli:startDate><xbrli:endDate>2020-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">qure:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_24_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_qg5NvBFGdUO4WsF-xZGEIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_7EhntjUcpUyhyXRTh2k0Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">qure:CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">qure:DerecognitionOfWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_0kUnhi7n702ffhqbWEJJFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">qure:CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">qure:DerecognitionOfWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_1_2021_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_H93jbZY3yUCB1OwXUnoDlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_4_30_2021_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_98YVZPFE5kO5F_BzYuxpRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_wO4YQLjtzUyL7xfd70wfWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_Q_fLWImhIU-2TPyxON_IlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">qure:VectoryB.vMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_UIrDwGaqv0i6xXmaQYspcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">qure:VectoryB.vMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_Bf9nD-pPCUi6779uMq-cCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">qure:VectoryB.vMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_Eyl_r3-QvkyaUu52pRzIrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_29_2021_To_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_VTx12u2MvECweTY9rrMN2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-29</xbrli:startDate><xbrli:endDate>2021-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2018_To_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_Faze52U7JEmiziY1euKKaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-06</xbrli:startDate><xbrli:endDate>2018-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2016Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_Y21A5QNU90qnhAq2_ca6ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_Lkz8BWrtm0OghqMAcJ8NmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_1_2020_dei_LegalEntityAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_y8tWzFCmok2XCsAFfg-1mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">qure:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_24_2021_To_6_24_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_BpZu_RynUUeTx_oJ_rCgLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_uevJahvpyU2rrC71LQx_GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_axABhO3W6UGp87WAJu9rUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_kzh0NdwaSkOA9RR8biOrAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_21_2021_woBf2SRzckevUj9Egzvr8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA"><xbrli:measure>qure:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_8DR84qYcA0iepwyX32ILmw"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Divide_EUR_shares_ZsMCFKBuQUe6RFYLkqqOSA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-top:1.0px;border-top:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;border-top:1.0pt solid #000000;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_2677d2bf_51fe_4ca8_ae66_e628e9225baa"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:DocumentType" id="Narr_FeC79tuB60usbwxX-X6WCA"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_ded29835_8311_4903_8fac_621be50c0f8f"></a><a id="_02f9c480_0eef_45bf_9813_f4b55634521a"></a><a id="_6bcac9f9_8731_4053_97e8_37103de5b803"></a><a id="_20bfe62f_77d2_4e4d_95ac_5bd8bac588f8"></a><a id="_7836b052_7228_49fd_be0d_a9e5be4ce33e"></a><a id="_a112ffa7_2da0_43cc_aa5f_1f8ca31a3036"></a><a id="_d410f688_e8ac_46fc_9bec_6e72e39e58dd"></a><a id="_6ddc344b_574d_4809_9667_9d66b4f0c48a"></a><a id="_3a97404a_04fc_4603_8708_b2e3a622e5ef"></a><a id="_a7262ca9_ef59_4583_a541_74770b296d24"></a><a id="_b990030a_2100_45af_b7b7_ad0920493f78"></a><a id="_bd5ec37a_5853_4d3f_9ca0_96282cc6a0e8"></a><a id="_cbf3abc9_fa38_450e_8211_bd9b6ef4b890"></a><a id="_6b073b37_09e7_4707_b93d_3dbad3ce331f"></a><a id="_e71a1d25_3cd4_4e19_b7c3_421bfeeecb63"></a><a id="_4b0d4f86_b905_4bba_9ed9_7b20501c8e05"></a><a id="_476dbeeb_a0bf_4a35_902e_15659f0c0c56"></a><a id="_67c6f5ce_1130_405e_93d9_4243340529f0"></a><a id="_45f6246d_dcae_4327_ac24_8d6cf02051f4"></a><a id="_bae142ca_99b8_4eda_92b3_b1a9dcf2716a"></a><a id="_3c96ffe4_eb4d_424a_a5c7_dc47a51dd236"></a><a id="_a86c25d9_b155_4aff_b42b_23d8424a4506"></a><a id="_46a5789b_26d6_4f35_a2d1_9c28e1f37f99"></a><a id="_972f6256_6aa3_4f86_bb40_7a62f21a7032"></a><a id="_38dec9b8_dec7_4649_92b6_1c77e1414341"></a><a id="Tc_JZZ9bk8zJUOsbgHcPG28KA_1_1"></a><a id="Tc_AgBdr-ku4Uurm_I1-6OhTw_3_1"></a><a id="Tc_mzQf54Jw3UmbxEGvb2Ci-w_5_1"></a><a id="_69109d71_016a_4d62_816d_23acb0955713"></a><a id="_116ae7f0_0edb_41aa_9cdd_2693e50ec86d"></a><a id="_285f95fd_5bcd_4ade_a50d_0130d3047704"></a><a id="_7b2b936b_e5af_4481_89a6_d0198b48935d"></a><a id="_a9204a20_b347_46a7_8f0b_1980a0a2b762"></a><a id="_f427c43d_7659_4a38_a775_c5fb31533eee"></a><a id="_f443849c_23a1_43fa_b88b_e53649edf9d4"></a><a id="_7932b325_aeaf_43e4_a288_d16385407fe3"></a><a id="_2ec0a198_dd27_409e_98b3_0403664b335b"></a><a id="_249cb4c8_b93b_4294_a53a_913ceb999ac7"></a><a id="_335a6d87_7f2b_4c9f_b382_ef17a3c8f1b1"></a><a id="_0f5e6485_f6fa_483c_93f9_3fe0dccb634e"></a><a id="_81464660_a9b7_47de_81a7_8c00473b112f"></a><a id="_ed0e9a1b_f106_4308_a688_1dee9a459b4f"></a><a id="Tc_W8QXhp7o2UmDlUbkG_fM4g_7_1"></a><a id="Tc_1R5lmfK5JUOnZYI8-yVamw_9_1"></a><a id="Tc_sdmhCrXBiUeNw0_F0cUVWg_11_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:DocumentQuarterlyReport" id="Tc_G1kFeZhIUkyTEFIz12Dhsg_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:DocumentPeriodEndDate" id="Narr_fYYqj917zEa0s4jb6AB1ZA"><b style="font-weight:bold;">June 30, 2021</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p></td></tr><tr><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:DocumentTransitionReport" id="Tc_CBVXvHVHPk2GA_b8iZ0cSQ_7_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the transition period from _______ to _______</b></p></td></tr><tr><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntityFileNumber" id="Narr_P_QTZ6qlU0W90JMknNl4zA"><b style="font-weight:bold;">001-36294</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntityRegistrantName" id="Narr_6UO6ZzEQJ0eDqVr-u1GDrg"><b style="font-weight:bold;">uniQure N.V.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of Registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_73a0da1e_1a96_4bba_a162_fa55e13d9695"></a><a id="_e12047a0_6668_472a_a0eb_2371c7af0a4d"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">The </b><ix:nonNumeric format="ixt-sec:edgarprovcountryen" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntityIncorporationStateCountryCode" id="Narr_Z9ue1jXMNUinMA9RS3YjMg"><b style="font-weight:bold;">Netherlands</b></ix:nonNumeric><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntityAddressAddressLine1" id="Narr_3RRnejxdpUWlnD9-LM8bVw"><b style="font-size:9pt;font-weight:bold;">Paasheuvelweg 25</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntityAddressCityOrTown" id="Narr_yty5bPF-4EqSBhZTUP3lHw"><b style="font-size:9pt;font-weight:bold;">1105 BP Amsterdam</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, The </b><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntityAddressCountry" id="Narr__osiiDWRNEGy95z9gUMRJA"><b style="font-size:9pt;font-weight:bold;">Netherlands</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of principal executive offices) (Zip Code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">+</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:CityAreaCode" id="Narr_pSfAri0UDk-vy_hpL1Fs3w"><b style="font-weight:bold;">31</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:LocalPhoneNumber" id="Narr_GqRF6zDEP0aqqKEU-4aFdw"><b style="font-weight:bold;">20-240-6000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_4fb4daa7_4d70_4e6f_9d32_d0ac0f56495a"></a><a id="Tc_J-kAhrQYjkWgrMv3J7O3Nw_1_0"></a><a id="Tc_WzfqNPDTXUaxL53REa9AIA_1_2"></a><a id="Tc_StKKuWtjWE6qphgyfLFiTA_1_4"></a><a id="_3348f40f_9284_4619_a12f_b66d8fb788d1"></a><a id="_39c65568_33ff_4ba9_9e72_2b7f4dcf358d"></a><a id="_23c1c0a2_ae9d_4f3c_8b18_eafb6a99540a"></a><a id="_db5218da_05d0_4d6e_8ec3_1eb3ad2b54d6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:98.51%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.95%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class:</b></p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:2.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:33.08%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:Security12bTitle" id="Tc_Q0SC4VY2V0qSBX1t6MJE4A_2_0">Ordinary Shares, par value &#8364;0.05</ix:nonNumeric></p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.83%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:TradingSymbol" id="Tc_cf62kM_KSEm9zT7pZD_wBA_2_2">QURE</ix:nonNumeric></p></td><td style="vertical-align:top;width:2.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.95%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:SecurityExchangeName" id="Tc_1hPHgz4UTkiXGd4ZsmH7AQ_2_4">The Nasdaq Global Select Market</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntityCurrentReportingStatus" id="Narr_D3NXsMaiIkWT6yp3_cK0rg">Yes</ix:nonNumeric> <span style="font-family:'Times New Roman';">&#8999;</span> No <span style="font-family:'Times New Roman';">&#9723;</span>. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntityInteractiveDataCurrent" id="Narr_gce2yyDwQEyPSRe_dRCwEQ">Yes</ix:nonNumeric> <span style="font-family:'Times New Roman';">&#8999;</span> No <span style="font-family:'Times New Roman';">&#9723;</span>. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_882bc0e1_7efb_4674_a141_dfc984ad83b9"></a><a id="_2c10e8db_8955_491a_9856_01349f89f349"></a><a id="_3c034761_50d7_4bc4_aef5_7f7002efdcfa"></a><a id="_e1121f7e_a403_4bd3_851f_afad38fdbb9f"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.85%;"><tr><td style="vertical-align:top;width:65.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntityFilerCategory" id="Narr_7UMd6y4cFUyJBSZvKDPFSg">Large accelerated filer</ix:nonNumeric>&#160;&#160;<span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Accelerated filer&#160;&#160;<span style="font-family:'Times New Roman';">&#9723;</span></p></td></tr><tr style="height:30.25pt;"><td style="vertical-align:top;width:65.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="white-space:pre-wrap;">Non-accelerated filer  </span><span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Smaller reporting company&#160;<ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntitySmallBusiness" id="Narr_OpVfcYRnukW6LUi3CFyQ5Q"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Emerging growth company <ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntityEmergingGrowthCompany" id="Narr_GJhQZyptp0OZxxJm-lQK6A"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act &#160;<span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)&#160;&#160;&#160;&#160;Yes <ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="dei:EntityShellCompany" id="Narr_E6RllXKJukWaxfbnv7EEGw"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric> No <span style="font-family:'Times New Roman';">&#8999;</span></p><a id="_368fbbc8_c2c1_4104_af01_1b06c0deacfe"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_36276a44_fa87_4c26_9f33_403dc4d0ded7"></a><a id="_1c4a9e36_278f_49f4_b613_4a18c56d3d2f"></a><a id="_dfdfdf17_ba40_4b13_bd7e_307a8ee3cca3"></a><a id="_9bb461eb_0ee9_49c6_8117_c1aa63048061"></a><a id="_9dbefdb2_785e_42b2_ad9c_5006809f2a9e"></a><a id="_9d5fdfa5_9bff_4b52_acea_1334bbe8434c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">As of July 22, 2021, the registrant had <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_7_21_2021_woBf2SRzckevUj9Egzvr8g" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_GcopNX7aX0mW02NTQwkj3g">46,073,373</ix:nonFraction> ordinary shares, par value &#8364;0.05, outstanding.</p><div style="padding-bottom:1.0px;border-bottom:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:justify;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4760541e_b817_4a20_9891_98b21791db57"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 0pt 41.05pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6b88103b_00b2_405e_9298_a62431fd04ba"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.18138885%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="background-color:#ffffff;vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PartIFINANCIALINFORMATION_914913"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_648632"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 1</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_648632"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Financial Statements</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">2</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 2</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">19</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3_Quantitative"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 3</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3_Quantitative"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">41</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_708461"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 4</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_708461"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Controls and Procedures</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">41</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PartIIOTHERINFORMATION_100303"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_62705"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 1</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_62705"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Legal Proceedings</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">42</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_129445"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 1A</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_129445"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Risk Factors</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">43</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 2</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">72</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_428783"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 3</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_428783"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Defaults Upon Senior Securities</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">72</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_199652"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 4</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_199652"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Mine Safety Disclosures</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">72</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:249pt;"></span><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_846000"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 5</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_846000"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Other Information</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">72</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_250186"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 6</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:81.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_250186"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Exhibits</b></a></p></td><td style="background-color:#ffffff;vertical-align:top;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">72</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_97a6e957_6874_4bbd_a7db_e059d43a6df5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">     This Quarterly Report on Form&#160;10-Q contains &#8220;forward-looking statements&#8221; as defined under federal securities laws. </span><span style="font-size:10pt;">Forward-looking statements are based on our current expectations of future events and </span><span style="font-size:10pt;">many of these statements can be identified using terminology such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;projects,&#8221; &#8220;continues,&#8221; &#8220;estimates,&#8221; &#8220;potential,&#8221; &#8220;opportunity&#8221; and similar expressions. These forward-looking statements,</span><span style="font-family:'TimesNewRomanPSMT';"> </span><span style="font-size:10pt;">include, but are not limited to, statements related to the COVID-19 coronavirus pandemic, our collaboration and license agreements, our cash runway, the advancement of our clinical trials, and the impact of regulatory actions on our regulatory submission timelines.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Forward-looking statements are only predictions based on management&#8217;s current views and assumptions and involve risks and uncertainties, and actual results could differ materially from those projected or implied. The most significant factors known to us that could materially adversely affect our business, operations, industry, financial position or future financial performance include those discussed in Part II, Item 1A &#8220;Risk Factors,&#8221; as well as those discussed in Part I, Item 2 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Quarterly Report on Form 10-Q, as well as other factors which may be identified from time to time in our other filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), including our most recent <a style="-sec-extract:exhibit;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Annual Report on Form 10-K filed with the SEC on March 1, 2021</span></a>, or in the documents where such forward-looking statements appear. You should carefully consider that information before you make an investment decision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. Our actual results or experience could differ significantly from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described in this Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, and in our <a style="-sec-extract:exhibit;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Annual Report on Form 10-K for the year ended December 31, 2020</span></a>, including in &#8220;Part I, Item 1A. Risk Factors,&#8221; as well as others that we may consider immaterial or do not anticipate at this time. These cautionary statements should be considered in connection with any written or oral forward-looking statements that we may make in the future or may file or furnish with the SEC. We do not undertake any obligation to release publicly any revisions to these forward-looking statements after completion of the filing of this Quarterly Report on Form&#160;10-Q to reflect later events or circumstances or to reflect the occurrence of unanticipated events. All forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2dc832df_970c_44f5_80b9_43c52af27801"></a><a id="PartIFINANCIALINFORMATION_914913"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 0pt 41.35pt;">Part I &#8211; FINANCIAL INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="Item1FinancialStatements_648632"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 1.</b></span><span style="display:inline-block;width:18pt;"></span><b style="font-weight:bold;">Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">uniQure N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 0pt 41.35pt;">UNAUDITED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_c9f165ac_496a_4bb4_9aea_3600bfa8246b"></a><a id="Tc_y6erpf5t7Em_wsooTh-olg_1_2"></a><a id="Tc_YYv1UmUVxUKGn7JF0HuDUw_1_5"></a><a id="Tc_6IOIV_iNF0mcElXGlDFz4g_2_2"></a><a id="Tc_GvqCrIUYekijSZtrfTnaMg_2_5"></a><a id="Tc_kgdI46frF0Oukz64arQ48Q_3_2"></a><a id="Tc_OPqGQGG9FUuAiTDLtl9l-w_4_0"></a><a id="Tc_61PNltxOkUCYxz0UVf7dww_5_0"></a><a id="Tc_usgTpBfi5UmEasMcPhObaw_5_2"></a><a id="Tc_fYBn-AE6PEawZd377rmZzQ_5_5"></a><a id="Tc_-PsUsuoDE0OZwft2L0fCeA_6_0"></a><a id="Tc_EeLZLOsWgUGx-XYujPvElA_7_0"></a><a id="Tc_fK4aNgYEgUC8oM8JyqzdFQ_8_0"></a><a id="Tc_MbikcyLxdk2QtoaJsQ4iWg_9_0"></a><a id="Tc_xQl1wxpvuEu934CXDOPwXQ_10_0"></a><a id="Tc_IU-Hy1acL0aDHogcQanW6Q_11_0"></a><a id="Tc_dn_wzJZgE0aL0jdiRHV95Q_12_0"></a><a id="Tc_O0shE1G8bEOonW5YBaHmUQ_13_0"></a><a id="Tc_-mL9evbUJ0yiNuVUQgsdgg_14_0"></a><a id="Tc_qNfX8SE0qEm9UjgA6WzQpQ_15_0"></a><a id="Tc_21bzin8dT0246qaTV_E_Gw_16_0"></a><a id="Tc_vBqRazk5y0q3LT06bVjdoQ_17_0"></a><a id="Tc_g4l7aOLswE2IjanC1Wlegg_18_0"></a><a id="Tc_p9dw4R7baEalIECGX93pPw_18_2"></a><a id="Tc_oSxGL4R3EUqDt-FmzM2-GA_18_5"></a><a id="Tc_CEwXjnPHL0m09KMme6T_Fg_19_0"></a><a id="Tc_uHQEdFeemEatvoqxyvZqAw_20_0"></a><a id="Tc_1fH0-4WyMEG7TdVvGDvxJg_20_2"></a><a id="Tc_iA3GK2kalkuYixOOuJGtZA_20_5"></a><a id="Tc_Y69UU_i7VEWBJy_QhoBm6Q_21_0"></a><a id="Tc_pE4s5wDuY0O7HSrTuaxYaw_22_0"></a><a id="Tc_A8ewZ-3Cwk6WHPC6yLBcqA_23_0"></a><a id="Tc_2MMqvzbTLk22vmvrC-sW0A_24_0"></a><a id="Tc_uXrBEWJprUW3aDcHYN6NDw_25_0"></a><a id="Tc_DkRgLKlIjkyML9BVIU_I2A_26_0"></a><a id="Tc_CmIM98fIjkyFmhn4hwVqKg_27_0"></a><a id="Tc_PVUXJPxx1k6SaZljXObNIw_28_0"></a><a id="Tc_6B-OVt2CkEOSl1W1pGT5sg_29_0"></a><a id="Tc_z1TlVVfhuEm-4xUNfY-UvA_30_0"></a><a id="Tc_TFT042-PcEyQ4O0LS7IKRA_31_0"></a><a id="Tc_4bkKsHOpXUu04J4jwju06g_32_0"></a><a id="Tc_rH0wPKpbs021CBT5vVICMw_33_0"></a><a id="Tc_5zXGrs2p10O-pIxCvep6Yg_34_0"></a><a id="Tc_0jvDRra_q0WxLMbsTOxliw_35_0"></a><a id="Tc_tBtGWGWGI0qFVfV3MN1HBA_36_0"></a><a id="Tc_ejwTwr3y6ky4QOleC1sjFw_37_0"></a><a id="Tc_IL09uB9qrkOvQQmhsQESCA_37_2"></a><a id="Tc_KNqoBbcu0EWaER4m6tFNpA_37_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:top;white-space:nowrap;width:37.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_3IRJwkxARkCcE8ymyR_7OA_5_3">677,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_lgSwLhU61kKs0N2baZLUEg_5_6">244,932</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_7wsvJTFhuEWzOUVxqGCv_Q_6_3">2,705</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_pEV1WR1C6EykrY7OLBWj7g_6_6">6,618</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_tTQe9OpKGkiIxQN3O9jEng_7_3">10,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_c_mJsyfUV0S86HOSj20IWw_7_6">4,337</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current assets and receivables</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="qure:OtherCurrentAssetsAndReceivables" scale="3" id="Tc_4lT93ruDzkSJJt15NQhQlQ_8_3">3,328</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="qure:OtherCurrentAssetsAndReceivables" scale="3" id="Tc_lwEbpNCWXkq3WmV6cKi44w_8_6">3,024</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_HwDFwTSAu0OdtkXVEWXX-w_9_3">694,224</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Psq7UmPNo0OobFVgUA2Mzw_9_6">258,911</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="Narr_-TN6t1TkyES2EAVB4P5O8A">37.3</ix:nonFraction> million as of June 30, 2021 and $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="Narr_-D8_6VLUgUyiEa4AuEE0ug">35.2</ix:nonFraction> million as of December 31, 2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_OCc9EEORDUSa0GKed_aYpA_11_3">38,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_H1LQ-HqaP0-aLwSS-l5PNg_11_6">32,328</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_-4htlZFEIkmB0JihLp0g6g_12_3">26,782</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_s7WE96G-x0-8z62gyfMXbw_12_6">26,086</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_IzJZize-JUCmfV_bjTqwYw_13_3">2,637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_pFyBxMFZ-EydYw9HEL18BA_13_6">3,361</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_Jgce3kE8AkOVkGNRV6j4VA_14_3">525</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_o_UZs0OsakKn-30Pyrsm2Q_14_6">542</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_-GRk9bRDb0mEj4ZWRLyXLA_15_3">15,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_sSlYm__IwUOcffMxr_e9oA_15_6">16,419</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_yj2gKl1puU2elgsYX7GCwQ_16_3">5,760</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_CT1DD6Yb20-etPUKQIU1Jg_16_6">2,748</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-current assets </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_fuwbdro7FUCdtJpLE43MJg_17_3">90,040</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_YEQjBOv04kWXpFDpcHYcqw_17_6">81,484</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_i1V9X-a1bUW6nb6PkZSP2Q_18_3">784,264</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_7jpx6KeW4UqhBlSq4Bklxg_18_6">340,395</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_4aKoaoYDj0K2dS5MiveelA_20_3">16,817</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_Yf3aW9S1SE-Y8f5TKxC8yw_20_6">3,772</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_fpfrCU0ZpEyK2mGMD-9Brg_21_3">23,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_G2d7pxtL2kypGMmeeNaCpg_21_6">18,038</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current portion of operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_DPsvwUhZT0K8JMteS-L-HA_22_3">5,752</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_8CDd5hOHPkiHcplLM8q2VQ_22_6">5,524</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_kvoizeQbg0KJIW8d75W-Ug_23_3">46,095</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_i3aTKIQMgEG4JoGCYdwnFw_23_6">27,334</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_keH2bS1MBE2qJm0tW2O8wg_25_3">70,780</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_Xweow8nd40-SXSfA3Qq8Jg_25_6">35,617</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities, net of current portion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_x9Wi3A1nZkOUT2dbWDZ4Ag_26_3">30,534</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_nw9DlVEofkCcr8FAQyGN8w_26_6">30,403</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_f7bTbhT1iUKDGLrgzXBpow_27_3">3,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_pRB7Vzvw8UaAUdorD_stVA_27_6">3,136</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-current liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_ABdD7TkiSEeESFji0t55qA_28_3">104,561</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_CBLz-eh-V02FYG0Kcx9soA_28_6">69,156</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_rTIDlJCxtUi7hPtR4WYhjw_29_3">150,656</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_1fdf4Hu9PUmmN11GLHBe8g_29_6">96,490</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Shareholders&#39; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ordinary shares, &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_ZsMCFKBuQUe6RFYLkqqOSA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Zs7cfYx1DUyzyw0BjnOvGw"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_ZsMCFKBuQUe6RFYLkqqOSA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_1zM_bxo7q0SMf5DTgIdVlw">0.05</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_3PcCyBTQAkazwiAEmi3KBQ">80,000,000</ix:nonFraction> shares authorized as of June&#160;30,&#160;2021 and <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_GhEtx9rEuUyZ6K_y4Hnlcg">60,000,000</ix:nonFraction> shares authorized as of December&#160;31,&#160;2020 and <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_0IX1BfUq-Eq6pjBvN3WY-g">46,050,250</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_HeAOlTpuCkirtMn1gJ-tfQ">44,777,799</ix:nonFraction> ordinary shares <span style="-sec-ix-hidden:Hidden_V30FJAMs5kyHjXPHAKDwBg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_iWDWSf8eDkasc3ZZLMhv3w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span> as of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, respectively</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_s6Yz7trPfUG9-Iurmesv9g_32_3">2,788</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_nw9bU8xa30eO_ZV6ohqyog_32_6">2,711</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional paid-in-capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_fiNLTAe-S0CFfDdBoNOD0g_33_3">1,062,234</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_weZxGmS3H0-CFQzeDLn7RQ_33_6">1,016,018</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated other comprehensive (loss) / income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_YTv3VbVWg0WzM1QY5H8nKg_34_3">4,595</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc__6LpVTd0B0qT7PcBJIgu9w_34_6">9,907</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_NpzQESeUJEGJLINe4HmEaQ_35_3">426,819</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_YTKNt2HFrkqKd5eF1QJiqA_35_6">784,731</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total shareholders&#39; equity</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Na633EskiUm03fOLVCpnaw_36_3">633,608</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-RPejH8AiU-3x7qDteA_6w_36_6">243,905</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:60.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities and shareholders&#39; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_VzQDgiihWEOoBNEwdGgH8Q_37_3">784,264</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_ELSD0qVn7UWjD7PZEsPe4A_37_6">340,395</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3915fe5a_b996_4494_bb38_1186812a215e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">uniQure N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMPREHENSIVE INCOME (LOSS)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3933b53e_9be5_40ea_8b5e_50d026278ee8"></a><a id="Tc_RXHqnlIQKkyeLQeKRnWCbg_1_2"></a><a id="Tc_SeehAp0v602cbLW-CuUP9g_1_8"></a><a id="Tc_yjfyYpWKBUOfgdwtswo5vQ_2_2"></a><a id="Tc_DZloN9_0DkanCVcOHvOjtw_2_5"></a><a id="Tc_EFAYP1Ayr0WFajEIyoLBgw_2_8"></a><a id="Tc_ojRygBirLEyfSikYozFtXg_2_11"></a><a id="Tc_zmW4mkkyEEi2SWhnFD62qw_3_2"></a><a id="Tc_8Bbr3rjFAk2WG1BpwPMHZg_3_8"></a><a id="Tc_G482ddrJh02VmzQU-R6uMw_4_0"></a><a id="Tc_Gdbs9ptTDkyR8xwyHcXFCA_4_6"></a><a id="Tc_DfOr2HpY3UmQTal7dh2cjg_4_12"></a><a id="Tc_hUTnurVWHECOV_wgouCaUA_5_0"></a><a id="Tc_CntgqF7osEmpTFyZqIBWBQ_5_3"></a><a id="Tc_sVDQOWsF2kyg4El5zUsTbw_5_9"></a><a id="Tc_xUpsJY01sE6U5ESTFWuBBQ_6_0"></a><a id="Tc_g9x6L2Kv-USslFlm5GfdFQ_6_6"></a><a id="Tc_beVQMpSqWUGC2emafBoLTA_6_12"></a><a id="Tc_yg-Q0TzNlUSUIoi6TgSV7A_7_0"></a><a id="Tc_VzDxe5bRIEOKRq0NyuM_JA_7_3"></a><a id="Tc_kw9C0A8zckumByEQrkxaIQ_7_9"></a><a id="Tc_8iDbc6TiG0unB6th8rrIVQ_8_0"></a><a id="Tc_J7sw5pX0kkC2_8Zza1xKwA_9_0"></a><a id="Tc_S_LHR-nUPUut8eK63suBsg_10_0"></a><a id="Tc_XaQ8sZjkdU6KMdadN5fnyg_10_6"></a><a id="Tc_GAA7jsGmaEiI3GevsrLk1A_10_12"></a><a id="Tc_PyeAM2buUkmjzQMVh166uw_11_0"></a><a id="Tc_-8wq8EJtxk2kefptADpciA_12_0"></a><a id="Tc_H8G5zOhSFU-iOcJmwVGf-A_13_0"></a><a id="Tc_4PBETaq0CUaQsMuZuWqCQw_14_0"></a><a id="Tc_GiR66OuwzkmQdqbkhVQ_Sw_15_0"></a><a id="Tc_oeSqBGUzMUOP4SpdEOlUkQ_16_0"></a><a id="Tc_XgPKzFzMh02Mjv9_f4mH_g_17_0"></a><a id="Tc_UpFBKoQ8vkmn_HTq5dQ6tA_18_0"></a><a id="Tc_2wRVL9ZmE0e7NeC5ZXt3Nw_19_0"></a><a id="Tc_-zQVTRGHVEiDbKVWIvaalw_20_0"></a><a id="Tc_Go22HmHGFUu4e9X1srEC1w_20_3"></a><a id="Tc_fnA8AM1xIkG9nhFBzG-hZg_20_9"></a><a id="Tc_JDulYKLckUubo5aCBt57sQ_21_0"></a><a id="Tc_uid_AfwOoU691ePcADlIZw_21_2"></a><a id="Tc_OjiHR3kNvkSCPNwHImL3Lw_21_5"></a><a id="Tc_Nx_JcLgJgk-H3gTO9vNriQ_21_8"></a><a id="Tc_C9JLeVRdlUaN5e5zFBnN-Q_21_11"></a><a id="Tc_GesnPwEY10-nj1ChfgAt0Q_22_0"></a><a id="Tc_yuFuszIxqk2zr6q1nvXZEw_22_6"></a><a id="Tc_mpyrIWbscU2of0ynlsGgWA_22_12"></a><a id="Tc_4OR3QiJwm0eB7W7wNI66pA_23_0"></a><a id="Tc_H4Zwcp9ixUGWFm37DKrgwQ_23_2"></a><a id="Tc_5jF_MtWvFEOMEZUXs_Bbxw_23_5"></a><a id="Tc_rcm_oCELY0arZPN-G5hHFw_23_8"></a><a id="Tc_zxVtb3IdvUiKaCErpuQW9Q_23_11"></a><a id="Tc_xrRpgBJl5k67_7ghWayNFw_24_0"></a><a id="Tc_8WgAY_D_Z0G3jwnvfJfZxQ_25_0"></a><a id="Tc_z-RfInxPrEeeZp_TgD4miQ_26_0"></a><a id="Tc_bcAQdzyt_Ey56HrI1EnW8w_26_2"></a><a id="Tc_MfLJm7E0z0CD8QZK7vmKkg_26_5"></a><a id="Tc_Z3NKAHNrUESm6KrRI49uNg_26_8"></a><a id="Tc_QkPvG49JVkCeWSCq-nm5lQ_26_11"></a><a id="Tc_2o3L3iWDO06PSanCwvjjpQ_27_0"></a><a id="Tc_qhRP_jzHJ0GqO6y6jKgytA_28_0"></a><a id="Tc_Mmec5lTMYUKnETw0_IH3lg_28_2"></a><a id="Tc_nAy-3-FUw0-PcAsPLw7MYw_28_5"></a><a id="Tc_-zghXNLY4UCP97SLBd0wzw_28_8"></a><a id="Tc_xeFqJiiLC0OdgfHQ0QztOQ_28_11"></a><a id="Tc_4LBDbL1Dpk2RonW0ZoeZTw_29_0"></a><a id="Tc_RR7kjqkX302nezkbmM18ag_30_0"></a><a id="Tc_keQTm1lS906A31TBRzVT3g_30_2"></a><a id="Tc_tGpFCWnUS06YiOWcN9KXxw_30_5"></a><a id="Tc_v_CFvJapvkO9Ox5T7Zgi-A_30_8"></a><a id="Tc_p1et06f5hECvjbQTHGCsTg_30_11"></a><a id="Tc_pMY69NuyE0CiVP9_OJU8Ew_31_0"></a><a id="Tc_FsGJPxy5j0CacRxa6VFuig_32_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">License revenues</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseMember_jHZhFitLrEOQNQKYgI7ZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_T3kxTsDOXEOrTUwvpyg1Gg_4_3">462,400</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseMember_9-058g41FkiUfUyhdRdA8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_hqS2xSAziUGK_Y8nIsAoIQ_4_9">462,400</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">License revenues from related party</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_LicenseRevenueFromRelatedPartyMember_Ktoe6WsNfUut5PLrxfJPGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_XANQq4bPL02LHD-Pc5bvKA_5_6">1,530</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_LicenseRevenueFromRelatedPartyMember_R4VI051DiE205Dp9r8_D5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_uYesz4XW10C6WUWhj9ABMw_5_12">1,577</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Collaboration revenues</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_0j8VHpWGtkqyg1Eoh_-56w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_ugRVXrhDfkm6iAqjtgQrmw_6_3">1,468</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_9iY6fqOrEE6pUHvNw-CSpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_BfZuwOTdHUmsECXinW0-Vw_6_9">1,922</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Collaboration revenues from related party</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_CollaborativeRevenueFromRelatedPartyMember_cprlgbYMcECa1gZndoHMVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_MPZUrNZz7EakjRAaEcXSsw_7_6">5</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_CollaborativeRevenueFromRelatedPartyMember_qHipUZ-S2kSLqtPAsxvUgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_MOUHV9o9pUKXaIc4S_PL2Q_7_12">62</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total revenues</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_DNVXtiVevEeGqXuMHJotPw_8_3">463,868</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_mBTYNTTYvUWxlTe_-KQxLA_8_6">1,535</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_Pa4StMi9IUmYsEOvljt08g_8_9">464,322</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_y1mhCYCz6U60fCq2Xoek2Q_8_12">1,639</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of contract revenues</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_WqvH1bnVA0SLX7RhzqVckw_10_3">23,178</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_fEHUvCqafUSz24MgINLj-A_10_9">23,178</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_kie-rsGfxEWJgMq9LZcoLQ_11_3">32,747</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Fn5b7uGnAES1uq2m52ZKjA_11_6">28,401</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_2kP_m-kmnU2J80Ox4zgXKg_11_9">64,777</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_gBccFirykkKT-NaDA9z8dg_11_12">54,414</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_E6s9VQ6zPEup2rSI0UWXxg_12_3">17,299</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_R-CX7z01906Y6bT_71m1IQ_12_6">11,511</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_WDIezqlRHUeHKxlPED64qQ_12_9">30,300</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_dAkyHdEwvUO7w3TtiQ85cw_12_12">20,583</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_Ib8f1f9Vv0CoNTxmkEAfpw_13_3">73,224</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_ot9VJU0H-kCRQoeYV_RVdg_13_6">39,912</ix:nonFraction>)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_kbBYiCiKjUmXnoFpX5PjnQ_13_9">118,255</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_o9S72fgybkG25FGjZ-7bpA_13_12">74,997</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="Tc_9a5fMonO7EWhJJglQf0mgw_14_3">7,590</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="Tc_owEbLROBl0qtSv3pjqDgtA_14_6">669</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="Tc_gEwFQpwYm0CsXEcQhqLmUA_14_9">7,942</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="Tc_aUIRyUZKO0ScVHRFd43q4g_14_12">1,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherExpenses" scale="3" id="Tc_UeyPGsRz2kiVPWTApBG7Gw_15_3">226</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherExpenses" scale="3" id="Tc_tkMLUje7Fkuvi92JCCIm0A_15_6">500</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherExpenses" scale="3" id="Tc_G_Dv53eecU2-IHJgw9wneA_15_9">459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherExpenses" scale="3" id="Tc_RrL6bco7WUq2ldUrVwz6Lw_15_12">839</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Income / (loss) from operations</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_VwrYgpyswU2A60u59jIV_Q_16_3">398,008</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_tkVMwAP73kOig9Xi3zBo3w_16_6">38,208</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_s4QCR4vEnEySxFyWUBtTFw_16_9">353,550</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_OZ7t2zZLAkWZhhLbPglyhg_16_12">72,671</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_H4RPQA-QG0OnJD7-PuihFA_17_3">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_gYNUUSrbZkScg1uG95dqfA_17_6">81</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_2TT8PJJ57kKpkisgvY0_0w_17_9">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_pJqWtFFVQ0CrgC0ULh_FWA_17_12">903</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_51Ydi-_K3kCsa4PaklXeQg_18_3">1,902</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_Eqf-mBbHikmmrId81n9Eug_18_6">970</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_F3sulOuugE2VaNybZHRetQ_18_9">3,453</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_hlzN5_X2N0azh4ps-l6OoQ_18_12">1,945</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency gains / (losses), net</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="Tc_yB6FzaJl10uZrAH9vUsy_Q_19_3">6,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="3" id="Tc_W-34oK-J5UeBeTUdmKQkTQ_19_6">3,645</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="Tc_Bsu-FucEOEqaqGzzQe9etA_19_9">11,209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="Tc_TvT0WhJFIUeR5DBYspDeiw_19_12">957</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-operating gains, net</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_OEPTfJtWA0G436FNpeFMMQ_20_6">191</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_ialgCRiHN0-uufI4KGHShg_20_12">2,206</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Income / (loss) before income tax expense</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_UFGywLSkHk-Wszrfcb5xlw_21_3">402,726</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_AZIbLX_E_E-usGd-Yj-aUg_21_6">42,551</ix:nonFraction>)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_r2PJK408yUShEY6Sb8XmNg_21_9">361,383</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_hHrrivateEuK5O7LLrp5qA_21_12">70,550</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_4msVsZkunUmPCjWJxosqYQ_22_3">3,258</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_nQ_LVqHSvUqWbd-uL5pjSw_22_9">3,471</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net income / (loss)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_GAQVjU2qKUmOrOKuuKtD8g_23_3">399,468</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_CdX8iwy7mkClaxJuXkfkRg_23_6">42,551</ix:nonFraction>)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_h3mJta2mDUqPTPgYIj64ZQ_23_9">357,912</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_ydkYSGQ63kOAct_5R4BNkQ_23_12">70,550</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other comprehensive (loss) / gain:</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation adjustments </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_wWwswelg_EGx9ZH_RLjbpA_25_3">6,942</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_fX2KliqamU61c0EbNyjCew_25_6">4,647</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_1nPNfIsjkUGw456WYHYn9w_25_9">14,502</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_1DcaS4MfnEaMm2Zqw83JxQ_25_12">630</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive gain / (loss)</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="Tc_F7O2QJXNWES97TckITbhvw_26_3">392,526</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_f8fufD4giUOwFlLXz47zzg_26_6">37,904</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="Tc_NCxv6EOSEUCRz2UmcGFBqQ_26_9">343,410</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_NWuX973Pj0-PUXq5hd6_uw_26_12">71,180</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Earnings per ordinary share - basic</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic net income / (loss) per ordinary share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_W-2YhiqQq0K7w6PXUgE7tg_28_3">8.68</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_YqJ84agnoEWZbh4iXEF-kg_28_6">0.96</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_rozmvINuvEym4qYVegNY4Q_28_9">7.82</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_G00fKTxFJUmubNfdHe1rfg_28_12">1.59</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Earnings per ordinary share - diluted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Diluted net income / (loss) per ordinary share</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_Z0tctxzfXUiBcb6_dCA-gg_30_3">8.51</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Ww7myrheOUWmMGrZ6ghw6w_30_6">0.96</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_zhhU1rewpEuNq1m-IE8C-g_30_9">7.67</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_8QLWfLUe9E-G2Ldfg1StAg_30_12">1.59</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares - basic</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_UMQt9WeLX0GMaSY3_oNgTA_31_3">46,037,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_7ZpJYvCAwUmV2WTCYvGSug_31_6">44,387,463</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_IrslrnEOnUel8E1u_ev3ew_31_9">45,754,766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_c1zMv3iEgkazIneCn9JK0Q_31_12">44,333,460</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares - diluted</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_1GczZ_eXRE24H7HRB4naNA_32_3">46,929,870</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_m6frIzpMPUiMLjpSmq4b-A_32_6">44,387,463</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_BBBIrgvryE6U_OSzKx0xAw_32_9">46,678,835</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_TAQhGZNisUKpjCNBqEF8kQ_32_12">44,333,460</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8a4f5a5f_c73b_4999_b62b_7c72617a4445"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">uniQure N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">UNAUDITED CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">FOR THE THREE-MONTH PERIOD ENDED JUNE 30</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9efe6683_c04e_4689_9e9b_2a43c906754d"></a><a id="Tc_YHq21OTX6kWKZGsvDMHGfA_1_9"></a><a id="Tc_3FuJn7IXEkqCRdskEB4u_w_2_6"></a><a id="Tc_4aWRMAKye0WF7ETshAIn6w_2_9"></a><a id="Tc_gOy7RW-Jck-Hb0NesZAq5w_2_15"></a><a id="Tc_D1CQ57ARJE-fdYehMfuIAA_3_1"></a><a id="Tc_mASRpBy0GEy2V8o9kPK3IQ_3_6"></a><a id="Tc_N7cXs8RqL0OW34e6teY7sw_3_9"></a><a id="Tc_PAcovuwYvUmfeipIro30Yw_3_12"></a><a id="Tc_--ILj6Et6UKswdhFOIXxWQ_3_15"></a><a id="Tc_fGtfmOwM7UW7DWCf4kpXig_4_1"></a><a id="Tc_6IaE8nnMlUeRJClRp4ZQAg_4_3"></a><a id="Tc_EiCCx4sjTE2y-gIhzEByiA_4_6"></a><a id="Tc_hUoDxLxurUWCbYP0lT01yA_4_9"></a><a id="Tc_UJT8clDauUW1q_LeetThbQ_4_12"></a><a id="Tc_MTNbVzA1gUGcCvAmo95bHQ_4_15"></a><a id="Tc_wcLDNd5lhUqvBtSfdUhjkg_5_1"></a><a id="Tc_LEaoJwBMS0SFcEY1WwsIdA_6_0"></a><a id="Tc_su1wV1tZ_Ey6d-g8gRN00g_6_3"></a><a id="Tc_yEcL9NSzzky098OAdy1etQ_6_6"></a><a id="Tc__x03iJPwGk-MBuG9nKvmUw_6_9"></a><a id="Tc_J9EBTYug9UaweuRU0O4ggQ_6_12"></a><a id="Tc_MQ9SrRUiFEyquo6-0boCNg_6_15"></a><a id="Tc_nSSUIX-G9E-ObG4oRv7ASA_7_0"></a><a id="Tc_WPGNfEjVEUm17waeJwQrOg_7_1"></a><a id="Tc_IIbbnET9CkWLg0tyObhapg_7_4"></a><a id="Tc_v_P9wigVd0WP920G8YJMPg_7_7"></a><a id="Tc_Hy760356_E2kgE4oFlu0Ew_7_10"></a><a id="Tc_UBGzDUX5kUKHFaEEcuSLHw_8_0"></a><a id="Tc_wvk17Ky3sEWb4zu_uYvONQ_8_1"></a><a id="Tc_pDq-zbx-AUOTzr7OWKK6RA_8_4"></a><a id="Tc_cFX5pKx1nkCpPaHqeTDX1Q_8_7"></a><a id="Tc_xk-Eh5GkKkCMO-3LRWO0ww_8_13"></a><a id="Tc_PYX2Ss1BtUyvuNuONWf0BA_9_0"></a><a id="Tc_m_8atG6IvESK-ZHn2SXbaw_9_10"></a><a id="Tc_VhygNTn2a0iXnSx6k0jkiw_9_13"></a><a id="Tc_JxB2WrZcK0KS6P0Sz2DrbQ_10_0"></a><a id="Tc_FD0SdjZwAkS9geYB23bunw_10_4"></a><a id="Tc_sB93mctTHk6AKKpItVVs5w_10_7"></a><a id="Tc_MZkH9Y2j0U6O8d2j5zdqZg_10_10"></a><a id="Tc_IZMALnTaKEm1LYTBb8rOLA_10_13"></a><a id="Tc_XoDAMNwBr0OB3SYoqhPq4A_10_16"></a><a id="Tc_dTLZk8GTHkuA4uhJ15ou4Q_11_0"></a><a id="Tc_JSoJV4_K8kqGAz9B96QkFQ_11_1"></a><a id="Tc_jNkr7Pm6c020nZeJPTDBHA_11_4"></a><a id="Tc_eV4gWVVaCkmg0PdHMnc7qw_11_10"></a><a id="Tc_GoOnhpXCQUiCnzevv_RZyw_11_13"></a><a id="Tc_QT3ZdbGWy0aDTZHygjR4rA_12_0"></a><a id="Tc_oKElUaw1gkWrpIlTvFlw7g_12_4"></a><a id="Tc_-JoWUn84pECftrG9cbY01w_12_10"></a><a id="Tc_2AaUXQlpAEiEVOZtCpBl-A_12_13"></a><a id="Tc_bxFKW4OHz0G-ZzbQYkOD7w_13_0"></a><a id="Tc_IkpPZkAzgE2zsw4k53TA1w_13_3"></a><a id="Tc_hX9S8B8Ut0m838Cr7G_Xmw_13_6"></a><a id="Tc_UYpF4ABnika04yxMPgWxaQ_13_9"></a><a id="Tc_kkSxwe7WnU-rU8gSZ2T3PA_13_12"></a><a id="Tc_RxUsvuv22UKwsstjjqdiow_13_15"></a><a id="Tc_9HiW9GCqREySmoFMmwyKQg_15_0"></a><a id="Tc_rW2_RtiwMUazR_x3M47Quw_15_3"></a><a id="Tc_LT-n-jCSuE6iceix7AnCVw_15_6"></a><a id="Tc_RpX1p_dkLkyn9tLRRkPYfA_15_9"></a><a id="Tc_wDl1ohSAgEa46ZsVas8Yaw_15_12"></a><a id="Tc_D93PLsxQcUW-EhaaI13YmQ_15_15"></a><a id="Tc_o9DkL-P4tEesNSxihpueMA_16_0"></a><a id="Tc_vLAXRDC960WF7jwBbHnNJw_16_1"></a><a id="Tc_HAkBlO9zmUuCPXMpk1QFEQ_16_4"></a><a id="Tc_YmjmQENYRUeKg_uj1Lq_xg_16_7"></a><a id="Tc_haAN9Ov0BkiQ1ZvkE7Cn5A_16_10"></a><a id="Tc_csq4xKKcIE-I6Att9Iml-Q_17_0"></a><a id="Tc_ZBYhNU3KkUOeNhxN0Or2iw_17_1"></a><a id="Tc__EntkuWV_Uydgtuu0QPUlQ_17_4"></a><a id="Tc_3nC58of8tUCwYQOkG5kFqA_17_7"></a><a id="Tc_j_wJplVWBkq1Ly9smwOBxw_17_13"></a><a id="Tc_Zm8jhRjRS06n-SFh4dX1WA_18_0"></a><a id="Tc_9lmYdyzaDkuNjLADZCdwlg_18_10"></a><a id="Tc_f-FZYjwz8kOdDdNbV5rPnA_18_13"></a><a id="Tc_rDLUqWaEA0yMVF6yNOKmIg_19_0"></a><a id="Tc_FY76JQNzBEafI_ObglxsDw_19_1"></a><a id="Tc_GNXTNLBJ_UuGc8fjPyJXFw_19_4"></a><a id="Tc_Vaw7R0iVx0GbSW4qAacjsA_19_10"></a><a id="Tc_TwA7ymlWTEu54x6AN4Ep4w_19_13"></a><a id="Tc_A58JU8iXTkK5EwtYO6FMAg_20_0"></a><a id="Tc_xuOqP5E2kESTpdo3F6l68Q_20_10"></a><a id="Tc_rpa4qckB_UeOBzvVXvYrPg_20_13"></a><a id="Tc_0k1uqbiTkE-5gub9YnBPWQ_21_0"></a><a id="Tc_er3c7eneaUye53KgemK39A_21_10"></a><a id="Tc_fYoVOY4HDk6PopeKAXFwLA_21_13"></a><a id="Tc_zRtx98_my0eZ2eTzWYccaA_21_16"></a><a id="Tc_F_4uqBkhbU6_1zK4x9zy6g_22_0"></a><a id="Tc_4bI71zD8yk-L2hO799B_Wg_22_1"></a><a id="Tc_GvBsO1SUe0yr70nLzDxYkA_22_4"></a><a id="Tc_UhV5gws0SUuTRfXTMSzcgw_22_10"></a><a id="Tc_HAdClC5njEyQQNWYpxkmaw_22_13"></a><a id="Tc_HLZlndFDj0uQetw77l11cA_23_0"></a><a id="Tc_6PVF1CAsBEKcKCzdIamV8w_23_3"></a><a id="Tc_5YB8aZXEhkacp4IW2QZNYw_23_6"></a><a id="Tc_xKJmM92wvkW_BTBudfjByg_23_9"></a><a id="Tc_KdtKo8XrEEKytgQIIBYZCw_23_12"></a><a id="Tc_yJc0-rcrqEShXCUnYpzCWw_23_15"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Accumulated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shareholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;No.&#160;of&#160;shares&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;Amount&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;capital&#160;&#160;&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equity</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="17" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:71.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_j3iYYSYmcUedzDpmYFlnzA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_-SdSWX0IIkCUVRowbeEgtA_6_1">44,299,596</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_j3iYYSYmcUedzDpmYFlnzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_HOzkf5ibNEW-f3BZytbDxQ_6_4">2,683</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B-LJE5DhoUS75c9QtNuw-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fvc3BH55GkukddqLIOjnRg_6_7">992,136</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_w6u8-eqmkEiHOgU-Dd9xOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_LhCbokh_7k64t93liRZYbA_6_10">11,966</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nPdO4wtnvEWlpbuGGdBg-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_6cSZ0JjAQE-M8sGkpM8c2g_6_13">687,706</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_3_31_2020_kg7c_qm1bEy7UDtpE53ICA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_z6Sk5u20E0KUp5tl5LPoEA_6_16">295,147</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qLQ5mvZzJUqhD9QUU80N6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_iF1qCL0cvkau0jtAogFoew_7_13">42,551</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_phLwdG6o70qXjXxjth8K6w_7_16">42,551</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MUECXMXIDUq79H4NmTlzIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_J-JbRheVIUu9Pj1KzbB5Cg_8_10">4,647</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_Uux0Msn9AkeVP8dvQH-bnQ_8_16">4,647</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of share options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyu1S0cqWU2xIkIh3ub-aw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_vxrpsKFl5EOugdiYctkIRw_9_1">139,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyu1S0cqWU2xIkIh3ub-aw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_VJZsyEtdoEqCoxCMrsScOw_9_4">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eRp_lKNL2EODSNZA9eiuHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_fF_ad3BatU6-DInJXo668w_9_7">2,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_y5m4MRN2C0Gl_vSf9pVrhQ_9_16">2,470</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted and performance share units distributed during the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyu1S0cqWU2xIkIh3ub-aw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" id="Tc_guJqe_7CQk2WF9IWLzc7zw_10_1">4,427</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eRp_lKNL2EODSNZA9eiuHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_6Q35pilQAEmDv8z_hkhueg_11_7">5,723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_bPrbDkElikK9GKrEyHPgWQ_11_16">5,723</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of ordinary shares relating to employee stock purchase plan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyu1S0cqWU2xIkIh3ub-aw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_oeZKVbpE60-Pw4zLTepQlA_12_1">1,204</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eRp_lKNL2EODSNZA9eiuHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_dXgHDgiyOEG7H4Hav4g0LQ_12_7">69</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_bGVwmj0f50ujrMP39rAApw_12_16">69</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v-LvwFQXTU-mEhIgrrFYHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_LFtRDqL0FkK5erWYm5UJwg_13_1">44,444,405</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v-LvwFQXTU-mEhIgrrFYHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RN_4abTH3EKB5NHUHKuxkw_13_4">2,692</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tqrT9yrb-06NxeDkwo4JTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NXgzPnii1Umv6Z22cbm1Ug_13_7">1,000,389</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_98hRD2QNWkGhe45TCCi4eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_sFyXuPyl-0mWaBeLq7FT8w_13_10">7,319</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0D6WZbsJ9EyfBMQ5KfZThg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_k3XpBPQgCkWy1QnMhAlElg_13_13">730,257</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8syMOzFa2EGqzpvR_MyEEQ_13_16">265,505</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K-wgrSYcl0aXW5Oo0TuS1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_gOenMsBtNE-1MrWRdvLMow_15_1">45,924,729</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K-wgrSYcl0aXW5Oo0TuS1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_KyaLbKRqpE-yK0GegVCp1g_15_4">2,780</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DsFKGwOurUui9rgpsgd2zg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_TLQoD77XekyYe4NrusxrHQ_15_7">1,049,850</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_L4tV3PEQJkC8fL3FzxLwNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__BDm97TGH0aFm79Z0L4Z1g_15_10">2,347</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HOv4QC1gA0CfyEdcEjfcYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_XaTNG0-qDU6PWp8uIfyGMQ_15_13">826,287</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_3_31_2021_iSci5KSdxkuiCG7kJ4B7Rg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_sAh60NVwkkSKNVDF0Gh03Q_15_16">228,690</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income for the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9yyiJreoCU29ZtH9tBKNqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_cLeZG7C2gEmEAuJpqPUi5w_16_13">399,468</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_PsVU-SR-6UC-ddeHMSDhwQ_16_16">399,468</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30Oj847Y4U66T9RvHLydUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_K2xW6n9cP0q8eFwkE8CDUA_17_10">6,942</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_fKlyriJVk06-nT9WG-f0kQ_17_16">6,942</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of ordinary shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_n5VMj450zkee7mlTk2m1KA_18_1">61,845</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_WTwwDJUpmECNZX_Wc3s3kw_18_4">3</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_axABhO3W6UGp87WAJu9rUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_mNhNQQRWb0KaKZHtJb8G7g_18_7">1,862</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_9XgzYHWkLUilOLfxc43cfg_18_16">1,865</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax benefit past share issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_axABhO3W6UGp87WAJu9rUA" decimals="-3" format="ixt:numdotdecimal" name="qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" scale="3" id="Tc_mzdCcG8XrkqlIlT2pd5diA_19_7">2,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" scale="3" id="Tc_IML8jbGqUEy7mxSbu4HDZQ_19_16">2,977</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of share options </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_04XMNbg_NkuDWMv3C7WMXQ_20_1">55,194</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Zzcj-d0vJ0qErdWeduyviw_20_4">4</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_axABhO3W6UGp87WAJu9rUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_qzmTIo3yzUWOCyB_0y1q4A_20_7">515</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_7MgRNr5dCUGQfVqyJPvQvA_20_16">519</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted share units distributed during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" id="Tc_uhk2Wiw1ukiO3_OWfBf5rg_21_1">8,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="Tc_wJH1hiWqOU-YYqdWNsSmUw_21_4">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_axABhO3W6UGp87WAJu9rUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" sign="-" scale="3" id="Tc__XpdBoMx7kaHk9MXTlYLlA_21_7">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_axABhO3W6UGp87WAJu9rUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_GmCFY2eFrk2Q-6qHB1RzoA_22_7">7,031</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_lm6pZ3j7_0CLTgUT8iOhBA_22_16">7,031</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_mgfIVNyUyFz4VtwWRMFw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_JzM3Bkhl20qFu_zjaTEFYw_23_1">46,050,250</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_mgfIVNyUyFz4VtwWRMFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_w-G19QMACEqgrlgJMB2HsQ_23_4">2,788</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NCAjWMQk0EWYAF5NG6CWtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_TT9KGMTk2EGDt3GjEGHhug_23_7">1,062,234</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2hvGL0bx6EimerX1R8EITw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_KT9JDNZRsEOFigjTJ4L6Bw_23_10">4,595</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S1XNLHXDj0CmAF9NqjS7Pg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_LK7-0EPP3kKaqxU65qNiBQ_23_13">426,819</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-nSef5sdCECPFxJOr35BRQ_23_16">633,608</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">uniQure N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">UNAUDITED CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">FOR THE SIX-MONTH PERIOD ENDED JUNE 30</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_970ed64f_5805_4610_a316_c9d99aacbf98"></a><a id="Tc_VGaDBG6wrEeCiRpKweVA_w_1_9"></a><a id="Tc_lg7EmK9Ca0yz2hGQBxn00Q_2_6"></a><a id="Tc_2qicSu191kuLQyO-IHF_1Q_2_9"></a><a id="Tc_QT9rXWhxCEGpViQW0izaXw_2_15"></a><a id="Tc_0hlarZEojkOGdNgipx3eZQ_3_1"></a><a id="Tc_YyF3K3aUTEWydVz6dOeOTw_3_6"></a><a id="Tc_CnmGWNf_9EetYGf_yC9P1A_3_9"></a><a id="Tc_vMkujJ8xh0WYmGxBgAraPQ_3_12"></a><a id="Tc_yrzZLi_x5kSBMIDZmeyIPw_3_15"></a><a id="Tc_hMBsMz1yrUun0s5II70Irw_4_1"></a><a id="Tc_FBTgobt43UeOOjDxIxiUyQ_4_3"></a><a id="Tc_NyGJ8qOBjES2Tk751CcpdA_4_6"></a><a id="Tc_yCkGXprFtUiPkK0oAXq2hQ_4_9"></a><a id="Tc_O-ucxLh390eIUFnJRZhVmA_4_12"></a><a id="Tc_jJI1XTiF20uKGZ1tIv1kQA_4_15"></a><a id="Tc__JG4yfTHmE2gz-teez3LKg_5_1"></a><a id="Tc_90yYOruirECPXs_QG51oJA_6_0"></a><a id="Tc_Tz_m1Eg2Bk-GE-J2eTJXvQ_6_3"></a><a id="Tc_CHaAH6hOn0e6h2yTiHieiA_6_6"></a><a id="Tc_seL5SutvekyyuXdn24ezVA_6_9"></a><a id="Tc_nzmVkAYfX0yH2hqkCS9NNw_6_12"></a><a id="Tc_BKJO4l4MPEuVE6e3_CrhfA_6_15"></a><a id="Tc_F0wroqvCBEyPdWNizTdf-Q_7_0"></a><a id="Tc_dqYibrX6a0-o0n2GkT8dUQ_7_1"></a><a id="Tc_eWYubSohM0SO7B_7beZX9g_7_4"></a><a id="Tc_kh3S5M8c5Uugs6wgWwHFzQ_7_7"></a><a id="Tc_0Km2WGDKuUibqfkOPuGUbQ_7_10"></a><a id="Tc_eVrvGFIOqUaRrgMePymJXA_8_0"></a><a id="Tc_OX5VycvEGEmAKeQPU4Kwfg_8_1"></a><a id="Tc_bsyWuWrbP0qUcZUh11r5tQ_8_4"></a><a id="Tc_nbuBPvaWQUaHHh7ePqlZcQ_8_7"></a><a id="Tc_1LfZu2katkeDVhVhr9krcg_8_13"></a><a id="Tc_klKeIFf1H02Flq8w9a6GfA_9_0"></a><a id="Tc_KOx-7yWY9Eu0v7A8l5Dxjg_9_10"></a><a id="Tc_l1mpmoCoYEW4hnWgFz5hAw_9_13"></a><a id="Tc_mtfPndV0VUGtPD7e2Ocbbw_10_0"></a><a id="Tc_5fcNrfsULEWIiImY-hCcsw_10_10"></a><a id="Tc_HUJV3jRNMkSN-59ocn66cw_10_13"></a><a id="Tc_O6lJNWyxzUKLX8_xKkN0Zg_10_16"></a><a id="Tc_ntm_J9QKFUa_MCJA_JV4zQ_11_0"></a><a id="Tc_BTcvtQnPEEaCiG6Phwlkig_11_1"></a><a id="Tc_fFgGvV9mTEaoOqF_Wecv7A_11_4"></a><a id="Tc_YQEVRQZI-U-W4-j1MovQbQ_11_10"></a><a id="Tc_07omWj-FGkuTQiBddAjZxA_11_13"></a><a id="Tc_9UgzdvLow02R4hhO5hvBxQ_12_0"></a><a id="Tc_KSzxlwmGTUWwdj6F_iDSgg_12_4"></a><a id="Tc_Tg3zB4OF10qP0Lhpntd_lw_12_10"></a><a id="Tc_jyYNban8AEacm8HUKiadIw_12_13"></a><a id="Tc_ccum2QX0KUiMlsIatKObTg_13_0"></a><a id="Tc_i7tX2XxKOECAVZ0D90PMKQ_13_3"></a><a id="Tc_zPbwytGhDE6dFheKAYYF8w_13_6"></a><a id="Tc__iuWspF-KkqD4rgcKEjh0w_13_9"></a><a id="Tc_jr3zuAEyG0mBp6kGhfqKJg_13_12"></a><a id="Tc_7PL93vdloE22U2ToNFK2Xw_13_15"></a><a id="Tc_uFrzp4_Ff0mlfA4vHbJ1JQ_15_0"></a><a id="Tc_2WhJXGxIJ0K1fQnBOAEMeA_15_3"></a><a id="Tc_GF-XKZsHAUmqUDgUhmpEmg_15_6"></a><a id="Tc_878-bTnu-kKh2hv2O-T53w_15_9"></a><a id="Tc_mRvXXRzpC0GAfa9A6r_6Qg_15_12"></a><a id="Tc_G1fX61R5c0ONzVX29Wp1Dw_15_15"></a><a id="Tc_XONohXHbBUq7_lwfQIlD8Q_16_0"></a><a id="Tc_2w7h3QvEpUeO-1b3GlBg6A_16_1"></a><a id="Tc_juOmdN_raEmopA3xR5pPew_16_4"></a><a id="Tc_PoFT78Prl06auHdK4IJKSw_16_7"></a><a id="Tc_AlSbqJwN1U6FwXEsDF2xaw_16_10"></a><a id="Tc_vPNl7S0GoU2KlHRThhaEeg_17_0"></a><a id="Tc_6W3oC6jLZEefvhThZs8Bzw_17_1"></a><a id="Tc_45zP0mDr9kWCkb0mM35NBQ_17_4"></a><a id="Tc_ehxZJZHps0q6XGCOeQ2tYA_17_7"></a><a id="Tc_kaXQvRmTXUa9LeJS0ErBaA_17_13"></a><a id="Tc_NmWRX_TplEKaQk6sLNz8YA_18_0"></a><a id="Tc__II6HWvfc0O6TZftcrRGnA_18_10"></a><a id="Tc_h0nk5eeCWUWq3DYMOD8_8w_18_13"></a><a id="Tc_BrNOkwZxLEOck3n-dxDGSg_19_0"></a><a id="Tc_Buh3Tdfu302nykVQPDyQUw_19_1"></a><a id="Tc_Ji_-_5lFRESP3pJDtjSqGw_19_4"></a><a id="Tc_qvaICLjnxkmQP0hmaQdaug_19_10"></a><a id="Tc_ZH9ZDvz1mk2lPwyyeUecxQ_19_13"></a><a id="Tc_ioD3cjHVvkuI8kp8X2YrXw_20_0"></a><a id="Tc_3ISnMySziU6ykabni9gSUw_20_10"></a><a id="Tc_KTq6TOdMbEK65GKEkjCh3A_20_13"></a><a id="Tc_sjMtF1QbZUG7ykk5VTxpDw_21_0"></a><a id="Tc_bnCcW4GsBkKR_s_5RtveGA_21_10"></a><a id="Tc_ej-9HoWPE0uJa4TqvPYjzg_21_13"></a><a id="Tc_s0hParp3QEGB4fgyz_Hbrg_21_16"></a><a id="Tc_g1BiKj5zNEi4fYwREfCBIg_22_0"></a><a id="Tc_yAhWiMh5b0CiQdLFQqbaaw_22_1"></a><a id="Tc_4gU0NLecR0yz21Uuj46j6g_22_4"></a><a id="Tc_qgUtdQvxpUq29cF-uN2rRw_22_10"></a><a id="Tc_QmyuE3B7qEqbgW-rCiAqUg_22_13"></a><a id="Tc_cuJAEnWS8UaAWcNElVfABQ_23_0"></a><a id="Tc_Z6I1lzH6zEC4CtZq62pbPA_23_4"></a><a id="Tc_Sl_0EHZL-UCzekIXI5rxCg_23_10"></a><a id="Tc_fNyB6TPCKUmjzMVVv-kUGg_23_13"></a><a id="Tc_1a61WQzPVkqp3xE0pS5VxQ_24_0"></a><a id="Tc_Wt7fOP3u1EGMWcvSy4JYkg_24_3"></a><a id="Tc_Sx02cFhw0USH5ZeOzY49Tg_24_6"></a><a id="Tc_iEnVLNFfDkuwpEWyRqucOg_24_9"></a><a id="Tc_3lsMtJYDCEemGeLg9hyjoA_24_12"></a><a id="Tc_XI6jNdYtvUC1z36kB-kZYA_24_15"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shareholders&#8217;</b></p></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">No.&#160;of&#160;shares&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital&#160;&#160;&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equity</b></p></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cZati_nTb0C-UhhIBOUNCQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_PFosCwaa-kyVJoxzwM5YpQ_6_1">43,711,954</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cZati_nTb0C-UhhIBOUNCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kVQNGjUyGE63s0dZ97xWYQ_6_4">2,651</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FiR-EdjoaE-NUqcozk-aQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0clO6YQVeUikrivAwn-I8w_6_7">986,803</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8TmbfDxKjUKS_aB_XtU_QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_dVKfy7t6HUKBkJkD1hAvXA_6_10">6,689</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XjeHbyUls0C0C2A5C4oucw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_JCpJHTB5PUKKRZTCD036kg_6_13">659,707</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2019_VrVcTXdK_ka4cFP6BumMkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_zigJKVpgGkapNZl9nmd0Fw_6_16">323,058</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XYYm-Buu4ECheKCzyils-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_ckjzdAvNH0q5RvyzHhM-Ng_7_13">70,550</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_-bEPV5Jui0e5OFFgNCtdjw_7_16">70,550</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FyQ6c103BEGWytFVswbKFQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_U-DuKH1L_0OuBd9MTUOvqA_8_10">630</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_hVb5Bj1zSE-RNU4ue0ulbQ_8_16">630</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of share options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LAamd-jnaESPNk8ZipEekg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc__Ow7-1mLEEGyh0ko2Qfpjg_9_1">203,940</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LAamd-jnaESPNk8ZipEekg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_mxi8-Dp2BkSWXRWihz4obw_9_4">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dR853wdTkmYUidJM4e8Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_-LLfj-S26kiHbiAj3ibxfA_9_7">3,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_MZfratVIakm3LLmTjdZa4g_9_16">3,402</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted and performance share units distributed during the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LAamd-jnaESPNk8ZipEekg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" id="Tc_PgGkthpIbU6BANwVX0gBOA_10_1">525,506</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LAamd-jnaESPNk8ZipEekg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="Tc_DhgE7m9RXkOxQHD_vK6YHQ_10_4">29</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dR853wdTkmYUidJM4e8Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" sign="-" scale="3" id="Tc_jhVM-Ei0OkG00rtzK95MBQ_10_7">29</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dR853wdTkmYUidJM4e8Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_wuSlLJvqyUumLMVAGa6t1Q_11_7">10,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_k3YCfITWRU2pl2gAVx6tdA_11_16">10,078</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of ordinary shares relating to employee stock purchase plan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LAamd-jnaESPNk8ZipEekg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_kqf3PvxyZkyv5RUjc8FxRw_12_1">3,005</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dR853wdTkmYUidJM4e8Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_E_-e2C17HEy8dCVWjKB-8w_12_7">147</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_Ewvz_TYnLEuXwMfBJRdpew_12_16">147</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v-LvwFQXTU-mEhIgrrFYHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_ubnQXPxNI06Jp9-0uxdHGg_13_1">44,444,405</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v-LvwFQXTU-mEhIgrrFYHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XnbRPX35D0WULj_i0nZIxw_13_4">2,692</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tqrT9yrb-06NxeDkwo4JTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YvYIb5GzmkuyGOLyze2Y3g_13_7">1,000,389</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_98hRD2QNWkGhe45TCCi4eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_HAE27zzjx0KRXkb7n-ewNw_13_10">7,319</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0D6WZbsJ9EyfBMQ5KfZThg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_GCNG3_d8S0iDSRMbBrMygw_13_13">730,257</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XwYe2ddzLUKaWJCrVa9Zgg_13_16">265,505</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_12u06vcwokqbZ_3H5sstHw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_4EUx94J1qEy2blhJOXUWiw_15_1">44,777,799</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_12u06vcwokqbZ_3H5sstHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9TqZNI2CyEGWw6Ua-sCJPg_15_4">2,711</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AJilnv7U0UKS6Pd__e9ntw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_mqYKnR9hJEmQ5GEtdYALBQ_15_7">1,016,018</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5Zz24Wjw0WmLw7GH5paxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VfI62c7LpE-Lv6mUSdTzjw_15_10">9,907</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OjQYcvlwLk6FKuTEnO6ixQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ADiIr99On0Wr99pswrgYjg_15_13">784,731</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_piObmh_7PEmoLPTXTumuMg_15_16">243,905</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income for the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rsNhF5HivUKK-feAZQNJXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_ARLZpAy5C0CozMyqW7G1Cg_16_13">357,912</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_X2VQ_4mzwkO6e91nbnwfog_16_16">357,912</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v04H0tAAR0aK-7lS6pBkDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_B2NimSkTXUSe8bTtEA4AFQ_17_10">14,502</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc__x1ZQIOvI062wCYtvDAYtw_17_16">14,502</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of ordinary shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_oQU2KjuAKEaKyUNWFAbf9Q_18_1">921,730</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_QkpzLSqmw0W-oqytqAM0GA_18_4">55</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_uEiumcHEFU69ztiD5dXYRw_18_7">29,509</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_b1JssXak6kubiEeW5_ncQQ_18_16">29,564</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax benefit past share issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg" decimals="-3" format="ixt:numdotdecimal" name="qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" scale="3" id="Tc_ZR1um7QGkEWd8aTm0kpSQQ_19_7">2,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" scale="3" id="Tc_Qs5WXkLzyEaX-f6PhZWSzQ_19_16">2,977</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of share options </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_izHvm9CaL06UVfWxQracVw_20_1">71,976</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_trJKZWAvWkWi4qKzgUKr6w_20_4">5</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Rbu77uRpvkyJTq73vD1y5A_20_7">906</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Up3hciRT-EaUeD1g3H3_iw_20_16">911</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted and performance share units distributed during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" id="Tc_uQLUhQP6ikyadNi-pJovog_21_1">277,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="Tc_IQ-sy-D7kEaqDvYeahUFVg_21_4">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" sign="-" scale="3" id="Tc_-hn3_8O6ZUOMJIEfYQW16g_21_7">17</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_4ZSJPUNEPk6NpZYe1tN40w_22_7">12,792</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_T5OHl91R4kSiAa3q0ukM4w_22_16">12,792</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of ordinary shares relating to employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_vKBI7Zg8AUWMzVkSj0tg0Q_23_1">1,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_CBGasfpkDE684MXkXql1WQ_23_7">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_udFx18BMO0O28E6itDY7LQ_23_16">49</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_mgfIVNyUyFz4VtwWRMFw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_c6nBvrfmYUu01IZ6R4sIAw_24_1">46,050,250</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_mgfIVNyUyFz4VtwWRMFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RtP52KOExUiMHTBvS2V3Vw_24_4">2,788</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NCAjWMQk0EWYAF5NG6CWtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8CpfDL2W_EKgk49PcNDInQ_24_7">1,062,234</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2hvGL0bx6EimerX1R8EITw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_i5xT-Ywz40qLWEZeNWRKSw_24_10">4,595</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S1XNLHXDj0CmAF9NqjS7Pg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_0jfbwmaDMEasT2ewZFWlXw_24_13">426,819</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ORTMEz9mc0Ke7ze3mP6HvQ_24_16">633,608</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">uniQure N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_9b2e2426_e9a0_42df_a5bb_9dac0367a91c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_67518a86_09b4_4d4a_bf2b_8183b3f7edc1"></a><a id="_67176536_7c16_4414_8192_44038961c9fc"></a><a id="_23646850_12cd_4d2a_bb77_8f60c35130ab"></a><a id="_6bbb113a_74f5_461c_af57_7a2b6879438c"></a><a id="_5fa140ea_0c70_4f18_a47d_5c0ed326d306"></a><a id="_0d5869f5_5d40_4edf_bf65_fe1b97b7a0f8"></a><a id="_2edcee50_ec6e_4b0a_8bce_c7da30911442"></a><a id="_b6972926_8a2b_4497_88b3_4dede9011062"></a><a id="_b0c45d3f_647b_4870_bffb_7eaee0bfee11"></a><a id="Tc_ZNkLCxWT4E-3zzkuldwBZQ_1_2"></a><a id="_633f5f78_1ce9_4e54_afbe_3a5e0569b58a"></a><a id="Tc_wlmyOSMHdECvrJEUdCYD7A_2_2"></a><a id="Tc_wng7hPxmtE6bYfrK6jgOsA_2_5"></a><a id="_bd84daca_acd3_4637_befa_6a2f378ca88f"></a><a id="Tc_-xz_gpUu40a1aouef7Wtbw_3_3"></a><a id="_e4272f15_74cd_42c2_8c27_f042535b9d31"></a><a id="Tc_3rxFP-fkvkynfIZeghvbJg_4_0"></a><a id="_da599ab2_ffe1_4416_a26e_0dd763729162"></a><a id="Tc_vzh2fvFnoEaGf6ptSNJieg_5_0"></a><a id="Tc_8SDtnbuuekeiYIWDvptKew_5_2"></a><a id="Tc_L1ypIok4KE-ctJ9DNHGjtg_5_5"></a><a id="_600ab878_e218_4e7b_a438_d7c2716e1467"></a><a id="Tc_dnzdrEZxLE-8vLasr5-mtQ_6_0"></a><a id="_92a479a9_68be_49c5_997a_cba31d409a90"></a><a id="Tc_f1cND9TQvUe6aZcA4e8DSQ_7_0"></a><a id="_d1bb8a70_2c5e_449e_af56_fc6ccd0364de"></a><a id="Tc_d2W-T4ekbE-vajeiUfe2TQ_8_0"></a><a id="_ad083579_8d62_4594_ad8f_9707c6b8e5a0"></a><a id="Tc_ayqocleyI0WHhFKpKRD6XA_9_0"></a><a id="Tc_1Xzo6dLe_0mqQYDxo3E4Qg_9_3"></a><a id="_edfd629d_f295_4f25_8439_225ebf27c8fe"></a><a id="Tc_VT2DTvcFdkqYiiaKju1Mpg_10_0"></a><a id="_fdabf019_beae_4b8d_b85a_346dcebb3137"></a><a id="Tc_dzFUPlvb2Uym6XxmvtWJRQ_11_0"></a><a id="_623d968c_bd84_4785_80d4_297aa44a93fd"></a><a id="Tc_6cJnBNoE3EWgyOicuVvBUw_12_0"></a><a id="_48cd0ee8_68a2_40a0_8f6b_0b01b707ffe1"></a><a id="Tc__TiTU_6p-U-okzE1vFO9kQ_13_0"></a><a id="_ab9d5069_b56e_4d60_9c93_77a5f130d96f"></a><a id="Tc_XmRAXK-F30qtTwkj_HNRNA_14_0"></a><a id="_cb240d33_80cb_4be9_90ee_0b059745e2bc"></a><a id="Tc_kyUemjbDL0G6J0kqz0QQ5Q_15_0"></a><a id="_ff30dd77_4942_4b79_86d3_52da596511eb"></a><a id="Tc_u_vuHdK6CEejcokt-fMDUg_16_0"></a><a id="_0b0a24a9_d219_4201_95c6_5a58b19e7385"></a><a id="Tc_uRasOQJUu0yiN-X3RLfAtw_17_0"></a><a id="_af4bc421_6d61_4026_a58d_d1074b5087ea"></a><a id="Tc_H3OH1zI8IkasMReinfv1Fg_18_0"></a><a id="Tc_LoboYELOYESjqG6Oyf9aQw_18_3"></a><a id="_3f0129c8_07b7_4242_936c_ec21e53a6746"></a><a id="Tc_wRK1J8jGSEyScJO9h1JX1Q_19_0"></a><a id="_f635bd1a_b810_46ff_b624_1ab0feb85ede"></a><a id="Tc_E0c2LpqJ9k6BMxx5v77k7Q_20_0"></a><a id="_de512127_f662_4bbe_ab04_423e961ea8a8"></a><a id="Tc_mTAg-W_NeEaAbEugzvY39w_21_0"></a><a id="_9953328a_11ae_4e74_b964_6b5b33735276"></a><a id="Tc_-hrCyqPJ2UiaI6WZbmH_7g_22_0"></a><a id="Tc_a5gZT9-D8U--1HzOnQkj0A_22_6"></a><a id="_cb90b35c_a3d1_4b94_890c_c3af19b76061"></a><a id="Tc_5Xd17Fua9EiiEPY3wLbwxg_23_0"></a><a id="Tc_wNUe0I5L-ki7xnXzaj42HQ_23_6"></a><a id="_9be93445_8ce2_45ec_b5ae_62117e122140"></a><a id="Tc_1X4D8PsT70O-3XDiSW2crQ_24_0"></a><a id="Tc_LS2a_KUpO0m6gDMfCH3P2Q_24_6"></a><a id="_2933c12f_0c2f_4b0f_8ae9_4215b4230f68"></a><a id="Tc_14foBpCmZUqAZw3AHWa_5g_25_0"></a><a id="_c9287631_064b_4fc0_81ce_84c5c159d40b"></a><a id="Tc_EPmNT-ngEk60PT5JL6NuZw_26_0"></a><a id="_35e0d41a_99d6_4bdf_943b_a6fe5618d278"></a><a id="Tc_SRIrd64vPkau4xgtpISasA_27_0"></a><a id="_fad1d036_9f91_42da_96f7_4e8dd9a12dc1"></a><a id="Tc_2XjQ8IVw_02Fe83uPaoICQ_28_0"></a><a id="_f9844cdc_bb3d_467c_88bf_c30008d139be"></a><a id="_562c3993_3efc_4a6f_9fc9_08105825fdb4"></a><a id="_f8b1f425_b634_41f6_af52_50335e3fc0d9"></a><a id="Tc_wlRZFI6QtkqW8hNvLAeIOA_29_0"></a><a id="_9a39abaa_cec1_4d1a_8e8a_cc53b1661fd5"></a><a id="Tc_flUxvZPizk-HuweDZUVyxQ_30_0"></a><a id="Tc_pIYrOP6aYEmcK8rlc8WIfQ_30_2"></a><a id="Tc_MOF2tWDmVEGh6b_2MjrswA_30_5"></a><a id="_afa42e55_ecb8_4c05_aec5_d737dc595798"></a><a id="Tc_e5mJnW2UpEWT2LSIQ0pTdw_31_0"></a><a id="Tc_S_I9dvGOi0m_o7H-7IFxxw_31_2"></a><a id="Tc_8HI0BrbpDkuuwrVdXciMAg_31_5"></a><a id="_7ed68202_c6ab_4d8d_87ba_8a47c8b0c124"></a><a id="Tc_ooeZIztCIEKXQoy3kmiVyA_32_0"></a><a id="_0d362b86_0232_4607_8fad_1e2b1030e6ad"></a><a id="Tc_GBG2qiFIsEmwIs5BqnfjxQ_33_0"></a><a id="Tc_2QIhVcwCz0mlTMji5tObEQ_33_2"></a><a id="Tc_afTfAioQw0WKmAnH1GV8Cw_33_5"></a><a id="_e9d19acd_af4d_4a93_b067_da07edea5348"></a><a id="Tc_OGCaDecxwECUm2qGNWnoSQ_34_0"></a><a id="_6db0f76c_6ea3_4492_a238_f89250a1267c"></a><a id="Tc_VHNS0jKzDECHXmnsI1693w_35_0"></a><a id="Tc_LCrVVAAOeECWYtp2aerUQg_35_2"></a><a id="Tc_SLaAYvcwq0y2e7x_qxs8kA_35_5"></a><a id="_528d9f69_892d_4edd_9e31_21f983b47c01"></a><a id="Tc_RGp_wRTje0KFsdyc7WTXJA_36_0"></a><a id="Tc_Wj0jBK5QLkSaw5ipm0r_Dg_36_2"></a><a id="Tc_y1pdCV1Lwk6tFO7olTBEWQ_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income / (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_Li5n9BqvT0-_BRau1jxeOA_5_3">357,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_5L6JZfwtLEm6vogX8u5JUQ_5_6">70,550</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net income / (loss) to net cash generated from / used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_uF8qnJkUX0yGDfSxbiL1Wg_7_3">3,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_j8oHb2C-GkiBbXjv858h5Q_7_6">3,505</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_DL6uAzLkbEeP7-W8jMw_5w_8_3">12,792</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Nj5hW0sqv0ylVE9x49L7KQ_8_6">10,078</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of derivative financial instruments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="qure:ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration" sign="-" scale="3" id="Tc_ZOSM57BQ_k6gNmzt4ct6AA_9_6">2,206</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized foreign exchange gains, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_qLw51KjaL0OxPpjuWeRSEg_10_3">12,279</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_8fsbkZ-ZQ0q26g3lNfYZjw_10_6">908</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other non-cash items, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_i4_l5IpeoUu_cf5ROivffQ_11_3">539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="Tc_cd2j11KVQkSn0UbgjT5mig_11_6">1,600</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in operating assets and liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts receivable, prepaid expenses, and other current assets and receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="qure:IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets" scale="3" id="Tc_BXtafurKzkyujAjYaM1XNw_13_3">3,355</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="qure:IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets" sign="-" scale="3" id="Tc_mUg8N3Z-NkSBlaaSvHzz1A_13_6">1,050</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_MIYDWk4YHUu_z-Kh2CJgBA_14_3">10,444</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_XjbDYmAr_UG6oOexP73yYg_14_6">981</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses, other liabilities, and operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_jsZG9ohjyk61Fh3XIDGVfg_15_3">5,486</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" sign="-" scale="3" id="Tc_wQXDHuVVT0u538uO6VyWIQ_15_6">1,332</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash generated from / (used) in operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_Ke-c7v8GVEm1Ajwe3Ft-DA_16_3">375,206</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_BHgIMYj_m0u6uzqutu7eoA_16_6">62,944</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of intangible assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_lshGgITxDkSAvLuDkZeWGA_18_6">2,214</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of property, plant, and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_qpaPdQf1PkuvnM39Ye9Zpw_19_3">6,191</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_KeuDvlo2u0issf-wEsUIeA_19_6">2,392</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_0SkbFRVOMESXsOFyi5ZYYQ_20_3">6,191</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Y63evr950UaCTeILyuEOIw_20_6">4,606</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from loan increment, net of debt issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="Tc_ZqUKueI90km2wQz90fyctA_22_3">34,603</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Tc_h-BP93NtNUaIttjH3I4CsQ_23_3">30,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuance costs from issuance of ordinary shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_SzzbOrZzEkqhvxInXnIluQ_24_3">1,334</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of ordinary shares related to employee stock option and purchase plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_ymUl5BCdO0-8pjiEWjvfsw_25_3">960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_3JvXgktU80SCprt9_oJEDg_25_6">3,549</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash generated from financing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_kkvVjF97AUy5QCeovpzg2w_26_3">65,128</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_IQH2BiT56Ey66MoYshlQYA_26_6">3,549</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Currency effect on cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc__DNDvwlmqkeFAOK2FzUyww_27_3">1,665</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_qVZ_4eureU-LqvBb4So75A_27_6">223</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase / (decrease) in cash, cash equivalents and restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_sjPlSKXXzUC9wP62_MASVg_28_3">432,478</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_wjI3ClEpIUa9Zu7S9mtqdw_28_6">63,778</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_syEZ2Y_8Uk6XWich0skGEw_29_3">247,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2019_VrVcTXdK_ka4cFP6BumMkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_nVSqQB4PUUKhTPNeyWPOlw_29_6">380,726</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash, cash equivalents and restricted cash at the end of period</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_J2hibDdEOkSXhyqXftesAA_30_3">680,158</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_OxPiL86AAkiNhNLPu7C4wQ_30_6">316,948</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_Jtm2ecuieEiXpR0WGkSuAQ_31_3">677,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc__wxWesMwMkubyiAMcSLj6w_31_6">314,265</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash related to leasehold and other deposits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_HMXFWpWRd0eKABFjjkkhOg_32_3">2,828</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_A5K6ngKgSEO9ReB8fUitjg_32_6">2,683</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_iEBI4IQOMEaumid1MWRTQw_33_3">680,158</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_qpAZA6f3pkSbN1xoRxCHjQ_33_6">316,948</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental cash flow disclosures:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_5du6LkAIYECGGrz2eAyANg_35_3">2,943</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_7o0H2NM9KUa9wJOUCUbr9w_35_6">2,545</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-cash increase in accounts payables and accrued expenses and other current liabilities related to purchases of intangible assets and property, plant, and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="qure:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets" scale="3" id="Tc_R5CYImwdkEq9_HFgu05ryw_36_3">3,488</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="qure:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets" scale="3" id="Tc_1vsJqyjP2EOpaEk1IW6cVg_36_6">1,021</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:NatureOfOperations" id="Tb_8Mq9JAvxNUGDEmt_SZS5iQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">1</b></span>General business information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">uniQure (the &#8220;Company&#8221;) was incorporated on January 9, 2012 as a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company&#8217;s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics (AMT) Holding N.V (&#8220;AMT&#8221;). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability (<i style="font-style:italic;">naamloze vennootschap</i>) and changed its legal name from uniQure B.V. to uniQure N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 1pt 0pt 1pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is registered in the trade register of the Chamber of Commerce (<i style="font-style:italic;">Kamer van Koophandel</i>) in Amsterdam, the Netherlands under number 54385229. The Company&#8217;s headquarters are in Amsterdam, the Netherlands, and its registered office is located at Paasheuvelweg 25, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol &#8220;QURE&#8221;.</p></ix:nonNumeric><a id="_Hlk494779513"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_ov7bFuILcES7CDVeW4rKTg" continuedAt="Tb_ov7bFuILcES7CDVeW4rKTg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">2</b></span>Summary of significant accounting policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_JWe1WRCcZ0SJ_XKymTLfMw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.1</b></span><b style="font-weight:bold;">Basis of preparation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company prepared these unaudited consolidated financial statements in compliance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The unaudited consolidated financial statements are presented in U.S. dollars, except where otherwise indicated. Transactions denominated in currencies other than U.S. dollars are presented in the transaction currency with the U.S. dollar amount included in parenthesis, converted at the foreign exchange rate as of the transaction date.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="qure:UnauditedInterimFinancialInformationPolicyTextBlock" id="Tb_iskgUAyBbkaW6qT3fxkfww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.2</b></span><b style="font-weight:bold;">Unaudited interim financial information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the financial position, results of operations and changes in financial position for the period presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. The results of operations for the six months ended June 30, 2021, are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or for any other future year or interim period. The accompanying financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company&#8217;s <a style="-sec-extract:exhibit;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021</span></a>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:UseOfEstimates" id="Tb_ONLnhHa8r02K-T35tTv28Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.3</b></span><b style="font-weight:bold;">Use of estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ov7bFuILcES7CDVeW4rKTg_cont1"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_swB95WXlqUikie1EYGRMpA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.4</b></span><b style="font-weight:bold;">Accounting policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">      The principal accounting policies applied in the preparation of these unaudited consolidated financial statements are described in the Company&#8217;s audited financial statements as of and for the year ended December 31, 2020, and the notes thereto, which are included in the Company&#8217;s </span><a style="-sec-extract:exhibit;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021</span></a>. There have been no material changes in the Company&#8217;s significant accounting policies during the six months ended June 30, 2021 except as noted below. <span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company determined its revenue recognition policies related to the CSL Behring Agreement (defined below) when the CSL Behring Agreement became fully effective on May 6, 2021. Refer to Note 3 (&#8220;Collaboration arrangements and concentration of credit risk&#8221;) for further detail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;"> </span>The Company for the first time recognized net income in the three and six months ended June 30, 2021. Net income / (loss) per ordinary share was calculated in accordance with ASC 260, Earnings Per Share. Refer to Note 11 (&#8220;Basic and diluted earnings per share&#8221;) for further detail. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_hTZv9IMilE6KxAcSQdE_fA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.5</b></span><b style="font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There have been no new accounting pronouncements or changes to accounting pronouncements during the six months ended June 30, 2021, as compared to the recent accounting pronouncements described in Note 2.3.22 of the Company&#8217;s <a style="-sec-extract:exhibit;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Annual Report on Form 10-K for the year ended December 31, 2020</span></a>, which could be expected to materially impact the Company&#8217;s unaudited consolidated financial statements. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_Hlk46324852"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="qure:CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock" id="Tb_7yLf5xGe50Gnvor6-vOMnA" continuedAt="Tb_7yLf5xGe50Gnvor6-vOMnA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Collaboration arrangements and concentration of credit risk</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">CSL Behring collaboration</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June 24, 2020, (&#8220;Signing&#8221;), uniQure biopharma B.V., a wholly-owned subsidiary of uniQure N.V., entered into a commercialization and license agreement (the &#8220;CSL Behring Agreement&#8221;) with CSL Behring LLC, (&#8220;CSL Behring&#8221;), pursuant to which CSL Behring received exclusive global rights to etranacogene dezaparvovec, the Company&#8217;s investigational gene therapy for patients with hemophilia B, (the &#8220;Product&#8221;). On May 6, 2021, the CSL Behring Agreement became fully effective (&#8220;Closing&#8221;) upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on May 5, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the CSL Behring Agreement, the Company has received a $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_6_24_2020_To_6_24_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_Ll8fzwuH2kqanQly9paw0w" decimals="-5" format="ixt:numdotdecimal" name="qure:UpfrontCashToReceiveUponClosingOfAgreement" scale="6" id="Narr_qeBq5bewL0WaqIoDJ0vOZA">450.0</ix:nonFraction> million upfront cash payment and $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_6_24_2021_To_6_24_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_BpZu_RynUUeTx_oJ_rCgLA" decimals="-5" format="ixt:numdotdecimal" name="qure:CollaborationAgreementOtherPaymentsReceived" scale="6" id="Narr_Qd9v3K_CDk6nOM-54nkMCw">12.4</ix:nonFraction> million in other payments related to the transfer of the license, during the three and six months ended June 30, 2021. The Company is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_24_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_qg5NvBFGdUO4WsF-xZGEIA" decimals="-8" format="ixt:numdotdecimal" name="qure:RegulatoryAndCommercialMilestonePaymentsReceivable" scale="9" id="Narr_j455ffqOAUO-hx4syerFtw">1.6</ix:nonFraction> billion in additional payments based on regulatory and commercial milestones. The CSL Behring Agreement also provides that the Company will be eligible to receive tiered double-digit royalties in a range of up to a low-twenties percent of net sales of the Product based on sales thresholds. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt;">On Signing, the Company and CSL Behring entered into a development and commercial supply agreement, pursuant to which, among other things, the Company will supply the Product to CSL Behring at an agreed-upon price commensurate with the stand-alone selling price (&#8220;SSP&#8221;). The Company will be responsible for supplying development and commercial Product until such time that these capabilities may be transferred to CSL Behring or a designated contract manufacturing organization. The Company will be completing the HOPE-B clinical trial and the validation of the manufacturing process on behalf of CSL Behring, as well as provide further development services if requested by CSL Behring. Activities related to on-demand development services as well as activities related to the completing the HOPE-B clinical trial will be reimbursed by CSL Behring at an agreed full-time-employee rate (&#8220;FTE-rate&#8221;) and CSL Behring will also reimburse agreed third-party expenses incurred in relation to performing these activities. The validation of the manufacturing process as well as the development and validation of a next generation manufacturing process (&#8220;Manufacturing Development Services&#8221;) will be reimbursed through a future milestone payment. If completed after certain contractually agreed dates, the milestone payment will be reduced in accordance with a contractually agreed mechanism.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that CSL Behring is a customer in accordance with Topic 606. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_7yLf5xGe50Gnvor6-vOMnA_cont1" continuedAt="Tb_7yLf5xGe50Gnvor6-vOMnA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company identified two material performance obligations related to the CSL Behring Agreement: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Sale of the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">exclusive global rights to the Product (&#8220;License&#8221;); and</span></td><td style="width:0.2pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Generate information to support the regulatory approval of the current and next generation manufacturing process of Product and to provide any such information generated to CSL Behring (&#8220;Manufacturing Development&#8221;).</span></td><td style="width:0.2pt;"></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">These performance obligations are considered distinct from one another, as CSL Behring can benefit from the identified service either on its own or together with other resources that are readily available to CSL Behring, and as the performance obligation is separately identifiable from other performance obligations in the CSL Behring Agreement. The Company continued to develop the Product between Signing and Closing and performed certain reimbursable activities to fulfill the transfer of the global rights (&#8220;Additional Covenants&#8221; and together with the License the &#8220;License Sale&#8221;). The Additional Covenants are not considered distinct from the performance obligation to sell the license to CSL Behring as CSL Behring could not benefit from the Additional Covenants on their own, or have these activities be performed with readily available resources. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">The Company determined that the fixed upfront payment of </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_6_24_2021_To_6_24_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_BpZu_RynUUeTx_oJ_rCgLA" decimals="-5" format="ixt:numdotdecimal" name="qure:UpfrontCashToReceiveUponClosingOfAgreement" scale="6" id="Narr_zLBWgS4wFkiRg8qGDeOzQA">450.0</ix:nonFraction></span><span style="background-color:#ffffff;"> million and the </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_6_24_2021_To_6_24_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_BpZu_RynUUeTx_oJ_rCgLA" decimals="-5" format="ixt:numdotdecimal" name="qure:CollaborationAgreementOtherPaymentsReceived" scale="6" id="Narr_Ug32I5hycUigE4BkUyw9eA">12.4</ix:nonFraction></span><span style="background-color:#ffffff;"> million that the Company received in relation to the Additional Covenants should be allocated to the License Sale. In addition, the Company concluded that variable milestone payments, sales milestone payments and royalties should be allocated to the License Sale performance obligation as well. The Company determined that the sale of the License was completed on May 6, 2021, when it transferred the License and CSL Behring assumed full responsibility for the development and commercialization of the Product. At Closing, the Company evaluated the amount of potential payments and the likelihood that the payments will be received. The Company utilized the most likely amount method to estimate the variable consideration to be included in the transaction price. Since the Company cannot control the achievement of regulatory and first commercial sales milestones, the Company concluded that the potential payments are constrained as of Closing. The Company determined that it will recognize revenue related to these payments only to the extent that it becomes probable that no significant reversal of recognized cumulative revenue will occur thereafter. The Company will include payments related to sales milestones in the transaction price when their achievement becomes probable, and it will include royalties on the sale of Product once these have been earned. The Company recognized </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_iR-v-TBnd0evOoVwhDOfvA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_UA10CTDvRkeGAFfR7pOrRQ"><ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_7HYeLAkKd06-2u6h39LYwg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_TKneex5G1EG1m_7KPEtK7g">462.4</ix:nonFraction></ix:nonFraction></span><span style="background-color:#ffffff;"> million of revenues related to the License Sale in the three and six months ended June 30, 2021. The costs associated with fulfilling this performance obligation are presented as &#8220;Cost of contract revenue&#8221; with the exception of the cost incurred prior to the Closing, which had been presented as &#8220;Research and development expenses</span>&#8221;. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;"><span style="background-color:#ffffff;">The Company determined that the variable milestone payment related to Manufacturing Development Services should be allocated to the Manufacturing Development performance obligation. The Company concluded that this milestone payment represents the SSP of the services based on the estimated cost of providing the services including a reasonable margin. The services related to Manufacturing Development will be provided between Closing and the completion of an agreed manufacturing development plan. The variable consideration will be reduced if the Company does not complete the development by pre-agreed dates. The Company utilized the most likely amount method to estimate the variable consideration to be included in the transaction price. Completion of Manufacturing Development is partially dependent on the timing of regulatory submissions by CSL Behring as well as regulatory approvals of the developed manufacturing processes. Since the Company cannot control the timing or outcome of any regulatory decisions, the Company concluded that it would recognize revenue related to this payment when it becomes probable that the milestone has been achieved. The Company did not recognize any revenue related to Manufacturing Development during the three and six months ended June 30, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_jB8MZBGsWEasEDd9-gnQoA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_CoQPzIbOlEuVv3QcFcvZLw">0.4</ix:nonFraction> million of collaboration revenue in the three and six months ended June 30, 2021, compared to <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_J6tdEUumu0qt9JK5Mqjr8Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_4jPSXZpSoU-KC-bhoDTkUA"><ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_-pQINOMXokKJREGZdwpa4A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_Cu_qPbqSiEuQbgLdce26wA">nil</ix:nonFraction></ix:nonFraction> in the same periods in the prior year. &#160;The Company generates such collaboration revenue from services rendered in relation to completing the HOPE-B clinical trial on behalf of CSL Behring. CSL Behring may request <span style="background-color:#ffffff;">additional development services or to request the Company to support the transfer of manufacturing to a party designated by CSL Behring. These collaboration services will be reimbursed at the pre-agreed FTE-rate. </span>The Company concluded that these rights at Closing do not represent material rights.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_099b92b2_4df0_48c3_a627_81e5c7025f4c"></a><a id="_b630b931_ea9f_4b8f_9197_c83ab4f8c235"></a><a id="_82b0722a_0c1e_449a_8dd7_344e7e749ea6"></a><a id="_51a94d63_59d9_48bf_81d8_615da2f7736e"></a><a id="_40892b0e_2974_48bf_9ba4_d55cb33c400a"></a><a id="_4e4e2730_30cf_4c57_89da_204ffa554474"></a><ix:continuation id="Tb_7yLf5xGe50Gnvor6-vOMnA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt 0.2pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span>As of June 30, 2021, the Company has an accounts receivable of $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_igOZK4wZWEOra8bKTcWHwQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_IzDlp9BElkGKHGQN0sKvcw">1.3</ix:nonFraction> million from CSL Behring. The Company collected the $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_eXzdB_wPDkSlyzIUnaikng" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_EJ8lHqoBtkKQMzDLjCUGRw">2.1</ix:nonFraction> million of accounts receivable related to reimbursable contract fulfillment costs that was outstanding as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Bristol-Myers Squibb collaboration</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In May 2015, the Company and Bristol-Myers Squibb (&#8220;BMS&#8221;) entered into a collaboration and license agreement and various related agreements with BMS (&#8220;BMS CLA&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The initial <ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_wO4YQLjtzUyL7xfd70wfWA" format="ixt-sec:durwordsen" name="qure:InitialResearchTerm" id="Narr_e2U8JeayAEaqEBGTRlCMUA">four-year</ix:nonNumeric> research term under the collaboration terminated on May 21, 2019. On December 1, 2020, the Company and BMS amended the BMS CLA (&#8220;amended BMS CLA&#8221;). Under the amended BMS CLA, BMS is limited to <ix:nonFraction unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA" contextRef="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ" decimals="INF" format="ixt-sec:numwordsen" name="qure:NumberOfCollaborationTargets" scale="0" id="Narr_l9aA1khLOEOhy5a8p_GftA">four</ix:nonFraction> Collaboration Targets. BMS may until November 30, 2021 replace up to <ix:nonFraction unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA" contextRef="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ" decimals="INF" format="ixt-sec:numwordsen" name="qure:CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced" scale="0" id="Narr_3BkZnptCbEqqFkAtwwt14g">two</ix:nonFraction> of these <ix:nonFraction unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA" contextRef="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ" decimals="INF" format="ixt-sec:numwordsen" name="qure:NumberOfCollaborationTargets" scale="0" id="Narr_bFan7o1T40OKM8-dgDldrw">four</ix:nonFraction> Collaboration Targets with up to <ix:nonFraction unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA" contextRef="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ" decimals="INF" format="ixt-sec:numwordsen" name="qure:ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease" scale="0" id="Narr_D7yuICdGtkCYsUXZnRC5BQ">two</ix:nonFraction> new targets in the field of cardiovascular disease. The Company continues to be eligible to receive research, development, and regulatory milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_1_2020_dei_LegalEntityAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_y8tWzFCmok2XCsAFfg-1mw" decimals="-5" format="ixt:numdotdecimal" name="qure:CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable" scale="6" id="Narr_tNk0p-BbtUC7bs6Gt8m8eg">217.0</ix:nonFraction> million for each Collaboration Target if defined milestones are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For as long as any of the <ix:nonFraction unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA" contextRef="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ" decimals="INF" format="ixt-sec:numwordsen" name="qure:NumberOfCollaborationTargets" scale="0" id="Narr_o09lZevidky8SXEEC00ORA">four</ix:nonFraction> Collaboration Targets are being advanced, BMS may place a purchase order to be supplied with research, clinical and commercial supplies. Subject to the terms of the amended BMS CLA, BMS has the right to terminate the research, clinical and commercial supply relationships, and has certain remedies for failures of supply, up to and including technology transfer for any such failure that otherwise cannot be reasonably resolved. Both BMS and the Company may agree to a technology transfer of manufacturing capabilities pursuant to the terms of the amended BMS CLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The amended BMS CLA does not extend the initial <ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_wO4YQLjtzUyL7xfd70wfWA" format="ixt-sec:durwordsen" name="qure:InitialResearchTerm" id="Narr_FXFy9B0LikKAs1adB66Qlw">four-year</ix:nonNumeric> research term. BMS may place purchase orders to provide limited services primarily related to analytical and development efforts in respect of the <ix:nonFraction unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA" contextRef="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ" decimals="INF" format="ixt-sec:numwordsen" name="qure:NumberOfCollaborationTargets" scale="0" id="Narr_7M56PzxgA0eWaTlSj7KeJg">four</ix:nonFraction> Collaboration Targets. BMS may request such services for a period not to exceed the earlier of (i) the completion of all activities under a Research Plan and (ii) either (A) three years after the last replacement target has been designated by BMS during the one-year replacement period ending on November 30, 2021, or (B) November 30, 2023 if no replacement targets are designated. BMS continues to reimburse the Company for these services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company evaluated the impact of the amended BMS CLA in relation to its performance obligation to provide access to BMS to its technology and know-how in the field of gene therapy and to participate in joint steering committee and other governing bodies (&#8220;License Revenue&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company determined that its remaining performance obligation under the amended BMS CLA was immaterial and recognized the remaining balance of unrecognized License Revenue as of November 30, 2020. The Company includes variable consideration related to any research, development, and regulatory milestone payments, in the transaction price once it is considered probable that including these payments in the transaction price would not result in the reversal of cumulative revenue recognized. Due to the significant uncertainty surrounding the development of gene-therapy product candidates and the dependence on BMS&#8217;s performance and decisions, the Company does <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_qure_CollaborativeArrangementLicenseRevenueMember_hIrNE1yg2EeFUIy3Z5A96A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_1q00us9C2k-bCHDdU3uc7Q">no</ix:nonFraction>t generally consider this probable and did not record any License Revenue during the six months ended June 30, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> &#160;</span></span><span style="display:inline-block;width:18pt;"></span> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_gmZNKUpVNEekiGvDO0dlSQ_1_2"></a><a id="Tc_q-8wf9BX5k2qIYi5nGAqug_1_5"></a><a id="Tc_NRQRRUkQHEGprrh9lK5sPQ_1_8"></a><a id="Tc_ESlTXu5UOEaebmo0Nq9TDg_1_11"></a><a id="Tc_t816jVwXm0K_U19HURLO3Q_1_14"></a><a id="Tc_RzuIXDP4ZEO9LiVfs1G7aQ_2_3"></a><a id="Tc_DkXoHH4JjUCr1zox3ApJSA_3_0"></a><a id="Tc_F333sKX5-0SZAuvFOU8XfA_4_0"></a><a id="Tc_0C7PymOHUka6LlCSXvAmoA_5_0"></a><a id="Tc_0RNljoemdEO7XwAdkxPyyA_5_2"></a><a id="Tc_G2pPUtZ7IkuwURuG1tcgFg_5_5"></a><a id="Tc_nKI-fY5-eE-Em23BvnUe2g_5_6"></a><a id="Tc_eG_jW773UU2nFvmhtzvprg_5_8"></a><a id="Tc_A6bPAVBiQEi4d38QxmOXgQ_5_9"></a><a id="Tc_6MpscFgYI0yfhz7irA-rzg_5_11"></a><a id="Tc_RSGUSAUs0EO5NNz75Zl8FA_5_14"></a><a id="Tc_ly6PqMECG0O7egTwaosVZA_6_0"></a><a id="Tc_lP-_VpTSEEmhFYWIZXQ_2g_6_2"></a><a id="Tc_qxpPQwwbiUuzt9f8WsG5dw_6_5"></a><a id="Tc_adunSTw8CkCqYb1ilD-O5Q_6_6"></a><a id="Tc_vaJDdHfWmEykQeyOXUIKhQ_6_8"></a><a id="Tc_LBoS4dBsaUGV1aVgdbXAiw_6_9"></a><a id="Tc_NqqPbSH9tkOJNaEnfxus3Q_6_11"></a><a id="Tc_34bbKoxIjkKk0pEmrT7IkQ_7_0"></a><a id="Tc_m5QjNCEzFUmlJYZe2P039Q_8_0"></a><a id="Tc_bitZd9_EHkS2YvU35niFow_8_3"></a><a id="Tc_vIFVgkMCxEqTvn8eYXNlZQ_8_6"></a><a id="Tc_e2r5vV5zhE6pBvjA544OBg_8_14"></a><a id="Tc_NcQDLqNPfEOqSVWn1koUFQ_9_0"></a><a id="Tc_KpEW7j_hAku0StGO62cI3A_9_2"></a><a id="Tc_6n-mN6DbhkaMsFV9A9-uNQ_9_3"></a><a id="Tc_90ksbGLM7kau7QfPpE9dVw_9_5"></a><a id="Tc_JtM2b1Z7XUKbzAyzaDpyCw_9_6"></a><a id="Tc_MpdHqMXvE0uE7Ao-xuwr7Q_9_8"></a><a id="Tc_a32lWRygbE-MIsuViA15KQ_9_11"></a><a id="Tc__kwhibc8HkG-LHx8-tfleg_10_0"></a><a id="Tc_YXQIvOD-q0iANQCZ1iBoMQ_11_0"></a><a id="Tc_QebR-wuGs0eNc-vBgz0WyQ_12_0"></a><a id="Tc_Ummf0dfNWUGaoCiKERjZhQ_12_2"></a><a id="Tc_5Khv80B0BUyQLyUPbPS8nQ_12_5"></a><a id="Tc_mMMosXQRjEm21LT22rT3ww_12_6"></a><a id="Tc_nQBUFdOVyUSHtxgYSfCgyA_12_8"></a><a id="Tc_2hSlOwZVhEijXXB1KGt_Vw_12_9"></a><a id="Tc_JyQ3gWAHvUuy86g6C2uwug_12_11"></a><a id="Tc_ErX554mdC0aWgHf_t1-EKw_12_14"></a><a id="Tc_u45SBBqtgEK_t1Y772YZiA_13_0"></a><a id="Tc_p0tRR0O-iE6EjT9TjozYsA_13_2"></a><a id="Tc_HTJwPwEHOE-ESgk6x7w38A_13_5"></a><a id="Tc_lQiaWaB3WUq4WgghRIdAyg_13_6"></a><a id="Tc_HhD1ZqAYI0yI7x5lS3370g_13_8"></a><a id="Tc_trMBcuFltUmN1nNBgkFCEw_13_9"></a><a id="Tc_hMc5ZfCJfUa2-3iADj1jFw_13_11"></a><a id="Tc_xQZQkfWXEUeJgyIb713TTw_14_0"></a><a id="Tc_0ku02p9HfEqm4Mbs_psYeQ_15_0"></a><a id="Tc_PM7wVLRWm06t6PkwwbDLaQ_15_2"></a><a id="Tc_nt33uom-f0qlMdwq4xJzsw_15_3"></a><a id="Tc_rge0_5E0s0uWNpzQv6XQvQ_15_5"></a><a id="Tc_RKs58TO_O0On3IItTDkxTA_15_6"></a><a id="Tc_6BSvmz1oQEGxx3FUd3b30w_15_8"></a><a id="Tc_DMPX_tm6VEeBVpt1BDqi9w_15_11"></a><a id="Tc_eJTUxlh6yEOu3FKxVnDuaw_15_14"></a><a id="Tc_1bBPre0xAUWKw_zl-Tscig_16_0"></a><a id="Tc_-056CV7PFEmn2PyPA_wI0w_16_2"></a><a id="Tc_pHQtm1nklkm-yiJpEJWD6Q_16_3"></a><a id="Tc_cYTOIiXwUkqh4gJONq7kPQ_16_5"></a><a id="Tc_He8C95vNq0ix-bY2dDBMPQ_16_6"></a><a id="Tc_E9etNyMTu0id3Dfgsd2hWw_16_8"></a><a id="Tc_RbumhOAhh0azD-1mwfKuUg_16_11"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_Lf8lze1oq0qlTklV9dA7YQ" continuedAt="Tb_Lf8lze1oq0qlTklV9dA7YQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;">4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:5pt;font-weight:bold;">&#160;</b>Fair value measurement</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company measures certain financial assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. U.S. GAAP requires disclosure of methodologies used in determining the reported fair values, and establishes a hierarchy of inputs used when available. The three levels of the fair value hierarchy are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 1 &#8211; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 2 &#8211; Valuations based on quoted prices for similar assets or liabilities in markets that are not active or models for which the inputs are observable, either directly or indirectly. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 3 &#8211; Valuations that require inputs that reflect the Company&#8217;s own assumptions that are both significant to the fair value measurement and are unobservable. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The carrying amount of cash and cash equivalents, accounts receivable, prepaid expenses, other assets, accounts payable, accrued expenses and other current liabilities reflected in the Consolidated balance sheets approximate their fair values due to their short-term maturities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table sets forth the Company&#8217;s assets and liabilities that are required to be measured at fair value on a recurring basis as of June 30, 2021, and December 31, 2020:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_vbWeB3OhLk6tVrPK5BqkVQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;prices<br />in&#160;active<br />markets<br />(Level&#160;1)</b></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant<br />other<br />observable<br />inputs<br />(Level&#160;2)</b></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant<br />unobservable<br />inputs<br />(Level&#160;3)</b></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:22.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification&#160;in&#160;Consolidated<br />balance&#160;sheets</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:top;width:38.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Assets:</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash, cash equivalents and restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fJtKgxuUvkyrzU-RtzqAcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_H3Nivdjj8UmnotqR9oZZ_Q_5_3">247,680</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kImN7dQ-PUeOCHGKL1wPsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_DNb8MOg18EOnkN6CUTkATA_5_12">247,680</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash and cash equivalents; other non-current assets</p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fJtKgxuUvkyrzU-RtzqAcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_kqDm60AHmU61BWvfWXmhwQ_6_3">247,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kImN7dQ-PUeOCHGKL1wPsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_-M1Ui1AwIECls60k6N6rVA_6_12">247,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Derivative financial instruments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_JOuPA4_0AkS3D-CstJPyIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_l7XY-Zm9N0uTuUJUcxL9xA_8_9">2,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kImN7dQ-PUeOCHGKL1wPsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_81qieV1yok26otRujgrr8Q_8_12">2,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other non-current liabilities</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_JOuPA4_0AkS3D-CstJPyIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Tc_qgxhT9MjW0yjuLNiSy1ZDw_9_9">2,645</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kImN7dQ-PUeOCHGKL1wPsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Tc_27pVzWpaTkyOCvIRNW-RSQ_9_12">2,645</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">At June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7OFIcgQjGUKozaeCn_JOaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_7G1bvDlxGkWNcmrroxSKTQ_12_3">680,158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wAnsudVWJ0eStn1YOEaRPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_Tq_TjM5PR0qzdETKqfGYhg_12_12">680,158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash and cash equivalents; other non-current assets</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7OFIcgQjGUKozaeCn_JOaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_BK21Z1g7qUyOMZsRQdG0kg_13_3">680,158</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wAnsudVWJ0eStn1YOEaRPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_lXXPPEtnw0Wq8IcjUTRQrA_13_12">680,158</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Derivative financial instruments </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1TMDu79eQ0e28WbVBlbIAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_pLK8fpLp0EacS-lyAL6lbA_15_9">2,645</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wAnsudVWJ0eStn1YOEaRPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_Mq4A9qzN4UunIy6CarOm1Q_15_12">2,645</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other non-current liabilities</p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1TMDu79eQ0e28WbVBlbIAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Tc_xY9aBqy5TkOYs8JSgvfM_A_16_9">2,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wAnsudVWJ0eStn1YOEaRPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Tc_1IudQtn6DUyi6iylPtot7Q_16_12">2,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognized <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="0" format="ixt-sec:numwordsen" name="qure:GainLossOnRecognitionOfDerivatives" scale="0" id="Narr_kNbCcRMUsU61xGddXFrQfg"><ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="0" format="ixt-sec:numwordsen" name="qure:GainLossOnRecognitionOfDerivatives" scale="0" id="Narr_gR4YV1d2tkWPXADIaoJfig">no</ix:nonFraction></ix:nonFraction> gains or losses related to changes in the fair market value of derivative financial instruments during the three and six months ended June 30, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Lf8lze1oq0qlTklV9dA7YQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 41pt;">Derivative financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 41pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company issued derivative financial instruments related to its collaboration with BMS. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.3pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In 2015, the Company granted BMS <ix:nonFraction unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="INF" format="ixt-sec:numwordsen" name="qure:NumberOfWarrantTypes" scale="0" id="Narr_teVcoXqq60yskdVTqgMiFg">two</ix:nonFraction> warrants that were subsequently terminated in connection with the amendment to the BMS CLA on December 1, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December 1, 2020, the Company and BMS agreed that upon the consummation of a change of control transaction of uniQure that occurs prior to December 1, 2026 or BMS&#8217; delivery of a target cessation notice for all <ix:nonFraction unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="INF" format="ixt-sec:numwordsen" name="qure:NumberOfCollaborationTargets" scale="0" id="Narr_3hpLKh2sUUa8JP8ymDwtzg">four</ix:nonFraction> Collaboration Targets, the Company (or its third party acquirer) shall pay to BMS a one-time, non-refundable, non-creditable cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-5" format="ixt:numdotdecimal" name="qure:CollaborationAgreementCashPayable" scale="6" id="Narr_Qk4XdFPA9EmSaU0YZgGtWQ">70.0</ix:nonFraction> million, provided that (x) if $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-5" format="ixt:numdotdecimal" name="qure:CollaborationAgreementCashPayable" scale="6" id="Narr_06Mzopoj6E-dK4vWfXLq6w">70.0</ix:nonFraction> million is greater than <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_0kUnhi7n702ffhqbWEJJFw" decimals="0" format="ixt-sec:numwordsen" name="qure:ThresholdPercentageOfNetProceeds" scale="0" id="Narr_0uY1iIqfiUiPj-mpEymafg">five</ix:nonFraction> percent (<ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_0kUnhi7n702ffhqbWEJJFw" decimals="1" format="ixt:numdotdecimal" name="qure:ThresholdPercentageOfNetProceeds" scale="0" id="Narr_AZtyrA57DkuekA6i4H2e1g">5.0</ix:nonFraction>%) of the net proceeds (as contractually defined) from such change of control transaction, the payment shall be an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_0kUnhi7n702ffhqbWEJJFw" decimals="0" format="ixt-sec:numwordsen" name="qure:PercentageOfNetProceedsPayable" scale="0" id="Narr_FMtr8cmeGk-YFQYg2chkoQ">five</ix:nonFraction> percent of such net proceeds, and (y) if $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-5" format="ixt:numdotdecimal" name="qure:CollaborationAgreementCashPayable" scale="6" id="Narr_QTa0lF4D2UujgFoTqJPvvA">70.0</ix:nonFraction> million is less than <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_7EhntjUcpUyhyXRTh2k0Nw" decimals="0" format="ixt-sec:numwordsen" name="qure:ThresholdPercentageOfNetProceeds" scale="0" id="Narr_AGYIlZeZwEiAs_fhHQdq5g">one</ix:nonFraction> percent of such net proceeds, the change of control payment shall be an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_7EhntjUcpUyhyXRTh2k0Nw" decimals="0" format="ixt-sec:numwordsen" name="qure:PercentageOfNetProceedsPayable" scale="0" id="Narr_NKGIqBUQI0Kwqo2jixCQ9w">one</ix:nonFraction> percent of such net proceeds (&#8220;CoC-payment&#8221;). The Company has not consummated any change of control transaction as of June 30, 2021 that would obligate it to make a CoC-payment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company determined that the CoC-payment should be recorded as a derivative financial liability as of December 1, 2020 and that subsequent changes in the fair market value of this derivative financial liability should be recorded in profit and loss. The fair market value of the derivative financial liability is materially impacted by probability that market participants assign to the likelihood of the occurrence of a change of control transaction that would give rise to a CoC-payment. This probability represents an unobservable input. The Company determined the fair market value of the derivative financial liability by using a present value model based on expected cash flow. The expected cash flows are materially impacted by the probability that market participants assign to the likelihood of the occurrence of a change of control transaction within the biotechnology industry. The Company estimated this unobservable input using the best information available as of June 30, 2021 and December 31, 2020. The Company obtained reasonably available market information that it believed market participants would use in determining the likelihood of the occurrence of a change-of control transaction within the biotechnology industry. Selecting and evaluating market information involves considerable judgement and uncertainty. Based on all such information and its judgment the Company estimated that the fair market value of the derivative financial liability (presented within &#8220;Other non-current liabilities&#8221;) as of June 30, 2021 and December 31, 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_dtZW9N0cZUGKCdQgqHQtOg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="Narr_ppY8MGS70UGFdQV2UxjC8w"><ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_4uX4YOxCI0Ku1yrWU3Qr-A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="Narr_S4aASXc7nEOuUOvIp41bdw">2.6</ix:nonFraction></ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_YzvqsSKWIUejUXqO7nSQLw_1_2"></a><a id="Tc_yKStpBXQkUqgy8g4v0ABlg_1_5"></a><a id="Tc_u2dQMOnjXEOlkrrOXovlmQ_2_2"></a><a id="Tc_CSBqBRf5L0iWWKxAhR1MCg_2_5"></a><a id="Tc_msamxS3YZEq7MbCXiayDhQ_3_2"></a><a id="Tc_cfJbyUiE9Eusm-PxUl7kmg_4_0"></a><a id="Tc_ZyEcwqioSEGehm-LDlpdlA_4_2"></a><a id="Tc_kLgrkc0h1kSi3PXdy3O56g_4_5"></a><a id="Tc_rJ7_itATNEqJmFUmRkvRRg_5_0"></a><a id="Tc_SGVXv21d9k2GUCsWjawIBQ_6_0"></a><a id="Tc_Q9NxzzId-EmsasFZm6bWEQ_6_3"></a><a id="Tc_eR2uvX30tkK0g6g003Trtg_7_0"></a><a id="Tc_Q1Bjw8zxjUasXOrlv8jlQg_7_2"></a><a id="Tc_wCBaqxVFs0CWaKbfdRypVA_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="qure:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" id="Tb_cY7tbaJVAUqoSFJqzqxBdQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Accrued expenses and other current liabilities</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities include the following items:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_o0Q0XfR5xEi5CQOPXGQFxA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accruals for services provided by vendors-not yet billed</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="qure:AccrualsForServicesProvidedByVendorsNotYetBilledCurrent" scale="3" id="Tc_WLTME-ISh0aZUPAYJwXlEQ_4_3">16,734</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="qure:AccrualsForServicesProvidedByVendorsNotYetBilledCurrent" scale="3" id="Tc_JesD44yksUOYXTeOdCZ9vg_4_6">8,269</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel related accruals and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_Jp9TcX76RUeN4YPLjw_xfw_5_3">6,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_GzU_RazayECW5BZTzdBThA_5_6">7,687</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_UusDTfVgEEWpylNdeIRZGQ_6_6">2,082</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_fBt1TTQ3OU2NuQbfpzcG8Q_7_3">23,526</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_VZCtkNnplkCme7XVBwM3-A_7_6">18,038</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:LongTermDebtTextBlock" id="Tb__JS9vld-_0eBE7oQndsAaQ" continuedAt="Tb__JS9vld-_0eBE7oQndsAaQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">6 </b></span><span style="display:inline-block;width:18pt;"></span><b style="font-weight:bold;">Long-term debt</b><span style="display:inline-block;width:4.51pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">On June 14, 2013, the Company entered into a venture debt loan facility with Hercules Capital, Inc. (formerly known as Hercules Technology Growth Capital, Inc.) (&#8220;Hercules&#8221;), which was amended and restated on June 26, 2014, and again on May 6, 2016 (&#8220;2016 Amended Facility&#8221;). On December 6, 2018, the Company signed an amendment that both refinanced the then-existing $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2016Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_931tErLp7EuUinvtjRhPIg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="Narr_YAr44hBjREatKo-BsT71gw">20.0</ix:nonFraction> million 2016 Amended Facility and allowed the Company to draw down an additional $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_12_6_2018_To_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_Faze52U7JEmiziY1euKKaA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="Narr_yovk4G996E2EYkJeI1FhBA">15.0</ix:nonFraction> million (&#8220;2018 Amended Facility&#8221;). The 2018 Amended Facility extended the loan&#8217;s maturity date from May 1, 2020 until June&#160;1, 2023.&#160;The interest-only period was initially extended from November&#160;2018 to January&#160;1, 2021 and was further extended to January 1, 2022 as a result of raising more than $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_Lkz8BWrtm0OghqMAcJ8NmA" decimals="-5" format="ixt:numdotdecimal" name="qure:DebtInstrumentAggregateAmountOfEquityFinancing" scale="6" id="Narr_Q5CAP3x3PEu-PfDVFqLVMQ">90.0</ix:nonFraction> million in equity financing in September 2019.&#160;The interest only period was again further extended to June 1, 2023 as a result of the January 2021 amendment (see below). &#160;The interest rate is adjustable and is the greater of (i)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_CfO51mljJ0eWh8ZOXwfRNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_zC1_IJjtCE2aZCRnRv8PyA">8.85</ix:nonFraction>% and (ii)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_12_6_2018_To_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_jJzGBF12x0arzA2m_P93oA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr__4d8AoN2tk2zDQvgK2NvhA">8.85</ix:nonFraction>% plus the prime rate less <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_Eyl_r3-QvkyaUu52pRzIrg" decimals="4" format="ixt:numdotdecimal" name="qure:DebtInstrumentInterestRateDiscountRatePercentage" scale="-2" id="Narr_LPmP7MA6-0Kqp80KMpzGjg">5.50</ix:nonFraction>% per annum. Under the 2018 Amended Facility, the Company owes a back-end fee of <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_12_6_2018_To_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_Faze52U7JEmiziY1euKKaA" decimals="4" format="ixt:numdotdecimal" name="qure:DebtInstrumentBackEndFeePercentage" scale="-2" id="Narr_HOX2g2sv7k-tVw5KcBLjwQ">4.95</ix:nonFraction>% of the outstanding debt. In addition, in May 2020 the Company paid a back-end fee of $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_5_31_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2016Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_Y21A5QNU90qnhAq2_ca6ig" decimals="-5" format="ixt:numdotdecimal" name="qure:DebtInstrumentBackEndFeeOne" scale="6" id="Narr_7GSnrhAo3kiD0WTDxRcowQ">1.0</ix:nonFraction> million in relation to the 2016 Amended Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="background-color:#ffffff;">On January 29, 2021, the Company and Hercules amended the 2018 Amended Facility (&#8220;2021 Amended Facility&#8221;). Pursuant to the 2021 Amended Facility, Hercules agreed to an additional Facility of </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_kzh0NdwaSkOA9RR8biOrAg" decimals="-5" format="ixt:numdotdecimal" name="qure:AdditionalUnconditionalBorrowingCapacity" scale="6" id="Narr_aD6dNTBK50qzFYDddO_AEg">100.0</ix:nonFraction></span><span style="background-color:#ffffff;"> million (&#8220;Tranche B&#8221;), increasing the aggregate principal amount of the term loan facilities from </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_kzh0NdwaSkOA9RR8biOrAg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="Narr_cYjZYRLGCE-l2Gzash90mQ">35.0</ix:nonFraction></span><span style="background-color:#ffffff;">&#160;million to up to </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_kzh0NdwaSkOA9RR8biOrAg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_QVLe67mZuEOimwDz82mGEA">135.0</ix:nonFraction></span><span style="background-color:#ffffff;">&#160;million. On January 29, 2021, the Company drew down </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_29_2021_To_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_VTx12u2MvECweTY9rrMN2w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="Narr_cwqq4qhoYU2h12TuLeHo4w">35.0</ix:nonFraction></span><span style="background-color:#ffffff;">&#160;million of the Tranche B. The Company may draw down the remaining </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_15_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1_tWzno1-kmrzxYDHva6OA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="Narr_81JPSqK3WU2JcbEwO8azKg">65.0</ix:nonFraction></span><span style="background-color:#ffffff;">&#160;million under the Tranche B in a series of one or more advances of not less than </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_15_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Hb9YyYVIVki_vUupPUugtQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="Narr_NJWLcrtZ3kO8KVGN0Na1AQ">20.0</ix:nonFraction></span><span style="background-color:#ffffff;">&#160;million each until December 15, 2021. Advances under Tranche B bear interest at a rate equal to the greater of (i)&#160;</span><span style="background-color:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="As_Of_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_kzh0NdwaSkOA9RR8biOrAg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_IWIkxsXVzEWteApSV8njaQ">8.25</ix:nonFraction>%</span><span style="background-color:#ffffff;"> or (ii)&#160;</span><span style="background-color:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="As_Of_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_kzh0NdwaSkOA9RR8biOrAg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Ldp-4PqVKEWwqXcukhpKFg">8.25</ix:nonFraction>%</span><span style="background-color:#ffffff;"> plus the prime rate, less&#160;</span><span style="background-color:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_29_2021_To_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_1Xb1Y17A2U231__SZnvguA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_MLeRawGDg0-ObGUmVrfX8Q">3.25</ix:nonFraction>%</span><span style="background-color:#ffffff;"> per annum. The principal balance and all accrued but unpaid interest on advances under Tranche B is due on June 1, 2023, which date may be extended by the Company by up to two twelve-month periods. Advances under Tranche B may not be prepaid prior to July 29, 2021, following which the Company may prepay all such advances without charge. </span>The Company owes a back-end fee of <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_29_2021_To_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_VTx12u2MvECweTY9rrMN2w" decimals="4" format="ixt:numdotdecimal" name="qure:DebtInstrumentBackEndFeePercentage" scale="-2" id="Narr_T9V6EBjm6UqZEqEWpEu-GQ">4.85</ix:nonFraction>% of amounts outstanding under Tranche B. The back-end fee is reduced if prepayment occurs at an earlier date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The amortized cost (including interest due presented as part of accrued expenses and other current liabilities) of the 2018 Amended Facility and 2021 Amended Facility was $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_MJTl_-uIN0WiFf9AUkk7rQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_Qxkr0xcrR0SrdNWNfWVkTQ">71.3</ix:nonFraction> million as of June 30, 2021, compared to $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_12_31_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_YpwOrDxTvEiUCcfw64tNMA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_XzLZN4SZKEec4v3Eaqk8pg">35.9</ix:nonFraction> million amortized cost for the 2018 Amended Facility as of December 31, 2020, and is recorded net of discount and debt issuance costs. The foreign currency gain on the facilities in the three months ended June 30, 2021, was $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_4CW_DXp0Ok6hoLPlu21sQg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainBeforeTax" scale="6" id="Narr_kTHdCm4TtUS21KLzNdhUsw">0.9</ix:nonFraction> million and the foreign currency loss on the facilities in the six months ended June 30, 2021, was $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_1sldxuu9EUKBKyfO334l3g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" scale="6" id="Narr_e9vKrVRLAkuo5yaB7Gc8nA">2.2</ix:nonFraction> million, compared to a foreign currency gain of $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_hv6WtwS-cEGRKyupdp3QwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" scale="6" id="Narr_XbO-9ZyqbEaUadBq8s0xEw">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_q56A2rcme0OqndPdj4St-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainBeforeTax" scale="6" id="Narr_Z55qWGXjaUCIECfqB-4ysA">0.0</ix:nonFraction> million during the same periods in 2020 for the 2018 Amended Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Interest expense associated with the 2018 Amended Facility and 2021 Amended Facility during the three and six months ended June 30, 2021, was $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_rsKxoYBI-UKgNQ9ydk4pHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_LYmLQ5CwukSFe3k7A4NOzg">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_su0H_LmbCk-jIOvLYq58hA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_KV5xDQRoEEO9ry1YMPFGfw">3.4</ix:nonFraction> million, compared to $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_CeTx4ptjcEaRDCkpZ_Y8fw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_kICTi_puwkWCLzqz35UkoA">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_WvP6wlihOUS6tnrgQEZHWg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_U5DkHVZaP0S00cD2Ov_o0A">1.8</ix:nonFraction> million, respectively, during the same periods in 2020 for the 2018 Amended Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">As a covenant in the 2018 Amended Facility and 2021 Amended Facility, the Company has periodic reporting requirements and is required to keep a minimum cash balance deposited in bank accounts in the United States, equivalent to the lesser of (i) <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_uevJahvpyU2rrC71LQx_GA" decimals="2" format="ixt:numdotdecimal" name="qure:DebtInstrumentPercentageOfWorldwideCashReserves" scale="-2" id="Narr_TSooilrhA0arjWk_PmocnA">65</ix:nonFraction>% of the outstanding balance of principal due or (ii) 100% of worldwide cash and cash equivalents. This restriction on cash and cash equivalents only relates to the location of the cash and cash equivalents, and such cash and cash equivalents can be used at the discretion of the Company. In combination with other covenants, the 2018 Amended Facility and 2021 Amended Facility restricts the Company&#8217;s ability to, among other things, incur future indebtedness and obtain additional debt financing, to make investments in securities or in other companies, to transfer assets, to perform certain corporate changes, to make loans to employees, officers, and directors, and to make dividend payments and other distributions to its shareholders. The Company secured the facilities by directly or indirectly pledging its total assets of $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_uevJahvpyU2rrC71LQx_GA" decimals="-5" format="ixt:numdotdecimal" name="qure:AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly" scale="6" id="Narr_WCkYZcSwUkCRRgVu6yTrXA">784.3</ix:nonFraction> million with the exception of $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_uevJahvpyU2rrC71LQx_GA" decimals="-5" format="ixt:numdotdecimal" name="qure:AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly" scale="6" id="Narr_2QU3a3Hf9UmoDZrn8w0voQ">103.5</ix:nonFraction> million of cash and cash equivalents and other current assets held by uniQure N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The 2018 Amended Facility and 2021 Amended Facility contain provisions that include the occurrence of a material adverse effect, as defined therein, which would entitle Hercules to declare all principal, interest and other amounts owed by the Company immediately due and payable. As of June 30, 2021, the Company was in material compliance with all covenants and provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__JS9vld-_0eBE7oQndsAaQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_BFuTfI5sI06fp52TgQx_Zw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">7</b></span><span style="display:inline-block;width:18pt;"></span>Shareholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 1, 2021, the Company entered into a Sales Agreement with SVB Leerink LLC (&#8220;SVB Leerink&#8221;) with respect to an at-the-market (&#8220;ATM&#8221;) offering program, under which the Company may, from time to time in its sole discretion, offer and sell through SVB Leerink, acting as agent, its ordinary shares, up to an aggregate offering price of $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_3_1_2021_To_3_1_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_orachVcrO0W16h4VtfgGfQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_DEjLMJSrrk6XQJgcp9Z0PQ">200.0</ix:nonFraction> million. The Company will pay SVB Leerink a commission equal to <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_3_1_2021_To_3_1_2021_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_H93jbZY3yUCB1OwXUnoDlA" decimals="2" format="ixt:numdotdecimal" name="qure:PercentageOfGrossProceedsOfSharesSold" scale="-2" id="Narr_eWev2cYlt0Os0CaEKYIBUw">3</ix:nonFraction>% of the gross proceeds of the sales price of all ordinary shares sold through it as sales agent under the Sales Agreement. In March and April 2021, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_3_1_2021_To_4_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_OssqgnSTskC6WxJuHZafpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr__nLDCRiWGUSSzOyJD0niRw">921,730</ix:nonFraction> ordinary shares at a weighted average price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="As_Of_4_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_PuxofUyxYUyj1pHnYLQF2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_a1I8MVJOkUe2KHVOGRKRdg">33.52</ix:nonFraction> per share, with net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_3_1_2021_To_4_30_2021_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_98YVZPFE5kO5F_BzYuxpRQ" decimals="-5" format="ixt:numdotdecimal" name="qure:NetProceedsFromIssuanceOfShares" scale="6" id="Narr_P5kWIEjKAUeBx5JuVij7WA">29.6</ix:nonFraction> million, after deducting underwriting discounts and net of offering expenses. The Company defers direct, incremental costs associated to this offering, except for the commission costs to SVB Leerink, which are a reduction to additional paid-in capital, and will deduct these costs from additional paid-in capital in the consolidated balance sheets proportionately to the amount of proceeds raised. During the three and six months ended June 30, 2021, $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_qure_DirectIncrementalLaborMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_MtE5A0KG6067RmXlMj46FA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="Narr_47KmSZfMuUWNDdydq2TijA">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_qure_DirectIncrementalLaborMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_H4D4ClXlxkaceIkX1aMBWQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="Narr_G2uqob_9MEito8HOinG2Dg">1.3</ix:nonFraction> million of direct, incremental costs were deducted from additional paid-in capital. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Following the release of the valuation allowance related to the years 2011 to 2018, the Company recognized the tax benefits of share issuance costs incurred in 2014, 2015, 2017 and 2018. This resulted in an increase of additional paid-in capital of $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-5" format="ixt:numdotdecimal" name="qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" scale="6" id="Narr_0jpS3537dkq-YhrojRW_LA"><ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-5" format="ixt:numdotdecimal" name="qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" scale="6" id="Narr_tcOO1dq2JkGrOHhs_R0hMQ">3.0</ix:nonFraction></ix:nonFraction> million in the three and six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="_51e97afc_4900_4957_b4e6_e78d20aa9980"></a><a id="_18ac7415_0618_456f_bbba_5d8c6955e678"></a><a id="_17c99c83_a3ed_4d36_b8e0_e647e2471a47"></a><a id="_0051b1e1_7997_4447_9fdf_10b30e2a0c81"></a><a id="_14b3ed89_d3f9_4a1f_8f10_1ce4f2c8a730"></a><a id="_26a76358_cd0e_45ba_9a27_046ea08762f7"></a><a id="_e6812b60_bb30_41bd_9d70_35cced81270a"></a><a id="_7b2b9218_0bac_4928_ac38_b9ccb8d87827"></a><a id="_850b7302_b999_404f_957c_7c5ae792fe82"></a><a id="_e45d7bc5_d65d_48bb_95eb_eadf546dc0c2"></a><a id="_58666a92_0788_40e3_a1e3_7abf9c9c499e"></a><a id="_f649c60c_74bf_4c18_a5b6_f68293a65e4c"></a><a id="_662caa88_ff90_4d01_a66a_62b436f869b3"></a><a id="_eca0a653_f8d8_41f5_82aa_7668297e1eb6"></a><a id="_110a1f52_f0e2_4b8d_8501_30b1af6246f5"></a><a id="Tc_dyOdW4HdREe8psX7AgysHA_1_2"></a><a id="Tc_o2W-zA0VZ06mIVsSa_AwHQ_1_8"></a><a id="_d2e36805_b690_4b17_9afe_13815d7a861b"></a><a id="Tc_Ae5LiELBT0KOfzPkKAoZBA_2_2"></a><a id="Tc_euChbQfx3Uir1SQI5OXHPA_2_5"></a><a id="Tc_H15zNVJZU0C6pQHp8knp3g_2_8"></a><a id="Tc_02-l9pYBWE2FzdCYR8ah_A_2_11"></a><a id="_2aab3796_0464_4a28_8c70_64a1aa6949cf"></a><a id="Tc_aabQ1MPMz06R60udUUW9yw_3_2"></a><a id="Tc_xrDnl4-O9E60zaV0M0sCRw_3_8"></a><a id="_c741ff4d_9864_440f_81a8_fd6afd3afadb"></a><a id="Tc_R5VSo1Rbj0y7C5msf332zw_4_0"></a><a id="Tc_mI9NfzdUYk-J8Ko9D5BsSg_4_2"></a><a id="Tc_ZbAMw6mvyEeT1mJZIqJUFQ_4_5"></a><a id="Tc_A4RbRT4SvEi4769HznWpGQ_4_8"></a><a id="Tc_HnofJAjrPEytJMpX7fiFCg_4_11"></a><a id="_71254b08_942e_4e0b_9f0d_cc0a6c09fc29"></a><a id="Tc_tmIyOOTDz0aeZddPKQInEA_5_0"></a><a id="_52ba4f3c_e579_4a2e_99e6_0bc7fa5c53c8"></a><a id="Tc_NAIXZsRWV06wa9Gm5wBoBw_6_0"></a><a id="Tc_R-dBqYRSUESRWxvDURHCYA_6_2"></a><a id="Tc_KiHfEBLt8k-NBgzKRGW83w_6_5"></a><a id="Tc_7LiZqxwdx0uoCFNB3TWqHw_6_8"></a><a id="Tc_5yEftKrZT0u-5BXDqLoxMA_6_11"></a><a id="_1c73c9d1_ee6b_47ec_bde4_7653f8a9f1cb"></a><a id="_41f0484d_26d9_44fd_8847_e3f5b5053b0b"></a><a id="_aac90535_0eae_4dcb_bd17_04b95b15e691"></a><a id="_bdd98e52_d3a2_4683_83b6_c01d0c0da0f4"></a><a id="_e1b17d6a_51ca_4f74_9e1c_9a51406242ee"></a><a id="_7089cd9e_ec3b_47ac_8e88_4c42224bbb0d"></a><a id="_18615db0_7927_44a4_ba98_3973b37d3dd3"></a><a id="_0af38710_b0bd_4c3f_881d_169e7ea108f8"></a><a id="_50c13c28_9116_49db_ad83_bb3a07185109"></a><a id="_76061992_3e5d_4c28_94d5_908bcc49f5fb"></a><a id="_a1de0658_1e0a_4a02_92ec_19c2d7fc3136"></a><a id="_f0bafa3e_910f_43d1_a9e8_ade0a0196374"></a><a id="_3aff23ea_af2b_4e6b_9f30_59e41f48426e"></a><a id="_c8f25b5c_7ccf_4a8f_9f2c_d1392d71f722"></a><a id="Tc_TQu9KTsO3kCXGi370f6ghw_1_2"></a><a id="Tc_IhwN0FViLUmahAy0paqK8A_1_8"></a><a id="_a0ddd4cb_5c07_4364_a7d3_2b394db59bf5"></a><a id="Tc__gdO6Zemnk-euFpX5FITJQ_2_2"></a><a id="Tc_DyUFLYdWNUGqJcQCMdMoUA_2_5"></a><a id="Tc_It-PRQN_FUGpsQhCE_ZyVA_2_8"></a><a id="Tc_5BrpRYQsrkWVuBzqzs-a-w_2_11"></a><a id="_26817ecc_17db_41be_b727_02b6d2224fa2"></a><a id="Tc_o6ofbsbmfU6AwsmdNLKtQw_3_2"></a><a id="Tc_WorbuqhgDEyDtBZZ9EznUw_3_8"></a><a id="_657177ce_4fcb_4dec_b767_fa34938c5ef1"></a><a id="Tc_Ki12xAfwPEav1IbW1S7_Zw_4_0"></a><a id="_769987e4_d0fd_422d_8668_36dc048bd653"></a><a id="Tc_6YSTn7euyEeeSjUyysD1lw_5_0"></a><a id="Tc_GjSBs94kzE2r9qdqzcROWw_5_2"></a><a id="Tc_xeFMEnD7zkeFvrsumA-75A_5_5"></a><a id="Tc_1gmotsNphk67xPycC1whhQ_5_8"></a><a id="Tc_06l0RW5L9k68JHzOSn02ew_5_11"></a><a id="_5b038f37_7007_49a1_b479_728a7c8aa1bc"></a><a id="Tc_O0KDNN5pZU6tivL75E2AVw_6_0"></a><a id="_54a33b92_f526_4b66_880b_306d85f13246"></a><a id="Tc_464StLFzcECZCMTQnfzuEA_7_0"></a><a id="_ee1534f7_51c7_4a0e_9e38_b98dd463d715"></a><a id="Tc_HC2dVfTgtECpZOlRFm7s-Q_8_0"></a><a id="Tc_HEuPBZCdBkO6ziSVG_ng9A_8_2"></a><a id="Tc_iDAOQyYNHU2K3siRQ286cw_8_5"></a><a id="Tc_d1l1M1Cb9ECbs3-ynzrA7Q_8_8"></a><a id="Tc_3y77J0AYz0ycIsgv9a_TPQ_8_11"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_sfOOhfWHk0KJqFWtG5TM5w" continuedAt="Tb_sfOOhfWHk0KJqFWtG5TM5w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">8</b></span><span style="display:inline-block;width:18pt;"></span>Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">The Company&#8217;s share-based compensation plans include the 2014 Amended and Restated Share Option Plan (the &#8220;2014 Plan&#8221;) and inducement grants under Rule 5653(c)(4) of the Nasdaq Global Select Market with terms similar to the 2014 Plan (together the &#8220;2014 Plans&#8221;). At the annual general meeting of shareholders in June 2021, the Company&#8217;s shareholders approved amendments of the 2014 Plan, increasing the shares authorized for issuance by&#160;</span><span style="background-color:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_omEFn-5NfEGkAMzAQ02EhA">4,000,000</ix:nonFraction></span><span style="background-color:#ffffff;">&#160;to a total of&#160;</span><span style="background-color:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_qdkOPyY6VkGQRdYO2alqaA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_RGqsI6rImEarilqs7PiReQ">12,601,471</ix:nonFraction></span><span style="background-color:#ffffff;">.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2014 Plans</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Share-based compensation expense recognized by classification included in the Consolidated statements of operations and comprehensive loss in relation to the 2014 Plans for the periods indicated below was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_6kciBLw9rkuMdB7wxKi_oQ" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.25%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_2QyWUqSll0SvgxvLV-w2Sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_2P7fpFBjAkigFUxdv5Ve3g_4_3">3,286</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_UovYXxgpLUq_6ozAyB8paA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_q5KeKD92MUmcxn_DPNhPKA_4_6">2,889</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_Y_O-r5G3Y0WsfXY0g7W7Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc__FqELsGdEkOW3uuS4qIuPQ_4_9">5,960</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lwLmmaw8u0StuP6cZ9EnJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HLggcYf76EO70lMlwxmcmw_4_12">5,271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_VqOyaS-XX0WhG4INMVMxnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_jbaL7yytgUCDdBC0eu2_5g_5_3">3,735</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_AG5JI3Sjjk21nqVDyvBZNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Rn3iHWvOZEalvkuMS17xfQ_5_6">2,825</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_Mt0t04auPESNygM01bISbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_el0UQFcgjU6xHa8tAUjs-g_5_9">6,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_ESty22Jv-0Sxj10FO4p7bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_R9x89PucSEKBuSl2CeiALA_5_12">4,783</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_YS6DOwKX1k6x5P_vJL_MIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_E2UWM5lbZUaDYAXJ1cGU8g_6_3">7,021</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_qure_The2014PlanMember_YbJyX63qJUCF1-xqxcPn-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_yG7lrj2lBUi7I1WgfAdyBg_6_6">5,714</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_YMQouEtWVUygyRXOlja_9Q_6_9">12,775</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_qure_The2014PlanMember_GDX-daUVNkiz9HBqranRrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4fJABhFa00akPpwAIHG4KA_6_12">10,054</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">Share-based compensation expense recognized by award type was as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Tb_NqD693lSZ0uDFbRHAEI3XQ" continuedAt="Tb_NqD693lSZ0uDFbRHAEI3XQ_cont1" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.25%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:22.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Award type</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share options</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_aWx6KZgGjUShkkBCZ5knmw_5_3">3,350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_y6OOLGIZUUWLQWqihlXdpg_5_6">2,746</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_hbkmSOyjXEuHxst9468tuA_5_9">6,190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9G_kAneeM0SgziGdwfsbMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_msnu-wGROUCS4lo8jAhq-Q_5_12">4,954</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted share units</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_jQQMIKMldkWohZCXDVcmdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_DGuX9KGboUizsG4ON0AKYA_6_3">3,222</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_2zEJuHZdn0KJM5hi1tu5YQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_QZX10c6G9Umf0cbLLjwmUQ_6_6">2,209</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ajuTtVnwrEqaZom30C2ZXQ_6_9">5,782</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_Ew8hAizqJU-URTHYHt1zAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4ksAaFSfwkOw5SLXZF0fog_6_12">3,653</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance share units</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_J1hFmEl5jE2V8o1LwylINA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_bLvRUliFgkOES8Zl1YirWQ_7_3">449</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lLWpawwVD0SS1ZQfITt7dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Sg6g0AzXcUe1tqYG9bqpow_7_6">759</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_glqCT3gHG0uMeAE2VUwFkg_7_9">803</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_fHzfNFAetEOpeFa4wvX2DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Ew6XfU7uUkSSJ3w5WzhDBw_7_12">1,447</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_YS6DOwKX1k6x5P_vJL_MIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Ff1uA3T9oUSKO8_dMxV20Q_8_3">7,021</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_qure_The2014PlanMember_YbJyX63qJUCF1-xqxcPn-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_w-i1U3tWBUeq5CVDLXxd1A_8_6">5,714</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ZSlrF4HYOkiNKaJ097NWKA_8_9">12,775</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_qure_The2014PlanMember_GDX-daUVNkiz9HBqranRrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_kCWouMarUUqccGyjQznCow_8_12">10,054</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_42ba55c6_4cbe_4494_aae4_7362094aa340"></a><a id="_e139d2ce_8f25_44d7_b6c9_a55fa2f5f6be"></a><a id="_27145e2e_1701_43d5_b5ad_7c584de1fa42"></a><a id="_273ae677_c518_4f73_b40a_a82693f38834"></a><a id="_c5842765_424e_48f4_9480_2b768823d5e4"></a><a id="_b96824ac_5bbe_4a48_b46d_e3b0fa6bb75f"></a><a id="_72e00959_1386_4e64_ac65_fb38e3c22a06"></a><a id="_9833ed19_7279_42d1_bb0c_0e69b0e28beb"></a><a id="Tc__uBlEQSYyE2bwcdSU-bLkQ_1_2"></a><a id="Tc_Qq6nF5a-nkafB7bphdRnBA_1_5"></a><a id="_09c35618_79df_4305_8574_205c44c4e986"></a><a id="Tc_Wam4Iai90kCNrI7yg_hi7A_2_2"></a><a id="Tc_2Ohh4xLsYUCDMDKINa3JmA_2_5"></a><a id="_d5d96024_f40d_4c32_bad1_a8d0b8b38674"></a><a id="Tc_xASyf329PE-GH_SYPty6Og_3_2"></a><a id="Tc_VGD6xOvWB0yOE8TysPjPfg_3_5"></a><a id="_36991f92_cbfd_4dd9_93be_280d0010cfc3"></a><a id="Tc_OklIpDf-sUeJFQUdscz_ww_4_2"></a><a id="Tc_oGXUo00hXEewQ4JtBsiblA_4_5"></a><a id="_17235982_2df0_4888_8bf0_8d29f44538f4"></a><a id="Tc_ORKDtqJHeEWD0kgZ_wsQ8A_5_2"></a><a id="Tc_YmI-EO0LkE6nkEYR_eASfA_5_5"></a><a id="_ba6ff2f9_c732_46ec_8bef_3ebfba4f6d48"></a><a id="Tc_t3IxbFufXE6mHIldfnuxvQ_6_0"></a><a id="_b62e192a_7147_48af_9ebd_e7b4262f6777"></a><a id="Tc_pcsfljdeZkakKVj6f18APw_7_0"></a><a id="Tc_tPI_yC07bUCFcG6rLkYZsA_7_2"></a><a id="_3c6713e7_d16e_4b3c_a097_d92451154b85"></a><a id="Tc_tog7tBy4vk-JaMdMoK8mDw_8_0"></a><a id="_1d7692e9_ebeb_49cc_b9e3_7475f787ab02"></a><a id="Tc_r6qapnfYgEeBwsLtIHnwlA_9_0"></a><a id="_1ba5afbf_c514_4cc0_969b_b765d8ef57de"></a><a id="Tc_9XQBIs30uEyjJUTloAOecw_10_0"></a><a id="Tc_Q8gCsHkKVkeueeI810AmVg_10_2"></a><a id="_ee717933_5a14_4b50_adaf_82a35f9bb663"></a><a id="_c675a311_312f_4552_a290_ff1507e7e88e"></a><a id="_80a1c3bb_3d9b_490c_9093_c44fbe6ae4d4"></a><a id="_209862c0_ebde_42f5_8160_f24c78a13217"></a><a id="_862ae8b3_db98_4176_a414_20ad7ddd9244"></a><a id="_4ab71bef_894b_4c04_a6f1_89c50d7d534d"></a><a id="_410b9d91_4662_46fd_b8bb_88c2adf317e5"></a><a id="_b3c312b8_8f5e_462c_bd80_3d083f77fcbe"></a><a id="_75125ad7_3722_4cc7_816a_558325c3bb60"></a><a id="_f3cd8300_58fb_4c41_8543_dd38e6a9e8bd"></a><a id="_34e7ab83_d5bc_4526_9eaa_a91f8d5dcf02"></a><a id="_d4a67842_e04b_4534_9fed_82a64f5329b1"></a><a id="_bbff2eff_cb28_4542_91ee_41c3bb127906"></a><a id="_2876f159_d0f1_463c_a0f6_a502975d313c"></a><a id="Tc_ITbBFOsCS0eaNss5DM2dBw_1_2"></a><a id="_55b515d6_0fd8_4a9c_bf45_04ce7dbb2fe1"></a><a id="Tc_xFbF-ATxIUKFhME7ZBCPKQ_2_2"></a><a id="Tc_MCNvwaZ4zUi3dpaMiVKdaA_2_4"></a><a id="_2bc1ec9f_9a6a_4587_afa9_565f45bf9a23"></a><a id="Tc_rl9GjiSf9kaK1UypJJpqvw_3_2"></a><a id="Tc_MwbrKpmL-EGvp_3qqIhIIw_3_4"></a><a id="_bb8ec54f_911a_4b9e_9233_a02c10e8cfc3"></a><a id="_8c91127f_623e_49bc_85c8_2dcf68119164"></a><a id="_6821d265_cda8_445e_baab_de87ec20fca8"></a><a id="_86193872_e6b4_40e7_acd5_1248699ca879"></a><a id="Tc_6m3p9xP9NUW3rgj9uaK2IA_5_0"></a><a id="Tc_wZKPMKvcDkOTi3vdvhhCQA_5_4"></a><a id="_11b04086_bef8_45ec_aa81_a8965c41e587"></a><a id="_ca291d43_5442_4da3_8080_a662f618f715"></a><a id="_3633402a_b334_47b1_b660_1294321eaee4"></a><a id="Tc_UTD95IWdMUK1qZeggEscpg_6_0"></a><a id="Tc_x9fQH1j_4UeAEcRSjNJcwQ_6_4"></a><a id="_86e48810_3a35_4961_956f_2e4b8d56f79d"></a><a id="_682a80bb_5808_46ba_a9db_93a1cd66ffb4"></a><a id="_a3bb8a99_30a9_42f5_a10a_14779f783576"></a><a id="Tc_oHlR7D4K0kCuHtxCGiW-6A_7_0"></a><a id="Tc_vx1eaXHpXE2RgtJL9nTeLQ_7_4"></a><a id="_517ed53f_dc91_4de8_a002_49a477dfb2d3"></a><a id="_54f412db_41b8_4a50_9afb_5c44730dd2cb"></a><a id="_3715cc18_cd0f_4ce8_9f57_ff17d814573a"></a><a id="Tc_OrB_s5WCRkC5N-FMUOYYqQ_8_0"></a><a id="Tc_AfgM6QYuVk-sz39zca_lnw_8_4"></a><a id="_27f971e6_c629_4d5f_9e2d_39b7b1200d22"></a><a id="_d98813fa_c7b5_4791_b07d_4e462baa572f"></a><a id="_9f7efcfa_34e0_45db_b5c5_d2c3fb6de020"></a><a id="Tc__PvBovibiEGf-MI4aLT6hA_9_0"></a><a id="Tc_hw7CgVb_4UewTtX5ZfDbmg_9_4"></a><a id="_0d5891c0_b6dd_4d6c_b8c8_cd029284f3fd"></a><a id="_2e53cfdd_1916_4468_8d85_c25597c4942d"></a><a id="_7fcd552a_b3ce_43b2_a72b_83383bf5af23"></a><a id="Tc_b8ZW8n9wnUaBS-cbz53s0Q_10_0"></a><a id="Tc_Xejq26gOU0e4ZflEfFjMVw_10_4"></a><a id="_3d007fef_14b9_473a_a86d_1bf00ac17e53"></a><a id="_836979b3_f6b2_43d2_8450_6528d022eb5c"></a><a id="_099cf058_392e_4c66_9a3f_b842133d0e30"></a><a id="Tc_Jrkya6uRVEWD45pUuoGp8Q_11_0"></a><a id="Tc_wOh86s47lEqYwaMgXej9HA_11_4"></a><a id="_03661983_f70c_4f1b_baed_b4bbac64ff28"></a><a id="_50e183e4_6941_48be_b159_34ddd052793c"></a><a id="_e66e37c9_543a_4a46_a003_de6bc2e2f676"></a><a id="Tc_Qkybi1RQ5k-lZORhit_Mow_12_0"></a><a id="Tc_QbNTnZ0Z3kOx-a61YKmQeg_12_4"></a><a id="_c7255106_a167_4b9f_8d44_d53dcf31bba5"></a><a id="_cf34076a_2c3c_4a59_896f_85c222f528b0"></a><a id="_431cbbcf_8cbc_4ef5_a8af_081ddd9ce177"></a><a id="_5ad5532d_82a8_4852_91d7_2b536ffdc85e"></a><a id="_0f9944e1_a21c_4000_a02a_babde7791400"></a><a id="_ea0bd6f8_3c20_46fc_894f_b45f74f2e391"></a><a id="_bbba620b_9991_44f4_9116_c01265c90ca8"></a><a id="_f353a08a_2f81_4807_9f11_7679170536ec"></a><a id="Tc_mQfQ0gRY6kyL2x06Mr-2dg_1_0"></a><a id="Tc_65zHAUvmH0euJCFWJLHKxQ_1_4"></a><a id="_1d654e6b_3f74_4dce_86dc_5ca358252175"></a><a id="Tc_xSgQ1kGXlUiT4WiqEy73Xw_2_0"></a><a id="Tc_7sakrGJhB06yr-9RFc9hCQ_2_4"></a><a id="_b8c33fe1_5249_4e9a_b9c8_a95a67ebd0a4"></a><a id="_b2009e69_a26c_4b1e_ba3a_aad6415d45b0"></a><a id="_57720e31_3461_4725_8351_e851b04130d2"></a><a id="_0c0f1305_f2c6_4548_b3b1_c12714f9fdbc"></a><a id="_42316711_14fc_4646_9823_4db34c838d5f"></a><a id="_4ff46284_5135_45d0_967e_dcdaff58fd69"></a><a id="_3eaa3e69_cd53_445b_bbd1_946800af544e"></a><a id="_9263d1e6_236b_4728_84f0_10053c05eda5"></a><a id="_45689842_198b_4335_8573_ab9f5fb12124"></a><a id="_d2c04532_e62e_4882_9bd3_9c273f968093"></a><a id="Tc_KvfkeNCFR06Odw4SHbJSuA_1_2"></a><a id="Tc_wFYQx8vnpEW0tK716NlyGg_1_6"></a><a id="_51fd613a_5a2b_449d_b62f_33ee164de0bb"></a><a id="Tc_WAwwDd6qFkmCSOocu5IV5Q_2_0"></a><a id="Tc_Fyom_BrBSEqQQhhJBeeTxQ_2_2"></a><a id="Tc_yJwXKKEsukm2nVpv4qQDKg_2_4"></a><a id="Tc_RyX4g0YUL0-YIzEBQ6iqcA_2_6"></a><a id="Tc_vTfPtWxsP0-Ae_HdU6EiIQ_2_8"></a><a id="_f3863645_b3a2_4443_a05f_e59eff798066"></a><a id="Tc_aquLFb98LkGNOVWQ-nuKwg_3_0"></a><a id="_0499658a_1041_4d3a_8753_6f8b88ec3ec1"></a><a id="Tc_7GiME9ChakuxQhTEK0xobg_4_0"></a><a id="_12946734_1c8e_4022_a6e6_8c268fe82676"></a><a id="_e9c0600f_cacd_4425_a15e_e6b8ea33c626"></a><a id="Tc_SsVZ8uDPSkWtOOnuOuPjUA_5_0"></a><a id="Tc_QsHsCuQOHUeM3tOWt_Iayw_5_2"></a><a id="Tc_19VeT9oH40eMNhE1nNRySA_5_4"></a><a id="Tc_ru_iIeRNxkCMhwKUAFgUQQ_5_6"></a><a id="Tc_YncezC_z8UaRpJcgHDRVrA_5_8"></a><a id="_2c3daed0_b93e_45d5_bfbb_02b5187d843c"></a><a id="Tc_PAdJW2lve0GRy9DjHGyOYQ_6_0"></a><ix:continuation id="Tb_sfOOhfWHk0KJqFWtG5TM5w_cont1" continuedAt="Tb_sfOOhfWHk0KJqFWtG5TM5w_cont2"><ix:continuation id="Tb_NqD693lSZ0uDFbRHAEI3XQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2021, the unrecognized share-based compensation expense related to unvested awards under the 2014 Plans were:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="Tb_WvK8juhfgkC-Bb18Z3pcTw" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrecognized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share-based</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">period for </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;recognition&#160;&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Award type</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share options</p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Tc_bdjSKe7i5E2Gr9cT4Za4cQ_7_3">34,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Tc_la2PgnTZE0mZJA0d7GXjsQ_7_5"> 2.99</ix:nonNumeric></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted share units</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9DvuX5iTKkaxcG2y02MZyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Tc_znRwEkupJEWI5LNc4wq-Mg_8_3">24,960</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Tc_npRmPCYLckSH-VYXW-pYLA_8_5"> 2.25</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance share units</p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_VhK3MGv9eEWEY7B8EG-TcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Tc_L-WZne6W1UyKylyhEuyD7A_9_3">792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Tc_dx75Y5fk3EKzRU_spZUWaw_9_5"> 0.58</ix:nonNumeric></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_qdkOPyY6VkGQRdYO2alqaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Tc_1WJMP3WmvUCf7KqAcOOORQ_10_3">60,607</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Tc_LsDF0LfSSEa7MzAPOmKe4w_10_5"><b style="font-weight:bold;"> 2.66</b></ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company satisfies the exercise of share options and vesting of Restricted Share Units (&#8220;RSUs&#8221;) and Performance Share Units (&#8220;PSUs&#8221;) through newly issued ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Share options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">Share options are priced on the date of grant and, except for certain grants made to non-executive directors, vest over a period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_l-c0we-IrkabMlqBFF99ow">four years</ix:nonNumeric>. The first <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9_e4JUkm00245rwV5zhg_g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_f7YxV8NOmEmGeMERag9UjA">25</ix:nonFraction>% vests after <ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9_e4JUkm00245rwV5zhg_g" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_L6Wp5EOdRUyNufS8k0nBmA">one year</ix:nonNumeric> from the initial grant date and the remainder vests in equal quarterly installments over years two, three and four. Certain grants to non-executive directors vest in full after <ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_hgABeo6nI0Sn_Cc_DbsdkA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_sserLgAMekuOTjqjV_sVZQ">one year</ix:nonNumeric>. Any options that vest must be exercised by the tenth anniversary of the initial grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">       </span>The following tables summarize option activity under the Company&#8217;s 2014 Plans for the six months ended June 30, 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_PlanIn2014Member_-Uv1a7oNgUKp-nwzRoa6rg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_mWRGwT3Rh06VnjXUTj0Mnw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise price</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_uJk1n3G3b0G2SAKAIt-9xQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_1EnZTtSpuk61P4zqEhiBhw_5_2">2,659,279</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_uJk1n3G3b0G2SAKAIt-9xQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_7z6pOmVjq0-B6FFlQ1PnrQ_5_5">28.13</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_E-4nJmJvi0uc-_HuAM1gtQ_6_2">914,118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_c5xnMoGna06_P3GYVYHNfw_6_5">36.36</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_JFo00EeGEECwPZ-PySKq-A_7_2">74,397</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Mwtq_txULUewB_Ylb01OWw_7_5">43.19</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_Ck6jsFKHukO5NFIN8APnLg_8_2">9,093</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_8ZVTUSmDVE6d6RMUUprk6g_8_5">44.14</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_PhK9EdcDekSHizXUsNgONQ_9_2">71,976</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_x_r5psU7lU6wZNtz0TRYtA_9_5">12.65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_5addOm1fRkm6bEuky1ceeg_10_2">3,417,931</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Vog--tO-vkGhq6Q0SxT1-Q_10_5">30.29</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereof, fully vested and exercisable at June&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_XjvNoKbvuUmfBeMsPNF7tA_11_2">1,774,059</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_7wF0tOsglUyDrAwTwDCGLg_11_5">21.68</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereof, outstanding and expected to vest after June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_5DRU7txeXUqZS2GG6VM-fw_12_2">1,643,872</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="2" format="ixt:numdotdecimal" name="qure:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice" scale="0" id="Tc_QwCdz0_Go0aM_uK6Of6zCQ_12_5">39.58</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total weighted average grant date fair value of options issued during the period (in $ millions)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Tc_VDceGk7DyEKbpm50rKbFNQ_1_5">19.4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from option sales during the period (in $ millions)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="Tc_HYilKBzqeUaUuTxJsGOygg_2_5">0.9</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of each option issued is estimated at the respective grant date using the Hull &amp; White option pricing model with the following weighted-average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_-2Uafrh52k25BE9Gwn9qtg" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Assumptions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_w_8ACX4wjk6kGcTXu-GlrA_3_2">75</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_J95qlX6ioUmC2EkFhYFVKA_3_4">70</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_ktjd_gd-cU-Ct7r-rbw-Dg_3_6">75</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9G_kAneeM0SgziGdwfsbMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_tz2dctj7IE2APeyn-jJ5oQ_3_8">70</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected terms</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_rQ4GWt0NfkSNEBbElY2F-w_4_2"><span style="font-size:9pt;">10 years</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_gIe43wNW90eg-GgQd2p6kg_4_4"><span style="font-size:9pt;">10 years</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_IvdJl6RwWUWcGzJ0zt4opg_4_6"><span style="font-size:9pt;">10 years</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9G_kAneeM0SgziGdwfsbMw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_ly0CHvkVbk-vO-0pIymGnA_4_8"><span style="font-size:9pt;">10 years</span></ix:nonNumeric></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_D1AI2o3NgUuUjIiBTQyNCw">1.72</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_KMa8JXCr60acHnwcUFCuDw">1.85</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_v4MLwW3BXkChJsPtA8WO3Q">0.76</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_D8AEuUEjckK6SCgcrhW-jw">0.83</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_RJqwqPREA0yEdrH_U9Q98w">1.21</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_FViaKFFJi0iFmrmqka2N9w">1.85</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9G_kAneeM0SgziGdwfsbMw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_4znFA0xymkeQakHbi8yzwQ">0.76</ix:nonFraction>% - 1.44%</p></td></tr><tr><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_ZzQh4AxAw0CAeJ94isLP4g_6_2">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_0lHlXtI0q061kltYBque4A_6_4">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_0OR5iVDkMk6NAbm5PmN1sw_6_6">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9G_kAneeM0SgziGdwfsbMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_Szct-SrpKEmmT-rNb5XMgg_6_8">0</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e09d6929_bad1_4684_abbf_1f5f903a5065"></a><a id="_4421576b_f12c_40ad_9786_c30111e273c1"></a><a id="_4d24cba3_92ee_4360_b619_e272821f8f62"></a><a id="_acb1ce1f_72fe_41f8_94ac_ea001da05e06"></a><a id="_0acdd44e_a002_42e5_821c_84262ccb0099"></a><a id="_1742c54e_8c3b_4ac3_9f42_c6131a8e4d75"></a><a id="_f34f7335_c440_4a7a_949f_d9b4e83abff8"></a><a id="Tc_fXB6YW5LzkqoKGdyP-DwjQ_1_2"></a><a id="_3421cac1_b0da_44a3_a726_333369185748"></a><a id="Tc_kqjocDpFh0KQlK8U6aXY8g_2_4"></a><a id="_1afd3df4_2e08_48e7_b9eb_c2425d68cfdc"></a><a id="Tc_272fXW_LC0KGT1tIvdWB6w_3_2"></a><a id="Tc_7N11ZpAxYEmLv11wjZlpCg_3_4"></a><a id="_adda521f_6c0b_4b09_b792_76780b0419f0"></a><a id="_e8d2b8b0_f747_4e9b_a34e_60adfdf5069c"></a><a id="_6a1a5938_58e1_4ee5_a7b9_009960e64f4f"></a><a id="Tc_hJs8crrFmUiEZWmWPkEv0g_4_2"></a><a id="Tc_3MdWyw33DkOlFAsYoshT1Q_4_4"></a><a id="_c2c28a22_ccdb_452c_9338_c689e7b51a4c"></a><a id="_8bc2b399_0717_44f5_9bc8_965c31d65a5a"></a><a id="_ae2c3d46_71ff_48ce_b371_877663ec594d"></a><a id="Tc_DKHPDrjtfEmp9WsMRnAU9A_5_0"></a><a id="Tc_fzHNNl2C1UWAufD2R8DKIw_5_4"></a><a id="_bc51f0a7_8238_4fe7_b905_f871d9a3520d"></a><a id="_b69e435e_bcdc_4fa0_a249_14b63f1b5951"></a><a id="_dc034036_1863_4737_8107_edef5d2550d3"></a><a id="Tc_NeSwwHIBM0ClreZi8Jk86A_6_0"></a><a id="Tc_sILwrTazXk6WgVTT0EbRQw_6_4"></a><a id="_b74378ea_a7bb_4340_ab35_10f7ecf2e68c"></a><a id="_d52535f1_4fec_42af_8ea9_4b5567d1179f"></a><a id="_24107701_73ea_4694_a5fa_def9571bd162"></a><a id="Tc_g0iRUFVRFk2a9ngeuuoUbQ_7_0"></a><a id="Tc_KanPhmEbdUit4hJxlFGLig_7_4"></a><a id="_519d64e3_59a7_41e1_b740_afa20e664ec2"></a><a id="_c331b5de_c9dd_4313_9644_c28b78579199"></a><a id="_fd0f3c5e_f9cb_4b49_ad58_6470bab57306"></a><a id="Tc_VcP6ipzqM0GlyWDYSX0k0A_8_0"></a><a id="Tc_rcW_g62BYk2Lo2qQWq-UHQ_8_4"></a><a id="_b3356fd0_b98c_412f_8817_073af08709c9"></a><a id="_cfeb7ccd_0ae7_47dc_8382_a3c47db1775d"></a><a id="_7f143d7b_95d9_49d5_9b77_4c6f99044266"></a><a id="Tc_CzbVPWrmZEOD7i-6hSZOBg_9_0"></a><a id="Tc__yDW1GmRXkGNMpLmnQJfbA_9_4"></a><a id="_5be1c71e_1a48_48ca_a11d_968be275dcce"></a><a id="_09db43a7_06ac_4c3c_b697_e00c6dd09e0c"></a><a id="_271a4c83_211b_4b52_b7ba_391fffd94bd9"></a><a id="_51e1046d_9314_401d_be2a_2d6d0a5bb429"></a><a id="_d2d9c0aa_39b1_4a18_8d30_94cc2ac725cf"></a><a id="Tc_DchLLhDNskKzd3QhxSup0w_11_0"></a><a id="Tc_A57UrjZ0oUy21fbLSxjTDw_11_4"></a><a id="_9cbd96df_6ad4_4606_8f19_21e0d0243330"></a><a id="_a7267595_d7df_4ecf_9116_47f3311ee711"></a><a id="_a1306e9f_bfb5_4274_ba6a_e5edc3cfe1fc"></a><a id="_f135f22c_e36f_42c8_a728_42fd56a06d20"></a><a id="_c1590135_6ea2_4f14_8166_89b235aaaae0"></a><a id="_c0497761_5896_43d6_9232_4182ac22766e"></a><a id="_65c8b8d6_255f_42b2_9a75_caa95347a1dc"></a><a id="Tc_SPFc4_ooFkqP_1MsmLa0XQ_1_2"></a><a id="_646a643d_7879_41b0_8af6_e9cdd52f4cf9"></a><a id="Tc_IDgtOOBwhk2BxoTfp3lSpQ_2_4"></a><a id="_dfacee75_d7c4_4eb6_b1eb_ea8569001957"></a><a id="Tc_tMtLagIK00eRwC72ZHQ5uQ_3_2"></a><a id="Tc_8QMxm1SqkUSXnDb2i4Aa6A_3_4"></a><a id="_5b7e3abc_5cef_4abe_b791_53335222ade2"></a><a id="Tc_2F_WoQlDk0OOW7cZlAvosQ_4_2"></a><a id="Tc_RINnpnsDx0SZOxIRAB-xuQ_4_4"></a><a id="_36c64643_2b5e_436f_b95a_9c5aca784aee"></a><a id="_714838a6_3ecf_4da9_87b8_28b7394ba21a"></a><a id="_4dc7fb8f_5f46_4beb_bbca_3f91f113d73f"></a><a id="Tc_Gb9dkItuK0-piMmEOTea8A_5_0"></a><a id="Tc_b-jhuXeHmEu-p1YuWvV9rA_5_4"></a><a id="_81ccb335_8434_469e_a573_6ba882e25f02"></a><a id="_541df198_7ac1_4b5a_ba06_33a9a40c24ba"></a><a id="_ee5038dc_5e1c_4033_83c8_3e5500b82e7f"></a><a id="Tc_gU4KMwcnbUuHHRKsbYP55A_6_0"></a><a id="Tc_2qiUNaxXT0yop7SE2OkzDw_6_4"></a><a id="_2a024a44_9a95_431b_95f3_d21e3e480368"></a><a id="_5fe43d7d_9ff4_40c9_b53e_4ada991e721a"></a><a id="_9ba2e0ed_849d_4f5e_84b8_139a327a449b"></a><a id="Tc_FjBAbvo_wEmD9rKXV2zySA_7_0"></a><a id="Tc_yKGH1A_tXka599mEsIMJqQ_7_4"></a><a id="_d6de9d2e_4b81_44da_8ac5_0a5ec37ffa88"></a><a id="_b9faa34b_514f_4fcf_9e8e_0adda695cedb"></a><a id="_3295078a_af77_49e5_aa15_2deaafe01a38"></a><a id="Tc_Pw2Rl5qwiUKI_cVOjh6jxA_8_0"></a><a id="Tc_BeHpLlE84ES0aaD2fxPZ_g_8_4"></a><ix:continuation id="Tb_sfOOhfWHk0KJqFWtG5TM5w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Restricted share units (&#8220;RSUs&#8221;) </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the RSUs activity for the six months ended June 30, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_GNuXQied-E-IXIyrstQFXg" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSU</b></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average</b></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant-date fair</b></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-vested at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_5NV54NsdkEinwOnU-elbdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_iFiQT9C6ikCAX2i4l2SmLw_5_2">467,344</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_5NV54NsdkEinwOnU-elbdw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_FC9v6YOydkqmyFes-oPwXA_5_5">43.56</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_RU1aIsheW0eGeQDRF7mTyA_6_2">481,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_4KdipQ4evkCWh5A0Lce4Vg_6_5">36.50</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_KoAdxtSWEUyO9HfgoD1JeA_7_2">145,203</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_IPRR6UF0B0GTBveV69Qgig_7_5">39.89</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited </p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_H5QhCIpsRUyviNF8JG6REQ_8_2">31,067</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_ULJkyRg9r0CGDSVQizMarA_8_5">42.86</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-vested at June&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9DvuX5iTKkaxcG2y02MZyQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_nY4YQPjd_UiSB0btLkZT0w_9_2">772,895</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9DvuX5iTKkaxcG2y02MZyQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_ZgU3MC-vcUadmxQntQBzSA_9_5">39.87</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total weighted average grant date fair value of RSUs granted during the period (in $ millions)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Tc_LhnqSlPLkkWbj4_vKOn3BA_11_5">17.6</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">RSUs vest over <span style="-sec-ix-hidden:Hidden_MCRGihcaXES2tnUHXX0Fgg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">one</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_l15cALnFH0u_MOExc4K0wA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_uA-cW7N-okSX87bHzJCIdg">three years</ix:nonNumeric>. RSUs granted to non-executive directors vest <ix:nonNumeric contextRef="Duration_3_1_2017_To_3_31_2017_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_7i4FeprKyk6MfKmRuuYBJQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_NSQLwitSxEeWxjT5hc2nwg">one year</ix:nonNumeric> from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Performance share units (&#8220;PSUs&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">The following table summarizes the PSUs activity for the six months ended June 30, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="Tb_jbotrJvJD0mooEVxhRGC2g" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PSU</b></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average</b></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant-date fair</b></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-vested at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_YNaFty5MakKmr7kgK48vHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_fyUn_cz9f0SD9IY-SBLyFQ_5_2">212,614</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_YNaFty5MakKmr7kgK48vHQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_7ITaS6UdYUyWG6bGovRmmQ_5_5">42.32</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_OQkSXRFId0W01pGa64FNDA_6_2">132,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_RGPCE_JhR0GJqq1snLMwgQ_6_5">33.09</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_e6jNT01BAkihg1-56L4_ug_7_2">2,916</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_h5dq0AKQwUehTOGaHhsAlg_7_5">57.56</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-vested at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_VhK3MGv9eEWEY7B8EG-TcA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_vTVH1PhzeUKHtU-GFkziZA_8_2">77,330</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_VhK3MGv9eEWEY7B8EG-TcA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_mMxXXhm-u0WALQXvtDz6_g_8_5">57.56</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.7pt 0pt 5pt;">The PSUs will vest on the third anniversary of the grant, subject to the grantee&#8217;s continued employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Employee Share Purchase Plan (&#8220;ESPP&#8221;)</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 5.05pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 5.05pt;">In June 2018, the Company&#8217;s shareholders adopted and approved an ESPP allowing the Company to issue up to <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_hyffprjeyUC_wzIZA8RTnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_7FK8v6DIbEa67JVV4GaUUA">150,000</ix:nonFraction> ordinary shares. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code of 1986. Under the ESPP, employees are eligible to purchase ordinary shares through payroll deductions, subject to any plan limitations. The purchase price of the ordinary shares on each purchase date is equal to <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_Fwx05CDlmUWbLjlZZ48Tqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="Narr_HJOXQM7kJkOLFHG92fKKLg">85</ix:nonFraction>% of the lower of the closing market price on the offering date and the closing market price on the purchase date of each three-month offering period. During the six months ended June 30, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_5Wm51a7LMUeByYsBhPlv-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_fyNzPoVQxk2CP2zGpUeotA">1,174</ix:nonFraction> ordinary shares were issued under the ESPP compared to <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_081a5t6cXUS5Pm3ISOEjBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_2liUpjOlBU25zzyAxyu3nQ">3,005</ix:nonFraction> during the same period in 2020. As of June 30, 2021, a total of <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_KP_4t1AgiEGnBsb8mhLMhg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_kZpgLVd7KU6AS7KnOYuwRQ">130,852</ix:nonFraction> ordinary shares remain available for issuance under the ESPP plan compared to a total of <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_YA8vUlYvg0e7cBJmuUUNoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_YFbPMbdqmEmsvt5dkteMTw">135,202</ix:nonFraction> as of June 30, 2020.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="qure:OtherIncomeTextBlock" id="Tb_rx9W5d2gfEqHEcVyNu5AwA" continuedAt="Tb_rx9W5d2gfEqHEcVyNu5AwA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">9</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Other income </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other income during the three and six months ended June 30, 2021, was $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="6" id="Narr_zCwNVRK3DkmlsHFXJoecFA">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="6" id="Narr_G1Hj8TNlyUmW9YhT61l0LA">7.9</ix:nonFraction> million, compared to $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="6" id="Narr_tSdRzQhJaU2mh41JpQI_5Q">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="6" id="Narr_xpWL5sERi0KU1iPH9qzmeQ">1.5</ix:nonFraction> million, respectively, during the same periods in 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other income in 2020 and 2021 includes income from payments received from European authorities to subsidize the Company&#8217;s research and development efforts in the Netherlands as well as income from subleasing part of the Amsterdam facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, other income during the three and six months ended June 30, 2021 includes $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-5" format="ixt:numdotdecimal" name="qure:EmployeeRetentionCreditIncome" scale="6" id="Narr_R7LtDewIPkaBvNfu42E3Nw"><ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-5" format="ixt:numdotdecimal" name="qure:EmployeeRetentionCreditIncome" scale="6" id="Narr_pKDahN9gNUKBHGwoiDn3Ig">1.3</ix:nonFraction></ix:nonFraction> million of employee retention credit received under the U.S. Coronavirus Aid, Relief, and Economic Security Act, as well as $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_Q_fLWImhIU-2TPyxON_IlA" decimals="-5" format="ixt:numdotdecimal" name="qure:EquityMethodInvestmentSettlementIncome" scale="6" id="Narr_PDjQsUoCn0aFJ-M_OplNnw">3.0</ix:nonFraction> million related to <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="As_Of_6_30_2021_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_OAjMTWyJ8E-817Ww2pMKxg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="Narr_8lI1NGVgJE-pnblPIdcGng">69,899</ix:nonFraction> shares in VectorY B.V. received in conjunction with a settlement agreement entered into in April 2021. <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_Bf9nD-pPCUi6779uMq-cCQ" decimals="-5" format="ixt-sec:numwordsen" name="qure:EmployeeRetentionCreditIncome" scale="6" id="Narr_pxzfW0JPHkKGtaQkBc63-w"><ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_UIrDwGaqv0i6xXmaQYspcQ" decimals="-5" format="ixt-sec:numwordsen" name="qure:EmployeeRetentionCreditIncome" scale="6" id="Narr_6sEXduBIkUGazqqyQUa8ig">No</ix:nonFraction></ix:nonFraction> such income was recorded in 2020.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_rx9W5d2gfEqHEcVyNu5AwA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:normal;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_jEG3tPPZZ0mZxKKWlIvqIQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Income taxes </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_mGNjQTBLNkSHLS1sU_tjBw">3.3</ix:nonFraction> million in income tax expense in the three months ended June 30, 2021, and $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_vwDVU3czGEm_qjHrEasS1g">3.5</ix:nonFraction> million in the six months ended June 30, 2021. The Company recorded <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_RvDt5BZcRkakXoRl6OVBQQ"><ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_ZbEVOZCYLUuhBr7B1zfGXA">no</ix:nonFraction></ix:nonFraction> income tax expense during the same periods in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2020, the Company had recorded a full valuation allowance against its Dutch net deferred tax assets. On May 6, 2021, the CSL Behring Agreement became effective (refer to Note 3 &#8220;Collaboration arrangements and concentration of credit risk&#8221;). The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_iR-v-TBnd0evOoVwhDOfvA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_CS9t0Ywak0-Cdg5IImNdRg">462.4</ix:nonFraction> million of license revenue related to closing the transaction. The Company intends to record such revenue in its Dutch tax return related to the 12-month period ended December 31, 2020. As such, the Company expects to file a return showing a taxable profit in the Netherlands in 2020, which would result in the consumption of substantially all of its Dutch net operating losses for the years 2011 to 2018. The Company&#8217;s remaining Dutch net operating tax losses carried forward would relate to 2019. The Dutch government on June 4, 2021 enacted legislation, whereby such net operating tax losses can be carried forward indefinitely. The Company expects to continue incurring tax losses for the foreseeable future including 2021. As such, the Company retained its full valuation allowance related to the net deferred assets as of June 30, 2021. The adjustment to the Company&#8217;s 2020 filing position resulting in the release and consumption of prior year net operating tax losses carried forward was treated as a discrete event in the three months ended June 30, 2021. The Company allocated part of the release to the tax benefit of share issuance cost incurred in 2014, 2015, 2017 and 2018. This resulted in an increase of additional paid-in capital as well as deferred tax expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-5" format="ixt:numdotdecimal" name="qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" scale="6" id="Narr_zoqk2R33YkS-8agMCB11gg">3.0</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company released its valuation allowance against the Company&#8217;s deferred tax assets in the United States as of December 31, 2020. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="Narr_6WdkeFjM0EmCzCpIsdGCaA">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="Narr_aadlNMzUO0qmmAdIsONqeQ">0.5</ix:nonFraction> million deferred tax expense in relation to its operations in the United States during the three and six months ended June 30, 2021, respectively. The Company recorded a <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="Narr_44s4QL_ky0yGgx15bMkapw"><ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="Narr_qYzPBLrMJEG_XcA4cplFtQ">nil</ix:nonFraction></ix:nonFraction> net deferred tax expense in the prior year as it had recorded a valuation allowance against its net deferred tax assets in the United States as of June 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The effective income tax rates of respectively -<ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_QxhmQstRh0y_OLMEb4rFhA">0.8</ix:nonFraction>% and -<ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_0hIaOr7b4UOBVRHNAlnQ9w">1.0</ix:nonFraction>% during the three and six months ended June 30, 2021, is substantially lower than the enacted rated of <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_gmsfN-g-p0K6ibhDmQzb1Q"><ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_cnh_RNcnvUumUxET4gwueg">25</ix:nonFraction></ix:nonFraction>% in the Netherlands as the Company recorded a valuation allowance against its remaining net deferred tax assets in the Netherlands as of December 31, 2020, and June 30, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="Tc_MvS-n9_QF0GWS0Ah5bLh6A_1_2"></a><a id="Tc_hZL5U6RV5EKzOkOeX4bgeA_1_8"></a><a id="Tc_XfD5F03CTkS1EvuM77rMtA_2_2"></a><a id="Tc_fvM2K6bwLUqFSY5eo2V2AQ_2_5"></a><a id="Tc_0iuke43tc0ycl9ptFyXZCw_2_8"></a><a id="Tc_SS1hGhCM8k-fFkhIgO04cw_2_11"></a><a id="Tc_sesAlmvLoUe10hIDflLEIA_3_2"></a><a id="Tc_g9QbbecX0UulMLfpFGpzKA_3_8"></a><a id="Tc_CIpROw1SlkmeJcHZCpeUrw_4_0"></a><a id="Tc_u97xQP03OEqynQcV_Bm-Zw_5_0"></a><a id="Tc_y6v0C-dNF0e0k_kO93dW5A_5_2"></a><a id="Tc_7S8rzwFWb0qwMGX7-OLfrw_5_5"></a><a id="Tc_Xrc32ayTR0-e4Gd1pBX2kw_5_8"></a><a id="Tc_qR8h3jKzukaK5idf7xq3UQ_5_11"></a><a id="Tc_S6-Zp8lWg0Wvm-xqMAYn1A_7_0"></a><a id="Tc_-SWhuk8lBU6WKM1ijDgJWQ_8_0"></a><a id="Tc_MXEGCmOUG0eqINoANM6VqA_9_0"></a><a id="Tc_4p7N9ha_Ikukkd-4YDNXvA_9_6"></a><a id="Tc_OgTjpiVQbUOMYIiGrB68jA_9_12"></a><a id="Tc_Kt4o_XTfJkamQYLUpigS8g_10_0"></a><a id="Tc_Kn0dDvEwBUy3AgLIh916Nw_10_6"></a><a id="Tc_KGbKOUjW60-s5HZuonwq3w_10_12"></a><a id="Tc_e54uPkBeNEadJhP2saRgbg_11_0"></a><a id="Tc_biAwEmQMkk2Ov55JrFKRhg_11_6"></a><a id="Tc_IQVIe-ZVWEKFM7Y483mx5Q_11_12"></a><a id="Tc_JNCl6jnW20GX0fz8X0Cv4w_12_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:EarningsPerShareTextBlock" id="Tb_1DHVDgW-lk-n09U_Ev1uaQ" continuedAt="Tb_1DHVDgW-lk-n09U_Ev1uaQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">11</b></span><span style="display:inline-block;width:18pt;"></span>Basic and diluted earnings per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Basic net income / (loss) per ordinary share is computed by dividing net income / (loss) for the period by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per ordinary share are calculated by adjusting the weighted average number of ordinary shares outstanding, assuming conversion of all potentially dilutive ordinary shares. For the three months and six months ended June 30, 2021, dilutive net income per ordinary share is computed using the treasury method. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table provides the calculation of basic and diluted earnings per ordinary share: </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_DubeJnz8kkemIUFU7zulMw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income / (loss) attributable to ordinary shares</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_0NIxGwaDMk2EAFfuOCKp0Q_5_3">399,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_c28d08SyHEKYi8biaA6X2Q_5_6">42,551</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_7RbNzANvxkKAf0TK2cJnow_5_9">357,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_Krhdm6mQHUG2EDb-7T8dtw_5_12">70,550</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_qWJisS7WJ0ul10drw0K3RQ_6_3">399,468</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_wv7mfFliwkijcCplkkb4oQ_6_6">42,551</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_ChTZaLXDekCUExT9uwXcFg_6_9">357,912</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_GwwQssBdGUuMJhJJFIVwBA_6_12">70,550</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average number of ordinary shares outstanding - basic</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_hWUjsla2oUGP-ddcUWO8AA_8_3">46,037,900</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_s-zaCIYld0GLdzUiA1PMUg_8_6">44,387,463</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_6Xdh7VPKAEW_6Z2qlu2vhQ_8_9">45,754,766</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_THsgIBv99EyTw1Klq3qWxA_8_12">44,333,460</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options under 2014 Plans and previous plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_7LQNKgj-qUKqmDaRdvBRmg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_DJgrGjx6ik6kdjS8Z2o5bw_9_3">797,165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_1bGUyXjk5Ee1HL6K4PJVRA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_nrDPuxok8U-d8GpnIG5b2Q_9_9">824,101</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-vested RSUs and PSUs</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_aitVdVnE4k67WD71TFPNZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_cNa0E-3mcEaKCzrS1E-zPQ_10_3">92,681</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_Qy8ygST_9k-q-6WvPt0QgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_jBAy0AMGE06fmCEEE3eZyw_10_9">98,514</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee share purchase plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_sDADOxy2gkuHqUBfnjTovQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_vdUCIoQkZk-1tXec-4CbiQ_11_3">2,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_qf3KA5AywE6IX9nX9Nuxmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_XZTxCE0XOUi_xMEhl0Fgjg_11_9">1,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average number of ordinary shares outstanding - diluted</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_mwbmsjS1MUGSBChSt59D5g_12_3">46,929,870</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_nAhWjpOjHEq88r51VlJxPQ_12_6">44,387,463</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_hIGQeNBPh0GN0RE_sfGhVQ_12_9">46,678,835</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_E6rlsaI5sUK8cRjNdfi7pg_12_12">44,333,460</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_hIgf6oEA30mNoZ4nKhc-8A_1_2"></a><a id="Tc_tOtMtULUD0ORCOJa41BkFg_1_8"></a><a id="Tc_9fe__1BUf0-L_yUJHXhpAA_2_2"></a><a id="Tc_0ViqY4H-5kaSpAxko4IGng_2_5"></a><a id="Tc_NVmQLCx7JE-ocmTCaRuDYg_2_8"></a><a id="Tc_MSojzKFBW0m79oFwYOgQVA_2_11"></a><a id="Tc_qoudZ65Xs06CYjm2xpOL_A_3_2"></a><a id="Tc_l5jn4Wdj00i-9a1Iv0o5Zw_3_8"></a><a id="Tc_yyf3V4_PSUmeNEmzy_fiGA_4_0"></a><a id="Tc_Fxd-POS5I0aIg2pcFSWp8g_5_0"></a><a id="Tc_huxSommAl0O_Mk2_pbuS7w_6_0"></a><a id="Tc_WglW8cTrnkSknuHt1SywBQ_7_0"></a><a id="Tc_BIe2-KJmQkyBxLhw28lOkQ_8_0"></a><a id="Tc_TmKG7sIB5kmJ6u_ry6edcQ_8_3"></a><a id="Tc_19-yRi2qeEqsykgC4HfEkw_8_9"></a><a id="Tc_wiVUCYdUWkCIvHBbzyYRZQ_9_0"></a><ix:continuation id="Tb_1DHVDgW-lk-n09U_Ev1uaQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents ordinary share equivalents that were excluded from the calculation of diluted net income / (loss) per ordinary share for the three and six months ended June 30, 2021 and 2020 as the effect of their inclusion would have been anti-dilutive.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="qure:ScheduleOfPotentialDilutiveCommonSharesTableTextBlock" id="Tb_3oGESuBQ0UankYV2nJYPWg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:22.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Anti-dilutive ordinary share equivalents</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options under 2014 Plans and previous plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_7LQNKgj-qUKqmDaRdvBRmg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_8qDWzctaIEOWBbYqTU0T_Q_5_3">2,634,766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_Hg1BxwkRVUyQ6vANQg5uvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_GNVfi1y3_U-M9ppsbM4X5A_5_6">2,893,733</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_1bGUyXjk5Ee1HL6K4PJVRA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_MhT9qY1J5UWDchIJ882mlw_5_9">2,607,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_9iYRZ8CW1k-TSh8NdyAR5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_SMfBMv3TjkOH72dYg1XIsA_5_12">2,893,733</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-vested RSUs and PSUs</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_aitVdVnE4k67WD71TFPNZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc__c_PHyzzGkmwQomaZQi78w_6_3">757,544</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_bIi4GQHMx0e79d3ltjcbDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Sm3pY3drX0W7XBst0TyN3w_6_6">645,636</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_Qy8ygST_9k-q-6WvPt0QgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_f2JanXyeuU6wO-saIDVPbw_6_9">751,711</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_oT74WQam8EeTmP8aiGGhow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_vF60N_scxEmy24V40TsSBw_6_12">645,636</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee share purchase plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_sDADOxy2gkuHqUBfnjTovQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_iE7czJHzq0upRUvuviqBSg_7_3">1,414</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_2y8V3lT85USL1EXFTeWauA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc__DwEjbFaaE6m9bVKLfCVCg_7_6">254</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_qf3KA5AywE6IX9nX9Nuxmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_jx4LvGxdvUS2Mx7UiqRYXg_7_9">1,802</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_g9VXfgfnr0G-HOsXC6wp3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_U7j7y70XaEO3bGET7YO8Fg_7_12">254</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">BMS warrants (derecognized as of December 1, 2020 - see Note 4, &quot;Fair value measurement&quot;)</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_BmsWarrantsMember_lc-W0vqpCUOjhIwUvmVlTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_T2BXnPFzRE6_znUt3hW4PA_8_6">8,060,500</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_BmsWarrantsMember_AuiBBwndmkigvQN248BGAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_VEShOsj6yUqY5J8ELgwFAQ_8_12">8,060,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total anti-dilutive ordinary share equivalents</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_I-_cUyYPLEeJkMb6NizeDA_9_3">3,393,724</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_dkBNoYTBq0KY4fMeD11eSQ_9_6">11,600,123</ix:nonFraction></b></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_JxGdg7nkFkiFX0O-13zHWA_9_9">3,361,343</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q" contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_AqslnEfjS0y-nY3nsieJ6w_9_12">11,603,143</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The anti-dilutive ordinary shares are presented without giving effect to the application of the treasury method or exercise prices that exceeded the price of the Company&#8217;s ordinary shares as of June 30, 2020. In addition, the BMS warrants were not exercisable as of June 30, 2020. This would have resulted in a lower number of potentially dilutive ordinary shares as some stock option grants as well as the BMS warrants would have been excluded.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk77596074"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" name="us-gaap:SubsequentEventsTextBlock" id="Tb_i3nPDoi0lkydoa0c2Wm4hg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">12</b></span><span style="display:inline-block;width:18pt;"></span>Subsequent event</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Business combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June 22, 2021, the Company announced that it entered into a definitive transaction agreement under which the Company will acquire Corlieve Therapeutics S.A.S. (&#8220;Corlieve&#8221;, together the &#8220;Corlieve Transaction&#8221;). The Corlieve Transaction has been approved by the Boards of both companies and does not require the Company&#8217;s shareholder approval. The transaction is subject to customary closing conditions as well as review by the French Ministry of Economy, Finance and Recovery (Minist&#232;re de l&#8217;Economie, des Finances et de la Relance) pursuant to articles L.151-3 and R.151-1 and seq. of the French Code Mon&#233;taire et Financier. Currently, the transaction is anticipated to be completed early in the third quarter of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Corlieve Transaction strengthens the Company&#8217;s pre-clinical program pipeline. Corlieve&#8217;s lead gene therapy program employs miRNA silencing technology to target suppression of aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (&#8220;TLE&#8221;) and will be known as AMT-260. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Upon closing of the Corlieve Transaction, the Company expects to pay EUR <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="Narr_mTqeWLErMEm92CPkXoNksg">46.3</ix:nonFraction> million in cash. The Company will fund the acquisition from its cash position. Corlieve&#8217;s shareholders are eligible to receive the following additional payments of which up to <ix:nonFraction unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw" contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w" decimals="2" format="ixt:numdotdecimal" name="qure:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage" scale="-2" id="Narr_jDQKuCmXf02C0fwfvXEEuA">25</ix:nonFraction>% will be payable in the Company&#8217;s ordinary shares at the Company&#8217;s election: up to EUR <ix:nonFraction unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-5" format="ixt:numdotdecimal" name="qure:DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi" scale="6" id="Narr_cHTjAEKYm0-VeCpTYGRbuw">43.7</ix:nonFraction> million in development milestones through Phase I/II and EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8DR84qYcA0iepwyX32ILmw" contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A" decimals="-5" format="ixt:numdotdecimal" name="qure:DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii" scale="6" id="Narr_sseU76UdoEuN3FeCuNXNUg">160.0</ix:nonFraction> million in milestones associated with Phase III development and the approvals of AMT-260 in the U.S and European Union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Corlieve Transaction is expected to be accounted for as a business combination, which requires that assets acquired and liabilities assumed be recognized at their fair value as of the acquisition date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 41.35pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:normal;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a967edf9_785b_4547_a924_c4bebbb18c22"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 2.</b></span><span style="display:inline-block;width:18pt;"></span>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand our results of operations and financial condition. This MD&amp;A is provided as a supplement to, and should be read in conjunction with, our unaudited consolidated financial statements and the accompanying notes thereto and other disclosures included in this Quarterly Report on Form 10-Q, including the disclosures under Part II, Item 1A &#8220;Risk Factors,&#8221; and our audited financial information and the notes thereto included in our </i><a style="-sec-extract:exhibit;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission ( the &#8220;SEC&#8221;) on March 1, 2021</i></a><i style="font-style:italic;">. Our unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the U.S. (&#8220;U.S. GAAP&#8221;) and unless otherwise indicated are presented in U.S. dollars.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a leader in the field of gene therapy and seek to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. We are advancing a focused pipeline of innovative gene therapies, including product candidates for the treatment of hemophilia B, which effective May 6, 2021, we licensed to CSL Behring pursuant to the CSL Behring Agreement (as defined below), and Huntington&#8217;s disease. We believe our validated technology platform and manufacturing capabilities provide us distinct competitive advantages, including the potential to reduce development risk, cost, and time to market. We produce our Adeno-associated virus (&#8220;AAV&#8221;) -based gene therapies in our own facilities with a proprietary, commercial-scale, current good manufacturing practices (&#8220;cGMP&#8221;)-compliant, manufacturing process. We believe our Lexington, Massachusetts-based facility is one of the world&#8217;s most versatile gene therapy manufacturing facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Business Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Below is a summary of our recent significant business developments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:6pt 0pt 0pt 17.85pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Acquisition of Corlieve Therapeutics</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June 21, 2021, we entered into a share and purchase agreement (&#8220;SPA&#8221;) to acquire all outstanding shares of Corlieve Therapeutics S.A.S (&#8220;Corlieve&#8221;). Corlieve&#8217;s lead gene therapy program employs miRNA silencing technology to target suppression of aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (&#8220;TLE&#8221;). TLE affects approximately 1.3 million people in the U.S. and Europe alone, of which approximately 800,000 patients are unable to adequately control acute seizures with currently approved anti-epileptic therapies. Patients with refractory TLE experience increased morbidity, excess mortality, and poor quality of life. The lead program will be known as AMT-260.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The transaction is subject to customary closing conditions as well as review by the French Ministry of Economy, Finance and Recovery (Minist&#232;re de l&#8217;Economie, des Finances et de la Relance) pursuant to articles L.151-3 and R.151-1 and seq. of the French Code Mon&#233;taire et Financier. Currently, the transaction is anticipated to be completed early in the third quarter of 2021. Upon closing of the Corlieve Transaction we expect to pay EUR 46.3 million in cash to acquire all outstanding ordinary shares of Corlieve. In accordance with the SPA we owe up to EUR 43.7 million in development milestones through Phase I/II and EUR 160.0 million in milestones associated with Phase III development and the approvals of AMT-260 in the U.S and European Union. At our election we can pay up to 25% of such milestone payments in our ordinary shares. The Corlieve transaction is expected to be accounted for as a business combination, which requires that assets acquired and liabilities assumed be recognized at their fair value as of the acquisition date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Corlieve has an established license and collaboration agreement with REGENXBIO Inc. that includes an exclusive license to AAV9 for the specific genetic target of AMT-260. Under the license and collaboration agreement, REGENXBIO Inc. is eligible to receive milestone payments and royalties on net sales of AMT-260.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:0pt 0pt 0pt 17.85pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">CSL Behring commercialization and license agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 24, 2020, (&#8220;Signing&#8221;), uniQure biopharma B.V., a wholly-owned subsidiary of uniQure N.V., entered into a commercialization and license agreement (as amended, the &#8220;CSL Behring Agreement&#8221;) with CSL Behring LLC (&#8220;CSL Behring&#8221;) pursuant to which CSL Behring received exclusive global rights to etranacogene dezaparvovec, our investigational gene therapy for patients with hemophilia B (the &#8220;Product&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The effectiveness of the transaction contemplated by the CSL Behring Agreement was contingent on the completion of review under the antitrust laws in the United States, Australia, and the United Kingdom. The transaction had previously been cleared by the Australian and United Kingdom antitrust authorities and became fully effective on May 6, 2021, after the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired on May 5, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As from May 6, 2021, CSL Behring will be responsible for the development and commercialization of the Product. We agreed to complete the validation of the current manufacturing process as well as to complete the development and validation of a next generation manufacturing process. We will be entitled to receive a development milestone payment if we complete these activities in accordance with an agreed development plan and timeline. CSL Behring will also be reimbursing us for our services to facilitate the completion of the HOPE-B clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On Signing, we and CSL Behring also entered into a development and commercial supply agreement, pursuant to which, among other things, we will supply the Product to CSL Behring at an agreed-upon price commensurate with the stand-alone selling price (&#8220;SSP&#8221;). We will be responsible to supply the Product until such time that these capabilities may be transferred to CSL Behring or its designated contract manufacturing organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recorded $462.4 million, including a $450.0 million upfront cash payment following the closing of the CSL Behring Agreement as license revenue in the three and six months ended June 30, 2021. We are eligible to receive more than $0.3 billion in regulatory, development, and first commercial sale milestones, $1.3 billion in additional commercial milestones, and tiered double-digit royalties of up to a low-twenties percentage of net product sales arising from the collaboration. Upon closing, we contractually owed to our licensors $16.7 million of the upfront payment received from CSL Behring. The payments we received significantly increased our cash and cash equivalents position to $677.3 million as of June 30, 2021. This is expected to fund our operations into the first half of 2024 (assuming a full repayment of funds borrowed from Hercules Growth Capital, Inc. under our term loan facilities by 2023, as well as payments we expected to make in relation to our acquisition of Corlieve). We expect that the achievement of the $0.3 billion regulatory, first commercial sales and development milestones would further extend our runway by 12 to 18 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:6pt 0pt 0pt 17.85pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Hemophilia B program &#8211; Etranacogene dezaparvovec (AMT-061)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Etranacogene dezaparvovec is our lead gene therapy candidate and includes an AAV serotype 5 (&#8220;AAV-5&#8221;) vector incorporating the functional human Factor IX (&#8220;FIX&#8221;) Padua variant. We are currently conducting a pivotal study in patients with severe and moderately-severe hemophilia B. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2021, we presented new data from the HOPE-B pivotal study related to the 52-week period post-infusion. Data showed that participants continued to demonstrate durable, sustained increases in FIX activity at 52-weeks post-infusion with a mean FIX activity of 41.5 percent of normal, as measured by a one-stage APTT-based clotting assay, compared to a mean FIX activity of 39.0 percent of normal at 26-weeks of follow-up. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the 52-week period, a single dose of etranacogene dezaparvovec significantly reduced the annualized rate of bleeding requiring treatment by 80 percent from a prospectively collected 3.39 at baseline to 0.68 bleeding episodes per year (p-value &lt;0.0001). The annualized rate of spontaneous bleeding requiring treatment was also significantly reduced by 85 percent from a prospectively collected 1.16 at baseline to 0.18 bleeds per year during the 52-week period (p-value &lt;0.0001). Usage of FIX replacement therapy (IU/year and infusions/year) in all patients declined 96 percent during the 52-week period, with 52 of 54 patients (96 percent) successfully discontinuing their prophylactic infusions. As previously announced, of the two non-responders, one patient only received a partial dose (less than 10 percent of the dosage) due to an infusion reaction and a second patient had an unusually high pre-existing NAb titer of 3,212, which is expected in less than 1 percent of the general population.&#160;We expect all patients to complete their 78-week follow-up visits by the end of the third quarter of 2021, and we expect a BLA to be submitted to the FDA and a MAA to be submitted to EMA in the first quarter of 2022.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On December 21, 2020, our clinical trials of etranacogene dezaparvovec had been placed on clinical hold by the FDA following a preliminary diagnosis of hepatocellular carcinoma (&#8220;HCC&#8221;), a form of liver cancer, in one patient in the HOPE-B trial who was treated with etranacogene dezaparvovec.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On March 26, 2021, we submitted to the FDA the results of a comprehensive investigation that found it is highly unlikely the HCC was caused by etranacogene dezaparvovec. On April 23, 2021, the FDA informed us that the clinical hold on our hemophilia B gene therapy program was removed after determining that we had satisfactorily addressed all issues identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Etranacogene dezaparvovec has been granted Breakthrough Therapy Designation by the FDA and access to the current priority medicines (&#8220;PRIME&#8221;) initiative by the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Huntington&#8217;s disease program (AMT-130) </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">AMT-130 is our novel gene therapy candidate for the treatment of Huntington&#8217;s disease. AMT-130 utilizes our proprietary, gene-silencing miQURE platform and incorporates an AAV vector carrying a miRNA specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment. AMT-130 has received orphan drug and Fast Track designations from the FDA and Orphan Medicinal Product Designation from the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 5, 2021 we announced the completion of enrollment of all ten patients in the first dose cohort of our Phase Ib/II clinical trial of AMT-130. On May 27, 2021, we announced that the study&#8217;s independent Data Safety Monitoring Board (&#8220;DSMB&#8221;) recommended we continue patient dosing after reviewing safety data from all 10 patients in the first dose cohort. On June 16, 2021, we announced that the first two patient procedures were completed in the second, higher-dose cohort, which will include 16 patients. The Phase I/II study is a double-blinded, randomized, and controlled clinical trial being conducted in the United States. To date, seven patients have been treated with AMT-130 across both dose cohorts, and five patients have received an imitation surgical procedure that will serve as a control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">On April 5, 2021 we also announced the initiation of a Phase Ib/II clinical trial in Europe. The planned Phase Ib/II study is expected to begin enrolling patients in the second half of 2021. This open-label study will enroll 15 patients with early manifest Huntington&#8217;s disease across two dose cohorts. Together with the U.S. study, the European study is intended to establish safety, proof of concept, and the optimal dose of AMT-130 to take forward into Phase III development or into a confirmatory study should an accelerated registration pathway be feasible.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Research and Development Day</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June 22, 2021, we held a research and development day to outline our vision and strategy of leveraging our AAV engine to deliver gene therapies within our key focus areas. We provided updates on our Fabry (AMT-191) and SCA3 (AMT-150) programs and announced additional new product candidates, including AMT-210 for Parkinson&#8217;s disease, AMT-240 for Alzheimer&#8217;s disease, and AMT-161 for Amyotrophic Lateral Sclerosis (&#8220;ALS&#8221;). These new programs are key components of our plan to expand our clinical pipeline. &#160;We also announced our plans to construct a second cGMP manufacturing facility located in Amsterdam, The Netherlands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Covid pandemic</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:39.6pt;margin:0pt 0pt 12pt 0pt;">The coronavirus disease (&#8220;Covid&#8221;) caused by the severe acute respiratory syndrome coronavirus 2 (&#8220;Sars-CoV 2 virus&#8221;) was characterized as a pandemic by the World Health Organization (&#8220;WHO&#8221;) on March 11, 2020. Since then, various, potentially more infectious, variants of the Sars-CoV 2 virus causing Covid have been identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:39.6pt;margin:0pt 0pt 12pt 0pt;">Throughout the pandemic, we have been implementing measures to address the impact of Covid on our business. We have implemented a series of protocols governing the operations of our Lexington facility to comply with the requirements of the various orders and guidance from the Commonwealth of Massachusetts and other related orders, guidance, laws, and regulations. We continue to monitor local government rules and recommendations and office protocols will be aligned with these rules and recommendations. Accordingly, we had mandated a work-from-home policy since March 2020 for all non-essential employees at our Amsterdam and Lexington facilities and had implemented additional protocols for our essential employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:39.6pt;margin:0pt 0pt 12pt 0pt;">Effective May 29, 2021, Massachusetts has lifted all industry restrictions, with the exceptions of remaining face-covering requirements for all public and private transportation systems and facilities housing vulnerable populations, and capacity has been increased to 100% for all industries. Furthermore, the state of emergency was lifted on June 15, 2021. Implementation of adequate cleaning and hygiene protocols are still encouraged. We have implemented a mandatory Covid PCR testing protocol in our Lexington facility effective February 11, 2021 that requires employees to have tested negative for Covid prior to entering the facility. Also in our Lexington facility, allowed occupancy has been increased to 100% in line with the permitted capacity guidelines and all employees are allowed to work at the Lexington facility subject to social distancing protocols, and a daily health screening and compliance with our Covid PCR testing policy for unvaccinated employees. All employees that are not essential employees, however, remain able to work remotely until December 31, 2021, and we have been operating significantly below 100% capacity. At least until August 1, 2021, for purposes of monitoring Covid surges due to relaxation of requirements, no employee or contractor may enter the Lexington facility unless they are either: (i) fully vaccinated; or (ii) have taken an approved test for Covid and obtained a negative result. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:39.6pt;margin:0pt 0pt 12pt 0pt;">On June 26, 2021, the Dutch government announced updated measures. Since July 1, we allow for an occupancy rate of 50% at our Amsterdam site as well as the limited presence of visitors. We continue to operate our laboratories at our Amsterdam site to comply with social distancing rules and to ensure the health and well-being of our employees under the current circumstances. Employees that can continue to work from home are encouraged to do so through at least August 2021, partly in conjunction with the ongoing expansion of our laboratory space.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:39.6pt;margin:0pt 0pt 12pt 0pt;">The broader implications of Covid, including the implications from the various variants, on our results of operations and overall financial performance remain uncertain. We have experienced increased lead times in the delivery of equipment and disposables that we use to manufacture materials for our various programs. Currently, these have not materially impacted our development timelines and we continue to adapt to the current environment to minimize the effect to our business. However, we may experience more pronounced disruptions in our operations in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Financing </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2020, a $35.0 million term loan was outstanding in accordance with the Second Amended and Restated Loan and Security Agreement (the &#8220;2018 Amended Facility&#8221;) between us and Hercules Capital, Inc. (&#8220;Hercules&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January 29, 2021, we and Hercules amended the 2018 Amended Facility (&#8220;2021 Amended Facility&#8221;). Pursuant to the 2021 Amended Facility, Hercules agreed to an additional Facility of $100.0 million (&#8220;Tranche B&#8221;) increasing the aggregate principal amount of the term loan facilities from $35.0 million to up to $135.0 million. On January 29, 2021, we drew down $35.0 million of the Tranche B. We may draw down the remaining $65.0 million under the Tranche B in a series of one or more advances of not less than $20.0 million each until December 15, 2021. Advances under Tranche B bear interest at a rate equal to the greater of (i) 8.25% or (ii) 8.25% plus the prime rate, less 3.25% per annum. The principal balance and all accrued but unpaid interest on advances under Tranche B is due on June 1, 2023, which date may be extended by us by up to two twelve-month periods. Advances under the 2021 Amended Facility may not be prepaid until July 29, 2021, following which we may prepay all such advances without charge. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to Tranche B, the 2021 Amended Facility also extends the interest only payment period of the previously funded $35.0 million term loan from January 1, 2022 to June l, 2023. End of term charges in respect of advances under the 2021 Amended Facility range from 1.65% to 6.85%, depending on the maturity date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 1, 2021, we entered into a Sales Agreement with SVB Leerink LLC (&#8220;SVB Leerink&#8221;) with respect to an at-the-market (&#8220;ATM&#8221;) offering program, under which we may, from time to time in our sole discretion, offer and sell through SVB Leerink, acting as agent, our ordinary shares, up to an aggregate offering price of $200.0 million. We will pay SVB Leerink a commission equal to 3% of the gross proceeds of the sales price of all ordinary shares sold through it as a sales agent under the Sales Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In March and April of 2021, we issued 921,730 ordinary shares at a weighted average price of $33.52 per share, with net proceeds of $29.6 million, after deducting underwriting discounts and net of offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Facility </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2021 we commenced the expansion of our Amsterdam site to build additional laboratories to support the expansions of our research and development activities as well the construction of a cleanroom designed to be capable of manufacturing cGMP materials at a 500-liter scale. In May 2021, we entered into a sublease agreement to let an additional approximately 1,080 square meters of office space to accommodate the hiring of additional full-time employees. The lease expires in October 2028 and includes an option to break the lease on October 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Organization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On May 17, 2021, Pierre Caloz was appointed as Chief Operating Officer. &#160;Mr. Caloz oversees all manufacturing operations, global CMC development and innovation, supply chain, and facilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June 15, 2021, Christian Klemt was appointed as Chief Financial Officer. Mr. Klemt was our Chief Accounting Officer from August 2017 to June 2021, and he will continue to serve as general manager of our Amsterdam site. Matthew Kapusta, who has been our Chief Executive Officer since December 2016 and had been our Chief Financial Officer from January 2015 to June 2021, will continue to serve as our Chief Executive Officer. In connection with his transition to Chief Financial Officer, Mr. Klemt will also serve as our Principal Financial Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June 16, 2021, our shareholders voted to approve the reappointment of Mr. David Meek and Ms. Paula Soteropoulos as non-executive directors of the Board of Directors. Mr. Meek has been appointed chairman of the Board. Mr. Philip Astley-Sparke did not stand for reappointment and retired from the Board on June 16, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:39.6pt;margin:6.59pt 0pt 0pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:39.6pt;margin:6.59pt 0pt 0pt 0pt;">On May 11, 2021, Pfizer, Inc. filed three petitions seeking <i style="font-style:italic;">Inter Partes Review</i> of U.S. Patent Nos. 9,982,248 (the &#8220;&#8217;248 Patent&#8221;) and 10,465,180 (the &#8220;&#8217;180 Patent&#8221; and together with the &#8216;248 Patent, the &#8220;Patents&#8221;). The petitions collectively seek to invalidate all claims of the Patents, which relate to the expression of factor IX protein using a modified &#8220;Padua&#8221; polypeptide having a leucine in position 338. We are in the process of responding to the petitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financial Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Key components of our results of operations include the following: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0edb87ef_b5d9_4868_9372_5f4c9374d73c"></a><a id="_5837bce4_c682_413a_bd4d_41c00971d4af"></a><a id="_2c1d8090_d128_4a4b_97b7_e4de7fe0f9ae"></a><a id="_f4cc2c08_4ec7_4e94_b25a_df881cc6bbb1"></a><a id="_011df795_b091_4e54_94c3_58bc39e96c55"></a><a id="_4556ccc3_f60c_4aac_8f7d_4b9503f63d66"></a><a id="_e1ad109d_bb2c_4ed8_a94c_c478179c19fa"></a><a id="_f5e28f41_a7db_4a9e_b854_ba9293909ddc"></a><a id="_52a673b6_3f3c_491e_9aef_77bc8c11cf12"></a><a id="_e57c0846_5594_45e5_89c6_e4c33341ea77"></a><a id="_d5d3bd41_9fde_4eca_a046_e1ae1876d857"></a><a id="_00ac479c_da2e_481e_b168_4c3c64f1dec9"></a><a id="_416c351e_5612_4a5c_8495_3a732d3cda32"></a><a id="_cfe42ede_4abb_4280_825e_e04ac2fe2e47"></a><a id="_2bf705a3_c0be_45f4_ad8f_d60bff6ecf18"></a><a id="_bd94ac20_86da_4628_aeb2_32bcbbc65fa3"></a><a id="_e02053d2_30d6_43d3_bbf0_20993e42539c"></a><a id="_14dcd833_cc3e_41e1_a4a4_e5aecf2fa589"></a><a id="_706116c9_889a_46e0_a839_4e0d2ac1fe80"></a><a id="_00421b26_34f0_4c2f_87c6_7adf59509eb5"></a><a id="_e72d99b9_4cf5_4180_8af2_2a5a58bf6e80"></a><a id="_d905a33c_5e3e_4026_9b30_054b0ccbad24"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.88%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:53.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:21.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:21.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 463,868</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,535</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 464,322</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,639</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of contract revenue</p></td><td style="vertical-align:middle;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,178)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,178)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,747)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,401)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (64,777)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (54,414)</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:middle;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17,299)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,511)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (30,300)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (20,583)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income / (loss)</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 399,468</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (42,551)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 357,912</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (70,550)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2021, and December 31, 2020, we had cash and cash equivalents of $677.3 million and $244.9 million, respectively. We had a net income of $399.5 million and $357.9 million in the three and six months ended June 30, 2021, compared to a net loss of $42.6 million and $70.6 million for the same periods in 2020. As of June 30, 2021, and December 31, 2020, we had accumulated deficits of $426.8 million and $784.7 million, respectively. We recorded a net income in the three and six months ended June 30, 2021 as a result of the closing of the CSL Behring transaction on May 6, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We anticipate that our expenses will increase substantially as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.85pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Advance the clinical development of AMT-130 for our Huntington&#8217;s disease gene therapy program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.85pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Advance multiple research programs related to gene therapy candidates targeting liver-directed and central nervous system (&#8220;CNS&#8221;) diseases;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.85pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Continue to expand our employee base to support research and development, as well as general and administrative functions; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.85pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Acquire or in-license rights to new therapeutic targets or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.85pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Continue to expand, enhance and optimize our technology platform, including our manufacturing capabilities, next-generation viral vectors and promoters, and other enabling technologies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.85pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Maintain, expand, and protect our intellectual property portfolio, including in-licensing additional intellectual property rights from third parties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.85pt;margin:6pt 0pt 0pt 0pt;">See &#8220;Results of Operations&#8221; below for a discussion of the detailed components and analysis of the amounts above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 59.75pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In preparing our consolidated financial statements in accordance with U.S. GAAP and pursuant to the rules and regulations promulgated by the SEC we make assumptions, judgments and estimates that can have a significant impact on our net income/loss and affect the reported amounts of certain assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and judgments, including those related to <span style="background-color:#ffffff;">the treatment of the CSL Behring Agreement, our arrangements with Bristol-Myers Squibb (&#8220;BMS&#8221;), including the amended collaboration and license agreement that we entered into with BMS in December 2020 (the &#8220;amended BMS CLA&#8221;), share-based payments, corporate income taxes related to valuation allowance and accounting for operating leases under ASC 842.</span> We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not clear from other sources. Actual results may differ from these estimates under different assumptions or conditions. In making estimates and judgments, management employs critical accounting policies. During the six months ended June 30, 2021, there were no material changes to our critical accounting policies as reported in our <a style="-sec-extract:exhibit;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 1, 2021</span></a>, with the exception of determining the accounting treatment in accordance with ASC 606 related to the CSL Behring Agreement as discussed below. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">We believe that the assumptions, judgments, and estimates related to <span style="background-color:#ffffff;">the treatment of the CSL Behring Agreement, the amended BMS CLA, share-based payments, corporate income taxes related to valuation allowance, and accounting for operating leases under ASC 842 </span>to be our critical accounting policies. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk75364477"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of our consolidated financial statements for the three- and six- month period ended June 30, 2021, required us to analyze the accounting treatment of the CSL Behring Agreement that we entered into on June 24, 2020 (&#8220;Signing&#8221;). <span style="background-color:#ffffff;">The effectiveness of the transaction had been contingent on completion of review under antitrust laws in the United States, Australia, and the United Kingdom. The transaction had previously been cleared by the Australian and United Kingdom antitrust authorities and became fully effective on May 6, 2021 (&#8220;Closing&#8221;), after the waiting period under the HSR Act expired on May 5, 2021. &#160; &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">      We identified two material performance obligations related to the CSL Behring Agreement:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Sale of the exclusive global rights to the Product (&#8220;License&#8221;); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Generate information to support the regulatory approval of the current and next generation manufacturing process of Product and to provide any such information generated to CSL Behring (&#8220;Manufacturing Development&#8221;).</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">We continued to develop the Product between Signing and Closing and performed certain reimbursable activities to fulfill the transfer of the global rights (&#8220;Additional Covenants&#8221; and together with the License the &#8220;License Sale&#8221;). We determined that the fixed upfront payment of $450.0 million and the $12.4 million that we received in relation to the Additional Covenants should be allocated to the License Sale. In addition, we concluded that variable milestone payments, sales milestone payments and royalties should be allocated to the License Sale performance obligation as well. We determined that the sale of the License was completed on May 6, 2021, when we transferred the License and CSL Behring assumed full responsibility for the development and commercialization of the Product. At Closing we evaluated the amount of potential payments and the likelihood that the payments will be received. We utilized the most likely amount method to estimate the variable consideration to be included in the transaction price. Since we cannot control the achievement of regulatory and first commercial sales milestones, we concluded that the potential payments are constrained as of Closing. We determined that we would recognize revenue related to these payments, only to the extent that it becomes probable that no significant reversal of recognized cumulative revenue will occur thereafter. We will include payments related to sales milestones in the transaction price when their achievement becomes probable, and we will include royalties on the sale of Product once these have been earned. We recognized $462.4 million of revenues related to the License Sale in the three and six months ended June 30, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">We determined that the variable milestone payment related to Manufacturing Development Services should be allocated to the Manufacturing Development performance obligation. We concluded that this milestone payment represents the SSP of the services based on the estimated cost of providing the services including a reasonable margin. The services related to Manufacturing Development will be provided between Closing and the completion of an agreed manufacturing development plan. The variable consideration will be reduced if we do not complete the development by pre-agreed dates. We utilized the most likely amount method to estimate the variable consideration to be included in the transaction price. Completion of Manufacturing Development is partially dependent on the timing of regulatory submissions by CSL Behring as well as regulatory approvals of the developed manufacturing processes. Since we cannot control the timing or outcome of any regulatory decisions, we concluded that we would recognize revenue related to this payment when it becomes probable that the milestone has been achieved. We did not recognize any revenue related to Manufacturing Development during the three and six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">We recognized $0.4 million of collaboration revenue in the three and six months ended June 30, 2021, compared to nil in the same periods in the prior year.</span> We generate such collaboration revenue from services rendered in relation to completing the HOPE-B clinical trial on behalf of CSL Behring. CSL Behring may request <span style="background-color:#ffffff;">additional development services or to request us to support the transfer of manufacturing to a party designated by CSL Behring. These collaboration services will be reimbursed at the pre-agreed full-time-employee rate (&#8220;FTE-rate&#8221;). </span>We concluded that these rights at Closing do not represent material rights.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also analyzed the impact of Closing on our net deferred tax asset in the Netherlands. Prior to Closing we had determined that the potential Closing would represent insufficient positive evidence to overcome the significant negative evidence of having been loss-making during the past three years. Accordingly, we had therefore recorded a full valuation allowance related to our net deferred tax assets. We determined that in accordance with Dutch tax law the upfront payment as well as payments related to the Additional Covenants, to the extend such activities were conducted in the 12 months ended December 31, 2020, can more likely than not be included in the Dutch tax return for the 12-month period ended December 31, 2020. Including this income in our 2020 tax position will consume substantially all of our Dutch net operating losses for the years 2011 to 2018. We treated the adjustment to our 2020 filing position resulting in the release of the valuation allowance related to our Dutch net operating losses for the years 2011 to 2018 as a discrete event in the three months ended June 30, 2021. We allocated part of the release to the tax benefit of share issuance cost incurred in 2014, 2015, 2017 and 2018. This resulted in an increase of additional paid- in capital as well as the recognition of deferred tax expenses of $3.0 million during the three and six months ended June 30, 2021. Based on changes to Dutch tax law enacted in June 2021 our remaining net operating tax loss related to 2019 can be carried forward indefinitely. We continue to expect incurring tax losses for the foreseeable future including 2021. As such, we retain our full valuation allowance related to the remaining net deferred asset as of June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Revenues</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">We estimate the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At inception of each arrangement that includes variable consideration, we evaluate the amount of potential payments and the likelihood that the payments will be received. We utilize either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur in a future period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">We allocate the transaction price based on the estimated SSP of each of the performance obligations. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts that we expect to receive for the satisfaction of each performance obligation. We recognize revenue when or as control of the performance obligation transfers to the customer. For performance obligations which consist of licenses and other promises, we utilize judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">CSL Behring &#160; &#160; </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.95pt;margin:6pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">       </span>Following the Closing of the CSL Behring agreement, we recognize license revenue related to the License Sale of the global rights to the Product. We evaluated that our performance obligation related to the License Sale was satisfied on Closing and recognized $462.4 million in license revenue related to a $450.0 million upfront payment and $12.4 million of payments in relation to Additional Covenants. We will recognize additional license revenue in relation to the License Sale when it becomes probable that regulatory and sales milestone events will be achieved as well as when royalties on sales of Product have been earned.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:30.95pt;margin:6pt 0pt 0pt 0pt;">We recognize collaboration revenues associated with Manufacturing Development. We will recognize collaboration revenue related to a contractual development milestone when it becomes probable the milestone will be achieved.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:30.95pt;margin:0pt;">We recognize collaboration revenues associated with Development Services that will be reimbursed by CSL Behring relating to clinical development activities. These services are provided by our employees. Collaboration revenue related to these contracted services is recognized when the performance obligations are satisfied. </p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">BMS</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In May 2015, we and Bristol-Myers Squibb (&#8220;BMS&#8221;) entered into a collaboration and license agreement and various related agreements with BMS (&#8220;BMS CLA&#8221;). We have recognized license revenues associated with the amortization of the non-refundable upfront payment and target designation fees we received from BMS in accordance with the BMS CLA. We evaluated our outstanding performance obligation following the amendment of the BMS CLA on December 1, 2020 (&#8220;amended BMS CLA&#8221;) and determined that our remaining performance obligation related to license revenues is immaterial. We updated our measure of progress accordingly and amortized the remaining balance of unrecognized revenue as of December 1, 2020. In accordance with the amended BMS CLA, we continue to be eligible to receive research, development, and regulatory milestone payments as well as sales milestone payments and royalties for each of the four active Collaboration Targets if defined milestones are achieved in relation to the license to our technology and know-how. We will recognize revenue from these payments when earned or as sales occur. </p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:30.95pt;margin:6pt 0pt 12pt 0pt;">We recognize collaboration revenues associated with Collaboration Target-specific pre-clinical analytical development and process development activities that are reimbursable by BMS under the BMS CLA and the amended BMS CLA as well as other related agreements. Collaboration revenue related to these contracted services is recognized when performance obligations are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Cost of Contract Revenues</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.3pt;margin:6pt 0pt 0pt 0pt;">We expense contract fulfillment costs associated with license revenue recognized under the CSL Behring Agreement as costs of contract revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Research and development expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.3pt;margin:6pt 0pt 0pt 0pt;">We expense research and development (&#8220;R&amp;D&#8221;) expenses as incurred. Our R&amp;D expenses generally consist of costs incurred for the development of our target candidates, which include:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Employee-related expenses, including salaries, benefits, travel and share-based compensation expense;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Costs incurred for laboratory research, preclinical and nonclinical studies, clinical trials, statistical analysis and report writing, and regulatory compliance costs incurred with clinical research organizations and other third-party vendors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Costs incurred to conduct consistency and comparability studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Costs incurred for the development and improvement of our manufacturing processes and methods;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Costs associated with our research activities for our next-generation vector and promoter platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Costs associated with the rendering of collaboration services as well as the continued development of Product between Signing and Closing; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance, and other supplies.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.29;text-align:justify;text-indent:36pt;margin:0pt 0.2pt 12pt 0pt;">Our research and development expenses may vary substantially from period to period based on the timing of our research and development activities, including manufacturing campaigns, regulatory submissions and enrollment of patients in clinical trials. The successful development of our product candidates is highly uncertain. Estimating the nature, timing or cost of the development of any of our product candidates involves considerable judgement due to numerous risks and uncertainties associated with developing gene therapies, including the uncertainty of:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the scope, rate of progress and expense of our research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">our ability to successfully manufacture and scale-up production;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">clinical trial protocols, speed of enrollment and resulting data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the effectiveness and safety of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">the timing of regulatory approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.35pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">our ability to agree to ongoing development budgets with collaborators who reimburse the costs of our development programs.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.29;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">A change in the outcome of any of these variables with respect to our product candidates that we may develop, including as a result of the Covid pandemic, could mean a significant change in the expenses and timing associated with the development of such product candidate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selling, general and administrative expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">Our general and administrative expenses consist principally of employee, office, consulting, legal and other professional and administrative expenses. We incur expenses associated with operating as a public company, including expenses for personnel, legal, accounting and audit fees, board of directors&#8217; costs, directors&#39; and officers&#39; liability insurance premiums, Nasdaq listing fees, expenses related to investor relations and fees related to business development and maintaining our patent and license portfolio. Our selling costs include employee expenses, as well as professional fees related to the preparation of a commercial launch of etranacogene dezaparvovec and advisory fees related to obtaining the CSL Behring Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other items, net</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">Our other income primarily consists of payments received to subsidize our research and development efforts, income from the subleasing of our Amsterdam facility, the recognition of the equity stake received in VectorY B.V., as well as an employee retention credit under the U.S. Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">Our other expense primarily consists of expenses we incur in relation to our subleasing income.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the three months ended June 30, 2021 and 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents a comparison of our results of operations for the three months ended June 30, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d9638164_9b45_4db1_8849_d697e3b85c16"></a><a id="_ad6619b2_77fe_4e06_945b_ec72508be465"></a><a id="_f81bf420_d841_4c59_86df_1f03dfe9c5a8"></a><a id="_d9bd29d2_e286_435a_924a_e0cf59a64098"></a><a id="_2dfe1551_cc12_4a5a_a49c_b40393125e14"></a><a id="_53d0410e_7735_4e54_b69e_6b38ac7ffd54"></a><a id="_da7e3b88_1b7a_43be_9828_eb92069365ae"></a><a id="_01b6f5ab_8124_4970_b69a_7c82eb440aba"></a><a id="_e48f1f53_431d_486e_94cb_e7f9c8592ee1"></a><a id="_60aa0b4f_2e12_4c07_9a21_5c89b685f069"></a><a id="_d3ed4682_186e_475d_b6f1_05bf70cfe09b"></a><a id="_f54d104a_22e4_42c1_95df_497463355632"></a><a id="_07c5cfd3_9f02_4ffd_88dc_a168fbf68726"></a><a id="_45d99266_eb2b_4c0d_8e44_85ff05217570"></a><a id="_0fe3dcce_c99c_41bb_8606_213c5d94dfee"></a><a id="_7a0eba4f_83f7_4b6e_9978_fb37d391a9bb"></a><a id="_9c70b886_9151_4850_abf5_a11eb00f776a"></a><a id="_f90c7c8a_7f99_48ca_9f52_2622332a91ce"></a><a id="_86e4c380_bdda_4cfb_95c9_4d12c37a7ed7"></a><a id="_e2a944c5_9eca_4bd2_bfe9_79542b6e4f34"></a><a id="_6dffed41_b185_4d82_a15a_f73f389f37d0"></a><a id="_4604fc13_34a2_477e_9f63_b7f83426b870"></a><a id="_b28d579f_b89d_4004_b4ef_53387f30ff54"></a><a id="_1797682a_23d3_4c99_b120_e20988daaf4d"></a><a id="_e9d49774_5910_4626_8e66_79319f8eb914"></a><a id="_017750fe_829b_4429_9c36_704e2eaa8b78"></a><a id="_8c5257c5_53d8_4e1a_8f1b_d17ec825010f"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:35.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021 vs 2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 463,868</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,535</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 462,333</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of contract revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,178)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,178)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,747)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,401)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,346)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17,299)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,511)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,788)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (73,224)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (39,912)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (33,312)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,590</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 669</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,921</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (226)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (500)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 274</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Income / (loss) from operations</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 398,008</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (38,208)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 436,216</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-operating items, net</p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,718</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,343)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,061</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net income / (loss) before income tax expense</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 402,726</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,551)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 445,277</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense </p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,258)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;white-space:pre-wrap;"> -</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,258)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net income / (loss) </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 399,468</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,551)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;"> </b><b style="font-weight:bold;">442,019</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our revenue for the three months ended June 30, 2021 and 2020 was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_453ec1aa_d257_44f9_9080_6acab21dae0c"></a><a id="_624f2b74_0dcf_461c_8fb0_4ce0581020bf"></a><a id="_dceaa271_4d44_4b66_8590_7974b8c46e33"></a><a id="_8ed7440e_b6a0_4f14_b2de_dbfb3982c6a3"></a><a id="_e04f49f3_6c73_4bbd_ae9a_24e39c736e36"></a><a id="_dc9fe91c_608f_47af_a8a8_d6ba776e3dac"></a><a id="_b1b0105b_d502_46d1_a741_f32404dfad72"></a><a id="_159455eb_d519_4542_8c58_9ef631f477d4"></a><a id="_da270f97_a50b_408b_87a5_83d657082e93"></a><a id="_c24da48d_8cb9_4da7_84c3_037ef5bfc36c"></a><a id="_4a71cf82_b56b_4bf0_b634_80f206edaa54"></a><a id="_5439262c_fb1c_4496_8d64_61bdd231ea1c"></a><a id="_c796d29b_17fa_4525_9a07_8b069b0d9c2e"></a><a id="_d0043f39_317e_4d23_9f91_99c274079e23"></a><a id="_fbccaacd_e5ad_4b26_87ab_9168b0c057dc"></a><a id="_765d489c_5634_4eb6_b712_a85d03ed5e40"></a><a id="_3d0a4b90_a029_4398_b1f9_f2a00dbb56fd"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1.25pt;"><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.3pt;"><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:36.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td></tr><tr style="height:10.1pt;"><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><div style="height:10.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.42%;margin:0pt;padding:0pt;"><div style="height:10.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.12%;margin:0pt;padding:0pt;"><div style="height:10.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.12%;margin:0pt;padding:0pt;"><div style="height:10.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:10.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021 vs 2020</b></p></div></div></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr style="height:11.3pt;"><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:top;white-space:normal;width:36.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr style="height:11.5pt;"><td style="background-color:#cceeff;vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">License revenue</p></td><td style="background-color:#cceeff;vertical-align:middle;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 462,400</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,530</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 460,870</span></p></td></tr><tr style="height:11.5pt;"><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Collaboration revenue</p></td><td style="vertical-align:middle;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,468</span></p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,463</span></p></td></tr><tr style="height:11.5pt;"><td style="background-color:#cceeff;vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total revenues</b></p></td><td style="background-color:#cceeff;vertical-align:middle;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.46%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.87%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 463,868</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.32%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.89%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,535</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.32%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.27%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 462,333</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognized $462.4 million in license revenue related to the License Sale on Closing of the CSL Behring Agreement in May 2021. We did not recognize any such license revenue related to the CSL Behring Agreement in the three months ended June 30, 2020. </p><a id="_Hlk77614638"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">We recognized $1.5 million in license revenue related to upfront payments and target designation fees received from BMS in 2015 under the BMS CLA for the three months ended June 30, 2020. We did not recognize any license revenue under the amended BMS CLA during the three months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>We recognized $1.5 million collaboration revenue in the three months ended June 30, 2021, compared to $0.0 million for the same period in 2020. Since May 6, 2021, we recognize collaboration revenue related to services we provide in accordance with the CSL Behring Agreement. Our collaboration revenue increased further as a result of increased services provided to BMS following our December 2020 amendment of the BMS CLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:10pt 0pt 10pt 18pt;"><i style="font-style:italic;">Cost of contract revenues</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:10pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="display:inline-block;width:18pt;"></span>We recognized $23.2 million in cost of contract revenues for the three months ended June 30, 2021, compared to nil the same period in 2020. We recorded $16.7 million of expenses related to payments owed to our licensors on Closing as well as $6.5 million of other external expenses incurred to fulfill the License Sale to CSL Behring.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt 0.2pt 12pt 0pt;"><i style="font-style:italic;">Research and development expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses for the three months ended June 30, 2021 were $32.7 million, compared to $28.4 million for the same period in 2020. Other research and development expenses are separately classified in the table below. These are not allocated as they are deployed across multiple projects under development.</p><a id="_1055182c_b0d0_4151_9d78_206450337f9b"></a><a id="_3e566e6a_8fd2_471c_9d89_f3ae40719a89"></a><a id="_c87328f0_3ffe_4083_aa98_d7b4c1700792"></a><a id="_39efb04e_399e_4363_8b3e_ebb5cfa3f16b"></a><a id="_3e213310_1fc6_465d_bf10_c5f6581e8c3b"></a><a id="_b05854ec_1b84_4da0_9f71_3bdd7c4b53b7"></a><a id="_e4c5af5f_2cff_4d1d_a30d_2e4ce2062a56"></a><a id="_a4d3663d_1bb0_4636_a9de_6cbdf99c5b2d"></a><a id="_fd08f66b_3be8_4d76_896a_c78d1fba2183"></a><a id="_f2411c24_e418_41a1_bfff_f34e3227e337"></a><a id="_9dae5145_e333_4841_982c_075f8e1d140a"></a><a id="_f8a790ea_bc9a_4bc2_af99_35f28840cf9d"></a><a id="_9723da86_7f51_49d4_b6da_224422fcfa5c"></a><a id="_3c6c2216_0cbb_41ca_b615_78c78fa12b51"></a><a id="_06a80bcb_9ddf_4116_81e7_5cf18e0ee6c4"></a><a id="_1dbc7a6e_ea75_4a89_ae89_ffd66ac74002"></a><a id="_ebde03df_995b_4f6e_afd3_3b244ade2f56"></a><a id="_455abf31_425e_4790_b2cf_5561645680d4"></a><a id="_92105009_01e7_41cb_a73b_6a662bde703e"></a><a id="_8a3ceb35_df8e_47a7_bbfc_c3074e9a1472"></a><a id="_f3d2d6c1_18bd_4969_abd1_52022a5eb349"></a><a id="_ea630c21_cc61_4c9c_9f09_f96994114808"></a><a id="_b2672564_c608_485d_ba71_6bb50f9cd320"></a><a id="_567c79b0_ac0c_46ec_aca4_1c3703352eed"></a><a id="_45fadc30_1e50_4828_9769_9f9666857ff5"></a><a id="_a7ada66a_cb63_4fce_9a41_b84a914b0afa"></a><a id="_43c6d827_7055_406d_8702_1fd3ddead58a"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021 vs 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:top;white-space:nowrap;width:35.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Etranacogene dezaparvovec (AMT-060/061)</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,332</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,673</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,341)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Huntington&#39;s disease (AMT-130)</p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,472</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,095</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 377</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Programs in preclinical development and platform related expenses</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,425</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,770</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 655</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total direct research and development expenses</b></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 7,229</b></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 8,538</b></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (1,309)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee and contractor-related expenses</p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,082</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,990</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,092</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facility expenses</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,397</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,185</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 212</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Disposables</p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,601</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,501</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,100</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,286</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,894</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 392</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expenses</p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,152</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 293</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 859</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total other research and development expenses</b></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 25,518</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 19,863</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 5,655</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total research and development expenses</b></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 32,747</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 28,401</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,346</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Direct research and development expenses </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Etranacogene dezaparvovec (AMT-060/061)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">In the three months ended June 30, 2021 and 2020, the external costs for our hemophilia B program were primarily related to the execution of our Phase III clinical trial. We enrolled patients into a six-month lead in phase between January 2018 and September 2019 and dosed a total of 54 patients between January 2019 and March 2020. We also incur costs related to the long-term follow-up of patients in our Phase I/II clinical trial of AMT-060 and our Phase IIb clinical trial of etranacogene dezaparvovec. During 2020 and up to the Closing of the CSL Behring Agreement we also incurred costs related to the preparation of a Biologics License Application (&#8220;BLA&#8221;) and marketing authorization application (&#8220;MAA&#8221;) and for commercialization of the Product. After the Closing, CSL Behring will be responsible for the clinical and regulatory development and commercialization of the Product. Direct research and development expenses related to clinical development incurred between Closing and June 30, 2021 are presented net of reimbursements due from CSL Behring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Huntington disease (AMT-130)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the three months ended June 30, 2021, and June 30, 2020, our external costs for the development of Huntington&#8217;s disease were primarily related to the execution of our Phase I/II clinical trial in the United States. In addition, our external costs in the three months ended June 30, 2021, included expenses related to the preparation of our Phase I/II clinical trial in Europe that we announced in April 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Preclinical programs &amp; platform development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the three months ended June 30, 2021, we incurred $2.4 million of costs primarily related to our preclinical activities primarily associated with product candidates, SCA3 (AMT-150) and Fabry disease (AMT-190 and AMT-191), as well as various other research programs and technology innovation projects, compared to costs of $1.8 million in the same period in 2020, which also included costs related to our product candidate for Hemophilia A (AMT-180) that was deprioritized in June 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk76756874"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Other research &amp; development expenses</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $13.1 million in personnel and contractor related expenses in the three months ended June 30, 2021, compared to $10.0 million for the same period in 2020. Our costs during the three months ended June 30, 2021 increased by $3.1 million as a result of the recruitment of personnel to support the development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $4.4 million in operating expenses and depreciation expenses related to our rented facilities in the three months ended June 30, 2021, compared to $4.2 million in the same period in 2020; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $3.3 million in share-based compensation expenses in the three months ended June 30, 2021, compared to $2.9 million for the same period in 2020 primarily driven by increase in awards granted, including those to newly recruited personnel.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:10pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, general and administrative expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0pt 10pt 0pt;">Selling, general and administrative expenses for the three months ended June 30, 2021 were $17.3 million, compared to $11.5 million for the same period in 2020. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $4.5 million in financial advisory fees in relation to our licensing transaction with CSL Behring in the three months ended June 30, 2021, compared to nil in the same period in 2020;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $4.2 million in personnel and contractor related expenses in the three months ended June 30, 2021, compared to $2.9 million in the same period in 2020. The increase in the three months ended June 30, 2021, relates to the recruitment of personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $3.7 million in share-based compensation expenses in the three months ended June 30, 2021, compared to $2.8 million in the same period in 2020 primarily driven by increase in awards granted, including those to newly recruited personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $2.0 million in professional fees in the three months ended June 30, 2021, compared to $3.0 million in the same period in 2020. </span><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We regularly incur accounting, audit and legal fees associated with operating as a public company. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 6pt 0pt;"><i style="font-style:italic;">Other items, net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">We recognized $3.0 million in other income in relation to the equity stake received in VectorY B.V. in conjunction with the Settlement Agreement in the three months ended June 30, 2021, compared to no such income for the same period in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">We recognized $1.3 million in other income of employee retention credit under the U.S. CARES Act in the three months ended June 30, 2021, compared to no such income for the same period in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">We recognized $3.0 million in other income from payments received from European authorities to subsidize our research and development efforts in the Netherlands in the three months ended June 30, 2021, compared to $0.3 million for the same period in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Other non-operating items, net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0pt 10pt 0pt;">We recognize interest income associated with our cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0pt 10pt 0pt;">We hold monetary items and enter into transactions in foreign currencies, predominantly in euros and U.S. dollars. We recognize foreign exchange results related to changes in these foreign currencies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"><span style="font-family:'Times';">We issued warrants to BMS in 2015. We recognize changes in the fair value of these warrants within other non-operating income / (expense). &#160;Following the termination of the BMS warrants on December 1, 2020, we no longer recognize changes in the fair value of these warrants within other non-operating (expense) / income. </span>As of the same date, we recognized a derivative financial liability related to a contingent payment due to BMS upon the consummation of a change of control transaction (&#8220;CoC-payment&#8221;) as described elsewhere in the Quarterly Report on Form 10-Q<span style="font-family:'Times';">. </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our other non-operating items, net, for the three months ended June 30, 2021 and 2020 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><a id="_fea89f80_32fc_4c10_b305_aa86af6f2c0d"></a><a id="_23df7324_38c3_446d_8860_9bc89e89f008"></a><a id="_dccd763a_d2ad_43a9_9766_3d10e55447d0"></a><a id="_17d358cf_5309_4074_bc70_868f447eae9a"></a><a id="_8d283915_18ff_4ce6_8613_bec1d5dbdd48"></a><a id="_ef652ccb_0eb4_4e57_9143_5085a40784fd"></a><a id="_ec101243_49a9_4b35_a65c_cfc010d72101"></a><a id="_6f8d1351_aea1_4815_8346_a2deae452927"></a><a id="_1ea5443c_b5da_4028_b693_3dd3426223f9"></a><a id="_24f32866_08e7_4953_ad1d_0bd05eb27a4f"></a><a id="_2ce7991e_4326_4b99_98fd_9ae9d1a84a2a"></a><a id="_ca27a4ee_5364_4747_ae84_09085d3ef73f"></a><a id="_a692182b_cd0c_4cb0_a051_74c2f43190c6"></a><a id="_4a0b6b35_3033_4b72_85ae_8c38fb908513"></a><a id="_33af9d42_c551_4a93_8d96_8711fa55478c"></a><a id="_9d30e17a_0728_4256_aa48_98fe8c7609bb"></a><a id="_d9cf0f27_d420_4065_acfa_56995c121c9c"></a><a id="_7a0a4194_4277_4c3f_b9ea_86a3aec532d8"></a><a id="_239e9f1f_0add_4008_9cb5_5a5ffeff6cf9"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:35.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021 vs 2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:62.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:top;white-space:normal;width:35.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 81</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (44)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense - Hercules long-term debt</p></td><td style="vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,902)</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (970)</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (932)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency gains / (losses), net</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,583</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,645)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,228</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-operating gains</p></td><td style="vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 191</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (191)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total other non-operating income / (loss), net</b></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,718</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (4,343)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 9,061</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">We recognized a net foreign currency gain, related to our borrowings from Hercules and our cash and cash equivalents as well as loans between entities within the uniQure group, of $6.6 million during the three months ended June 30, 2021, compared to a net loss of $3.6 million during the same period in 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the three months ended June 30, 2021, we recognized income of nil within other non-operating gains as there was no change in the fair value of the BMS derivative financial liability for the CoC-payment, compared to income of $0.2 million during the same period in 2020 related to changes in the fair value of the BMS warrants from the BMS CLA. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Income tax expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">We recognized $3.3 million of deferred tax expense in the three months ended June 30, 2021, and nil in the same period ended 2020. &#160;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">Comparison of the six months ended June 30, 2021 and 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;"><span style="background-color:#ffffff;">The following table presents a comparison of the six months ended June 30, 2021 and 2020.</span></p><a id="_879a5b01_1da2_4101_9144_cba1f1eaf7e3"></a><a id="_50cc47de_faca_4dfb_a396_d2c2722eb53a"></a><a id="_5d712895_e136_48ea_9cbd_e661404cf302"></a><a id="_28cefbe6_4b64_4aab_8213_bd951fc833ca"></a><a id="_b9f66db0_ae96_4258_b242_ec2f47bd3d76"></a><a id="_3f531449_9add_4223_853f_e8c8a10fa692"></a><a id="_186771a8_c2a9_4641_a13f_f2c4a3cfc916"></a><a id="_5e1d706c_ef7a_46c0_a4ca_bc09923c5f88"></a><a id="_e2fdbd55_b046_48c8_8b51_4446c109d218"></a><a id="_6c17636a_6d82_4c09_a786_9973204e709a"></a><a id="_aed11c4f_d3cf_4903_8d80_771c065bf7fa"></a><a id="_b15844cf_7fa4_4aee_88bb_b2c73061d475"></a><a id="_225a5c89_228a_4d55_9850_cec2c5e526b1"></a><a id="_5d7b170d_bb5a_4463_bd5b_59ac5ace357c"></a><a id="_809a4832_917a_4cca_843f_720ae1a66768"></a><a id="_51dfeb1a_0777_430f_a602_6b6459eb793f"></a><a id="_d5fc82e4_0cf7_48cd_9582_dcdaea483463"></a><a id="_1b657956_6136_48c9_ab28_df1d94b6f38e"></a><a id="_29422011_b70b_4ffe_86f3_70346922e576"></a><a id="_0e2a7421_cddc_4494_b100_f29100169b7a"></a><a id="_88c99714_1cef_42e4_bc30_9c046307b557"></a><a id="_3d7a52b5_ea9e_4eb9_b611_3393472a38ce"></a><a id="_f4f1731c_5716_4306_91cf_8044e7bd5c55"></a><a id="_ad3a2bc8_6563_4d51_9855_2609d0195faf"></a><a id="_0559588f_24ef_4f05_9c12_9d69400ddecd"></a><a id="_a7b5a96f_889e_4da5_bd2c_4edbaa676ebb"></a><a id="_2c75de95_e49f_4e67_957e_3e6cc295e792"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:35.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021 vs 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:top;white-space:nowrap;width:35.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 464,322</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,639</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 462,683</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of contract revenues</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,178)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,178)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (64,777)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (54,414)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,363)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (30,300)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (20,583)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,717)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (118,255)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (74,997)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (43,258)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,942</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,526</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,416</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (459)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (839)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 380</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Income / (loss) from operations</b></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 353,550</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (72,671)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 426,221</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-operating items, net</p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,833</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,121</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,712</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Income / (loss) before income tax expense</b></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 361,383</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (70,550)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 431,933</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,471)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,471)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net income / (loss)</b></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 357,912</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (70,550)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 428,462</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:6pt 0pt 12pt 0pt;"><i style="background-color:#ffffff;font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18pt;margin:6pt 0pt 12pt 18pt;">Our revenue for the six months ended June 30, 2021 and 2020 was as follows:</p><a id="_f3fd631b_0024_47d8_965e_a61d932b8587"></a><a id="_9147a399_3804_4cfa_8a35_c4fd9a2b77ee"></a><a id="_ab303684_5866_49ab_b32c_49c31632c4f6"></a><a id="_00b4ebc2_90c1_41e8_a3dc_1c8cb1294300"></a><a id="_b77417cc_29e3_4c5f_b846_ad8ed0276692"></a><a id="_c7317f0c_0955_42db_af63_d5650d709d8d"></a><a id="_52702400_2c74_42d9_a49d_d51d9a4665de"></a><a id="_9be56271_0cad_4989_b85f_fdff507b2860"></a><a id="_313f1d48_3ca0_4de2_958a_46218ac7983a"></a><a id="_49741283_55bc_4a62_b958_1859299715a0"></a><a id="_176e44a3_25ed_45ce_bbbe_a72acf232aa0"></a><a id="_56321150_a29c_49e1_8f31_a9232846f58c"></a><a id="_a5735618_a13d_44ef_8136_5f43293a2830"></a><a id="_84c61ec9_b006_4802_a9d0_900f103bc8b6"></a><a id="_4dae1622_a3c7_4745_a8db_3a19e66ba161"></a><a id="_61ca3e74_d58a_4e98_bba9_12366c0c5318"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021 vs 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">License revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 462,400</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,577</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 460,823</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Collaboration revenue</p></td><td style="vertical-align:middle;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,922</span></p></td><td style="vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 62</span></p></td><td style="vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,860</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total revenues</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 464,322</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,639</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 462,683</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">We recognized $462.4 million license revenue related to the License Sale on Closing of the CSL Behring Agreement in May 2021. We did not recognize any such license revenue related to the CSL Behring Agreement in the six months ended June 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">We recognized $1.6 million license revenue related to upfront payments and target designation fees received from BMS in 2015 under the BMS CLA for the six months ended June 30, 2020. We did not recognize any license revenue under the amended BMS CLA during the six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">We recognized $1.9 million collaboration revenue in the six months ended June 30, 2021, compared to $0.1 million for the same period in 2020. The increase in collaboration revenue primarily relates to the increased activities under the amended BMS CLA and the CSL Behring Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:10pt 0pt 10pt 18pt;"><i style="font-style:italic;">Cost of contract revenues</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:10pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="display:inline-block;width:18pt;"></span>We recognized $23.2 million in cost of contract revenues for the six months ended June 30, 2021 compared to nil the same period in 2020. We recorded $16.7 million of expenses related to payments owed to our licensors on Closing as well as $6.5 million of other external expenses incurred to fulfill the License Sale to CSL Behring.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Research and development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">       </span>Research and development expenses for the six months ended June 30, 2021 were $64.8 million, compared to $54.4 million for the same period in 2020. Other research and development expenses are separately classified in the table below. These are not allocated as they are deployed across multiple projects under development.</p><a id="_b6bed325_53df_47b1_8e0b_6823f861499b"></a><a id="_3f67f064_8bf6_43e2_932c_5ac782dfce1a"></a><a id="_f6cfcf6c_4916_43df_8bf1_5588bc8f7164"></a><a id="_96cb4e4a_252d_489b_8836_226c73d1290c"></a><a id="_8df7030a_756d_464b_a2e2_5f0788e62974"></a><a id="_fe03f902_9c42_445a_b32f_94b6de78fde9"></a><a id="_976d64f9_d4ab_422d_88e1_d1c740c30929"></a><a id="_8c2c6aa9_9e67_45a6_aa60_aecc3f4d7cfd"></a><a id="_22fbd9cb_aa1b_4491_986d_cfb252844969"></a><a id="_96fec72a_8301_4dd5_8ca2_72a307440ba5"></a><a id="_3bb8b800_1dc9_49e9_bcdb_4c63188d38de"></a><a id="_d2814c51_93b5_4000_a3b1_1d7c6e3cd188"></a><a id="_fa7dc6de_7ecc_4ffc_8b8e_cc8f51f12316"></a><a id="_e844688a_7a58_4d8c_bb15_c8a80857b3f3"></a><a id="_bf584882_5a0f_4e78_a4c4_c2deef9771ca"></a><a id="_a056702e_4a6b_409b_8e37_96ea6d32cb64"></a><a id="_457ffffb_2896_4e98_a956_ff7485065c85"></a><a id="_1a848fb0_01ea_4d51_88fe_b1d0d7454e1b"></a><a id="_d822e6b5_5b44_44c2_b150_d8eab5887028"></a><a id="_fd843242_6a78_492f_9d91_29f52825d71b"></a><a id="_e19174f1_e352_410f_8994_bd5162539343"></a><a id="_3f0b7597_ab1c_4f87_a398_b5e6ee764c49"></a><a id="_3b7cb67c_fe7f_447b_be5f_b2b2e36640b6"></a><a id="_0c0497a2_9ea4_494e_a6af_efd54e4a0b8c"></a><a id="_f6804571_ace3_40e7_8a9a_6e5e310bbb32"></a><a id="_7dcac728_c997_4dfd_a0a5_a61725d52859"></a><a id="_24a23bf0_be3d_465b_a382_aad4623e87c1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:50.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021 vs 2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:top;white-space:nowrap;width:50.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Etranacogene dezaparvovec (AMT-060/061)</p></td><td style="background-color:#cceeff;vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,979</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,213</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,234)</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Huntington&#39;s disease (AMT-130)</p></td><td style="vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,443</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,155</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,288</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Programs in preclinical development and platform related expenses</p></td><td style="background-color:#cceeff;vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,714</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,225</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,489</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total direct research and development expenses</b></p></td><td style="vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 15,136</b></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 15,593</b></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (457)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee and contractor-related expenses</p></td><td style="vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,677</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,338</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,339</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facility expenses</p></td><td style="background-color:#cceeff;vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,021</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,201</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 820</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Disposables</p></td><td style="vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,945</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,911</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,034</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,960</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,289</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 671</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expenses</p></td><td style="vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,038</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,082</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,956</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total other research and development expenses</b></p></td><td style="background-color:#cceeff;vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 49,641</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 38,821</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 10,820</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total research and development expenses</b></p></td><td style="background-color:#cceeff;vertical-align:middle;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 64,777</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 54,414</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 10,363</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Direct research and development expenses </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Etranacogene dezaparvovec (AMT-060/061)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">In the six months ended June 30, 2021 and 2020, the external costs for our hemophilia B program were primarily related to the execution of our Phase III clinical trial. We enrolled patients into a six-month lead in phase between January 2018 and September 2019 and dosed a total of 54 patients between January 2019 and March 2020. We also incur costs related to the long-term follow-up of patients in our Phase I/II clinical trial of AMT-060 and our Phase IIb clinical trial of etranacogene dezaparvovec. During 2020 and up to the Closing of the CSL Behring Agreement, we also incurred costs related to the preparation of a BLA and MAA and for commercialization of the Product. After the Closing, CSL Behring will be responsible for the clinical and regulatory development and commercialization of the Product. Direct research and development expenses related to clinical development incurred between Closing and June 30, 2021, are presented net of reimbursements due from CSL Behring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Huntington disease (AMT-130)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the six months ended June 30, 2021 and June 30, 2020, our external costs for the development of Huntington&#8217;s disease were primarily related to the execution of our Phase I/II clinical trial in the United States. In addition, our external costs in the six months ended June 30, 2021, included expenses related to the preparation of our Phase I/II clinical trial in Europe that we announced in April 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Preclinical programs &amp; platform development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the six months ended June 30, 2021, we incurred $4.7 million of costs primarily related to our preclinical activities primarily associated with product candidates, SCA3 (AMT-150) and Fabry disease (AMT-190 and AMT-191), as well as various other research programs and technology innovation projects, compared to costs of $3.2 million in the same period in 2020, which also included costs related to our product candidate for Hemophilia A (AMT-180) that was deprioritized in June 2020.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk76756859"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Other research &amp; development expenses</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $24.7 million in personnel and contractor related expenses in the six months ended June 30, 2021, compared to $19.3 million for the same period in 2020. Our costs during the six months ended June 30, 2021 increased by $5.4 million as a result of the recruitment of personnel to support the development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $9.0 million in operating expenses and depreciation expenses related to our rented facilities in the six months ended June 30, 2021, compared to $8.2 million in the same period in 2020 as a result of expanding our organization; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $6.0 million in share-based compensation expenses in the six months ended June 30, 2021, compared to $5.3 million for the same period in 2020 primarily driven by increase in awards granted, including those to newly recruited personnel.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:10pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, general and administrative expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0pt 10pt 0pt;">Selling, general and administrative expenses for the six months ended June 30, 2021 were $30.3 million, compared to $20.6 million for the same period in 2020. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $8.1 million in personnel and contractor related expenses in the six months ended June 30, 2021, compared to $6.1 million in the same period in 2020. The increase in the six months ended June 30, 2021, relates to the recruitment of personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $6.8 million in share-based compensation expenses in the six months ended June 30, 2021, compared to $4.8 million in the same period in 2020 primarily driven by increase in awards granted, including those to newly recruited personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $5.0 million in professional fees in the six months ended June 30, 2021, compared to $4.2 million in the same period in 2020. </span><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We regularly incur accounting, audit and legal fees associated with operating as a public company; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We incurred $4.5 million in financial advisory fees in relation to our licensing transaction with CSL Behring in the six months ended June 30, 2021, compared to nil in the same period in 2020.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 6pt 0pt;"><i style="font-style:italic;">Other items, net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">We recognized $3.0 million in other income in relation to the equity stake received in VectorY B.V. in conjunction with the Settlement Agreement in the six months ended June 30, 2021, compared to no such income for the same period in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">We recognized $1.3 million in other income of employee retention credit under the U.S. CARES Act in the six months ended June 30, 2021, compared to no such income for the same period in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">We recognized $3.0 million in income from payments received from European authorities to subsidize our research and development efforts in the Netherlands in the six months ended June 30, 2021, compared $0.5 million for the same period in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Other non-operating items, net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0pt 10pt 0pt;">We recognize interest income associated with our cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0pt 10pt 0pt;">We hold monetary items and enter into transactions in foreign currencies, predominantly in euros and U.S. dollars. We recognize foreign exchange results related to changes in these foreign currencies. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times';">We issued warrants to BMS in 2015. We recognize changes in the fair value of these warrants within other non-operating income / (expense). &#160;Following the termination of the BMS warrants on December 1, 2020, we no longer recognize changes in the fair value of these warrants within other non-operating (expense) / income. </span>As of the same date, we recognized a derivative financial liability related to a contingent payment due to BMS upon the consummation of a CoC-payment as described elsewhere in the Quarterly Report on Form 10-Q<span style="font-family:'Times';">. </span></p><a id="_7a078626_a6ee_465e_8ef8_0a1c2857483a"></a><a id="_dab2a811_5326_4a2f_8673_d6d6abdcb07a"></a><a id="_bfb7c7e3_09f0_4696_97fb_a25c5144b751"></a><a id="_f0c58bb1_32f6_4fcd_ac9d_9466f2a8fc6e"></a><a id="_176a4283_d646_4528_9c2c_691f2d786278"></a><a id="_9bc9aaaf_5bbb_4681_a20f_e0f8cc89da39"></a><a id="_5fca86c2_9955_4bb0_895b_5b994f34519a"></a><a id="_5cff3f8f_b16e_406a_b7b1_dac305fa7110"></a><a id="_d6062684_1148_4239_945e_c2c16156e127"></a><a id="_f5ec6489_090e_42db_96d6_7ac20c0169ce"></a><a id="_593c681a_0267_40ca_bd8e_ade345c3ff02"></a><a id="_0664e9f8_d914_4e93_9e4a_9effdd0b9c22"></a><a id="_371a0fa1_398f_4501_886d_befd6a0ddcd3"></a><a id="_52869e3d_ae1b_480f_985d_c0605ba7d892"></a><a id="_439eff94_c535_48f7_8c11_05a9277eb8d3"></a><a id="_2b4e2453_6d42_43f0_9028_06ba50dd4481"></a><a id="_97d46cb5_b556_41b7_b3c2_9c504d9a1164"></a><a id="_9b48c186_642d_4b6d_9f0a_9cdfb45948cb"></a><a id="_03a2b27c_7193_4c1a_85f1_5b6e32821575"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:top;width:2.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021 vs 2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 77</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 903</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (826)</span></p></td></tr><tr><td style="vertical-align:top;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,453)</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,945)</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,508)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency gains, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,209</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 957</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,252</span></p></td></tr><tr><td style="vertical-align:top;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-operating gains, net</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,206</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,206)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-operating income, net</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 7,833</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,121</b></p></td><td style="background-color:#cceeff;vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 5,712</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">We recognized a net foreign currency gain, related to our borrowings from Hercules and our cash and cash equivalents as well as loans between entities within the uniQure group, of $11.2 million during the six months ended June 30, 2021, compared to a net gain of $1.0 million during the same period in 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the six months ended June 30, 2021, we recognized income of nil within other non-operating items as there was no change in the fair value of the BMS derivative financial liability for the CoC-payment, compared to income of $2.2 million during the same period in 2020 related to changes in the fair value of the BMS warrants from the BMS CLA. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Income tax expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">We recognized $3.5 million of deferred tax expense for the six months ended June 30, 2021 and nil in the same period ended 2020. &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Financial Position, Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">As of June 30, 2021, we had cash, cash equivalents and restricted cash of $680.2&#160;million which include payments received from CSL Behring following the Closing. This is expected to fund our operations into the first half of 2024 (assuming a full repayment of funds borrowed from Hercules under our term loan facility by 2023, as well as payments we expected to make in relation to our acquisition of Corlieve). We expect that the achievement of $0.3 billion of regulatory, first commercial sale, and development milestones would further extend our runway by 12 to 18 months.</p><a id="_48d3285e_7875_4e0f_9f6e_bf5afc4104c6"></a><a id="_e824a7b8_d908_47a0_9a4a_6e09a42d0dc9"></a><a id="_91da039d_328f_46b2_b0a0_1c7a1cd57563"></a><a id="_e226b45b_bd0f_42f6_b5b7_b3fbeffdaf75"></a><a id="_85895e8a_91f8_4011_b813_4b9319eb2223"></a><a id="_e028de91_05ba_4e69_81a4_697cbf692df0"></a><a id="_153f4bbc_0fe1_4144_b11e_8c87379f3082"></a><a id="_39230938_501c_4d31_846f_401b5d8537dd"></a><a id="_ad305a72_343e_4750_81d2_20e67667dfc5"></a><a id="_98c9c324_0b53_4bcd_9e89_30c189b2176b"></a><a id="_48e9d23d_1627_4c46_9f5d_52ee494316d6"></a><a id="_d4c9642c_2a86_46df_9129_eaa83d316fd5"></a><a id="_4f46669f_0ea9_4c36_906a_132710472ee0"></a><a id="_b734c822_e8d1_4b6b_96cb_3d112bd7aa68"></a><a id="_5a8c8353_b296_461e_9109_1c4fc5412dde"></a><a id="_f0a35eb1_7bdc_4d5a_b07d_5064186e5234"></a><a id="_abb26ba2_884c_49a2_bd98_7a5b0b0837b6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash at the beginning of the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 247,680</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 380,726</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net cash generated from / (used in) operating activities</p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 375,206</span></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (62,944)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net cash used in investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,191)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,606)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net cash generated from financing activities</p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,128</span></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,549</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign exchange impact</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,665)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 223</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash, cash equivalents and restricted cash at the end of period</b></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 680,158</b></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 316,948</b></p></td></tr></table><a id="_Hlk488862413"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had previously incurred losses and cumulative negative cash flows from operations since our business was founded by our predecessor entity AMT Therapeutics (&#8220;AMT&#8221;) Holding N.V. in 1998. As a result of receiving the upfront payment upon Closing of the CSL Behring Agreement, we generated $375.2 million cash flows from operations during the six months ended June 30, 2021. We recorded net income of $399.5 million and $357.9 during the three and six months ended June 30, 2021, compared to a net loss of $42.6 million and $70.6 million during the same period in 2020. As of June 30, 2021, we had an accumulated deficit of $426.8 million.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Sources of liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">From our first institutional venture capital financing in 2006 through May 2021, we funded our operations primarily through private and public placements of equity securities and convertible and other debt securities as well as payments from our collaboration partners. In May 2021, we received a $462.4 million cash payment due from CSL Behring upon Closing. In addition, we could potentially receive up to $0.3 billion in regulatory, first commercial sales and development milestone payments from CSL Behring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 1, 2021, we entered into a Sales Agreement with SVB Leerink with respect to an ATM offering program, under which we may, from time to time in our sole discretion, offer and sell through SVB Leerink, acting as agent, our ordinary shares, up to an aggregate offering price of $200.0 million. We will pay SVB Leerink a commission equal to 3% of the gross proceeds of the sales price of all ordinary shares sold through it as a sales agent under the Sales Agreement. In the six months ended June 30, 2021, we issued 921,730 million ordinary shares for net proceeds of $29.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">On December 6, 2018, we signed the 2018 Amended Facility with Hercules that both refinanced our then-existing $20.0 million credit facility and provided us with an additional unconditional commitment of $15.0 million as well as a conditional commitment of $15 million that expired on June 30, 2020. At signing, we drew down an additional $15.0 million, for a total outstanding amount of $35.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">The 2018 Amended Facility extended the loan&#8217;s maturity date until June 1, 2023. The interest-only period was initially extended from November 2018 to January 1, 2021. The interest-only period was further extended to January 1, 2022 as a result of raising more than $90.0 million in equity financing in September 2019. The interest-only period was again further extended to June 1, 2023 as a result of the 2021 Amended Facility. &#160;The variable interest rate of the 2018 Amended Facility is equal to the greater of (i) 8.85% or (ii) 8.85% plus the prime rate less 5.50%. Under the 2018 Amended Facility, we paid a facility fee equal to 0.50% at signing of the $35.0 million loan outstanding and will owe a back-end fee of 4.95% of the outstanding debt. In addition, in May 2020, we paid a back-end fee of $1.0 million in relation to the 2016 Amended Facility. </p><a id="_Hlk63097644"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:39.6pt;margin:0pt 0pt 12pt 0pt;">On January 29, 2021, we and Hercules entered into the 2021 Amended Facility. Pursuant to the 2021 Amended Facility, Hercules agreed to an additional Facility of $100.0 million (&#8220;Tranche B&#8221;), increasing the aggregate principal amount of the term loan facilities from $35.0 million to up to $135.0 million. On January 29, 2021, we drew down $35.0 million of the Tranche B. We may draw down the remaining $65.0 million under the Tranche B in a series of one or more advances of not less than $20.0 million each until December 15, 2021. Advances under the Tranche B bear interest at a rate equal to the greater of (i) 8.25% or (ii) 8.25% plus the prime rate, less 3.25% per annum. The principal balance and all accrued but unpaid interest on advances under the Tranche B is due on June 1, 2023, which date may be extended by us by up to two twelve-month periods. Advances under the Tranche B may not be prepaid until six-months after the Closing Date, following which we may prepay all such advances without charge. As of June 30, 2021, $70.0 million was outstanding under the 2018 Amended Facility and the 2021 Amended Facility (December 31, 2020: $35.0 million under the 2018 Amended Facility). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">We are subject to the same covenants under our 2018 Amended Facility and 2021 Amended Facility and may become subject to covenants under any future indebtedness that could limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends, which could adversely impact our ability to conduct our business. In addition, our pledge of assets as collateral to secure our obligations under the 2018 Amended Facility and 2021 Amended Facility may limit our ability to obtain debt financing. To the extent we need to finance our cash needs through equity offerings or debt financings, such financing may be subject to unfavorable terms including without limitation, the negotiation and execution of definitive documentation, as well as credit and debt market conditions, and we may not be able to obtain such financing on terms acceptable to us or at all. If financing is not available when needed, including through debt or equity financings, or is available only on unfavorable terms, we may be unable to meet our cash needs. If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, which could have a material adverse effect on our business, financial conditions, results of operations and cash flows.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Cash generated from / used in operating activities</span></p><a id="_Hlk488862500"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">Net cash generated from operating activities was $375.2 million for the six months ended June 30, 2021 and consisted of net income of $357.9 million adjusted for non-cash items, including depreciation and amortization expense of $3.7 million, share-based compensation expense of $12.8 million, unrealized foreign exchange gains of $12.3 million and other non-cash items, net, of $0.5 million. Net cash generated from operating activities also included favorable changes in operating assets and liabilities of $12.6 million. These changes primarily related to a net increase in accounts receivable, prepaid expenses, and other current assets and receivables of $3.4 million primarily related to an increase in various prepayments and a net increase in accounts payable, accrued expenses, other liabilities, and operating leases of $15.9 million primarily related to an increase in amounts to be paid to licensors upon the CSL Behring Closing. Net income primarily consisted of $462.4 million license revenue recognized on Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">Net cash used in operating activities was $62.9 million for the six months ended June 30, 2020 and consisted of a net loss of $70.6 million adjusted for non-cash items, including depreciation and amortization expense of $3.5 million, share-based compensation expense of $10.1 million, fair value gains on derivative financial instruments of $2.2 million, unrealized foreign exchange gain of $0.9 million, and a decrease in other non-cash items, net of $1.6 million. Net cash used in operating activities also included unfavorable changes in operating assets and liabilities of $1.3 million. These changes primarily related to a net decrease in accounts receivable and accrued income, prepaid expenses, and other current assets of $1.1 million and a net decrease in accounts payable, accrued expenses and other liabilities of $2.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;margin:6pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net cash used in investing activities </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">In the six months ended June 30, 2021, we used $6.2 million in our investing activities compared to $4.6 million for the same period in 2020. </p><a id="_750e1c5f_512a_4a1f_87b5_dfee74c94679"></a><a id="_65a1a0f7_a542_4e7c_a6cd_a47644352883"></a><a id="_1e025b6b_bf80_4602_954e_bfac26f0b802"></a><a id="_42f3a18f_c377_4ea7_b14f_513df19043e7"></a><a id="_a718986c_64eb_40f0_b937_1257d2c0aa55"></a><a id="_fa8d637f_4c1a_4ee1_8737_d696f25a6db1"></a><a id="_06baa37f_aa3a_4ec8_af17_1839c0da8d44"></a><a id="_5fdb2cb7_afe5_4632_bebe_b9605eb8a0f4"></a><a id="_8031e523_d081_46a8_891c_ad2dba89bcb5"></a><a id="_4dea7ba6_785b_4e37_bdd1_f3b6cedcb7e8"></a><a id="_fb39d274_491b_412a_b5d0_ebc989152951"></a><a id="_59257818_aa1e_41f3_9bfb_b60167f54ed8"></a><a id="_043a344a_a71d_4c8a_9797_b5fd345b0695"></a><a id="_b7e627f3_9562_43b9_94d6_7cbf55d9b903"></a><a id="_43fad8a0_6cbb_4fe5_ad3b_ad5325cc5bdf"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:31.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Build out of Amsterdam site</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,470)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:12.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,816)</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Build out of Lexington site</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,721)</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (576)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition of licenses, patents, and other rights</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,214)</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total investments</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (6,191)</b></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.57%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:12.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (4,606)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="display:inline-block;width:18pt;"></span>The build out of the Amsterdam site consumed $4.5 million cash during the six months ended June 30, 2021, compared to $1.8 million for the same period in 2020. The increase is a result of the construction of additional laboratories to support the expansions of our research and development activities as well as the construction of a cleanroom designed to be capable of manufacturing cGMP materials at a 500-liter scale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10.1pt;text-indent:-10.1pt;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net cash generated from financing activities </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">In the six months ended June 30, 2021, we generated $65.1 million in our financing activities compared to $3.5 million for the same period in 2020. </p><a id="_f6493911_cf4e_4da4_9fd3_6a02986274a1"></a><a id="_9b4804ed_1f62_4a58_b813_9926ffb1ccf3"></a><a id="_44876a9f_04d0_485f_a296_9bca57c8d0a6"></a><a id="_871bd2a4_ff43_428d_9068_ef73ca455154"></a><a id="_e8a2a928_826e_49e8_a43f_636aa4a4e33d"></a><a id="_e2a2e839_e125_414c_835c_293b373faef9"></a><a id="_e0956c0c_954b_43e0_ae12_dc0d93968e84"></a><a id="_50f1b5cd_da11_4b19_8bfa_733334247f55"></a><a id="_2edcd740_b5ae_4b1f_ba12_ca75153282e3"></a><a id="_c20db456_ad97_4ce6_83a0_43ceb3c310f6"></a><a id="_9e3572e0_c1e0_4ac3_826f_af611712fe5b"></a><a id="_7123c1ef_b0ee_4066_afcd_6ac36d8cfb70"></a><a id="_0c980a43_0da3_4820_8487_426edead1c06"></a><a id="_888219b0_60fc_44b4_8e84_701cacb0602d"></a><a id="_7dfbba03_9f4c_4215_9aca_c1391ad0a49c"></a><a id="_568b96e2_a7ec_448a_a2dd_cca6391023a4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:75.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:75.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from loan increment, net of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34,603</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of ordinary shares, net of issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,565</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="vertical-align:top;width:75.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of shares related to employee stock option and purchase plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 960</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,549</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:75.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash generated from financing activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 65,128</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,549</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In January 2021, we received $34.6 million net proceeds from the Hercules 2021 Amended Facility. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">We received net proceeds of $29.6 million associated with our ATM offering in March and April 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During the six months ended June 30, 2021, we received $1.0 million from the exercise of options to purchase ordinary shares in relation to our share incentive plans compared to $3.5 million for the same period in 2020.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Funding requirements </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe our cash and cash equivalents as of June 30, 2021, will fund our operations into the first half of 2024 (assuming a full repayment of funds borrowed from Hercules under our term loan facilities by 2023, as well as payments we expected to make in relation to our acquisition of Corlieve). We expect that the achievement of the $0.3 billion in regulatory, first commercial sales and development milestones would further extend our runway by 12 to 18 months. Our future capital requirements will depend on many factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">achieving the milestones and royalties as defined within the CSL Behring Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">payments we will make in relation to the contemplated acquisition of Corlieve;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the scope, timing, results, and costs of our current and planned clinical trials, including those for AMT-130 in Huntington&#8217;s disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the extent to which we acquire or in-license other businesses, products, product candidates or technologies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the amount and timing of revenue, if any, we receive from commercial sales of any product candidates for which we, or our collaboration partner, receives marketing approval in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the amount and timing of revenue, if any, we receive from manufacturing products for CSL Behring.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the scope, timing, results and costs of preclinical development and laboratory testing of our additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the need for additional resources and related recruitment costs to support the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">preclinical and clinical development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;text-decoration:line-through;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the need for any additional tests, studies, or trials beyond those originally anticipated to confirm the safety or efficacy of our product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the cost, timing and outcome of regulatory reviews associated with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">our ability to enter into collaboration arrangements in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the costs and timing of preparing, filing, expanding, acquiring, licensing, maintaining, enforcing, and prosecuting patents and patent applications, as well as defending any intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the repayments of the principal and other fees associated with our venture debt loan with Hercules, which following the January 29, 2021 amendment will be due in June 2023;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the costs associated with maintaining quality compliance and optimizing our manufacturing processes, including the operating costs associated with our Lexington, Massachusetts manufacturing facility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the costs associated with increasing the scale and capacity of our manufacturing capabilities; and</span></td></tr></table><a id="_32fb28ad_ce6b_47a1_99ed_88f76aabcc9f"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.6pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the costs associated with process validation and inspection readiness of etranacogene dezaparvovec. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contractual obligations and commitments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The table below sets forth our contractual obligations and commercial commitments as of June 30, 2021, that are expected to have an impact on liquidity and cash flows in future periods. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:29.1pt;margin:0pt 0pt 0pt 6.9pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_a8694afb_60c6_44da_ac31_15a3e686106c"></a><a id="_a4cbedb4_c1c1_4b23_a631_68496ab6b4b6"></a><a id="_34562654_b1f6_4c07_85cf_e3f635718438"></a><a id="_082259c8_d6ed_4501_97fc_b861abe94809"></a><a id="_28551063_6e76_4c6f_af38_63e7b4841aaf"></a><a id="_06c0af32_0b1b_46dc_94bd_b211f52a7c5c"></a><a id="_48cee9e8_a3c1_403f_b2b6_73fa9782e480"></a><a id="_5f398d13_a984_45bc_a88d_d07761674de3"></a><a id="_af1d02ee_4d00_4967_90fd_3fc9eb32beb9"></a><a id="_71adcf71_96df_4c42_be2f_4bb44431aebe"></a><a id="_57bf2a9c_8c4d_42f7_8b41_6fe6e91d1c9a"></a><a id="_811aa53d_51e9_4d69_bc73_af3afe19ad83"></a><a id="_84695bb0_12d2_4aea_b0b8_343aa08b91fc"></a><a id="_b374833c_e789_40c0_9a2f_48cf10422124"></a><a id="_aebf53be_6751_4a22_b200_a9f4baf437b5"></a><a id="_8f032b59_8713_4848_bdce_0a3e09e5f2ce"></a><a id="_f36ddd97_c8dd_46ab_bc8a_f69657190952"></a><a id="_6e1fd805_d140_40a1_bf19_920dc7add4d0"></a><a id="_7ec6ab6a_9a2b_42af_9686_d70bd6b0199c"></a><a id="_4bf02173_bde6_4fd1_aacf_d1f556b86b5e"></a><a id="_4538ccdc_4074_4f38_9fa8_12ffa28000d8"></a><a id="_43af7f3f_ff90_4ec4_b23c_1ce75ba96f94"></a><a id="_3eb2f134_2e82_42c2_b667_161b2fa8281b"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 1</b></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between 1</b></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between 3</b></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and&#160;3&#160;years</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and&#160;5&#160;years</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Over&#160;5&#160;years</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="16" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;width:66.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Debt obligations (including $15.6 million interest payments)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,068</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 79,498</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 85,566</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Operating lease obligations</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,862</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,712</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,576</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,954</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 58,104</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 11,930</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 92,210</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 13,576</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 25,954</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 143,670</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:0pt;">We also have obligations to make future payments to third parties that become due and payable on the achievement of certain development, regulatory and commercial milestones (such as the start of a clinical trial, filing of a BLA, approval by the FDA or product launch). We have not included these commitments on our balance sheet or in the table above because the achievement and timing of these milestones is not fixed and determinable. We also have obligations to make future payments that become due and payable upon the collection of milestone payments from CSL Behring. We have not included these commitments on our balance sheet or in the table above because the achievement and timing of these milestones is not fixed and determinable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with clinical research organizations (&#8220;CROs&#8221;) for preclinical research studies and clinical trials, research supplies and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancelable contracts and not included in the table of contractual obligations and commitments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 59.55pt 0pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">As of June 30, 2021, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7311b121_5900_4d1f_b4b2_a6f8592d2e5f"></a><a id="Item3_Quantitative"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 0.35pt;"><span style="display:inline-block;text-indent:0pt;width:35.65pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 3.</b></span><span style="display:inline-block;width:18pt;"></span>Quantitative and Qualitative Disclosures about Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We are exposed to a variety of financial risks in the normal course of our business, including market risk (including currency, price and interest rate risk), credit risk and liquidity risk. Our overall risk management program focuses on preservation of capital and the unpredictability of financial markets and has sought to minimize potential adverse effects on our financial performance and position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Our market risks and exposures to such market risks during the six months ended June 30, 2021, have not materially changed from our market risks and our exposure to market risk discussed in Part II, Item 7A of our <a style="-sec-extract:exhibit;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 1, 2021</span></a>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6790d1b5_f734_4ada_8dc6_44ccebf65342"></a><a id="Item4ControlsandProcedures_708461"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 4.</b></span><span style="display:inline-block;width:18pt;"></span>Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Our management, with the participation of our chief executive officer (&#8220;CEO&#8221;) and chief financial officer (&#8220;CFO&#8221;), evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) as of June 30, 2021. Based on such evaluation, our CEO and CFO concluded that as of June 30, 2021, our disclosure controls and procedures were effective <span style="background-color:#ffffff;">to ensure that information required to be disclosed by it in reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such material information is accumulated and communicated to the Company&#8217;s management, including its Principal Executive Officer and Principal Financial Officer, to allow timely decisions regarding required disclosure. Because of the inherent limitations in all control systems, any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Furthermore, the Company&#8217;s controls and procedures can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of such control, and misstatements due to error or fraud may occur and not be detected on a timely basis</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During the second quarter of 2021, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting except for additional controls established in relation to the revenue recognition under the CSL Behring Agreement and for calculating diluted earnings per ordinary share. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PartIIOTHERINFORMATION_100303"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 0pt 18pt;">Part II &#8211; OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_3f71e06e_d782_4427_b60a_315cfaa63ffb"></a><a id="Item1LegalProceedings_62705"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 0.35pt;"><span style="display:inline-block;text-indent:0pt;width:35.65pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 1.</b></span><span style="display:inline-block;width:18pt;"></span>Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 0.35pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On or about February 22, 2021, Dr. Konstantinova, VectorY B.V., and Forbion International Management B.V. commenced a summary proceeding in the Netherlands primarily seeking an order: (i) allowing VectorY and Dr. Konstantinova to continue their employment relationship; (ii) suspending the non-competition agreement between uniQure biopharma B.V. and Dr. Konstantinova; and (iii) precluding any monetary penalties pursuant to that non-competition agreement. The complaint also sought payment of the costs of legal proceedings and a monetary monthly payment to Dr. Konstantinova in lieu of a promise by uniQure biopharma B.V. to release Dr. Konstantinova from her obligations under the non-competition agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On April 16, 2021, we settled all matters related to the dispute described above (the &#8220;Settlement&#8221;). In connection with the Settlement, we received, among other things, preference shares in VectorY representing 5% of the fully diluted share capital in VectorY. In addition, we and certain related Forbion entities entered into a Cooperation Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the terms of the Cooperation Agreement, we and the Forbion entities agreed to certain non-disparagement provisions, and the Forbion entities agreed, among other things, for a period of two years from April &#160;16, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">To vote all of their ordinary shares in uniQure N.V. (1) in favor of the re-election of any persons serving on the Board of Directors of the Company (the &#8220;Board&#8221;) as of the date of the Cooperation Agreement and nominated by the Board for re-election; (2) against any nominees to serve on the Board who have not been recommended by the Board, and (3) with respect to all other matters, other than certain defined exempt matters, in accordance with the Board&#8217;s recommendations as identified in our notice of general meeting or any supplement thereto.&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Not to make any announcement or proposal with respect to, or offer, seek, propose, or indicate an interest in (A) any form of business combination or acquisition or other transaction relating to assets or securities of the uniQure N.V. or any of its subsidiaries, (B) any form of restructuring, recapitalization, or similar transaction with respect to the uniQure N.V. or any of its subsidiaries or (C) any form of tender or exchange offer for the ordinary shares of the uniQure N.V.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Not to make, engage in, assist with, or in any way participate in, directly or indirectly, any solicitation of proxies or written consents to vote (or withhold the vote of) any voting securities of uniQure N.V.&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Not to take certain other specified actions aimed at changing or influencing the Board, management, or control of the uniQure N.V.&#160;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fd96ceb2_e87d_4aa1_9e62_94f1b848b1c7"></a><a id="Item1ARiskFactors_129445"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 1A.</b></span>Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">An investment in our ordinary shares involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Quarterly Report on Form 10-Q, including our financial statements and related notes thereto, and the risk factors discussed in Part I, Item 1A &#8220;Risk Factors&#8221; in our </i><a style="-sec-extract:exhibit;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021</i></a><i style="font-style:italic;">, before deciding to invest in our ordinary shares. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties, including those that we do not currently consider material, may impair our business. If any of the risks discussed below actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This could cause the value of our securities to decline, and you may lose all or part of your investment.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Summary Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 18pt;">The following is a summary of the principal risks associated with an investment in our ordinary shares:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We may encounter substantial delays in, and impediments to the progress of our clinical trials or fail to demonstrate the safety and efficacy of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our business and operations have been, and may continue to be, materially and adversely affected by the ongoing Covid pandemic.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We may not be successful in our efforts to use our gene therapy technology platform to build a pipeline of additional product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We may not be successful in our efforts to in-license or acquire product candidates that align with our research and development strategy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our manufacturing facility is subject to significant government regulations and approvals. If we fail to comply with these regulations or to maintain these approvals our business could be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our resources might be adversely affected if we are unable to meet our product development and supply needs and obligations, including our ability to complete the validation of our existing manufacturing processes as well as to develop larger scale manufacturing processes, which could adversely affect our ability to sufficiently meet our future production needs or regulatory filing timelines.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We cannot predict when or if we will obtain marketing approval to commercialize a product candidate. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We are exposed to a number of external factors such as competition, insurance coverage of and pricing and reimbursement for our product candidates that may adversely affect our product revenue and that may cause our business to suffer. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We rely on licenses of intellectual property from third parties, and such licenses may not provide adequate rights or may not be available in the future on commercially reasonable terms or at all, and our licensors may be unable to obtain and maintain patent protection for the technology or products that we license from them. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection is not sufficiently broad, our ability to successfully commercialize our products may be impaired.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our reliance on third parties may require us to share our trade secrets, which could increase the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We will likely need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain capital when needed may force us to delay, limit or terminate our product development efforts or other operations which could have a material adverse effect on our business, financial condition, results of operations, and cash flows. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our relationships with customers and third-party payers will be subject to applicable anti-kickback, anti-bribery, fraud and abuse and other laws and regulations, which, if we are found in violation thereof, could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We are subject to laws governing data protection in the different jurisdictions in which we operate. The implementation of such data protection regimes is complex, and should we fail to fully comply, we may be subject to penalties that may have an adverse effect on our business, financial condition, and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">If we fail to maintain an effective system of internal controls, we may be unable to accurately report our results of operations or prevent fraud or fail to meet our reporting obligations, and investor confidence and the market price of our ordinary shares may be materially and adversely affected. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to the Current Covid Pandemic</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations have been, and may continue to be, materially and adversely affected by the ongoing Covid pandemic.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The ongoing outbreak of Covid originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States and the Netherlands. On March 11, 2020, the WHO declared the outbreak a pandemic. The Covid pandemic is affecting the United States and global economies and has affected and may continue to affect our operations and those of third parties on which we rely. The Covid pandemic has caused and may continue to cause disruptions in our raw material supply, our commercial-scale manufacturing capabilities for AAV-based gene therapies, the development of our product candidates, employee productivity and the conduct of current and future clinical trials. In addition, the Covid pandemic has affected and may continue to affect the operations of the FDA, EMA, and other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">As evidenced by the postponement of procedures for two patients in our Phase I/II clinical study of AMT-130, the evolving Covid pandemic has impacted the pace of enrollment and procedures in our clinical trials, as well as caused challenges in scheduling follow-up visits and managing other aspects of our clinical trials. We may be affected by similar delays as patients may avoid or may not be able to travel to healthcare facilities and physicians&#8217; offices unless due to a health emergency and clinical trial staff can no longer get to the clinic. Such facilities and offices have been and may continue to be required to focus limited resources on non-clinical trial matters, including treatment of Covid patients, thereby decreasing availability, in whole or in part, for clinical trial services. In addition, employee disruptions and remote working environments related to the Covid pandemic, and federal, state, and local public health measures designed to mitigate the spread of the virus, have impacted and could continue to negatively impact the efficiency and pace with which we work and develop our product candidates and our manufacturing capabilities. Further, while the potential economic impact brought by, and the duration of, the Covid pandemic is difficult to assess or predict, the impact of the Covid pandemic on global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. The ultimate impact of the Covid pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, financing, or clinical trial activities or on healthcare systems or the global economy as a whole. However, these negative effects could have a material impact on our liquidity, capital resources, operations, and business and those of the third parties on whom we rely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to the Development of Our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">None of our product candidates have been approved for commercial sale and they might never receive regulatory approval or become commercially viable. We have never generated any significant revenue from product sales and may never be profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span><span style="display:inline-block;width:18pt;"></span>All our product candidates are in research or development. We have not generated any revenues from the sale of products or manufacturing of our product for a licensee and do not expect to generate any such revenue before 2022. Our product candidates, including AMT-130 and any of our other potential product candidates, will require extensive preclinical and/or clinical testing, manufacture development and regulatory approval prior to commercial use. Our research and development efforts may not be successful. Even if our clinical development efforts result in positive data, our product candidates may not receive regulatory approval or be successfully introduced and marketed at prices that would permit us to operate profitably.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">     </span><span style="font-style:italic;font-weight:bold;">We may encounter substantial delays in and impediments to the progress of our clinical trials or fail to demonstrate the safety and efficacy of our product candidates. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">Clinical and non-clinical development is expensive, time-consuming, and uncertain as to outcome. Our product candidates are in different stages of clinical or preclinical development, and there is a significant risk of failure or delay in each of these programs. We cannot guarantee that any preclinical tests or clinical trials will be completed as planned or completed on schedule, if at all. A failure of one or more preclinical tests or clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development, as well as product candidate approval, include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.6pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">occurrence of serious adverse events associated with a product candidate that are viewed to outweigh its potential benefits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.6pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">delays in reaching a consensus with regulatory agencies on study design;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.6pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">delays in reaching agreement on acceptable terms with prospective clinical research organizations (&#8220;CROs&#8221;) and clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">delays in receiving regulatory authorization to conduct the clinical trials or a regulatory authority decision that the clinical trial should not proceed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">delays in obtaining or failure to obtain required IRB and IBC approval at each clinical trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">requirements of regulatory authorities, IRBs, or IBCs to modify a study in such a way that it makes the study impracticable to conduct;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">regulatory authority requirements to perform additional or unanticipated clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">regulatory authority refusal to accept data from foreign clinical study sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">disagreements with regulatory authorities regarding our study design, including endpoints, our chosen indication, or our interpretation of data from preclinical studies and clinical trials or a finding that a product candidate&#8217;s benefits do not outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">delays in obtaining or failure to obtain required approvals from a DSMB or other required approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">imposition of a clinical hold by regulatory agencies after an inspection of our clinical trial operations or trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">suspension or termination of clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks, undesirable side effects, or other unexpected characteristics (alone or in combination with other products) of the product candidate, or due to findings of undesirable effects caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">failure by CROs, other third parties or us to adhere to clinical trial requirements or otherwise properly manage the clinical trial process, including meeting applicable timelines, properly documenting case files, including the retention of proper case files, and properly monitoring and auditing clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">failure of sites or clinical investigators to perform in accordance with Good Clinical Practice or applicable regulatory guidelines in other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">failure of patients to abide by clinical trial requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">difficulty or delays in patient recruiting into clinical trials or in the addition of new investigators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the impact of the COVID-19 pandemic on the healthcare system or any clinical trial sites; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">delays or deviations in the testing, validation, manufacturing, and delivery of our product candidates to the clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">delays in having patients complete participation in a study or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">clinical trial sites or patients dropping out of a study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the number of patients required for clinical trials of our product candidates being larger than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">clinical trials producing negative or inconclusive results, or our studies failing to reach the necessary level of statistical significance, requiring that we conduct additional clinical trials or abandon product development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">interruptions in manufacturing clinical supply of our product candidates or issues with manufacturing product candidates that meet the necessary quality requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">unanticipated clinical trial costs or insufficient funding, including to pay substantial application user fees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">occurrence of serious adverse events or other undesirable side effects associated with a product candidate that are viewed to outweigh its potential benefits; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">disagreements with regulatory authorities regarding the interpretation of our clinical trial data and results, or the emergency of new information about or impacting our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">determinations that there are issues with our manufacturing facility or process; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:21.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">changes in regulatory requirements and guidance, as well as new, revised, postponed, or frozen regulatory requirements, especially in light of the change in the United States administration, that require amending or submitting new clinical protocols, undertaking additional new tests or analyses, or submitting new types or amounts of clinical data.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Such trials and regulatory review and approval take many years. It is impossible to predict when or if any of our clinical trials will demonstrate that product candidates are effective or safe in humans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">If the results of our clinical trials are inconclusive, or fail to meet the level of statistical significance required for approval or if there are safety concerns or adverse events associated with our product candidates, we may:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">be delayed in or altogether prevented from obtaining marketing approval for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">be subject to changes with the way the product is administered;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">be subject to the addition of labeling statements, such as warnings or contraindications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">be sued; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">experience damage to our reputation.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Because of the nature of the gene therapies we are developing, regulators may also require us to demonstrate long-term gene expression, clinical efficacy and safety, which may require additional or longer clinical trials, and which may not be able to be demonstrated to the regulatory authorities&#8217; standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Our ability to recruit patients for our trials is often reliant on third parties, such as clinical trial sites. Clinical trial sites may not have the adequate infrastructure established to handle gene therapy products or may have difficulty finding eligible patients to enroll into a trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">In addition, we, or any collaborators we may have may not be able to locate and enroll enough eligible patients to participate in these trials as required by the FDA, the EMA or similar regulatory authorities outside the United States and the European Union. This may result in our failure to initiate or continue clinical trials for our product candidates or may cause us to abandon one or more clinical trials altogether. Because our programs are focused on the treatment of patients with rare or orphan or ultra-orphan diseases, our ability to enroll eligible patients in these trials may be limited or slower than we anticipate considering the small patient populations involved and the specific age range required for treatment eligibility in some indications. In addition, our potential competitors, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions, may seek to develop competing therapies, which would further limit the small patient pool available for our studies. Also, patients may be reluctant to enroll in gene therapy trials where there are other therapeutic alternatives available or that may become available, which may be for various reasons including uncertainty about the safety or effectiveness of a new therapeutic such as a gene therapy and the possibility that treatment with a gene therapy therapeutic could preclude future gene therapy treatments due to the formation of antibodies following and in response to the treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Any inability to successfully initiate or complete preclinical and clinical development could result in additional costs to us or impair our ability to receive marketing approval, to generate revenues from product sales or obtain regulatory and commercialization milestones and royalties. In addition, if we make manufacturing or formulation changes to our product candidates, including changes in the vector or manufacturing process used, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. It is also possible that any such manufacturing of formulation changes may have an adverse impact on the performance of the product candidate. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may materially harm our business, financial condition, and results of operations. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our progress in early-stage clinical trials may not be indicative of long-term efficacy in late-stage clinical trials, and our progress in trials for one product candidate may not be indicative of progress in trials for other product candidates. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Study designs and results from previous studies are not necessarily predictive of our future clinical study designs or results, and initial, top-line, or interim results may not be confirmed upon full analysis of the complete study data. Our product candidates may fail to show the required level of safety and efficacy in later stages of clinical development despite having successfully advanced through initial clinical studies. Changes to product candidates may also impact their performance in subsequent studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">By example, our initial clinical trials in hemophilia B were conducted with AMT-060. Following these studies, we made modifications to AMT-060, substituting two nucleotides in the coding sequence for FIX. This modified product candidate is etranacogene dezaparvovec. In 2017, we announced our plans to advance etranacogene dezaparvovec, which includes an AAV5 vector carrying the FIX-Padua transgene, into a pivotal study. While we believe etranacogene dezaparvovec and AMT-060, our product candidate that was previously studied in a Phase I/II study, have been demonstrated to be materially comparable in nonclinical studies and manufacturing quality assessments, it is possible that ongoing or future clinical studies of etranacogene dezaparvovec may show unexpected differences from AMT-060. Should these differences have an unfavorable impact on clinical outcomes, or should they not have their intended effect of increasing the product candidate&#8217;s FIX activity, they may adversely impact our ability to achieve regulatory approval or market acceptance of etranacogene dezaparvovec<span style="background-color:#ffffff;">. We may also need to conduct additional or longer-term studies, which may delay regulatory submissions or approvals and which the regulatory authorities may ultimately not accept or approve.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">In our Phase I/II clinical study of AMT-060, we screened patients for pre-existing anti-AAV5 antibodies to determine their eligibility for the trial. Three of the ten patients screened for the study tested positive for anti-AAV5 antibodies on reanalysis using a more sensitive antibody assay. Since we did not observe any ill-effects or correlation between the level of anti-AAV5 antibodies and clinical outcomes, patients who have anti-AAV5 antibodies are permitted to enroll in our planned pivotal study of etranacogene dezaparvovec. Since we only have been able to test a limited number of patients and have limited clinical and pre-clinical data, it is possible that ongoing or future clinical studies may not confirm these results, and if so, negatively impact the outcome of our study. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">In advance of treating patients in the pivotal study of etranacogene dezaparvovec, we conducted a short study to confirm the dose expected to be used in the pivotal trial. The dose-confirmation study enrolled three patients, who were administered a single dose of 2x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">13</sup> gc/kg. We have relied on the short-term data from this study, including FIX activity and safety outcomes during the weeks following administration of etranacogene dezaparvovec, to confirm the dose to be used in the pivotal study. Following the results of this study, our Data Monitoring Committee confirmed the dose of 2x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">13</sup> gc/kg for administration in the pivotal study. Given the limited number of patients and short follow-up period, data from this study may differ materially from the future results of our planned pivotal study of etranacogene dezaparvovec.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later-stage clinical trials even after achieving promising results in early-stage clinical trials. If a larger population of patients does not experience positive results during clinical trials, if these results are not reproducible or if our products show diminishing activity over time, our product candidates may not receive approval from the FDA or EMA. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit, or prevent regulatory approval. In addition, we may encounter regulatory delays or rejections because of many factors, including changes in regulatory policy during the period of product development. Failure to confirm favorable results from earlier trials by demonstrating the safety and effectiveness of our products in later-stage clinical trials with larger patient populations could have a material adverse effect on our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Additionally, where there are differences in the early-stage and late-stage trials, such as the differences between AMT-060 and AMT-061, regulatory authorities may require additional or longer-term data in late-stage trials, which may delay regulatory submissions or approvals and which the regulatory authorities may ultimately not accept or approve.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Fast track product, breakthrough therapy, priority review, or Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designation by the FDA, or access to the PRIME scheme by the EMA, for our product candidates may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We have obtained and may in the future seek one or more of fast track designation, breakthrough therapy designation, RMAT designation, PRIME scheme access or priority review designation for our product candidates. A fast track product designation is designed to facilitate the clinical development and expedite the review of drugs intended to treat a serious or life-threatening condition and which demonstrate the potential to address an unmet medical need. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A RMAT designation is designed to accelerate approval for regenerative advanced therapies. Priority review designation is intended to speed the FDA marketing application review timeframe for drugs that treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. PRIME is a scheme provided by the EMA, similar to the FDA&#8217;s breakthrough therapy designation, to enhance support for the development of medicines that target an unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">For drugs and biologics that have been designated as fast track products, RMAT, or breakthrough therapies, or granted access to the PRIME scheme, interaction and communication between the regulatory agency and the sponsor of the trial can help to identify the most efficient path for clinical development. Sponsors of fast track products, RMAT products, or breakthrough therapies may also be able to submit marketing applications on a rolling basis, meaning that the FDA may review portions of a marketing application before the sponsor submits the complete application to the FDA, if the sponsor pays the user fee upon submission of the first portion of the marketing application and the FDA approves a schedule for the submission of the remaining sections. For products that receive a priority review designation, the FDA&#39;s marketing application review goal is shortened to six months, as opposed to ten months under standard review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Designation as a fast track product, breakthrough therapy, RMAT, PRIME, or priority review product is within the discretion of the regulatory agency. Accordingly, even if we believe one of our product candidates meets the relevant criteria, the agency may disagree and instead determine not to make such designation. In any event, the receipt of such a designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional regulatory procedures and does not assure ultimate marketing approval by the agency. In addition, the FDA may later decide that the products no longer meet the applicable conditions for qualification as either a fast track product, RMAT, or a breakthrough therapy or, for priority review products, decide that the period for FDA review or approval will not be shortened. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"> &#160; &#160; &#160; <span style="font-style:italic;font-weight:bold;">We may not be successful in our efforts to use our gene therapy technology platform to build a pipeline of additional product candidates. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">An element of our strategy is to use our gene therapy technology platform to expand our product pipeline and to progress these candidates through preclinical and clinical development ourselves or together with collaborators. Although we currently have a pipeline of programs at various stages of development, we may not be able to identify or develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development. Research programs to identify new product candidates require substantial technical, financial, and human resources. We or any collaborators may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. If we do not continue to successfully develop and commercialize product candidates based upon our technology, we may face difficulty in obtaining product revenues in future periods, which could result in significant harm to our business, results of operations and financial position and materially adversely affect our share price.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our strategy of obtaining rights to key technologies through in-licenses may not be successful. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We seek to expand our product pipeline from time to time in part by in-licensing the rights to key technologies, including those related to gene delivery, genes, and gene cassettes. The future growth of our business will depend in significant part on our ability to in-license or otherwise acquire the rights to additional product candidates or technologies, particularly through our collaborations with academic research institutions. However, we may be unable to in-license or acquire the rights to any such product candidates or technologies from third parties on acceptable terms or at all. The in-licensing and acquisition of these technologies is a competitive area, and many more established companies are also pursuing strategies to license or acquire product candidates or technologies that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be competitors may be unwilling to license rights to us. Furthermore, we may be unable to identify suitable product candidates or technologies within our areas of focus. If we are unable to successfully obtain rights to suitable product candidates or technologies, our business, financial condition, and prospects could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. The risk of cancer remains a concern for gene therapy, and we cannot assure that it will not occur in any of our planned or future clinical studies. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">A small number of patients have experienced serious adverse events during our clinical trials of either AMT-060 (our first-generation hemophilia B gene therapy) or etranacogene dezaparvovec. In each instance of a serious adverse event, whether or not attributed to one of our product candidates, the issues resolved without delay in the respective clinical trial. However, adverse events in our clinical trials or those conducted by other parties (even if not ultimately attributable to our product candidates), and the resulting publicity, could result in delay, a hold or termination of our clinical trials, increased governmental regulation, unfavorable public perception, failure of the medical community to accept and prescribe gene therapy treatments, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. If any of these events should occur, it may have a material adverse effect on our business, financial condition and results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain of our product candidates may require medical devices for product administration and/or diagnostics, resulting in our product candidates being deemed combination products. This may result in the need to comply with additional regulatory requirements. If we are unable to meet these regulatory requirements, we may be delayed or not be able to obtain product approval. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Certain of our product candidates, such as AMT-130, require medical devices, such as a stereotactic, magnetic resonance imaging guided catheter, for product administration. &#160;Other of our product candidates may also require the use of a companion diagnostic device to confirm the presence of specific genetic or other biomarkers. &#160;This may result in our product candidates being deemed to be combination products, potentially necessitating compliance with the FDA&#8217;s investigational device regulations, separate marketing application submissions for the medical device component, a demonstration that our product candidates are safe and effective when used in combination with the medical devices, cross labeling with the medical device, and compliance with certain of the FDA&#8217;s device regulations. &#160;If we are not able to comply with the FDA&#8217;s device regulations, if we are not able to effectively partner with the applicable medical device manufacturers, if we or any partners are not able to obtain any required FDA clearances or approvals of the applicable medical devices, or if we are not able to demonstrate that our product candidates are safe and efficacious when used with the applicable medical devices, we may be delayed in or may never obtain FDA approval for our product candidates, which would materially harm our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Moreover, certain of our delivery modalities, such as direct delivery of product candidates to the brain, may require significant physician ability and skill. &#160;If physicians are not able to effectively deliver our product candidates to the applicable site of action or if delivery modalities are too difficult, we may never be able to obtain approval for our product candidates, may be delayed in obtaining approval, or, following approval, physicians may not adopt our product candidates, any of which may materially harm our business. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our manufacturing facility is subject to significant government regulations and approvals. If we fail to comply with these regulations or maintain these approvals our business will be materially harmed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Our manufacturing facility in Lexington is subject to ongoing regulation and periodic inspection by the FDA, EMA, and other regulatory bodies to ensure compliance with current cGMP. Moreover, before approving a BLA for any product candidate, the FDA will inspect our manufacturing facility and processes. Any failure to follow and document our adherence to such cGMP regulations or other regulatory requirements may lead to significant delays in the availability of products for commercial sale or clinical study, may result in the termination of or a hold on a clinical study, or may delay or prevent filing or approval of marketing applications for our products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Failure to comply with applicable regulations could also result in the FDA, EMA, or other applicable authorities taking various actions, including levying fines and other civil penalties; imposing consent decrees or injunctions; requiring us to suspend or put on hold one or more of our clinical trials; suspending or withdrawing regulatory approvals; delaying or refusing to approve pending applications or supplements to approved applications; requiring us to suspend manufacturing activities or product sales, imports or exports; requiring us to communicate with physicians and other customers about concerns related to actual or potential safety, efficacy, and other issues involving our products; mandating or recommending product recalls or seizing products; imposing operating restrictions; and seeking criminal prosecutions, among other outcomes. Poor control of production processes can also lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be detectable in final product testing and that could have an adverse effect on clinical studies, or patient safety or efficacy. Moreover, if our manufacturing facility is not able to follow regulatory requirements, we may need to implement costly and time-consuming remedial actions. Any of the foregoing could materially harm our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Moreover, if we are not able to manufacture a sufficient amount of our product candidates for clinical studies or eventual commercialization, our development program and eventual commercial prospects will be harmed. &#160;If we cannot produce an adequate amount of our product candidates in compliance with the applicable regulatory requirements, we may need to contract with a third party to do so, in which case third party manufacturers may not be available or available on favorable terms. &#160;The addition of a new manufacturer may also require FDA approvals, which we may not be able to obtain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Gene therapies are complex and difficult to manufacture. We could experience capacity, production or technology transfer problems that result in delays in our development or commercialization schedules or otherwise adversely affect our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The insect-cell based manufacturing process we use to produce our products and product candidates is highly complex and in the normal course is subject to variation or production difficulties. Issues with any of our manufacturing processes, even minor deviations from the normal process, could result in insufficient yield, product deficiencies or manufacturing failures that result in adverse patient reactions, lot failures, insufficient inventory, product recalls and product liability claims. Additionally, we may not be able to scale up some or all of our manufacturing processes that may result in delays in regulatory approvals or otherwise adversely affect our ability to manufacture sufficient amounts of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Many factors common to the manufacturing of most biologics and drugs could also cause production interruptions, including raw materials shortages, raw material failures, growth media failures, equipment malfunctions, facility contamination, labor problems, natural disasters, disruption in utility services, terrorist activities, or cases of force majeure and acts of god (including the effects of the Covid pandemic) beyond our control. We also may encounter problems in hiring and retaining the experienced specialized personnel needed to operate our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Any problems in our manufacturing processes or facilities could make us a less attractive collaborator for academic research institutions and other parties, which could limit our access to additional attractive development programs, result in delays in our clinical development or marketing schedules and materially harm our business. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our use of viruses, chemicals and other hazardous materials requires us to comply with regulatory requirements and exposes us to significant potential liabilities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Our development and manufacturing processes involve the use of viruses, chemicals, other (potentially) hazardous materials and produce waste products. Accordingly, we are subject to national, federal, state, and local laws and regulations in the United States and the Netherlands governing the use, manufacture, distribution, storage, handling, treatment, and disposal of these materials. In addition to ensuring the safe handling of these materials, applicable requirements require increased safeguards and security measures for many of these agents, including controlling access and screening of entities and personnel who have access to them, and establishing a comprehensive national database of registered entities. In the event of an accident or failure to comply with environmental, occupational health and safety and export control laws and regulations, we could be held liable for damages that result, and any such liability could exceed our assets and resources, and could result in material harm to our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our resources might be adversely affected if we are unable to validate our manufacturing processes or develop new processes to meet our product supply needs and obligations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The manufacture of our AAV gene therapies, including etranacogene dezaparvovec, is complex and requires significant expertise.&#160; Even with the relevant experience and expertise, manufacturers of gene therapy products often encounter difficulties in production, particularly in scaling out and validating initial production, and ensuring that the product meets required specifications. These problems include difficulties with production costs and yields, quality control, including stability and potency of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. &#160;In the past, we have manufactured certain batches of etranacogene dezaparvovec, and other product candidates, intended for nonclinical, clinical and process validation purposes that have not met all of our pre-specified quality parameters.&#160; To meet our expected future production needs and our regulatory filing timelines for etranacogene dezaparvovec, as well as other gene therapy product candidates, we will need to complete the validation of our existing manufacturing processes as well as to develop larger scale manufacturing processes. If we are unable to consistently manufacture etranacogene dezaparvovec, or other gene therapy product candidates, in accordance with our pre-specified quality parameters and applicable regulatory standards, it could adversely impact our ability to validate our manufacturing processes, to meet our production needs, to file our BLA or other regulatory submissions, to develop our other proprietary programs, to conserve our cash, or to receive financial payments pursuant to our agreements with third parties, including with CSL Behring in return for supplying etranacogene dezaparvovec following regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Regulatory Approval of Our Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We cannot predict when or if we will obtain marketing approval to commercialize a product candidate. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The development and commercialization of our product candidates, including their design, testing, manufacture, safety, efficacy, purity, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States, the EMA, and other regulatory agencies of the member states of the European Union, and similar regulatory authorities in other jurisdictions. Failure to obtain marketing approval for a product candidate in a specific jurisdiction will prevent us from commercializing the product candidate in that jurisdiction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The process of obtaining marketing approval for our product candidates in the United States, the European Union, and other countries is expensive and may take many years, if approval is obtained at all. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application, may decide that our data are insufficient for approval, may require additional preclinical, clinical, or other studies and may not complete their review in a timely manner. Further, any marketing approval we ultimately obtain may be for only limited indications or be subject to stringent labeling or other restrictions or post-approval commitments that render the approved product not commercially viable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">If we experience delays in obtaining marketing approval for any of our product candidates in the United States, the European Union, or other countries, the commercial prospects of our other product candidates may be harmed and our ability to generate revenues will be materially impaired. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The risks associated with the marketing approval process are heightened by the status of our products as gene therapies. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We believe that all our current product candidates will be viewed as gene therapy products by the applicable regulatory authorities. While there are a number of gene therapy product candidates under development, in the United States, the FDA has only approved a limited number of gene therapy products, to date. Accordingly, regulators, like the FDA, may have limited experience with the review and approval of marketing applications for gene therapy products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Both the FDA and the EMA have demonstrated caution in their regulation of gene therapy treatments, and ethical and legal concerns about gene therapy and genetic testing may result in additional regulations or restrictions on the development and commercialization of our product candidates that are difficult to predict. The FDA and the EMA have issued various guidance documents pertaining to gene therapy products, with which we likely must comply to gain regulatory approval of any of our product candidates in the United States or European Union, respectively. The close regulatory scrutiny of gene therapy products may result in delays and increased costs and may ultimately lead to the failure to obtain approval for any gene therapy product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Regulatory requirements affecting gene therapy have changed frequently and continue to evolve, and agencies at both the U.S. federal and state level, as well as congressional committees and foreign governments, have sometimes expressed interest in further regulating biotechnology. In the United States, there have been a number of recent changes relating to gene therapy development. By example, FDA issued a number of new guidance documents on human gene therapy development, one of which was specific to human gene therapy for hemophilia and another of which was specific to rare diseases. Moreover, the European Commission conducted a public consultation in early 2013 on the application of EU legislation that governs advanced therapy medicinal products, including gene therapy products, which could result in changes in the data we need to submit to the EMA for our product candidates to gain regulatory approval or change the requirements for tracking, handling and distribution of the products which may be associated with increased costs. In addition, divergent scientific opinions among the various bodies involved in the review process may result in delays, require additional resources, and ultimately result in rejection. The FDA, EMA, and other regulatory authorities will likely continue to revise and further update their approaches to gene therapies in the coming years. These regulatory agencies, committees and advisory groups and the new regulations and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenues to maintain our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our failure to obtain or maintain orphan product exclusivity for any of our product candidates for which we seek this status could limit our commercial opportunity, and if our competitors are able to obtain orphan product exclusivity before we do, we may not be able to obtain approval for our competing products for a significant period. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. While certain of our product candidates have received orphan drug designation, there is no guarantee that we will be able to receive such designations in the future. The FDA may grant orphan designation to multiple sponsors for the same compound or active molecule and for the same indication. If another sponsor receives FDA approval for such product before we do, we would be prevented from launching our product in the United States for the orphan indication for a period of at least seven years unless we can demonstrate clinical superiority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Moreover, while orphan drug designation neither shortens the development or regulatory review time, nor gives the product candidate advantages in the regulatory review or approval process, generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the relevant indication, the product is entitled to a period of market exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same drug for the same indication for that period. The FDA and the EMA, however, may subsequently approve a similar drug or same drug, in the case of the United States, for the same indication during the first product&#39;s market exclusivity period if the FDA or the EMA concludes that the later drug is clinically superior in that it is shown to be safer or more effective or makes a major contribution to patient care. Orphan exclusivity in the United States also does not prevent the FDA from approving another product that is considered to be the same as our product candidates for a different indication or a different product for the same orphan indication. &#160;If another product that is the same as ours is approved for a different indication, it is possible that third-party payors will reimburse for products off-label even if not indicated for the orphan condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective, or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition or if the incidence and prevalence of patients who are eligible to receive the drug in these markets materially increase. The inability to obtain or failure to maintain adequate product exclusivity for our product candidates could have a material adverse effect on our business prospects, results of operations and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Additionally, regulatory criteria with respect to orphan products is evolving, especially in the area of gene therapy. &#160;By example, in the United States, whether two gene therapies are considered to be the same for the purpose of determining clinical superiority is subject to change, and depends on a number of factors, including the expressed transgene, the vector, and other product or product candidate features. Accordingly, whether any of our product candidates will be deemed to be the same as another product or product candidate is uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;">      </span><span style="font-style:italic;font-weight:bold;">As appropriate, we intend to seek all available periods of regulatory exclusivity for our product candidates. However, there is no guarantee that we will be granted these periods of regulatory exclusivity or that we will be able to maintain these periods of exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The FDA grants product sponsors certain periods of regulatory exclusivity, during which the agency may not approve, and in certain instances, may not accept, certain marketing applications for competing drugs. For example, biologic product sponsors may be eligible for twelve years of exclusivity from the date of approval, seven years of exclusivity for drugs that are designated to be orphan drugs, and/or a six-month period of exclusivity added to any existing exclusivity period for the submission of FDA requested pediatric data. While we intend to apply for all periods of market exclusivity that we may be eligible for, there is no guarantee that we will be granted any such periods of market exclusivity. By example, regulatory authorities may determine that our product candidates are not eligible for periods of regulatory exclusivity for various reasons, including a determination by the FDA that a BLA approval does not constitute a first licensure of the product. Additionally, under certain circumstances, the FDA may revoke the period of market exclusivity. Thus, there is no guarantee that we will be able to maintain a period of market exclusivity, even if granted. In the case of orphan designation, other benefits, such as tax credits and exemption from user fees may be available. If we are not able to obtain or maintain orphan drug designation or any period of market exclusivity to which we may be entitled, we could be materially harmed, as we will potentially be subject to greater market competition and may lose the benefits associated with programs. It is also possible that periods of exclusivity will not adequately protect our product candidates from competition. For instance, even if we receive twelve years of exclusivity from the FDA, other applicants will still be able to submit and receive approvals for versions of our product candidates through a full BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">If we do not obtain or maintain periods of market exclusivity, we may face competition sooner than otherwise anticipated. &#160;For instance, in the United States, this could mean that a competing biosimilar product may be able to submit an application to the FDA and obtain approval. This may require that we undertake costly and time-consuming patent litigation, to the extent available, or defend actions brought by the biosimilar applicant for declaratory judgement. If a biosimilar product does enter the market, it is possible that it could be substituted for one of our product candidates, especially if it is available at a lower price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">It is also possible that, at the time we obtain approval of our product candidates, regulatory laws and policies around exclusivities may have changed. For instance, there have been efforts to decrease the United States period of exclusivity to a shorter timeframe. Future proposed budgets, international trade agreements and other arrangements or proposals may affect periods of exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to successfully commercialize our product candidates or experience significant delays in doing so, our business could be materially harmed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:4pt 0pt 0pt 0pt;">Our ability to generate product revenues will depend on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">successful execution of our contractual relationship with CSL Behring for the commercialization of etranacogene dezaparvovec; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">successful completion of preclinical studies and clinical trials, and other work required by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">receipt and maintenance of marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">our ability to timely manufacture sufficient quantities of our products according to required quality specifications;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">obtaining and maintaining patent and trade secret protection and non-patent, orphan drug exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">obtaining and maintaining regulatory approvals using our manufacturing facility in Lexington, Massachusetts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">launch and commercialization of our products, if approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">identifying and engaging effective distributors or resellers on acceptable terms in jurisdictions where we plan to utilize third parties for the marketing and sales of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">acceptance of our products, if approved, by patients, the medical community, and third-party payers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">effectively competing with existing therapies and gene therapies based on safety and efficacy profiles;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the strength of our marketing and distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">achieve optimal pricing based on durability of expression, safety, and efficacy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the ultimate content of the regulatory authority approved label, including the approved clinical indications, and any limitations or warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">any distribution or use restrictions imposed by regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the interaction of our products with any other medicines that patients may be taking or the restriction on the use of our products with other medicines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the standard of care at the time of product approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the relative convenience and ease of administration of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">obtaining and maintaining healthcare coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">any price concessions, rebates, or discounts we may need to provide;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">complying with any applicable post-approval requirements and maintaining a continued acceptable overall safety profile; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">obtaining adequate reimbursement for the total patient population and each subgroup to sustain a viable commercial business model in U.S. and EU markets.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">By example, even if our product candidates are approved, they may be subject to limitations that make commercialization difficult. There may be limitations on the indicated uses and populations for which the products may be marketed. They may also be subject to other conditions of approval, may contain significant safety warnings, including boxed warnings, contraindications, and precautions, may not be approved with label statements necessary or desirable for successful commercialization, or may contain requirements for costly post-market testing and surveillance, or other requirements, including the submission of a risk evaluation and mitigation strategy, or REMS, to monitor the safety or efficacy of the products. Failure to achieve or implement any of the above elements could result in significant delays or an inability to successfully commercialize our product candidates, which could materially harm our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">The affected populations for our gene therapies may be smaller than we or third parties currently project, which may affect the size of our addressable markets. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Our projections of the number of people who have the diseases we are seeking to treat, as well as the subset of people with these diseases who have the potential to benefit from treatment with our therapies, are estimates based on our knowledge and understanding of these diseases. The total addressable market opportunities for these therapies will ultimately depend upon many factors, including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient consent, patient access and product pricing and reimbursement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Prevalence estimates are frequently based on information and assumptions that are not exact and may not be appropriate, and the methodology is forward-looking and speculative. The use of such data involves risks and uncertainties and is subject to change based on various factors. Our estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of the diseases we seek to address. The number of patients with the diseases we are targeting may turn out to be lower than expected or may not be otherwise amenable to treatment with our products, reimbursement may not be sufficient to sustain a viable business for all sub populations being studied, or new patients may become increasingly difficult to identify or access, any of which could adversely affect our results of operations and our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The addressable markets for AAV-based gene therapies may be impacted by the prevalence of neutralizing antibodies to the capsids, which are an integral component of our gene therapy constructs. Patients that have pre-existing antibodies to a particular capsid may not be eligible for administration of a gene therapy that includes this particular capsid. For example, etranacogene dezaparvovec, our gene therapy candidate for hemophilia B patients, incorporates an AAV5 capsid. In our Phase I/II clinical study of AMT-060, we screened patients for pre-existing anti-AAV5 antibodies to determine their eligibility for the trial. Three of the ten patients screened for the study tested positive for anti-AAV5 antibodies on reanalysis. Although we did not observe any ill-effects or correlation between the level of anti-AAV5 antibodies and clinical outcomes in these three patients, suggesting that patients who have anti-AAV5 antibodies may still be eligible for AAV5-based gene therapies, since we only have been able to test a limited number of patients and have limited clinical and pre-clinical data, we do not know if future clinical studies will confirm these results. This may limit the addressable market for etranacogene dezaparvovec and any future revenues derived from the sale of the product, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any approved gene therapy we seek to offer may fail to achieve the degree of market acceptance by physicians, patients, third party payers and others in the medical community necessary for commercial success. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Doctors may be reluctant to accept a gene therapy as a treatment option or, where available, choose to continue to rely on existing treatments. The degree of market acceptance of any of our product candidates that receive marketing approval in the future will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the efficacy and potential advantages of our therapies compared with alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">our ability to convince payers of the long-term cost-effectiveness of our therapies and, consequently, the availability of third-party coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the cost of treatment with gene therapies, including ours, in comparison to traditional chemical and small-molecule treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the limitations on use and label requirements imposed by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the convenience and ease of administration of our gene therapies compared with alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the willingness of the target patient population to try new therapies, especially a gene therapy, and of physicians to administer these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">limited access to site of service that can perform the product preparation and administer the infusion; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">any restrictions by regulators on the use of our products.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">A failure to gain market acceptance for any of the above reasons, or any reasons at all, by a gene therapy for which we receive regulatory approval would likely hinder our ability to recapture our substantial investments in that and other gene therapies and could have a material adverse effect on our business, financial condition, and results of operation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to expand our commercialization capabilities or enter into agreements with third parties to market and sell any of our product candidates for which we obtain marketing approval, we may be unable to generate any product revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">To successfully commercialize any products that may result from our development programs, we need to continue to expand our commercialization capabilities, either on our own or with others. The development of our own market development effort is, and will continue to be, expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We may enter into collaborations regarding our other product candidates with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any current or future collaborators do not commit sufficient resources to commercialize our products, or we are unable to develop the necessary capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded medical affairs, marketing, and sales operations to recruit, hire, train and retain marketing and sales personnel. We also may face competition in any search for third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If the market opportunities for our product candidates are smaller than we believe they are, our product revenues may be adversely affected, and our business may suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We focus our research and product development on treatments for severe genetic and orphan diseases. Our understanding of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates. These estimates may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of these diseases. The number of patients in the United States, the EU and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our products or patients may become increasingly difficult to identify and access, any of which could adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Further, there are several factors that could contribute to making the actual number of patients who receive other potential products less than the potentially addressable market. These include the lack of widespread availability of, and limited reimbursement for, new therapies in many underdeveloped markets. Further, the severity of the progression of a disease up to the time of treatment, especially in certain degenerative conditions, could diminish the therapeutic benefit conferred by a gene therapy. Lastly, certain patients&#8217; immune systems might prohibit the successful delivery of certain gene therapy products to the target tissue, thereby limiting the treatment outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our gene therapy approach utilizes vectors derived from viruses, which may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of our product and product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Gene therapy remains a novel technology. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians who specialize in the treatment of genetic diseases targeted by our product and product candidates, if approved, prescribing treatments that involve the use of our product and product candidates, if approved, in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. For example, earlier gene therapy trials led to several well-publicized adverse events, including cases of leukemia and death seen in other trials using other vectors. Serious adverse events in our clinical trials, or other clinical trials involving gene therapy products or our competitors&#8217; products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any products for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ethical, legal, and social issues may reduce demand for any gene therapy products for which we obtain marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Prior to receiving certain gene therapies, patients may be required to undergo genetic testing. Genetic testing has raised concerns regarding the appropriate utilization and the confidentiality of information provided by genetic testing. Genetic tests for assessing a person&#8217;s likelihood of developing a chronic disease have focused public attention on the need to protect the privacy of genetic information. For example, concerns have been expressed that insurance carriers and employers may use these tests to discriminate on the basis of genetic information, resulting in barriers to the acceptance of genetic tests by consumers. This could lead to governmental authorities restricting genetic testing or calling for limits on or regulating the use of genetic testing, particularly for diseases for which there is no known cure. Any of these scenarios could decrease demand for any products for which we obtain marketing approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we obtain approval to commercialize any of our product candidates outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We expect that we will be subject to additional risks in commercializing any of our product candidates outside the United States, including:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">different regulatory requirements for approval of drugs and biologics in foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">reduced protection for intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">unexpected changes in tariffs, trade barriers and regulatory requirements which may make it more difficult or expensive to export or import products and supplies to or from the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods, and fires.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face substantial competition, and others may discover, develop, or commercialize competing products before or more successfully than we do. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The development and commercialization of new biotechnology and biopharmaceutical products, including gene therapies, is highly competitive. We may face intense competition with respect to our product candidates, as well as with respect to any product candidates that we may seek to develop or commercialize in the future, from large and specialty pharmaceutical companies and biotechnology companies worldwide, who currently market and sell products or are pursuing the development of products for the treatment of many of the disease indications for which we are developing our product candidates. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. In recent years, there has been a significant increase in commercial and scientific interest and financial investment in gene therapy as a therapeutic approach, which has intensified the competition in this area. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We are aware of numerous companies focused on developing gene therapies in various indications, including Applied Genetic Technologies Corp., Abbvie, Abeona Therapeutics, Adverum Biotechnologies, Ally Therapeutics, Apic Bio, Asklepios BioPharmaceutical, Astellas, AVROBIO, Bayer, Biogen, BioMarin, bluebird bio, CRISPR Therapeutics, Editas Medicine, Expression Therapeutics, Fate, Freeline Therapeutics, Generation Bio, Genethon, GlaxoSmithKline, Homology Medicines, Intellia Therapeutics, Johnson &amp; Johnson, Krystal Biotech, Lexeo Therapeutics, LogicBio Therapeutics, Lysogene, MeiraGTx, Milo Biotechnology, Mustang Bio, Novartis, Orchard Therapeutics, Oxford Biomedica, Passage Bio, Pfizer, REGENXBIO, Renova Therapeutics, Roche, Rocket Pharmaceuticals, Sangamo Therapeutics, Sanofi, Selecta Biosciences, Sarepta Therapeutics, Sio Therapeutics, Solid Biosciences, SwanBio, Takeda, Taysha Gene Therapies, Ultragenyx, Vivet Therapeutics, and Voyager Therapeutics, as well as several companies addressing other methods for modifying genes and regulating gene expression. We may also face competition with respect to the treatment of some of the diseases that we are seeking to target with our gene therapies from protein, nucleic acid, antisense, RNAi and other pharmaceuticals under development or commercialized at pharmaceutical and biotechnology companies such as Alnylam Pharmaceuticals, Bayer, BioMarin, CSL Behring, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, Novartis, Novo Nordisk, Pfizer, Translate Bio, Roche, Sanofi, Sobi, Takeda, WaVe Life Sciences, and numerous other pharmaceutical and biotechnology firms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than the products that we develop. Our competitors also may obtain FDA, EMA, or other regulatory approval for their products more rapidly than we do, which could result in our competitors establishing a strong market position before we are able to enter the market. A competitor approval may also prevent us from entering the market if the competitor receives any regulatory exclusivities that block our product candidates. Because we expect that gene therapy patients may generally require only a single administration, we believe that the first gene therapy product to enter the market for a particular indication will likely enjoy a significant commercial advantage and may also obtain market exclusivity under applicable orphan drug regimes. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Many of the companies with which we are competing or may compete in the future have significantly greater financial resources and expertise than we do in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and, as a result, our stock price may decline. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">For planning purposes, we estimate the timing of the accomplishment of various scientific, clinical, regulatory, and other product development goals, or development milestones. These development milestones may include the commencement or completion of scientific studies, clinical trials, the submission of regulatory filings, and approval for commercial sale. From time to time, we publicly announce the expected timing of some of these milestones. All these milestones are based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in many cases for reasons beyond our control. If we do not meet these milestones, including those that are publicly announced, the commercialization of our products may be delayed and, as a result, our stock price may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Dependence on Third Parties </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We rely on third parties, study sites, and others to conduct, supervise, and monitor our preclinical and clinical trials for our product candidates and do not currently plan to independently conduct clinical or preclinical trials of any other potential product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical and scientific institutions, and clinical and preclinical investigators, to conduct our preclinical studies and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">While we have agreements governing the activities of such third parties, we have limited influence and control over their actual performance and activities. For instance, our third-party service providers are not our employees, and except for remedies available to us under our agreements with such third parties we cannot control whether or not they devote sufficient time and resources to our ongoing clinical, non-clinical, and preclinical programs. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our trials may be repeated, extended, delayed, or terminated, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates, we may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates, or we or they may be subject to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business may be materially and adversely affected. Our third-party service providers may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting trials or other therapeutic development activities that could harm our competitive position.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our reliance on these third-parties for development activities will reduce our control over these activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our trials is conducted in accordance with the general investigational plan and protocols for the trial. We must also ensure that our preclinical trials are conducted in accordance with GLPs, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with GCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical and preclinical investigators, and trial sites. If we or any of our third-party service providers fail to comply with applicable GCPs or other regulatory requirements, we or they may be subject to enforcement or other legal actions, the data generated in our trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">In addition, we will be required to report certain financial interests of our third-party investigators if these relationships exceed certain financial thresholds or meet other criteria. The FDA or comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted by investigators who may have conflicts of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We cannot assure that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our trials complies with the applicable regulatory requirements. In addition, our clinical trials must be conducted with product candidates that were produced under GMP conditions. Failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register certain clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in enforcement actions and adverse publicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Agreements with third parties conducting or otherwise assisting with our clinical or preclinical studies might terminate for a variety of reasons, including a failure to perform by the third parties. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative providers or to do so on commercially reasonable terms. Switching or adding additional third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, if we need to enter into alternative arrangements, it could delay our product development activities and adversely affect our business. Though we carefully manage our relationships with our third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We also rely on other third parties to store and distribute our products for the clinical and preclinical trials that we conduct. Any performance failure on the part of our distributors could delay development, marketing approval, or commercialization of our product candidates, producing additional losses and depriving us of potential product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties for important aspects of our development programs. If these parties do not perform successfully or if we are unable to enter into or maintain key collaboration or other contractual arrangements, our business could be adversely affected. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We have in the past entered into, and expect in the future to enter into, collaborations with other companies and academic research institutions with respect to important elements of our development programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Any collaboration may pose several risks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">we may have limited or no control over the design or conduct of clinical trials sponsored by collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">we may be hampered from entering into collaboration arrangements if we are unable to obtain consent from our licensors to enter into sublicensing arrangements of technology we have in-licensed; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">if any collaborator does not conduct the clinical trials they sponsor in accordance with regulatory requirements or stated protocols, we will not be able to rely on the data produced in such trials in our further development efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">collaborators may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">collaborators may also have relationships with other entities, some of which may be our competitors;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">collaborators may not pursue development and commercialization of any product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#39; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">collaborators could develop, independently or with third parties, products that compete directly or indirectly with our products or product candidates, if, for instance, the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">our collaboration arrangements may impose restrictions on our ability to undertake other development efforts that may appear to be attractive to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">a collaborator with marketing and distribution rights that achieves regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">disagreements with collaborators, including over proprietary rights, contract interpretation or the preferred course of development, could cause delays or termination of the research, development or commercialization of product candidates, lead to additional responsibilities for us, delay or impede reimbursement of certain expenses or result in litigation or arbitration, any of which would be time-consuming and expensive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our rights or expose us to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">collaborations may in some cases be terminated for the convenience of the collaborator and, if terminated, we could be required to expend additional funds to pursue further development or commercialization of the applicable product or product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">If any collaboration does not result in the successful development and commercialization of products or if a collaborator were to terminate an agreement with us, we may not receive future research funding or milestone or royalty payments under that collaboration, and we may lose access to important technologies and capabilities of the collaboration. All the risks relating to product development, regulatory approval and commercialization described herein also apply to the activities of any development collaborators. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on licenses of intellectual property from third parties, and such licenses may not provide adequate rights or may not be available in the future on commercially reasonable terms or at all, and our licensors may be unable to obtain and maintain patent protection for the technology or products that we license from them. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We currently are heavily reliant upon licenses of proprietary technology from third parties that is important or necessary to the development of our technology and products, including technology related to our manufacturing process, our vector platform, our gene cassettes and the therapeutic genes of interest we are using. These and other licenses may not provide adequate rights to use such technology in all relevant fields of use. Licenses to additional third-party technology that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, which could have a material adverse effect on our business and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. In addition, some of our agreements with our licensors require us to obtain consent from the licensor before we can enforce patent rights, and our licensor may withhold such consent or may not provide it on a timely basis. Therefore, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. In addition, if third parties who license patents to us fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose rights that are important to our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Our licensing arrangements with third parties may impose diligence, development and commercialization timelines, milestone payment, royalty, insurance, and other obligations on us. If we fail to comply with these obligations, our counterparties may have the right to terminate these agreements either in part or in whole, in which case we might not be able to develop, manufacture or market any product that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or amended agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection is not sufficiently broad, our ability to successfully commercialize our products may be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We rely, in part, upon a combination of forms of intellectual property, including in-licensed and owned patents to protect our intellectual property. Our success depends in a large part on our ability to obtain and maintain this protection in the United States, the European Union, and other countries, in part by filing patent applications related to our novel technologies and product candidates. Our patents may not provide us with any meaningful commercial protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. For example, patents we own currently are and may become subject to future patent opposition or similar proceedings, which may result in loss of scope of some claims or the entire patent. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Successful challenges to our patents may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The patent prosecution process is expensive, time-consuming, and uncertain, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Additionally, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, EU patent law with respect to the patentability of methods of treatment of the human body is more limited than U.S. law. Publications of discoveries in the scientific literature often lag the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after their priority date, or in some cases at all. Therefore, we cannot know with certainty whether we were the first to make the inventions or that we were the first to file for patent protection of the inventions claimed in our owned or licensed patents or pending patent applications. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the European Union, the United States or other countries may diminish the value of our patents or narrow the scope of our patent protection. Our inability to obtain and maintain appropriate patent protection for any one of our products could have a material adverse effect on our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, or third parties may assert their intellectual property rights against us, which could be expensive, time consuming and unsuccessful. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Competitors may infringe our owned or licensed patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, maintained in more narrowly amended form or interpreted narrowly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, increase our operating losses, reduce available resources, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have an adverse effect on the price of our ordinary shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. For example, outside of the United States two of the patents we own are subject to patent opposition. If these or future oppositions are successful or if we are found to otherwise infringe a third party&#39;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. We may not be able to obtain the required license on commercially reasonable terms or at all. Even if we could obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product or otherwise to cease using the relevant intellectual property. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#39; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease or materially modify some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">For example, we are aware of patents owned by third parties that relate to some aspects of our programs that are still in development. In some cases, because we have not determined the final methods of manufacture, the method of administration or the therapeutic compositions for these programs, we cannot determine whether rights under such third-party patents will be needed. In addition, in some cases, we believe that the claims of these patents are invalid or not infringed or will expire before commercialization. However, if such patents are needed and found to be valid and infringed, we could be required to obtain licenses, which might not be available on commercially reasonable terms, or to cease or delay commercializing certain product candidates, or to change our programs to avoid infringement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">In addition to seeking patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and confidential and proprietary information. To maintain the confidentiality of our trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and other third parties who have access to our trade secrets. Our agreements with employees also provide that any inventions conceived by the individual while rendering services to us will be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, in the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants, or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;"> </span>Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information including a breach of our confidentiality agreements. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time consuming, and the outcome is unpredictable. In addition, some courts in and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. The disclosure of our trade secrets or the independent development of our trade secrets by a competitor or other third party would impair our competitive position and may materially harm our business, financial condition, results of operations, stock price and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our reliance on third parties may require us to share our trade secrets, which could increase the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Because we collaborate from time to time with various organizations and academic research institutions on the advancement of our gene therapy platform, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, materials transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#39;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">In addition, these agreements typically restrict the ability of our collaborators, advisors, and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, if we are notified in advance and may delay publication for a specified time to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those with whom they communicate, from using that technology or information to compete with us. &#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Risks Related to Pricing and Reimbursement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face uncertainty related to insurance coverage of, and pricing and reimbursement for product candidates for which we may receive marketing approval. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We anticipate that the cost of treatment using our product candidates will be significant. We expect that most patients and their families will not be capable of paying for our products themselves. There will be no commercially viable market for our product candidates without reimbursement from third party payers, such as government health administration authorities, private health insurers and other organizations. Even if there is a commercially viable market, if the level of third-party reimbursement is below our expectations, most patients may not be able to afford treatment with our products and our revenues and gross margins will be adversely affected, and our business will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Government authorities and other third-party payers, such as private health insurers and health maintenance organizations, decide for which medications they will pay and, subsequently, establish reimbursement levels. Reimbursement systems vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis. Government authorities and third-party payers have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications and procedures and negotiating or requiring payment of manufacturer rebates. Increasingly, third party payers require drug companies to provide them with predetermined discounts from list prices, are exerting influence on decisions regarding the use of particular treatments and are limiting covered indications. Additionally, in the United States and some foreign jurisdictions, pending or potential legislative and regulatory changes regarding the healthcare system and insurance coverage could result in more rigorous coverage criteria and downward pressure on drug prices, and may affect our ability to profitably sell any products for which we obtain marketing approval. For example, on November 27, 2020, CMS issued an interim final rule implementing a Most Favored Nation payment model under which reimbursement for certain Medicare Part B drugs and biologicals will be based on a price that reflects the lowest per capita GDP-adjusted price of any non-U.S. member country of the OECD with a GDP per capita that is at least sixty percent of the U.S. GDP per capita.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The pricing review period and pricing negotiations for new medicines take considerable time and have uncertain results. Pricing review and negotiation usually begins only after the receipt of regulatory marketing approval, and some authorities require approval of the sale price of a product before it can be marketed. In some markets, particularly the countries of the European Union, prescription pharmaceutical pricing remains subject to continuing direct governmental control and to drug reimbursement programs even after initial approval is granted and price reductions may be imposed. Prices of medical products may also be subject to varying price control mechanisms or limitations as part of national health systems if products are considered not cost-effective or where a drug company&#39;s profits are deemed excessive. In addition, pricing and reimbursement decisions in certain countries can lead to mandatory price reductions or additional reimbursement restrictions in other countries. Because of these restrictions, any product candidates for which we may obtain marketing approval may be subject to price regulations that delay or prohibit our or our partners&#39; commercial launch of the product in a particular jurisdiction. In addition, we or any collaborator may elect to reduce the price of our products to increase the likelihood of obtaining reimbursement approvals. If countries impose prices, which are not sufficient to allow us or any collaborator to generate a profit, we or any collaborator may refuse to launch the product in such countries or withdraw the product from the market. If pricing is set at unsatisfactory levels, or if the price decreases, our business could be harmed, possibly materially. If we fail to obtain and sustain an adequate level of coverage and reimbursement for our products by third party payers, our ability to market and sell our products could be adversely affected and our business could be harmed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Due to the generally limited addressable market for our target orphan indications and the potential for our therapies to offer therapeutic benefit in a single administration, we face uncertainty related to pricing and reimbursement for these product candidates. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The relatively small market size for orphan indications and the potential for long-term therapeutic benefit from a single administration present challenges to pricing review and negotiation of our product candidates for which we may obtain marketing authorization. Most of our product candidates target rare diseases with relatively small patient populations. If we are unable to obtain adequate levels of reimbursement relative to these small markets, our ability to support our development and commercial infrastructure and to successfully market and sell our product candidates for which we may obtain marketing approval could be adversely affected. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We also anticipate that many or all our gene therapy product candidates may provide long-term, and potentially curative benefit, with a single administration. This is a different paradigm than that of other pharmaceutical therapies, which often require an extended course of treatment or frequent administration. As a result, governments and other payers may be reluctant to provide the significant level of reimbursement that we seek at the time of administration of our gene therapies or may seek to tie reimbursement to clinical evidence of continuing therapeutic benefit over time. Additionally, there may be situations in which our product candidates will need to be administered more than once, which may further complicate the pricing and reimbursement for these treatments. In addition, considering the anticipated cost of these therapies, governments and other payers may be particularly restrictive in making coverage decisions. These factors could limit our commercial success and materially harm our business. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses in prior years and expect to incur losses over the next several years and may never achieve or maintain profitability. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We had a net gain of $357.9 million in the six months ended June 30, 2021, and a net loss of $125.0 in the full year 2020 and $124.2 million in the full year 2019. As of June 30, 2021, we had an accumulated deficit of $426.8 million. In the past, we have financed our operations primarily through the sale of equity securities and convertible debt, venture loans, upfront payments from our collaboration partners and, to a lesser extent, subsidies and grants from governmental agencies and fees for services. We expect to finance our operations in 2021 and 2022 primarily from the $462.4 million payments we collected from CSL Behring in May 2021. We have devoted substantially all our financial resources and efforts to research and development, including preclinical studies and clinical trials. We expect to continue to incur significant expenses and losses over the next several years, and our net losses may fluctuate significantly from quarter to quarter and year to year. Our profit in the three and six months ended June 30, 2021 was materially impacted by the amount of license revenue that we recognized as a result of the Closing of the transaction under the CSL Behring Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We anticipate that our expenses will increase substantially as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.85pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Advance the clinical development of AMT-130 for our Huntington&#8217;s disease gene therapy program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.85pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Advance multiple research programs related to gene therapy candidates targeting liver-directed and CNS diseases;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.85pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Continue to expand our employee base to support research and development, as well as general and administrative functions; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.85pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Acquire or in-license rights to new therapeutic targets or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.85pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Continue to expand, enhance, and optimize our technology platform, including our manufacturing capabilities, next-generation viral vectors and promoters, and other enabling technologies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.85pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Maintain, expand, and protect our intellectual property portfolio, including in-licensing additional intellectual property rights from third parties.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We may never succeed in these activities and, even if we do, may never generate revenues that are sufficient to achieve or sustain profitability. Our failure to become and remain profitable would depress the value of our company and could impair our ability to expand our business, maintain our research and development efforts, diversify our product offerings, or even continue our operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will likely need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain capital when needed may force us to delay, limit or terminate our product development efforts or other operations which could have a material adverse effect on our business, financial condition, results of operations and cash flows. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We expect to incur significant expenses in connection with our on-going activities and that we will likely need to obtain substantial additional funding in connection with our continuing operations. In addition, we have based our estimate of our financing requirements on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Adequate capital may not be available to us when needed or may not be available on acceptable terms. Our ability to obtain debt financing may be limited by covenants we have made the 2018 Amended Facility and our 2021 Amended Facility with Hercules and our pledge to Hercules of substantially all our assets as collateral. If we raise additional capital through the sale of equity or convertible debt securities, our shareholders&#39; ownership interest could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our ordinary shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">If we raise additional funds through collaborations, strategic alliances, or marketing, distribution, or licensing arrangements with third parties, we may have to issue additional equity, relinquish valuable rights to our technologies, future revenue streams, products, or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce, or eliminate our research and development programs or any future commercialization efforts, which would have a negative impact on our financial condition, results of operations and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:4pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our existing and any future indebtedness could adversely affect our ability to operate our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">As of June 30, 2021, we had $70.0 million of outstanding principal of borrowings under the 2018 Amended Facility and 2021 Amended Facility, which following our January 2021 amendment we are required to repay in June 2023. We could in the future incur additional debt obligations beyond our borrowings from Hercules. Our existing loan obligations, together with other similar obligations that we may incur in the future, could have significant adverse consequences, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">requiring us to dedicate a portion of our cash resources to the payment of interest and principal, reducing money available to fund working capital, capital expenditures, research and development and other general corporate purposes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">increasing our vulnerability to adverse changes in general economic, industry and market conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">placing us at a disadvantage compared to our competitors that have less debt or better debt servicing options.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We may not have sufficient funds, and may be unable to arrange for additional financing, to pay the amounts due under our existing loan obligations. Failure to make payments or comply with other covenants under our existing debt could result in an event of default and acceleration of amounts due. Under the 2018 Amended Facility as well as the 2021 Amended Facility, the occurrence of an event that would reasonably be expected to have a material adverse effect on our business, operations, assets, or condition is an event of default. If an event of default occurs and the lender accelerates the amounts due, we may not be able to make accelerated payments, and the lender could seek to enforce security interests in the collateral securing such indebtedness, which includes substantially all our assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Risks Related to Other Legal Compliance Matters </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:4pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our relationships with customers and third-party payers will be subject to applicable anti-kickback, anti-bribery, fraud and abuse and other laws and regulations, which, if we are found in violation thereof, could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:4pt 0pt 0pt 0pt;">Healthcare providers, physicians and third-party payers will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our future arrangements with third party payers and customers may expose us to broadly applicable anti-bribery laws, including the Foreign Corrupt Practices Act, as well as fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we would be able to market, sell and distribute any products for which we obtain marketing approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable laws and regulations could involve substantial costs. If our operations, or the activities of our collaborators, distributors or other third-party agents are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs and the curtailment or restructuring of our operations. The costs associated with any of these actions could be substantial and could cause irreparable harm to our reputation or otherwise have a material adverse effect on our business, financial condition, and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to laws governing data protection in the different jurisdictions in which we operate. The implementation of such data protection regimes is complex, and should we fail to fully comply, we may be subject to penalties that may have an adverse effect on our business, financial condition, and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Many national and state laws govern the privacy and security of health information and other personal and private information. They often differ from each other in significant ways. For instance, the EU has adopted a comprehensive data protection law called the General Data Protection Regulation (&#8220;GDPR&#8221;) that took effect in May 2018. The GDPR, together with the national legislation of the EU member states governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data relates, the information provided to the individuals, the transfer of personal data out of the EU, security breach notifications, security and confidentiality of the personal data, and imposition of substantial potential fines for breaches of the data protection obligations. The GDPR imposes penalties for non-compliance of up to the greater of EUR 20.0 million or 4% of worldwide revenue. Data protection authorities from the different EU member states may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing personal data in the EU. Guidance on implementation and compliance practices are often updated or otherwise revised. The significant costs of compliance with, risk of regulatory enforcement actions under, and other burdens imposed by the GDPR as well as under other regulatory schemes throughout the world related to privacy and security of health information and other personal and private data could have an adverse impact on our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits could cause us to incur substantial liabilities and to limit commercialization of our therapies. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We face an inherent risk of product liability related to the testing of our product candidates in human clinical trials and in connection with product sales. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">decreased demand for any product candidates or products that we develop or sell;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">negative publicity or public opinion surrounding gene therapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">withdrawal of clinical trial participants or sites, or discontinuation of development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">significant costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">initiation of investigations, and enforcement actions by regulators; and product recalls, withdrawals, revocation of approvals, or labeling, marketing, or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">reduced resources of our management to pursue our business strategy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the inability to further develop or commercialize any products that we develop.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Dependent upon the country where the clinical trial is conducted, we currently hold coverages ranging from EUR 500,000 to EUR 6,500,000 per occurrence and per clinical trial. Such coverage may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials. In addition, insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. In the event insurance coverage is insufficient to cover liabilities that we may incur, it could have a material adverse effect on our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare legislative and regulatory reform measures may have a material adverse effect on our financial operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Our industry is highly regulated and changes in law may adversely impact our business, operations, or financial results. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA, is a sweeping measure intended to, among other things, expand healthcare coverage within the United States, primarily through the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions of the law may affect us and increase certain of our costs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, other legislative changes have been adopted since the PPACA was enacted. These changes include aggregate reductions in Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, following passage of the Bipartisan Budget Act of 2018, will remain in effect through 2027 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and, accordingly, our financial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We anticipate that the PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the reimbursement our customers may receive for our products. Further, there have been, and there may continue to be, judicial and Congressional challenges to certain aspects of the PPACA. For example, the U.S. Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &quot;individual mandate&quot;. Additional legislative and regulatory changes to the PPACA, its implementing regulations and guidance and its policies, remain possible in the 117th U.S. Congress and under the Biden Administration. However, it remains unclear how any new legislation or regulation might affect the prices we may obtain for any of our product candidates for which regulatory approval is obtained. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. The size and complexity of our information technology systems, and those of our collaborators, contractors and consultants, and the large amounts of confidential information stored on those systems, make such systems vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication, and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering, and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient. The increased number of employees working remotely due to Covid might increase our vulnerability to the above risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">While we have not experienced a system failure, accident, cyber-attack, or security breach that has resulted in a material interruption in our operations to date, we have experienced and addressed recent system failures, cyber-attacks, and security breaches. In the future, such events could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets, data, or other proprietary information or other similar disruptions. Additionally, any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation, cause us not to comply with federal and/or state breach notification laws and foreign law equivalents and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. Security breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures to protect our information technology systems and infrastructure, there can be no assurance that such measures will prevent service interruptions or security breaches that could adversely affect our business and the further development and commercialization of our product and product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Employee Matters and Managing Growth</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future success depends on our ability to retain key executives and technical staff and to attract, retain and motivate qualified personnel. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We are highly dependent on hiring, training, retaining and motivating key personnel to lead our research and development, clinical operations and manufacturing efforts. Although we have entered into employment agreements with our key personnel, each of them may terminate their employment on short notice. We do not maintain key person insurance for any of our senior management or employees. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The loss of the services of our key employees could impede the achievement of our research and development objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing senior management and key employees may be difficult and may take an extended period because of the limited number of individuals in our industry with the breadth and depth of skills and experience required to successfully develop gene therapy products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Ordinary Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">The price of our ordinary shares has been and may in the future be volatile and fluctuate substantially. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Our share price has been and may in the future be volatile. From the start of trading of our ordinary shares on the Nasdaq Global Select Market on February 4, 2014 through July 22, 2021, the sale price of our ordinary shares ranged from a high of $82.49 to a low of $4.72. The closing price on July 22, 2021, was $26.49 per ordinary share. The stock market in general and the market for smaller biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our ordinary shares may be influenced by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the success of competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">results of clinical trials of our product candidates or those of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">public perception of gene therapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">regulatory delays and greater government regulation of potential products due to adverse events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">regulatory or legal developments in the European Union, the United States, and other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the recruitment or departure of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the level of expenses related to any of our product candidates or clinical development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">mergers, acquisitions, licensing, and collaboration activity among our peer companies in the pharmaceutical and biotechnology sectors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">general economic, industry and market conditions.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our directors, executive officers and major shareholders, if they choose to act together, will continue to have a significant degree of control with respect to matters submitted to shareholders for approval. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Our directors, executive officers and major shareholders holding more than 5% of our outstanding ordinary shares, in the aggregate, beneficially own approximately 54.9% of our issued shares (including such shares to be issued in relation to exercisable options to purchase ordinary shares) as at June 30, 2021. As a result, if these shareholders were to choose to act together, they may be able, as a practical matter, to control many matters submitted to our shareholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, could control the election of the board directors and the approval of any merger, consolidation or sale of all or substantially all our assets. These shareholders may have interests that differ from those of other of our shareholders and conflicts of interest may arise. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions of our articles of association or Dutch corporate law might deter acquisition bids for us that might be considered favorable and prevent or frustrate any attempt to replace our board.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Certain provisions of our articles of association may make it more difficult for a third party to acquire control of us or effect a change in our board. These provisions include:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">staggered terms of our directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">a provision that our directors may only be removed at a general meeting of shareholders by a two-thirds majority of votes cast representing more than half of the issued share capital of the Company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">a requirement that certain matters, including an amendment of our articles of association, may only be brought to our shareholders for a vote upon a proposal by our board.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We do not expect to pay dividends in the foreseeable future. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We have not paid any dividends since our incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend that earnings, if any, will be reinvested in our business and that dividends will not be paid until we have an established revenue stream to support continuing dividends. Accordingly, shareholders cannot rely on dividend income from our ordinary shares and any returns on an investment in our ordinary shares will likely depend entirely upon any future appreciation in the price of our ordinary shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to maintain an effective system of internal controls, we may be unable to accurately report our results of operations or prevent fraud or fail to meet our reporting obligations, and investor confidence and the market price of our ordinary shares may be materially and adversely affected. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">If we fail to maintain the adequacy of our internal control over financial reporting, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting. If we fail to maintain effective internal control over financial reporting, we could experience material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading price of our ordinary shares. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from The Nasdaq Global Select Market, regulatory investigations and civil or criminal sanctions. Our reporting and compliance obligations may place a significant strain on our management, operational and financial resources and systems for the foreseeable future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks for U.S. Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have in the past qualified and in the future may qualify as a passive foreign investment company, which may result in adverse U.S. federal income tax consequence to U.S. holders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Based on our average value of our gross assets, our cash and cash equivalents as well as the price of our shares we qualified as a passive foreign investment company (&#8220;PFIC&#8221;) for U.S. federal income tax for 2016 but not between 2017 and 2020. A corporation organized outside the United States generally will be classified as a PFIC for U.S. federal income tax purposes in any taxable year in which at least 75% of its gross income is passive income or on average at least 50% of the gross value of its assets is attributable to assets that produce passive income or are held to produce passive income. Passive income for this purpose generally includes dividends, interest, royalties, rents and gains from commodities and securities transactions. Our status in any taxable year will depend on our assets and activities in each year, and because this is a factual determination made annually after the end of each taxable year, there can be no assurance that we will continue to qualify as a PFIC in future taxable years. The market value of our assets may be determined in large part by reference to the market price of our ordinary shares, which is likely to fluctuate, and may fluctuate considerably given that market prices of biotechnology companies have been especially volatile. If we were considered a PFIC for the current taxable year or any future taxable year, a U.S. holder would be required to file annual information returns for such year, whether the U.S. holder disposed of any ordinary shares or received any distributions in respect of ordinary shares during such year. In certain circumstances a U.S. holder may be able to make certain tax elections that would lessen the adverse impact of PFIC status; however, to make such elections the U.S. holder will usually have to have been provided information about the company by us, and we do not intend to provide such information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The U.S. federal income tax rules relating to PFICs are complex. U.S. holders are urged to consult their tax advisors with respect to the purchase, ownership and disposition of our shares, the possible implications to them of us being treated as a PFIC (including the availability of applicable election, whether making any such election would be advisable in their particular circumstances) as well as the federal, state, local and foreign tax considerations applicable to such holders in connection with the purchase, ownership, and disposition of our shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any U.S. or other foreign judgments may be difficult to enforce against us in the Netherlands. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Although we now report as a U.S. domestic filer for SEC reporting purposes, we are incorporated under the laws of the Netherlands. Some of the members of our board and senior management reside outside the United States. As a result, it may not be possible for shareholders to effect service of process within the United States upon such persons or to enforce judgments against them or us in U.S. courts, including judgments predicated upon the civil liability provisions of the federal securities laws of the United States. In addition, it is not clear whether a Dutch court would impose civil liability on us or any of our Board members in an original action based solely upon the federal securities laws of the United States brought in a court of competent jurisdiction in the Netherlands. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The United States and the Netherlands currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the Netherlands. To obtain a judgment which is enforceable in the Netherlands, the party in whose favor a final and conclusive judgment of the U.S. court has been rendered will be required to file its claim with a court of competent jurisdiction in the Netherlands. Such party may submit to the Dutch court the final judgment rendered by the U.S. court. If and to the extent that the Dutch court finds that the jurisdiction of the U.S. court has been based on grounds which are internationally acceptable and that proper legal procedures have been observed, the Dutch court will, in principle, give binding effect to the judgment of the U.S. court, unless such judgment contravenes principles of public policy of the Netherlands. Dutch courts may deny the recognition and enforcement of punitive damages or other awards. Moreover, a Dutch court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or damages. Enforcement and recognition of judgments of U.S. courts in the Netherlands are solely governed by the provisions of the Dutch Civil Procedure Code. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Therefore U.S. shareholders may not be able to enforce against us or our board members or senior management who are residents of the Netherlands or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">The rights and responsibilities of our shareholders and directors are governed by Dutch law and differ in some important respects from the rights and responsibilities of shareholders under U.S. law. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Although we now report as a U.S. domestic filer for SEC purposes, our corporate affairs are governed by our articles of association and by the laws governing companies incorporated in the Netherlands. The rights of our shareholders and the responsibilities of members of our board under Dutch law are different than under the laws of some U.S. jurisdictions. In the performance of their duties, our board members are required by Dutch law to consider the interests of uniQure, its shareholders, its employees, and other stakeholders and not only those of our shareholders (as would be required under the law of most U.S. jurisdictions). As a result of these considerations our directors may take action that would be different than those that would be taken by a company organized under the law of some U.S. jurisdictions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_786b47cb_f8f3_43ab_9334_470b364c2160"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 2.</b></span><span style="display:inline-block;width:18pt;"></span>Unregistered Sales of Equity Securities and Use of Proceeds</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cb7371d3_2d1e_4cd9_b909_1924e9e1103d"></a><a id="Item3DefaultsUponSeniorSecurities_428783"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 3.</b></span><span style="display:inline-block;width:18pt;"></span>Defaults Upon Senior Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_031885d5_ab5e_497c_97a4_54f30613673d"></a><a id="Item4MineSafetyDisclosures_199652"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 4.</b></span><span style="display:inline-block;width:18pt;"></span>Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_76a606e1_b2a8_4b8c_8f32_9afee5aeb2b8"></a><a id="Item5OtherInformation_846000"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 5.</b></span><span style="display:inline-block;width:18pt;"></span>Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1a256b6e_db76_4e9a_a8f4_2e902bec7839"></a><a id="Item6Exhibits_250186"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 6.</b></span><span style="display:inline-block;width:18pt;"></span>Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">See the Exhibit Index immediately preceding the signature page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2cb72c68_137b_4856_8dae_a7f68600b694"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT INDEX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:6pt 0pt 12pt 0pt;"><a style="-sec-extract:exhibit;" href="qure-20210630xex2d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;white-space:pre-wrap;">2.1*&#8224;     Sale and Purchase Agreement, executed June 21, 2021, by and between uniQure N.V. and Corlieve Therapeutics SAS</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:6pt 0pt 12pt 0pt;"><a style="-sec-extract:exhibit;" href="qure-20210630xex3d1.htm"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;">3.1*</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;white-space:pre-wrap;">       Amended Articles of Association of the Company, effective as of June 16, 2021.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:6pt 0pt 12pt 0pt;"><a style="-sec-extract:exhibit;" href="qure-20210630xex4d1.htm"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;">4.1*t</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;">2014 Share Incentive Plan, Amended and Restated, effective as of June 16, 2021.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:6pt 0pt 12pt 0pt;"><a style="-sec-extract:exhibit;" href="qure-20210630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;white-space:pre-wrap;">10.1*t    Employment Agreement, effective May 17, 2021, by and between uniQure biopharma B.V. and Pierre Caloz</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:6pt 0pt 12pt 0pt;"><a style="-sec-extract:exhibit;" href="qure-20210630xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;white-space:pre-wrap;">10.2*t    Equity Side Letter, effective May 17, 2021, by and between uniQure N.V. and Pierre Caloz</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:6pt 0pt 12pt 0pt;"><a style="-sec-extract:exhibit;" href="qure-20210630xex10d3.htm"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;">10.3*t</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;">Amended and Restated Employment Agreement, effective June 15, 2021, by and between uniQure biopharma B.V. and Christian Klemt</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:6pt 0pt 12pt 0pt;"><a style="-sec-extract:exhibit;" href="qure-20210630xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;">31.1*&#160;&#160;&#160;&#160;&#160;Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer</span></a> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:6pt 0pt 12pt 0pt;"><a style="-sec-extract:exhibit;" href="qure-20210630xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;">31.2*&#160;&#160;&#160;&#160;&#160;Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:6pt 0pt 12pt 0pt;"><a style="-sec-extract:exhibit;" href="qure-20210630xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;">32.1&#177;&#160;&#160;&#160;&#160;&#160;Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 12pt 0pt;">101*&#160;&#160;&#160;&#160;&#160;&#160;The following financial information from our Quarterly Report on Form 10-Q for the period ended June 30, 2021, filed with the Securities and Exchange Commission on July 26, 2021, is formatted in Inline Extensible Business Reporting Language (&#8220;iXBRL&#8221;): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations and Comprehensive Loss; (iii) Consolidated Statements of Shareholders&#8217; Equity; (iv) Consolidated Statements of Cash Flows; and (v) Notes to Consolidated Financial Statements (tagged as blocks of text)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 12pt 0pt;">104* &#160; &#160; &#160;The cover page from our Quarterly Report on Form 10-Q for the period ended June 30, 2021, filed with the Securities and Exchange Commission on July 26, 2021, is formatted in Inline Extensible Business Reporting Language (&#8220;iXBRL&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">&#8224;            Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;">*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;">&#177;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Furnished herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">t</span></span>Indicates a management contract or compensatory plan or arrangement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.72%;border:0;margin:30pt 10.64% 30pt 10.64%;"></div><div style="max-width:100%;padding-left:10.64%;padding-right:10.64%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3399beda_912a_425a_bfb2_12dfe65ce428"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">SIGNATURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 12pt 261pt;"><b style="font-weight:bold;">UNIQURE, N.V.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 261.35pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 261.35pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:justify;border-bottom:1px solid #000000;margin:0pt 0pt 0pt 261.35pt;">By: /s/ Matthew Kapusta</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 261.35pt;">Matthew Kapusta</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 261.35pt;">Chief Executive Officer </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 261.35pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 261.35pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 261.35pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:justify;border-bottom:1px solid #000000;margin:0pt 0pt 0pt 261.35pt;">By: /s/ Christian Klemt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 261.35pt;">Christian Klemt </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 261.35pt;">Chief Financial Officer </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 261.35pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated July 26, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.64%;margin-right:10.64%;margin-top:30pt;page-break-after:avoid;width:78.72%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>qure-20210630xex2d1.htm
<DESCRIPTION>EX-2.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 7/26/2021 08:01:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-align:right;text-indent:-72pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 2.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-align:right;text-indent:-72pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SALE AND PURCHASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">by and among</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">UNIQURE N.V.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">EACH OF THE SHAREHOLDERS OF CORLIEVE THERAPEUTICS PARTY HERETO,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">THE HOLDER REPRESENTATIVE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Dated as of June 21, 2021</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">In presence of Corlieve</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;"><img src="qure-20210630xex2d1001.jpg" alt="Graphic" style="display:inline-block;height:21pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:134.25pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Condor House</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">5-10 St. Paul&#8217;s Churchyard</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">London EC4M 8AL</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Tel. +44 (0)20 3201 5000</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Fax: +44 (0)20 3201 5001</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">www.morganlewis.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">SHARE PURCHASE AGREEMENT</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">1</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">INTRODUCTION</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">1</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">ARTICLE 1 DEFINITIONS AND CONSTRUCTION</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">2</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">ARTICLE 2 SALE OF THE SHARES</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">18</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">ARTICLE 3 REPRESENTATIONS AND WARRANTIES REGARDING THE SELLERS</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">26</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">ARTICLE 4 REPRESENTATIONS AND WARRANTIES REGARDING CORLIEVE</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">28</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF PURCHASER</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">41</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">ARTICLE 6 COVENANTS AND AGREEMENTS</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">42</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">ARTICLE 7 POST-CLOSING COVENANTS</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">47</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">ARTICLE 8 CLOSING CONDITIONS</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">49</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">ARTICLE 9 INDEMNIFICATION</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">51</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">ARTICLE 10 TERMINATION</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">57</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">ARTICLE 11 MISCELLANEOUS</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">59</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">EXHIBIT A: THE SELLERS</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">65</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">EXHIBIT B: THE FREE SHARES HOLDERS</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">66</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;white-space:pre-wrap;">EXHIBIT C: RESALE PROSPECTUS SUPPLEMENT;  </font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">67</font></p></td></tr><tr><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">EXHIBIT D: FORM OF FRENCH SHORT FORM TRANSFER AGREEMENT</font></p></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">70</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SHARE PURCHASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This SHARE PURCHASE AGREEMENT (this &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Agreement</u><font style="font-size:11pt;">&#8221;) dated as of June 21, 2021 (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Agreement Date</u><font style="font-size:11pt;">&#8221;) is made and entered into by and among uniQure N.V., a public company with limited liability </font><i style="font-size:11pt;font-style:italic;">(naamloze vennootschap)</i><font style="font-size:11pt;"> formed under the laws of the Netherlands and registered with the Dutch trade register under number 54385229 (&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Purchaser</u><font style="font-size:11pt;">&#8221;); all shareholders of Corlieve Therapeutics SAS, a </font><i style="font-size:11pt;font-style:italic;">soci&#233;t&#233; par actions simplifi&#233;e</i><font style="font-size:11pt;"> formed under the laws of France (&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Corlieve</u><font style="font-size:11pt;">&#8221; or the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Company</u><font style="font-size:11pt;">&#8221;), party hereto acting severally and not jointly (</font><i style="font-size:11pt;font-style:italic;">non solidairement</i><font style="font-size:11pt;">) for the purposes hereof (&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Sellers</u><font style="font-size:11pt;">&#8221; and each, individually, a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Seller</u><font style="font-size:11pt;">&#8221;); and the Holder Representative hereunder (collectively, the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Parties</u><font style="font-size:11pt;">&#8221;), in presence of Corlieve for purposes of </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 4</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">INTRODUCTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">WHEREAS, the Sellers currently own 100,000 ordinary shares of Corlieve (excluding Free Shares) (&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Ordinary Shares</u><font style="font-size:11pt;">&#8221;) in the aggregate and 602,488 ordinary shares called &#8220;Series A&#8221; shares for identification purposes only of Corlieve (&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Series A Shares</u><font style="font-size:11pt;">&#8221;) in the aggregate, as set forth in further detail on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u><font style="font-size:11pt;"> attached hereto;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">WHEREAS, </font><font style="font-size:11pt;">Corlieve has allocated 52,296 free</font><font style="font-size:11pt;"> shares (</font><i style="font-size:11pt;font-style:italic;">actions gratuites</i><font style="font-size:11pt;">), of which 5,464 have been cancelled effective on the Closing Date. &#160;The </font><font style="font-size:11pt;">holders of the remaining free shares (&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Free Shares Holders</u><font style="font-size:11pt;">&#8221; and each, individually, a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Free Share Holder</u><font style="font-size:11pt;">&#8221;) currently own 46,832 free shares </font><font style="font-size:11pt;">as set forth in further detail on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> attached hereto, representing all of the issued and outstanding free shares and securities giving access to the share capital of Corlieve </font><font style="font-size:11pt;">(the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Free Shares</u><font style="font-size:11pt;">&#8221;)</font><font style="font-size:11pt;">;</font><sup style="font-size:8.25pt;vertical-align:top;">1</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">WHEREAS, in connection with the execution of this Agreement, Purchaser and REGENXBIO INC., a corporation organized under the laws of the State of Delaware, with offices at </font><font style="font-size:11pt;">9804 Medical Center Drive, Rockville, MD 20850</font><font style="font-size:11pt;"> (&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">RGX</u><font style="font-size:11pt;">&#8221;), have reached certain agreements in respect of the RGX License Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">WHEREAS, certain of the Sellers have extended a shareholder loan to Corlieve (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Shareholder Loan</u><font style="font-size:11pt;">&#8221;), which will be repaid before the Closing Date by way of set-off against the capital contribution obligation resulting from a share capital increase in favor of certain of the Sellers, representing the issuance of new Series A Shares, at a price of &#8364;10 each (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Loan Conversion</u><font style="font-size:11pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">WHEREAS, the Sellers and the Free Share Holders shall hold, on the Closing Date, 100% of the issued and outstanding share capital and of the voting rights in Corlieve (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Shares</u><font style="font-size:11pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">WHEREAS, the Sellers desire to sell, or cause to be sold, to Purchaser, and Purchaser desires to acquire from the Sellers, on the Closing Date, all of the Shares upon the terms and conditions hereinafter set forth;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">WHEREAS, Purchaser desires to acquire from the Free Share Holders all of the Free Shares upon the terms and conditions hereinafter set forth;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">WHEREAS, for certain limited purposes, and subject to the terms set forth herein, the Holder Representative shall serve as a representative of the Sellers; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">WHEREAS, provisions of the SER Merger Code (</font><i style="font-size:11pt;font-style:italic;">SER-Fusiegedragsregels</i><i style="font-size:11pt;font-style:italic;"> 2015</i><font style="font-size:11pt;">) and the Act on the works councils (</font><i style="font-size:11pt;font-style:italic;">Wet op de ondernemingsraden</i><font style="font-size:11pt;">) are not applicable to the transactions contemplated hereunder</font><font style="font-size:11pt;">.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="vertical-align:top;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">DEFINITIONS AND CONSTRUCTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">1.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Definitions</u><font style="font-size:11pt;">. As used in this Agreement, the following terms shall have the meanings set forth or as referenced below:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">AAV9</u><font style="font-size:11pt;">&#8221; means (a) the recombinant adeno-associated virus serotype 9 vector with the specified sequence set forth in GenBank ([*]) and (b) any recombinant adeno-associated virus derivatives of such serotype 9 vector that are covered by the claims of the Valid RGX AAV9 Patents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Acceptable Undertaking</u><font style="font-size:11pt;">&#8221; means the undertaking by the Purchaser and its Affiliates to take any of the following actions or commitments: </font><b style="font-size:11pt;font-weight:bold;">(a) </b><font style="font-size:11pt;">to ensure that the Corlieve Intellectual Property remains available for use in France by Corlieve; </font><b style="font-size:11pt;font-weight:bold;">(b)</b><font style="font-size:11pt;"> to cause Corlieve to </font><i style="font-size:11pt;font-style:italic;">(i)</i><font style="font-size:11pt;"> file in France any patent application relating to a patentable invention developed by Corlieve for the purposes of its activities, without prejudice to the ability of Corlieve to additionally register such patent(s) in any territory other than France, and </font><i style="font-size:11pt;font-style:italic;">(ii)</i><font style="font-size:11pt;"> ensure that Patents filed pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">subparagraph </u><i style="font-size:11pt;font-style:italic;text-decoration:underline;text-decoration-color:#000000;">(i)</i><font style="font-size:11pt;"> remain available for use in France by Corlieve; </font><b style="font-size:11pt;font-weight:bold;">(c) </b><font style="font-size:11pt;">to maintain Corlieve&#8217;s registered office in France and substantially the same level of human resources and equipment in France to continue operating the Business for a period of not more than two years from Closing; and </font><b style="font-size:11pt;font-weight:bold;">(d) </b><font style="font-size:11pt;">to grant the </font><font style="font-size:11pt;">French Ministry of Economy, Finance and Recovery (</font><i style="font-size:11pt;font-style:italic;">Minist&#232;re de l&#8217;Economie, des Finances et de la Relance</i><font style="font-size:11pt;">) </font><font style="font-size:11pt;">with information, audit and access rights customarily required for the purpose of monitoring the above undertakings, provided that such rights do not unreasonably disrupt the normal operations of Corlieve.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Accredited Investor</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.11(d)</u><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">.</b><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Affiliate</u><font style="font-size:11pt;">&#8221; shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by or is under common control with such Person. For the purposes of this definition, the term &#8220;control&#8221; (including, with correlative meanings, the terms &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">controlled by</u><font style="font-size:11pt;">&#8221; and &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">under common control with</u><font style="font-size:11pt;">&#8221;) as used with respect to a Person shall mean (a) direct or indirect ownership of more than fifty percent (50%) of the voting securities or other voting interest of any Person (including attribution from related parties) or (b) the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities, by Contract, as a general partner, as a manager, or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Agreement</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the Preamble of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Agreement Date</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the Preamble of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Alternative Product</u><font style="font-size:11pt;">&#8221; shall mean any pharmaceutical product in all forms, presentations, formulations, methods of administration and dosage forms, that targets the expression of the Grik2 Gene Sequence for the treatment of epilepsy in humans that uses Corlieve Intellectual Property, &#160;excluding any Corlieve Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Alternative Transaction</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;6.5</u><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ANSM</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4.23(b)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">API</u><font style="font-size:11pt;">&#8221; means active pharmaceutical ingredient.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Applicable Law</u><font style="font-size:11pt;">&#8221; shall mean, with respect to any Person, any Law applicable to such Person or any of such Person&#8217;s property and assets or such Person&#8217;s legal representatives, officers, directors, employees, consultants or agents in their capacity as such Person&#8217;s legal representatives, officers, directors, employees, consultants or agents, respectively.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Benefits</u><font style="font-size:11pt;">&#8221; shall mean: (i) all compensation or benefits provided by any Contract signed with any existing or former employee, and (ii) all medical, dental, health, welfare, life insurance agreements, programs, policies, commitments or other arrangements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">BLA</u><font style="font-size:11pt;">&#8221; means a Biological License Application (BLA) pursuant to 21 C.F.R. &#167; 601.2 (or any successor regulation thereto), or a NDA filed with the FDA as described in 21 C.F.R. &#167; 314 (or any successor regulation thereto) for purposes of obtaining Regulatory Approval for a new biologic in the United States, or any equivalent filing in a country or regulatory jurisdiction other than the United States.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">BPI Loan Agreement</u><font style="font-size:11pt;">&#8221; shall mean that certain loan agreement (</font><i style="font-size:11pt;font-style:italic;">contrat d&#8217;aide en avance r&#233;cup&#233;rable n&#176;DOS0138446/00</i><font style="font-size:11pt;">) between BPIFrance Financement and Corlieve, dated 6 January 2021. &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Business</u><font style="font-size:11pt;">&#8221; shall mean the business of Corlieve as conducted as of the Agreement Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Business Day</u><font style="font-size:11pt;">&#8221; shall mean any day other than a Saturday, a Sunday or a day on which banks in New York City, New York, Paris, France or Amsterdam, The Netherlands, are authorized or obligated by Law or executive order to close.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Bylaws</u><font style="font-size:11pt;">&#8221; shall mean the by-laws (</font><i style="font-size:11pt;font-style:italic;">statuts</i><font style="font-size:11pt;">) of Corlieve, updated as of 27 March 2021.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Cap</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.5(c)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Capitalization Table</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 4.3(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">CHMP</u><font style="font-size:11pt;">&#8221; shall mean the Committee for Medicinal Products for Human Use of the EMA and any successor committee thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Claim Notice</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.3(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Claim Response</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.3(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.2</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Date</u><font style="font-size:11pt;">&#8221; shall mean the date on which the Closing occurs.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Date Allocation Schedule</u><font style="font-size:11pt;">&#8221; shall mean a schedule, which shall be prepared in good faith by the Holder Representative, that sets forth (i) the amount of Closing Date Cash Consideration payable to each Seller and (ii) the Pro Rata Share of each Seller at Closing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Date Cash Balance</u><font style="font-size:11pt;">&#8221; shall mean the aggregate amount as of the Closing Date of cash and cash equivalents of Corlieve, as determined in accordance with French GAAP.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Date Cash Consideration</u><font style="font-size:11pt;">&#8221; shall mean an amount equal to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Such amount, not less than [*], as is determined by the Purchaser in its sole discretion and notified by the Purchaser to the Holder Representative by the close of business on the second Business Day prior to Closing;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">plus</u><font style="font-size:11pt;"> the Closing Date Cash Balance;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">plus</u><font style="font-size:11pt;"> the Net Working Capital (which may be positive or negative);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">plus</u><font style="font-size:11pt;"> the Specified Costs;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">less</u><font style="font-size:11pt;">&#160;the Transaction Expenses; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">less</u><font style="font-size:11pt;">&#160;the Closing Date Indebtedness.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Date Consideration</u><font style="font-size:11pt;">&#8221; shall mean an amount equal to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">[*];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">plus</u><font style="font-size:11pt;"> the Closing Date Cash Balance;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">plus</u><font style="font-size:11pt;"> the Net Working Capital (which may be positive or negative);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">plus</u><font style="font-size:11pt;"> the Specified Costs;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">less</u><font style="font-size:11pt;">&#160;the Transaction Expenses; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">less</u><font style="font-size:11pt;">&#160;the Closing Date Indebtedness.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Date Indebtedness</u><font style="font-size:11pt;">&#8221; shall mean the aggregate amount of Indebtedness of Corlieve as of the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Statement</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4(b)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Commercially Reasonable Efforts</u><font style="font-size:11pt;">&#8221; means, with respect to a Party, such level of efforts that would be used by a similarly situated group as such Party and its Affiliates in conducting the development and registration of pharmaceutical products to which it has rights, taking into account product labeling, anticipated labeling, safety and efficacy, market potential, medical and clinical consideration, regulatory environment, profitability, manufacturability and competitive market conditions, the nature and extent of market exclusivity (including patent coverage and regulatory exclusivity), development costs and time, financial return on such product and other relevant considerations, all of which may be evaluated for each particular market. It is understood that such efforts may change from time to time based upon changes to the above factors. As a result, the exercise of diligence by Purchaser and its Affiliates is to be determined by judging Purchaser&#8217;s commercially reasonable efforts taken as a whole. &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Commercially Reasonable Efforts&#8221;</u><font style="font-size:11pt;"> shall be determined on a country-by-country (or region-by-region, where applicable) and indication-by-indication basis, without regard to the particular circumstances of a Party, including any other product opportunities of such Party and without regard to any payments owed by such Party to the other Party under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Confidentiality Agreement</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;6.2</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Contract</u><font style="font-size:11pt;">&#8221; shall mean any binding agreement, lease, license, commitment, purchase order, arrangement, mortgage, indenture, note, bond, deed, loan, evidence of Indebtedness, security agreement or other contract.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Control</u><font style="font-size:11pt;">&#8221; means, with respect to any material, information, or Intellectual Property right, that a Party and/or any Affiliate(s) of such Party (a) owns such material, information, or Intellectual Property right, or (b) has a license to or a right to use such material, information, or Intellectual Property right; in each case of (a) or (b), with the ability to grant to the other Party (and, with respect to Purchaser, as an Affiliate of Corlieve) access, a right to use, or a license or sublicense (as applicable) to such material, information, or Intellectual Property right, on the terms and conditions set forth herein, without </font><b style="font-size:11pt;font-weight:bold;">(i)</b><font style="font-size:11pt;"> violating the terms of any agreement or other arrangement with or obligation to any Third Party in</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:4pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">existence as of the time such Party and/or any Affiliate(s) of such Party would first be required hereunder to grant the other Party such access, right to use or (sub)license or </font><b style="font-size:11pt;font-weight:bold;">(ii)</b><font style="font-size:11pt;"> paying any sums of money to any Third Party that assigned or licensed such material, information, or Intellectual Property right to such first Party and/or any Affiliate(s) of such Party that become payable in connection with the other Party&#8217;s exploitation thereof hereunder, unless such sums are payable under any Existing License Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Corlieve</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the Preamble of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Corlieve Intellectual Property</u><font style="font-size:11pt;">&#8221; shall mean any Intellectual Property Controlled by Corlieve as of the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Corlieve Partner</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4.23(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Corlieve Patents</u><font style="font-size:11pt;">&#8221; shall mean any Patents Controlled by Corlieve as of the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Corlieve Product</u><font style="font-size:11pt;">&#8221; shall mean any pharmaceutical product using AAV9 to knock down the expression of the Grik2 Gene Sequence, which product </font><font style="font-size:11pt;">(i)</font><font style="font-size:11pt;"> contains a DNA sequence encoding an RNA sequence that </font><font style="font-size:11pt;">is Covered or specifically disclosed (without reference to percent sequence identity or variants thereof) in any </font><font style="font-size:11pt;">Corlieve Patents, or (ii) contains a DNA sequence encoding an &#160;RNA sequence that has been listed on Schedule 1.1 (or delivered on an updated Schedule 1.1 at Closing), or (iii</font><font style="font-size:11pt;">) is developed after the Closing Date and </font><font style="font-size:11pt;">contain</font><font style="font-size:11pt;">s</font><font style="font-size:11pt;"> a DNA sequence encoding an RNA sequence with two or less nucleotide substitutions, deletions and/or additions to the &#8220;guide&#8221; nucleotide sequence of the DNA sequences </font><font style="font-size:11pt;">referred to</font><font style="font-size:11pt;"> in subclauses (i) and (ii), in each case (alone or with other APIs), in all forms, presentations, formulations, methods of administration and dosage forms, for all indications and diagnostic uses in humans, including all human disease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Court Order</u><font style="font-size:11pt;">&#8221; shall mean any judgment, decision, award, consent decree, injunction, ruling or order of any federal, state, local or other domestic or foreign court, arbitral tribunal or Governmental Authority that is binding on any Person or its property.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Cover</u><font style="font-size:11pt;">&#8221;, &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Covered</u><font style="font-size:11pt;">&#8221; or &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Covering</u><font style="font-size:11pt;">&#8221; means, with respect to any given product and Patents, that the composition of matter, method of manufacture or use of such product is claimed by a Valid Claim of such Patent (i.e., in the absence of a license under, or ownership of, such Patent, the manufacture, use or sale of such would infringe such Patent as issued or, in the case of a patent application, evaluating such patent application as if it were issued as a Patent as of the date of such evaluation).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Covered Parties</u><font style="font-size:11pt;">,&#8221; collectively, and &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Covered Party</u><font style="font-size:11pt;">,&#8221; individually, shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(c)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">CRO</u><font style="font-size:11pt;">&#8221; shall mean a contract research organization.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Current Assets</u><font style="font-size:11pt;">&#8221; shall mean Corlieve&#8217;s: (a) inventories; (b) accounts receivable from third parties (including trade and service accounts receivable owed); (c) other receivables from third parties, including receivables related to Tax Credits (including for the avoidance of doubt, any claim for Tax Credit reimbursement for which the relevant filing application has been made by Corlieve prior to the date hereof); (d) prepaid insurance; (e) prepaid expenses; (f) commissions and advances to third parties; (g) subsidies; and (h) prepaid custom duties; </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided, however,</u><font style="font-size:11pt;"> that in no event shall &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Current Assets</u><font style="font-size:11pt;">&#8221; hereunder include or be deemed to include any item or amount included in or described in the definition of &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Date Cash Balance</u><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Current Liabilities</u><font style="font-size:11pt;">&#8221;</font><sup style="font-size:8.25pt;vertical-align:top;">&#160;</sup><font style="font-size:11pt;">shall mean Corlieve&#8217;s: (a) accounts payable; (b) accrued expenses including Transaction Bonus; and (c) Taxes currently payable, in each case excluding any Liabilities incurred by Corlieve with the consent of Purchaser between the Agreement Date and the Closing Date,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">as the case may be, such consent to be withheld in Purchaser&#8217;s sole discretion (other than any Liabilities expressly included in the definition of &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transaction Expenses</u><font style="font-size:11pt;">&#8221;); </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided, however,</u><font style="font-size:11pt;"> that in no event shall &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Current Liabilities</u><font style="font-size:11pt;">&#8221; hereunder include or be deemed to include any item or amount included in or described in the definition of &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Date Indebtedness</u><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Damages</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">De Minimis Amount</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.5(a))</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Default</u><font style="font-size:11pt;">&#8221; shall mean (a) any actual breach, violation or default or (b) the existence of circumstances or the occurrence of an event that with the passage of time or the giving of notice or both will constitute a breach, violation or default or give rise to a right of termination, renegotiation or acceleration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Deprioritization</u><font style="font-size:11pt;">&#8221; shall mean the manufacturing of a batch of at least 20 liters of an Alternative Product (and &#8220;Deprioritize&#8221; shall have the corresponding meaning).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Development Notice&#8221;</u><font style="font-size:11pt;"> shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.9(h)(ii).</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Disclosure Letter</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the preamble to&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Article</u><font style="font-size:11pt;"> 4.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Disclosure Notification</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;6.7</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Disputed Amounts</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4(d)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Dollars</u><font style="font-size:11pt;">&#8221; and &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">$</u><font style="font-size:11pt;">&#8221; shall each mean lawful money of the United States.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Downstream Milestone 4b Payment</u><font style="font-size:11pt;">&#8221; </font><font style="font-size:11pt;">shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.9(c)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Downstream Milestone 5b Payment</u><font style="font-size:11pt;">&#8221; </font><font style="font-size:11pt;">shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(d)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Downstream Payments</u><font style="font-size:11pt;">&#8221; </font><font style="font-size:11pt;">shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(d)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">EMA</u><font style="font-size:11pt;">&#8221; shall mean the European Medicines Agency and any successor agency thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Employees</u><font style="font-size:11pt;">&#8221; shall mean each of the employees of Corlieve.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Encumbrance</u><font style="font-size:11pt;">&#8221; shall mean with respect to any asset, any adverse claim of title, lien, pledge, option, charge, easement, servitude, title defect, security interest, deed of trust, mortgage, conditional sales agreement, encumbrance, preemptive right, right of first refusal or first offer, restriction or other right of any third party, whether voluntarily incurred or arising by operation of law, and includes any agreement to give any of the foregoing in the future other than mandatory licenses arising by operation of law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Environmental Claim</u><font style="font-size:11pt;">&#8221; shall mean any claim, notice, order, or Proceeding alleging Liability for, or an obligation with respect to, any investigation, monitoring, remediation, removal, cleanup, response, corrective action, damages to natural resources, personal injury, property damage, fines, penalties or other costs resulting from, related to or arising out of (i) the presence, release or threatened release of Hazardous Material at any location or (ii) any violation or alleged violation of any Environmental Law, and shall include any claim, notice, order, or Proceeding seeking Damages, contribution, cost recovery, compensation or injunctive relief resulting from, related to or arising out of the presence, release or threatened release of Hazardous Material or alleged injury or threat of injury to health, safety or the environment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Environmental Law</u><font style="font-size:11pt;">&#8221; shall mean all Applicable Law relating to pollution or protection of human health and safety or the environment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Escrow Account</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.12(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Escrow Agent</u><font style="font-size:11pt;">&#8221; shall mean the escrow agent to be selected by the Holder Representative and Purchaser.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Escrow Agreement</u><font style="font-size:11pt;">&#8221; shall mean that certain Escrow Agreement, dated as of the Closing Date, by and among Purchaser, the Escrow Agent and the Holder Representative. The Escrow Agreement will be in customary form, contain terms and conditions consistent with this Agreement, and be mutually reasonably acceptable to Purchaser, the Escrow Agent and the Holder Representative.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Escrow Release Date</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.12(b)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Escrowed Amount</u><font style="font-size:11pt;">&#8221; shall mean an amount in cash from time to time being held in escrow by the Escrow Agent pursuant to the terms of the Escrow Agreement, which shall be equal to [*] the following amount: [*] minus the Non GMP Batch Payment minus the Free Share Holdback, provided that if all or part of the Non GMP Batch Payment or the Free Share Holdback are paid by the Purchaser pursuant to this Agreement prior to the Escrow Release Date, a portion thereof equal to [*] of each such payment will be made to the Escrow Account.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Closing Date Cash Balance</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Closing Date Cash Consideration</u><font style="font-size:11pt;">&#8221; shall be determined by the Purchaser based on the Estimated Closing Date Consideration and the definition of Closing Date Cash Consideration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;white-space:pre-wrap;"> </font><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Closing Date Consideration</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;2.4(a))</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Closing Date Indebtedness</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Closing Statement</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Net Working Capital</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Transaction Expenses</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Euros</u><font style="font-size:11pt;">&#8221; and &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8364;</u><font style="font-size:11pt;">&#8221; shall each mean the currency introduced at the start of the third stage of the European economic and monetary union pursuant to the treaty establishing the European Community, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Existing License Agreement</u><font style="font-size:11pt;">&#8221; shall mean the contracts listed at </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 4.18(b)</u><font style="font-size:11pt;"> of the Disclosure Letter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">FDA</u><font style="font-size:11pt;">&#8221; shall mean the U.S. Food and Drug Administration and any successor agency thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Financial Statements</u><font style="font-size:11pt;">&#8221; shall mean reports of the statutory auditors, as applicable, and notes contained therein in respect of Corlieve as at December 31, 2020.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Foreign Investment Approval</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8.1(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Founders</u><font style="font-size:11pt;">&#8221; shall mean [*] and the Scientific Founders.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">French GAAP</u><font style="font-size:11pt;">&#8221; shall mean generally accepted accounting principles in France, as consistently applied over all relevant periods.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Free Shares</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the Recitals.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Free Shares Holdback</u><font style="font-size:11pt;">&#8221; shall mean the Pro Rata Share of the Closing Date Consideration and any Milestone Payments, as applicable, corresponding to the Free Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Free Shares Holder</u><font style="font-size:11pt;">&#8221; and &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Free Shares Holders</u><font style="font-size:11pt;">&#8221; shall have the respective meanings set forth in the Recitals.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Free Share Transfer Date</u><font style="font-size:11pt;">&#8221; shall mean, with respect to any given Free Share, the date on which such Free Share can be transferred in accordance with Applicable Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Fundamental Representations</u><font style="font-size:11pt;">&#8221; shall mean the representations and warranties set forth in</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section 3.1</u><font style="font-size:11pt;">&#160;(</font><i style="font-size:11pt;font-style:italic;">Power and Authorization</i><font style="font-size:11pt;">), </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;3.4</u><font style="font-size:11pt;"> (</font><i style="font-size:11pt;font-style:italic;">Ownership of the Shares</i><font style="font-size:11pt;">), </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;3.6</u><font style="font-size:11pt;"> (</font><i style="font-size:11pt;font-style:italic;">No Brokers</i><font style="font-size:11pt;">), </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4.1</u><font style="font-size:11pt;"> (</font><i style="font-size:11pt;font-style:italic;">Organization of Corlieve</i><font style="font-size:11pt;">), </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4.3</u><font style="font-size:11pt;"> (</font><i style="font-size:11pt;font-style:italic;">Capitalization</i><font style="font-size:11pt;">) and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4.22</u><font style="font-size:11pt;"> (</font><i style="font-size:11pt;font-style:italic;">No Brokers</i><font style="font-size:11pt;">).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Governmental Authority</u><font style="font-size:11pt;">&#8221; shall mean any: (a) nation, state, province, territory, county, municipality, district or other jurisdiction of any nature; (b) international, multinational, federal, state, local, municipal, foreign or other government, agency or authority; or (c) governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, Regulatory Authority, commission, instrumentality, official, organization, unit, body or Person and any court or other judicial or arbitral tribunal).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Governmental Order</u><font style="font-size:11pt;">&#8221; shall mean any order, writ, judgment, injunction, decree, stipulation, determination or award of any Governmental Authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Grik2 Gene Sequence</u><font style="font-size:11pt;">&#8221; means the gene sequence encoding human glutamate ionotropic receptor kainite type subunit 2 (GluK2: previously known as ionotropic glutamate receptor 6).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Hazardous Materials</u><font style="font-size:11pt;">&#8221; shall mean any hazardous or toxic substance, material, chemical, pollutant, contaminant or waste which is regulated under any Environmental Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Holdback Amount</u><font style="font-size:11pt;">&#8221; shall mean a cash amount equal to [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Holder Representative</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.4(a).</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Holder Representative&#8217;s Costs</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.4(e)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Holder Representative&#8217;s Fund</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.4(f)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Indebtedness</u><font style="font-size:11pt;">&#8221; shall mean (without duplication), as to any Person, (a) all obligations for the payment of principal, accrued and unpaid interest, prepayment or redemption penalties, unpaid fees or expenses and other monetary obligations in respect of (i) indebtedness of such Person for borrowed money or (ii) indebtedness evidenced by notes debentures, bonds or other similar instruments for the payment of which such Person is liable, in each case including any breakage costs and costs and expenses related to the termination, discharge and release of all related Encumbrances, (b) any obligations to reimburse the issuer of any letter of credit, surety bond, performance bond, bank guarantee or similar obligation, in each case to the extent drawn or otherwise not contingent, (c) all capitalized lease obligations of such Person that are, or should be, classified as balance sheet liability in accordance with French GAAP, (d) all indebtedness of third parties secured by an Encumbrance (other than a Permitted Encumbrance) on property owned or acquired by such Person, (e) any obligation that would be required to be reflected as debt on the balance sheet of such Person under French GAAP, (f) any unfunded benefit liabilities, (g) all indebtedness arising out of overdrafts, acceptance credit or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">similar facilities, (h) all Indebtedness of others referred to in clauses (a) through (g) above guaranteed directly or indirectly in any manner by such Person, or in effect guaranteed directly or indirectly by such Person through an agreement to pay or purchase such Indebtedness, to advance or supply funds for the payment or purchase of such Indebtedness or otherwise to assure a creditor against loss, in each case including all accrued interest and prepayment penalties, if any, and (i) the amount of repayable advances under the BPI Loan Agreement not paid prior to Closing that are in excess of &#160;[*] of all such repayable advances; </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">however</u><font style="font-size:11pt;">, that (1) no amount under subclauses (h) or (i) shall be counted more than one time and (2) in no event shall &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Indebtedness</u><font style="font-size:11pt;">&#8221; hereunder include or be deemed to include any item, amount, Liability or obligation (i) included in or described in the definitions of &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Current Liabilities</u><font style="font-size:11pt;">&#8221; or &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transaction Expenses</u><font style="font-size:11pt;">&#8221; or (ii) incurred by Corlieve with the consent of Purchaser between the Agreement Date and the Closing Date, as the case may be, such consent to be withheld in Purchaser&#8217;s sole discretion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Indemnifying Party</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.3(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Independent Accountants</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4(d)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Instrument</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.4(c)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Intellectual Property</u><font style="font-size:11pt;">&#8221; means any and all intellectual property rights or similar proprietary rights throughout the world, including all (i) national and multinational statutory invention registrations, patents and patent applications of any type issued or applied for in any jurisdiction, including all provisionals, non-provisionals, divisions, continuations, continuations-in-part, reissues, extensions, supplementary protection certificates, reexaminations and the equivalents of any of the foregoing in any jurisdiction, and all inventions claimed in each such registration, patent or patent application (collectively, &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Patents</u><font style="font-size:11pt;">&#8221;), (ii) trademarks, service marks, trade dress, logos, brand names, certification marks, domain names, trade names, corporate names and other indications of origin, whether or not registered, in any jurisdiction, and all registrations and applications for registration of the foregoing in any jurisdiction, and all goodwill associated with the foregoing (collectively, &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Trademarks</u><font style="font-size:11pt;">&#8221;), (iii) copyrights (whether or not registered) and registrations and applications for registration thereof in any jurisdiction, including all derivative works, moral rights, renewals, extensions, reversions or restorations associated with such copyrights, regardless of the medium of fixation or means of expression (collectively, &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Copyrights</u><font style="font-size:11pt;">&#8221;), (iv) trade secrets, information, data, specifications, processes, methods, knowledge, experience, formulae, skills, techniques, schematics, drawings, blue prints, utility models, designs, technology, software, inventions, discoveries, ideas and improvements, including manufacturing information and processes, assays, engineering and other manuals and drawings, standard operating procedures, flow diagrams, regulatory, chemical, pharmacological, toxicological, pharmaceutical, structural activity relationship information, physical and analytical, safety, quality assurance, quality control and clinical data, technical information, research records and similar data and information (collectively, &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Know-How</u><font style="font-size:11pt;">&#8221;), (v) database rights, industrial designs, industrial property rights, publicity rights and privacy rights (vi) computer software and firmware, including data files, source code, object code and software-related specifications and documentation (collectively &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Software</u><font style="font-size:11pt;">&#8221;) and (vii) the right to assert, claim or sue and collect damages for the past, present or future infringement, misappropriation or other violation of any of the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Knowledge</u><font style="font-size:11pt;">&#8221; shall mean (i) in the case of the Company, the actual knowledge of the Company, after due inquiry of the Company&#8217;s President </font><font style="font-size:11pt;">and, with respect to Section 4.18, of the Company&#8217;s President and the Scientific Founders (each designated Person, at their actual knowledge, and with respect to &#160;</font><font style="font-size:11pt;">[*]</font><font style="font-size:11pt;">, after reasonable inquiry of Corlieve employees with respect to subject matters falling within the responsibilities of such employees) or</font><font style="font-size:11pt;"> (ii) in the case of the Purchaser, the actual knowledge of the Purchaser, after due inquiry of &#160;[*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Laws</u><font style="font-size:11pt;">&#8221; shall mean any federal, state, local or foreign law (including common law), statute, code, ordinance, rule, regulation, directive, judgment, order, award, writ, injunction, decree or other Court Order of any Governmental Authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Liabilities</u><font style="font-size:11pt;">&#8221; shall mean any and all debts, liabilities, claims, losses and obligations, whether accrued or fixed, known or unknown, absolute or contingent, matured or unmatured, asserted or unasserted, due or to become due, determined, determinable or otherwise, and whether or not required under French GAAP, as applicable, to be accrued on the financial statements of a Person, including all costs and expenses relating thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Licensed Know-How Schedule</u><font style="font-size:11pt;">&#8221; shall mean a schedule, dated as of the Closing Date, which shall reasonably reflect all material written documents delivered, disclosed or otherwise transferred by RGX to Corlieve pursuant to the RGX License Agreement as of the Closing Date which contain material Know-How, including an index of (A) the collaboration folder named [*], which contains (i) a folder named [*] containing documents which have been shared between the parties to the MTA (as such term is defined in the RGX License Agreement), and (ii) folders containing documents exchanged between Corlieve and RGX in the conduct of the Research Plan (as such term is defined in the RGX Agreement), and (B) the Know-How provided by RGX to Corlieve pursuant to Section 2.8 (b) of the RGX Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Litigation Conditions</u><font style="font-size:11pt;">&#8221; shall mean, with respect to a Third Party Claim, (a) such Third Party Claim does not seek injunctive or equitable relief or non-monetary damages from the Covered Party; (b) such Third Party Claim does not relate to or arise in connection with any criminal proceeding, action, indictment, allegation or investigation; (c) the Indemnifying Party agrees that it will be liable to a Covered Party for any indemnifiable Damages relating to the Third Party Claim; (d) the Indemnifying Party is able to reasonably demonstrate that it has sufficient financial resources to defend such Third Party Claim; (e) the amount remaining under the Cap at the time of the Third Party Claim is reasonably sufficient to satisfy any likely judgment or settlement resulting from such Third Party Claim; and (f) such Third Party Claim has not been asserted directly or indirectly by or on behalf of a Person that is a licensee or supplier of Purchaser or Corlieve.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Loan Conversion</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the Recitals.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Major EU Country</u><font style="font-size:11pt;">&#8221; shall mean each of France, Germany, Italy and Spain.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Majority of Sellers</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.4</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Material Adverse Effect</u><font style="font-size:11pt;">&#8221; shall mean any change, event, condition, circumstance, development, occurrence or effect that is, or would reasonably be expected to constitute, individually or in the aggregate, a material adverse effect on the business, assets, liabilities, financial condition or results of operations of Corlieve as a whole or on the ability of Corlieve or the Sellers to consummate the transactions contemplated by this Agreement, other than any change, event, condition, circumstance, development, occurrence or effect arising from or related to (i) general changes in business, economic, political, social, legal or regulatory conditions, (ii) changes in conditions generally applicable to the industry in which Corlieve operates, (iii) general changes in financial, banking or securities markets (including any disruption thereof), (iv) changes in Applicable Laws or French GAAP, (v) pandemics, outbreak of hostilities, terrorist attack (whether against a nation or otherwise) or war, or (vi) the announcement of this Agreement or the transactions contemplated hereby, in each case, that do not disproportionately adversely affect Corlieve in relation to others who participate in the same business as Corlieve.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Material Contracts</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4.6(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Milestone #1&#8221;</u><font style="font-size:11pt;"> shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Milestone #2&#8221;</u><font style="font-size:11pt;"> shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Milestone #3&#8221;</u><font style="font-size:11pt;"> shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Milestone #4a&#8221;</u><font style="font-size:11pt;"> shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Milestone #4b&#8221;</u><font style="font-size:11pt;"> shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Milestone #5a&#8221;</u><font style="font-size:11pt;"> shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Milestone #5b&#8221;</u><font style="font-size:11pt;"> shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Milestone Payment</u><font style="font-size:11pt;">&#8221; shall mean the payments set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;"> with respect to Milestone #1, Milestone #2, Milestone #3, Milestone #4a or Milestone #4b and Milestone #5a or Milestone #5b, subject to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.7</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Set-Off</u><font style="font-size:11pt;">&#8221; </font><font style="font-size:11pt;">shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.10</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Milestones</u><font style="font-size:11pt;">&#8221; shall mean Milestone #1, Milestone #2, Milestone #3, Milestone #4a, Milestone #4b, Milestone #5a and Milestone #5b.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Milestone Shares</u><font style="font-size:11pt;">&#8221; shall mean the uniQure Ordinary Shares, if any, that are issued by the Purchaser to satisfy its obligation to make the Milestone Payments, as the case may be.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Milestone Shares Cap&#8221;</u><font style="font-size:11pt;"> shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(f)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Most Recent Balance Sheet</u><font style="font-size:11pt;">&#8221; shall mean the audited statutory accounts of Corlieve as at December 31, 2020.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Nasdaq</u><font style="font-size:11pt;">&#8221; shall mean The Nasdaq Global Select Market (or any successor thereto).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">NDA</u><font style="font-size:11pt;">&#8221; means a new drug application as described in 21 C.F.R. &#167; 314.50, including all amendments and supplements to the application, submitted to the FDA under Section 505(b) of the FDC Act for approval to commercialize a new drug in the United States.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Net Working Capital</u><font style="font-size:11pt;">&#8221; shall mean (a) the Current Assets as of the Closing Date minus (b) the Current Liabilities as of the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Non-GMP Batch Delivery</u><font style="font-size:11pt;">&#8221; shall mean the delivery by RGX to Corlieve of Corlieve Product manufactured in accordance with Non-GMP specifications to support a pivotal GLP toxicology IND-enabling study by a process representative of the GMP process to be used in GMP manufacture of such Corlieve Product, as well as supporting analytics and all CMC Data required to enable lot release and IND filing, as contemplated in Section 5.1.1 of the RGX License Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Non GMP Batch Payment</u><font style="font-size:11pt;">&#8221; shall mean (i) with respect to the Closing Date Consideration, an amount to be notified by the Holder Representative to the Purchaser not less &#160;[*] prior to Closing, estimated to be &#160;[*] (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Initial Non GMP Batch Payment</u><font style="font-size:11pt;">&#8221;) and (ii) with respect to any Milestone Payment if and when due, the relative increase in the Pro Rata Share of RGX following payment of the Initial Non GMP Batch Payment, if any, as set out on Schedule 2.7.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Ordinary Course of Business</u><font style="font-size:11pt;">&#8221; or &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Ordinary Course</u><font style="font-size:11pt;">&#8221; shall mean the ordinary and usual course of the normal day-to-day operations of Corlieve, consistent with the past practice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:3pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Ordinary Shares</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the Recitals.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Outside Date</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;10.1(b)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Parties</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the Preamble.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Patents</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the definition of &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Intellectual Property</u><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Paying Agent</u><font style="font-size:11pt;">&#8221; has the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.3(a)(ii)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Paying Agent Agreement</u><font style="font-size:11pt;">&#8221; shall mean that certain Paying Agent Agreement, dated as of the Closing Date, by and among Purchaser, the Paying Agent and the Holder Representative. The Paying Agent Agreement will be in customary form, contain terms and conditions consistent with this Agreement (including that any Seller who transfers its right to receive the Milestone Payments must provide notice to Purchaser and the Paying Agent, and that Purchaser may require an opinion of counsel in connection with such transfer), and be mutually reasonably acceptable to Purchaser, the Paying Agent and the Holder Representative.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Permit</u><font style="font-size:11pt;">&#8221; shall mean each permit, certificate, license, consent, registration, approval or authorization of any Governmental Authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Permitted Encumbrance</u><font style="font-size:11pt;">&#8221; shall mean (a) liens for Taxes, assessments and other governmental charges, in each case, not yet due and payable or which are being contested in good faith by appropriate proceedings and for which adequate reserves have been established in accordance with French GAAP or U.S. GAAP, as applicable, (b) statutory liens arising in the Ordinary Course of Business for sums not yet due, (c) statutory and contractual landlord liens under leases pursuant to which Corlieve is a lessee and not in Default, (d) licenses to service providers (such as contract manufacturing organizations and contract research organizations) in the Ordinary Course of Business or licenses back to licensors expressly granted pursuant to the Material Contracts, (e) pledges or deposits made in the Ordinary Course of Business which do not in the aggregate materially detract from the value of the related assets or properties or materially impair the use thereof in the operation of the Business as currently conducted, and (f) deposits and pledges made in connection with, or to secure payment of, workers&#8217; compensation, unemployment insurance or similar programs.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Permitted Transfer</u><font style="font-size:11pt;">&#8221; shall mean a transfer of the right to receive the Milestone Payments by any Seller (a) upon death of such Seller by will or intestacy; (b) pursuant to a Court Order; (c) by operation of law (including by consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; or (d) to any Person if such transfer is of such Seller&#8217;s entire right to receive the remaining portion of the Milestone Payments which such Seller is entitled to receive;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, that, in connection with any such transfer, (i) such transferee agrees in writing with Purchaser to be bound by the restriction on transfer contained in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.9(j)</u><font style="font-size:11pt;">&#160;as a Seller, (ii) such transfer complies with all applicable securities Laws, and (iii) such transfer is registered with the Paying Agent as provided in the Paying Agent Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Person</u><font style="font-size:11pt;">&#8221; shall mean an individual, a limited liability company, a joint venture, a corporation, a company, a partnership, an association, a business trust, a trust, an estate, a Governmental Authority, a division or operating group of any of the foregoing or any other entity or organization.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Phase I/II Clinical Trial</u><font style="font-size:11pt;">&#8221; shall mean a first in human clinical trial that is primarily intended to test the safety of the product for a specific indication in patients with the disease or condition under study, or an analogous study or trial of a medical device intended to evaluate scientifically valid evidence to be submitted in an application to a Regulatory Authority for the applicableproduct.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Phase III Clinical Trial</u><font style="font-size:11pt;">&#8221; means a clinical trial intended to meet the requirements for approval of an NDA or BLA for the product, or an analogous study intended to establish scientifically valid evidence to be submitted in an application to a Regulatory Authority for the product, including any Phase II Clinical Trial that meets the requirements of the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Post-Closing Adjustment</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4(f)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">President</u><font style="font-size:11pt;">&#8221; shall mean the Company&#8217;s president (</font><i style="font-size:11pt;font-style:italic;">Pr&#233;sident</i><font style="font-size:11pt;">).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Proceeding</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4.16</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Pro Rata Share</u><font style="font-size:11pt;">&#8221; shall mean, with respect to each Seller, as to </font><b style="font-size:11pt;font-weight:bold;">(i)</b><font style="font-size:11pt;"> any indemnifiable Damages, </font><b style="font-size:11pt;font-weight:bold;">(ii)</b><font style="font-size:11pt;"> the Escrowed Amount, </font><b style="font-size:11pt;font-weight:bold;">(iii)</b><font style="font-size:11pt;"> the Milestone Shares or </font><b style="font-size:11pt;font-weight:bold;">(iv)</b><font style="font-size:11pt;"> otherwise for purposes of this Agreement, the percentage of the Closing Date Cash Consideration (including the Free Share Holdback but excluding the Non GMP Batch Payment) to which such Seller (including any Free Share Holder) is entitled; provided that if the Non GMP Batch Payment is earned by RGX, the Pro Rata Share of each Seller shall be recalculated to reflect the relative increase in the Pro Rata Share of RGX, as illustrated on Schedule 2.7, which will be updated prior to the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Purchaser</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the Preamble of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Purchaser Indemnified Party</u><font style="font-size:11pt;">&#8221; and &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Purchaser Indemnified Parties</u><font style="font-size:11pt;">&#8221; shall have the respective meanings set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Reference Market Value</u><font style="font-size:11pt;">&#8221; means, with respect to any date, the volume-weighted average price of uniQure Ordinary Shares as reported on Nasdaq for the twenty (20) consecutive Trading Day period ending two (2) Business Days prior to such date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Regulation S</u><font style="font-size:11pt;">&#8221; shall mean Regulation S promulgated under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Regulatory Approval</u><font style="font-size:11pt;">&#8221; shall mean, with respect to a country or extra-national territory, all approvals, licenses, registrations or authorizations of any Regulatory Authority necessary in order to commercially market, distribute and sell a pharmaceutical product in such country or some or all of such extra-national territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Regulatory Authority</u><font style="font-size:11pt;">&#8221; shall mean, with respect to a country or region, any national (</font><i style="font-size:11pt;font-style:italic;">e.g.</i><font style="font-size:11pt;">, the FDA for the United States), supra-national (</font><i style="font-size:11pt;font-style:italic;">e.g.</i><font style="font-size:11pt;">, the EMA for the European Union), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Authority that has jurisdiction with respect to the safety, efficacy, reliability, manufacture, investigation, sale or marketing of pharmaceuticals products or otherwise has jurisdiction with respect to the safety, efficacy, reliability, manufacture, investigation, sale or marketing of any pharmaceutical product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Regulatory Authorizations</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4.23(g)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Released Closing Date Cash Consideration</u><font style="font-size:11pt;">&#8221; shall mean an amount of cash equal to the Estimated Closing Date Cash Consideration </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">less</u><font style="font-size:11pt;"> (i) the Holdback Amount, (ii) the Initial Non GMP Batch Payment and (iii) the Free Share Holdback.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Released Damages</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7.2</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Representative</u><font style="font-size:11pt;">&#8221; shall mean, with respect to any Person, any officer, director, principal, member, manager, attorney, agent, advisor, employee or other representative of such Person.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Resolution Period</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4(c)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:4pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Response Period</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.3(b)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Restricted Period</u><font style="font-size:11pt;">&#8221; shall mean the period commencing on the Closing Date and ending on the second (2</font><sup style="font-size:8.25pt;vertical-align:top;">nd</sup><font style="font-size:11pt;">) anniversary of the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Review Period</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4(c)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">RGX License Agreement</u><font style="font-size:11pt;">&#8221; shall mean the license and collaboration agreement between Corlieve and RGX dated 24 June 2020.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Safety/Regulatory Reason</u><font style="font-size:11pt;">&#8221; means that the Purchaser reasonably determines that the medical risk/benefit of such Corlieve Product is sufficiently unfavorable as to be incompatible with the welfare of patients, poses an unacceptable safety risk or is unlikely to obtain Regulatory Approval, which determination shall be supported by relevant scientific data as well as requests of CHMP or FDA, and a confirmation by Purchaser that it has determined in good faith that such issues are unlikely to be resolved within a reasonable period of time, as shall be disclosed (together with a summary of the data and requests supporting such reason) to the Holder Representative.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Scientific Founders</u><font style="font-size:11pt;">&#8221; shall mean &#160;[*]</font><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Securities Act</u><font style="font-size:11pt;">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Seller</u><font style="font-size:11pt;">&#8221; and &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Sellers</u><font style="font-size:11pt;">&#8221; shall have the respective meanings set forth in the Preamble to this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Seller Indemnified Party</u><font style="font-size:11pt;">&#8221; and &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Seller Indemnified Parties</u><font style="font-size:11pt;">&#8221; shall have the respective meanings set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(c)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Seller Releasing Party</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7.2</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Series A Shares</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the Recitals.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Shareholders Agreement</u><font style="font-size:11pt;">&#8221; shall mean that certain Shareholders Agreement, dated as of 24 June 2020, by and among Corlieve and the shareholders of Corlieve, and all related contractual undertakings entered into with Free Share Holders.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Shareholder Loan&#8221;</u><font style="font-size:11pt;"> shall have the meaning set forth in the Recitals.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Shares</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the Recitals.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Software</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the definition of &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Intellectual Property</u><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Specified Costs</u><font style="font-size:11pt;">&#8221; shall mean costs that Corlieve has incurred or will incur or commit prior to the Closing Date as set forth in Section 1.1 of the Disclosure Letter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Specified Representations</u><font style="font-size:11pt;">&#8221; shall mean the representations and warranties set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 4.18</u><font style="font-size:11pt;"> (</font><i style="font-size:11pt;font-style:italic;">Intellectual Property</i><font style="font-size:11pt;">).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Statement of Objections</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4(c)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Subsidiary</u><font style="font-size:11pt;">&#8221; shall mean, with respect to any Person, (a) any corporation more than fifty percent (50%) of whose shares of any class or classes is owned by such Person directly or indirectly through one or more Subsidiaries of such Person and (b) any partnership, association, joint venture or other</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:3pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">entity in which such Person directly or indirectly through one or more Subsidiaries of such Person has more than a fifty percent (50%) equity interest.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Subsidies</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4.24</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Survival End Date</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.1</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Swiss Subsidiary</u><font style="font-size:11pt;">&#8221; shall mean Corlieve Therapeutics AG, a Swiss corporation having its registered office at c/o Switzerland Innovation Park Basel Area AG, Gewerbestrasse 24, 4123 Allschwil, Switzerland, and registered under number CHE-486.007.268.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Tax</u><font style="font-size:11pt;">&#8221; (including with correlative meaning, the terms &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Taxes</u><font style="font-size:11pt;">&#8221; and &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Taxable</u><font style="font-size:11pt;">&#8221;) shall mean (a) any and all, direct or indirect, taxes and duties and similar governmental charges, levies, imposts or withholdings (including net income, gross income, gross receipts, gains, net wealth, net worth, equity, asset value, value added tax, turnover, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, social security contributions, employment, excise, severance, stamp, occupation, premium, property, windfall profits, escheat, customs, duties or other taxes) in the nature of a tax whenever and by whatever Governmental Authority imposed, and whether of the French or a foreign, state or local jurisdiction, together with in any such case any interest, fines, penalties, surcharges and charges incidental or relating to the imposing of any of such Taxes and any additions to tax or additional amounts with respect thereto, (b) any Liability for the payment of any items described in clause (a) above as a result of being (or ceasing to be) a member of an affiliated, consolidated, combined, unitary or aggregate group (or being included (or being required to be included)) in any Tax Return related to such group, and (c) any Liability for the payment of any amounts as a result of any express or implied obligation to indemnify any other Person, or any successor or transferee liability, by Contract or otherwise in respect of any items described in clause (a) or (b) above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Tax Credit</u><font style="font-size:11pt;">&#8221; shall mean any amount which can be subtracted from the payment of Taxes to any Taxing Authority or that can be reimbursed by any Taxing Authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Tax Law</u><font style="font-size:11pt;">&#8221; shall mean all currently Applicable Law and guidelines released by any Taxing Authority relating to or regulating the assessment, determination, collection or imposition of Taxes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Tax Period</u><font style="font-size:11pt;">&#8221; shall mean any period prescribed by any Taxing Authority for which a Tax Return is required to be filed or a Tax is required to be paid.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Tax Return</u><font style="font-size:11pt;">&#8221; individually, or &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Tax Returns</u><font style="font-size:11pt;">,&#8221; collectively, shall mean any return, declaration, report, statement, information statement and other document (including any amendment thereof or attachment thereto) required to be filed with a Governmental Authority with respect to Taxes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Taxing Authority</u><font style="font-size:11pt;">&#8221; shall mean any Governmental Authority having jurisdiction over the assessment, determination, collection, or imposition of any Taxes (domestic or foreign).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Third Party</u><font style="font-size:11pt;">&#8221; shall mean any Person other than the Purchaser Indemnified Parties and the Seller Indemnified Parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Third Party Claim</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.4(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Threshold</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.5(b)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Total Consideration</u><font style="font-size:11pt;">&#8221; shall mean the Closing Date Consideration and the Milestone Payments.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;white-space:pre-wrap;"> </font><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Trademarks</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the definition of &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Intellectual Property</u><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Trading Day</u><font style="font-size:11pt;">&#8221; shall mean a day on which Nasdaq is open for trading.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:3pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transaction Agreements</u><font style="font-size:11pt;">&#8221; shall mean this Agreement, the Escrow Agreement and all other agreements, instruments and certificates to be executed by any party hereto at or prior to the Closing pursuant to this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transaction Bonus</u><font style="font-size:11pt;">&#8221; shall mean the bonuses that will be paid by Corlieve to its employees or consultants in connection with the transactions contemplated in this Agreement, up to a maximum aggregate amount of &#160;[*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transaction Expenses</u><font style="font-size:11pt;">&#8221; shall mean all fees, costs (including Taxes but excluding Tax Credits), payments and expenses of Corlieve (and of the Sellers to the extent such fees, costs, payments and expenses are to be borne by Corlieve and are not paid before the Closing Date) payable to third parties, including legal counsel, that were incurred in connection with (i) the negotiation, preparation (including due diligence), drafting, review, execution, delivery or performance of this Agreement or any other document delivered or to be delivered in connection with the transactions contemplated hereby, (ii) except as otherwise set forth in this Agreement, the preparation and submission of any filing or notice required to be made or given prior to the Closing in connection with any of the transactions contemplated hereby, or (iii) the obtaining of any consent, waiver or approval required to be obtained in connection with any of the transactions contemplated hereby, including legal and accounting fees, investment banking fees, and related disbursements in connection with any of the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transaction Expenses of the Sellers</u><font style="font-size:11pt;">&#8221; shall mean all fees, costs, payments and expenses of the Holder Representative and the Paying Agent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transfer Taxes</u><font style="font-size:11pt;">&#8221; shall mean all direct and indirect stock transfer Taxes, stock registration, documentary or recording Taxes, stamp Taxes and similar Taxes (including any penalties and interest) incurred, imposed, assessed or payable pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7.1</u><font style="font-size:11pt;">&#160;in connection with the transfer of Shares pursuant to this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">uniQure Ordinary Shares</u><font style="font-size:11pt;">&#8221; shall mean the Ordinary Shares in the capital of uniQure N.V., nominal value &#8364;0.05 per share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">U.S. GAAP</u><font style="font-size:11pt;">&#8221; shall mean generally accepted accounting principles in the United States and consistently applied over all relevant periods.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">U.S. Person</u><font style="font-size:11pt;">&#8221; shall have the meaning given to such term by Regulation S.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Valid Claim</u><font style="font-size:11pt;">&#8221; shall mean with respect to a particular country, a claim of any existing or future issued and unexpired Patent that has not (A) lapsed, been cancelled or abandoned or dedicated to the public (subject, in case of abandonment or dedication to the public of a Patent, to Purchaser providing notice to the Holder Representative reasonably promptly before such abandonment or dedication to the public) or (B) revoked, held unenforceable, invalid or unpatentable by a decision of a court or other government body (which decision is unappealed or unappealable within the time allowed for appeal), including through opposition, reexamination or reissue, and which has not been rendered unenforceable through disclaimer or otherwise;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, that, on a country-by-country basis, a Patent application pending for more than five (5) years from the earliest priority date of such application shall not be considered to have any Valid Claim for purposes of this Agreement from and after such five (5) year date unless and until a Patent with respect to such application issues.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Valid RGX AAV9 Patent</u><font style="font-size:11pt;">&#8221; shall mean a validly issued, unexpired Patent owned or Controlled by RGX &#160;that is included in Exhibit A of the RGX License Agreement and that Covers the composition of matter of the AAV9.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Worker</u><font style="font-size:11pt;">&#8221; or &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Workers</u><font style="font-size:11pt;">&#8221; shall mean any individual performing services in the capacity of an employee, legal representative, officer, director, and/or is an independent contractor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Worker Agreements</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4.12(d)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">1.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Other Definitional and Interpretive Matters</u><font style="font-size:11pt;">. In this Agreement, unless the context otherwise requires:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">when calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded. If the last day of such period is a non-Business Day, the period in question shall end on the next succeeding Business Day;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">the &#8220;Euro equivalent of&#8221; means on any day, for purposes of determining the Euro equivalent of on an amount on any non-Euro currency, the Euro amount obtained by the application to such non-Euro amount of the rate at which such currency may be exchanged into Euros at the time of determination on such day as quoted by Bloomberg on www.bloomberg.com/markets/currencies/fxc .html, or as displayed on such other information service which publishes that rate of exchange from time to time in place of Bloomberg. In the event that such rate is not displayed by Bloomberg on the webpage specified in the immediately preceding sentence, the exchange rate shall be determined by reference to such other publicly available service for displaying exchange rates as may be agreed upon by the Parties;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">&#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;and/or&#8221;;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">words expressed in the singular number shall include the plural and vice versa, and words expressed in the masculine shall include the feminine and neuter genders and vice versa;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">references to Articles, Sections, Exhibits, Schedules and Recitals are references to articles, sections, exhibits, schedules and recitals of this Agreement, unless another agreement is specified;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">references to &#8220;day&#8221; or &#8220;days&#8221; are to calendar days;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:11pt;">references to this &#8220;Agreement&#8221; or any other agreement or document shall be construed as references to this Agreement or, as the case may be, such other agreement or document as the same may have been, or may from time to time be, amended, supplemented or otherwise modified;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><font style="font-size:11pt;">each reference to a Law, statute, regulation or other government rule is to it as amended from time to time and, as applicable, is to corresponding provisions of successor Laws,&#160;statutes, regulations or other government rules;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">&#8220;include,&#8221; &#8220;includes,&#8221; and &#8220;including&#8221; are deemed to be followed by &#8220;without limitation&#8221; whether or not they are in fact followed by such words or words of similar import;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(j)</font></font><font style="font-size:11pt;">the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereto,&#8221; &#8220;hereby,&#8221; &#8220;hereunder&#8221; and derivative or similar words refer to this Agreement as an entirety and not solely to any particular provision of this Agreement; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(k)</font></font><font style="font-size:11pt;">terms expressed in the French language or to which a French translation has been added shall be interpreted for the purposes of this Agreement under the meaning assigned to them by the French term and/or translation under French law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SALE OF THE SHARES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Sale of the Shares</u><font style="font-size:11pt;">. Upon the terms and subject to the conditions of this Agreement and on the basis of the representations, warranties, covenants and agreements herein contained, at the Closing, (a) Purchaser shall purchase, acquire and accept from each Seller, and (b) each Seller shall sell, transfer, assign, convey and deliver to Purchaser, all of the right, title and interest in and to their respective Shares, free and clear of all Encumbrances.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing</u><font style="font-size:11pt;">. Subject to the terms and conditions of this Agreement, including, without limitation, the satisfaction or waiver (where applicable) of the conditions set forth in&#160;Article 8, and unless otherwise terminated pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;10.1</u><font style="font-size:11pt;">, the sale and purchase of the Shares contemplated by this Agreement shall take place at a closing (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing</u><font style="font-size:11pt;">&#8221;) to take place at the offices of Morgan, Lewis &amp; Bockius UK LLP, 68 Rue du Faubourg Saint-Honor&#233;, 75008 Paris, France, no later than five (5) Business Days following the date on which all of the conditions set forth in&#160;Article 8 have been satisfied or waived (other than those that by their terms are to be satisfied or waived at the Closing), or at such other place or on such other date as Purchaser and the Holder Representative may mutually agree to in writing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Payment of Closing Date Consideration</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Date Consideration</u><font style="font-size:11pt;">. The Closing Date Consideration payable on the Closing Date by Purchaser in consideration for all of the outstanding Shares shall be paid as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">the Released Closing Date Cash Consideration, payable to a paying agent appointed by the Holder Representative (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Paying Agent</u><font style="font-size:11pt;">&#8221;); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">the issuance and deposit of the Escrowed Amount into the Escrow Account at the Closing in accordance with the terms of the Escrow Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Payment of Closing Date Cash Consideration</u><font style="font-size:11pt;">. On the Closing Date, the Holder Representative shall direct the Paying Agent to make a cash payment to (i) each Seller in accordance with the Closing Date Allocation Schedule by wire transfer in immediately available funds, in an amount equal to the portion of the Released Closing Date Cash Consideration that such Seller is entitled to hereunder in respect of the Shares held by such Seller immediately prior to Closing (after deduction of the Transaction Expenses of the Sellers), and thereafter such Seller shall be entitled to receive any other portion of the Closing Date Consideration (after deduction of the Transaction Expenses of the Sellers) in respect of the Shares held by such Seller immediately prior to Closing to which it is entitled pursuant to the Transaction Agreements and (ii) the relevant payee with respect to the Transaction Expenses of the Sellers which the Sellers expressly acknowledge and agree;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, that Purchaser shall not be responsible for the payment to any Seller of any further amounts with respect to the Closing Date Consideration, other than the Post-Closing Adjustment, if applicable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.4</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Date Cash Consideration Adjustment</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">At least [*] before the Closing, (A) the Sellers, within the limit of their respective powers within the Company as officer and/or shareholder, shall cause Corlieve to prepare and the Holder Representative shall deliver to Purchaser a complete and accurate Closing Date Allocation Schedule and (B) a statement (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Closing Statement</u><font style="font-size:11pt;">&#8221;) setting forth its good faith estimate calculated in accordance with French GAAP of the Closing Date Consideration (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Closing Date Consideration</u><font style="font-size:11pt;">&#8221;), Closing Date Cash Balance (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Closing Date Cash Balance</u><font style="font-size:11pt;">&#8221;), Net Working Capital (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Net Working Capital</u><font style="font-size:11pt;">&#8221;), Closing Date Indebtedness (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Closing Date Indebtedness</u><font style="font-size:11pt;">&#8221;) and Transaction Expenses (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Estimated Transaction Expenses</u><font style="font-size:11pt;">&#8221;)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(without giving effect to the transactions contemplated herein), and a certificate of Purchaser and the Holder Representative that the Estimated Closing Statement was prepared in accordance with French GAAP consistently applied using the same accounting methods, practices, principles, policies and procedures, with consistent classifications, judgments and valuation and estimation methodologies that were used in the preparation of the financial statements of Corlieve for the most recent fiscal year end as if such Estimated Closing Statement was being prepared and audited as of a fiscal year end.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">Within [*] after the Closing Date, Purchaser shall prepare and deliver to the Holder Representative a statement (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Statement</u><font style="font-size:11pt;">&#8221;) setting forth its calculation of the Closing Date Cash Consideration, Closing Date Cash Balance, Net Working Capital, Closing Date Indebtedness and Transaction Expenses (without giving effect to the transactions contemplated herein) and a certificate of Corlieve and Purchaser that the Closing Statement was prepared in accordance with French GAAP applied using the same accounting methods, practices, principles, policies and procedures, with consistent classifications, judgments and valuation and estimation methodologies that were used in the preparation of the Estimated Closing Statement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">After receipt of the Closing Statement, the Sellers shall have [*] (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Review Period</u><font style="font-size:11pt;">&#8221;) to review the Closing Statement. During the Review Period, the Holder Representative&#8217;s accountants shall have reasonable access (during regular business hours, upon reasonable advance notice, under reasonable circumstances, subject to restrictions under applicable Law and without undue disruption to the normal business activities of Corlieve) to the books and records of Corlieve and work papers prepared by Corlieve and/or Corlieve&#8217;s accountants to the extent that they relate to the Closing Statement and to such historical financial information (to the extent in Corlieve&#8217;s possession) relating to the Closing Statement as the Holder Representative may reasonably request for the purpose of reviewing the Closing Statement and to prepare a Statement of Objections, if any. On or prior to the last day of the Review Period, the Holder Representative may object to the Closing Statement by delivering to Purchaser a written statement setting forth the Holder Representative&#8217;s objections in reasonable detail, indicating each disputed item or amount and the basis for the Holder Representative&#8217;s disagreement therewith (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Statement of Objections</u><font style="font-size:11pt;">&#8221;). If the Holder Representative fails to deliver the Statement of Objections before the expiration of the Review Period, the Closing Statement and the Post-Closing Adjustment, as the case may be, reflected in the Closing Statement shall be deemed to have been accepted by the Holder Representative. If the Holder Representative delivers the Statement of Objections before the expiration of the Review Period, Purchaser and the Holder Representative shall negotiate in good faith to resolve such objections within [*] after the delivery of the Statement of Objections (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Resolution Period</u><font style="font-size:11pt;">&#8221;), and, if the same are so resolved within the Resolution Period, the Post-Closing Adjustment and the Closing Statement with such changes as may have been agreed in writing by Purchaser and the Holder Representative shall be final and binding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">If the Holder Representative and Purchaser fail to reach an agreement with respect to all of the matters set forth in the Statement of Objections before expiration of the Resolution Period, then any amounts remaining in dispute (&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Disputed Amounts</u><font style="font-size:11pt;">&#8221;) shall be submitted for resolution to EY or, if EY is unable to serve, Purchaser and the Holder Representative shall appoint by mutual agreement an impartial public accounting firm of nationally recognized standing in France other than the Holder Representative&#8217;s or any Seller&#8217;s accountants or Purchaser&#8217;s accountants (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Independent Accountants</u><font style="font-size:11pt;">&#8221;) who, acting as experts and not arbitrators, shall resolve the Disputed Amounts only and make any adjustments to the Post-Closing Adjustment and the Closing Statement, as the case may be. All adjustments shall be made without regard to materiality. The Independent Accountants shall only decide the specific items under dispute by the parties and their decision for each Disputed Amount must be within the range of values assigned to each such item in the Closing Statement and the Statement of Objections, respectively.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">The Holder Representative shall pay (which payment shall be from the Holder Representative&#8217;s Fund if there is one) a portion of the fees and expenses of the Independent Accountants equal to [*] multiplied by a fraction, the numerator of which is the amount of Disputed Amounts</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">submitted to the Independent Accountants that are resolved in favor of Purchaser (that being the difference between the Independent Accountants&#8217; determination and the Holder Representative&#8217;s determination) and the denominator of which is the total amount of Disputed Amounts submitted to the Independent Accountants (that being the sum total by which Purchaser&#8217;s determination and the Holder Representative&#8217;s determination differ from the determination of the Independent Accountants). Purchaser shall pay that portion of the fees and expenses of the Independent Accountants that the Holder Representative is not required to pay hereunder. The Independent Accountants shall make a determination as soon as practicable within [*] (or such other time as the Parties shall agree in writing) after their engagement, and their resolution of the Disputed Amounts and their adjustments to the Closing Statement and/or the Post-Closing Adjustment shall be conclusive and binding upon the Parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">The post-closing adjustment to the Closing Date Cash Consideration shall be an amount equal to the Estimated Closing Date Cash Consideration as set forth in the Estimated Closing Statement minus the Closing Date Cash Consideration as set forth on the Closing Statement as finally determined under subsection (c) or (d) above (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Post-Closing Adjustment</u><font style="font-size:11pt;">&#8221;). If the Post-Closing Adjustment is a negative number, Purchaser shall pay to the Paying Agent (i) the Holdback Amount and (ii) an amount in cash equal to the absolute value of the Post-Closing Adjustment (and the Paying Agent shall pay such amounts to the Sellers based upon their Pro Rata Share). If the Post-Closing Adjustment is a positive number, Purchaser shall retain that portion of the Holdback Amount equal to the absolute value of the Post-Closing Adjustment and, in the event the Post-Closing Adjustment due by the Sellers to Purchaser exceeds the Holdback Amount, such amount by which the Post-Closing Adjustment due by the Sellers to Purchaser exceeds the Holdback Amount shall be paid in cash by the Sellers (based upon their Pro Rata Share) to Purchaser;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, that Purchaser shall have the right to set-off any such amount due by the Sellers to Purchaser in excess of the Holdback Amount from any Milestone Payment that may become due by Purchaser under this Agreement and reduce the amount of any such Milestone Payment due to the Sellers accordingly. If the Post-Closing Adjustment is a positive number that is less than the Holdback Amount, Purchaser shall pay to the Paying Agent an amount in cash equal to the difference between the Holdback Amount and the Post-Closing Adjustment (and the Paying Agent shall pay such amounts to the Sellers based upon their Pro Rata Share). Any payments made pursuant to this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.4</u><font style="font-size:11pt;">&#160;shall be treated as an adjustment to the Closing Date Cash Consideration by the Parties for Tax purposes, unless otherwise required by Applicable Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.5</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Payment of Closing Date Transaction Expenses</u><font style="font-size:11pt;">. On the Closing Date, upon the terms and conditions of this Agreement, Purchaser shall pay, in cash by wire transfer of immediately available funds, the Estimated Transaction Expenses, in the amount and to the extent set forth in the Estimated Closing Statement delivered hereunder, and pursuant to the wiring instructions provided by the Holder Representative at least [*] prior to the Closing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.6</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Treatment of Free Shares</u><font style="font-size:11pt;">. With respect to any given Free Share, within five (5) Business Days following the applicable Free Share Transfer Date, each Free Share Holder shall deliver a share transfer certificate (</font><i style="font-size:11pt;font-style:italic;">ordre de mouvement</i><font style="font-size:11pt;">) duly signed by the Free Share Holder, and within [*] of receipt thereof, Purchaser shall pay, in cash by wire transfer of immediately available funds, the portion of the Free Share Holdback corresponding to such Free Share and pursuant to the wiring instructions provided by the applicable Free Share Holder, provided that, if any such payment is to be made prior to the Escrow Release Date, &#160;a portion thereof equal to [*] of the applicable Free Share Holdback shall be paid to the Escrow Account. &#160;Each Free Share Holder shall hold all Free Shares in trust for Purchaser until such transfer is consummated, and hereby agrees, prior to such transfer, to vote all such Free Shares in accordance with the recommendations of the Purchaser. In no event shall any Free Share Holder transfer the beneficial or legal interest in any Free Share to any person other than the Purchaser.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.7</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Non GMP Batch Payment</u><font style="font-size:11pt;">. Within [*] following the Non-GMP Batch Delivery, if any, Purchaser shall pay the Non-GMP Batch Payment to RGX, provided that, if any such payment is to be made prior to the Escrow Release Date, &#160;a portion thereof equal to [*] of the Non-GMP Batch Payment</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">shall be paid to the Escrow Account; and the relative Pro Rata Share of each Seller shall be automatically amended as set forth on Schedule 2.7.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.8</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Withholding Tax</u><font style="font-size:11pt;">. Subject to prior consultation with the Holder Representative, Purchaser shall be entitled to deduct and withhold, and to cause the Escrow Agent to deduct and withhold, from any amounts payable in respect of the Shares, such amount, if any, as Purchaser or the Escrow Agent may be required to deduct and withhold with respect to the making of such payment under domestic or foreign Tax Law, and shall pay over (or cause to be paid over) such amounts to the proper Taxing Authority. To the extent that amounts are so deducted and withheld in accordance with the preceding sentence and paid to the proper Taxing Authority, such amounts shall be treated for all purposes of this Agreement as having been paid to, or for the benefit of, the former holder of the Shares in respect of which such deduction or withholding was made. &#160;Based on its review of current Applicable Laws, the Purchaser has not identified any withholding taxes applicable to the Closing Date Consideration or the Total Consideration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.9</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Payments</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">As additional consideration for the Shares and upon the first achievement by Purchaser, any of its Affiliates or any of the respective licensees, sublicensees, assignees or transferees of Purchaser or any of its Affiliates (or any Affiliates of such licensees, sublicensees, assignees or transferees) of any of the events set forth in the table below under &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Trigger Event</u><font style="font-size:11pt;">&#8221;, Purchaser shall promptly (and in any event no later than [*] thereafter) notify the Holder Representative of such achievement and, within [*] of such notice, pay or deposit with the Paying Agent, subject to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.10</u><font style="font-size:11pt;">, either in cash or a combination of cash and issuance of uniQure Ordinary Shares (such uniQure Ordinary Shares being referred to as the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Shares</u><font style="font-size:11pt;">&#8221;), the amount set forth in the table below under &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Payment</u><font style="font-size:11pt;">&#8221; opposite such &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Trigger Event</u><font style="font-size:11pt;">&#8221; (each, a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Payment</u><font style="font-size:11pt;">&#8221;), and net of any required withholding of Taxes under Applicable Law, which shall be promptly paid over to the applicable Taxing Authority by Purchaser. &#160;Promptly following the payment or deposit of any Milestone Payment, the Paying Agent, as instructed by Holders Representative, shall, subject to &#8206;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(k)</u><font style="font-size:11pt;">, pay to each Seller, by wire transfer of immediately available funds, such Seller&#8217;s Pro Rata Share of such Milestone Payment. &#160;It is expressly understood and agreed that Purchaser, the Company and their respective Affiliates shall have no Liability to any Seller with respect to any portion of any Milestone Payment that has been paid or deposited by or on behalf of Purchaser to the Paying Agent. For clarity, the Milestones shall by payable only once for the first Corlieve Product to achieve such Milestone Trigger Event.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">For the avoidance of doubt, (i) the maximum aggregate amount Purchaser and any of its Affiliates shall be obligated to pay pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;"> with respect to Milestones shall be [*] and (ii) no more than one Milestone Payment shall be payable with respect to any Milestone (other than, for the avoidance of doubt, any additional payments in respect of Milestone #4b and Milestone #5b to the extent they become payable as set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(c)</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(c)</u><font style="font-size:11pt;"> below).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">In the event that Milestone #4b is triggered pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a</u><font style="font-size:11pt;">) with respect to any Corlieve Product, then upon expiry of the Valid RGX AAV9 Patent Covering such Corlieve Product in the United States, the Sellers shall be entitled to receive a payment in an amount equal to [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">In the event that Milestone #5b is triggered pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;">, then upon expiry of the Valid RGX AAV9 Patent Covering such Corlieve Product in all Major EU Countries, &#160;the Sellers shall be entitled to receive a payment in an amount equal to [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Valuation of the Milestone Shares</u><font style="font-size:11pt;">. If any Milestone Payment becomes due, if Purchaser elects to make any portion of a Milestone Payment by issuing uniQure Ordinary Shares, each</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:4pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Milestone Share issued by Purchaser will be deemed to have a value equal to the Euro equivalent of the Reference Market Value with respect to the date on which the relevant Milestone payment is made.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Shares Cap</u><font style="font-size:11pt;">. Notwithstanding any other provision in this Agreement, the total number of Milestone Shares that may be issued to each Seller in respect of each of the Milestones shall be limited to a number of Milestone Shares having an aggregate value equal to [*] of such Seller&#8217;s Pro Rata Share of such aggregate Milestone Payment (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Shares Cap</u><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Payments Not Certain</u><font style="font-size:11pt;">. Each of Purchaser, Corlieve and each of the Sellers hereby acknowledges that the achievement of the Milestones is uncertain, and it is therefore not assured that Purchaser&#8217;s obligation to pay any Milestone Payments will ever arise, despite Purchaser&#8217;s use of the efforts required pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.9(h)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Diligence</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">Following the Closing, Purchaser and its Affiliates shall have the right, in their sole and absolute discretion, to direct and control the research, development and commercialization of the Corlieve Product in all respects, including the determination to test, develop, pursue, market, make any regulatory filings with respect to, or make any strategic product portfolio decisions affecting, any such Corlieve Product; provided that Purchaser and its Affiliates shall use Commercially Reasonable Efforts with respect to the Corlieve Product to develop and seek Regulatory Approval in the United States and at least one Major EU Country for the Corlieve Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">If the Purchaser, or its Affiliates, or any of the respective licensees, sublicensees, assignees or transferees of Purchaser or any of its Affiliates, as the case may be, makes a definitive determination to cease research, development or commercial activities for the Corlieve Product due to a Safety/Regulatory Reason, then (x) Purchaser or its Affiliates shall promptly notify the Holders Representative of such determination together with all supporting data and regulatory information in writing (a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Development Notice</u><font style="font-size:11pt;">&#8221;) and (y) no additional Milestone Payments or Downstream Payments shall be payable with respect to a Corlieve Product or Alternative Product pursuant to this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><font style="font-size:11pt;">Provided that no such Development Notice has been delivered pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(h)(ii)</u><font style="font-size:11pt;"> herein, and provided further that any Milestone Payments payable pursuant to this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(h)(iii)</u><font style="font-size:11pt;"> shall be payable once for the first Corlieve Product or Alternative Product (as the case may be) to reach the applicable Milestone, then:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">a)</font><font style="display:inline-block;width:26.68pt;"></font><font style="font-size:11pt;">To the extent that Purchaser, or its Affiliates, or any of the respective licensees, sublicensees, assignees or transferees of Purchaser or any of its Affiliates, makes the decision to Deprioritize or cease to develop the Corlieve Product within two (2) years of the Closing Date, then the Milestone Payments in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;"> will be payable upon achievement of the corresponding Milestone by the Corlieve Product or the Alternative Product whichever comes first, provided that with respect to the Alternative Product, no Milestone Payments in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;"> shall be payable by the Purchaser or its Affiliates after ten (10) years following the Deprioritization; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">b)</font><font style="display:inline-block;width:26pt;"></font><font style="font-size:11pt;">To the extent that Purchaser or its Affiliates or any of the respective licensees, sublicensees, assignees or transferees of Purchaser or any of its Affiliates, makes a Deprioritization decision more than two (2) years after the Closing Date, then the Milestone Payments in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;"> will be payable upon achievement of the corresponding Milestone by the Corlieve Product or the Alternative Product whichever comes first, provided that with respect to such Alternative Product, no Milestone Payments in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(a)</u><font style="font-size:11pt;"> shall be payable by the Purchaser or its Affiliates after [*] following the Deprioritization;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iv)</font></font><font style="font-size:11pt;">For purposes of this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.9(h)</u><font style="font-size:11pt;">, Purchaser shall notify the Holder Representative of its rationale for any Safety/Regulatory Reason determination or Deprioritization decision, with supporting information, and discuss it in good faith with the Holder Representative.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(v)</font></font><font style="font-size:11pt;">Further, no later than December 15</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> of each year until the fifth (5</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;">) &#160;anniversary of the Closing Date, Purchaser shall provide an annual report on the development of the Corlieve Product and Alternative Products by Purchaser, its Affiliates and any of the respective licensees, sublicensees, assignees or transferees of Purchaser or any of its Affiliates, over the preceding twelve months. Purchaser shall respond to all reasonable questions that the Holder Representative may have on such report and related activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Nontransferability of Rights to Milestone Payments</u><font style="font-size:11pt;">. The right of the Sellers to receive the Milestone Payments pursuant to this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.9</u><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">.</b><font style="font-size:11pt;"> may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer. For the avoidance of doubt, if Purchaser elects to make any portion of a Milestone Payment by issuing Milestone Shares, such Milestone Shares will not be subject to the restriction provided in the previous sentence, but will be subject to any applicable restrictions on transfer provided in any applicable securities Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(j)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Payments an Integral Part of Consideration</u><font style="font-size:11pt;">. The Parties acknowledge that the right of the Sellers to receive the Milestone Payments represents an integral part of the consideration the Sellers are receiving in exchange for their Shares and is a significant factor in the willingness of the Sellers to enter into this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(k)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Tax Treatment</u><font style="font-size:11pt;">. Any payments made pursuant to this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.9</u><font style="font-size:11pt;">&#160;shall be treated as an adjustment to the Total Consideration for all Tax purposes, unless otherwise required by Applicable Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.10</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Set-Off.</u><font style="font-size:11pt;"> Notwithstanding any provision of this Agreement to the contrary, the parties hereby acknowledge and agree that, in addition to any other right hereunder, Purchaser shall have the right, but not the obligation, to set off against any Milestone Payment (or Downstream Payment that is owed and has not yet been paid the following amounts, to the extent not disputed in good faith by the Holder Representative [*] (each, a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Set-Off</u><font style="font-size:11pt;">&#8221;). &#160;To the extent that any amounts of any Milestone Payment are set-off in accordance with this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.10</u><font style="font-size:11pt;">, such amounts shall be treated for all purposes of this Agreement as having been paid to the Sellers. For the avoidance of doubt, once actually paid to the Sellers, the Milestone Payments shall not be recoverable by Purchaser pursuant to the set-off rights contained in this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.10</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.11</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Form of Consideration Payable by Purchaser</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">uniQure Ordinary Shares Issued as part of a Milestone Payment</u><font style="font-size:11pt;">. Subject to the provisions of </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.9</u><font style="font-size:11pt;">&#160;and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.11(c)</u><font style="font-size:11pt;">, upon its election, Purchaser may satisfy part of its obligation to make any portion of a Milestone Payment by the issuance to each Seller of such Seller&#8217;s Pro Rata Share of the Milestone Shares being issued by Purchaser, with any fraction of a uniQure Ordinary Share being treated as provided in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.11(d)</u><font style="font-size:11pt;">&#160;below, subject to the Milestone Shares Cap.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Covenants</u><font style="font-size:11pt;">. Subject to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.12</u><font style="font-size:11pt;">, prior to the issuance of any uniQure Ordinary Shares pursuant to this Agreement, Purchaser shall cause the following to occur:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">any and all uniQure Ordinary Shares issued pursuant to this Agreement shall be saleable, subject to any restrictions that would be imposed under applicable Law as a result of a Seller&#8217;s individual circumstance (</font><i style="font-size:11pt;font-style:italic;">i.e.</i><font style="font-size:11pt;">, the restrictions under Regulation S and any volume limitations imposed pursuant to Rules 144 or 145 under the Securities Act), without requiring further registration</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">under the Securities Act, but subject to any holding period or similar restrictions arising under Rule 144;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">any and all uniQure Ordinary Shares issued pursuant to this Agreement shall be listed on each securities exchange on which similar securities, including as to class and series, issued by Purchaser are then listed and, if not so listed, such shares shall be listed on Nasdaq, subject only to notice of issuance;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><font style="font-size:11pt;">any and all such uniQure Ordinary Shares issued pursuant to this Agreement shall be duly authorized and reserved for issuance, and upon issuance thereof in accordance with this Agreement, be validly issued, fully paid and nonassessable; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iv)</font></font><font style="font-size:11pt;">any and all Milestone Shares shall be subject to the right contained in</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;7.4</u><font style="font-size:11pt;">&#160;to have Purchaser register such Milestone Shares for resale.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Fractional Shares</u><font style="font-size:11pt;">. Notwithstanding anything to the contrary herein, no fractional uniQure Ordinary Shares shall be issued pursuant to this Agreement, but an amount in cash equal to the aggregate Reference Market Value of all such fractional shares shall instead be deposited with the Holder Representative by Purchaser and shall be an addition to the Holder Representative&#8217;s Fund if there is one.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Status of Seller</u><font style="font-size:11pt;">. In no event shall Purchaser issue Milestone Shares to any Seller who is a U.S. Person unless such Seller is (i) an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act or (ii) a &#8220;qualified institutional buyer&#8221; as defined in Rule 144A promulgated under the Securities Act ((i) and (ii), an &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Accredited Investor</u><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.12</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Escrow</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Escrowed Amount</u><font style="font-size:11pt;">. At the Closing, Purchaser shall deposit the Escrowed Amount into an escrow account (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Escrow Account</u><font style="font-size:11pt;">&#8221;) to be held by the Escrow Agent pursuant to the terms of the Escrow Agreement. The Escrowed Amount shall serve as security for the indemnity obligations under </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Sections&#160;9.2(a)</u><font style="font-size:11pt;"> and&#160;9.2(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Release of Escrow</u><font style="font-size:11pt;">. The Escrow Agreement shall provide that on the date that is twelve (12) months after the Closing Date (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Escrow Release Date</u><font style="font-size:11pt;">&#8221;), the Escrow Agent shall release the entire Escrowed Amount then remaining in the Escrow Account in accordance with the Closing Date Allocation Schedule,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, that if prior to the Escrow Release Date, a Purchaser Indemnified Party has delivered a Claim Notice pertaining to a matter described in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Sections&#160;9.2(a)</u><font style="font-size:11pt;"> or&#160;9.2(b)&#160;and, despite the Purchaser&#8217;s and the Holder Representative&#8217;s good faith discussion, &#160;such Claim Notice remains unresolved as of the Escrow Release Date, then Purchaser shall be entitled to instruct the Escrow Agent to retain such portion of the remaining Escrowed Amount as, in Purchaser&#8217;s reasonable judgment, may be necessary to satisfy any unresolved or unsatisfied claims for indemnifiable Damages specified in such Claim Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Escrow Agent Fees and Expenses</u><font style="font-size:11pt;">. Any fees and expenses of the Escrow Agent shall be paid one half by Purchaser and one half by the Holder Representative (such payment to be made from the Holder Representative&#8217;s Fund if there is one). The Sellers shall be entitled to receive, upon the release of the Escrowed Amount, any and all interest on such Escrowed Amount (provided, however, that if the Escrow Agent charges &#8220;negative&#8221; interest on the Escrowed Amount, such expense shall be shared one half by Purchaser and one half by the Sellers) or dividends paid by Purchaser on uniQure Ordinary Shares during the period in which the Escrowed Amount are retained in the Escrow Account.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.13</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Deliverables</u><font style="font-size:11pt;">. At the Closing:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Deliveries to Purchaser</u><font style="font-size:11pt;">. Purchaser shall have received the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">a certified copy of the power and authority of the individual(s) acting on behalf of any of the Sellers, or any of the Free Shares Holders, of the Holder Representative for the purposes of the Closing;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">the share transfer forms (</font><i style="font-size:11pt;font-style:italic;">ordres de mouvement</i><font style="font-size:11pt;">) related to the Shares, duly completed and signed by each Seller in favor of Purchaser;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><font style="font-size:11pt;">three (3) originals of the French Short Form Transfer Agreement, duly executed by the Sellers in the form of the draft attached hereto as&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit D</u><font style="font-size:11pt;">;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iv)</font></font><font style="font-size:11pt;">the up-to-date originals of (i) the share transfer register (</font><i style="font-size:11pt;font-style:italic;">registre des mouvements de titres</i><font style="font-size:11pt;">) of Corlieve, (ii) the shareholders&#8217; accounts (</font><i style="font-size:11pt;font-style:italic;">comptes d&#8217;actionnaires</i><font style="font-size:11pt;">) of Corlieve, (iii) the registries of the minutes of the meetings of the </font><i style="font-size:11pt;font-style:italic;">Comit&#233; de Supervision </i><font style="font-size:11pt;">(</font><i style="font-size:11pt;font-style:italic;">supervisory board</i><font style="font-size:11pt;">) and of the decisions of the President, (iv) the registry(ies) of the minutes of the general shareholders&#8217; meetings of Corlieve (</font><i style="font-size:11pt;font-style:italic;">registre(s) des proc&#232;s-verbaux des Assembl&#233;es G&#233;n&#233;rales</i><font style="font-size:11pt;">) and the attendance sheets to such shareholders&#8217; meetings (</font><i style="font-size:11pt;font-style:italic;">feuilles de pr&#233;sence aux Assembl&#233;es G&#233;n&#233;rales</i><font style="font-size:11pt;">);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(v)</font></font><font style="font-size:11pt;">a copy of the Escrow Agreement, signed by the Holder Representative and the Escrow Agent;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(vi)</font></font><font style="font-size:11pt;">the resignations, effective as of the Closing, of all of the members of the management (including the President of Corlieve) and the </font><i style="font-size:11pt;font-style:italic;">Comit&#233; de Supervision</i><font style="font-size:11pt;"> (supervisory board) of Corlieve;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(vii)</font></font><font style="font-size:11pt;">a certificate duly executed by the Holder Representative, dated the Closing Date, certifying that the conditions with respect to Purchaser&#8217;s obligations under this Agreement set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8.2(a)</u><font style="font-size:11pt;">&#160;and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8.2(b)</u><font style="font-size:11pt;">&#160;have been satisfied;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(viii)</font></font><font style="font-size:11pt;">an instrument evidencing the termination of the Shareholders Agreement, signed by each party thereto;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ix)</font></font><font style="font-size:11pt;">a copy of the Paying Agent Agreement, signed by the Holder Representative and the Paying Agent;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(x)</font></font><font style="font-size:11pt;">a copy of the Licensed Know-How Schedule, dated as of the Closing Date;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xi)</font></font><font style="font-size:11pt;">Execution and delivery of such other documents and agreements as have been mutually agreed by the Parties as of the date hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xii)</font></font><font style="font-size:11pt;">Execution and delivery of new employment agreements (including in respect of the amended vesting terms of outstanding unvested Free Share awards, with a vesting at six (6) months following the Closing Date) between the Purchaser or its Affiliates and each of [*] on the terms mutually agreed as of the date hereof ; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xiii)</font></font><font style="font-size:11pt;">such other certificates or other documents reasonably requested and necessary to effectuate the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Deliveries to the Holder Representative</u><font style="font-size:11pt;">. The Holder Representative shall have received the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">a certified copy of the power and authority of the individual(s) acting on behalf of Purchaser for the purposes of the Closing;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">evidence of the deposit of the Closing Date Cash Consideration by wire transfer in immediately available funds to the Paying Agent;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><font style="font-size:11pt;">evidence of the deposit of the Escrowed Amount in the Escrow Account;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iv)</font></font><font style="font-size:11pt;">a certificate duly executed by Purchaser, dated the Closing Date, certifying that the conditions with respect to the Sellers&#8217; obligations under this Agreement set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8.3(a)</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8.3(b)</u><font style="font-size:11pt;"> have been satisfied</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(v)</font></font><font style="font-size:11pt;">a copy of the Escrow Agreement, signed by Purchaser;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(vi)</font></font><font style="font-size:11pt;">three (3) originals of the French Short Form Transfer Agreement, duly executed by Purchaser in the form of the draft attached hereto as&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit D</u><font style="font-size:11pt;">;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(vii)</font></font><font style="font-size:11pt;">evidence of the obtaining of the Foreign Investment Approval;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(viii)</font></font><font style="font-size:11pt;">a copy of the Paying Agent Agreement, signed by Purchaser; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ix)</font></font><font style="font-size:11pt;">such other certificates or other documents reasonably requested and necessary to effectuate the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.14</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Payments to Paying Agent</u><font style="font-size:11pt;">. The Sellers and the Holder Representative agree that any payment made by or on behalf of Purchaser (including via release of the Holdback Amount, the Non GMP Batch Payment, the Free Share Holdback, release from the Escrow Account or with respect to payment of Milestone Payments) to the Paying Agent in accordance with this Agreement for distribution to a given Seller shall be deemed to be a payment made by Purchaser directly to such Seller and shall be deemed to satisfy the corresponding obligation of Purchaser to such Seller to the extent of such amount paid to the Paying Agent. Notwithstanding anything to the contrary contained herein, any amounts paid to the Paying Agent for distribution to the Sellers shall be deemed to be paid to the Sellers, and upon such payment, neither Purchaser, Corlieve nor any of their respective Affiliates shall have any further Liability for any payment owed to any Seller if so paid to the Paying Agent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.15</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Further Assurances</u><font style="font-size:11pt;">. If at any time after the Closing Date, Purchaser shall determine, in its reasonable discretion, that any deeds, bills of sale, instruments of conveyance, assignments, assurances or any other actions or things are necessary or desirable to vest, perfect or confirm of record or otherwise in Purchaser its right, title or interest in, the Shares and to or under any of the rights, properties or assets of Corlieve indirectly acquired by Purchaser as a result of, or in connection with, the transaction contemplated by this Agreement or otherwise to carry out this Agreement, then the officers and directors of Purchaser shall be authorized to execute and deliver, in the name and on behalf of Corlieve, all such deeds, bills of sale, instruments of conveyance, assignments and assurances and to take and do, in the name and on behalf of Corlieve, all such other actions and things as may be necessary or desirable to vest, perfect or confirm any and all right, title or interest in, to and under such rights, properties or assets in Purchaser or otherwise to carry out this Agreement, so long as such action is consistent with the terms of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES REGARDING THE SELLERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Each Seller, severally and not jointly (</font><i style="font-size:11pt;font-style:italic;">sans solidarit&#233; entre eux</i><font style="font-size:11pt;">), hereby represents and warrants to Purchaser that the statements contained in this&#160;Article 3 are true and correct as of the Agreement Date and as of the Closing Date:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Power and Authorization</u><font style="font-size:11pt;">. Such Seller has full capacity, legal right, power, and authority (including pursuant to his/her respective matrimonial regime) to enter into and perform its</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:4pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">obligations and consummate the transactions contemplated under this Agreement. Such Seller that is an entity is validly existing and is in good standing under the Applicable Laws of the jurisdiction of its organization and has all requisite power and authority to own, lease and operate properties and carry on its business as now conducted. The execution, delivery, and performance by such Seller of this Agreement and the other Transaction Agreements to which such Seller will be a party, and the consummation by such Seller of the transactions contemplated hereby and thereby, have been duly authorized with respect to such Seller by all necessary action. This Agreement has been, and each other Transaction Agreement to which such Seller will be a party will be, duly and validly executed and delivered by such Seller and constitutes, or will constitute, the legal, valid, and binding obligation of such Seller, enforceable against such Seller in accordance with its terms, except as enforcement may be limited by equitable principles limiting the right to obtain specific performance or other equitable remedies, or by applicable bankruptcy or insolvency laws and related decisions affecting creditors&#8217; rights generally.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Conflicts</u><font style="font-size:11pt;">. The execution, delivery, and performance of this Agreement and the other Transaction Agreements to which such Seller will be a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not (with or without the passage of time or the giving of notice):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">violate or conflict with any provision of the organizational documents of such Seller;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">violate any Applicable Law or Governmental Order applicable to such Seller or by which any of the properties or assets of such Seller are bound;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">violate or conflict with, result in a breach of, or constitute a Default or otherwise cause any loss of benefit under any Contract or Permit to which such Seller is a party, or give to others any rights (including rights of termination, foreclosure, cancellation or acceleration), in or with respect to such Seller or the Shares or Free Shares as applicable, held by such Seller; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">result in, require or permit the creation or imposition of any Encumbrances of any nature upon or with respect to the Shares held by such Seller.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Absence of Litigation</u><font style="font-size:11pt;">. There are no judicial, administrative or other governmental actions, proceedings or investigations pending or, to the knowledge of such Seller, threatened involving such Seller that question any of the transactions contemplated by, or the validity of, this Agreement which, if adversely determined, would materially impair the ability of such Seller to enter into or perform its obligations under this Agreement or materially delay, affect or prohibit the consummation of the transactions contemplated by this Agreement. Such Seller has not received any request from any Governmental Authority for information with respect to the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.4</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Ownership of the Shares</u><font style="font-size:11pt;">. Such Seller owns the Shares set forth opposite such Seller&#8217;s name in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u><font style="font-size:11pt;">, beneficially and of record, free and clear of any Encumbrances. There are no shareholder or other agreements &#160;that will not be terminated at the Closing Date affecting the right of such Seller to convey the Shares to Purchaser or any other right of such Seller with respect to the Shares that will not be terminated prior to Closing, and at the Closing such Seller will have the absolute right, authority, power, and capacity to sell, assign, and transfer the Shares owned by it to Purchaser free and clear of any Encumbrance (except for restrictions imposed generally by Applicable Law). Upon the exchange of the documents mentioned in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.15</u><font style="font-size:11pt;">, Purchaser will acquire good, valid, and marketable title to the Shares, free and clear of any Encumbrances. Such Seller does not own any shares in the capital of Corlieve, nor does such Seller own or claim any other interest in any options, warrants or other rights to acquire any shares in the capital of Corlieve.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.5</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Approvals, etc.</u><font style="font-size:11pt;">&#160;Except for the approval of the French Ministry of Economy, Finance and Recovery (</font><i style="font-size:11pt;font-style:italic;">Minist&#232;re de l&#8217;Economie, des Finances et de la Relance</i><font style="font-size:11pt;">) and the supervisory board&#8217;s</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">meeting of Corlieve pursuant to Article 14.11 of the Bylaws, all consents, approvals, authorizations and orders (corporate, governmental or otherwise) necessary for the due authorization, execution and delivery by such Seller of this Agreement and the other Transaction Agreements to which such Seller will be a party, the performance of such Seller of any of its obligations hereunder and thereunder and the consummation of the transactions contemplated hereby and thereby will have been obtained as of the Closing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.6</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Brokers</u><font style="font-size:11pt;">. Such Seller and its officers, directors or employees have not entered into any Contract with any broker, finder or similar agent or any Person which will result in an obligation of Purchaser, Corlieve, or any of their respective Affiliates to pay any finder&#8217;s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.7</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Compliance with Securities Laws</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Such Seller (i) is either not a U.S. Person or qualifies as an Accredited Investor, (ii) acknowledges that, subject to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7.4</u><font style="font-size:11pt;">, the Milestone Shares are not registered under the Securities Act, and that the Milestone Shares may not be transferred or sold except pursuant to the registration provisions of the Securities Act or pursuant to an applicable exemption therefrom and, accordingly, that it may not be able to liquidate the Milestone Shares, and (iii) is able to bear the economic risk of holding the Milestone Shares (including total loss of its investment).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">If such Seller is not a U.S. Person, such Seller is not acquiring the Milestone Shares for the account or benefit of any U.S. Person.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">If such Seller is an Accredited Investor, such Seller is acquiring the Milestone Shares solely for its own account for investment purposes and not with a view to, or for offer or sale in connection with, any distribution thereof in violation of the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.8</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Ownership of uniQure Ordinary Shares</u><font style="font-size:11pt;">. Such Seller does not, directly or indirectly, own any uniQure Ordinary Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES REGARDING CORLIEVE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Except as set forth herein or in the disclosure letter delivered by the Holder Representative to Purchaser in connection with the execution of this Agreement as may be updated pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 6.10</u><font style="font-size:11pt;"> (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Disclosure Letter</u><font style="font-size:11pt;">&#8221;), the Company hereby represents and warrants to Purchaser that the statements contained in this&#160;Article 4 are true and correct as of the Agreement Date and as of the Closing Date (except for the representations and warranties that are made as of a specific date, which shall be true and correct as of such date). The Disclosure Letter will be arranged in sections corresponding to the numbered and lettered paragraphs contained in this Article 4. The Sellers shall not be liable under&#160;Article 9 for a breach of a specific representation or warranty for any fact or item fairly disclosed in the Disclosure Letter against such specific representation and warranty;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, that any fact or item disclosed on any Section of the Disclosure Letter shall be deemed disclosed on all other Sections of the Disclosure Letter to which an appropriate cross-reference is made or in all other Sections of the Disclosure Letter where it is reasonably apparent on its face that such disclosure fairly applies to such other Sections of the Disclosure Letter&#160;(irrespective of the language in which they are disclosed).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Organization of Corlieve</u><font style="font-size:11pt;">. Corlieve is duly incorporated and organized, validly existing and in good standing under Applicable Laws of France with full power and authority to conduct its business as it is presently being conducted, and to own, lease or operate, as applicable, its assets and properties. A true, correct and complete copy of the Bylaws, and all amendments thereto, have</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:3pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">heretofore been made available to Purchaser and are accurate and complete as of the Agreement Date. Corlieve is not in violation of the Bylaws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Subsidiaries</u><font style="font-size:11pt;">. All the outstanding shares of capital stock of, or other equity or voting interests in the Swiss Subsidiary have been validly issued and are fully paid and nonassessable and are owned by Corlieve free and clear of all liens and are duly authorized, validly issued, full paid and nonassessable. &#160;Other than the Swiss Subsidiary, neither the Company nor the Swiss Subsidiary owns or has owned any capital stock of, or other equity or voting interests of any nature in, or any interest convertible, exchangeable or exercisable for, capital stock of, or other equity or voting interests of any nature in, any other Person. With the exception of the Swiss Subsidiary, Corlieve does not have, and has never had, any Subsidiary and does not otherwise own or control, directly or indirectly, or hold any rights to acquire, any capital stock or any other securities, interests or investments (other than investments that constitute cash or cash equivalents) in any other corporation, partnership, trust, joint venture, association or other Person.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Capitalization</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Section&#160;4.3(a)&#160;of the Disclosure Letter sets forth the name of each shareholder of Corlieve and the number of Shares held by each such shareholder as at the date hereof and the Closing Date. At the Closing, the Shares held by the Sellers will represent 100% of the issued, outstanding and authorized capital of Corlieve. All of the Shares have been and will be duly and validly issued. None of the Shares were or will be issued in violation of preemptive or similar rights or in violation of any applicable securities laws. Section&#160;4.3(a)&#160;of the Disclosure Letter also sets forth a capitalization table of Corlieve as of the Agreement Date (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Capitalization Table</u><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">Section&#160;4.3(b)&#160;of the Disclosure Letter sets forth the name of each Free Share Holder and the number of Free Shares held by each Free Share Holder. Except as set forth on Section 4.3(b)&#160;of the Disclosure Letter, there is no existing option, warrant, call, right (including preemptive rights, subscription rights, rights of first refusal and commitments) or Contract of any character to which Corlieve is a party requiring, and there are no securities of Corlieve outstanding which upon conversion or exchange would require, the issuance of any shares in the capital of Corlieve or other securities convertible into, exchangeable for or evidencing the right to subscribe for or purchase any shares in the capital of Corlieve or that provides for any share appreciation or similar right. Except as set forth in Section&#160;4.3(b)&#160;of the Disclosure Letter, Corlieve is not a party to any voting trust or other Contract or arrangement with respect to the voting, redemption, sale, transfer or other disposition of any shares in the capital, or other equity securities of Corlieve.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.4</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Title to Properties and Assets</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Corlieve has good and marketable title to or, in the case of leased properties or properties held under license, a good and valid leasehold or license interest in all of its properties and assets free and clear of any Encumbrances other than Permitted Encumbrances.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">All of the tangible assets of Corlieve are in reasonably serviceable operating condition and repair (giving due account to the age and length of use of same, ordinary wear and tear excepted) and are adequate for the conduct of the Business in substantially the same manner as it has heretofore been conducted.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">Corlieve does not own or lease, and has never owned or leased, any real property.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.5</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Absence of Certain Activities or Changes</u><font style="font-size:11pt;">. Except as set forth in Sections 4.5(ii) and 4.5(viii) of the Disclosure Letter or for the Specified Costs, since the date of the Most Recent Balance Sheet, (a) Corlieve has conducted its operations in the Ordinary Course of Business, (b) there has been no Material Adverse Effect and (c) Corlieve has not:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">made any capital expenditures in excess of [*];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">amended or changed the Bylaws;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><font style="font-size:11pt;">changed its accounting methods, principles or practices;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iv)</font></font><font style="font-size:11pt;">sold, assigned, transferred, encumbered, abandoned, licensed or permitted to lapse or expire any Corlieve Intellectual Property or other intangible assets other than in the Ordinary Course of Business;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(v)</font></font><font style="font-size:11pt;">sold or disposed of any material assets or rights;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(vi)</font></font><font style="font-size:11pt;">been involved in any transaction or event which has given rise to a Tax Liability other than in respect of matters arising in the Ordinary Course of Business.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(vii)</font></font><font style="font-size:11pt;">made, changed or rescinded any of its Tax elections, filed any Tax Return out of the ordinary course or in a manner that is not consistent with past practice and applicable law, filed any amended Tax Returns, settled or compromised any claim or assessment, entered into any closing agreement, settled or compromised any claim, action, suit, litigation, proceeding, arbitration, investigation, audit controversy relating to a material amount of Taxes, except as required by applicable law or French GAAP, made any change to any of its methods of reporting income or deductions for federal income Tax purposes from those employed in the preparation of Corlieve&#8217;s most recent income Tax Return; surrendered any claim for a refund of Taxes; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(viii)</font></font><font style="font-size:11pt;">except for </font><i style="font-size:11pt;font-style:italic;">(x)</i><font style="font-size:11pt;"> the Transaction Bonus, </font><i style="font-size:11pt;font-style:italic;">(y)</i><font style="font-size:11pt;"> non significant changes in the Ordinary Course of Business, changed the employment terms of, paid any bonus to, increased any salary or wages for, or entered into any employment, consulting or other service Contract with, any Person, or instituted, adopted, amended or terminated any Benefit (all except as required by Applicable Law or in accordance with existing contracts).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.6</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Material Contracts</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Section&#160;4.6(a)&#160;of the Disclosure Letter sets forth all of the following outstanding Contracts to which Corlieve is a party or by which it is bound (collectively, the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Material Contracts</u><font style="font-size:11pt;">&#8221;):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">Contracts that contain covenants requiring Corlieve not to (or that otherwise restrict or limit Corlieve&#8217;s ability to) compete in any line of business or geographical area (including any covenant not to compete with respect to the research, development, manufacture, marketing, distribution or sale of any product or product line) or transact business or deal in any other manner with any other Person;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">Contracts that involve real property;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><font style="font-size:11pt;">Contracts that involve a joint venture, strategic alliance, partnership or limited liability company relationship;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iv)</font></font><font style="font-size:11pt;">Contracts that govern or relate to Indebtedness for borrowed money (other than accounts payable), or guarantees for money borrowed by others;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(v)</font></font><font style="font-size:11pt;">supply agreements involving aggregate payments in excess of [*] per annum;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(vi)</font></font><font style="font-size:11pt;">Contracts that relate to the acquisition or disposition of any assets in excess of [*] outside of the Ordinary Course of Business;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(vii)</font></font><font style="font-size:11pt;">Contracts that require payments or the receipt of payments by Corlieve in excess of [*] per annum outside of the Ordinary Course of Business;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(viii)</font></font><font style="font-size:11pt;">powers of attorney pursuant to which Corlieve has granted authority to act on its behalf;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ix)</font></font><font style="font-size:11pt;">Contracts that involve the payment of royalties or other amounts calculated upon the revenues or income of Corlieve or income or revenues related to any product or Intellectual Property of Corlieve in excess of [*] per annum;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(x)</font></font><font style="font-size:11pt;">Contracts between Corlieve and any Person that relate to the acquisition, transfer, assignment, sale, use, development, sharing, license or commercialization (including covenants not to sue) of Intellectual Property or any Corlieve Product (other than (A) agreements between Corlieve and its Workers in Corlieve&#8217;s standard forms thereof, (B) non-exclusive licenses to third-party Software with license fees less than [*] per year and (C) customary confidentiality agreements, material transfer agreements, or service agreements with third parties that provide only a license to evaluate the Intellectual Property subject to such agreement or provide the services contemplated in such agreement or transfer Intellectual Property to Corlieve in the Ordinary Course of Business);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xi)</font></font><font style="font-size:11pt;">Contracts in which Corlieve has granted any exclusive rights, rights of first refusal or rights of first negotiation, including with respect to any Intellectual Property of Corlieve, to any Person;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xii)</font></font><font style="font-size:11pt;">employment Contracts and Contracts with any consultant requiring an annual payment of cash compensation in excess of [*];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xiii)</font></font><font style="font-size:11pt;">Contracts with any current or former officer, director, Affiliate or shareholder of Corlieve;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xiv)</font></font><font style="font-size:11pt;">Contracts to which any Governmental Authority is a party (other than clinical trial agreements).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">True, correct and complete copies of all Material Contracts, and all amendments thereto, have been provided (or made available) to Purchaser. Each Material Contract is in full force and effect and is valid, binding and enforceable against Corlieve and, to the Knowledge of Corlieve, each other party thereto in accordance with its terms except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium and other Laws affecting enforcement of creditors&#8217; rights generally and except insofar as the availability of equitable remedies may be limited by Applicable Law. Corlieve is not in Default under any Material Contract and, to the Knowledge of Corlieve, no other party is in Default under such Material Contracts. No written notice of any claim of Default under a Material Contract has been given to Corlieve. Except as set forth in Section 4.6(b) of the Disclosure Letter, immediately following the Closing, Corlieve will continue to be permitted to exercise all of its rights under each Material Contract pursuant to the terms thereof without the payment of any additional amounts of consideration other than ongoing fees, royalties or payments that Corlieve would otherwise be required to pay in accordance with the terms of such Material Contract had the transactions contemplated by each Transaction Agreement not occurred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">Except as set forth in Section 4.6(c) of the Disclosure Letter or as required by Applicable Law, no Person (including, in particular, any current or former employee, legal representative, officer and/or consultant of Corlieve) has any option or any other right to participate in or receive any payment as a result of the development, commercialization and/or marketing of any Corlieve Products under any Contract (including employment contracts) to which Corlieve is party or by which it is bound.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.7</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Compliance with Other Instruments</u><font style="font-size:11pt;">. The execution, delivery and performance of and compliance with each Transaction Agreement and the consummation of the transactions contemplated hereby and thereby will not (i) assuming delivery of the document referenced in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.15(a)(v)</u><font style="font-size:11pt;">, result in a violation or breach of, or be in conflict with any provision of the Bylaws, (ii) assuming the consents and approvals referred to in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4.15</u><font style="font-size:11pt;">&#160;are duly obtained, result in a violation of, or be in conflict with or constitute, with or without the passage of time or the giving of notice or both, a Default under, any Applicable Laws, Court Orders or Permits applicable to Corlieve, (iii) assuming the consents and approvals referred to in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;4.15</u><font style="font-size:11pt;">&#160;are duly obtained, violate, conflict with, result in a Default under, or result in the creation of any Encumbrance (other than a Permitted Encumbrance) upon any of the material properties or material assets of Corlieve, or (iv) result in a Default under a Material Contract.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.8</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Financial Statements</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">The Financial Statements have been prepared in accordance with French GAAP applied on a consistent basis during the periods referred to in the Financial Statements and fairly present, in all material respects, the financial condition of Corlieve as at the respective dates referred to in the Financial Statements, and the results of operations and cash flows of Corlieve for the respective periods referred to in the Financial Statements. The Financial Statements have been prepared in accordance with the books and records of Corlieve, which books and records are accurate and complete in all material respects. There have been no instances of fraud by Corlieve or its officers, whether or not material, that occurred during any period covered by the Financial Statements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.9</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Liabilities</u><font style="font-size:11pt;">. Except as set forth in Section 4.9 of the Disclosure Letter, Corlieve has no Liabilities of any nature which would be required to be disclosed on a balance sheet or in any notes thereto prepared in accordance with French GAAP applied consistently with the Most Recent Balance Sheet that were not so disclosed, except for Liabilities (i)&#160;incurred or accrued in Corlieve&#8217;s Ordinary Course of Business since the date of its Most Recent Balance Sheet, (ii) reasonably incurred in connection with the execution of this Agreement or the other Transaction Agreements (iii) included within the Specified Costs, or (iv) disclosed in the Disclosure Letter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.10</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Taxes</u><font style="font-size:11pt;">. Corlieve has duly, timely and correctly filed all Tax Returns it is required to have filed on or prior to the date of the Agreement and maintained all records and supplied all other information in relation to Tax which they were required to make, give, maintain or supply and all such Tax Returns, notices, records and information were accurate, complete and correct in all material respects. Corlieve has delivered to Purchaser true, complete and correct copies of all Tax Returns of Corlieve relating to Taxes for all Tax Periods for which the applicable statute of limitations has not yet expired.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Corlieve has timely paid all Taxes required to have been paid (whether or not shown as due on any Tax Return) and all Taxes due in connection with its operations have been timely paid in all material respects. Taxes that have accrued and/or are due but have not been paid have been fully provided for in the Most Recent Balance Sheet.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">Each transaction between any of the Sellers on the one hand and Corlieve on the other hand and between Corlieve and its Affiliates has been carried out on an arm&#39;s length basis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">There neither is nor has been any dispute, including litigation, between Corlieve and any Tax Authority, nor have Corlieve been the subject of any extraordinary investigation by any Tax Authority and there are no facts which are likely to give rise to any such dispute or investigation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">For all periods for which the applicable statute of limitations has not expired, with respect to Corlieve:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">no written claim has been made by any Taxing Authority in any jurisdiction where Corlieve does not file Tax Returns that it is or may be subject to Tax by that jurisdiction;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">no extensions or waivers of (A) statutes of limitations with respect to the Tax Returns of Corlieve or (B) the period of collection of any Taxes of Corlieve, in each case have been given by or requested from Corlieve; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><font style="font-size:11pt;">no written claim for assessment or collection of Taxes has been asserted against Corlieve which remains unpaid or unresolved, and there is no presently pending audit examination, refund claim, litigation, Proceeding, proposed adjustment or matter in controversy with respect to any Taxes of or with respect to Corlieve.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">Corlieve has always been resident for Tax purposes in the jurisdiction in which it is incorporated and has never been resident in any other jurisdiction or, except for the Swiss Subsidiary, traded through a branch or permanent establishment located outside such jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">All deficiencies asserted or assessments made against Corlieve as a result of any examinations by any Taxing Authority have been fully paid.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:11pt;">There are no Encumbrances for Taxes (other than Permitted Encumbrances) upon the assets of Corlieve.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><font style="font-size:11pt;">Corlieve is not party to or bound by any Tax indemnity, Tax sharing, Tax allocation or similar agreement, other than an agreement entered into in the Ordinary Course of Business, the principal purpose of which is not the sharing of Taxes (such as a lease).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">Corlieve is not party to or bound by any ruling, closing agreement, offer in compromise or other agreement with any Taxing Authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(j)</font></font><font style="font-size:11pt;">Corlieve has never (1) made an election to be treated as a United States domestic corporation for United States tax purposes, (2) made an election to be classified for United States federal income tax purposes as an entity that is not an association Taxable as a corporation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.11</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Environmental Matters</u><font style="font-size:11pt;">. Corlieve has been and is in material compliance with applicable Environmental Laws. There have been no disposals, releases or, to Corlieve&#8217;s Knowledge, &#160;threatened releases of Hazardous Materials by Corlieve. There has never been an Environmental Claim pending or, to the Knowledge of Corlieve, threatened against Corlieve. Corlieve is not subject to any Court Order, letter or memorandum by or with any Governmental Authority imposing any Liability under any Environmental Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.12</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Employee Benefits</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Section&#160;4.12(a)&#160;of the Disclosure Letter sets forth a true, complete and accurate list of each Benefit other than those required by Applicable Laws. True, correct and complete copies of each benefit plan have been provided or made available to Purchaser as of the Agreement Date, including true, correct and complete copies of, where applicable, (i) all material documents embodying and relating to each Benefit, including any plan document (or, in the case of an unwritten Benefit, a written description thereof) and all amendments thereto, the most recent summary plan description (and any summaries of material modifications with respect thereto), and (ii) all material written Contracts, instruments or agreements relating to each Benefit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">Each Benefit complies in form and has been established, maintained and administered in accordance with its terms, and in compliance in all material respects with the requirements of Applicable Law. All payments with respect to each Benefit, including without limitation all contributions (including all employer contributions and employee salary reduction contributions),</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:4pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">insurance premiums or intercompany charges, required to have been made under the terms of any document providing for such Benefit or other agreement or by Applicable Law, have been made or paid by the due date thereof in accordance with the provisions of each document providing for the Benefit, Applicable Law, and all contributions or payments for any period ending on or before the Closing Date which are not yet due will have been paid or accrued prior to the Closing Date in accordance with the provisions of each document providing for the Benefit, Applicable Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">With respect to each Benefit of Corlieve that is funded mostly or partially through an insurance policy, Corlieve has no liability in the nature of retroactive rate adjustment, loss sharing arrangement or other actual or contingent liability arising wholly or partially out of events occurring on or before the Closing Date or is reasonably expected to have such liability with respect to periods through the Closing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">Section&#160;4.12(d)&#160;of the Disclosure Letter sets forth a list of all (i) employment agreements with officers of Corlieve, (ii) agreements with consultants who are individuals obligating Corlieve to make, pursuant to which Corlieve has made, or pursuant to which it is reasonably likely that Corlieve will in the future make, annual cash payments in an amount of [*] or more, (iii) Contracts, programs and policies of Corlieve under which Corlieve may be obligated to provide a Worker severance or any other compensation or benefits as a result of the transaction contemplated by this Agreement or upon termination of employment or any other relationship with Corlieve, (iv) plans, programs, agreements and other arrangements of Corlieve with or relating to its Workers that contain change in control benefit provisions and (v) all written agreements between Corlieve and any Worker of Corlieve (collectively, the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Worker Agreements</u><font style="font-size:11pt;">&#8221;). Corlieve has provided or made available to Purchaser true, correct and complete copies of all such Worker Agreements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">Except for any Free Shares and Transaction Bonus, the execution and delivery of this Agreement by the Sellers and the consummation of the transactions contemplated hereby (either alone will not (i) result in any payment becoming due, or increase the amount of any compensation or benefits due, to any current or former Worker of Corlieve under any Worker Agreement or otherwise or with respect to any benefit plan of Corlieve; (ii) increase any benefits or payments otherwise payable under any Worker Agreement or any Benefit of Corlieve; (iii) result in the acceleration of the time of payment or vesting of any such compensation or benefits; or (iv) result in the forgiveness in whole or in part of any outstanding loans made by Corlieve to any Person.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">None of the Benefits or Worker Agreements provide retiree health or welfare insurance benefits to any current or former employee of Corlieve except as may be required by Applicable Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:11pt;">None of Corlieve or any of its existing or former employees, current legal representatives, officers, directors, shareholders or other Workers has made any promises or commitments, whether legally binding or not, to create any additional Worker Agreement or Benefits, agreement or arrangement, or to modify or change in any material way any existing Worker Agreement or Benefit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><font style="font-size:11pt;">Corlieve has no unfunded liabilities pursuant to any Contract or other arrangement implementing a Benefit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.13</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Compliance with Law</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">The operation of Corlieve&#8217;s business has been and is being conducted in all material respects in compliance with all Applicable Laws and all Court Orders applicable to Corlieve or its business. Corlieve has not received any written notice from a Governmental Authority to the effect that, or otherwise been advised that, it is not in compliance with any such Applicable Laws or Court Orders, and, to Corlieve&#8217;s Knowledge, no circumstance exists that could reasonably be expected to result in material violations of any Applicable Law or Court Order.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">Corlieve is not required by Applicable Law to notify or consult with its employees in respect of the sale of the Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.14</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Permits</u><font style="font-size:11pt;">. Corlieve has all Permits required for the operation of the Business as presently conducted, all of which are valid and in full force and effect. Section&#160;4.14&#160;of the Disclosure Letter sets forth a complete list of all such Permits issued to Corlieve, and true, correct and complete copies of such Permits have been made available to Purchaser. Corlieve is not in Default, nor has it received any written notice of any claim of Default, with respect to any such Permit. No suspension, termination, revocation, cancellation or restriction of any such Permits is pending or, to the Knowledge of Corlieve, threatened. No Governmental Authority is challenging or has threatened in writing to challenge the right of Corlieve to design, research, develop, pre-clinically or clinically test, manufacture, license, commercialize, offer or sell any of its products or services.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.15</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Consents and Approvals</u><font style="font-size:11pt;">. Except for the approval of the French Ministry of Economy, Finance and Recovery (</font><i style="font-size:11pt;font-style:italic;">Minist&#232;re de l&#8217;Economie, des Finances et de la Relance</i><font style="font-size:11pt;">), no consent, approval, order or authorization of, or declaration to, or filing or registration with, any Governmental Authority, or any other Person, is required to be made, obtained or given by Corlieve in connection with the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.16</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Litigation</u><font style="font-size:11pt;">. There is no action, suit, proceeding, claim, arbitration, audit of Governmental Authority, criminal prosecution, unfair labor practice charge or complaint, examination or investigation from any third party (&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Proceeding</u><font style="font-size:11pt;">&#8221;) pending (or, to the Knowledge of Corlieve, threatened) against Corlieve, or relating to its activities, business, properties or assets, or, to Corlieve&#8217;s Knowledge, against any officer, director or employee of Corlieve in connection with such officer&#8217;s, director&#8217;s or employee&#8217;s relationship with, or actions taken on behalf of, Corlieve. None of Corlieve or its assets or properties is a party to or subject to the provisions of any Court Order, and there is no Proceeding by Corlieve currently pending or which Corlieve intends to initiate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.17</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Labor Matters</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Corlieve has no labor unions, works councils or other organizations representing any employees of Corlieve. No Person (including consultants, independent workers, temporary workers, agents, trainees, apprentices and fixed-term/seasonal employees), other than the employees of Corlieve, has the right to claim the status of employee or permanent employee of Corlieve.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">Corlieve is and has been in compliance in all material respects with all Applicable Laws regarding employment, termination of employment, employment practices, terms and conditions of employment, wages and hours, duration of work, overtime, applicable collective bargaining, employment discrimination, leaves of absence, immigration, civil rights, safety and health, workers&#8217; compensation, pay equity, classification of employees, the collection and payment of withholding and/or social security Taxes and other employment related Taxes. In addition, each employee of Corlieve is in compliance with all applicable visa and work permit requirements. Except as set forth in Section 4.17 of the Disclosure Letter, no visa or work permit held by an employee of Corlieve will expire during the six (6)-month period beginning at the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">No claims, disputes, grievances, controversies or labor disputes are pending, or to Corlieve&#8217;s Knowledge, threatened or anticipated involving any Worker or group of Workers of Corlieve. There have been no written claims, charges, investigations, administrative proceedings or written complaints of harassment, discrimination (including discrimination based upon sex, age, marital status, race, national origin, sexual orientation, disability or veteran status), retaliatory action pertaining to any Worker against Corlieve or any employee, legal representative, officer or director of Corlieve at any time during the past four (4) years, and to the Knowledge of Corlieve, no facts exist that could reasonably be expected to give rise to such claims or actions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:4pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">Section&#160;4.17(e)&#160;of the Disclosure Letter sets forth an accurate and complete list of all (i) employees of Corlieve, including each employee&#8217;s name, title or position, present annual compensation (including bonuses, commissions and deferred compensation), accrued and unused paid vacation and other paid leave, years of service, interests in any incentive compensation plan, vested and unvested equity interests, and estimated entitlements to receive supplementary retirement benefits or allowances (whether pursuant to a contractual obligation or otherwise), and (ii) individuals who are currently performing services for Corlieve who are classified as independent contractors, including the respective compensation of each consultant or independent contractor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">To the Knowledge of Corlieve, no existing or former employee of Corlieve is or has been in any material respect in violation of any term of any employment Contract, non-disclosure agreement, non-competition agreement, or any restrictive covenant to a former employer relating to the right of any such employee to be employed by Corlieve because of the nature of the business conducted or presently proposed to be conducted by Corlieve or to the use of trade secrets or proprietary information of others.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.18</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Intellectual Property</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Section&#160;4.18(a)&#160;of the Disclosure Letter sets forth, with respect to all Corlieve Intellectual Property, a complete and accurate list of all (1) Patents and other indicia of ownership or license of any invention issued or filed with any Governmental Authority, (2) trade names, common law trademarks, common law service marks, registered trademarks, registered service marks, and applications for trademark registration or service mark registration, (3) registered Copyrights and (4) domain name registrations and websites in each case owned, licensed, used or held for use by Corlieve in the conduct of its business, specifying as to each such item, as applicable (i) the owner(s) and licensor or licensee, of the item, (ii) the jurisdictions in which the item is issued or registered or in which any application for issuance or registration has been filed, (iii) the respective issuance, registration, and application number of the item, and (iv) the date of application and issuance or registration of the item.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">Section&#160;4.18(b)&#160;of the Disclosure Letter sets forth, with respect to Corlieve, a complete and accurate list of all written licenses, sublicenses, consents and other agreements (whether written or otherwise) (i) pertaining to any Intellectual Property held for use or used by Corlieve in the conduct of its business (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Head Licenses</u><font style="font-size:11pt;">&#8221;), or (ii) by which Corlieve licenses or otherwise authorizes a third party to use or covenants not to sue or grants an immunity from suit any Corlieve Intellectual Property (other than (1) agreements between Corlieve and its employees in Corlieve&#8217;s standard forms thereof, (2) non-exclusive licenses to third-party Software with license fees less than [*] per year and (3) customary confidentiality agreements, material transfer agreements or service agreements with third parties that provide only a license to evaluate the Intellectual Property subject to such agreement or provide the services contemplated in such agreement). Neither Corlieve nor, to Corlieve&#8217;s Knowledge, any Third Party is in Default under any such license or other agreement in any material respect, and each such license or other agreement is now and immediately following the Closing shall be in full force and effect. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby will not result in the loss, forfeiture, termination, license, or impairment of, or give rise to a right to limit, terminate, or consent to the continued use of any Corlieve Intellectual Property. To Corlieve&#8217;s Knowledge the Corlieve Intellectual Property includes all Intellectual Property necessary for the conduct of the business of Corlieve as currently conducted and contemplated to be conducted as of the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">To Corlieve&#8217;s Knowledge, the making, using or selling of the Corlieve Products and Corlieve&#8217;s operation of the business do not and have not infringe(d), misappropriate(d) or otherwise violate(d) the Intellectual Property rights of any Person, or constitute unfair competition or trade practices under the Laws of any jurisdiction. To Corlieve&#8217;s Knowledge, no Person is infringing, misappropriating or otherwise violating, &#160;or has infringed, misappropriated or otherwise violated, the Corlieve Intellectual Property, and Corlieve has not filed or threatened in writing any claims alleging</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">that a Third Party has infringed, misappropriated or otherwise violated any Corlieve Intellectual Property. No Third Party has filed or threatened to file any claims alleging that Corlieve has infringed, misappropriated or otherwise violated any Person&#8217;s Intellectual Property rights. Except in the Material Contracts, Corlieve has not given any indemnification, release or covenant to any Third Party against infringement, misappropriation or other violation of Intellectual Property related to &#160;Corlieve Products or Corlieve Intellectual Property. Except as set forth in Section 4.18(c) of the Disclosure Letter, Corlieve has not requested (whether or not received) any written opinion of patent or other intellectual property counsel and Corlieve has not been provided with any written of opinion of patent or other intellectual property counsel, that concerns infringement, validity or enforceability of any Person&#8217;s Intellectual Property &#160;rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">All of the items listed in Section&#160;4.18(a)&#160;of the Disclosure Letter are, except as otherwise indicated therein, owned solely and exclusively by Corlieve, or licensed solely and exclusively to Corlieve through sole and exclusive ownership of the respective licensor, or co-owned with Corlieve in accordance with the terms of the applicable Material Contracts, and are free and clear of all Encumbrances (other than co-ownership listed in Section 4.18(a) of the Disclosure Letter, the terms of the applicable Material Contracts, or Permitted Encumbrances). &#160; The issued Patents listed in Section&#160;4.18(a)&#160;of the Disclosure Letter are not the subject of any cancellation, opposition, nullity, reexamination proceeding or any other proceeding challenging their scope, validity, enforceability, ownership, or use. &#160;No opposition, extension of time to oppose, interference, rejection, or refusal (such rejection or other refusal only in the normal course of Patent prosecution prior to grant) to register has been filed in connection with any patent or patent application listed in Section&#160;4.18(a)&#160;of the Disclosure Letter. &#160;The issued Patents listed in Section&#160;4.18(a)&#160;of the Disclosure Letter are valid and enforceable, and the ownership of the entire right, title and interest therein of each owned or licensed item listed in Section&#160;4.18(a)&#160;of the Disclosure Letter is recorded or registered with the applicable Governmental Authority solely in the name of Corlieve or its licensor(s). All fees, Taxes, annuities and other payments associated with filing, prosecuting, issuing, recording, registering or maintaining any such Intellectual Property have been paid in full in a timely manner to the proper Governmental Authority. None of the Intellectual Property owned, co-owned, or licensed by Corlieve is subject of any order, decree or injunction of any Governmental Authority and Corlieve has not been subject to any order, decree or injunction of any Governmental Authority in respect of any other Person&#8217;s Intellectual Property. None of the Intellectual Property used by Corlieve is the subject of any order, decree or injunction of any Governmental Authority and Corlieve has not been subject to any order, decree or injunction of any Governmental Authority in respect of any other Person&#8217;s Intellectual Property. &#160;The items listed in Section&#160;4.18(a)&#160;of the Disclosure Letter as co-owned by Corlieve and another party, are either (i) exclusively licensed to Corlieve, or (ii) are subject to Corlieve&#8217;s exclusive option to be exclusively licensed to Corlieve under the terms of the applicable Material Contracts.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">None of the trade secrets or material confidential or proprietary information of Corlieve has been disclosed to any Person unless such disclosure was necessary and made pursuant to an appropriate confidentiality agreement and, to Corlieve&#8217;s Knowledge, there has not been any breach by any such Person of any such agreement. All Workers either (i) work in jurisdictions where their inventions are automatically assigned to Corlieve by operation of law, or (ii) have entered into a written agreement automatically assigning to Corlieve all rights to such contributions, which law or agreement includes a present-tense assignment of future inventions, discoveries, and data, copies of which have been provided to Purchaser prior to the Agreement Date. All Workers have entered into a written confidentiality agreement with Corlieve, copies of which have been provided to Purchaser prior to the Agreement Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">Except for any fees payable (i) to a Governmental Authority to issue, register or maintain any of the Intellectual Property listed in Section&#160;4.18(a)&#160;of the Disclosure Letter, (ii) as required by Applicable Law and (iii) the payments due under the Head Licenses, no payment of any kind is required to be made by Corlieve to any Person (including directors, officers, employees, consultants, contractors and agents of Corlieve and inventors of owned or licensed Corlieve Intellectual</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Property) for the ownership, license or use of any Corlieve Intellectual Property. Except for mandatory licenses listed in Section 4.18(f) of the Disclosure Letter, no Governmental Authority or other Third Party has any rights in the Corlieve Intellectual Property.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:11pt;">All data and personal information used or maintained by Corlieve has been collected, maintained,</font><b style="font-size:11pt;font-weight:bold;">&#160;</b><font style="font-size:11pt;">used and transferred in accordance with Corlieve&#8217;s applicable data protection and privacy principles and policies and in all material respects in accordance with Applicable Law. No Person has claimed any compensation from Corlieve for the loss of or unauthorized disclosure or transfer of personal data or information, and, to Corlieve&#8217;s Knowledge, no facts or circumstances exist that might give rise to such a claim.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><font style="font-size:11pt;">RGX had and continues to have the right to grant all rights and licenses it purported to grant to Corlieve in the RGX License Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">The French National Institute of Health and Medical Research (INSERM), Universite de Bordeaux, Aix-Marseille Universit&#233; and Centre National de Recherche Scientifique (CNRS), are the sole owners of the patent family claiming priority to patent filing [*], any foreign patent application corresponding thereto, and any divisional, additions, continuations, continuations in part, or re-examination application, as well as national or foreign equivalents, and each patent that issues or reissues from any of these patent applications.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(j)</font></font><font style="font-size:11pt;">Except as set forth in Section 4.18(j) of the Disclosure Letter, the inventions disclosed and claimed in the Corlieve Intellectual Property, (i) were not conceived, discovered, developed or otherwise made in connection with any research activities funded, in whole or in part, by any Governmental Authority, and (ii) no entity other than Corlieve and its licensors has any ownership, license or other interest in such inventions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(k)</font></font><font style="font-size:11pt;">To the Company&#8217;s Knowledge, the Licensed Know-How Schedule shall be true and accurate in all material respects as of the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.19</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transactions with Certain Persons</u><font style="font-size:11pt;">. Except for the Material Contracts or employment agreements of Corlieve, no officer, director, Seller, Free Share Holder or Affiliate of Corlieve or, to the Knowledge of Corlieve, any individual in such officer&#8217;s, director&#8217;s, Seller&#8217;s or Free Share Holder&#8217;s immediate family has or has had, either directly or indirectly, a material interest in: (i) any Person or entity which purchases from or sells, licenses or furnishes to Corlieve any material goods, property, technology, intellectual or other property rights, (ii) any Material Contract to which Corlieve is a party or by which it is bound or to which any of its properties or assets is subject, or (iii) any property used by Corlieve with a book value or market value in excess of [*]. To the Knowledge of Corlieve, no officer, director, Seller or Free Share Holder of Corlieve has a claim or cause of action against Corlieve or Purchaser.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.20</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Insurance</u><font style="font-size:11pt;">. Section&#160;4.20&#160;of the Disclosure Letter sets forth a complete and correct list of all insurance policies of Corlieve of any kind currently in force, including for each such policy the type of coverage, the name of the insureds, the insurer, the expiration date, and the amounts of coverage. True, correct and complete copies of such insurance policies have been provided or made available to Purchaser. All such insurance policies are in full force and effect and all premiums due thereunder have been paid. The insurance policies maintained by Corlieve insure Corlieve against such losses and risks (including risks related to clinical trials and product liability) and in such amounts as are prudent and customary in the business in which it is engaged and are sufficient for compliance in all material respects with all requirements of Applicable Law and of all Material Contracts. There is no claim pending under any such policies. Corlieve is not in Default under any material provision of any such insurance policy, and Corlieve has not taken any action or failed to take any action which, with notice or lapse of time, would constitute a Default under any material provision of any such insurance policy. Corlieve has not</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">received notice of an increase in premiums with respect to, or cancellation, nonrenewal or termination of, any such insurance policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.21</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Certain Business Practices</u><font style="font-size:11pt;">. To the Knowledge of Corlieve, none of the directors, officers, agents or employees of Corlieve or any of their Affiliates has, in each case in connection with Corlieve&#8217;s business, (i) used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses, including unlawful expenses related to political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to foreign or domestic political parties or campaigns, made any bribes or kickback payments or violated any provision of any Applicable Law, or (iii) made any payment to any customer or supplier of Corlieve, or given any other consideration to any such customer or supplier in respect of Corlieve&#8217;s business that violates any Applicable Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.22</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Brokers</u><font style="font-size:11pt;">. Neither Corlieve nor any of its officers, directors, employees or Affiliates has entered into any Contract with any broker, finder or similar agent or any Person which will result in an obligation of Purchaser, Corlieve, or any of their respective Affiliates to pay any finder&#8217;s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.23</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Regulatory Matters</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Corlieve has no Knowledge (and has not been notified by a Corlieve Partner) of any pending investigation, review, enforcement action or adverse regulatory action by any Regulatory Authority against Corlieve or any Person that manufactures or develops Corlieve Products pursuant to a development, contract research, manufacturing, supply or other collaboration arrangement with Corlieve (each, a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Corlieve Partner</u><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">All Corlieve Products are being and have been developed, manufactured, used, processed, packaged, labeled, stored and tested by or on behalf of Corlieve in compliance in all material respects with all applicable requirements under all Applicable Laws, including, as applicable, those requirements relating to the conduct of preclinical and clinical studies under the French National Agency for the Safety of Medicine and Health Products (&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ANSM</u><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">Neither Corlieve nor, to the Knowledge of Corlieve, any of its respective agents or subcontractors or the Corlieve Partners has been convicted of any crime or engaged in any conduct which could result in debarment or disqualification by any Regulatory Authority, and there are no Proceedings pending or threatened in writing that would reasonably be expected to result in criminal liability or debarment or disqualification by any Regulatory Authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">Corlieve, and to Corlieve&#8217;s Knowledge the Corlieve Partners, have not imported, exported, marketed, sold, offered for sale, or distributed any investigational drug substance or drug product except in compliance with all Applicable Laws. Corlieve has made available to Purchaser true, correct, complete and unredacted copies of all material data and information with respect to the Corlieve Products and any material correspondence to and from any Regulatory Authority, including each clinical trial application submitted to the ANSM, adverse event files and manufacturing records. All applications, notifications, submissions, information, claims, reports and statistics and other data that have been utilized, or prepared with the intention to be utilized, as the basis for or submitted in connection with any regulatory or marketing approvals or Permits from ANSM or any other Regulatory Authority relating to the Corlieve Products were true, complete and correct in all material respects as of the date of preparation and submission, as applicable, and any necessary or required updates, changes, corrections or modifications to such applications, submissions, information and data have been submitted to ANSM or other Regulatory Authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">Corlieve and, to Corlieve&#8217;s Knowledge, the Corlieve Partners have not received from any Regulatory Authority any (i) inspection reports, (ii) notices of adverse findings, warnings, untitled</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">letters, minutes of meetings, or (iii) other correspondence from any Regulatory Authority concerning the Corlieve Products in which any Regulatory Authority asserted that the operations of Corlieve may not be in compliance with Applicable Law or that the Corlieve Products may not be approvable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">Corlieve has not received written notice from any Corlieve Partner of any interruption of supply or manufacturing capacity, shortage of raw materials, components or other manufacturing problems that would have a material effect on the subsequent development (as such development is contemplated as of the Closing Date) of the Corlieve Products, nor do any conditions currently exist that reasonably could be expected to lead to such manufacturing problems.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:11pt;">Section&#160;4.23(g)&#160;of the Disclosure Letter sets forth a true and complete list of all authorizations, approvals, applications, clearances, consents, qualifications and other rights from any Regulatory Authority relating to the ability of Corlieve to research, develop and manufacture the Corlieve Products (&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Regulatory Authorizations</u><font style="font-size:11pt;">&#8221;) and there are no other Regulatory Authorizations required for the Corlieve Products in connection with the conduct of the Business as presently conducted. All such Regulatory Authorizations are (i) validly registered and on file with applicable Regulatory Authorities and (ii) in compliance with all formal filing and maintenance requirements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><font style="font-size:11pt;">The studies, tests and preclinical studies conducted by Corlieve and, to the Knowledge of Corlieve, the studies, tests and preclinical tests conducted on behalf of the Corlieve, were and, if still pending, are being conducted in all material respects in accordance with approved experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Applicable Laws, including, without limitation, the applicable regulations in France. Corlieve is not aware of any studies, tests or trials the results of which Corlieve believes reasonably call into question the study, test, or trial results when viewed in the context of the clinical state of development. Corlieve has not received any notices or other written correspondence from any Regulatory Authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of Corlieve.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.24</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Subsidies</u><font style="font-size:11pt;">. Section&#160;4.24&#160;of the Disclosure Letter sets forth a list of (i) all subsidies and/or grants granted to Corlieve by any Governmental Authority or any other Person and which are outstanding, (ii) all repayable or reimbursable subsidies and/or grants, whether outstanding or not, granted to Corlieve, including, without limitation, in the form of repayable advances, and (iii) all other subsidies and grants received by Corlieve since its incorporation (collectively the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Subsidies</u><font style="font-size:11pt;">&#8221;). Corlieve is not in breach of any of the terms and conditions governing the Subsidies and Corlieve and, other than the transactions contemplated hereunder, the Sellers have not undertaken to do anything that would result in the granting Governmental Authority or Person being entitled to claim for the repayment or reimbursement, in whole or in part, of any such Subsidies.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.25</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Books and Records</u><font style="font-size:11pt;">. Corlieve has made and kept (and made available to Purchaser) correct and complete, in all material respects, minute books and records and accounts, which, in reasonable detail, accurately and fairly summarize the material corporate activities of Corlieve. The minute books of Corlieve made available to Purchaser accurately and adequately reflect all action previously taken by the shareholders of Corlieve, the President of Corlieve, and the&#160;</font><i style="font-size:11pt;font-style:italic;">Comit&#233; de Supervision </i><font style="font-size:11pt;">(supervisory board) of Corlieve. All registration and publication formalities required to be carried out pursuant to Applicable Laws have duly and timely been carried out by Corlieve.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.26</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Bank Accounts</u><font style="font-size:11pt;">. Section&#160;4.26&#160;of the Disclosure Letter contains a true, correct and complete list of all bank accounts maintained by Corlieve, including each account number and the name and address of each bank and the name of each Person who has signature power with respect to each such account or power of attorney to act on behalf of Corlieve.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES OF PURCHASER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Purchaser represents and warrants to the Sellers that the following statements contained in this Article 5 are true and correct as of the Agreement Date and as of the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Organization and Standing</u><font style="font-size:11pt;">. Purchaser is a public company with limited liability under the laws of the Netherlands </font><i style="font-size:11pt;font-style:italic;">(naamloze vennootschap)</i><font style="font-size:11pt;">, validly existing and in good standing under the Laws of the Netherlands. &#160;Purchaser has all requisite corporate power and authority to execute and deliver this Agreement and the other Transaction Agreements, to consummate the transactions contemplated hereby and thereby and to perform its obligations hereunder and thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Authorization</u><font style="font-size:11pt;">. All proceedings required to be taken on the part of Purchaser to authorize Purchaser to enter into and carry out this Agreement and the other Transaction Agreements have been duly and properly taken. This Agreement has been, and each other Transaction Agreement will be, duly executed and delivered by Purchaser &#160;and is, or will be, the valid and binding obligation of Purchaser enforceable against &#160;Purchaser in accordance with its terms, except as enforcement may be limited by equitable principles limiting the right to obtain specific performance or other equitable remedies, or by applicable bankruptcy or insolvency Laws and related decisions affecting creditors&#8217; rights generally.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Compliance</u><font style="font-size:11pt;">. The execution and delivery of this Agreement and the other Transaction Agreements, and the consummation of the transactions contemplated hereby and thereby, will not:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">result in the breach of any of the terms or conditions of, or constitute a Default under or violate, as the case may be, the articles of association of Purchaser; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">violate any Law or Governmental Order applicable to Purchaser, or by which any of the properties or assets of Purchaser is bound, solely to the extent that such breach or violation would have a material adverse impact on Purchaser&#8217;s ability to consummate the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.4</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Milestone Shares</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">The Milestone Shares, if and when issued as contemplated herein, will be duly authorized, validly issued, fully paid, nonassessable, and free of preemptive rights and Encumbrances, except for restrictions on transfer imposed under applicable securities Laws. The issuance of such Milestone Shares does not contravene any Law or the rules and regulations of The NASDAQ Stock Market. Assuming the accuracy of the representations and warranties in&#160;Article 3, compliance by each Seller with the covenants in&#160;Article 7&#160;and the compliance by each Seller with his or her obligations set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.13</u><font style="font-size:11pt;">, the offer, issuance and sale of the Milestone Shares will be exempt from registration pursuant to Regulation S promulgated under the Securities Act and other applicable state securities Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.5</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Absence of Litigation</u><font style="font-size:11pt;">. There are no judicial, administrative or other governmental actions, proceedings or investigations pending or, to the Knowledge of Purchaser, threatened against Purchaser that question any of the transactions contemplated by, or the validity of, this Agreement which, if adversely determined, would materially impair the ability of Purchaser to enter into or perform</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">its obligations under this Agreement or materially delay, affect or prohibit the consummation of the transactions contemplated by this Agreement. Purchaser has not received any request from any governmental agency or instrumentality for information with respect to the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.6</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Approvals, etc.</u><font style="font-size:11pt;"> Except for the approval of the French Ministry of Economy, Finance and Recovery (</font><i style="font-size:11pt;font-style:italic;">Minist&#232;re de l&#8217;Economie, des Finances et de la Relance</i><font style="font-size:11pt;">), all consents, approvals, authorizations and orders (corporate, governmental or otherwise) necessary for the due authorization, execution and delivery by Purchaser of this Agreement and the other Transaction Agreements, the performance of Purchaser of any of its obligations hereunder and thereunder and the consummation of the transactions contemplated hereby and thereby will have been obtained as of the Closing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.7</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Funding</u><font style="font-size:11pt;">. Purchaser has and will have sufficient available funds on hand at Closing to pay the Closing Date Cash Consideration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.8</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Brokers</u><font style="font-size:11pt;">. Neither Purchaser nor any of its officers, directors or employees has entered into any Contract with any broker, finder or similar agent or any Person which will result in an obligation of the Sellers to pay any finder&#8217;s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.9</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">SEC Reports</u><font style="font-size:11pt;">. Purchaser has timely filed all reports, registration statements, proxy statements and other materials, together with any amendments required to be made with respect thereto, that it was required to file with the SEC since December 31, 2019, and all such reports, registration statements, proxy statements, other materials and amendments have complied in all material respects with all legal requirements relating thereto (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Public Documentation</u><font style="font-size:11pt;">&#8221;). None of the Public Documentation, as of its respective date, contained &#160;any untrue statement of a material fact or, when taken together, omitted to state a material fact necessary to make the statements therein in the light of the circumstances under which such statements were made, not misleading.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">COVENANTS AND AGREEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Public Disclosures</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Without the prior written consent of Purchaser, the Sellers shall not, and shall not authorize or permit Corlieve or any of their Representatives or Affiliates to, use Purchaser&#8217;s name or refer to Purchaser in a manner in which Purchaser&#8217;s identity is readily apparent in connection with Purchaser&#8217;s relationship with Corlieve, including in any media interview, advertisement, news release, press release or professional or trade publication, or in any print media, whether or not in response to an inquiry, unless otherwise required by Applicable Law. Notwithstanding anything herein to the contrary, (i) Purchaser and the Holder Representative shall mutually agree on the content of an initial press release announcing the entry into this Agreement and a subsequent press release on the Closing, and (ii) the Parties shall be entitled to use the content of such press releases and any other mutually approved press release in subsequent communication and public disclosure.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">Without limiting any other provision of this Agreement, except as otherwise contemplated by this Agreement, no Party shall make (or cause or permit any controlled Affiliate to make), directly or indirectly, any public announcement with respect to this Agreement and the transactions contemplated hereby without the consent of Purchaser and the Holder Representative, except as may be required by Applicable Law or the regulations of The NASDAQ Stock Market, in which case the party making such public announcement shall inform Purchaser or the Holder Representative, as applicable, promptly by written notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Confidentiality</u><font style="font-size:11pt;">. Purchaser and the Sellers each acknowledge that the information provided to it in connection with this Agreement and the transactions contemplated hereby is subject to the terms of the confidentiality agreement between Purchaser and Corlieve dated January 20, 2021 (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Confidentiality Agreement</u><font style="font-size:11pt;">&#8221;). Effective upon, and only upon, the Closing, Purchaser&#8217;s obligations under the Confidentiality Agreement shall terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Access to Information</u><font style="font-size:11pt;">. Prior to the Closing, the Sellers, within the limit of their respective powers within the Company as officer and/or shareholder, shall cause Corlieve to provide Purchaser, from time to time, with reasonable access to the offices, properties, appropriate officers, books and records of Corlieve (during regular business hours, upon reasonable advance notice, under reasonable circumstances, subject to restrictions under applicable Law and without undue disruption to the normal business activities of Corlieve). Purchaser and its Representatives shall cooperate with Corlieve and its Representatives and they shall use their reasonable efforts to minimize any disruption to the Business. Notwithstanding anything herein to the contrary, no such investigation or examination shall be permitted to the extent that it would require Corlieve or any of the Sellers to disclose information subject to attorney-client privilege.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.4</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conduct of the Business Pending the Closing</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conduct in the Ordinary Course of Business</u><font style="font-size:11pt;">. Prior to the Closing, except: (i) as required by applicable Law; (ii) as expressly contemplated by this Agreement; or (iii) with the prior written consent of Purchaser (which consent shall not be unreasonably withheld, delayed or conditioned), the Sellers, within the limit of their respective powers within the Company as officer and/or shareholder, shall cause Corlieve to conduct the Business in the Ordinary Course of Business and, to the extent consistent therewith, use reasonable efforts to preserve business relationships with suppliers and others with whom Corlieve deals with in connection with the conduct of the Business.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Restricted Conduct</u><font style="font-size:11pt;">. Prior to the Closing, except (i) as required by applicable Law, (ii) as expressly contemplated by this Agreement, (iii) proposed agreements set out on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Schedule&#160;6.4(a)</u><font style="font-size:11pt;">, or (iv) with the prior written consent of Purchaser (which consent shall not be unreasonably withheld, delayed or conditioned and shall be deemed granted in the absence of a response by Purchaser within [*] of Corlieve&#8217;s request), the Sellers, within the limit of their respective powers within the Company as officer and/or shareholder, &#160;shall cause Corlieve not to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">transfer, issue, sell or dispose of any shares in the capital, or other securities of, Corlieve or grant options, warrants, calls or other rights to purchase or otherwise acquire any shares in the capital, or other securities, of Corlieve;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">declare or pay any non-cash dividends on or make other non-cash distributions in respect of any of its share capital or other equity interests;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><font style="font-size:11pt;">effect any split, combination, capitalization or reclassification of any capital stock or any like change in the capitalization of Corlieve;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iv)</font></font><font style="font-size:11pt;">(A) increase the annual level of compensation payable or to become payable by Corlieve to any of their respective legal representatives, members of the </font><i style="font-size:11pt;font-style:italic;">Comit&#233; de Supervision </i><font style="font-size:11pt;">(supervisory board) or employees (other than any increase required by Applicable Laws or the terms of existing Contracts); (B) grant any bonus, benefit or other direct or indirect compensation to any legal representative, members of the </font><i style="font-size:11pt;font-style:italic;">Comit&#233; de Supervision </i><font style="font-size:11pt;">(supervisory board) or employee (other than Transaction Bonus) of Corlieve other than as contemplated by existing Contracts or materially amend any term of their employment Contract with Corlieve; or (C) hire any new employee;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(v)</font></font><font style="font-size:11pt;">incur, create, assume, guarantee or become liable for any Indebtedness other than (A) in the Ordinary Course of Business, (B) any draw under the Shareholder Loan, or (C) any loan made to Corlieve by Purchaser;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(vi)</font></font><font style="font-size:11pt;">subject any of the properties or assets (whether tangible or intangible) of Corlieve to any Encumbrance, except for Permitted Encumbrances;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(vii)</font></font><font style="font-size:11pt;">enter into, adopt, extend, renew or amend any collective bargaining agreement or other Contract with any labor organization, union or association;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(viii)</font></font><font style="font-size:11pt;">acquire or commit to acquire by merger or consolidation with, or merge or consolidate with, or purchase substantially all of the assets of, any corporation, partnership, association, joint venture or other business organization or division thereof, or acquire any material properties or assets (except for the acquisition of supplies in the Ordinary Course of Business);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ix)</font></font><font style="font-size:11pt;">sell, assign, license, sublicense, transfer, convey, lease, abandon, permit to lapse or otherwise dispose of any of the properties or assets material to the Business, including Corlieve Intellectual Property (except for the purpose of disposing of obsolete or worthless assets or in the Ordinary Course of Business);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(x)</font></font><font style="font-size:11pt;">cancel or compromise any material debt or claim owing to Corlieve;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xi)</font></font><font style="font-size:11pt;">enter into any Contract that restricts or limits the conduct or operations of the Business in any material respect;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xii)</font></font><font style="font-size:11pt;">adopt or enter into any plan of complete or partial liquidation, dissolution, restructuring or other reorganization, or file a petition in bankruptcy under any provisions of any bankruptcy or similar Law or consent to the filing of any bankruptcy petition against it under any bankruptcy or similar Law;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xiii)</font></font><font style="font-size:11pt;">make or rescind any material election relating to Taxes, settle or compromise any claim, action, suit, litigation, proceeding, arbitration, investigation, audit controversy relating to Taxes, or except as required by Applicable Law or French GAAP, make any change to any of its methods of reporting income or deductions for income Tax purposes from those employed in the preparation of Corlieve&#8217;s most recent Tax Return; enter into any closing agreement, settle or compromise any material claim or assessment, amend any Tax Return, file any Tax Return out of the ordinary course or in a manner that is not consistent with past practice and applicable law; or surrender any claim for a refund of material Taxes;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xiv)</font></font><font style="font-size:11pt;">fail to pay or discharge when due and payable any Liabilities;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xv)</font></font><font style="font-size:11pt;">change the accounting methods, principles or practices used by Corlieve to keep its books and records, except as required by French GAAP;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xvi)</font></font><font style="font-size:11pt;">extend, modify, terminate, cancel or renew, or waive a material right under, any Material Contract, except in the Ordinary Course of Business or pursuant to the terms of such Material Contract as of the date hereof;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xvii)</font></font><font style="font-size:11pt;">enter into any Contract which would qualify as a Material Contract;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xviii)</font></font><font style="font-size:11pt;">initiate, settle or compromise any litigation or other disputes (whether or not commenced prior to the date of this Agreement)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xix)</font></font><font style="font-size:11pt;">enter into or be a party to any transaction with any Seller or Free Share Holder other than in accordance with existing Contract or in the Ordinary Course of Business;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xx)</font></font><font style="font-size:11pt;">take any action inconsistent with this Agreement of the consummation of the transactions contemplated by this Agreement; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(xxi)</font></font><font style="font-size:11pt;">agree, whether in writing or otherwise, to do any of the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.5</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exclusivity</u><font style="font-size:11pt;">. From the Agreement Date until the earlier of the termination of this Agreement and the Closing, the Sellers will not, will cause Corlieve not to, and will use their reasonable efforts to cause their Representatives not to, directly or indirectly, facilitate or attempt to obtain or arrange for (i) any equity capital financing that would have the effect of any Person (other than the Purchaser or its Affiliates) acquiring equity interests (or rights convertible into equity interests) of Corlieve (other than as expressly contemplated herein), (ii) the merger, acquisition, consolidation, or recapitalization of Corlieve or (iii) a sale of the securities of Corlieve or a material portion of the assets of Corlieve, in each case to any third party (excluding Purchaser and its Affiliates) (each such transaction in the above subclauses (i), (ii) and (iii), an &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Alternative Transaction</u><font style="font-size:11pt;">&#8221;) or discuss or provide any other Person (other than Purchaser and its Affiliates and their respective Representatives) any information in connection with any such Alternative Transaction. In the event that Corlieve, its Representatives or any of its equityholders, including a Seller, receives, at any time between the date hereof and the Closing Date, a written notice or an inquiry from any Person (other than Purchaser and its Affiliates and their respective Representatives) regarding an Alternative Transaction, the Holder Representative will promptly notify Purchaser and provide such information regarding such Alternative Transaction as Purchaser reasonably requests.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.6</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Consents and Approvals</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Each of the parties agrees to use its reasonable efforts to take, or cause to be taken, all actions to file, or cause to be filed, all documents and to do, or cause to be done, all things necessary, proper or advisable to consummate the transactions contemplated by this Agreement, including preparing and filing as promptly as practicable all documentation to effect or obtain all necessary filings, consents, waivers, approvals, authorizations, permits, licenses or orders from all Governmental Authorities, including the French Ministry of Economy, Finance and Recovery (</font><i style="font-size:11pt;font-style:italic;">Minist&#232;re de l&#8217;Economie, des Finances et de la Relance</i><font style="font-size:11pt;">) as provided in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8.1(a)</u><font style="font-size:11pt;">, or any other third party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">With respect to the condition precedent set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8.1(a)</u><font style="font-size:11pt;">, Purchaser hereby undertakes:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">to make all necessary notifications and filings with the relevant Governmental Authorities with respect to the transactions contemplated herein in order to obtain the Foreign Investment Approval as soon as reasonably possible and in compliance with Applicable Laws. Purchaser shall further respond as soon as reasonably possible to any requests received from any relevant Governmental Authority for additional documents or information;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">to take all actions reasonably necessary under Applicable Law to obtain the Foreign Investment Approval. Notwithstanding the foregoing, if the competent Governmental Authority requests any material condition to the granting of the Foreign Investment Approval (other than, without limitation, any Acceptable Undertaking), such as Purchaser&#8217;s undertaking to divest, dispose of, or hold separate any of the businesses or assets of Corlieve or Purchaser and/or any of its Affiliates, then Purchaser &#160;shall not be required to comply with any condition, obligation or other requirement imposed or contained in any decision by such relevant Governmental Authority;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><font style="font-size:11pt;">to keep the Holder Representative regularly informed of the processing of the above filings and notifications in particular, if it becomes aware of any fact or event which could reasonably result in the Foreign Investment Approval being delayed or denied;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iv)</font></font><font style="font-size:11pt;">to provide the Holder Representative, as soon as reasonably practicable, with copies of all material relevant correspondence, documents or other communications received from or sent to the relevant Governmental Authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(v)</font></font><font style="font-size:11pt;">to give notice to the Holder Representative of the obtaining of the Foreign Investment Approval within [*] of becoming aware of the same.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">For the purposes of the covenant contained in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;6.6(b)</u><font style="font-size:11pt;">, the Sellers hereby undertake to provide, through the Holder Representative, and to cause Corlieve to provide, all assistance reasonably required by Purchaser in respect of the filings and notifications relating to the Foreign Investment Approval and any requests for information relating to Corlieve and/or the Sellers from the competent Governmental Authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">Further, and without limiting any other provision of this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;6.6</u><font style="font-size:11pt;">, each of the parties shall cooperate in all respects with each other in connection with any filing or submission and in connection with any investigation or other inquiry and shall promptly: (i) furnish on a confidential basis to the other such necessary information and reasonable assistance as the other parties may request in connection with the foregoing; (ii) inform the other of any communication from any Governmental Authority regarding transactions contemplated by this Agreement; and (iii) provide counsel for the other parties with copies of all filings made by such party, and all correspondence between such party (and its advisors) with any Governmental Authority and any other information supplied by such party and such party&#8217;s Affiliates to a Governmental Authority or received from a Governmental Authority in connection with the transactions contemplated by this Agreement;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">however</u><font style="font-size:11pt;">, that materials may be redacted as necessary to comply with contractual arrangements and with Applicable Law. Each party hereto shall, subject to Applicable Law, permit counsel for the other parties to review in advance, and consider in good faith the views of the other parties in connection with, any proposed written communication to any Governmental Authority in connection with the transactions contemplated by this Agreement. The parties agree not to participate, or to permit their Affiliates to participate, in any substantive meeting or discussion, either in person or by telephone, with any Governmental Authority in connection with the transactions contemplated hereby unless it consults with the other parties in advance and, to the extent not prohibited by such Governmental Authority, gives the other parties the opportunity to attend and participate. The parties further agree to execute or deliver any additional instruments necessary to consummate the transactions contemplated by, and to fully carry out the purposes of, this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.7</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Notification of Certain Matters</u><font style="font-size:11pt;">. During the period from the Agreement Date until the earlier of the Closing and the termination of this Agreement, each party hereto shall give prompt notice to the other parties hereto of (a) the occurrence of any event that would cause any representation or warranty of such party in this Agreement to be materially untrue or inaccurate at or prior to the Closing Date, (b) any material failure of such party to comply with or satisfy its covenants, conditions, agreements and other obligations in this Agreement, (c) in the case of Corlieve, the occurrence of an event that has had or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, or (d) in the case of Purchaser, the occurrence of an event that would reasonably be expected to have a material adverse effect on the ability of Purchaser to consummate the transactions contemplated by this Agreement. The Holder Representative shall have the right (but not the obligation) to provide updates to the Disclosure Letter (each a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Disclosure Notification</u><font style="font-size:11pt;">&#8221;) with respect to events, facts or circumstances (i) arising after the Agreement Date or (ii) that came to the Knowledge of Corlieve after the Agreement Date only for those representations and warranties that are qualified by any reference to the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Knowledge of the Sellers</u><font style="font-size:11pt;">&#8221;. Except for the delivery of an updated Capitalization Table that reflects any changes to the Capitalization Table arising between the Agreement Date and the Closing Date, no Disclosure Notification shall be deemed incorporated into or to supplement and amend the Disclosure Letter for purposes of determining whether the condition with respect to Purchaser&#8217;s obligations under the Agreement set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8.2(a)</u><font style="font-size:11pt;"> has been satisfied. Following the Closing, no claim for indemnification pursuant to&#160;Article 9 may be made by a Purchaser Indemnified Party with</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">respect to any matter included in a Disclosure Notification, any such claim being hereby irrevocably waived and released with respect to such matter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.8</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Waiver of Rights Under Shareholders Agreement</u><font style="font-size:11pt;">. The Sellers hereby agree to waive as from the Closing Date any rights under the Shareholders Agreement that may be exercisable in connection with the transactions contemplated by this Agreement, including any preemptive rights. The Sellers hereby agree that any exercise of any such preemptive rights shall be null and void and that Purchaser may seek to enjoin the exercise of such preemptive rights pursuant to the provisions of this Agreement, including </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.12</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.9</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Directed Selling Efforts</u><font style="font-size:11pt;">. Neither Purchaser nor any of its Affiliates nor any person acting on its or their behalf has engaged or will engage in any &#8220;directed selling efforts&#8221; (as defined in Regulation S) in connection with the offering of the Milestone Shares, and Purchaser has complied and will comply with the offering restrictions requirement of Regulation S.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.10</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Update to the Disclosure Letter</u><font style="font-size:11pt;">. No later than [*] before the Closing Date, Corlieve shall provide to the Seller an updated version of the Disclosure Letter, including possible facts and circumstances occurred after the date hereof, or with respect to representations and warranties qualified by Corlieve&#8217;s Knowledge, that came to the Knowledge of Corlieve after the Signing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.11</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Free Shares</u><font style="font-size:11pt;">. In the event that Closing has not occurred by July 22, 2021, [*] &#160;and Corlieve shall enter into agreements, prior to July 24, 2022 amending the vesting terms of certain Free Share awards on the terms mutually agreed among the Purchaser, [*] and Corlieve as of the date hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">POST-CLOSING COVENANTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transfer Taxes</u><font style="font-size:11pt;">. Transfer Taxes payable in connection with the consummation of the transactions contemplated hereby, if any, shall be borne and paid by the Purchaser.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Release by Sellers</u><font style="font-size:11pt;">. Effective as of the Closing, each Seller, on behalf of itself and its Subsidiaries and Affiliates and each of their respective directors, officers, shareholders, managers, members, partners, principals, employees, agents, Representatives, heirs, predecessors, successors and assigns (each, a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Seller Releasing Party</u><font style="font-size:11pt;">&#8221;), hereby (i) voluntarily and knowingly releases, remises, acquits and forever discharges Purchaser, Corlieve, any Person who controls (as such term is defined in Section&#160;15 of the Securities Act) any of the foregoing, and their respective directors, officers, shareholders, managers, members, partners, principals, employees, Affiliates, agents, Representatives, heirs, predecessors, successors and assigns from any and all Damages, whether known or unknown, certain or speculative, asserted or unasserted, that any Seller Releasing Party may have had prior to, or has as of, the Closing or that arise in the future based on events occurring prior to or as of the Closing, including with respect to any rights contained in the Shareholders Agreement and including with respect to any liquidation right or preference any Seller may be entitled to under the Bylaws (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Released Damages</u><font style="font-size:11pt;">&#8221;); (ii) expressly waives any defense that the release provided under this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7.2</u><font style="font-size:11pt;">&#160;does not extend to Damages such Seller Releasing Party did not know or suspect to exist on the Closing Date; (iii) represents and warrants that none of the Released Damages of such Seller Releasing Party has been sold, assigned or transferred to any other Person; and (iv) agrees and covenants not to commence or cause to be commenced any Proceeding seeking Damages or remedies of any kind based on, related to or arising from the Released Damages;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">however</u><font style="font-size:11pt;">, that the Released Damages do not include any Damages by any of the Seller Releasing Parties related to (a) the payment of the Total Consideration subject to the terms and conditions of this Agreement, (b) with respect to RGX, any of its rights contained in the RGX License Agreement or (c) subject to the terms and conditions of this Agreement, the enforcement of, or the exercise of any rights and remedies, if any, under any provisions of this</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Agreement, any exhibit to this Agreement or any document delivered in connection with this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Compliance with the Securities Act</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Each Seller agrees to resell the Milestone Shares received pursuant to the transactions contemplated by this Agreement only (i) in accordance with the provisions of Regulation S, (ii) pursuant to registration under the Securities Act or (iii) pursuant to an available exemption from registration under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">Each Seller agrees not to engage in hedging transactions with regard to the Milestone Shares unless such hedging transactions are made in compliance with the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.4</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Registration Rights with Respect to Milestone Shares</u><font style="font-size:11pt;">. If a Milestone Payment becomes due and Purchaser elects to make any portion of a Milestone Payment by issuing uniQure Ordinary Shares, Purchaser shall register such Milestone Shares for resale by the Sellers in accordance with the provisions of </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit C</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.5</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transfer of Milestone Shares</u><font style="font-size:11pt;">. Purchaser shall refuse to register any transfer of Milestone Shares not made (a) in accordance with the provisions of Regulation S, (b) pursuant to registration under the Securities Act, or (c) pursuant to an available exemption from registration under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.6</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing Statement</u><font style="font-size:11pt;">. &#160;The Sellers shall ensure that all information reasonably requested by the Purchaser and necessary for the accurate and complete preparation of the Closing Statement described in Section 2.4(b) is provided or made available to the Purchaser no later than [*] following Closing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.7</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Restrictive Covenants</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Non-Competition</u><font style="font-size:11pt;">. Each of the Founders hereby irrevocably agrees that, during the Restricted Period, he or she shall not, directly or indirectly, as a proprietor, partner, stockholder, director, executive, employee, consultant, independent contractor, joint venturer, member, investor, lender or otherwise:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">in the case of [*], carry out in North America, Europe, Japan or China any research or development activities intended to treat epilepsy by directly inhibiting the expression of the kainate receptor subunits named GluK2 and/or GluK5 (the &#8220;Restricted Field&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">hold any shares, or have any other financial interest, in any commercial enterprise (other than up to [*] of the share capital of publicly listed companies) engaged in the Restricted Field;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><font style="font-size:11pt;">employ or solicit any manager (</font><i style="font-size:11pt;font-style:italic;">dirigeant social</i><font style="font-size:11pt;">), employee, agent or contractor (with respect to the latter two categories, in a manner that would have a detrimental impact on their relationship as agent or contractor of the other Party) of Corlieve or the Purchaser or any of its affiliates or of the Company, without the prior written consent of the Purchaser; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iv)</font></font><font style="font-size:11pt;">participate in any research or development activities in the Restricted Field, other than pursuant to an agreement with Corlieve or the Purchaser.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exclusions</u><font style="font-size:11pt;">. Notwithstanding the foregoing, outside the Restricted Field, the Scientific Founders, acting as public agents, shall be entitled to conduct any research activities, including:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">any research and development activities to develop any approach to treat epilepsy which is not based on the Grik2 Gene Sequence; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">any research and development activities on the Grik2 Gene Sequence which are not aimed at treating epilepsy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Non-Solicitation</u><font style="font-size:11pt;">. Each of the Sellers (other than RGX), agrees that, during the Restricted Period, such Seller shall not (except on behalf of Purchaser, Corlieve or any of their Affiliates) knowingly, directly or indirectly, on his or her own behalf or on behalf of any other Person, solicit, employ or interfere with (or attempt to do any of the foregoing) any individual who either &#160;is employed by Purchaser, Corlieve or any of their Subsidiaries at the time of such solicitation, employment, interference or attempt thereof in a manner that conflict with his employment by Purchaser, Corlieve or any of their Subsidiaries.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Blue Pencil</u><font style="font-size:11pt;">. If for any reason any court of competent jurisdiction shall find any provisions of this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7.7</u><font style="font-size:11pt;">&#160;(including the defined terms used herein) unreasonable in duration or geographic scope or otherwise, it is the intention of the Parties that such restrictions and prohibitions shall be modified by the court to be effective to the fullest extent allowed under applicable law in such jurisdiction. Each Seller acknowledges that the territorial and time limitations set forth in this</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;7.6</u><font style="font-size:11pt;">&#160;(including the defined terms used herein) are reasonable and properly required for the adequate protection of the business of Purchaser and its Affiliates, and each Seller hereby waives, to the extent permitted by law, any and all right to contest the validity of any provision of this</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;7.6</u><font style="font-size:11pt;">&#160;(including the defined terms used herein) on the ground of breadth of its geographic or service coverage or length of term or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Future Employers; Third Party Beneficiaries</u><font style="font-size:11pt;">. Each of the Sellers (other than RGX) shall inform any future employer of the non-competition and non-solicitation restrictions to which he or she is subject and provide such employer with a copy thereof, prior to the commencement of that employment. Each Affiliate of Purchaser is an intended third party beneficiary of the non-competition and non-solicitation restrictions set forth in this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7.7</u><font style="font-size:11pt;"> (including the defined terms used herein) and may enforce the terms of this section as if it was a party hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.8</font></font><font style="font-size:11pt;">Within three (3) months after the Closing Date, the Purchaser may ask the assistance of &#160;[*] and the Scientific Founders to comprehensively identify the Know-How and to determine whether items of Know How provided by RGX as specifically identified in the Purchaser&#8217;s request are Licensed Background Know-How or Licensed Foreground Know-How pursuant to the RGX License.&#160; [*] and the Scientific Founders shall use reasonable efforts to respond to such request.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">CLOSING CONDITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conditions Precedent to the Obligations of Each Party</u><font style="font-size:11pt;">. The respective obligations of each party hereto to consummate the transactions contemplated by this Agreement shall be subject to the satisfaction at or prior to the Closing Date of the following conditions, any one of which may be waived on behalf of Purchaser by Purchaser or on behalf of the Sellers by the Holder Representative:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Foreign Investment Clearance</u><font style="font-size:11pt;">. The foreign investment notification has been made with the French Ministry of Economy, Finance and Recovery (</font><i style="font-size:11pt;font-style:italic;">Minist&#232;re de l&#8217;Economie, des Finances et de la Relance</i><font style="font-size:11pt;">) pursuant to articles L.151-3 and R.151-1 and seq</font><i style="font-size:11pt;font-style:italic;">.</i><font style="font-size:11pt;">&#160;of the French&#160;</font><i style="font-size:11pt;font-style:italic;">Code&#160;Mon&#233;taire et Financier</i><font style="font-size:11pt;">, and in relation to said notification, (i) the&#160;French Ministry of Economy, Finance and Recovery (</font><i style="font-size:11pt;font-style:italic;">Minist&#232;re de l&#8217;Economie, des Finances et de la Relance</i><font style="font-size:11pt;">) has provided notification that the transactions contemplated hereunder do not fall within its approval requirement pursuant to the above-mentioned legislation, (ii) the underlying approval has been granted or (iii) all appropriate waiting</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">periods (including any extensions thereof) have expired, lapsed or been waived (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Foreign Investment Approval</u><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Order</u><font style="font-size:11pt;">. Without prejudice to the Foreign Investment Approval, no Governmental Authority of any competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any statute, rule, regulation, executive order, decree, injunction or other Court Order which (i) is in effect and (ii) has the effect of otherwise prohibiting or preventing the consummation of the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conditions Precedent to the Obligations of Purchaser</u><font style="font-size:11pt;">. The obligation of Purchaser to effect the transactions contemplated by this Agreement shall be subject to the satisfaction at or prior to the Closing Date of the following conditions, any one of which may be waived in writing by Purchaser in its sole discretion:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Representations and Warranties</u><font style="font-size:11pt;">. The representations and warranties contained in</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;4.3</u><font style="font-size:11pt;">, as such representations and warranties may be updated by the delivery of an updated Capitalization Table pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;6.7</u><font style="font-size:11pt;">, shall be true and correct in all respects except for de minimis inaccuracies as of the Agreement Date and the Closing Date. Each of the other representations and warranties contained in&#160;Article 3 and&#160;Article 4 of this Agreement shall be true and correct in all material respects as of the Agreement Date and the Closing Date (except that those representations and warranties which address matters only as of a particular date or range of dates shall be limited to the date or range of dates so specified). For purposes of the condition contained in this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8.2(a)</u><font style="font-size:11pt;">, the references contained in any representation or warranty contained in&#160;Article 3 and&#160;Article 4 of this Agreement to &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Material Adverse Effect</u><font style="font-size:11pt;">,&#8221; &#8220;material,&#8221; &#8220;in all material respects&#8221; or other materiality qualifications (or correlative terms), including as expressed in accounting concepts, shall be disregarded.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Covenants</u><font style="font-size:11pt;">. The Sellers shall have performed or complied in all material respects with all agreements and covenants required by this Agreement and the other Transaction Agreements to be performed or complied with at or prior to the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Material Adverse Effect</u><font style="font-size:11pt;">. During the period from the Agreement Date until Closing, no Material Adverse Effect shall have occurred, and no event shall have occurred that, individually or in the aggregate, with or without notice or the lapse of time, would reasonably be expected to result in a Material Adverse Effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Equityholders</u><font style="font-size:11pt;">. The Sellers having signed the Agreement as at the Agreement Date shall hold Shares representing 100% of the issued and outstanding Ordinary Shares of Corlieve and all said Sellers shall be effectively represented at Closing and transfer their Shares in accordance with this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">Exercise of the options under the Collaboration Agreements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">Delivery by the Holder Representative of an updated </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 2.7</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conditions Precedent to the Obligations of the Sellers</u><font style="font-size:11pt;">. The obligations of the Sellers to consummate the transactions contemplated by this Agreement are subject to the fulfillment prior to or at the Closing Date of each of the following conditions, any one or more of which may be waived in writing by the Holder Representative in its sole discretion:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Representations and Warranties</u><font style="font-size:11pt;">. Each of the representations and warranties of Purchaser contained in&#160;Article 5&#160;of this Agreement (i) that is qualified by any reference to &#8220;material,&#8221; &#8220;in all material respects&#8221; or other materiality qualifications (or correlative terms) shall be true and correct in all respects as of the Agreement Date and the Closing Date and (ii) that is not so qualified is</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><font style="font-size:11pt;">true and correct in all material respects as of the Agreement Date and the Closing Date (except that those representations and warranties which address matters only as of a particular date or range of dates shall be limited to the date or range of dates so specified).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Covenants</u><font style="font-size:11pt;">. Purchaser shall have performed or complied in all material respects with all agreements and covenants required by this Agreement and the other Transaction Agreements to be performed or complied with by it on or prior to the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Material Adverse Effect</u><font style="font-size:11pt;">. During the period from the Agreement Date until Closing, no event has occurred that would reasonably be expected to have a material adverse effect on the ability of Purchaser to consummate the transactions contemplated by this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.4</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Shareholder Meeting</u><font style="font-size:11pt;">. One or more shareholders&#8217; meetings of Corlieve shall be held immediately prior to the Closing Date (subject to the condition precedent of Closing) or immediately after the Closing Date in order to (i) issue the Shares corresponding to the Loan Conversion, (ii) acknowledge the resignation of the members of the </font><i style="font-size:11pt;font-style:italic;">Comit&#233; de Supervision </i><font style="font-size:11pt;">(supervisory board) and of the President and (ii) appoint a new President and, at Purchaser&#8217;s option, new members of the </font><i style="font-size:11pt;font-style:italic;">Comit&#233; de Supervision </i><font style="font-size:11pt;">(supervisory board).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-size:11pt;font-weight:bold;">INDEMNIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Survival</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">All covenants and agreements contained in this Agreement that by their nature are required to be performed by the Sellers by or prior to Closing shall expire and will no longer be required to be performed as of the Closing Date;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, that Purchaser may make a claim with respect to such covenants for a period of twelve (12) months following the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">All covenants contained in this Agreement that by their nature are required to be performed after Closing by any Party hereto shall survive according to their respective terms.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">The representations and warranties contained in this Agreement (other than the Fundamental Representations and the Specified Representations) shall survive the Closing and continue in full force and effect for the twelve (12) month period immediately following the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">The Fundamental Representations shall survive the Closing and continue in full force and effect indefinitely.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">The Specified Representations shall survive the Closing and continue in full force and effect for a period of three (3) years thereafter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">Any claim based on fraud or intentional misrepresentation shall survive the Closing and continue in full force and effect indefinitely.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:11pt;">Immediately following the last day of each such survival period (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Survival End Date</u><font style="font-size:11pt;">&#8221;), such representations and warranties shall expire automatically. If written notice of a claim has been given in accordance with </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.3</u><font style="font-size:11pt;">&#160;prior to the expiration of the applicable representations, warranties, covenants or agreements, then the applicable representations, warranties, covenants or agreements shall survive as to such claim, until such claim has been finally resolved. Following the expiration of a representation, warranty, covenant or agreement, no claim, action, suit or Proceeding may be initiated by any Purchaser Indemnified Party or Seller Indemnified Party with respect thereto, regardless of any statute of limitations period that would otherwise apply. For the avoidance of doubt, if the Closing does not occur as a result of any condition precedent not being satisfied or waived, none</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">of the Sellers or Purchaser shall have any Liability whatsoever, including for breach of covenant or otherwise, except with respect to its breach of the obligations surviving termination of this Agreement as set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;10.3</u><font style="font-size:11pt;">&#160;or for its fraud or willful breach of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Indemnification</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Following and subject to the occurrence of the Closing, subject to the limitations described in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.1</u><font style="font-size:11pt;">&#160;and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.5</u><font style="font-size:11pt;">, each Seller shall, severally but not jointly (</font><i style="font-size:11pt;font-style:italic;">sans solidarit&#233;</i><font style="font-size:11pt;">), indemnify, defend, and hold harmless each of Purchaser and its Affiliates, their respective directors, officers and employees, and their respective heirs, successors and assigns (each, a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Purchaser Indemnified Party</u><font style="font-size:11pt;">&#8221; and, collectively, the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Purchaser Indemnified Parties</u><font style="font-size:11pt;">&#8221;), subject to the provisions of this&#160;Article 9, from and against any and all losses, costs, reasonable expenses, claims, damages, actions, suits, proceedings, hearings, investigations, charges, complaints, demands, injunctions, judgments, orders, decrees, rulings, directions, fines, deficiencies, amounts paid in settlement, Liabilities, Taxes, liens, and fees and court costs, including interest, penalties, and reasonable attorneys&#8217;, consultants&#8217; and other professional fees and disbursements and reasonable expenses of investigation and enforcement of rights under this Agreement (collectively, &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Damages</u><font style="font-size:11pt;">&#8221;) incurred by such Purchaser Indemnified Party that arise out of or result from:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">any breach of any representation or warranty contained in&#160;Article 4&#160;of this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">any breach of any covenant or obligation in this Agreement that the Sellers are to cause Corlieve to perform at or prior to the Closing;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><font style="font-size:11pt;">any breach of any covenant or obligation in this Agreement to be performed by the Holder Representative;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(iv)</font></font><font style="font-size:11pt;">any inaccuracies in the Closing Date Allocation Schedule; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(v)</font></font><font style="font-size:11pt;">any error by the Paying Agent in executing its responsibilities under the Paying Agent Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">With respect to Damages referred to in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(a)</u><font style="font-size:11pt;">, each Seller shall only be liable for the portion of such Damages corresponding to its Pro Rata Share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">Following and subject to the occurrence of the Closing, subject to the limitations described in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.1</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.5</u><font style="font-size:11pt;">, each Seller, severally and not jointly (</font><i style="font-size:11pt;font-style:italic;">sans solidarit&#233;</i><font style="font-size:11pt;">), shall indemnify, defend, and hold harmless the Purchaser Indemnified Parties from and against any and all Damages incurred by such Purchaser Indemnified Party that arise out of or relate to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">any breach of any representation or warranty of such Seller contained in&#160;Article 3 of this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">any breach of any covenant or obligation in this Agreement to be performed by such Seller.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">With respect to Damages referred to in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 9.2(b)</u><font style="font-size:11pt;">, only the relevant breaching Seller shall be liable&#160;for the full amount of the relevant Damages and the other Sellers shall not be liable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">Following and subject to the occurrence of the Closing, subject to the limitations described in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.1</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.5</u><font style="font-size:11pt;">, Purchaser shall indemnify, defend, and hold harmless the Sellers and each of their respective heirs and Affiliates (each, an &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Seller Indemnified Party</u><font style="font-size:11pt;">&#8221; and, collectively, the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Seller Indemnified Parties</u><font style="font-size:11pt;">,&#8221; and, collectively with the Purchaser Indemnified Parties,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Covered Parties</u><font style="font-size:11pt;">,&#8221; and each, a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Covered Party</u><font style="font-size:11pt;">&#8221;) from and against any and all Damages incurred by such Seller Indemnified Party that arise out of or relate to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">any breach of any representation or warranty made by Purchaser in&#160;Article 5 of this Agreement or in any other Transaction Agreement; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:11pt;">any breach of any covenant or obligation in this Agreement to be performed by Purchaser.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">For the avoidance of doubt, neither Party shall be liable under this Agreement and any Transaction Agreement in respect of any loss of profit, loss of revenue, loss of contract, loss of goodwill, loss of claim, indirect Damages, punitive Damages or consequential Damages, except to the extent such Damages are payable to a Third Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Notice of Claims</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Any Covered Party seeking indemnification hereunder shall, no later than [*] upon becoming aware of a potential claim for indemnification and in all cases prior to the relevant Survival End Date, give to Purchaser, in the case of a Seller Indemnified Party, or to the Holder Representative, in the case of a Purchaser Indemnified Party, (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Indemnifying Party</u><font style="font-size:11pt;">&#8221;) a bona fide notice describing in reasonable detail the facts giving rise to any claims for indemnification hereunder, together with an good faith estimate of the claimed amount and all supporting documents (a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Claim Notice</u><font style="font-size:11pt;">&#8221;);&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, that failure to give such notice in accordance with the requirements of this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 9.3(a)</u><font style="font-size:11pt;"> shall not affect such Covered Party&#8217;s right to indemnification hereunder except to the extent the Indemnifying Party shall have been materially prejudiced by such failure, in which case Sellers shall not be liable under this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Article 9</u><font style="font-size:11pt;"> for the portion of the relevant Damage resulting from such failure.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">Each Indemnifying Party to whom a Claim Notice is given shall respond to any Covered Party that has given a Claim Notice (a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Claim Response</u><font style="font-size:11pt;">&#8221;) within [*] (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Response Period</u><font style="font-size:11pt;">&#8221;) after the date that the Claim Notice is given. Any Claim Response must either (i) agree to the amount or method of determination set forth in the Claim Notice and to pay such amount to (or on behalf of) such Covered Party by wire transfer of immediately available funds (or release of all or a portion of the Escrowed Amount to a Purchaser Indemnified Party) or (ii) to provide such Covered Party with notice that they disagree with the amount or method of determination set forth in the Claim Notice. If any Indemnifying Party fails to give a Claim Response within the Response Period, such Indemnifying Party shall be deemed not to dispute the claim described in the related Claims Notice. If any Indemnifying Party elects not to dispute a claim described in a Claims Notice, whether by failing to give a timely Claim Response or otherwise, then the amount of such claim shall be conclusively deemed to be an obligation of such Indemnifying Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">If an Indemnifying Party delivers a Claim Response disputing the claim of indemnification, the Covered Party that has given the Claim Notice and the Indemnifying Party shall attempt in good faith for a period of [*]</font><b style="font-size:11pt;font-weight:bold;">&#160;</b><font style="font-size:11pt;">after receipt of the Claim Response to resolve such objection. If the Indemnifying Party and the Covered Party shall so agree, a memorandum setting forth such agreement shall be prepared and signed by both parties, and shall be binding and conclusive upon the Indemnifying Party and the Covered Party. If no such agreement can be reached during the 30-day period for good faith negotiation, then upon the expiration of such 30-day period, either the Indemnifying Party or the Covered Party may bring suit in accordance with </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.10</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">Subject to the terms of the Escrow Agreement, if, pursuant to the procedures described in this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.3</u><font style="font-size:11pt;">, an Indemnifying Party is determined to be obligated to indemnify a Covered Party hereunder, the Indemnifying Party shall pay (or cause to be paid) to such Covered Party the amount to which such Covered Party shall be entitled within [*] after such amount has been finally determined in accordance with this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.3</u><font style="font-size:11pt;">. Subject to the provisions of this&#160;Article 9, the Purchaser Indemnified</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Parties shall recover the amount of any Damages first from the Escrow Account, in which case Purchaser and the Holder Representative shall jointly instruct the Escrow Agent to distribute from the Escrow Account an amount of cash equal to the amount of any such Damages .</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.4</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Third&#160;Party&#160;Claims</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">If a Covered Party receives written notice of a claim from a Third Party that such Covered Party believes may result in a claim for indemnification under this&#160;Article 9 (a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Third Party Claim</u><font style="font-size:11pt;">&#8221;), such Covered Party shall deliver a Claim Notice to the Indemnifying Party in accordance with the provisions of </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.3</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">So long as the Litigation Conditions are satisfied, the Indemnifying Party shall have the right to assume and control the defense of the Third Party Claim, at its own expense with counsel selected by it and reasonably acceptable to the Covered Party, by delivering written notice of its assumption of such defense to the Covered Party within [*] of its receipt of a Claim Notice of such Third Party Claim;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">however</u><font style="font-size:11pt;">, that the Covered Party shall have the right to retain its own counsel and assume and control the defense of such Third Party Claim, with the reasonable fees and expenses to be paid by the Indemnifying Party, if (i) the Covered Party receives advice from outside counsel that (A) representation of the Covered Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or reasonably anticipated potential conflicts of interests between such Covered Party and the Indemnifying Party or (B) there may be legal defenses or counterclaims available to the Covered Party that are inconsistent with, different from or in addition to those available to the Indemnifying Party, or (ii) at any time the Litigation Conditions are not satisfied with respect to such Third Party Claim. If the Indemnifying Party assumes and controls the defense of such Third Party Claim, the Indemnifying Party shall keep the Covered Party reasonably apprised of the status of the Third Party Claim (including by providing copies of all pleadings, notices and communications with respect to the Third Party Claim to the extent that receipt of such documents does not affect attorney-client privilege) and the Covered Party shall be entitled to participate in, but not determine or conduct, the defense of, and/or any settlement negotiations with respect to, such Third Party Claim at its sole cost and expense.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">If the Litigation Conditions are not satisfied, or if the Indemnifying Party does not assume the defense of the Third Party Claim as described in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.4(b)</u><font style="font-size:11pt;">, the Covered Party shall assume and control the defense of such Third Party Claim at the expense of the Indemnifying Party and shall not settle or compromise the Third Party Claim without the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld, conditioned or delayed. If the Covered Party assumes and controls the defense of such Third Party Claim, the Covered Party shall keep the Indemnifying Party reasonably apprised of the status of the Third Party Claim (including by providing copies of all pleadings, notices and communications with respect to the Third Party Claim to the extent that receipt of such documents does not affect attorney-client privilege) and the Indemnifying Party shall be entitled to participate in, but not determine or conduct, the defense of, and/or any settlement negotiations with respect to, such Third Party Claim at its sole cost and expense.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">If the Indemnifying Party has assumed and controls the defense of the Third Party Claim in accordance with </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.4(b)</u><font style="font-size:11pt;">, then (i) the Covered Party shall not settle or compromise the Third Party Claim without the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld, conditioned or delayed and (ii) the Indemnifying Party shall not (A) settle or compromise the Third Party Claim or consent to the entry of any judgment which does not include an unconditional written release by the claimant or plaintiff of the Covered Party from all Liability in respect of such Third Party Claim, or (B) settle or compromise the Third Party Claim if the settlement imposes equitable remedies or material obligations on the Covered Party other than financial obligations for which such Covered Party will be indemnified hereunder, in each case, without the prior written consent of the Covered Party. In each case, the party that is not controlling the defense of the Third Party Claim shall reasonably cooperate with the party that is controlling the defense of such Third Party</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Claim, at the non-controlling party&#8217;s expense, and shall make available to the controlling party all pertinent information under the control of the non-controlling party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.5</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Limitation on Indemnity</u><font style="font-size:11pt;">. Notwithstanding anything to the contrary contained in this Agreement:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">No amount payable by either Purchaser or the Sellers pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(a)(i)</u><font style="font-size:11pt;">,</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;9.2(b)(i)</u><font style="font-size:11pt;">&#160;or </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(c)(i)</u><font style="font-size:11pt;">&#160;shall become due until and unless the Damages in respect of any individual claim or series of related claims exceeds [*] (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">De Minimis Amount</u><font style="font-size:11pt;">&#8221;);&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">however</u><font style="font-size:11pt;">, that any series of related claims shall be considered as one single claim for the purposes of the De Minimis Amount; and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">further</u><font style="font-size:11pt;">, that the De Minimis Amount shall not apply to breaches of Fundamental Representations or with respect to fraud or intentional misrepresentation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">No amount payable by either Purchaser or the Sellers pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;&#160;9.2(a)(i)</u><font style="font-size:11pt;">,</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;9.2(b)(i)</u><font style="font-size:11pt;">&#160;or </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(c)(i)</u><font style="font-size:11pt;"> shall become due until and unless the aggregate amount of all Damages shall exceed [*] (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Threshold</u><font style="font-size:11pt;">&#8221;), whereupon Purchaser or the Sellers, as applicable, shall be liable for the relevant Damages from the first Euro, </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided however</u><font style="font-size:11pt;">, that the Threshold shall not apply to breaches of Fundamental Representations or with respect to fraud or intentional misrepresentation. In calculating whether the Threshold has been exceeded, only individual claims or series of related claims in excess of the De Minimis Amount shall be considered.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">Subject to the remainder of this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">subparagraph (c)</u><font style="font-size:11pt;">, the maximum aggregate amount of Damages for which indemnity may be recovered by the Purchaser Indemnified Parties from the Sellers pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(a)(i)</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(b)(i)</u><font style="font-size:11pt;">&#160;shall be an amount equal to the Escrowed Amount (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Cap</u><font style="font-size:11pt;">&#8221;). The Cap shall not apply to any claim by any Purchaser Indemnified Party against the Sellers pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(a)(i)</u><font style="font-size:11pt;"> through&#160;9.2(a)(v) or</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;9.2(b)(i)</u><font style="font-size:11pt;">&#160;or&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(b)(ii)</u><font style="font-size:11pt;">, for breaches of Fundamental Representations, or with respect to fraud or intentional misrepresentation. Notwithstanding the foregoing, no Seller shall be liable for Damages pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(a)(i)</u><font style="font-size:11pt;"> through&#160;9.2(a)(v) or</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;9.2(b)(i)</u><font style="font-size:11pt;">&#160;or&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(b)(ii)</u><font style="font-size:11pt;"> or for breaches of Fundamental Representations in an amount in excess of the Total Consideration which such Seller has actually received hereunder (subject to the right of Purchaser under </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.10</u><font style="font-size:11pt;">&#160;to set-off from part of the future Milestone Payments due to such Seller any Damages referred to in said </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;&#160;2.10</u><font style="font-size:11pt;"> that a Purchaser Indemnified Party would be entitled to from such Seller but for this limitation). Further, notwithstanding the foregoing, the Cap shall not apply to any claim by any Purchaser Indemnified Party against the Sellers for breaches of Specified Representations; </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided, however</u><font style="font-size:11pt;">, that the only recourse of the Purchaser in respect of the amount of any such Damages in excess of the Cap shall be the right of Purchaser under </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;&#160;2.10</u><font style="font-size:11pt;">&#160;to set-off from part of the future Milestone Payments due to such Seller any Damages referred to in said </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;&#160;2.10</u><font style="font-size:11pt;"> that a Purchaser Indemnified Party would be entitled to from such Seller in respect of such breach, up to a maximum amount equal to [*] of the total Milestone Payments potentially payable hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">The maximum aggregate amount of Damages for which indemnity may be recovered by the Seller Indemnified Parties from Purchaser pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(c)(i)</u><font style="font-size:11pt;">&#160;shall be an amount equal to the Escrowed Amount; provided, however, that this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.5(d)</u><font style="font-size:11pt;">&#160;shall not limit in any way Purchaser&#8217;s obligation to pay the Sellers the Closing Date Consideration, the Milestone Payments. Purchaser shall not be liable for Damages pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(c)(ii)</u><font style="font-size:11pt;">&#160;in an amount in excess of the Total Consideration Purchaser has actually paid hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">The right to indemnification or other remedy based on the representations, warranties, covenants, obligations and agreements herein will not be affected or deemed waived by reason of any investigation or audit made by or on behalf of any party (including by any of its Representatives) or by reason of the fact that such party or any of its Representatives knew or should have known that any such representation or warranty is, was or might be inaccurate, except when set forth in the Disclosure Letter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">To the extent permitted by Applicable Law, any payment made by an Indemnifying Party to a Covered Party pursuant to this&#160;Article 9 shall be treated on the Parties&#8217; Tax Returns and otherwise as an adjustment to the Total Consideration for all Tax purposes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:11pt;">For purposes of calculating the amount of Damages incurred out of or relating to any breach of a representation or warranty contained in&#160;Article 3, Article 4 or any Transaction Agreement delivered by any Seller or the Holder Representative, the references to &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Material Adverse Effect</u><font style="font-size:11pt;">,&#8221; &#8220;material,&#8221; &#8220;in all material respects&#8221; or other materiality qualifications (or correlative terms), including as expressed in accounting concepts, shall be disregarded.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><font style="font-size:11pt;">No Seller shall have, exercise or assert (or attempt to exercise or assert), any right of contribution, right of indemnity or other right or remedy against Purchaser or Corlieve, or any of their respective directors, officers, employees, Affiliates, agents, attorneys, Representatives, assigns or successors, for any indemnification claims asserted by any Purchaser Indemnified Parties in connection with any indemnification obligation or any other Liability to which such Seller may become subject under or in connection with this Agreement, it being acknowledged that the representations, warranties, covenants and agreements of the Sellers are solely for the benefit of the Purchaser Indemnified Parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.6</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Sole Remedies</u><font style="font-size:11pt;">. Subject to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.5</u><font style="font-size:11pt;">, if the Sellers shall be obligated to indemnify the Purchaser Indemnified Parties with respect to a claim for Damages pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(a)(i)</u><font style="font-size:11pt;">, recovery and payment therefor shall be made first from the Escrowed Amount and then, to the extent that the then-remaining Escrowed Amount is insufficient to fully indemnify the Purchaser Indemnified Parties for such Damages, the Purchaser Indemnified Parties shall have the right to &#160;set-off such Damages from part of the future Milestone Payments pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.10</u><font style="font-size:11pt;">. For the avoidance of doubt, the Purchaser shall have no right to seek recovery and payment of Damages directly against the Sellers, except in respect of Damages described in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 9.2(b)</u><font style="font-size:11pt;"> or for breaches of Fundamental Representations by each relevant Seller.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.7</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Treatment of Insurance</u><font style="font-size:11pt;">. With respect to each claim for indemnification, any Damages that may be recovered by the Covered Party with respect to such claim shall be net of any insurance proceeds actually received with respect thereto (net of the out-of-pocket costs reasonably incurred in pursuing or obtaining such insurance proceeds, deductibles and any increased premium amounts directly attributable to such claim). To the extent that insurance proceeds are actually collected after an indemnification claim has been settled, the Covered Party shall restore the Indemnifying Party to the same economic position as would have existed had such insurance proceeds been collected prior to the settlement of such indemnification claim (net of the out-of-pocket costs reasonably incurred in pursuing or obtaining such insurance proceeds, deductibles and any increased premium amounts directly attributable to such claim).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.8</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Tax reassessment</u><font style="font-size:11pt;">. The Sellers shall not be liable under Article 9 in respect of any breach of the Sellers&#8217; representations contained in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 4.10</u><font style="font-size:11pt;"> until such breach has resulted in (i) an enforceable decision (&#8220;</font><i style="font-size:11pt;font-style:italic;text-decoration:underline;text-decoration-color:#000000;">titre ex&#233;cutoire</i><i style="font-size:11pt;font-style:italic;">&#8221;</i><font style="font-size:11pt;">) of the competent Tax Authority, or a competent court delivered against Corlieve, or (ii) a settlement agreement entered into between Corlieve and the Tax Authority, provided, however, that this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 9.8</u><font style="font-size:11pt;"> shall not have the effect of preventing the Purchaser from validly making a claim in respect of any Sellers&#8217; representations contained in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 4.10</u><font style="font-size:11pt;"> within (where applicable) the respective time limits specified in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.1</u><font style="font-size:11pt;">, even though no such enforceable decision or settlement agreement is provided for yet.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.9</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Tax Benefit</u><font style="font-size:11pt;">. To the extent a Damage gives rise to a Tax benefit or saving in the form of an actual and effective reduction in the corporate tax paid by Corlieve or Purchaser with respect to the tax year during which such Damage is recorded in the accounts of Corlieve (including, without limitation, a Tax reduction or loss, basis adjustment and/or shifting income, deductions, gains, loss and/or credits but to the exclusion of any increase in the amount of available tax losses carried forward or carried back), the amount of the Damage shall be reduced by the amount of such actual and effective</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">reduction. In determining the amount of such Tax benefit or saving during the fiscal year in which the loss is recorded in the accounts of Corlieve, the impact of any allowance or cancellation of reserves by Corlieve shall be neutralized.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.10</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Tax exclusions</u><font style="font-size:11pt;">. The consequences from any Tax reassessment whose effect would merely be a shift of Tax from a fiscal year to the following fiscal year shall not be taken into account except for any interest or penalties resulting therefrom. The consequences from any increased liability to value added Tax will not be taken into account, except for any interest or penalties resulting therefrom, where such value added Tax can be (from a Tax and commercial perspective) deducted or recovered from third parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.11</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Reserves</u><font style="font-size:11pt;">. The amount of the indemnification/price reduction obligation of the Sellers with respect to any Damage shall be reduced by the amount of the reserves included in the Financial Statements to the extent such reserves are directly and specifically related to such Damage.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.12</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Changes in Laws</u><font style="font-size:11pt;">. The Sellers shall not be held liable for Damages directly and exclusively arising (i) from changes in Laws applicable to the operations of Corlieve not in force on or prior to the Closing Date, (ii) post-Closing reorganizations, or (iii) changes in accounting policies or procedures of Corlieve, Purchaser or its Affiliates applied after the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.13</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Duty to Mitigate</u><font style="font-size:11pt;">. Each Covered Party shall be responsible for taking or causing to be taken all commercially reasonable steps to mitigate its Damages upon and after becoming aware of any event or condition that could reasonably be expected to give rise to any Damages that are indemnifiable under this&#160;Article 9.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.14</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Remedies</u><font style="font-size:11pt;">. The remedies in this&#160;Article 9 shall be the sole and exclusive remedies of the Parties with respect to any breach of the respective representations, warranties, covenants, obligations and agreements pursuant to this Agreement or otherwise arising out of this Agreement, regardless of the theory or cause of action pled, except for the remedies of specific performance, injunction and other similar equitable relief;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">however</u><font style="font-size:11pt;">, that no party shall be deemed to have waived any rights, claims, causes of action or remedies, and the limitations set forth in</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;9.5</u><font style="font-size:11pt;">&#160;shall not limit any recovery related thereto, if and to the extent fraud or intentional misrepresentation is proven on the part of a party by another party or such rights, claims, causes of action or remedies may not be waived under Applicable Law;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">further</u><font style="font-size:11pt;">, that in the event fraud or intentional misrepresentation is proven, each Seller shall be liable for Damages under </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.2(b)</u><font style="font-size:11pt;">&#160;in excess of the Cap only to the extent such Damages arise out of such fraud or intentional misrepresentation committed by such Seller.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.15</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Duplication</u><font style="font-size:11pt;">. Any liability for indemnification hereunder shall be calculated without duplication by reason of the same set of facts giving rise to such liability constituting a breach of more than one representation, warranty, covenant, obligation or agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 10</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">TERMINATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">10.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Termination</u><font style="font-size:11pt;">. This Agreement may be terminated at any time prior to the Closing Date:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">by mutual written consent of Purchaser and the Holder Representative;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">by either Purchaser or the Holder Representative upon written notice if the Closing shall not have occurred on or before October 30, 2021 (the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Outside Date</u><font style="font-size:11pt;">&#8221;);&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">however</u><font style="font-size:11pt;">, that the right to terminate this Agreement under this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;10.1(b)</u><font style="font-size:11pt;">&#160;shall not be available to any party</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">whose breach of any covenant or agreement hereunder caused, or resulted in, the failure of the Closing to occur on or before the Outside Date;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">by Purchaser, if (i) there is a breach of any representation, warranty, covenant or obligation of the Sellers such that the conditions set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8.1(a)</u><font style="font-size:11pt;">&#160;or </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8.1(b)</u><font style="font-size:11pt;">&#160;would not be satisfied; (ii) Purchaser shall have delivered to the Holder Representative a written notice of such breach; and (iii) at least [*] shall have elapsed since the delivery of such notice without such breach being cured;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">however</u><font style="font-size:11pt;">, that Purchaser shall have no right to terminate this Agreement pursuant to this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;10.1(c)</u><font style="font-size:11pt;">&#160;if Purchaser is in material breach of its representations and warranties under this Agreement or has failed in any material respect to perform its obligations under this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">by the Holder Representative, if: (i) there is a breach of any representation, warranty, covenant or obligation of Purchaser such that the conditions set forth in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;8.3(a)</u><font style="font-size:11pt;">&#160;or</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;8.3(b)</u><font style="font-size:11pt;">&#160;would not be satisfied; (ii) Holder Representative shall have delivered to Purchaser a written notice of such breach; and (iii) at least [*] shall have elapsed since the delivery of such notice without such breach being cured;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">however</u><font style="font-size:11pt;">, that the Holder Representative shall have no right to terminate this Agreement pursuant to this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;10.1(d)</u><font style="font-size:11pt;">&#160;if the Sellers are in material breach of their representations and warranties under this Agreement or have failed in any material respect to perform their obligations under this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">by either Purchaser or the Holder Representative, if (i) a Governmental Authority of any competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any Law or Governmental Order which (1) is in effect, (2) has the effect of permanently restraining, enjoining or otherwise prohibiting the Closing and (3) is final and non-appealable; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">by Purchaser, in its sole discretion pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 6.6(a)</u><font style="font-size:11pt;">, if the competent Governmental Authority requests any material condition to the granting of the Foreign Investment Approval, such as Purchaser&#8217;s undertaking to divest, dispose of, or hold separate any of the businesses or assets of Corlieve or Purchaser and/or any of its Affiliates, other than an Acceptable Undertaking; provided, however that, prior to so terminating this Agreement, the Purchaser shall first consult with the Holder Representative regarding such conditions for a period of at least [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">10.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Notice of Termination</u><font style="font-size:11pt;">. If Purchaser wishes to terminate this Agreement pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Sections 10.1(b)</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">10.1(c)</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">10.1(e)</u><font style="font-size:11pt;"> or&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">10.1(f)</u><font style="font-size:11pt;">, Purchaser shall deliver to the Holder Representative a written notice stating that Purchaser is terminating this Agreement and setting forth a brief description of the basis on which Purchaser is terminating this Agreement. If the Holder Representative wishes to terminate this Agreement pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Sections 10.1(b)</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">10.1(d</u><font style="font-size:11pt;">) or&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">10.1(e)</u><font style="font-size:11pt;">,&#160; the Holder Representative shall deliver to Purchaser a written notice stating that the Holder Representative is terminating this Agreement and setting forth a brief description of the basis on which the Holder Representative is terminating this Agreement. Except for any termination pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Sections 10.1(c)</u><font style="font-size:11pt;">&#160;or&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">10.1(d)</u><font style="font-size:11pt;">, which shall be effective in accordance with the terms thereof, any termination of this Agreement under </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;10.1</u><font style="font-size:11pt;">&#160;shall be effective immediately upon the delivery of a valid written notice of the terminating Party to the other Party as set forth in this</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;10.2</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">10.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Effect of Termination</u><font style="font-size:11pt;">. In the event of the termination of this Agreement as provided under </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;10.1</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;10.2</u><font style="font-size:11pt;">, this Agreement shall be of no further force or effect and the parties hereto shall be relieved of their duties and obligations arising under this Agreement after the date of such termination and such termination shall be without Liability to Purchaser, Corlieve or the Sellers;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, that </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;6.1</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;10.4</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.3</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.10</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.11</u><font style="font-size:11pt;"> and this</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;10.3</u><font style="font-size:11pt;"> shall survive the termination of this Agreement; and&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">further</u><font style="font-size:11pt;">, that nothing herein shall relieve any party from Liability for (i) fraud or (ii) any willful breach of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">10.4</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Expenses</u><font style="font-size:11pt;">. Except as otherwise set forth herein, all fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby, including fees and expenses</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">of financial advisors, legal counsel and other advisors, shall be paid by the party incurring such expenses whether or not the transactions contemplated hereby are consummated.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 11</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Binding Effect; Assignment</u><font style="font-size:11pt;">. No Party may, without the consent of the other Parties, assign or transfer any of its rights and obligations hereunder;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">&#160;that no such consent is required for an assignment or transfer by Purchaser, in whole or in part, to (i) a Subsidiary of Purchaser (and a Subsidiary of Purchaser may assign this Agreement to another Subsidiary of Purchaser or to Purchaser) or (ii) a successor-in-interest of Purchaser by reason of merger or consolidation or sale of all or substantially all of the assets of Purchaser relating to the subject matter of this Agreement;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, that any shares that may be used to make a Milestone Payment must be either uniQure Ordinary Shares or shares of a successor-in-interest of Purchaser whose stock is publicly traded. Subject to the foregoing, this Agreement shall inure to the benefit of and be binding on the Parties&#8217; successors and permitted assigns. Any assignment or transfer in violation of the foregoing shall be null and void&#160;</font><i style="font-size:11pt;font-style:italic;">ab initio</i><font style="font-size:11pt;">, the assignee or transferee in any such assignment or transfer shall acquire no rights whatsoever, and the non-assigning, non-transferring Party shall not recognize, nor shall it be required to recognize, such assignment or transfer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Notices</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">All notices, deliveries and other communications pursuant to this Agreement will be in writing and will be deemed given if delivered personally, by facsimile, by email or delivered by globally recognized express delivery service to the parties at the addresses or facsimile numbers set forth below or to such other address or facsimile number as the party to whom notice is to be given may have furnished to the other Parties in writing in accordance herewith. Any such notice, delivery or communication will be deemed to have been delivered and received (i) in the case of personal delivery, on the date of such delivery, (ii) in the case of facsimile, on the Business Day that the party giving notice receives electronic confirmation of sending from the sending telecopy machine or, if the facsimile is not sent on a Business Day, the next Business Day after sending, (iii) in the case of email, on the day that the party giving notice receives electronic confirmation of sending from their email provider and (iv) in the case of a globally recognized express delivery service, on the Business Day that receipt by the addressee is confirmed pursuant to the service&#8217;s systems.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">If to Purchaser:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">uniQure N.V.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Attention: [*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Paasheuvelweg 25A</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">1105 BP Amsterdam</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Netherlands</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><font style="font-size:11pt;">Email: [*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">with copies (which shall not constitute notice) to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">uniQure, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Attention: [*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">113 Hartwell Avenue</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Lexington, MA 02421</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><font style="font-size:11pt;">Email: [*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Morgan Lewis UK LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Condor House, 5-10 St. Paul&#39;s Churchyard </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">London EC4M 8AL</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">United Kingdom</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Attention: Timothy Corbett</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><font style="font-size:11pt;">Email: timothy.corbett@morganlewis.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><font style="font-size:11pt;">If to the Holder Representative, to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Kurma Partners</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">24 Rue Royale</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">75008 Paris</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">France</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Attn: </font><font style="font-size:11pt;">[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><font style="font-size:11pt;">Email: </font><font style="font-size:11pt;">[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">with copies (which shall not constitute notice) to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">McDermott Will &amp; Emery AARPI</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">23 rue de l&#39;Universit&#233;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">75007 Paris</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">France</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Atte</font><font style="font-size:11pt;">ntion: Emmanuelle Trombe</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Fax&#160;+33 1 81 69 15 15</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><font style="font-size:11pt;">Email: etrombe@mwe.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">If to a Seller, to the address set forth on the signature page of such Seller.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Entire Agreement; Amendments and Waivers</u><font style="font-size:11pt;">. This Agreement, the Confidentiality Agreement and the other documents and instruments referred to herein and all exhibits and schedules hereto, constitutes the entire agreement among the Parties pertaining to the subject matter hereof and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, of the Parties. Any provision of this Agreement may be amended or waived if, but only if such amendment or waiver is in writing and is signed by Purchaser and the Holder Representative (it being acknowledged and agreed that the Holder Representative may amend this Agreement and waive matters on behalf of the Sellers, all as contemplated by </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.4</u><font style="font-size:11pt;">&#160;hereof). No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar), nor shall such waiver constitute a continuing waiver unless otherwise expressly provided. No failure on the part of any party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the exercise of any other right, power or remedy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.4</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Appointment of the Holder Representative</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Appointment</u><font style="font-size:11pt;">. As used in this Agreement, the term &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Holder Representative</u><font style="font-size:11pt;">&#8221; shall mean that Person designated by the Sellers who together were entitled to receive a majority of the Closing Date Cash Consideration (including RGX) (a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Majority of Sellers</u><font style="font-size:11pt;">&#8221;), who shall initially be Kurma Partners until Closing and as from Closing, a service provider as appointed pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.4(b)</u><font style="font-size:11pt;">. By execution hereof, the Holder Representative hereby accepts its appointment as the initial Holder Representative. Effective upon the execution of this Agreement, without any further action by any other Person, the Holder Representative shall be appointed and constituted in respect of each Seller, as his, her or its agent, to act in his, her or its name, place and stead, as such Seller&#8217;s attorney-in-fact, as more fully set forth in</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;11.4(c)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:4pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Election and Replacement</u><font style="font-size:11pt;">. From and after the execution of this Agreement until the date when all obligations under this Agreement have been discharged (including all indemnification obligations under&#160;Article 9), a Majority of Sellers may, from time to time upon written notice to the Holder Representative and Purchaser, (i) remove any Holder Representative (including any Holder Representative appointed by Purchaser as provided below) or (ii) appoint a new Holder Representative to fill any vacancy created by the death, incapacitation, resignation or removal of any Holder Representative. If a Majority of Sellers is required to but has not appointed a successor Holder Representative to fill any vacancy within [*] after Purchaser has sent a written notice to a Majority of Sellers requesting that they appoint a successor Holder Representative, Purchaser shall have the right to appoint a Holder Representative to fill any such vacancy;&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">,&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">however</u><font style="font-size:11pt;">, that a Majority of Sellers shall thereafter retain the right to remove the Holder Representative or appoint a new Holder Representative pursuant to this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.4(b)</u><font style="font-size:11pt;">. A copy of any appointment by a Majority of Sellers of any successor Holder Representative shall be provided to Purchaser promptly after it shall have been effected. Each successor Holder Representative shall have all of the power, authority, rights and privileges conferred by this Agreement upon the original Holder Representative, and the term &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Holder Representative</u><font style="font-size:11pt;">&#8221; as used herein shall be deemed to include any successor Holder Representative.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Authority</u><font style="font-size:11pt;">. The Holder Representative shall be authorized, on behalf of each and every Seller, (i) to execute, as Holder Representative, this Agreement and any agreement or instrument entered into or delivered in connection with the transactions contemplated hereby (including, for the avoidance of doubt, the Disclosure Letter for and on behalf of the Sellers); (ii) to discuss, negotiate, agree to, enter into, consent to, resolve and fully and finally settle on behalf of the Sellers when it relates to all Sellers (but not individual Seller) any claims for indemnification by any Purchaser Indemnified Party under&#160;Article 9 hereof, including the authorization to comply with Court Orders with respect to any such claim for indemnification and the delivery to Purchaser of cash from the Escrow Account in satisfaction of claims asserted by Purchaser pursuant to&#160;Article 9&#160;hereof; (iii) to object to such claims pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;9.3</u><font style="font-size:11pt;">; (iv) to act as, or retain a, Paying Agent for the Closing Date Cash Consideration and any post-closing distribution of the Holdback Amount, the Non GMP Batch Payment or the Milestone Payments; (v) to receive all documents, certificates and notices and make all determinations on behalf of the Sellers required under this Agreement. &#160;A decision, act, consent or instruction of the Holder Representative in accordance with this Agreement shall constitute a decision of the Sellers and shall be final, binding and conclusive upon the Sellers. Purchaser shall have the right to rely in good faith upon an Instrument received from Holder Representative and to act in accordance with the Instrument without independent investigation. Any notice or communication given or received by, and any decision, action, failure to act within a designated period of time, agreement, consent, settlement, resolution or instruction of, the Holder Representative that is within the scope of the Holder Representative&#8217;s authority under </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.4</u><font style="font-size:11pt;">&#160;shall constitute a notice or communication to or by, or a decision, action, failure to act within a designated period of time, agreement, consent, settlement, resolution or instruction of all the Sellers and shall be final, binding and conclusive upon each such Seller.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Liability of Holder Representative or Purchaser</u><font style="font-size:11pt;">. Neither the Holder Representative, nor any of the directors, officers, agents or employees of the Holder Representative, if applicable, shall be liable to any Seller or any other Person for any error of judgment, or any action taken, suffered or omitted to be taken, under this Agreement, except in the case of the Holder Representative&#8217;s fraud, gross negligence or willful misconduct. The Holder Representative may consult with legal counsel, independent public accountants and other experts selected by the Holder Representative and shall not be liable to any Seller for any action taken or omitted to be taken in good faith in accordance with the advice of such counsel, accountants or experts. As to any matters not expressly provided for in this Agreement, the Holder Representative shall not be required to exercise any discretion or take any action. Neither Purchaser, nor Corlieve nor any of their Affiliates shall have any Liability to any of the Sellers or otherwise arising out of the acts or omissions of the Holder Representative or any disputes among the Sellers or between the Sellers and the Holder Representative. Purchaser may rely entirely on its</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">dealings with, and notices to and from, the Holder Representative to satisfy any obligations it may have under this Agreement or otherwise to the Sellers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Indemnity; Costs and Expenses</u><font style="font-size:11pt;">. Each Seller shall, severally and not jointly (</font><i style="font-size:11pt;font-style:italic;">sans solidarit&#233;</i><font style="font-size:11pt;">), in proportion to the portion of the Closing Date Cash Consideration then previously received by such Sellers (or if no portion of the Closing Date Cash Consideration has been paid, in proportion to the portion of the Closing Date Cash Consideration to which such Seller is entitled), indemnify, hold harmless and defend the Holder Representative (and its directors, officers, employees, shareholders, agent and representatives) against any Damages incurred without fraud, gross negligence or willful misconduct by the Holder Representative and arising out of or in connection with the acceptance, performance or administration of the Holder Representative&#8217;s duties under this Agreement. Any Damages (including costs of defending claims prior to the final adjudication or settlement of such claims) incurred by the Holder Representative in connection with the acceptance, performance and administration of its duties as the Holder Representative pursuant to this Agreement (including the hiring of legal counsel, accountants or auditors and other advisors pursuant to the terms of this Agreement, but excluding any of the foregoing arising out of the Holder Representative&#8217;s fraud, gross negligence or willful misconduct) and all fees payable hereunder to the Holder Representative by the Sellers (&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Holder Representative&#8217;s Costs</u><font style="font-size:11pt;">&#8221;) shall be paid as follows: (i) first by recourse to the Holder Representative&#8217;s Fund, if any; and (ii) if such amounts are insufficient to pay such Holder Representative&#8217;s Costs, then by recourse directly to the Sellers (in proportion to the portion of the Closing Date Cash Consideration then previously received by each such Seller (or if no portion of the Closing Date Cash Consideration has been paid, in proportion to the portion of the Closing Date Cash Consideration to which such Seller is entitled).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Holder Representative&#8217;s Fund</u><font style="font-size:11pt;">. At the Closing, the Paying Agent may deposit with the Holder Representative an amount to be determined in the reasonable discretion of the Sellers, which shall be held by the Holder Representative in trust solely for the purpose of paying the expenses, if any, incurred by the Holder Representative in connection with the transactions contemplated by this Agreement (such fund created by the provision of such amount, the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Holder Representative&#8217;s Fund</u><font style="font-size:11pt;">&#8221;). Upon request of all Sellers, the Holder Representative shall distribute the remaining Holder Representative&#8217;s Fund (if any) to the Sellers, in accordance with the Closing Date Allocation Schedule. Purchaser shall have no obligation whatsoever with respect to the Holder Representative&#8217;s Fund, if any, and Purchaser shall not have Liability for the manner in which the Holder Representative administers the Holder Representative&#8217;s Fund, or for causing or ensuring that all or any portion of the Holder Representative&#8217;s Fund is ultimately paid or distributed to the Sellers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.5</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Counterparts; Electronic Delivery of Signatures</u><font style="font-size:11pt;">. This Agreement may be executed (including by facsimile or by email of a .pdf attachment) in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument, it being understood that all Parties need not sign the same counterpart. In the event that any signature is delivered by facsimile or by email of a .pdf attachment, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or .pdf signature page were an original thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.6</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Severability</u><font style="font-size:11pt;">. If any term or other provision of this Agreement is deemed or held to be invalid, illegal, or unenforceable in any respect, all other terms or provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the Agreement is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal, or unenforceable in any respect, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner. If it is ever held that any restriction hereunder is too broad to permit enforcement of such restriction to its fullest extent, each party agrees that a court of competent jurisdiction may enforce such restriction to the maximum extent permitted by Law, and each party</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">hereby consents and agrees that such scope may be judicially modified accordingly in any proceeding brought to enforce such restriction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.7</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Third Party Beneficiaries</u><font style="font-size:11pt;">. Other than as provided in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7.7</u><font style="font-size:11pt;">&#160;and&#160;Article 9, nothing expressed or referred to in this Agreement will be construed to give any Person other than the Parties to this Agreement (and their successors and permitted assigns) any legal or equitable right, remedy, or claim under or with respect to this Agreement or any provision of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.8</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Strict Construction</u><font style="font-size:11pt;">. The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.9</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">GOVERNING LAW</u><font style="font-size:11pt;">. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK, IRRESPECTIVE OF THE CHOICE OF LAWS PRINCIPLES OF THE STATE OF NEW YORK, AS TO ALL OTHER MATTERS, INCLUDING MATTERS OF VALIDITY, CONSTRUCTION, ENFORCEABILITY, PERFORMANCE AND REMEDIES.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.10</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Jurisdiction; Venue; Service of Process.</u><font style="font-size:11pt;"> Except as otherwise provided in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;11.12</u><font style="font-size:11pt;">, all disputes arising out of or in connection with this Agreement shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by three arbitrators. The claimant shall nominate an arbitrator in its request for arbitration. The respondent shall nominate an arbitrator in its answer. The two arbitrators shall nominate a third arbitrator [*] after the nomination of the second arbitrator. The third arbitrator shall act as president of the tribunal. If any of the three arbitrators is not nominated within the time limits prescribed above, then the International Court of Arbitration of the International Chamber of Commerce shall appoint that arbitrator. The place of arbitration shall be Geneva Switzerland. The language of the arbitration shall be English. The arbitration award shall be final and binding on the Parties. The Parties undertake to carry out any award without delay and waive their right to any form of recourse based on grounds other than those contained in the United Nations Convention on the Recognition and Enforcement of Foreign Arbitral Awards of 1958 insofar as such waiver can validly be made. Judgment upon the award may be entered by any court having jurisdiction thereof or having jurisdiction over the relevant Party or its assets.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.11</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">WAIVER OF JURY TRIAL</u><font style="font-size:11pt;">. EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY HERETO CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HERETO HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF SUCH PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS&#160;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">SECTION 11.11</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.12</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Injunctive Relief; Specific Performance</u><font style="font-size:11pt;">. The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement, including the restrictive covenants</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">contained in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7.7</u><font style="font-size:11pt;">, were not performed in accordance with their specific terms or were otherwise breached, and that money damages or legal remedies would not be an adequate remedy for any such damages. Therefore, it is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent or restrain any breach or threatened breach of this Agreement, including</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"> Section&#160;7.7</u><font style="font-size:11pt;">, by any other Party and to enforce specifically the terms and provisions of this Agreement, including </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7.7</u><font style="font-size:11pt;">, to prevent breaches or threatened breaches of, or to enforce compliance with, the covenants and obligations of any other Party in any court of competent jurisdiction, in addition to any and all other rights and remedies at law or in equity. Each of the Parties hereto hereby waives (i) the defense that monetary damages would be an adequate remedy in any action for specific performance or any other form of equitable relief and (ii) any requirement under any Law to post a bond or any other security as a prerequisite to obtaining equitable relief.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.13</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Headings</u><font style="font-size:11pt;">. The descriptive headings used in this Agreement have been inserted for convenience of reference only, and are not intended to describe, interpret, define or limit the scope, extent or intent of this Agreement or any provision hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">EXHIBIT A: THE SELLERS [*]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">EXHIBIT B: THE FREE SHARES HOLDERS [*]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">EXHIBIT C: RESALE PROSPECTUS SUPPLEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:11.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">1.&#160;</font></font><font style="display:inline-block;width:36pt;"></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Registrable Securities</u><font style="font-size:11pt;">. For purposes of this Agreement, the term &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Registrable Securities</u><font style="font-size:11pt;">&#8221; shall mean all of the Milestone Shares actually issued to Sellers under this Agreement, other than Milestone Shares issued to a Seller that has not provided the information required by </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Paragraph 7</u><font style="font-size:11pt;"> of this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit C</u><font style="font-size:11pt;"> at least one Business Day prior to the filing of the applicable Resale Registration Statement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:11.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.&#160;</font></font><font style="display:inline-block;width:36pt;"></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Resale Registration Statement</u><font style="font-size:11pt;">. Purchaser agrees that it will file a prospectus supplement to Purchaser&#8217;s registration statement on Form&#160;S-3ASR&#160;filed on March 1, 2021 (File&#160;No.&#160;333-253749)&#160;(or another registration statement on Form&#160;S-3,&#160;or such other form under the Securities Act then available to Purchaser), providing for the resale pursuant to Rule 415 from time to time, and on a continuing basis, by each holder thereof (each a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Holder</u><font style="font-size:11pt;">&#8221;), of the Registrable Securities (such registration statement, including the prospectus, any&#160;pre-effective&#160;or post-effective amendments and supplements thereto, all exhibits thereto and all material incorporated by reference or deemed to be incorporated by reference, if any, therein being hereinafter referred to as a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Resale Registration Statement</u><font style="font-size:11pt;">&#8221; and such prospectus supplement, including the base prospectus included in a Resale Registration Statement, a &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Resale Prospectus Supplement</u><font style="font-size:11pt;">&#8221;). Purchaser agrees to file a Resale Prospectus Supplement in respect of any Milestone Shares within </font><font style="font-size:11pt;">[*]</font><font style="font-size:11pt;"> after the issuance thereof; provided, however, that Purchaser will be permitted to postpone or suspend (upon written notice to the Holders) the filing or use of a Resale Prospectus Supplement or a Resale Registration Statement if the disclosure requirements of the Securities Act in connection with such Resale Registration Statement would require Purchaser to include material non-public information (including information to supplement, update or correct existing disclosures) that has not theretofore been included or incorporated by reference in such Resale Registration Statement or otherwise in the public domain and Purchaser&#8217;s Board of Directors has determined in its reasonable judgment that Purchaser has a bona fide business reason not to disclose such material non-public information; provided, that the aggregate number of days Purchaser shall be permitted to so postpone or suspend the use of each such Resale Prospectus Supplement or effectiveness of each such Resale Registration Statement shall not exceed </font><font style="font-size:11pt;">[*]</font><font style="font-size:11pt;"> or an aggregate of </font><font style="font-size:11pt;">[*]</font><font style="font-size:11pt;">&#160;days in any period of </font><font style="font-size:11pt;">[*]</font><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:11.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.&#160;</font></font><font style="display:inline-block;width:36pt;"></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Withdrawal</u><font style="font-size:11pt;">. Any Holder on behalf of whom any Registrable Securities have been included in a Resale Prospectus Supplement shall have the right to withdraw any or all of the Registrable Securities to be registered thereby by giving written notice to such effect to Purchaser prior to the filing of such Resale Prospectus Supplement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:11.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.&#160;</font></font><font style="display:inline-block;width:36pt;"></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Registration Procedures</u><font style="font-size:11pt;">. In connection with a Resale Registration Statement, Purchaser shall:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) </font></font><font style="font-size:11pt;">use reasonable best efforts to cause the registration statement to remain effective until the termination of the Purchaser&#8217;s registration obligations pursuant to </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Paragraph 6</u><font style="font-size:11pt;"> of this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit C</u><font style="font-size:11pt;">, and shall use reasonable best efforts to obtain as promptly as is practicable the withdrawal of any order suspending the registration or qualification (or the effectiveness thereof) or suspending or preventing the use of any related prospectus in any jurisdiction with respect thereto;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) </font></font><font style="font-size:11pt;">notify as promptly each seller of Registrable Securities of each of (A)&#160;the filing of the Resale Prospectus Supplement and any amendment or supplements thereto, (B)&#160;the receipt of any comments from the SEC or any state securities law authorities or any other Governmental Authorities with respect to any such registration statement or Resale Prospectus Supplement or any amendments or supplements thereto, and (C)&#160;any oral or written stop order with respect to such registration, any suspension of the registration or qualification of the sale of such Registrable Securities in any jurisdiction, or any initiation or threatening of any proceedings with respect to any of the foregoing; provided that Purchaser shall not be required to notify sellers of Registrable Securities of any events</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">described in (A)&#160;to (C) of this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Paragraph 4</u><font style="font-size:11pt;"> related to any Shelf Registration Statement that do not affect the availability of the applicable Resale Prospectus Supplement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">if requested, furnish to each seller of Registrable Securities, the underwriters, and the sales or placement agent, if any, and counsel for each of the foregoing, a conformed copy of such registration statement and each amendment and supplement thereto (in each case, including all exhibits thereto and documents incorporated by reference therein) and such additional number of copies of such registration statement, each amendment, and supplement thereto (in such case without such exhibits and documents), the prospectus (including each preliminary prospectus) included in such registration statement, and the Resale Prospectus Supplements and all exhibits thereto and documents incorporated by reference therein, and such other documents as such seller, underwriter, agent, or counsel may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such seller; provided, that Purchaser shall have no obligation to provide any document pursuant to this section that is available on the SEC&#8217;s EDGAR system;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">use reasonable best efforts to register or qualify such Registrable Securities under such securities or &#8220;blue sky&#8221; laws of such jurisdictions as the Holders of Registrable Securities reasonably request and do any and all other acts and things that may be reasonably necessary or advisable to enable the holders of Registrable Securities to consummate the disposition in such jurisdictions of the Registrable Securities owned by such Holders and keep such registration or qualification in effect for so long as the registration statement remains effective under the Securities Act (provided that Purchaser shall not be required to (x)&#160;qualify generally to do business in any jurisdiction in which it would not otherwise be required to qualify but for this subparagraph, (y)&#160;subject itself to taxation in any such jurisdiction in which it would not otherwise be subject to taxation but for this subparagraph, or (z)&#160;consent to the general service of process in any jurisdiction in which it would not otherwise be subject to general service of process but for this subparagraph);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">notify each seller of such Registrable Securities, at any time when a prospectus relating thereto is required to be delivered under the Securities Act and the rules and regulations thereunder, upon the discovery that, or of the happening of any event as a result of which, the registration statement covering such Registrable Securities, as then in effect, contains an untrue statement of a material fact or omits to state any material fact required to be stated therein or any fact necessary to make the statements therein not misleading, and as promptly as reasonably practicable prepare and furnish to each such seller a supplement or amendment to the Resale Prospectus Supplement to such registration statement so that such registration statement shall not, and such Resale Prospectus Supplement as thereafter delivered to the purchasers of such Registrable Securities shall not, contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or any fact necessary to make the statements therein not misleading;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f) </font></font><font style="font-size:11pt;">use reasonable best efforts to cause all Registrable Securities so registered to be listed on The Nasdaq Global Select Market or such other national securities exchange or established&#160;over-the-counter&#160;market as is then the principal market on which or through which similar securities of Purchaser are then listed or traded; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g) </font></font><font style="font-size:11pt;">use reasonable best efforts to comply with all applicable laws related to such registration statement and offering and sale of securities and all applicable rules and regulations of Governmental Authorities in connection therewith (including, without limitation, the Securities Act and the Exchange Act).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:11.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.&#160;</font></font><font style="display:inline-block;width:36pt;"></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Expenses</u><font style="font-size:11pt;">. All expenses incident to Purchaser&#8217;s performance of, or compliance with, its obligations under this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit C</u><font style="font-size:11pt;">, including, without limitation, all registration and filing fees, all fees and expenses of compliance with securities and &#8220;blue sky&#8221; laws, all printing and copying expenses, all messenger and delivery expenses, all fees and expenses of Purchaser&#8217;s independent counsel &#160;shall be borne by Purchaser. Purchaser shall not be responsible for the fees and expenses of any counsel, or any of the accountants, agents, or experts retained by the Holders in connection with the sale of Registrable Securities. Purchaser will pay its internal expenses (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties, the expense of any annual</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">audit, and the expense of any liability insurance) and the expenses and fees for listing the securities to be registered on each securities exchange and included in each established&#160;over-the-counter&#160;market on which similar securities issued by Purchaser are then listed or traded or for listing on any other exchange or automated quotation system.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:11.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.&#160;</font></font><font style="display:inline-block;width:36pt;"></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Termination</u><font style="font-size:11pt;">. Purchaser&#8217;s obligations under </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.12</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 7.4</u><font style="font-size:11pt;"> of the Agreement and this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit C</u><font style="font-size:11pt;"> shall terminate, with respect to each Holder, on the earliest date on which all of such Holder&#8217;s Registrable Securities have: (a)&#160;been registered on a Resale Registration Statement and disposed of in accordance therewith; (b)&#160;become eligible to be sold, without volume or manner of sale limitations, pursuant to Rule 144 under the Securities Act or any successor rule or regulation thereto that may be adopted by the SEC, (c)&#160;ceased to be outstanding, whether as a result of redemption, repurchase, cancellation, exchange or otherwise, or (d)&#160;been sold to the public pursuant to Rule 144 under the Securities Act or any successor rule or regulation thereto that may be adopted by the SEC. Purchaser will take such action as may reasonably requested by any Holder to remove any restrictive legend or other restriction on resale with respect to any Registrable Securities for which Purchaser&#8217;s obligations under this Schedule shall have terminated pursuant to this subparagraph.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:11.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.&#160;</font></font><font style="display:inline-block;width:36pt;"></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Selling Shareholder Information</u><font style="font-size:11pt;">. Each of the Holders shall furnish such information as may reasonably be required by Purchaser with respect to itself and its Registrable Securities to be included in a Resale Prospectus Supplement. In connection therewith, each Holder shall be required to represent to Purchaser that all such information which is given is both complete and accurate in all material respects when made.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:11.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.&#160;</font></font><font style="display:inline-block;width:36pt;"></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Adjustments</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">In the event that Purchaser is prohibited from filing a Resale Prospectus Supplement in respect of the Milestone Shares only as a result of a suspension period outlined in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section 2</u><font style="font-size:11pt;"> within </font><font style="font-size:11pt;">[*]</font><font style="font-size:11pt;"> following the issuance of such Milestone Shares and files the Resale Prospectus Supplement more than </font><font style="font-size:11pt;">[*]</font><font style="font-size:11pt;"> following such issuance date </font><font style="font-size:11pt;">[*] </font><font style="font-size:11pt;">following the issuance date, the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Target Date</u><font style="font-size:11pt;">&#8221; with respect to such Milestone Shares), the date on which such Resale Prospectus Supplement is actually filed and available for use shall be the &#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Measurement Date</u><font style="font-size:11pt;">&#8221; with respect to such Milestone Shares, and the provisions of this </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Paragraph 8</u><font style="font-size:11pt;"> shall apply.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">If the closing price of the uniQure Ordinary Shares on Nasdaq on the Trading Day immediately preceding the applicable Measurement Date is more than </font><font style="font-size:11pt;">[*] </font><font style="font-size:11pt;">lower than such price on the Trading Day immediately preceding the applicable Target Date, Purchaser shall pay to the Sellers, as additional consideration, an amount equal to such difference, in cash or additional uniQure Ordinary Shares, at the discretion of Purchaser. Such additional consideration shall be paid or delivered by no later than </font><font style="font-size:11pt;">[*]</font><font style="font-size:11pt;"> following the Measurement Date and shall not be subject to the market restrictions of </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Sections 9</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">10</u><font style="font-size:11pt;"> below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">EXHIBIT D: FORM OF FRENCH SHORT FORM TRANSFER AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><i style="font-size:11pt;font-style:italic;">[Signature Pages Follow]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted<br>and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the<br>Securities Exchange Act of 1934, as amended.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">IN WITNESS WHEREOF, each party has executed this Agreement or caused this Agreement to be duly executed on its behalf by its officer thereunto duly authorized, all as of the date first above written.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:66.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">uniQure N.V.</b></p></td><td style="vertical-align:bottom;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 19pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Kapusta</p></td><td style="vertical-align:bottom;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:33.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:66.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:28.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">Matthew Kapusta</p></td><td style="vertical-align:bottom;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:bottom;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SELLERS</b></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">[*]</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">HOLDER REPRESENTATIVE</b></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">[*] on behalf of Kurma Partners</font></p></td><td style="vertical-align:top;width:66.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>qure-20210630xex3d1.htm
<DESCRIPTION>EX-3.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 7/26/2021 08:01:52 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit&#160;3.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5.05pt 99.7pt;"><font style="color:#07070a;font-size:10.5pt;font-style:italic;font-weight:bold;">NOTE ABOUT TRANSLATION:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:1.9pt;margin:0pt 0pt 2.59pt 98.3pt;"><i style="color:#060607;font-size:11pt;font-style:italic;">This document is an English translation of a document prepared in Dutch. In preparing this document, an attempt has been made to translate as literally as possible without jeopardizing the overall continuity of the text. Inevitably, however, differences may occur in translation and if they do, the Dutch text will govern by law.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:1.7pt;margin:0pt 0pt 0pt 98.3pt;"><i style="color:#060607;font-size:11pt;font-style:italic;">In this translation, Dutch legal concepts are expressed in English terms and not in their original Dutch terms. The concepts concerned may not be identical to concepts described by the English terms as such terms may be understood under the laws of other jurisdictions.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:1.7pt;margin:0pt 0pt 0pt 98.3pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:1.7pt;margin:0pt 0pt 0pt 98.3pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 1.6pt 102.65pt;"><b style="color:#060607;font-size:11pt;font-weight:bold;">ARTICLES OF ASSOCIATION OF</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.25pt 100.3pt;"><i style="color:#060607;font-size:11pt;font-style:italic;">&quot;uniQure N. V.&quot;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.45pt;text-indent:-0.45pt;margin:0pt 0pt 0.5pt 100.5pt;"><font style="color:#050505;font-size:11pt;">as these read after the execution of the deed of amendment of the articles of association executed on 16 June 2021 before C. Holdinga, civil-law notary in Amsterdam.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:100.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.85pt;margin-top:0pt;"><b style="color:#070709;font-size:11pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.85pt;margin-top:0pt;"><b style="color:#070709;font-size:11pt;font-weight:bold;">DEFINITIONS.</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.8pt;margin:0pt 0pt 0.15pt 135.8pt;"><font style="color:#050505;font-size:11pt;">In the articles of association the following terms shall have the meaning as defined below:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 0pt 164.3pt;"><b style="color:#050506;font-size:11pt;font-weight:bold;">Annual Accounts: </b><font style="color:#050506;font-size:11pt;">the annual accounts referred to in section 2:361 DCC;</font><b style="color:#050506;font-size:11pt;font-weight:bold;"> <br>Annual Statement of Accounts: </b><font style="color:#050506;font-size:11pt;">the Annual Accounts and, if applicable, the Annual Report as well as the additional information referred to in section 2:392 DCC;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.4pt;text-align:justify;text-indent:-0.4pt;margin:0pt 0pt 0pt 164.75pt;"><b style="color:#040405;font-size:11pt;font-weight:bold;">Board: </b><font style="color:#040405;font-size:11pt;">the corporate body of the Company consisting of the Executive Directors of the board in office and the Non-Executive Directors of the board in office;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.25pt;text-align:justify;text-indent:-0.25pt;margin:0pt 0pt 0pt 165.2pt;"><b style="color:#07051e;font-size:11pt;font-weight:bold;">Board Membe</b><b style="color:#0b0453;font-size:11pt;font-weight:bold;">r</b><b style="color:#07051e;font-size:11pt;font-weight:bold;">s: </b><font style="color:#07051e;font-size:11pt;">the Executive Directors of the Board in office and the Non-Executive Directors of the Board in office;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 0pt 164.85pt;"><b style="color:#050506;font-size:11pt;font-weight:bold;">Chief Executive Officer: </b><font style="color:#050506;font-size:11pt;">the Executive Director appointed as chief executive officer as referred to in article 7.3.;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.15pt;text-indent:-0.15pt;margin:0pt 0pt 0pt 164.8pt;"><b style="color:#050505;font-size:11pt;font-weight:bold;">Company: </b><font style="color:#050505;font-size:11pt;">the public limited company which organisation is laid down in these articles of association;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 1.25pt 164.8pt;"><b style="color:#050507;font-size:11pt;font-weight:bold;">Executive Director: </b><font style="color:#050507;font-size:11pt;">a Board member appointed as executive director;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 1.64pt 165.65pt;"><b style="color:#050507;font-size:11pt;font-weight:bold;">DCC: </b><font style="color:#050507;font-size:11pt;">the Dutch Civil Code;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.05pt;margin:0pt 0pt 0pt 165.4pt;"><b style="color:#050506;font-size:11pt;font-weight:bold;">General Meeting: </b><font style="color:#050506;font-size:11pt;">the corporate body that consists of Shareholders entitled to vote and all other persons entitled to vote/ the meeting in which Shareholders and all other persons entitled to attend general meetings assemble;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.05pt;margin:0pt 0pt 0pt 165.4pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.1pt;margin:0pt 0pt 0pt 163.05pt;"><b style="color:#050506;font-size:11pt;font-weight:bold;">Management Report: </b><font style="color:#050506;font-size:11pt;">the annual report referred to in section 2:391 DCC; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.1pt;margin:0pt 0pt 0pt 163.05pt;"><b style="color:#050506;font-size:11pt;font-weight:bold;">Meeting Rights: </b><font style="color:#050506;font-size:11pt;">the right to, either in person or by proxy authorised in writing, attend the General Meeting and to address such meeting;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 0pt 163.4pt;"><b style="color:#050506;font-size:11pt;font-weight:bold;">Non-Executive Director: </b><font style="color:#050506;font-size:11pt;">a Board member appointed as non-executive director;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.25pt;text-indent:-0.25pt;margin:0pt 0pt 0pt 163.45pt;"><b style="color:#050506;font-size:11pt;font-weight:bold;">Persons entitled to attend General Meetings: </b><font style="color:#050506;font-size:11pt;">Shareholders as well as holders of a right of use and enjoyment </font><i style="color:#050506;font-size:11pt;font-style:italic;">(vruchtgebruik) </i><font style="color:#050506;font-size:11pt;">and holders of a right of pledge with Meeting Rights;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.2pt;margin:0pt 0pt 0pt 163.7pt;"><b style="color:#050506;font-size:11pt;font-weight:bold;">Persons entitled to vote: </b><font style="color:#050506;font-size:11pt;">Shareholders with voting rights as well as holders of a right of use and enjoyment </font><i style="color:#050506;font-size:11pt;font-style:italic;">(vruchtgebruik) </i><font style="color:#050506;font-size:11pt;">and holders of a right of pledge with voting rights;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 1.35pt 163.75pt;"><b style="color:#050505;font-size:11pt;font-weight:bold;">Secretary: </b><font style="color:#050505;font-size:11pt;">the secretary of the Company as referred to in article 7.8.;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 1.54pt 163.75pt;"><b style="color:#050505;font-size:11pt;font-weight:bold;">Share: </b><font style="color:#050505;font-size:11pt;">a share in the share capital of the Company;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 1.64pt 163.7pt;"><b style="color:#050506;font-size:11pt;font-weight:bold;">Shareholder: </b><font style="color:#050506;font-size:11pt;">a holder of a Share;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 1.29pt 163.5pt;"><b style="color:#050507;font-size:11pt;font-weight:bold;">Subsidiary: </b><font style="color:#050507;font-size:11pt;">a subsidiary as referred to in section 2:24a DCC.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.54pt;margin-top:0pt;"><b style="color:#08070a;font-size:11pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.54pt;margin-top:0pt;"><b style="color:#08070a;font-size:11pt;font-weight:bold;">NAME. CORPORATE SEAT.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><font style="color:#050507;font-size:11pt;">2.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><font style="color:#050507;font-size:11pt;">The name of the Company is: </font><b style="color:#050507;font-size:11pt;font-weight:bold;">uniQure N.V.</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.35pt;margin:0pt 0pt 0pt 135.65pt;"><font style="color:#050505;font-size:11pt;">Its corporate seat is in Amsterdam, the Netherlands, and it may establish branch offices elsewhere.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.15pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.25pt;margin-top:0pt;"><font style="color:#070708;font-size:11pt;">2.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.25pt;margin-top:0pt;"><b style="color:#070708;font-size:11pt;font-weight:bold;">Objects.</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 1.75pt 135.35pt;"><font style="color:#050505;font-size:11pt;">The objects of the Company are:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:133.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:45.15pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">to research, develop, produce and commercialise products, services and technology in the(bio-)pharmaceutical sphere;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:133.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:44.95pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">to incorporate, participate in, conduct the management of and take any other financial interest in other companies and enterprises;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:133.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:44.95pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">to render administrative, technical, financial, economic or managerial services to other companies, persons or enterprises;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:133.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:45.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#04040a;font-size:11pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#04040a;font-size:11pt;">to acquire, dispose of manage and exploit real and personal property, including patents, marks, licenses, permits and other intellectual property rights;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:45.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#050405;font-size:11pt;">(e)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#050405;font-size:11pt;">to borrow and/or lend moneys, act as surety or guarantor in any other manner, and bind itself jointly and severally or otherwise in addition to or on behalf of others,</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.15pt;text-indent:-0.15pt;margin:0pt 0pt 0pt 158pt;"><font style="color:#050505;font-size:11pt;">the foregoing, whether or not in collaboration with third parties, and inclusive of the performance and promotion of all activities which directly and indirectly relate to those objects, all this in the broadest sense.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:101.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.55pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;"><b style="color:#09090b;font-size:11pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;"><b style="color:#09090b;font-size:11pt;font-weight:bold;">SHARE STRUCTURE.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:100.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><font style="color:#070609;font-size:11pt;">3.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><b style="color:#070609;font-size:11pt;font-weight:bold;">Authorised share capital</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.95pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">3.1.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">The authorised share capital of the Company amounts to three million euro(EUR 4.000.000,00) and is divided into sixty million (80,000,000) shares, each with a nominal value of five cent(&#8364; 0.05).</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:42.95pt;text-indent:-42.95pt;margin:0pt 0pt 0pt 136.7pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">3.1.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">The Shares shall be in registered form and shall be consecutively numbered from 1 onwards.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.35pt;margin-top:0pt;"><font style="color:#070707;font-size:11pt;">3.1.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.35pt;margin-top:0pt;"><font style="color:#070707;font-size:11pt;">No share certificates shall be issued.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:101.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.95pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><font style="color:#070709;font-size:11pt;">3.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><b style="color:#070709;font-size:10.5pt;font-weight:bold;">Issue of Shares.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">3.2.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Shares shall be issued pursuant to a resolution of the Board if by resolution of the General Meeting the Board has been authorised for a specific period not exceeding five (5) years to issue Shares. The resolution granting the aforesaid authorisation must determine the number and class of the Shares that may be issued. The authorisation may from time to time be extended for a period not exceeding five (5) years. Unless otherwise stipulated at its grant, the authorisation cannot be withdrawn.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">3.2.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">If and insofar as an authorisation as referred to in article 3.2.1 is not in force, the General Meeting shall have the power, upon the proposal of the Board to resolve to issue Shares.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.45pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">3.2.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Article 3.2.1 and 3.2.2 shall equally apply to a grant of rights to subscribe for Shares, but shall not apply to an issue of Shares to a person who exercises a previously acquired right to subscribe for Shares.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">3.2.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">Save for the provisions of section 2:80 DCC, the issue price may not be below nominal value of the Shares.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.9pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">3.2.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Shares shall be issued by deed in accordance with the provisions of sections 2:86c and 2:96 DCC.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:102pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.9pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><font style="color:#080809;font-size:11pt;">3.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><b style="color:#080809;font-size:10.5pt;font-weight:bold;">Payment for Shares.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.65pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">3.3.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Shares may only be issued against payment in full of the amount at which such Shares are issued and with due observance of the provisions of sections 2:80a and 2:80b DCC.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#04050d;font-size:11pt;">3.3.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#04050d;font-size:11pt;">Payment must be made in cash, unless an alternative contribution has been agreed. Payment other than in cash is made with due observance of the provisions of section 2:94b DCC.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:138.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">3.3.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Payment in cash may be made in a foreign currency if the Company agrees to this. In that case, the payment obligation shall be fulfilled for the amount up to which the amount paid up can be freely exchanged into euro. This rate of exchange shall be determined by the rate of exchange prevailing on the day of payment or, after application of the provisions of the next sentence, on the day referred to there. The Company may demand payment at the rate of exchange prevailing on a specific day within two (2) months prior to the last day on which payment must have been made, provided that the Shares shall be included on the official list of any stock exchange immediately following the issue.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:14pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.45pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">3.3.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Company may grant loans for the purpose of a subscription for or an acquisition of Shares in its share capital subject to any applicable statutory provisions.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.45pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">3.3.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Board may perform legal acts as referred to in section 2:94 DCC without the prior approval of the General Meeting.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:98.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.85pt;margin-top:0pt;"><font style="color:#070609;font-size:11pt;">3.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.85pt;margin-top:0pt;"><b style="color:#070609;font-size:10.5pt;font-weight:bold;">Pre-emptive rights.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">3.4.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">Upon the issue of Shares, each Shareholder shall have a pre-emptive right to acquire such newly issued Shares in proportion to the aggregate amount of his Shares, it being understood that this pre&#173;emptive right shall not apply to:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:177.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.6pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.6pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">any issue of Shares to employees of the Company or employees of a group Company;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:177.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.85pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.85pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">Shares which are issued against payment in kind.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">3.4.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">Pre-emptive rights may be limited or excluded by resolution of the General Meeting upon proposal of the Board. The Board shall have the power to resolve upon the limitation or exclusion of the pre-emptive right, if and to the extent the Board has been designated by the General Meeting. Such designation shall only be valid for a specific period of not more than five (5) years and may from time to time be extended with a period of not more than five (5) years. Unless provided otherwise in the designation, the designation cannot be cancelled.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.1pt;text-indent:-0.1pt;margin:0pt 0pt 0pt 178.09pt;"><font style="color:#050505;font-size:11pt;">A resolution of the General Meeting to limit or exclude the pre&#173;emptive rights as well as a resolution to designate the Board as referred to in this article 3.4.2 requires a two thirds majority of the votes cast if less than half the issued share capital is represented at a meeting.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#05040b;font-size:11pt;">3.4.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#05040b;font-size:11pt;">Without prejudice to section 2:96a DCC, the General Meeting or the Board, as the case may be, shall, when adopting a resolution to issue Shares, determine the manner in which and the period within which such pre-emptive rights may be exercised.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">3.4.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Company shall announce the issue with pre-emptive rights and the period within which such rights can be exercised in such manner as shall be prescribed by applicable law and applicable stock exchange regulations, including, but not limited to, an announcement published by electronic means of communication.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">3.4.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">This article 3.4 shall equally apply to a grant of rights to subscribe for Shares, but shall not apply to an issue of Shares to a person who exercises a previously acquired right to subscribe for Shares.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:100.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#07070a;font-size:11pt;">3.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#07070a;font-size:10.5pt;font-weight:bold;">Depositary receipts for shares</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36.4pt;text-indent:-36.4pt;margin:0pt 0pt 0pt 100.74pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36.4pt;text-indent:-36.4pt;margin:0pt 0pt 0pt 100.74pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36.4pt;text-indent:-36.4pt;margin:0pt 0pt 0pt 100.74pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36.4pt;text-indent:-36.4pt;margin:0pt 0pt 0pt 100.74pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36.4pt;text-indent:-36.4pt;margin:0pt 0pt 0pt 100.74pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36.4pt;text-indent:-36.4pt;margin:0pt 0pt 0pt 100.74pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36.4pt;text-indent:-36.4pt;margin:0pt 0pt 0pt 100.74pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36.4pt;text-indent:-36.4pt;margin:0pt 0pt 0pt 100.74pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36.4pt;text-indent:-36.4pt;margin:0pt 0pt 0pt 100.74pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36.4pt;text-indent:-36.4pt;margin:0pt 0pt 0pt 100.74pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36.4pt;text-indent:-36.4pt;margin:0pt 0pt 0pt 100.74pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36.4pt;text-indent:-36.4pt;margin:0pt 0pt 0pt 100.74pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.45pt;text-indent:-0.45pt;margin:0pt 0pt 0.44pt 135.1pt;"><font style="color:#050506;font-size:11pt;">The Company is not authorised to cooperate in the issue of depositary receipts for Shares.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><b style="color:#08070a;font-size:10.5pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><b style="color:#08070a;font-size:10.5pt;font-weight:bold;">OWN SHARES. CAPITAL REDUCTION.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.29pt;margin-top:0pt;"><font style="color:#060608;font-size:11pt;">4.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.29pt;margin-top:0pt;"><b style="color:#060608;font-size:10.5pt;font-weight:bold;">Acquisition of Shares.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.65pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">4.1.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">Subject to authorisation by the General Meeting and with due observance of the applicable relevant statutory provisions, the Board may resolve on the acquisition by the Company of fully paid-up Shares. Such authorisation shall only be valid for a specific period of not more than eighteen (18) months and may from time to time be extended with a period of not more than eighteen (18) months. Acquisition by the Company of non-paid up Shares is null and void.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">4.1.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The authorisation of the General Meeting as referred to in article 4.1.1 shall not be required if the Company acquires fully paid-up Shares for the purpose of transferring such Shares, by virtue of an applicable employee stock purchase plan, to persons employed by the Company or by a group Company, provided such Shares are quoted on the official list of any stock exchange.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:100.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.54pt;margin-top:0pt;"><font style="color:#070609;font-size:11pt;">4.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.54pt;margin-top:0pt;"><b style="color:#070609;font-size:10.5pt;font-weight:bold;">Capital reduction.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">4.2.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">With due observance of the statutory requirements the General Meeting may resolve at the proposal of the Board to reduce the issued share capital by (i) reducing the nominal value of Shares by amending the articles of association, or (ii) cancelling:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.9pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">Shares in its own share capital which the Company holds itself in the Company&#39;s share capital, or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:179.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">all issued Shares against repayment of the amount paid-up on those Shares;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43.25pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">4.2.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Partial repayment on Shares pursuant to a resolution to reduce their nominal value will be made proportionally.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:101.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.55pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.95pt;margin-top:0pt;"><b style="color:#060608;font-size:10.5pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.95pt;margin-top:0pt;"><b style="color:#060608;font-size:10.5pt;font-weight:bold;">TRANSFER.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:101.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.55pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><font style="color:#060522;font-size:11pt;">5.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><b style="color:#060522;font-size:10.5pt;font-weight:bold;">Form of transfer of Shares.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">5.1.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The transfer of a Share shall require a deed executed for that purpose and, save in the event that the Company itself is a party to the transaction, written acknowledgement by the Company of the transfer. The acknowledgement is to be made either in the transfer deed, or by a dated statement endorsed upon the transfer deed or upon a copy of or extract from that deed certified by a notary (notaris) or bailiff (deurwaarder), or in the manner as referred to in article</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.35pt;margin:0pt 0pt 0pt 180.55pt;"><font style="color:#050505;font-size:11pt;">5.1.2.</font><font style="display:inline-block;width:1.24pt;"></font><font style="color:#050505;font-size:11pt;">Service of notice of the transfer deed or of the aforesaid copy or extract upon the Company shall be the equivalent of acknowledgement as stated in this paragraph.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.35pt;margin:0pt 0pt 0pt 180.55pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.3pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">5.1.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The preceding paragraph shall apply mutatis mutandis to the transfer of any limited right to a Share, provided that a pledge may also be created without acknowledgement by or service of notice upon the Company and that section 3:239 DCC applies, in which case acknowledgement by or service of notice upon the Company shall replace the announcement referred to section 3:239, subsection 3 DCC.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:101.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:34.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.5pt;margin-top:0pt;"><b style="color:#070708;font-size:10.5pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.5pt;margin-top:0pt;"><b style="color:#070708;font-size:10.5pt;font-weight:bold;">REGISTERS. PLEDGE. USE AND ENJOYMENT </b><font style="color:#070708;font-size:11pt;font-style:italic;font-weight:bold;">(vruchtgebruik)</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:101.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.15pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><font style="color:#050507;font-size:11pt;">6.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><b style="color:#050507;font-size:11pt;font-weight:bold;">Shareholders register.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:41.95pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">6.1.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">With due observance of the applicable statutory provisions in respect of registered shares, a shareholders register shall be kept by or on behalf of the Company, which register shall be regularly updated and, at the discretion of the Board, may, in whole or in part, be kept in more than one copy and at more than one address. Part of the shareholders register may be kept abroad in order to comply with applicable foreign statutory provisions or applicable listing rules.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.4pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">6.1.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">Each Shareholder&#39;s name, his address and such further information as required by law or considered appropriate by the Board, shall be recorded in the shareholders register.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">6.1.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">The form and the contents of the shareholders register shall be determined by the Board with due observance of the articles 6.1.1 and 6.1.2.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43.05pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">6.1.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">Upon his request a Shareholder shall be provided free of charge with written evidence of the contents of the shareholders register with regard to the Shares registered in his name, and the statement so issued may be validly signed on behalf of the Company by a person to be designated for that purpose by the Board.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.4pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#05050f;font-size:11pt;">6.1.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#05050f;font-size:11pt;">The provisions of the articles 6.1.3 and article 6.1.4 shall equally apply to persons who hold a right of use and enjoyment (vruchtgebruik) or a right of pledge on one or more Shares.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 1.6pt 102.95pt;"><font style="color:#080808;font-size:11pt;">6.2.</font><font style="display:inline-block;width:17.25pt;"></font><b style="color:#080808;font-size:11pt;font-weight:bold;">Joint holding.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.4pt;margin:0pt 0pt 0pt 159.1pt;"><font style="color:#050505;font-size:11pt;">If through any cause whatsoever one or more Shares are jointly held by two or more persons, such persons may jointly exercise the rights arising from those Shares, provided that these persons be represented for that purpose by one from their midst or by a third party authorised by them for that purpose by a written power of attorney.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.8pt;text-indent:-0.8pt;margin:0pt 0pt 0pt 159.05pt;"><font style="color:#050505;font-size:11pt;">The Board may, whether or not subject to certain conditions, grant an exemption for the provision of the previous sentence.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:102.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.2pt;margin-top:0pt;"><font style="color:#08080b;font-size:11pt;">6.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.2pt;margin-top:0pt;"><b style="color:#08080b;font-size:11pt;font-weight:bold;">Right of pledge.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:138.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">6.3.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">Shares may be encumbered with a pledge as security for a debt.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:42.6pt;text-indent:-42.6pt;margin:0pt 0pt 0pt 138.5pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">6.3.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">If a Share is encumbered with a pledge, the voting right attached to that Share shall vest in the Shareholder, unless at the creation of the pledge the voting right has been granted to the pledgee.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">6.3.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">Shareholders who as a result of a right of pledge do not have voting rights, have Meeting Rights.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.5pt;margin-top:0pt;"><font style="color:#070709;font-size:11pt;">6.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.5pt;margin-top:0pt;"><b style="color:#070709;font-size:10.5pt;font-weight:bold;">Right of use and enjoyment </b><font style="color:#070709;font-size:11pt;font-style:italic;font-weight:bold;">(vruchtgebruik).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.65pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">6.4.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">Shares may be encumbered with a right of use and enjoyment.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">6.4.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">If a Share is encumbered with a right of use and enjoyment, the voting right attached to that Share shall vest in the Shareholder, unless at the creation of the right of use and enjoyment the voting right has been granted to the holder of the right of use and enjoyment.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">6.4.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">Shareholders who as a result of a right of use and enjoyment do not have voting rights, have Meeting Rights.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.65pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.85pt;margin-top:0pt;"><b style="color:#08070b;font-size:10.5pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.85pt;margin-top:0pt;"><b style="color:#08070b;font-size:10.5pt;font-weight:bold;">BOARD.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.75pt;margin-top:0pt;"><font style="color:#070709;font-size:11pt;">7.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.75pt;margin-top:0pt;"><b style="color:#070709;font-size:10.5pt;font-weight:bold;">Board: composition.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.5pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">7.1.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.5pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Company shall be managed by the Board.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">7.1.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Board shall consist of one or more Executive Directors and one or more Non-Executive Directors The board shall determine the number of Executive Directors and the number of Non-Executive Directors, provided that the number of Executive Directors shall at all times be less than the number of Non-Executive Directors.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 1.35pt 177.95pt;"><font style="color:#050506;font-size:11pt;">Only natural persons can be Non-Executive Director.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.7pt;margin-top:0pt;"><font style="color:#060608;font-size:11pt;">7.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.7pt;margin-top:0pt;"><b style="color:#060608;font-size:10.5pt;font-weight:bold;">Board: appointment, suspension </b><font style="color:#060608;font-size:11pt;">and </font><b style="color:#060608;font-size:10.5pt;font-weight:bold;">dismissal.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">7.2.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Executive Directors and the Non-Executive Directors shall be appointed as such by the General Meeting at the binding nomination of the Non-Executive Directors.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">7.2.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">If an Executive Director or Non-Executive Director is to be appointed, the Non-Executive Directors shall make a binding nomination of at least the number of persons as prescribed by law.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.4pt;text-indent:-0.4pt;margin:0pt 0pt 0pt 177.9pt;"><font style="color:#050507;font-size:11pt;">The General Meeting may at all times overrule the binding nomination by a resolution adopted by at least a two thirds majority of the votes cast, provided such majority represents more than half the issued share capital. If the General Meeting overruled the binding nomination, the Non-Executive Directors shall make a new nomination.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.05pt;text-indent:-0.05pt;margin:0pt 0pt 0pt 178.55pt;"><font style="color:#050505;font-size:11pt;">The nomination shall be included in the notice of the General Meeting at which the appointment shall be considered.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0.6pt;margin:0pt 0pt 0pt 178.8pt;"><font style="color:#050505;font-size:11pt;">If a nomination has not been made or has not been made in due time, this shall be stated in the notice and the General Meeting shall be free to appoint a Board Member at its discretion.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0.6pt;margin:0pt 0pt 0pt 178.8pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">7.2.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">A resolution to appoint a Board Member that was not nominated by the Non-Executive Directors may only be adopted by at least a two thirds majority of the votes cast, provided such majority represents more than half the issued share capital.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.65pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">7.2.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">When a proposal for appointment of a person as Executive Director is made, the following particulars shall be stated: his age and the position he holds or has held, insofar as these are relevant for the performance of the duties of an Executive Director. The proposal must state the reasons on which it is based.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">7.2.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">When a proposal for appointment of a person as Non-Executive Director is made, the following particulars shall be stated: his age, his profession, the number of shares he holds and the positions he holds or has held, insofar as these are relevant for the performance of the duties of a Non-Executive Director. Furthermore, the names of the legal entities of which he is already a non-executive director shall be indicated; if those include legal entities which belong to the same group, reference of that group will be sufficient. The proposal must state the reasons on which it is based.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">7.2.6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">Board Members are appointed for a maximum term of four (4) years, provided that, unless a Board Member resigns earlier, his term of appointment shall end at the close of the annual General Meeting to be held in the fourth year after the year of his appointment.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.1pt;text-indent:-0.1pt;margin:0pt 0pt 0pt 179.4pt;"><font style="color:#040404;font-size:11pt;">A Board Member may be reappointed with due observance of the preceding sentence. The Board shall draw up a retirement schedule for the Board Members.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040409;font-size:11pt;">7.2.7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040409;font-size:11pt;">The General Meeting shall at all times be entitled to suspend or dismiss a Board Member. The General Meeting may only adopt a resolution to suspend or dismiss a Board Member by at least a two thirds majority of the votes cast, provided such majority represents more than half the issued share capital.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.25pt;text-indent:-0.25pt;margin:0pt 0pt 0pt 179.8pt;"><font style="color:#040405;font-size:11pt;">A second General Meeting as referred to in section 2:120, subsection 3 DCC may not be convened.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.45pt;text-indent:-0.45pt;margin:0pt 0pt 0pt 179.4pt;"><font style="color:#040404;font-size:11pt;">The Board shall also at all times be entitled to suspend (but not to dismiss) an Executive Director. Within three (3) months after a suspension of a Board Member has taken effect, the General Meeting or the Board if the Board resolves to suspend the Board Member, will resolve to either terminate or extend the suspension for a maximum period of another three (3) months. The suspended Board Member shall be given the opportunity to account for his actions at that meeting.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.45pt;text-indent:-0.45pt;margin:0pt 0pt 0pt 179.4pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:133.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.45pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">7.2.8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">If neither such resolution is adopted or the General Meeting has resolved to dismiss the Board Member, the suspension shall terminate after the period of suspension has expired.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43.05pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">7.2.9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">In the event of the absence or inability to act of one or more Board Members, the powers of the Board remain intact, provided that:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:177.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.9pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">the Non-Executive Directors shall be authorised to temporarily fill the vacant position for a period up to the first General Meeting or, in case of a Board Member unable to act, up to the moment he is no longer unable to act;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:177.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">in the event of the absence or inability to act of all members of the Board, the Secretary shall temporarily be responsible for the management of the Company until the vacancies have been filled.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.45pt;margin:0pt 0pt 0pt 177.25pt;"><font style="color:#050405;font-size:11pt;">In the event of the absence or inability to act of all members of the Board, the Secretary shall as soon as possible take the necessary measures to make a definitive arrangement.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.6pt 177.1pt;"><font style="color:#050405;font-size:11pt;">The term prevented from acting means:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:177.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.54pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.54pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">suspension;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:177.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;"><font style="color:#060607;font-size:11pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;"><font style="color:#060607;font-size:11pt;">illness;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:177.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">(iii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">inaccessibility,</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.1pt;margin:0pt 0pt 0pt 177.5pt;"><font style="color:#050405;font-size:11pt;">in the events referred to under sub (ii) and (iii) without the possibility of contact between the Board Member concerned and the Company for a period of five (5) days, unless the Board or the Secretary sets a different term in the case at hand.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><font style="color:#070608;font-size:11pt;">7.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><b style="color:#070608;font-size:11pt;font-weight:bold;">Chief Executive Officer. Chairman of the Board.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">7.3.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">The Board shall appoint an Executive Director as Chief Executive Officer for such period as the Board may decide. In addition, the Board may grant other titles to an Executive Director.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="color:#05050d;font-size:11pt;">7.3.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="color:#05050d;font-size:11pt;">The Board shall appoint a Non-Executive Director to be chairman of the Board for such period as the board may decide.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">7.3.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Board may appoint one or more of the Non-Executive Directors as vice-chairman of the Board for such period as the Board may decide. If the chairman is absent or unwilling to take the chair, a vice-chairman shall be entrusted with such duties of the chairman as the Board may decide.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">7.3.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">If no chairman has been appointed or if the chairman is absent or unwilling to take the chair, a meeting of the Board shall be presided over by a vice-chairman or in the event of his absence or unwillingness to take the chair, by a Board Member or another person present designated for such purpose by the meeting.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:100.65pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#08070a;font-size:11pt;">7.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#08070a;font-size:11pt;font-weight:bold;">Board: remuneration.</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:35.85pt;text-indent:-35.85pt;margin:0pt 0pt 0pt 100.65pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:138.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.4pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">7.4.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">The Company must establish a policy in respect of the remuneration of the Board. The remuneration policy is adopted by the General Meeting upon the proposal of the Non-Executive Directors.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.2pt;text-indent:-0.2pt;margin:0pt 0pt 0pt 181.1pt;"><font style="color:#040405;font-size:11pt;">The remuneration of the Executive Directors shall be determined by the Non-Executive Directors with due observance of the remuneration policy adopted by the General Meeting. The remuneration of the Non&#173; Executive Directors shall be determined by the Board with due observance of the remuneration policy adopted by the General Meeting.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:138.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">7.4.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">A proposal with respect to remuneration schemes in the form of Shares or rights to Shares is submitted by the Non-Executive Directors to the General Meeting for its approval.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.25pt;text-indent:-0.25pt;margin:0pt 0pt 0pt 181.5pt;"><font style="color:#040404;font-size:11pt;">This proposal must set out at least the maximum number of Shares or rights to Shares to be granted to members of the Board and the criteria for granting or amendment.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:103.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.2pt;margin-top:0pt;"><font style="color:#080809;font-size:11pt;">7.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.2pt;margin-top:0pt;"><b style="color:#080809;font-size:11pt;font-weight:bold;">Board: meetings.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:139.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">7.5.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">Meetings of the Board may be called at any time, either by one or more Board Members or, on his or their instructions, by the Secretary.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:139.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.65pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;"><font style="color:#040404;font-size:11pt;">7.5.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;text-align:justify;"><font style="color:#040404;font-size:11pt;">The Secretary may attend the meetings of the Board. The board may decide to permit others to attend a meeting as well.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:139.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43.05pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">7.5.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">Each Board Member will have the right to cast one (1) vote. The Board shall adopt its resolutions by an absolute majority of votes cast. In the event of a tie, the proposal shall be considered rejected.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:139.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">7.5.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">A Board Member will not participate in deliberations and the adoption of resolutions in respect of which he has a personal direct or indirect conflict of interest with the company or its enterprise. If all Board Members have a conflict of interest, the resolution concerned will be adopted by the General Meeting.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:139.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">7.5.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">The minutes of meetings of the Board shall be kept by the Secretary. </font><font style="color:#05040d;font-size:11pt;">The minutes shall be adopted by the Board at the same meeting or at a subsequent meeting.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.85pt;margin:0pt 0pt 0pt 182.35pt;"><font style="color:#050505;font-size:11pt;">If the Board has adopted resolutions without holding a meeting, the Secretary shall keep a record of each resolution adopted without holding a meeting. Such record shall be signed by the chairman and the Secretary.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:104.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><font style="color:#080809;font-size:11pt;">7.6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><b style="color:#080809;font-size:11pt;font-weight:bold;">Board: powers, division of duties, restrictions.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:140.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">7.6.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">The Board shall be entrusted with the management of the Company and shall for such purpose have all the powers within the limits of the law that are not granted by the articles of association to others. The day to day management of the Company shall be entrusted to the Executive Directors. The task to supervise the performance by the</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:42.8pt;text-indent:-42.8pt;margin:0pt 0pt 0pt 140.25pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.25pt;text-indent:-0.25pt;margin:0pt 0pt 0.2pt 178.55pt;"><font style="color:#050506;font-size:11pt;">Directors of their duties cannot be taken away from the Non-Executive Directors.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">7.6.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">With due observance of the articles of association the Board shall adopt one or more sets of regulations dealing with such matters as its internal organisation, the manner in which decisions are taken, the composition, the duties and organisation of committees as referred to in article 7.6.4. and any other matters concerning the Board, the Chief Executive Officer, the Executive Directors, the Non-Executive Directors and the committees established by the Board.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.4pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">7.6.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Executive Directors may adopt legally valid resolutions with respect to matters that fall within the scope of their duties referred to in article 7.6.1. and 7.6.2. The Non-Executive Directors may also adopt legally valid resolutions with respect to matters that fall within the scope of their duties referred to in article 7.6.1. and 7.6.2.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.9pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#050505;font-size:11pt;">7.6.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#050505;font-size:11pt;">The Board may establish such committees as it may deem necessary which committees may consist of one or more Board Members or of other persons.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">7.6.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">The Executive Directors shall timely provide the Non-Executive Directors with all information required for the exercise of their duties.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">7.6.6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Without prejudice to any other applicable provisions of these articles of association, the Board shall require the approval of the General Meeting for resolutions of the Board regarding a significant change in the identity or nature of the Company or the enterprise, including in any event:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:179.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.95pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">the transfer of the enterprise or practically the entire enterprise to a third party;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:179.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="color:#040408;font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="color:#040408;font-size:11pt;">the entry into or termination of any long-lasting cooperation by the Company or a Subsidiary with any other legal person or company or as a fully liable general partner of a limited partnership or a general partnership, provided that such cooperation or the termination thereof is of significant importance to the Company; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:179.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.95pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">the acquisition or disposal of a participating interest in the capital of a Company with a value of at least one-third of the sum of the assets according to the consolidated balance sheet with explanatory notes thereto according to the last adopted Annual Accounts of the Company, by the Company or a Subsidiary.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:101.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;"><b style="color:#070608;font-size:11pt;font-weight:bold;">7.7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;"><b style="color:#070608;font-size:11pt;font-weight:bold;">Representation.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">7.7.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">The Board as well as two</font><b style="color:#050506;font-size:11pt;font-weight:bold;"> </b><font style="color:#050506;font-size:11pt;">(2) Executive Directors acting jointly are authorised to represent the Company. In case only one Executive</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:42.5pt;text-indent:-42.5pt;margin:0pt 0pt 0pt 136.8pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.2pt;margin:0pt 0pt 0pt 177.5pt;"><font style="color:#050505;font-size:11pt;">Director is in office, such Executive Director is authorised to represent the Company acting independently</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">7.7.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Board may grant one or more persons, whether or not employed by the Company, the power to represent the Company </font><i style="color:#050505;font-size:11pt;font-style:italic;">(procuratie) </i><font style="color:#050505;font-size:11pt;">or grant the power to represent the Company on a continuing basis in a different manner.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:98.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.2pt;margin-top:0pt;"><font style="color:#070709;font-size:11pt;">7.8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.2pt;margin-top:0pt;"><b style="color:#070709;font-size:11pt;font-weight:bold;">Secretary.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.25pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">7.8.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.25pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Board shall appoint a Secretary from outside its members.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.95pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">7.8.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Secretary shall participate in the meetings of the Board, as well as the meetings of the committees established by the Board, this in conformity with the regulations to be decided upon.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#050505;font-size:11pt;">7.8.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#050505;font-size:11pt;">The Secretary shall further have such powers as are assigned to him by the articles of association and, subject to the articles of association, by the Board on or after his appointment.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.54pt;margin-top:0pt;text-align:justify;"><font style="color:#050505;font-size:11pt;">7.8.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.54pt;margin-top:0pt;text-align:justify;"><font style="color:#050505;font-size:11pt;">The Secretary may be removed from office at any time by the Board.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.54pt;margin-top:0pt;"><font style="color:#070709;font-size:11pt;">7.9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.54pt;margin-top:0pt;"><b style="color:#070709;font-size:11pt;font-weight:bold;">Indemnification Board Members.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43.15pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">7.9.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">Unless Dutch law provides otherwise, the following shall be reimbursed to current and former members of the Board:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:178.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">the reasonable costs of conducting a defence against claims based on acts or failures to act in the exercise of their duties or any other duties currently or previously performed by them at the Company&#39;s request;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:179.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.4pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.75pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.75pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">any damages or fines payable by them as a result of an act or failure to act as referred to under a;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:178.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.4pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">the reasonable costs of appearing in other legal proceedings in which they are involved as current or former members of the Board, with the exception of proceedings primarily aimed at pursuing a claim on their own behalf.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 0pt 178.8pt;"><font style="color:#050510;font-size:11pt;">There shall be no entitlement to reimbursement as referred to above if and to the extent that:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:179.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">a Dutch court or, in the event of arbitration, an arbitrator has established in a final and conclusive decision that the act or failure to act of the person concerned can be characterised as wilful </font><i style="color:#050505;font-size:11pt;font-style:italic;">(opzettelijk), </i><font style="color:#050505;font-size:11pt;">intentionally reckless </font><i style="color:#050505;font-size:11pt;font-style:italic;">(bewust roekeloos) </i><font style="color:#050505;font-size:11pt;">or seriously culpable </font><i style="color:#050505;font-size:11pt;font-style:italic;">(ernstig verwijtbaar) </i><font style="color:#050505;font-size:11pt;">conduct, unless Dutch law provides otherwise or this would, in view of the circumstances of the case, be unacceptable according to standards of reasonableness and fairness; or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.3pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(e)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">the costs or financial loss of the person concerned are covered by an insurance and the insurer has paid out the costs or financial loss.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:28.3pt;text-indent:-28.3pt;margin:0pt 0pt 0pt 180.05pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-indent:0.6pt;margin:0pt 0pt 0.34pt 177.95pt;"><font style="color:#050505;font-size:11pt;">If and to the extent that it has been established by a Dutch court or, in the </font><i style="color:#050505;font-style:italic;">event </i><font style="color:#050505;font-size:11pt;">of arbitration, an arbitrator in a final and conclusive decision that the person concerned is not entitled to reimbursement as referred to above, he shall immediately repay the amount reimbursed by the Company.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.25pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">7.9.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Company may take out liability insurance for the benefit of the persons concerned.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">7.9.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">The Board may by agreement give further implementation to the above.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.6pt;margin-top:0pt;"><b style="color:#07070b;font-size:11pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.6pt;margin-top:0pt;"><b style="color:#07070b;font-size:11pt;font-weight:bold;">GENERAL MEETINGS.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:100.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.85pt;margin-top:0pt;"><font style="color:#050507;font-size:11pt;">8.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.85pt;margin-top:0pt;"><b style="color:#050507;font-size:11pt;font-weight:bold;">General Meetings.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">8.1.l.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">General Meetings shall be held in Amsterdam or in the municipality of Haarlemmermeer (Schiphol Airport).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">8.1.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">A General Meeting shall be held once a year, no later than six (6) months after the end of the financial year of the Company.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">8.1.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">The Board shall provide the General Meeting with all requested information, unless this would be contrary to an overriding interest of the Company. If the Board invokes an overriding interest, it must give reasons.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:100.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.35pt;margin-top:0pt;"><font style="color:#070607;font-size:11pt;">8.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.35pt;margin-top:0pt;"><b style="color:#070607;font-size:11pt;font-weight:bold;">Extraordinary General Meetings.</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.45pt;margin:0pt 0pt 0pt 136.4pt;"><font style="color:#050505;font-size:11pt;">Extraordinary General Meetings shall be convened by the Board or by those who are authorised by law or pursuant to these articles of association to do so.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:101.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.4pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><font style="color:#060609;font-size:11pt;">8.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><b style="color:#060609;font-size:11pt;font-weight:bold;">General Meetings: notice and agenda.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">8.3.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">Notice of the General Meeting shall be given by the Board or by those who are authorised by law or pursuant to these articles of association to do so upon a term of at least such number of days prior to the day of the meeting as required by law, in accordance with law and the regulations of the stock exchange where the Shares in the share capital of the Company at the Company&#39;s request are officially listed.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.4pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050509;font-size:11pt;">8.3.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050509;font-size:11pt;">The Board or the person who is authorised by law or pursuant to these articles of association to convene the meeting may decide that the convocation letter in respect of a person authorised to attend a General Meeting who agrees thereto, is replaced by a legible and reproducible message sent by electronic mail to the address indicated by him to the Company for such purpose.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">8.3.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The notice shall state the subjects on the agenda or shall inform the persons authorised to attend a General Meeting that they may inspect the agenda at the office of the Company and that copies thereof are obtainable at such places as are specified in the notice.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">8.3.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">The agenda for the annual General Meeting shall in any case include the following items:</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:43.05pt;text-indent:-43.05pt;margin:0pt 0pt 0pt 137.84pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:176.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.14pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.14pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">the consideration of Annual Statement of Accounts;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:176.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.95pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.44pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.44pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">the adoption of the Annual Accounts;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:176.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.65pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.25pt;margin-top:0pt;"><font style="color:#060506;font-size:11pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.25pt;margin-top:0pt;"><font style="color:#060506;font-size:11pt;">the appropriation of profits;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:177.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.9pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.64pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.64pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">proposals relating to the composition of the Board, including the filling of any vacancies in the Board;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:177.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;"><font style="color:#050505;font-size:11pt;">(e)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;"><font style="color:#050505;font-size:11pt;">the proposals placed on the agenda by the Board together with proposals made by Shareholders in accordance with provisions of the law and the provisions of the articles of association.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">8.3.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">A matter, the consideration of which has been requested in writing by one or more Shareholders, representing solely or jointly at least the percentage prescribed by law of the issued share capital, will be placed on the notice or will be announced in the same manner if the Company has received the request not later than on the date as prescribed by law.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">8.3.6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Board shall inform the General Meeting by means of a shareholders&#39; circular or explanatory notes to the agenda of all facts and circumstances relevant to the proposals on the agenda.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.5pt;margin-top:0pt;"><font style="color:#060608;font-size:11pt;">8.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.5pt;margin-top:0pt;"><b style="color:#060608;font-size:10.5pt;font-weight:bold;">General Meetings: attendance of meetings.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.25pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">8.4.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The persons who are entitled to attend the General Meeting are persons who:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:177.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">are a Shareholder or a person who is otherwise entitled to attend the General Meeting as per a certain date, determined by the Board, such date hereinafter referred to as: the &quot;record date&quot;;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:177.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.95pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">are as such registered in a register (or one or more parts thereof) designated thereto by the Board, hereinafter referred to as: the &quot;register&#39;&#39;; and</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:28.05pt;text-indent:-28.05pt;margin:0pt 0pt 1.04pt 178.09pt;"><font style="color:#050505;font-size:11pt;">(i)</font><font style="display:inline-block;width:18.85pt;"></font><font style="display:inline-block;width:0.05pt;"></font><font style="color:#050505;font-size:11pt;">have given notice in writing to the Company prior to a date set in the notice that they will attend a General Meeting,</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.05pt;margin:0pt 0pt 0.44pt 178.05pt;"><font style="color:#070613;font-size:11pt;">rega</font><font style="color:#0d073d;font-size:11pt;">r</font><font style="color:#070613;font-size:11pt;">dless of who will be Sha</font><font style="color:#0d073d;font-size:11pt;">r</font><font style="color:#070613;font-size:11pt;">eholde</font><font style="color:#0d073d;font-size:11pt;">r </font><font style="color:#070613;font-size:11pt;">at the time of the meeting. The notice will contain the name and the number of Shares the person will represent in the meeting. The provision above under (iii) concerning the notice to the Company also applies to the proxy holder of a person authorised to attend a General Meeting.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">8.4.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Board may decide that Persons entitled to attend General Meetings and vote thereat may, within a period prior to the General Meeting to be set by the Board, which period cannot begin prior to the record date as meant in article 8.4.1, cast their votes electronically in a manner to be decided by the Board. Votes cast in accordance with the previous sentence are equal to votes cast at the meeting.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:42.75pt;text-indent:-42.75pt;margin:0pt 0pt 0pt 135.75pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">8.4.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Board may decide that the business transacted at a General Meeting can be taken note of by electronic means of communication.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">8.4.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">The Board may decide that each person entitled to attend General Meetings and vote thereat may, either in person or by written proxy, vote at that meeting by electronic means of communication, provided that such person can be identified via the electronic means of communication and furthermore provided that such person can directly take note of the business transacted at the General Meeting concerned. The Board may attach conditions to the use of the electronic means of communication, which conditions shall be announced at the convocation of the General Meeting and shall be posted on the Company&#39;s website.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">8.4.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Board Members shall have admission to the General Meetings. They shall have an advisory vote at the General Meetings.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.3pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">8.4.6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Furthermore, admission shall be given to the persons whose attendance at the General Meeting is approved by the chairman of the meeting.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">8.4.7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">All issues concerning the admittance to the General Meeting shall be decided by the chairman of the meeting.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:101.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.2pt;margin-top:0pt;"><font style="color:#070709;font-size:11pt;">8.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.2pt;margin-top:0pt;"><b style="color:#070709;font-size:10.5pt;font-weight:bold;">General Meetings: order of the meeting, minutes.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.4pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">8.5.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">The General Meeting will be chaired by the chairman of the Board or in his absence by one of the other Non-Executive Directors designated by the Board; if none of the Non-Executive Directors is present at the meeting, the meeting will be chaired by one of the Executive Directors designated by the Board. The chairman shall designate the secretary.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">8.5.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">The chairman of the meeting shall determine the order of proceedings at the meeting with due observance of the agenda and he may restrict the allotted speaking time or take other measures to ensure orderly progress of the meeting.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.4pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040408;font-size:11pt;">8.5.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040408;font-size:11pt;">All issues concerning the proceedings at the meeting, shall be decided by the chairman of the meeting.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.4pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">8.5.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Minutes shall be kept of the business transacted at the meeting unless a notarial record is prepared thereof. Minutes shall be adopted and in evidence of such adoption be signed by the chairman and the secretary of the meeting concerned.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:137.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040407;font-size:11pt;">8.5.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040407;font-size:11pt;">A certificate signed by the chairman and the secretary of the meeting confirming that the General Meeting has adopted a particular resolution, shall constitute evidence of such resolution vis-&#224;-vis third parties.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:101.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#070709;font-size:11pt;">8.6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#070709;font-size:10.5pt;font-weight:bold;">General Meetings: adoption of resolutions.</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:35.6pt;text-indent:-35.6pt;margin:0pt 0pt 0pt 101.45pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.05pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">8.6.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">Unless another majority of votes or quorum is required by virtue of the law, all resolutions of the General Meeting shall be adopted by at least a simple majority of the votes cast, in a meeting where more than one-third of the issued share capital is represented.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.2pt;margin:0pt 0pt 0.1pt 178.15pt;"><font style="color:#050506;font-size:11pt;">A second meeting referred to in article 2:120, subsection 3 DCC cannot be convened.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43.25pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.3pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">8.6.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.3pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">Each Share confers the right to cast one (1) vote at the General Meeting.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.8pt;margin:0pt 0pt 0pt 178.15pt;"><font style="color:#050505;font-size:11pt;">Blank votes and invalid votes shall be regarded as not having been cast.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">8.6.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">No votes may be cast at the General Meeting in respect of Shares which are held by the Company or any of its Subsidiaries.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0.65pt;margin:0pt 0pt 0pt 178.35pt;"><font style="color:#050505;font-size:11pt;">Holders of a right of use and enjoyment </font><i style="color:#050505;font-size:11pt;font-style:italic;">(vruchtgebruik) </i><font style="color:#050505;font-size:11pt;">and pledgees of Shares which belong to the Company or its Subsidiaries shall not be excluded from the right to vote if the right of use and enjoyment or pledge was created before the Shares concerned were held by the Company or a Subsidiary of the Company and at the creation of the right of pledge or the right of use and enjoyment, the voting rights were granted to the pledgee or holder of the right of use and enjoyment.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.15pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.65pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.5pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">8.6.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.5pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The chairman of the General Meeting determines the method of</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 1.64pt 178.65pt;"><font style="color:#050505;font-size:11pt;">voting.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">8.6.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">The ruling pronounced by the chairman of the General Meeting in respect of the outcome of any vote taken at a General Meeting shall be decisive. The same shall apply to the contents of any resolution passed.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">8.6.6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Any and all disputes with regard to voting for which neither the law nor the articles of association provide shall be decided by the chairman of the General Meeting.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:100.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><b style="color:#070520;font-size:10.5pt;font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><b style="color:#070520;font-size:10.5pt;font-weight:bold;">FINANCIAL YEAR. AUDITOR.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:100.65pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><font style="color:#070609;font-size:11pt;">9.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.79pt;margin-top:0pt;"><b style="color:#070609;font-size:10.5pt;font-weight:bold;">Financial year; Annual Statement of Accounts.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">9.1.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.64pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The financial year of the Company shall be the calendar year.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">9.1.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">Annually, within the term set by law, the Board shall prepare Annual Accounts.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.2pt;text-indent:-0.2pt;margin:0pt 0pt 0pt 179.15pt;"><font style="color:#050506;font-size:11pt;">The Annual Accounts shall be accompanied by the auditor&#39;s statement referred to in article 9.2.1, if the instruction referred to in that article has been given, by the Report of the Board of Directors, unless section 2:391 DCC does not apply to the Company, as well as by the other particulars to be added to those documents by virtue of applicable statutory provisions.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.2pt;text-indent:-0.2pt;margin:0pt 0pt 0pt 179.15pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.45pt;text-indent:-0.45pt;margin:0pt 0pt 0pt 177.25pt;"><font style="color:#050505;font-size:11pt;">The Annual Accounts shall be signed by all Board Members; if the signature of one or more of them is lacking, this shall be disclosed, stating the reasons therefor.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">9.1.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Company shall ensure that the Annual Accounts as prepared, the Report of the Board of Directors (if applicable) and the other particulars referred to in article 9.1.2 shall be made available at the office of the Company as of the date of the notice of the General Meeting at which they are to be discussed.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:0.4pt;text-align:justify;text-indent:-0.4pt;margin:0pt 0pt 0pt 177.3pt;"><font style="color:#050505;font-size:11pt;">The Shareholders and other Persons entitled to attend General Meetings may inspect the above documents at the office of the Company and obtain a copy thereof free of charge.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;"><font style="color:#070709;font-size:11pt;">9.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;"><b style="color:#070709;font-size:10.5pt;font-weight:bold;">Auditor.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:134.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">9.2.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The General Meeting shall instruct a registered accountant or another expert, as referred to in section 2:393, subsection 1 DCC, both hereinafter called: the &quot;auditor&quot;, to audit the Annual Accounts prepared by the Board, in accordance with the provisions of section 2:393, subsection 3 DCC. The auditor shall report on his audit to the Board and shall present the results of his examination regarding the accuracy of the Annual Accounts in an auditor&#39;s statement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">9.2.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">If the General Meeting fails to give such instructions, then the Board shall be so authorised.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">9.2.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The instruction given to the auditor may be revoked by the General Meeting and by the corporate body which has given such instruction. The instruction may only be revoked for good reasons with due observance of section 2:393, subsection 2 DCC.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.65pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">9.2.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050405;font-size:11pt;">The Board may give instructions to the auditor or any other auditor at the expense of the Company.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.7pt;margin-top:0pt;"><b style="color:#07070a;font-size:10.5pt;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.7pt;margin-top:0pt;"><b style="color:#07070a;font-size:10.5pt;font-weight:bold;">PROFITS.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:99.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;"><font style="color:#060608;font-size:11pt;">10.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;"><b style="color:#060608;font-size:10.5pt;font-weight:bold;">Profit and loss. Distributions on Shares.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.65pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">10.1.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">The Board will keep a share premium reserve and profit reserve for the Shares.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">10.1.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The Company may make distributions on Shares only to the extent that its shareholders&#39; equity exceeds the sum of the paid-up and called-up part of the capital and the reserves which must be maintained by law.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.9pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">10.1.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">Distributions of profit, meaning the net earnings after taxes shown by the adopted Annual Accounts, shall be made after the adoption of the Annual Accounts from which it appears that they are permitted, without prejudice to any of the other provisions of these articles of association.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:42.9pt;text-indent:-42.9pt;margin:0pt 0pt 0pt 135.45pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.15pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">10.1.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">The Board may determine that any amount out of the profit shall be added to the reserves.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">10.1.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">The profit remaining after application of article 10.1.4 shall be at the disposal of the General Meeting, which may resolve to carry it to the reserves or to distribute it among the Shareholders.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.4pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">10.1.6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">On a proposal of the Board the General Meeting may resolve to distribute to the Shareholders a dividend in the form of Shares in the share capital of the Company.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">10.1.7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Subject to the other provisions of this article 10.1 the General Meeting may, on a proposal made by the Board resolve to make distributions to the Shareholders to the debit of one (1) or several reserves which the Company is not prohibited from distributing by virtue of the law.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">10.1.8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#040405;font-size:11pt;">No dividends shall be paid on Shares held by the Company in its own share capital, unless such Shares are encumbered with a right of use and enjoyment </font><i style="color:#040405;font-size:10.5pt;font-style:italic;">(vruchtgebruik) </i><font style="color:#040405;font-size:11pt;">or pledge.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:100.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.95pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.6pt;margin-top:0pt;"><font style="color:#080809;font-size:11pt;">10.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.6pt;margin-top:0pt;"><b style="color:#080809;font-size:11pt;font-weight:bold;">Interim distributions.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">10.2.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">The Board may resolve to make interim distributions to the Shareholders if an interim statement of assets and liabilities shows that the requirement of article 10.1.2 has been met.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">10.2.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">The interim statement of assets and liabilities shall relate to the condition of the assets and liabilities on a date no earlier than the first day of the third month preceding the month in which the resolution to distribute is published. It shall be prepared on the basis of generally acceptable valuation methods. The amounts to be reserved under the law and these articles of association shall be included in the statement of assets and liabilities. It shall be signed by the Board Members. If the signature of one or more of them is lacking, this shall be disclosed, stating the reasons therefor.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:135.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040409;font-size:11pt;">10.2.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040409;font-size:11pt;">Any proposal for distribution of dividend on Shares and any resolution to distribute an interim dividend on Shares shall immediately be published by the Board in accordance with the regulations of the stock exchange where the Shares at the Company&#39;s request are officially listed. The notification shall specify the date when and the place where the dividend shall be payable or - in the case of a proposal for distribution of dividend - is expected to be made payable.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">10.2.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040405;font-size:11pt;">Dividends shall be payable no later than thirty (30) days after the date they were declared, unless the body declaring the dividend determines a different date.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">10.2.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#040404;font-size:11pt;">Dividends which have not been claimed upon the expiry of five (5) years and one (1) day after the date when they became payable shall be forfeited to the Company and shall be carried to the reserves.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:42.85pt;text-indent:-42.85pt;margin:0pt 0pt 0pt 136.29pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><font style="color:#051820;font-size:11pt;">HOLDINGA </font><font style="color:#07404b;font-size:11pt;">M</font><font style="color:#051820;font-size:11pt;white-space:pre-wrap;">ATTHIJSSEN  KRAAK</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.35pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">10.2.6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="color:#050506;font-size:11pt;">The Board may determine that distributions on Shares shall be made payable either in euro or in another currency.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:100.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.9pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#080709;font-size:10.5pt;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="color:#080709;font-size:10.5pt;font-weight:bold;">AMENDMENT OF THE ARTICLES OF ASSOCIATION, DISSOLUTION OF THE COMPANY.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:100.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.8pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">11.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">A resolution to amend the articles of association or to dissolve the Company may only be adopted at the proposal of the Board.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:101.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.7pt;margin-top:0pt;"><font style="color:#070708;font-size:11pt;">11.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:1.7pt;margin-top:0pt;"><b style="color:#070708;font-size:10.5pt;font-weight:bold;">Liquidation.</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.7pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">11.2.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">On the dissolution of the Company, the liquidation shall be carried out by the Board, unless otherwise resolved by the General Meeting.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">11.2.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">Pending the liquidation the provisions of these articles of association shall remain in force to the fullest extent possible.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:136.65pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.75pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">11.2.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="color:#050505;font-size:11pt;">The surplus assets of the Company remaining after satisfaction of its debts shall, in accordance with the provisions of section 2:23b DCC, be for the benefit of the Shareholders in proportion to the nominal value amount of the Shares held by each of them.</font></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>qure-20210630xex4d1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 7/26/2021 08:01:55 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 4.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">uniQure N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">2014 Share Incentive Plan</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Amended and Restated effective as of June&#160;16, 2021)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Purpose</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The purpose of this 2014 Share Incentive Plan, as herein amended and restated (the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) of uniQure N.V., a public limited company incorporated under the laws of the Netherlands (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), is to advance the interests of the Company&#8217;s shareholders by enhancing the Company&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company&#8217;s shareholders. Except where the context otherwise requires, the term &#8220;<b style="font-weight:bold;">Company</b>&#8221; shall include any of the Company&#8217;s present or future parent or subsidiary corporations as defined in Sections 424(e)&#160;or (f)&#160;of the U.S. Internal Revenue Code of 1986, as amended, and any regulations thereunder (the &#8220;<b style="font-weight:bold;">Code</b>&#8221;) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the &#8220;<b style="font-weight:bold;">Board</b>&#8221;). The Plan was initially effective as of January&#160;9, 2014 and was amended and restated effective as of June&#160;10, 2015, June 15, 2016, and June&#160;13, 2018. This amended and restated Plan will be effective as of June 16, 2021, subject to the approval of the Company&#8217;s shareholders (the &#8220;<b style="font-weight:bold;">Amendment Effective Date</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Changes made pursuant to this amendment and restatement shall only apply to Awards granted on or after the Amendment Effective Date. Awards granted prior to the Amendment Effective Date shall continue to be governed by the applicable Award agreements and the terms of the Plan, without giving effect to changes made pursuant to this amendment and restatement, and the Board shall administer such Awards in accordance with the Plan, without giving effect to changes made pursuant to this amendment and restatement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Eligibility</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">All of the Company&#8217;s employees, executive directors and non-executive directors, as well as consultants and advisors to the Company (as such terms are defined and interpreted for purposes of Form&#160;S-8 under the Securities Act of 1933, as amended (the &#8220;<b style="font-weight:bold;">Securities Act</b>&#8221;), or any successor form) are eligible to be granted Awards under the Plan. Eligibility to participate in the Plan shall be determined at the sole discretion of the Board. Each person who is granted an Award under the Plan is deemed a &#8220;<b style="font-weight:bold;">Participant</b>.&#8221; &#8220;<b style="font-weight:bold;">Award</b>&#8221; means Options (as defined in Section&#160;5), SARs (as defined in Section&#160;6), Restricted Shares (as defined in Section&#160;7), Restricted Share Units (as defined in Section&#160;7) and Other Share-Based Awards (as defined in Section&#160;8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Administration and Delegation</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Administration by the Board</u><font style="font-size:10pt;">. The Plan will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe and interpret the terms of the Plan and any Award agreements entered into under the Plan. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board&#8217;s sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Appointment of Committees</u><font style="font-size:10pt;">. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (a &#8220;</font><b style="font-size:10pt;font-weight:bold;">Committee</b><font style="font-size:10pt;">&#8221;). All references in the Plan to the &#8220;</font><b style="font-size:10pt;font-weight:bold;">Board</b><font style="font-size:10pt;">&#8221; shall mean the Board or a Committee of the Board to the extent that the Board&#8217;s powers or authority under the Plan have been delegated to such Committee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Shares Available for Awards</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Number of Shares; Share Counting</u><font style="font-size:10pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Authorized Number of Shares. Subject to adjustment under Section&#160;9, the aggregate number of ordinary shares (&#8364;0.05 par value per share) of the Company (the &#8220;</font><b style="font-size:10pt;font-weight:bold;">Ordinary Shares</b><font style="font-size:10pt;">&#8221;) that may be issued on or after the Amendment Effective Date with respect to Awards granted under the Plan shall not exceed 12,601,471.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Share Counting</u><font style="font-size:10pt;">. For purposes of counting the number of shares available for the grant of Awards under the Plan:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:108pt;margin:0pt;"><font style="font-size:10pt;">(A)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">the gross number of Ordinary Shares covered by SARs shall be counted against the number of shares available for the grant of Awards under the Plan; provided, however, that (i)&#160;SARs that may be settled only in cash shall not be so counted and (ii)&#160;if the Company grants a SAR in tandem with an Option for the same number of Ordinary Shares and provides that only one such Award may be exercised (a &#8220;</font><b style="font-size:10pt;font-weight:bold;">Tandem SAR</b><font style="font-size:10pt;">&#8221;), only the shares covered by the Option, and not the shares covered by the Tandem SAR, shall be so counted, and the expiration of one in connection with the other&#8217;s exercise will not restore shares to the Plan;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:108pt;margin:0pt;"><font style="font-size:10pt;">(B)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">if any Award (i)&#160;expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of Ordinary Shares subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or (ii)&#160;results in any Ordinary Shares not being issued (including as a result of a SAR that was settleable either in cash or in shares actually being settled in cash), the unused Ordinary Shares covered by such Award shall again be available for the grant of Awards; provided, however, that (1)&#160;in the case of Incentive Share Options, the foregoing shall be subject to any limitations under the Code, (2)&#160;in the case of the exercise of a SAR, the number of shares counted against the shares available under the Plan shall be the gross number of shares subject to the SAR multiplied by the percentage of the SAR actually exercised, regardless of the number of shares actually used to settle such SAR upon exercise and (3)&#160;the shares covered by a Tandem SAR shall not again become available for grant upon the expiration or termination of such Tandem SAR; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:108pt;margin:0pt;"><font style="font-size:10pt;">(C)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Ordinary Shares delivered (either by actual delivery, attestation, or net exercise) to the Company by a Participant to (i)&#160;purchase Ordinary Shares upon the exercise of an Award or (ii)&#160;satisfy tax withholding obligations with respect to Options and SARs (including shares retained from the Option or SAR creating the tax obligation) shall not be added back to the number of shares available for the future grant of Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Substitute Awards</u><font style="font-size:10pt;">. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity, the Board may grant Awards in substitution for any options or other share or share-based awards granted by such entity or an affiliate thereof. Substitute Awards may be granted on such terms as the Board deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in Section&#160;4(a), except as may be required by reason of Section&#160;422 and related provisions of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Share Options</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">General</u><font style="font-size:10pt;">. The Board may grant options to purchase Ordinary Shares (each, an &#8220;</font><b style="font-size:10pt;font-weight:bold;">Option</b><font style="font-size:10pt;">&#8221;) and determine the number of Ordinary Shares to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to applicable securities laws, as it considers necessary or advisable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Incentive Share Options</u><font style="font-size:10pt;">. An Option that the Board intends to be an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code (an &#8220;</font><b style="font-size:10pt;font-weight:bold;">Incentive Share Option</b><font style="font-size:10pt;">&#8221;) shall only be granted to employees of uniQure N.V., any of uniQure N.V.&#8217;s present or future parent or subsidiary corporations as defined in Sections 424(e)&#160;or (f)&#160;of the Code, and any other entities the employees of which are eligible to receive Incentive Share Options under the Code, and shall be subject to and shall be construed consistently with the requirements of Section&#160;422 of the Code. An Option that is not intended to be an Incentive Share Option shall be designated a &#8220;</font><b style="font-size:10pt;font-weight:bold;">Share Option</b><font style="font-size:10pt;">.&#8221; The Company shall have no liability to a Participant, or any other party, if an Option (or any part thereof) that is intended to be an Incentive Share Option is not an Incentive Share Option or if the Company converts an Incentive Share Option to a Share Option. Awards with respect to a maximum of 200,000 Ordinary Shares may be granted in the form of Incentive Share Options under the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Exercise Price</u><font style="font-size:10pt;">. The Board shall establish the exercise price of each Option and specify the exercise price in the applicable Option agreement which shall be not less than 100% of the Fair Market Value per Ordinary Share on the date the Option is granted; provided, however, that if the Board approves the grant of an Option with an exercise price to be determined on a future date, the exercise price shall be not less than 100% of the Fair Market Value on such future date. For purposes of the Plan, unless otherwise required by applicable law, the Fair Market Value per Ordinary Share as of any date shall be (A)&#160;if the Ordinary Shares are readily tradeable on a national securities exchange or other market system, either (I)&#160;or (II), as determined by the Board on or prior to the date of grant, where (I)&#160;is the average of the closing sales prices of the Ordinary Shares during regular trading hours for the ten trading days following the date of grant and (II)&#160;is the closing sales price of the Ordinary Shares during regular trading hours on the date of grant, or (B)&#160;if the Ordinary Shares are not readily tradeable on a national securities exchange or other market system, the amount determined in good faith by (or in a manner approved by) the Board (&#8220;</font><b style="font-size:10pt;font-weight:bold;">Fair Market Value</b><font style="font-size:10pt;">&#8221;). Notwithstanding the foregoing (x)&#160;for purposes of any Option intended to be an Incentive Share Option, Fair Market Value shall be determined in accordance with the applicable provisions of Section&#160;422 of the Code and the corresponding regulations, (y)&#160;for purposes of any Share Option granted to a Participant who is subject to taxation in the United States, Fair Market Value shall be determined in accordance with the applicable provisions of Section&#160;409A of the Code and the corresponding regulations and (z)&#160;in no event shall the exercise price of any Option be less than the nominal value per Ordinary Share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Duration of Options</u><font style="font-size:10pt;">. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable option agreement; provided, however, that no Option will be granted with a term in excess of 10 years.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Exercise of Options</u><font style="font-size:10pt;">. Options may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved by the Company, together with payment in full (in the manner specified in Section&#160;5(f)) of the exercise price for the number of shares for which the Option is exercised. Ordinary Shares subject to the Option will be delivered by the Company as soon as practicable following exercise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Payment Upon Exercise</u><font style="font-size:10pt;">. Ordinary Shares purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">By wire transfer, in cash or by check, payable to the order of the Company;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">except as may otherwise be provided in the applicable Option agreement or approved by the Board, in its sole discretion, by (i)&#160;delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii)&#160;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;">(3)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">to the extent provided for in the applicable Option agreement or approved by the Board, in its sole discretion, by delivery (either by actual delivery or attestation) of Ordinary Shares owned by the Participant valued at their Fair Market Value, provided (i)&#160;such method of payment is then permitted under applicable law, (ii)&#160;such Ordinary Shares, if acquired directly from the Company, were owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (iii)&#160;such Ordinary Shares are not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;">(4)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">to the extent provided for in the applicable Share Option agreement or approved by the Board in its sole discretion, by delivery of a notice of &#8220;net exercise&#8221; to the Company, as a result of which the Participant would receive (i)&#160;the number of shares underlying the portion of the Option being exercised, less (ii)&#160;such number of shares as is equal to (A)&#160;the aggregate exercise price for the portion of the Option being exercised divided by (B)&#160;the Fair Market Value on the date of exercise;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;">(5)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">to the extent permitted by applicable law and provided for in the applicable Option agreement or approved by the Board, in its sole discretion, by payment of such other lawful consideration as the Board may determine; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:10pt;">(6)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">by any combination of the above permitted forms of payment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Share Appreciation Rights</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">General</u><font style="font-size:10pt;">. The Board may grant Awards consisting of share appreciation rights (&#8220;</font><b style="font-size:10pt;font-weight:bold;">SARs</b><font style="font-size:10pt;">&#8221;) entitling the holder, upon exercise, to receive an amount of Ordinary Shares or cash or a combination thereof (such form to be determined by the Board) determined by reference to appreciation, from and after the date of grant, in the Fair Market Value of an Ordinary Share over the measurement price established pursuant to Section&#160;6(b). The date as of which such appreciation is determined shall be the exercise date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Measurement Price</u><font style="font-size:10pt;">. The Board shall establish the measurement price of each SAR and specify it in the applicable SAR agreement. The measurement price shall not be less than 100% of the Fair Market Value on the date the SAR is granted; provided that if the Board approves the grant of a SAR effective as of a future date, the measurement price shall be not less than 100% of the Fair Market Value on such future date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Duration of SARs</u><font style="font-size:10pt;">. Each SAR shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable SAR agreement; provided, however, that no SAR will be granted with a term in excess of 10 years.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Exercise of SARs</u><font style="font-size:10pt;">. SARs may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved by the Company, together with any other documents required by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Restricted Shares; Restricted Share Units</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">General</u><font style="font-size:10pt;">. The Board may grant Awards entitling recipients to acquire Ordinary Shares (&#8220;</font><b style="font-size:10pt;font-weight:bold;">Restricted Shares</b><font style="font-size:10pt;">&#8221;), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. The Board may also grant Awards entitling the recipient to receive Ordinary Shares or cash to be delivered at the time such Award vests (&#8220;</font><b style="font-size:10pt;font-weight:bold;">Restricted Share Units</b><font style="font-size:10pt;">&#8221;) (Restricted Shares and Restricted Share Units are each referred to herein as a &#8220;</font><b style="font-size:10pt;font-weight:bold;">Restricted Share Award</b><font style="font-size:10pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Terms and Conditions for All Restricted Share Awards</u><font style="font-size:10pt;">. The Board shall determine the terms and conditions of a Restricted Share Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Additional Provisions Relating to Restricted Shares</u><font style="font-size:10pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Dividends</u><font style="font-size:10pt;">. Unless otherwise provided in the applicable Award agreement, any dividends (whether paid in cash or shares) declared and paid by the Company with respect to shares of Restricted Shares (&#8220;</font><b style="font-size:10pt;font-weight:bold;">Accrued Dividends</b><font style="font-size:10pt;">&#8221;) shall be paid to the Participant only if and when such shares become free from the restrictions on transferability and forfeitability that apply to such shares. Each payment of Accrued Dividends will be made no later than the end of the calendar year in which the dividends are paid to shareholders of that class of shares or, if later, the 15th day of the third month following the lapsing of the restrictions on transferability and the forfeitability provisions applicable to the underlying shares of Restricted Share. For the avoidance of doubt, dividends declared and paid by the Company with respect to Restricted Shares that are subject to performance-based restrictions on transfer and forfeitability shall be paid if and to the extent that the restrictions on transfer and forfeitability with respect to the underlying Restricted Shares lapse, as determined by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Additional Provisions Relating to Restricted Share Units</u><font style="font-size:10pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Settlement</u><font style="font-size:10pt;">. Upon the vesting of and/or lapsing of any other restrictions (i.e., settlement) with respect to each Restricted Share Unit, the Participant shall be entitled to receive from the Company the number of shares of Ordinary Shares set forth in the applicable Award agreement or (if so provided in the applicable Award agreement) an amount of cash equal to the Fair Market Value of one of such number of Ordinary Shares. The Board may, in its discretion, provide that settlement of Restricted Share Units shall be deferred, on a mandatory basis or at the election of the Participant in a manner that complies with Section&#160;409A of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Voting Rights</u><font style="font-size:10pt;">. A Participant shall have no voting rights with respect to any Restricted Share Units.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;">(3)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Dividend Equivalents</u><font style="font-size:10pt;">. The Award agreement for Restricted Share Units may provide Participants with the right to receive an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding Ordinary Shares (&#8220;</font><b style="font-size:10pt;font-weight:bold;">Dividend Equivalents</b><font style="font-size:10pt;">&#8221;). Dividend Equivalents may be paid currently or credited to an account for the Participant, may be settled in cash and/or Ordinary Shares and may be subject to the same restrictions as the Restricted Share Units with respect to which paid, in each case to the extent provided in the Award agreement. Notwithstanding the foregoing, Dividend Equivalents with respect to Restricted Share Units that are subject to performance-based restrictions shall only be paid if and to the extent that the restrictions with respect to the underlying Restricted Share Units lapse, as determined by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Other Share-Based Awards</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">General</u><font style="font-size:10pt;">. Other Awards of Ordinary Shares, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, Ordinary Shares or other property, may be granted hereunder to Participants (&#8220;</font><b style="font-size:10pt;font-weight:bold;">Other Share-Based-Awards</b><font style="font-size:10pt;">&#8221;). Such Other Share-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Share-Based Awards may be paid in Ordinary Shares or cash, as the Board shall determine.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Terms and Conditions</u><font style="font-size:10pt;">. Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other Share-Based Award, including any purchase price applicable thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Adjustments for Changes in Ordinary Shares and Certain Other Events</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Changes in Capitalization</u><font style="font-size:10pt;">. In the event of any share split, share consolidation, share dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Ordinary Shares other than an ordinary cash dividend, (i)&#160;the number and class of securities available under the Plan, (ii)&#160;the share counting rules&#160;set forth in Section&#160;4(a), (iii)&#160;the number and class of securities and exercise price per share of each outstanding Option, (iv)&#160;the share and per-share provisions and the measurement price of each outstanding SAR, (v)&#160;the number of shares subject to and the repurchase price per share subject to each outstanding Restricted Share Award and (vi)&#160;the share and per-share-related provisions and the purchase price, if any, of each outstanding Restricted Share Unit or Other Share-Based Award, shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board. Without limiting the generality of the foregoing and subject to compliance with Section&#160;409A of the Code, if applicable, in the event the Company effects a split of the Ordinary Shares by means of a share dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then an optionee who exercises an Option between the record date and the distribution date for such share dividend shall be entitled to receive, on the distribution date, the share dividend with respect to the Ordinary Shares acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such share dividend.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Reorganization Events</u><font style="font-size:10pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:72pt;margin:0pt;"><font style="font-size:10pt;">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Definition</u><font style="font-size:10pt;">. A &#8220;</font><b style="font-size:10pt;font-weight:bold;">Reorganization Event</b><font style="font-size:10pt;">&#8221; shall be deemed to have occurred upon any of the following events:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:108pt;margin:0pt;"><font style="font-size:10pt;">(A)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">any person or other entity (other than any of the Company&#8217;s subsidiaries or any employee benefit plan sponsored by the Company or any of its subsidiaries), including any person as defined in Section&#160;13(d)(3)&#160;of the Securities Exchange Act of 1934, as amended (the &#8220;</font><b style="font-size:10pt;font-weight:bold;">Exchange Act</b><font style="font-size:10pt;">&#8221;), becomes the beneficial owner, as defined in Rule&#160;13d-3 under the Exchange Act, directly or indirectly, of more than 50% of the total combined voting power of all classes of capital stock of the Company normally entitled to vote for the election of directors of the Company (the &#8220;Voting Stock&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:108pt;margin:0pt;"><font style="font-size:10pt;">(B)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">consummation of the sale of all or substantially all of the property or assets of the Company; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:108pt;margin:0pt;"><font style="font-size:10pt;">(C)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">consummation of a consolidation or merger of the Company with another corporation (other than with any of the Company&#8217;s subsidiaries), which results in the stockholders of the Company immediately before the occurrence of the consolidation or merger owning, in the aggregate, less than 51% of the Voting Stock of the surviving entity.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notwithstanding the foregoing, the Board may provide for a different definition of &#8220;Change in Control&#8221; in an Award agreement if it determines that such different definition is necessary or appropriate, including without limitation, to comply with the requirements of Section&#160;409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:10pt;">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Consequences of a Reorganization Event on Awards</u><font style="font-size:10pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:108pt;margin:0pt;"><font style="font-size:10pt;">(A)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">In connection with a Reorganization Event where the Company is not the surviving corporation (or survives only as a subsidiary of another corporation), unless the Board determines otherwise, all outstanding Awards that are not exercised or paid at the time of the Reorganization Event shall be assumed by, or replaced with Awards that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation). After a Reorganization Event, references to the &#8220;Company&#8221; as they relate to employment matters shall include the successor employer, unless the Board provides otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:108pt;margin:0pt;"><font style="font-size:10pt;">(B)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Unless the Award agreement provides otherwise, if a Participant&#8217;s employment or other service is terminated by the Company without cause (as determined by the Board) upon or within 12 months following a Reorganization Event, the Participant&#8217;s outstanding Awards shall become fully exercisable and any restrictions on such Awards shall lapse as of the date of such termination; provided that if the restrictions on any such Awards is based, in whole or in part, on performance, the applicable Award agreement shall specify how the portion of the Award that becomes vested pursuant to this Section&#160;9(b)(2)&#160;shall be calculated.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:108pt;margin:0pt;"><font style="font-size:10pt;">(C)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">In connection with a Reorganization Event, if all outstanding Awards are not assumed by, or replaced with Awards that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation), the Board may take any one or more of the following actions as to all or any (or any portion of) outstanding Awards on such terms as the Board determines without the consent of any Participant (except to the extent specifically provided otherwise in an applicable Award agreement or another agreement between the Company and the Participant): (i)&#160;upon written notice to a Participant, provide that all of the Participant&#8217;s unexercised and/or unvested Awards will terminate immediately prior to the consummation of such Reorganization Event unless exercised by the Participant (to the extent then exercisable) within a specified period following the date of such notice, (ii)&#160;provide that outstanding Awards shall become exercisable, realizable, or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (iii)&#160;in the event of a Reorganization Event under the terms of which holders of Ordinary Shares will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the &#8220;</font><b style="font-size:10pt;font-weight:bold;">Acquisition Price</b><font style="font-size:10pt;">&#8221;), make or provide for a cash payment to Participants with respect to each Award held by a Participant equal to (I)&#160;the number of shares of Ordinary Shares subject to the vested portion of the Award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such Reorganization Event) multiplied by (II)&#160;the excess, if any, of (x)&#160;the Acquisition Price over (y)&#160;the exercise, measurement or purchase price of such Award and any applicable tax withholdings, in exchange for the termination of such Award, (iv)&#160;provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings) and (v)&#160;any combination of the foregoing. In taking any of the actions permitted under this Section&#160;9(b)(2), the Board shall not be obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically. Such surrender, termination or payment shall take place as of the date of the Reorganization Event or such other date as the Board may specify. Without limiting the foregoing, (1)&#160;if the per share Acquisition Price does not exceed the per share Option exercise price or SAR measurement price, as applicable, the Company shall not be required to make any payment to the Participant upon surrender of the Option or SAR and (2)&#160;upon the occurrence of a Reorganization Event involving the liquidation or dissolution of the Company, except to the extent specifically provided to the contrary in the instrument evidencing any Restricted Shares or any other agreement between a Participant and the Company, all restrictions and conditions on all Restricted Shares then outstanding shall automatically be deemed terminated or satisfied.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:108pt;margin:0pt;"><font style="font-size:10pt;">(D)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Notwithstanding the foregoing in this Section&#160;9(b)(2), in the case of outstanding Restricted Share Units that are subject to Section&#160;409A of the Code: (i)&#160;if the applicable Restricted Share Unit agreement provides that the Restricted Share Units shall be settled upon a &#8220;change in control event&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">within the meaning of U.S. Treasury Regulation Section&#160;1.409A-3(i)(5)(i), and the Reorganization Event constitutes such a &#8220;change in control event&#8221;, then no assumption or substitution shall be permitted pursuant to Section&#160;9(b)(2)(A)&#160;and the Restricted Share Units shall instead be settled in accordance with the terms of the applicable Restricted Share Unit agreement; and (ii)&#160;the Board may only undertake the actions set forth in clauses (ii), (iii)&#160;or (iv)&#160;of Section&#160;9(b)(2)(C)&#160;if the Reorganization Event constitutes a &#8220;change in control event&#8221; as defined under U.S. Treasury Regulation Section&#160;1.409A-3(i)(5)(i)&#160;and such action is permitted or required by Section&#160;409A of the Code; if the Reorganization Event is not a &#8220;change in control event&#8221; as so defined or such action is not permitted or required by Section&#160;409A of the Code, and the acquiring or succeeding corporation does not assume or substitute the Restricted Share Units pursuant to Section&#160;9(b)(2)(A), then the unvested Restricted Share Units shall terminate immediately prior to the consummation of the Reorganization Event without any payment in exchange therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:108pt;margin:0pt;"><font style="font-size:10pt;">(E)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">For purposes of Section&#160;9(b)(2)(A), an Award (other than Restricted Shares) shall be considered assumed if, following consummation of the Reorganization Event, such Award confers the right to purchase or receive pursuant to the terms of such Award, for each Ordinary Share subject to the Award immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Ordinary Shares for each Ordinary Share held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Ordinary Shares); provided, however, that if the consideration received as a result of the Reorganization Event is not solely ordinary shares or common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise or settlement of the Award to consist solely of such number of ordinary shares or common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determined to be equivalent in value (as of the date of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding Ordinary Shares as a result of the Reorganization Event.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">General Provisions Applicable to Awards</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Transferability of Awards</u><font style="font-size:10pt;">. Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution applicable to such Participant or, other than in the case of an Incentive Share Option, pursuant to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant; provided, however, that the Board may permit or provide in an Award for the gratuitous transfer of the Award by the Participant to or for the benefit of any immediate family member, family trust or other entity established for the benefit of the Participant and/or an immediate family member thereof if the Company would be eligible to use a Form&#160;S-8 under the Securities Act for the registration of the sale of the Ordinary Shares subject to such Award to such proposed transferee; provided further, that the Company shall not be required to recognize any such permitted transfer until such time as such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument in form and substance satisfactory to the Company confirming that such transferee shall be bound by all of the terms and conditions of the Award. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees. For the avoidance of doubt, nothing contained in this Section&#160;10(a)&#160;shall be deemed to restrict a transfer to the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Documentation</u><font style="font-size:10pt;">. Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each Award may contain terms and conditions in addition to those set forth in the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Board Discretion</u><font style="font-size:10pt;">. Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Termination of Status</u><font style="font-size:10pt;">. The Board shall determine the effect on an Award of the disability, death, termination or other cessation of employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant&#8217;s legal representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Award. &#8220;</font><b style="font-size:10pt;font-weight:bold;">Designated Beneficiary</b><font style="font-size:10pt;">&#8221; means (i)&#160;the beneficiary designated, in a manner determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">event of the Participant&#8217;s death or (ii)&#160;in the absence of an effective designation by a Participant, the Participant&#8217;s estate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Withholding</u><font style="font-size:10pt;">. The Participant must satisfy all applicable Dutch, United States and other applicable national, federal, state, and local or other income, national insurance, social and employment tax withholding obligations before the Company will deliver or otherwise recognize ownership of Ordinary Shares under an Award. The Company may decide to satisfy the withholding obligations through additional withholding on salary or wages. If the Company elects not to or cannot withhold from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a broker tender to the Company cash equal to the withholding obligations. Payment of withholding obligations is due before the Company will issue any shares on exercise, vesting or release from forfeiture of an Award or at the same time as payment of the exercise or purchase price, unless the Company determines otherwise. If provided for in an Award or approved by the Board in its sole discretion, a Participant may satisfy such tax obligations in whole or in part by delivery (either by actual delivery or attestation) of Ordinary Shares, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value; provided, however, except as otherwise provided by the Board, that the total tax withholding where shares are being used to satisfy such tax obligations cannot exceed the Company&#8217;s minimum statutory withholding obligations (based on minimum statutory withholding rates for Dutch, United States and other applicable national, federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income). Shares used to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Amendment of Award</u><font style="font-size:10pt;">. Subject to Section&#160;11(c), the Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or realization, and converting an Incentive Share Option to a Share Option. The Participant&#8217;s consent to such action shall be required unless (i)&#160;the Board determines that the action, taking into account any related action, does not materially and adversely affect the Participant&#8217;s rights under the Plan or (ii)&#160;the change is permitted under Section&#160;9.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Conditions on Delivery of Ordinary Shares</u><font style="font-size:10pt;">. The Company will not be obligated to deliver any Ordinary Shares pursuant to the Plan or to remove restrictions from shares previously issued or delivered under the Plan until (i)&#160;all conditions of the Award have been met or removed to the satisfaction of the Company, (ii)&#160;in the opinion of the Company&#8217;s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock market rules&#160;and regulations, and (iii)&#160;the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules&#160;or regulations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Acceleration</u><font style="font-size:10pt;">. Notwithstanding Section&#160;10(i), the Board may at any time provide that any Award shall become immediately exercisable in whole or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Minimum Vesting</u><font style="font-size:10pt;">. Awards granted under the Plan shall vest or become exercisable over a period that is not less than one year from the date of grant. Subject to any adjustments made in accordance with Section&#160;9(a)&#160;above, up to 5% of the Ordinary Shares subject to the share reserve set forth in Section&#160;4(a)(1)&#160;may be granted without regard to the minimum vesting requirement of this Section&#160;10(i).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Miscellaneous</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">No Right To Employment or Other Status</u><font style="font-size:10pt;">. No person shall have any claim or right to be granted an Award by virtue of the adoption of the Plan, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan, except as expressly provided in the applicable Award. This Plan will not be considered a part of any employment agreement in force between the Participant and the Company and/or a group company. The grant of an Award does not qualify as an employment condition and shall not be included in the calculation of any severance payment or any other payments in connection with the Participant&#8217;s employment agreement or the termination thereof. The granting of an Award or the vesting thereof does not in any way affect the scope or level of the Participant&#8217;s pension rights, pension entitlements and/or of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">any other entitlements vis-a-vis the Company and/or a group company. The granting of an Award is at the sole discretion of the Board and does not entitle the Participant to any future Awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">No Rights As Shareholder</u><font style="font-size:10pt;">. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a shareholder with respect to any Ordinary Shares to be distributed with respect to an Award until becoming the record holder of such shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">No Repricing</u><font style="font-size:10pt;">. Except in connection with a corporate transaction involving the Company (including, without limitation, any stock dividend, distribution (whether in the form of cash, Ordinary Shares, other securities or property), stock split, extraordinary cash dividend, recapitalization, change in control, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of Ordinary Shares or other securities, or similar transactions), the Company may not, without obtaining shareholder approval, (i)&#160;amend the terms of outstanding Options or SARs to reduce the exercise price of such outstanding Options or measurement price of such SARs, (ii)&#160;cancel outstanding Options or SARs in exchange for Options or SARs with an exercise price or measurement price, as applicable, that is less than the exercise price or measurement price of the original Options or SARs or (iii)&#160;cancel outstanding Options or SARs with an exercise price or measurement price, as applicable, above the current stock price in exchange for cash or other securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Effective Date and Term of Plan</u><font style="font-size:10pt;">. The Plan became effective on January&#160;9, 2014, which is the date the Plan is approved by the Company&#8217;s shareholders (the &#8220;</font><b style="font-size:10pt;font-weight:bold;">Effective Date</b><font style="font-size:10pt;">&#8221;). No Awards shall be granted under the Plan after the expiration of 10 years from the Effective Date, but Awards previously granted may extend beyond that date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Amendment of Plan</u><font style="font-size:10pt;">. Subject to Section&#160;11(c), the Board may amend, suspend or terminate the Plan or any portion thereof at any time provided that no amendment that would require shareholder approval under the rules&#160;of the NASDAQ Stock Market may be made effective unless and until the Company&#8217;s shareholders approve such amendment. In addition, if at any time the approval of the Company&#8217;s shareholders is required as to any other modification or amendment under Section&#160;422 of the Code or any successor provision with respect to Incentive Share Options, the Board may not effect such modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance with this Section&#160;11(e)&#160;shall apply to, and be binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, provided the Board determines that such amendment, taking into account any related action, does not materially and adversely affect the rights of Participants under the Plan. No Award shall be made that is conditioned upon shareholder approval of any amendment to the Plan unless the Award provides that (i)&#160;it will terminate or be forfeited if shareholder approval of such amendment is not obtained within no more than 12 months from the date of grant and (ii)&#160;it may not be exercised or settled (or otherwise result in the issuance of Ordinary Shares) prior to such shareholder approval.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Authorization of Sub-Plans</u><font style="font-size:10pt;">. The Board may from time to time establish one or more sub-plans under the Plan for purposes of satisfying applicable securities, tax or other laws of various jurisdictions. The Board shall establish such sub-plans by adopting supplements to the Plan containing (i)&#160;such limitations on the Board&#8217;s discretion under the Plan as the Board deems necessary or desirable or (ii)&#160;such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Compliance with Section&#160;409A of the Code</u><font style="font-size:10pt;">. Except as provided in individual Award agreements initially or by amendment, if and to the extent (i)&#160;any portion of any payment, compensation or other benefit provided to a Participant pursuant to the Plan in connection with his or her employment termination constitutes &#8220;nonqualified deferred compensation&#8221; within the meaning of Section&#160;409A of the Code and (ii)&#160;the Participant is a specified employee as defined in Section&#160;409A(a)(2)(B)(i)&#160;of the Code, in each case as determined by the Company in accordance with its procedures, by which determinations the Participant (through accepting the Award) agrees that he or she is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six months plus one day after the date of &#8220;separation from service&#8221; (as determined under Section&#160;409A of the Code) (the &#8220;</font><b style="font-size:10pt;font-weight:bold;">New Payment Date</b><font style="font-size:10pt;">&#8221;), except as Section&#160;409A of the Code may then permit. The aggregate of any payments that otherwise would have been paid to the Participant during the period between the date of separation from service and the New Payment Date shall be paid to the Participant in a lump sum on such New Payment Date, and any remaining payments will be paid on their original schedule.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company makes no representations or warranty and shall have no liability to the Participant or any other person if any provisions of or payments, compensation or other benefits under the Plan are determined to constitute nonqualified deferred compensation subject to Section&#160;409A of the Code but do not to satisfy the conditions of that section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Limitations on Liability</u><font style="font-size:10pt;">. Notwithstanding any other provisions of the Plan, no individual acting as a supervisory director, managing director, employee or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan, nor will such individual be personally liable with respect to the Plan because of any contract or other instrument he or she executes in his or her capacity as a supervisory director, managing director, employee or agent of the Company. The Company will indemnify and hold harmless each supervisory director, managing director, employee or agent of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been or will be delegated, against any cost or expense (including attorneys&#8217; fees) or liability (including any sum paid in settlement of a claim with the Board&#8217;s approval) arising out of any act or omission to act concerning the Plan unless arising out of such person&#8217;s own fraud or bad faith.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Data Protection</u><font style="font-size:10pt;">. The Participant hereby fully consents to the processing and transfer of all relevant data in the context of the administration of this Plan and the Award Agreement. The Participant shall keep the Company fully informed of any changes in the relevant data.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Share Trading, Recoupment and Other Policies</u><font style="font-size:10pt;">. All Awards made under the Plan shall be subject to any applicable clawback and recoupment policies, share trading policies and other policies that may be implemented by the Board from time to time, including, without limitation, the Company&#8217;s right to recover Awards, Ordinary Shares or any gains upon the sale of Ordinary Shares issued under the Plan in the event of a financial restatement due in whole or in part to fraud or misconduct by one or more of the Company&#8217;s executives or in the event a Participant violates any applicable restrictive covenants in favor of the Company to which the Participant is subject.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="font-size:10pt;text-decoration:underline;text-decoration-color:#000000;">Governing Law</u><font style="font-size:10pt;">. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of the Netherlands, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than the Netherlands. Any disputes arising out of or in connection with the Plan shall, to the extent permitted by law, be submitted exclusively to the competent court of Amsterdam, the Netherlands.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>qure-20210630xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 7/26/2021 08:01:59 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt 0pt 24pt 0pt;"><b style="font-size:21pt;font-weight:bold;">Employment Agreement</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 0pt;"><font style="font-size:12pt;">dated 17 May 2021</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 0pt;"><font style="font-size:12pt;">by and between</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:80.39%;border-top:1px solid #a69d64;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">uniQure biopharma B.V., </b></p></td><td style="vertical-align:top;width:19.6%;border-top:1px solid #a69d64;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">(the</font><b style="font-size:12pt;font-weight:bold;"> Company</b><font style="font-size:12pt;">)</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Paasheuvelweg 25a</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">1105 BP Amsterdam</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">The Netherlands</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:80.39%;border-top:1px solid #a69d64;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pierre Caloz</b></p></td><td style="vertical-align:top;width:19.6%;border-top:1px solid #a69d64;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">(the</font><b style="font-size:12pt;font-weight:bold;"> Employee</b><font style="font-size:12pt;">)</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 24pt 0pt;"><font style="font-size:12pt;">(The Company and the Employee are also referred to as </font><b style="font-size:12pt;font-weight:bold;">Party</b><font style="font-size:12pt;"> or </font><b style="font-size:12pt;font-weight:bold;">Parties</b><font style="font-size:12pt;">)</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 9pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">1 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Table of Contents</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:13pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">1.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Condition Precedent</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">5</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">2.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Commencement Date</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">5</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">3.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Function and Job Title</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">5</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">4.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Group Structure</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">5</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">5.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Duties and Responsibilities</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">5</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">6.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Work for Third Parties</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">6</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">7.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Officer Position</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">6</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">8.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Conflict of Interests</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">7</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">9.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Gifts</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">7</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">10.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Place of Work</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">7</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">10.1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Remote Working</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">7</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">10.2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Standards for Remote Working</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">8</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">10.3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Equipment and Data Safety regarding Remote Working</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">8</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">10.4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Remote Working Allowance</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">9</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">11.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Compensation</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">9</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">11.1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Base Salary</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">9</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">11.2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bonus</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">10</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">11.3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Participation Plan</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">10</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">11.4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Sign-On Bonus</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">11</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">11.5. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Acknowledgements of the Employee</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">12</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">11.6. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No other Compensation</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">12</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">11.7. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Social security, tax and deductions</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">12</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">12.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Expenses</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">13</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">13.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Probation Period and Termination</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">14</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">13.1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Probation Period</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">14</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">2 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">13.2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Termination</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">14</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">13.3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Severance Generally</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">14</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">13.4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Severance on a Change of Control</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">15</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">13.5. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Release from Work (Garden Leave) </font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">17</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">14.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Work Equipment and Obligation to Return Work Equipment</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">18</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">15.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Working Time</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">18</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">15.1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;General</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">18</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">15.2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional Work</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">18</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">16.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Vacation</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">19</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">17.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Public Holidays and Short Absences</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">19</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">17.1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Public Holidays</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">19</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">17.2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:12pt;">Short Absences</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">20</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">18.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Incapacity to Work and Insurances</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">20</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">18.1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Medical Certificate</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">20</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">18.2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Salary in case of Employee&#8217;s Incapacity to Work</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">20</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">18.3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Occupational and Non-occupational Accidents</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">21</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">18.4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Health Insurance (Illness) </font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">21</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">18.5. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pension Plan</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">21</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">19.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Intellectual Property Rights and Work Results</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">22</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">20.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Data Protection</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">23</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">21.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Non-Competition and Non-Solicitation</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">23</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">21.1.</font><font style="font-size:12pt;"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:12pt;">General</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">23</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">21.2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-Competition during Employment</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">24</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">21.3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Post-Contractual Non-Competition</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">24</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">21.4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Post-Contractual Non-Solicitation</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">25</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">21.5. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Penalty</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">25</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">22.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidentiality</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">26</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">23.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Regulations and Policies</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">27</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">24.</b></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Miscellaneous</b></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">27</b></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">24.1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Entire Agreement</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">27</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">3 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">24.2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Severability</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">28</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">24.3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amendments</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">28</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">24.4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Applicable Law</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">28</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">24.5. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Place of Jurisdiction</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">28</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">24.6. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Execution</font></p></td><td style="vertical-align:top;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">28</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">4 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Condition Precedent</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">None.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Commencement Date</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">This Employment shall start on 17 May 2021 (the </font><b style="font-size:12pt;font-weight:bold;">Commencement Date</b><font style="font-size:12pt;">). It shall be concluded for an indefinite period.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Function and Job Title</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee shall assume the function as Chief Operations Officer and shall be working 100%. The function and/or the job title may be adjusted by the Company at any time to reflect current circumstances.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The detailed duties of the Employee are set out in Job Description as per Annex A, which may be unilaterally amended by the Company at any time to provide additional or different duties consistent with the customary role of a Chief Operations Officer.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Group Structure</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The Employee acknowledges that the Company is part of a group of companies ultimately controlled by uniQure N.V. (each such company including the holding company a </font><b style="font-size:12pt;font-weight:bold;">Group Company</b><font style="font-size:12pt;">, together the</font><b style="font-size:12pt;font-weight:bold;"> Group</b><font style="font-size:12pt;">). The Employee acknowledges that the Employee will need to work with and/or report to other employees and/or officers of other Group Companies. The Employee acknowledges that this does not create separate employment relationships with other Group Companies.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Duties and Responsibilities</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">It is understood that the duties and responsibilities arising out of the above function include all tasks customarily or reasonably incidental to such function and those expressly mentioned in the Job Profile.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">5 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Company may assign to the Employee any other, additional or new duties or responsibilities as deemed reasonable or appropriate by the Company in the course and fulfilment of its business.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The Employee undertakes to use the Employee&#8217;s entire working ability to fulfill the Employee&#8217;s contractual obligations and to loyally safeguard and foster the business and the interests of the Company. The Employee shall carefully perform all work and tasks assigned to the Employee.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Work for Third Parties</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee is not entitled to work for any third party or to engage in any gainful or unpaid employment, whether full-time or part-time, for the duration of the Employment Agreement without the prior written approval of the Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">Membership of the boards of directors of other companies and other institutions that are related to the business purpose of the Company or otherwise affect the interests of the Company or a Group Company also requires the prior consent of the Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Officer Position</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">In fulfilment of the Employee&#8217;s duties, the Employee may have to act as officer, director or in any other corporate function within the Company or any Group Company. The Company may decide at its full discretion when such function shall end, and the Employee will retire from such functions and sign the necessary documentation upon first request.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">The base salary as defined in Section 11.1 includes any and all remuneration for such functions and positions. In case the law provides for a mandatory remuneration the Company will decide whether such compensation shall be forwarded to the Company or be set off against the base salary as defined in Section 11.1 paid to the Employee by the Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">6 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Conflict of Interests</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee shall avoid any conflict of interest and inform the Company immediately if any potential conflict of interest arises.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">A conflict of interest arises especially in case of a participation in suppliers or clients of the Company or in a Group Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Gifts</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">In connection with the performance of his duties, the Employee is prohibited from accepting or stipulating, either directly or indirectly, any commission, reimbursement or payment, in whatever form, or gifts from third parties. The foregoing does not apply to standard promotional gifts having little monetary value.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Place of Work</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">10.1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Remote Working</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee is allowed to work mainly from the Employee&#8217;s home (but not in any other countries should the Employee change residence). At the request of the Company, the Employee must be present at the Company&#39;s business premises.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">Nevertheless, the Employee understands and agrees that the Employee may, in the course of the Employment and where reasonably requested by the Company, be required to travel to and work in other places and countries in order to perform the Employee&#8217;s obligations and duties under the Employment Agreement. In particular, the Employee will need to be regularly present in the head offices of the Company in the Netherlands.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee is obliged to track any days not worked in Switzerland, including place of work, and submit such schedule regularly to the Company upon request.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">The Company will work with you to determine a reasonable budget for costs associated with travel between your home, and Company facilities</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">7 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">in Amsterdam, Netherlands and Lexington, Massachusetts to include airfare, lodging and associated expenses while doing business on behalf of the Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">In the event that you relocate to the Amsterdam, Netherlands area, the Company intends to provide executive relocation financial support.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">10.2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Standards for Remote Working</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee confirms that the Employee has sufficient office space in the Employee&#8217;s residential home which is suitable for the performance of the Employee&#8217;s tasks. The Employee&#8217;s office at home must meet the applicable Swiss standards and legal requirements of work safety and accident prevention. The suitability of the Employee&#8217;s office at home may be verified by the Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The furnishing of the residential place of work with office furniture falls strictly to the Employee. ln the process, it must be ensured that the office furniture complies with the requirements of occupational ergonomics and work safety.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The Employee undertakes under no circumstances to give the impression that the Company has a branch in the Employee&#8217;s place of residence. Accordingly, the Employee may not, for example, mark the name of the Company on the Employee&#8217;s letterbox or affix a Company sign at the Employee&#8217;s place of residence.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">10.3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Equipment and Data Safety regarding Remote Working</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee is obliged to have the necessary technical connection devices available in the Employee&#8217;s office at home.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The necessary technical work equipment for the Employee&#8217;s office at home shall not be provided by the Company, except for a laptop and mobile phone.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">The work equipment provided to the Employee may be used solely for business purposes. It must neither be made accessible nor be left to third parties. The Employee is responsible for ensuring that the loaned work equipment is protected against unauthorized access by third parties. Passwords and access paths to the data network of the Company must not be disclosed to third parties. The Company may restrict the use of the communication devices provided</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">8 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">to the Employee by means of appropriate technical measures and may verify usage on the basis of the monthly fees.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">At the Employee&#8217;s office at home, the Employee is required to pay particular attention to the protection of data and information with respect to third parties. The Employee undertakes to observe and apply the statutory provisions and the Company&#39;s internal regulations on data protection and data security. ln particular, the Employee must ensure that third parties cannot gain access to confidential information and passwords.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee agrees to store and safeguard all work equipment and documents provided in such a way that any access by third parties, including in particular persons living in the common household with the Employee, is excluded.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">Confidential documents must be kept locked up or otherwise sufficiently safeguarded.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">Any work equipment and documents no longer required shall be returned and/or destroyed safely by the Employee.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">10.4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Remote Working Allowance</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The Employee shall receive a flat allowance of CHF 275 gross per month to cover all costs of the office at home (rent, electricity, phone, internet, use of furniture, work equipment not provided, etc.) (</font><b style="font-size:12pt;font-weight:bold;">Remote Working Allowance</b><font style="font-size:12pt;white-space:pre-wrap;">). During any release from work (garden leave), the Employee shall not be entitled to any Remote Working Allowance.  The allowance may be deducted from the Employee&#8217;s base salary at the discretion of the Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Compensation</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Base Salary</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">The Employee shall receive an annual base salary of CHF 463,760 gross (the </font><b style="font-size:12pt;font-weight:bold;">Base Salary</b><font style="font-size:12pt;">), payable in 12 monthly instalments at the end of the month to a bank or postal account to be specified by the Employee.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">9 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Bonus</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee may, if applicable, participate in a bonus program of the Company or a Group Company, which the Company or the issuing Group Company shall determine at its full discretion. If no bonus program is issued, any bonus shall be determined at the discretion of the Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Company may set targets for the bonus, according to which the amount of the bonus is determined. However, the Company is free to deviate at its own discretion upwards or downwards from the targets set in its final determination of the bonus. If no targets are set, any bonus shall be determined at the discretion of the Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">Initially, the target bonus (&#8220;Target Bonus&#8221;) shall correspond to 50% of the Base Salary for a full financial year.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Target Bonus will be prorated in the first calendar year of employment based on the total number of days worked during the calendar year.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;white-space:pre-wrap;">In the event of termination of the Employment, the Employee has no entitlement to a bonus, not even on a pro rata basis.  To be eligible for any bonus pursuant to this Agreement or otherwise pursuant to Employee&#8217;s employment with Employer, Employee must be in service of Employer on the date any bonus is paid.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Participation Plan</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee may be given the opportunity by uniQure N.V. to participate in the growth of the Group pursuant to a participation plan such as, for instance, an employee share option plan or a share plan, and as amended from time to time (the </font><b style="font-size:12pt;font-weight:bold;">Participation Plan</b><font style="font-size:12pt;">). It is in the full discretion of uniQure N.V. to issue and/or to unilaterally amend such Participation Plan at any time.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">The Employee expressly acknowledges that the Employee does not have any right or claim under the Participation Plan against the Company, but only against uniQure N.V. or the Group Company issuing the Participation Plan. The Employee also confirms that any participation in the Participation Plan does not constitute an employment relationship with uniQure N.V. or the issuing Group Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">10 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Sign-On Bonus</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Company will pay the Employee a one-off cash sign-on bonus of CHF 180,103.00 gross, payable within 30 days of the Commencement Date (the </font><b style="font-size:12pt;font-weight:bold;">Due Date</b><font style="font-size:12pt;">).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee is not entitled to receive the sign-on bonus if (for whatever reason and howsoever caused), at the Due Date, the Employee is no longer an employee of the Company or has given or received notice to terminate the Employment.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">If, within twelve months after the Commencement Date (the receipt of notice of termination is relevant in this respect), the Employment:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">has been terminated by the Employee;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">has been terminated without notice for good cause by the Company (in accordance with Article 337 CO); or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">has been terminated by the Company due to the Employee having given the Company good cause to do so (in accordance with Article 340c(2) CO)</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">the Employee shall either repay the sign-on bonus to the Company or the Company shall be entitled to set off its claim. The amount of the repayment or offsetting shall be in accordance with the following scale. Such repayment shall be made within 30 days after the date of termination of the Employment:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">Termination less than 12 months after the Commencement Date &#8211; 100% of sign-on bonus;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">Termination at least 12 months, but less than 18 months, after the Commencement Date &#8211; 50% of sign-on bonus;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">Termination at least 18 months, but less than 24 months, after the Commencement Date &#8211; 25% of sign-on bonus</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">The Employee accepts any set-off and accepts that this provision to repay or set-off the sign-on bonus to the Company is fair and reasonable under the circumstances.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">11 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Acknowledgements of the Employee</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The Employee acknowledges and agrees that any entitlements granted and payments made in addition to the Base Salary, including, but not limited to any bonuses, participations, or gratuities of the Company or any Group Company (the </font><b style="font-size:12pt;font-weight:bold;">Additional Payments</b><font style="font-size:12pt;">) are not part of the salary legally or contractually owed by the Company and are made at full discretion of the Company or the Group Company granting such bonus, participation or gratuity. Any Additional Payments shall not create any obligation of the Company or any Group Company to make such Additional Payments in the future and shall not create any right or claim of the Employee to such Additional Payments in the future even if paid over consecutive years and without express reservation.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">No other Compensation</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The Employee acknowledges and agrees that the Employee shall not be entitled to receive any other compensation or benefit of any nature from the Company except as expressly provided for in this Employment Agreement.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Social security, tax and deductions</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">As long as legally possible, the Employee is insured according to the Federal Laws on old age (AHVG), disability (IVG), compensation for the loss of earnings (EOG), unemployment insurance (AVIG), accident insurance (UVG), sickness benefits insurance, if any, and pension plan (BVG). </font><font style="font-size:12pt;">From any and all gross compensation hereunder &#8211; if provided by law, regulations or policies &#8211; any portions of the Employee&#8217;s contributions to the sickness benefits insurance, if any, and withholding taxes, if any, will be deducted and withheld by the Company from the payments made to the Employee.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">Any portions of the Employee&#8217;s social security contributions in accordance with the AHVG, IVG, EOG, AVIG, UVG and premiums to pension schemes (BVG) must be paid by the Employee to the respective insurance institutions in Switzerland in accordance with the separately signed agreement according to art. 21 para. 2 of Regulation (EC) No. 987/09 as per Annex B to this Employment Agreement. In accordance with said agreement is the Employee further obliged to pay the Company&#8217;s social security contributions portions in accordance with the AHVG, IVG, EOG, AVIG, UVG and premiums to pension schemes (BVG). Therefore, the Company transfers any and all compensation hereunder after having deducted</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">12 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">any portions of the Employee&#8217;s contributions to the sickness benefits insurance, if any, and withholding taxes, if any. In addition, the Company transfers the Company&#8217;s social security contributions portions in accordance with the AHVG, IVG, EOG, AVIG, UVG and premiums to pension schemes (BVG) as provided by law, regulations or policies, to the Employee.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Company reserves the right to unilaterally terminate this agreement according to art. 21 para. 2 of Regulation (EC) No. 987/09 at any time, to register as a company and thus to pay the social security contributions due (employee and employer contributions) itself. In case of such unilateral termination of said agreement, the Employee shall be notified by the Company in due time. In this case, from any and all gross compensation hereunder &#8211; if provided by law, regulations or policies &#8211; any portions of the Employee&#8217;s social security contributions in accordance with the AHVG, IVG, EOG, AVIG, UVG, sickness benefits insurance, if any, premiums to pension schemes and withholding taxes, if any, will be deducted and withheld by the Company from the payments made to the Employee.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">Where it will not be possible anymore to remain in the Swiss social security system, the Employee will be insured according to the applicable social security system in accordance with the respective applicable legislation, Company policies, as well as insurance policies and regulations.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Expenses</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">The Employee shall be entitled to reimbursement by the Company of out-of-pocket business expenses reasonably incurred by the Employee during the Employment in the performance of the Employee&#8217;s duties under this Employment Agreement. The provisions in Section&#160;10.4 shall be reserved. However, the reimbursement is subject to (i) the submission of relevant vouchers and receipts indicating the amount and purpose of the expenses, and (ii) the compliance with the reimbursement policies of the Company issued and unilaterally amended from time to time.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">13 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">13.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Probation Period and Termination</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">13.1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Probation Period</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The first 2 months of the Employment are deemed to be the probation period. During the probation period, either Party may terminate the Employment at any time with a notice period of seven days to the end of any calendar day.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">13.2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Termination</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">After expiration of the probation period, the Employment may be terminated by either Party with a notice period of 4 months (the &#8220;Notice Period&#8221;).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">Upon observance of the notice period, termination shall be effective as of the end of a calendar day and not the end of a calendar month.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The Employment is being terminated automatically at the end of the month in which the Employee reaches the retirement age according to the Federal Law on Old-age and Survivors&#8217; Insurance (</font><i style="font-size:12pt;font-style:italic;">AHVG</i><font style="font-size:12pt;">). In case of a permanent disability to work the same applies. In case of a partial permanent disability the Employment ends to the same extent as the Employee is declared disabled.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">13.3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Severance Generally</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 49.7pt;"><font style="font-size:12pt;">lf the Employment is terminated by the Company, except</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:82.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">in case of a summary dismissal for good cause by the Company (in accordance with Article 337 CO);</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:82.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">in case the Employee having given the Company good cause to do so (in accordance with Article 340c(2) CO); or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:82.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">(iii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">in case the Employee the Employee is in breach of any duties and failed to remedy such breach within 30 days after having been asked in writing to do so;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:82.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">(iv)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">in case the Employee is terminated after an illness lasting for at least 6 months; or</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">14 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:82.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">(v)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">in case of poor performance after having been put on a performance improvement plan for at least 90 days and having failed to meet the set targets,</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 49.6pt;"><font style="font-size:12pt;">then the Company shall grant the Employee severance pay (</font><b style="font-size:12pt;font-weight:bold;">Severance</b><font style="font-size:12pt;">) equal to</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:82.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">100% of the annual Base Salary (less any pay received during the Notice Period);</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:82.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">100% an amount corresponding to the target Bonus (i.e. 50% of Base Salary) amount of the Target Bonus; plus</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:82.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">(iii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">an amount corresponding to a prorated target Bonus amount for the year of termination as provided. The pro-rata Bonus shall be the product of the formula B x D/365 where B represents the target Bonus (i.e. 50% of the Base Salary), and D represents the number of days elapsed in the calendar year through the date of notice to the Employee),</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;white-space:pre-wrap;">Any severance payment is subject to the condition that the Employee signs a termination agreement with the Company including a full waiver of any other claims and the reinstatement of all restrictive covenants. For the avoidance of any doubt, no other bonus or severance shall become payable in such case.  Except as expressly provided in this clause, bonus payments, if any, will not be taken into account for the calculation of any possible severance payment upon termination of the Agreement.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">13.4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Severance on a Change of Control</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 49.7pt;"><font style="font-size:12pt;">lf the Employment is terminated by the Company within the period beginning ninety (90) days before and continuing until twelve (12) months after a Change of Control (as defined below), and subject to the conditions for Severance as per Section 13.3 above being fulfilled, the Company shall grant the Employee a severance pay (</font><b style="font-size:12pt;font-weight:bold;">Change of Control Severance</b><font style="font-size:12pt;">) equal to</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:82.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">150% of the annual Base Salary (less any pay received during the Notice Period);</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">15 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:82.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">150% an amount corresponding to the Target Bonus (i.e. 50% of Base Salary) amount of the Target Bonus; plus</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:82.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.1pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">(iii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">an amount corresponding to a prorated Target Bonus amount for the year of termination as provided. The pro-rata Bonus shall be the product of the formula B x D/365 where B represents the Target Bonus (i.e. 50% of the Base Salary), and D represents the number of days elapsed in the calendar year through the date of notice to the Employee).</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;white-space:pre-wrap;">The Change of Control Severance is subject to the condition that the Employee signs a termination agreement with the Company including a full waiver of any other claims and the reinstatement of all restrictive covenants. For the avoidance of any doubt, no other bonus or severance shall become payable in such case.  Except as expressly provided in this clause, bonus payments, if any, will not be taken into account for the calculation of any possible severance payment upon termination of the Agreement.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">In the event of a Change of Control as defined below, the vesting conditions that may apply to any stock options, restricted shares, restricted stock units, performance stock units or other grants of equity held by Employee pursuant to this Agreement and the Company&#8217;s Amended and Restated 2014 Share Incentive Plan will be automatically waived and shall be deemed fully vested immediately prior to the Change of Control event. All Stock Options will be deemed to be fully exercisable commencing on the date of and immediately prior to the Change of Control and ending on the eighteen (18) month anniversary of the Change of Control or, if earlier, the expiration of the term of such Stock Options</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">For the purposes of this Employment Agreement, </font><b style="font-size:12pt;font-weight:bold;">Change of Control</b><font style="font-size:12pt;"> shall mean the date on which any of the following events occurs:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">any &#8220;person,&#8221; as such term is used in Sections 13(d) and 14(d) of the United States Securities Exchange Act of 1934, as amended (the </font><b style="font-size:12pt;font-weight:bold;">Act</b><font style="font-size:12pt;">) (other than uniQure N.V., any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the uniQure N.V. or any of its subsidiaries), together with all &#8220;affiliates&#8221; and &#8220;associates&#8221; (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the &#8220;beneficial owner&#8221; (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the uniQure N.V. representing forty (40) percent or more</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">16 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 85.05pt;"><font style="font-size:12pt;">of the combined voting power of uniQure N.V.&#8217;s then outstanding securities having the right to vote in an election of the Board (&#8220;Voting Securities&#8221;) (in such case other than as a result of an acquisition of securities directly from the uniQure N.V.); or</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><font style="font-size:12pt;">a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><font style="font-size:12pt;">c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><font style="font-size:12pt;">the consummation of (i) any consolidation or merger of uniQure N.V. where the stockholders of uniQure N.V., immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than fifty (50) percent of the voting shares of uniQure N.V. issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (ii) any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of uniQure N.V.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">13.5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Release from Work (Garden Leave)</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Company may at any time (including during the Notice Period) and with immediate effect release the Employee from the duty to work. In such case, the Employee continues to be paid the Base Salary. Vacation, any overtime and time compensation entitlements, if any, shall be offset against the time of release from work. The Company may set forth further conditions applying to the release from duties.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">17 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">14.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Work Equipment and Obligation to Return Work Equipment</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Company shall provide the Employee with the necessary work equipment such as laptops or mobile phones. The work equipment shall remain the property of the Company and the Company shall have the right to replace and/or reclaim the work equipment at any time.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">At the Company&#8217;s first request, but no later than upon termination of this Employment Agreement for any reason, the Employee shall return to the Company everything the Employee produced in the course of the Employee&#8217;s work for the Company, everything which was given to the Employee throughout the course of this Employment and everything which otherwise fell into the Employee&#8217;s possession. The obligation to return work equipment includes in particular but is not limited to keys, mobile phones, laptops, badges as well as data carriers and records of any kind, including any copies. Any possible retention right of the Employee is explicitly waived.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">15.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Working Time</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">15.1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">General</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The weekly working time depends on the needs to perform the position successfully but is at least 40 hours per week on an average basis (100% position).</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">15.2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Additional Work</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">The Employee shall work overtime, if this is necessary to fulfil the Employee&#8217;s duties under this Employment Agreement. Considering the Employee&#8217;s independent position and duties the Swiss Labour Act is not applicable to the Employment. The Employee shall therefore have no entitlement to additional compensation for any such extra work (overtime, extra hours, Sunday work, work on public holidays, or night work). All such extra and overtime work is already compensated by the Base Salary and the vacation days exceeding the statutory minimum.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">18 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">16.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Vacation</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee is entitled to 30 business days of vacation per calendar year (for a 100% stint). The 10 additional, days of vacation granted exceeding the statutory minimum entitlement of 20 days shall be granted expressly as compensation for any overtime worked and may be offset against any time off entitlements.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Company has the right to determine by giving one (1) month advance notice when the Employee shall take vacation days. In exceptional situations, this advance notice period is shortened to up to one week. Nevertheless, the Company will consider wishes of the Employee. If the Employee requests to take vacation, the Employee shall, reasonably prior to the intended vacation, inform the responsible executive. In any event the Employee shall provide for suitable internal representation during the Employee&#8217;s vacation.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">For the year in which the Employment begins or ends, the vacation entitlement is calculated </font><i style="font-size:12pt;font-style:italic;">pro rata temporis</i><font style="font-size:12pt;">.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">It is the Employee&#8217;s duty to refund to the Company any vacation salary received for vacation days in excess of the vacation entitlement of the Employee.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The Employee shall take vacation days within the calendar year for which such entitlement accrues. The Employee shall not, without prior consultation and approval of the Company and/or the responsible executive or otherwise as allowed pursuant to Company policy, roll such days over to the subsequent calendar year.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">17.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Public Holidays and Short Absences</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">17.1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Public Holidays</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">The Employee is not obliged to work on federal and cantonal public holidays at the primary place of work in Switzerland. The Employee is not entitled to any compensation whether in cash or in kind for such public holidays when such public holidays are on weekends.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">19 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">17.2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Short Absences</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee shall, upon request, be granted the usual hours or days off without deduction from the salary, provided that they necessarily fall within working hours. The extent of such absences shall be determined in accordance with the Company&#39;s current practice.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">Such short absences shall not be grounds for a deduction of the Employee&#8217;s entitlements to the Base Salary or vacation days, unless the absence exceeds the time period as set forth above.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">Such absences shall not be grounds for a deduction of the Employee&#8217;s entitlements to the Base Salary or vacation days, unless the absence exceeds the time period as set forth above.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">18.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Incapacity to Work and Insurances</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The Employee shall notify the Company immediately about any incapacity to work and its probable duration, stating the respective reasons.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">18.1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Medical Certificate</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">If the Employee&#39;s incapacity to work due to illness or accident exceeds 3 business days, the Employee shall without request by the Company furnish a medical certificate in an ongoing Employment. The Company reserves the right to request a medical certificate even in the event of a shorter duration of incapacity to work. If the Employment has been terminated, the Employee shall in any case be obliged to furnish a medical certificate to the Company from the first day of incapacity to work. In all cases of illness and accident, the Company is entitled to ask the Employee to be examined by an independent medical examiner at the Company&#8217;s expense.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">18.2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Salary in case of Employee</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">&#8217;</b><b style="font-size:12pt;font-weight:bold;">s Incapacity to Work</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">If the Employee is prevented from work due to illness or accident, the Company shall continue to pay the remuneration hereunder in accordance with the law (Berne scale) unless a daily sickness benefits insurance exists.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">20 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">In case a daily sickness benefits insurance exists, the Employee will receive the benefits due under such insurance in accordance with the corresponding insurance policy and the respective Company regulations and policies, as amended from time to time. The Employee will be notified accordingly by the Company in such case.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">In any case, continued salary payment obligation of the Company ceases at the end of the employment relationship.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">18.3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Occupational and Non-occupational Accidents</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">If the Employee works for the Company for an average of less than 8 hours per week, the Employee is only insured for certain medical expenses for occupational accidents. However, if the Employee works for the Company for an average of more than 8 hours per week, the Employee is insured for certain medical expenses for both occupational and non-occupational accidents. Premiums for occupational accident insurance and occupational sickness insurance are paid by the Company. Premiums for non-occupational accident insurance are paid by the Employee.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">18.4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Health Insurance (Illness)</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">Health insurance is compulsory in Switzerland and needs to be obtained by the Employee. The Company is not providing any coverage of costs related to illness.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">18.5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Pension Plan</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">Provided that the Employee meets the regulatory requirements, the Employee is, through a pension plan (the </font><b style="font-size:12pt;font-weight:bold;">Pension Plan</b><font style="font-size:12pt;">), insured against the economic consequences of retirement, disability and death.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">The Employee will be covered by the Pension Plan as amended from time to time.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">21 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">19.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Intellectual Property Rights and Work Results</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Company shall own all work results (including but not limited to data, know-how, documentation, concepts, drafts, inventions, works, applications, software, etc.) and all intellectual property rights therein, irrespective of their protectability under the applicable law, (including but not limited to trademarks, patents, designs, and copyrights) (the foregoing all together &#8220;</font><b style="font-size:12pt;font-weight:bold;">Work Results</b><font style="font-size:12pt;">&#8221;) created by the Employee in the course of the Employment (regardless of whether within or outside agreed office or workplaces and within or outside working hours).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">All such Work Results shall vest automatically in the Company upon their creation. If the Company has not become the automatic owner of the Work Results and/or if the Work Results are not transferred to the Company by law, the Employee is obliged to irrevocably transfer and assign and hereby transfers and assigns said Work Results to the Company. If such Work Product cannot be transferred to the Company for any reason whatsoever, the Employee grants the Company an exclusive, worldwide, transferable, unlimited, irrevocable, sub-licensable and royalty-free license to use and exploit the Work Result.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">Further, the Employee waives the right (i) to be mentioned as inventor, author or creator of a Work Result, (ii) to object to any change, modification, revision, translation or alteration of the Work Result or (iii) to determine the first publication of any Work Result.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee is obliged to take all steps reasonably requested by the Company in order to fulfil the Employee&#8217;s obligations according to the above sections. This obligation continues even after termination of the Employment.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">If Employee has created the Work Result with the assistance of another individual or legal entity that is not legally or contractually obliged to transfer the Work Result to the Company, the Employee ensures to take the required actions to have such third party&#8217;s share in the Work Result transferred to the Company or (if a transfer is not possible) to have it licensed to the Company according to the terms above. In addition, the Employee ensures that the third party waives the right (i) to be mentioned as inventor, author or creator of a Work Result, (ii) to object to any change, modification, revision, translation or alteration of the Work Result or (iii) to determine the first publication of any Work Result.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">22 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">Compensation for the transfer or licensing of any and all Work Results according to the above sections, in particular intellectual property rights and/or licensing rights, is included in the Employee&#8217;s Base Salary according to Section 11.1.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">If a Work Result is created by the Employee in the course of the Employment but outside of the duties under the Employment Agreement, the Employee shall immediately inform the Company thereof in writing. The Company shall have the right to acquire ownership of such Work Result for a reasonable additional compensation, provided that the Company notifies the Employee in writing of its will to exercise this option within six (6) months as of the Employee&#8217;s notice of the creation of the Work Result.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">20.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Data Protection</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Company informs the Employee about the processing of the Employee&#8217;s personal information in a privacy notice (</font><b style="font-size:12pt;font-weight:bold;">Personal Data</b><font style="font-size:12pt;">).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The Company may amend the privacy notice and respective policies at any time.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">21.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Non-Competition and Non-Solicitation</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">21.1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">General</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">The Employee acknowledges and agrees to adhere to undertakings in this Section 21 as the Company and the Group have a serious business interest in binding the Employee to the non-competition and non-solicitation undertakings, due to the fact that (i) within the organization of the Company and the Group competition-sensitive information as well as confidential information related to the Company, the Group and their clients and relations, such as but not limited to products, or research or development or commercialization of the Company and the Group (</font><b style="font-size:12pt;font-weight:bold;">Sensitive Business Information</b><font style="font-size:12pt;">) are available and (ii) in the position of Chief Operations Officer the Employee has access to this Sensitive Business Information and/or will become aware of this Sensitive Business Information and/or will maintain (commercial) contacts with clients, suppliers, competitors etc. Given the aforesaid considerations (i) and (ii) in this clause, combined with the education and capacities of the Employee, the Company and the Group have a well-founded fear that their business interests will be harmed</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">23 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">substantially if the Employee performs competing activities as set forth in this Section 21.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">21.2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Non-Competition during Employment</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 49.6pt;"><font style="font-size:12pt;">The Employee shall refrain from competing with the Company during the Employment, i.e. the Employee is obliged in particular not to:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8211;</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">directly or indirectly, once, occasionally or professionally, under the Employee</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s name or under a third-party name, on behalf of the Employee</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s own or on behalf of third parties</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8217;</font><font style="font-size:12pt;"> account compete with the Company or any Group Company; or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8211;</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">engage in any way in any enterprise competing with the Company or any Group Company, and the Employee also agrees not to found, assist or promote any business being active in the same line of business as the Company or any Group Company.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">Any solicitation or referral of clients and/or employees of the Company or any Group Company is prohibited.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">In the event of a breach of this non-competition or non-solicitation obligation as set out in this Section&#160;21.2, the Employee agrees to pay to the Company a penalty equal to one (1) month&#39;s Base Salary (including salary increases as granted from time to time) for each breach.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">21.3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Post-Contractual Non-Competition</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 49.6pt;"><font style="font-size:12pt;">The Employee agrees that for a period of 12 months after termination of the Employment the Employee will neither:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8211;</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">directly or indirectly, once, occasionally or professionally, under the Employee</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s name or under a third-party name, on behalf of the Employee</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s own or on behalf of third parties</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8217;</font><font style="font-size:12pt;"> account compete with the Company or any Group Company; nor</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8211;</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">engage in any way in any enterprise competing with the Company or any Group Company, and the Employee also agrees not to found, assist or</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">24 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 82.8pt;"><font style="font-size:12pt;">promote any business being active in the same line of business as the Company or any Group Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 49.6pt;"><font style="font-size:12pt;">Particularly, any gene therapy activity (including the manufacture or development of a gene therapy) shall be considered as competing activity.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">This non-competition obligation shall apply to the whole territory for which the Employee was responsible during the Employment and/or to the whole territory in which the Employee was working with products of the Company or any Group Company during the Employment, but at least to the territories and in relation to the markets of Switzerland, the European Union, Australia, and the United States.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">21.4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Post-Contractual Non-Solicitation</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 49.6pt;"><font style="font-size:12pt;">For a period of 12 months after termination of the Employment the Employee shall abstain directly or indirectly from:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8211;</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">enticing away, soliciting or interfering with any personnel from the Company or any Group Company with whom the Employee was in contact during the Employment; or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:33.2pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8211;</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><font style="font-size:12pt;">enticing away, soliciting or interfering with clients or contacts of the Company or any Group Company with whom the Employee was in contact during the last three years prior to termination of the Employment or about whom the Employee gained knowledge during the Employment.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">21.5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Penalty</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">If the Employee violates the post-contractual non-competition obligation according to Section&#160;21.3, the Employee shall pay to the Company a penalty in the amount of 3 monthly Base Salaries Salary (incl. salary increases as granted from time to time) for each violation.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">If the Employee violates the post-contractual non-solicitation obligation with respect to co-workers according to Section&#160;21.4, the Employee shall pay the Company a penalty of 1 monthly Base Salary (incl. salary increases as granted from time to time) for each violation.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">25 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">If the Employee violates the post-contractual non-solicitation obligation with respect to clients according to Section&#160;21.4, the Employee shall pay to the Company a penalty in the amount of 2 monthly Base Salaries (including salary increases as granted from time to time) for each violation.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">If the breach consists in non-authorized participation in a competing company or in entering into a long-term obligation (such as an employment, service, agency or consultant contract), the penalty shall be increased by EUR 1&#8217;000 for each month or part thereof in which the breach continues (the </font><b style="font-size:12pt;font-weight:bold;">Continuous Breach</b><font style="font-size:12pt;">).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">Multiple breaches of the obligations each trigger separate penalties, if necessary several times within one month. If individual breaches occur within a Continuous Breach, they shall be covered by the penalty which has to be paid for the Continuous Breach.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The payment of the penalty does not release the Employee from the obligation to comply with the non-competition and/or non-solicitation obligations. The Company shall be entitled to seek injunctive measures or any other type of immediate relief to stop the infringement as soon as possible, regardless of whether any penalty is offered or paid.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">Further, the Company reserves the right to claim compensation for damages (in addition to the penalty or penalties).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">22.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidentiality</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee will have access to confidential and proprietary information relating to the business and operations of the Company, any Group Companies and their clients, in particular to business and manufacturing secrets. Such confidential and proprietary information constitutes a unique and valuable asset of the Company and any Group Companies and their acquisition required great time and expense. The disclosure or any other use of such confidential or proprietary information, other than for the sole benefit of the Company or any Group Company, would cause irreparable harm to the Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">The Employee is under a strict duty to keep all confidential and proprietary information strictly and permanently confidential and, accordingly, shall not during the Employment or after termination of the Employment directly or indirectly for any purpose other than for the sole benefit of the Company or any</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">26 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">Group Company disclose or permit to be disclosed to any third party any confidential or proprietary information without first obtaining the written consent of the responsible executive and the party concerned, if applicable, except if required to do so by law.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Employee may not make any statement to the media, as far as the Employee is not authorized to do so by the Company and/or the responsible executive.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">In the event the Employee breaches the obligations pursuant to this Section a disciplinary penalty of one monthly Base Salary (including salary increases as granted from time to time) shall be owed by the Employee to the Company for each breach.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">However, the payment of the penalty does not release the Employee from further complying with the confidentiality obligation.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The Company reserves the right to claim compensation for damages in addition to the penalty.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">23.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Regulations and Policies</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">The Employee confirms that he is familiar with the regulations and policies of the Company and will comply with them at all times. The Employee acknowledges that the Company may amend existing regulations and policies from time to time and may issue new regulations and policies from time to time.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">24.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Miscellaneous</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">24.1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Entire Agreement</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;">This Employment Agreement constitutes the complete Employment Agreement between the Parties regarding its subject matter and supersedes all prior oral and/or written agreements, representations and/or communications concerning the subject matter hereof.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">27 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">24.2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Severability</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">Should any of the provisions of this Employment Agreement be or become legally invalid, such invalidity shall not affect the validity of the remaining provisions. Any gap resulting from such invalidity shall be filled by a provision consistent with the spirit and purpose of the Employment Agreement. In the same way shall be proceeded if a contractual gap appears.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">24.3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Amendments</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">Any amendments or supplementation of this Employment Agreement shall require written form and must be signed by both Parties. The written form may be dispensed only in writing.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">Upon 30 day written notice to the Employee, the Company may convert any amounts owed under this agreement (including any Base Salary, allowance or other payment) from CHF (Swiss Francs) to Euros using a generally accepted exchange rate at the time of such conversion.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">24.4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Applicable Law</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">This Employment Agreement shall be construed in accordance with and governed by Swiss law (without giving effect to the principles of conflicts of law).</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">24.5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Place of Jurisdiction</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 24pt 49.6pt;"><font style="font-size:12pt;">Any dispute arising out of or in connection with this Employment Agreement and the Employment resulting therefrom shall be exclusively submitted to and determined by the ordinary courts at the domicile of the Company, subject to mandatory places of jurisdiction.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:49.6pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">24.6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Execution</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 9pt 49.6pt;"><font style="font-size:12pt;">The Parties have duly executed this Employment Agreement in two originals, each Party receiving one original.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">28 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Signatures</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 18pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt 0pt 9pt 0pt;"><b style="font-size:12pt;font-weight:bold;">uniQure biopharma B.V. (Company)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">/s/ Lilly Burggraaf</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;border-top:1px dotted #a69d64;margin:0pt;"><font style="font-size:12pt;">Lilly Burggraaf</font></p><p style="border-top-style:none;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:0pt;margin:0pt 0pt 9pt 0pt;"><font style="font-size:12pt;">VP, Global Human Resources</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt 0pt 9pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Employee</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:33.32%;border-bottom:1px dotted #a69d64;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><font style="font-size:12pt;">May 17, 2021</font></p></td><td style="vertical-align:top;width:17.51%;border-bottom:1px dotted #a69d64;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.15%;border-bottom:1px dotted #a69d64;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><font style="font-size:12pt;">/s/ Pierre Caloz</font></p></td></tr><tr><td style="vertical-align:top;width:33.32%;border-top:1px dotted #a69d64;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><font style="font-size:12pt;">Date</font></p></td><td style="vertical-align:top;width:17.51%;border-top:1px dotted #a69d64;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.15%;border-top:1px dotted #a69d64;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><font style="font-size:12pt;">Pierre Caloz</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">29 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Annex A - Job Description</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Chief Operations Officer (COO)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.2pt 5.6pt;">Reporting to the CEO and based either in Amsterdam, Netherlands or in Lexington, MA, the Chief Operations Officer (COO) will be responsible for all cGMP relevant activities within uniQure including oversight of cGMP manufacturing, supply chain, facilities and all technical operations, including process and analytical development. While cGMP manufacturing is consolidated in the company<font style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</font>s Lexington, MA facility, this is an end-to-end global role that includes early product development functions located in Amsterdam, Netherlands. Areas of specific responsibility and accountability include:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.2pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Designing the Company<font style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</font>s CMC strategy and tactical execution, including oversite of cGMP manufacturing, supply chain, facilities, and all technical operations, including process and analytical development.</div><div style="margin-top:0.05pt;"></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.2pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Supplying drug substance and drug product for large animal studies, clinical trials, and commercial applications in compliance with all relevant regulatory requirements.</div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.2pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Ensuring appropriate CMC capacity and delivering high quality and cost-effective development and manufacturing of the Company<font style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</font>s products and product candidates.</div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.2pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Investing in and maintaining the Company<font style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</font>s premises, utilities, and equipment.</div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.25pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Developing and directing strategies for upstream and downstream process development, analytical development, formulation development and manufacturing in alignment with Clinical, Quality, Regulatory and Commercial requirements.</div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.25pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Collaborating with Quality and other functional areas to efficiently manage technology transfer, process scale-up and design of validation strategies with regards to routine/non-routine development and cGMP activities (e.g., deviations/investigations, process improvements, change controls, shelf-life extensions, CAPAs, etc.).</div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.25pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Developing batch records, experimental data, protocols, reports, analytical methods, SOPs, etc.</div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.25pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Authoring and reviewing technical sections for company<font style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</font>s global regulatory submissions (INDs, IMPDs, BLAs, MAAs, Meeting Requests, Briefing Documents, responses to Health Authority questions, etc.) related to assigned programs.</div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.25pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Conducting any process verification and qualification studies.</div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.25pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Contributing to the generation and protection of company intellectual property.</div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.25pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Overseeing the development and maintenance of the budget for assigned program activities, including the preparation of cost estimates for new work.</div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.25pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Defining, implementing, maintaining, and improving processes and systems, supported by meaningful Key Performance Indicators (KPI<font style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</font>s).</div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0.05pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.25pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Building best-in-class operations teams and leaders, including recruitment, performance management, mentorship, career development and succession planning.</div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:25.2pt;margin-top:0pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;"><font style="color:#002e5d;display:inline-block;font-family:'Times New Roman';min-width:9.25pt;text-indent:0pt;white-space:nowrap;">&#9726;</font>Collaborating seamlessly with other functional disciplines to ensure day-to-day cooperation and advance the Company<font style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</font>s business objectives.</div><div style="margin-top:0.05pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 0pt 25.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">30 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Employment Agreement</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:1pt;border-top:1px solid #a69d64;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Annex B - Employer-Employee Agreement in accordance with Article 21, para. 2</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:24pt 0pt 0pt 0pt;">31 of 31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>qure-20210630xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 7/26/2021 08:02:01 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.2</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;"><img src="qure-20210630xex10d2001.jpg" alt="Graphic" style="display:inline-block;height:42.6pt;width:131.65pt;"></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:75.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Jamie Brady</b></p></td></tr><tr><td style="vertical-align:top;width:75.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Chief Human Resources Officer</p></td></tr><tr><td style="vertical-align:top;width:75.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">May 17, 2021</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Pierre Caloz</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">RE:  Side Letter Agreement re Equity Grants</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Dear Pierre,</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Subject to Board of Directors approval at the next regularly scheduled uniQure N.V. Board meeting after the execution of this Agreement and subject to the commencement of employment pursuant to your employment agreement with uniQure biopharma B.V., uniQure N.V. (the &#8220;Company&#8221;) agrees to grant you:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Twenty-Five Thousand (25,000) restricted stock units of the Company (RSUs), such RSUs vesting pro-rata on each of the first three anniversaries of the grant date;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">An option to purchase Seventy-Five Thousand (75,000) ordinary shares of the Company, having an exercise price as of the closing share price on the date of grant, such option vesting over a period of four years, with one-quarter of the shares vesting on the first anniversary of the grant date and the remaining shares vesting quarterly on a pro-rata basis during the remainder of the vesting period; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">A supplemental grant of Ten Thousand (10,000) RSUs vesting in full on the first anniversary of the grant date.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Each grant will be pursuant to uniQure N.V.&#8217;s Amended and Restated 2014 Share Incentive Plan, and the terms will otherwise reflect the standard vesting and other terms and conditions contained in the Share Incentive Plan and the Company&#8217;s standard equity grant agreements.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Such option will be approved by the Board of Directors of uniQure N.V. not later than at its next regularly scheduled meeting. If the Board fails to make the grants at such regularly scheduled meeting, it shall be deemed a good reason for termination of the employment agreement by you subject to the payment of severance.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">You will be eligible for future equity grants pursuant to the Company&#8217;s policies and procedures.  Any additional grants during the first year of employment (not including those provided above) will be prorated based on hire date, and all future grants of equity shall be subject to the provisions of this Agreement, including, without limitation, provisions related to change of control and termination.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Sincerely,</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Agreed and Acknowledged:</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Jamie Brady</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Pierre Caloz</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Jamie Brady</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Pierre Caloz</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="color:#c45911;">uniQure |Paasheuvelweg 25a |1105BP Amsterdam</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>7
<FILENAME>qure-20210630xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 7/26/2021 08:02:05 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="qure-20210630xex10d3001.jpg" alt="Graphic" style="display:inline-block;height:47.24pt;width:179.22pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:42%;" align="center"><tr style="height:1pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr style="height:28.35pt;"><td style="vertical-align:middle;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EMPLOYMENT AGREEMENT PURSUANT TO SECTION 7:610 (et seq.) of the Dutch Civil Code (DCC)</b></p></td></tr><tr style="height:27.75pt;"><td style="vertical-align:middle;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 15, 2021</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Employment agreement between</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">uniQure biopharma B.V.,</b> a company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid)</i>, with registered office at Amsterdam and principal place of business at Paasheuvelweg 25a, (1105 BP) Amsterdam (the <b style="font-weight:bold;">Employer</b>); and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Christian Klemt </b>(the <b style="font-weight:bold;">Employee</b>);</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">each &#8220;a Party&#8221;, collectively, &#8220;the Parties&#8221;.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;">The Parties agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">1</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Commencement date Agreement and position</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">This employment agreement (the &#8220;Agreement&#8221;) is effective as of June 15, 2021 (the &#8220;Effective Date&#8221;). &#160;As of the Effective Date, Employee shall continue his employment with Employer in the position of Chief Financial Officer. Employee undertakes to perform all the duties and responsibilities customary or reasonable of a Chief Financial Officer of a public company listed on the Nasdaq stock exchange as well as other duties that may reasonably be assigned to him by or on behalf of the Employer and which are related to position of Chief Financial Officer and the Employer&#39;s business. To the best of his ability in doing so, the Employee will comply with the instructions given to him by or on behalf of the Employer. Employee&#8217;s role includes, without limitation, serving as the principal financial officer of uniQure N.V. and encompasses performing duties as Chief Financial Officer for Employer and its affiliates (the &#8220;uniQure Group Companies&#8221;). Employee shall report to the Chief Executive Officer of the uniQure Group Companies.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">This Agreement replaces and supersedes the prior Employment Agreement dated March 1, 2020, which is contemporaneously terminated as of the Effective Date of this Agreement. No agreements other than this Agreement govern the employment relationship between Employer and Employee. As of the Effective Date, Employee no longer holds the title of Chief Accounting Officer.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employer shall be entitled to assign other duties than the usual activities of the Employee, or to alter the position of the Employee if in the reasonable opinion of the Employer the business circumstances so require.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">1.4</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employee shall not be engaged in any business activity which, in the judgment of the Employer, conflicts with Employee&#8217;s ability to carry out his duties for the Employer.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">1.5</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The work will be performed at the office of the Employer at Paasheuvelweg 25a (1105 BP) in Amsterdam provided, however, that the Employee shall be required to travel from time to time for business purposes. The Employer reserves the right to change the location where the work is performed after consultation with the Employee.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">1.6</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The normal working hours for a full-time, 1.0 FTE position are 40 hours per week. The working hours are normally 8.5 hours a day with a thirty (30) minute lunch break.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Paasheuvelweg 25a</font></p></td><td style="vertical-align:top;width:70.89%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Chamber of Commerce:</font></p></td><td style="vertical-align:top;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;">1</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">P.O. Box 22506</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">34275365</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">1100 DA Amsterdam, NL</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#ff6e00;">legal entity: uniQure biopharma B.V.</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">T: +31 20 240 6000</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">www.uniQure.com</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">F: +31 20 240 6020</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">info@uniQure.com</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="qure-20210630xex10d3001.jpg" alt="Graphic" style="display:inline-block;height:47.24pt;width:179.22pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.55pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2</b></font><b style="font-weight:bold;">Term and termination Agreement</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Agreement has been entered into for an indefinite period of time.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Agreement will in any event, without notice being required, terminate as of the first day of the month following the date the Employee reaches the State pension age (AOW-gerechtigde leeftijd).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.3</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Agreement can be terminated by each of the Parties with due observance of the statutory notice period of 4 months for the Employer and 2 months for the Employee.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.4</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Severance Payments</b>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.4.1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">lf the Agreement is terminated on the initiative of Employer, other than in the case of summary dismissal as referred to in article 7:677 of the Dutch Civil Code, long-term illness (article 7:669 section 3 under b Dutch Civil Code) or severely culpable acts or omissions by Employee as referred to in article 7:669 section 3 under the Dutch Civil Code, Employer shall grant the Employee severance pay equal to 100% of (i) the annual Base Salary, plus (ii) the amount of the Target Bonus (<i style="font-style:italic;">i.e.</i>, Forty percent (40%) of the annual Base Salary (as defined in Clause 3)), (hereinafter: &#39;Severance Pay&#39;) subject to deductions that are authorized by Employee and/or required by applicable laws and regulations.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.4.2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">lf the Agreement is terminated on the initiative of Employer within the period beginning ninety (90) days before and continuing until twelve (12) months after a Change of Control (as defined below), long-term illness (article 7:669 section 3 under b Dutch Civil Code) or severely culpable acts or omissions by Employee as referred to in article 7:669 section 3 under the Dutch Civil Code, clause 2.4.1 shall not apply and, instead, Employer shall grant the Employee severance pay equal to 150% of (i) the annual Base Salary, plus (ii) the amount of the Target Bonus (<i style="font-style:italic;">i.e.</i>, Forty percent (40%) of the annual Base Salary), (hereinafter: &#39;Severance Pay on a Change of Control&#39;) subject to deductions that are authorized by Employee and/or required by applicable laws and regulations. &#160;Employer shall not owe any payments or partial payments of any kind under both clauses 2.4.1 and 2.4.2, which are mutually exclusive.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.4.3</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">If Severance Pay under clause 2.4.1 or Severance Pay on a Change of Control under clause 2.4.2 is owed to the Employee, then the Employer shall grant the Employee additional severance pay equal to a prorated Target Bonus amount for the year of termination as provided in this clause (the &#8220;Pro-rata Bonus&#8221;). The Pro-rata Bonus shall be the product of the formula B x D/365 where B represents the Target Bonus (<i style="font-style:italic;">i.e.</i>, Forty percent (40%) &#160;of the annual Base Salary)), and D represents the number of days elapsed in the calendar year through the date of the separation of Executive&#8217;s employment from the Employer.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.4.4</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">lf and insofar as Employee is entitled to the transition payment as referred to in article 7:673 of the Dutch Civil Code, this transition payment shall be deemed to be factored into the Severance pay, the Severance pay on a Change of Control, and the Pro-Rata Bonus.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.4.5</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">In the event of a termination under this clause 2.4, the Employer shall provide 4 months&#39; notice to the Employee. The Employer, in its sole discretion subject to applicable law, may choose to put the Employee on garden leave at any time during the notice period. Garden leave will be considered equal to continuation of full-time employment, but the Employee will be released from his working duties. In the event that the Employee is placed on garden</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Paasheuvelweg 25a</font></p></td><td style="vertical-align:top;width:70.89%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Chamber of Commerce:</font></p></td><td style="vertical-align:top;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;">2</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">P.O. Box 22506</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">34275365</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">1100 DA Amsterdam, NL</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#ff6e00;">legal entity: uniQure biopharma B.V.</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">T: +31 20 240 6000</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">www.uniQure.com</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">F: +31 20 240 6020</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">info@uniQure.com</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="qure-20210630xex10d3001.jpg" alt="Graphic" style="display:inline-block;height:47.24pt;width:179.22pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">leave, the amount of the severance pay under this clause 2.4 will be reduced by an amount equivalent to the Base Salary during the Employee&#39;s garden leave, and the effective date of the garden leave shall be the date of the separation of Executive&#8217;s employment from the Employer for purposes of calculating the Pro-rata Bonus of clause 2.4.3.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.4.6</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">In the event of a Change of Control as defined below, the vesting conditions that may apply to any stock options, restricted shares, restricted stock units, performance stock units or other grants of equity held by Executive pursuant to this Agreement and the Company&#8217;s Amended and Restated 2014 Share Incentive Plan will be automatically waived and shall be deemed fully vested immediately prior to the Change of Control event. All Stock Options will be deemed to be fully exercisable commencing on the date of and immediately prior to the Change of Control and ending on the eighteen (18) month anniversary of the Change of Control or, if earlier, the expiration of the term of such Stock Options.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.4.7</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">For purposes of this Agreement, &#8220;Change of Control&#8221; shall mean the date on which any of the following events occurs:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.4.7.1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">any &#8220;person,&#8221; as such term is used in Sections 13(d) and 14(d) of the United States Securities Exchange Act of 1934, as amended (the &#8220;Act&#8221;) (other than uniQure N.V. (the &#8220;Company&#8221;), any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with all &#8220;affiliates&#8221; and &#8220;associates&#8221; (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the &#8220;beneficial owner&#8221; (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing forty (40) percent or more of the combined voting power of the Company&#8217;s then outstanding securities having the right to vote in an election of the Board (&#8220;Voting Securities&#8221;) (in such case other than as a result of an acquisition of securities directly from the Company); or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.4.7.2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2.4.7.3</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">the consummation of (i) any consolidation or merger of the Company where the stockholders of the Company, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than fifty (50) percent of the voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (ii) any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of the Company.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Salary, bonus, equity and holiday allowance</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employee&#8217;s annual salary will be EUR Three Hundred Twenty-Five Thousand(&#8364; 325,000) (the &#8220;Base Salary&#8221;), including an 8% holiday allowance on the basis of full-time employment. The salary, including the holiday allowance, shall be paid in 12 equal, monthly instalments ultimately by the end of each calendar month. The Employee will work on a fulltime basis, 1,0 FTE and, therefore, the actual monthly salary is EUR 27,083,33. &#160;In case of part time employment, all earnings will be pro-rated.</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Paasheuvelweg 25a</font></p></td><td style="vertical-align:top;width:70.89%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Chamber of Commerce:</font></p></td><td style="vertical-align:top;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;">3</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">P.O. Box 22506</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">34275365</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">1100 DA Amsterdam, NL</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#ff6e00;">legal entity: uniQure biopharma B.V.</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">T: +31 20 240 6000</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">www.uniQure.com</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">F: +31 20 240 6020</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">info@uniQure.com</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="qure-20210630xex10d3001.jpg" alt="Graphic" style="display:inline-block;height:47.24pt;width:179.22pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">3.2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employee shall be eligible for a bonus payment amounting to a target amount of Forty percent (40%) of his Base Salary (the &#8220;Target Bonus&#8221;). The Employee&#8217;s eligibility for a Target Bonus or any other bonus payment shall be dependent on the Employer guidelines and is at the full discretion of the Board.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">3.3</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Except as provided in clause 2.4, bonus payments, if any, will not be taken into account for the calculation of any possible severance payment upon termination of the Agreement. To be eligible for any bonus pursuant to this Agreement or otherwise pursuant to Employee&#8217;s employment with Employer, Employee must be in service of Employer on the date any bonus is paid.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Overtime</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">The Employee undertakes to work overtime at the request of the Employer. The Employer does not pay any compensation for overtime.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Expenses</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">5.1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The costs for travelling from home to office shall be compensated in accordance with the Employer policy.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">5.2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">To the extent that the Employer has given prior approval for business travels, the Employer shall reimburse reasonable travel and accommodation expenses relating to such business travel incurred by the Employee in the performance of his duties upon submission of all the relevant invoices and vouchers within 30 days following completion of the business travel.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">6</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Holidays</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">6.1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employee is entitled to 30 business days holiday per year or a pro rata portion thereof if the Agreement commences and/or terminates during the calendar year and/or the Employee works part-time.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">6.2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The statutory holiday days (20 days of the 30 per year on full time employment) shall be forfeited after 6 months after the end of the year in which the holiday days were accrued.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;text-align:justify;">6.3</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;text-align:justify;">The Employer shall determine the commencement and the end of the holiday in consultation with the Employee. The Employee shall take his holidays in the period that the activities best allow this.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">7</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Illness</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">In the event of illness in the sense of section 7:629 Dutch Civil Code, the Employee must report sick to the Employer as soon as possible, but no later than 9 a.m. on the first day of illness. The Employee undertakes to comply with the rules related to reporting and inspection in the case of illness, as adopted from time to time by the Employer.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Insurance</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">The Employer will comply with the obligations under the Dutch Health Care Insurance Act.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Paasheuvelweg 25a</font></p></td><td style="vertical-align:top;width:70.89%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Chamber of Commerce:</font></p></td><td style="vertical-align:top;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;">4</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">P.O. Box 22506</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">34275365</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">1100 DA Amsterdam, NL</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#ff6e00;">legal entity: uniQure biopharma B.V.</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">T: +31 20 240 6000</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">www.uniQure.com</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">F: +31 20 240 6020</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">info@uniQure.com</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="qure-20210630xex10d3001.jpg" alt="Graphic" style="display:inline-block;height:47.24pt;width:179.22pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">9</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Pension</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">The Employee shall be entitled to participate in the pension scheme of the Employer following Employer guidelines.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Confidentiality obligation</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">10.1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Both during the term of the Agreement and after the Agreement has been terminated for any reason whatsoever, the Employee shall not make any statements in any way whatsoever to anyone whomsoever (including other personnel of the Employer, unless these should be informed of anything in connection with the work they perform for the Employer), regarding matters, activities and interests of a confidential nature related to the business of the Employer and/or the Employer&#8217;s affiliates, of which the Employee became aware within the scope of his work for the Employer and the confidential nature of which he is or should be aware (&#8220;Confidential Information&#8221;). The Confidential Information includes, <i style="font-style:italic;">inter alia</i>, information about the Employer&#8217;s products, processes and services, including but not limited to, information relating to research, development, inventions, manufacture, purchasing, engineering, marketing, merchandising and selling.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">10.2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">For all oral and written publications by the Employee, which can or could harm the interests of the Employer, prior approval from the Employer has to be obtained. This approval shall only be refused on sincere grounds based on those interests.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">10.3</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">All information exchanged via the Employer&#8217;s email system is considered to be Employer&#8217;s proprietary information and should be taken care of accordingly.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">10.4</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employee agrees that the confidentiality obligations set forth in this clause 10 supersede the Employee&#8217;s obligations to any other company, fund or other organization with which the Employee may have a relationship (&#8220;Affiliated Entities&#8221;) and that any Confidential Information that Employee receives will only be used within the scope of his employment under this Agreement or any successor agreement with Employer and will not be used during the course of his relationship, or communicated through by any means to, any Affiliated Entity.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">11</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Documents</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">The Employee is prohibited from in any way having documents and/or correspondence and/or other information carriers and/or copies thereof in his possession that belong to the Employer and/or to the Employer&#8217;s affiliates, with the exception of the extent to which and as long as required for the performance of his activities for the Employer. In any event, the Employee is required, even without any request being made to that end, to return such documents and/or correspondence and/or other information carriers and/or copies thereof to the Employer immediately upon the end of the Agreement, or in the event the Employee is on non-active duty for any reason whatsoever.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">12</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Ban on ancillary jobs</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">During the term of the Agreement, without the prior written consent of the Employer, the Employee shall not accept any paid work or time-consuming unpaid work at or for third parties and will refrain from doing business for his own account.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:114pt;"></font><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Paasheuvelweg 25a</font></p></td><td style="vertical-align:top;width:70.89%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Chamber of Commerce:</font></p></td><td style="vertical-align:top;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;">5</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">P.O. Box 22506</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">34275365</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">1100 DA Amsterdam, NL</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#ff6e00;">legal entity: uniQure biopharma B.V.</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">T: +31 20 240 6000</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">www.uniQure.com</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">F: +31 20 240 6020</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">info@uniQure.com</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="qure-20210630xex10d3001.jpg" alt="Graphic" style="display:inline-block;height:47.24pt;width:179.22pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">13</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Non-competition and business relationship clause</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">13.1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Both during the term of the Agreement and for a period of one year after the Agreement has been terminated for any reason whatsoever, without the prior written consent of the Employer, the Employee shall not be engaged or involved or have any share in any manner whatsoever, directly or indirectly, whether on his own behalf or for third parties, in any enterprise which conducts activities in a field similar to or otherwise competing with that of the Employer and/or the Employer&#8217;s affiliates, nor act, in any manner whatsoever, directly or indirectly, whether on his own behalf or for third parties, as an intermediary in relation to such activities.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">13.2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Both during the term of the Agreement and for a period of one year after the Agreement has been terminated for any reason whatsoever, without the prior written consent of the Employer, the Employee shall not perform or have performed professional services in connection with any product or research or development or commercialization that competes with products, or research or development or commercialization of Employer, directly or indirectly, whether on his own behalf or for third parties, nor enter into contacts, in that respect, directly or indirectly, whether on his own behalf or for third parties, with clients and/or relations of the Employer and/or the Employer&#8217;s affiliates and/or purchasers of products and/or services of the Employer and/or the Employer&#39;s affiliates.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">13.3</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Clients and/or relations of the Employer and/or the Employer&#8217;s affiliates such as set out in article 13.2 of this Agreement shall in all events mean relations of the Employer and/or the Employer&#8217;s affiliates with which the Employer has or has had (business) contact in any manner whatsoever throughout the course of, or otherwise prior to the termination of, the Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">13.4</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Both during the term of the Agreement and for a period of one year after the Agreement has been terminated for any reason whatsoever, without the prior written consent of the Employer, the Employee shall refrain from becoming engaged or involved in any manner whatsoever, directly or indirectly, whether on his own behalf or for third parties, in actively enticing away, taking (or causing to have taken) into employment, nor make use of, in any manner whatsoever, directly or indirectly, whether on his own behalf or for third parties, the type of work of employees or persons who in a period of one year prior to the termination of the Agreement of the Employee are or have been in the employment of the Employer and/or the Employer&#8217;s affiliates.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">13.5</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Employee acknowledges and agrees to adhere to this clause as the Employer has a serious business interest in binding the Employee to the non-competition and business relationship clause, due to the fact that (i) within the organization of the Employer competition-sensitive information as well as confidential information related to the Employer and its clients and relations, such as but not limited to products, or research or development or commercialization of Employer (&#8220;Sensitive Business Information&#8221;) are available and (ii) in the position of <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Chief Financial Officer</b> the Employee has access to this Sensitive Business Information and/or will become aware of this Sensitive Business Information and/or will maintain (commercial) contacts with clients, suppliers, competitors etc. Given the aforesaid considerations (i) and (ii) in this clause, combined with the education and capacities of the Employee, the Employer has a well-founded fear that its business interest will be harmed substantially if the Employee performs competing activities as set forth in clauses 13.1 up to and including 13.5 of the Agreement within a period of 12 months after termination of the Agreement.</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Paasheuvelweg 25a</font></p></td><td style="vertical-align:top;width:70.89%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Chamber of Commerce:</font></p></td><td style="vertical-align:top;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;">6</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">P.O. Box 22506</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">34275365</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">1100 DA Amsterdam, NL</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#ff6e00;">legal entity: uniQure biopharma B.V.</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">T: +31 20 240 6000</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">www.uniQure.com</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">F: +31 20 240 6020</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">info@uniQure.com</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="qure-20210630xex10d3001.jpg" alt="Graphic" style="display:inline-block;height:47.24pt;width:179.22pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">13.6</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">13.1. to 13.5 shall not apply in the case of summary dismissal as referred to in article 7:677 of the Dutch Civil Code.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">14</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Intellectual and industrial property</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">14.1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employer is or will be considered to be, to the fullest extent allowed by law, the maker/producer/designer/breeder of all that which is made, created, improved, produced, designed, invented or discovered by the Employee during his activities performed for the Employer (the <b style="font-weight:bold;">Works</b>).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">14.2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employee is obliged to fully and comprehensibly disclose all Works to the Employer in writing immediately after they are created or after the creation becomes known to the Employee, and in any case at the request of the Employer.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">14.3</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employee hereby transfers and assigns all his rights to and in connection with the Works to the Employer in advance.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">14.4</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employee is obliged, at first request of the Employer, to transfer and assign to the Employer all rights to and in connection with the Works that do not belong to the Employer by operation of law (<i style="font-style:italic;">van rechtswege</i>), and that are not transferred to the Employer pursuant to article 14.3 of this Agreement. This concerns all rights, anywhere in the world, to and arising from or in connection with the Works. This obligation of the Employee remains in force even after the end of this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">14.5</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employee agrees to perform, to the extent necessary and/or at the request of the Employer, such further acts as may be necessary or desirable to apply for, obtain and/or maintain protection for the Works, <i style="font-style:italic;">inter alia</i> by means of the establishment of intellectual and industrial property rights. The Employee hereby grants permission and power of attorney to the Employer to the extent necessary to carry out every required act on behalf of the Employee to obtain protection for the Works, or to transfer the Works and any rights relating thereto, to the Employer. The Employer will compensate the reasonable costs made in respect hereof, in so far as the payment that the Employee receives pursuant to article 3.1 of this Agreement cannot be considered as compensation for such costs. This obligation of the Employee remains in force even after the end of the Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">14.6</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employee acknowledges that the payment ex article 3.1 of this Agreement includes a reasonable compensation for any possible deprivation of any intellectual and industrial property rights. To the extent legally possible, the Employee hereby waives his right to any additional compensation with respect to the Works.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">15</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Gifts</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">In connection with the performance of his duties, the Employee is prohibited from accepting or stipulating, either directly or indirectly, any commission, reimbursement or payment, in whatever form, or gifts from third parties. The foregoing does not apply to standard promotional gifts having little monetary value.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">16</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Penalty clause</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">In the event the Employee acts in violation of any of the obligations under the articles 10 through 15 of this Agreement, the Employee shall, contrary to section 7:650 paragraphs 3, 4</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Paasheuvelweg 25a</font></p></td><td style="vertical-align:top;width:70.89%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Chamber of Commerce:</font></p></td><td style="vertical-align:top;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;">7</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">P.O. Box 22506</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">34275365</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">1100 DA Amsterdam, NL</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#ff6e00;">legal entity: uniQure biopharma B.V.</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">T: +31 20 240 6000</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">www.uniQure.com</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">F: +31 20 240 6020</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">info@uniQure.com</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="qure-20210630xex10d3001.jpg" alt="Graphic" style="display:inline-block;height:47.24pt;width:179.22pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">and 5 Dutch Civil Code, without notice of default being required, forfeit to the Employer for each such violation, a penalty in the amount of EUR 10.000,00 as well as a penalty of EUR 1.000,00 for each day such violation has taken place and continues. Alternatively, the Employer will be entitled to claim full damages.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">17</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Transfer of an undertaking</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">The Employee shall remain under the obligation to adhere the set out in the articles 10 through 16 of this Agreement vis-&#224;-vis the Employer, if the enterprise of the Employer or a part thereof is transferred to a third party within the meaning of section 7:662 and onwards Dutch Civil Code and this Agreement terminates before or at the time of such transfer, whereas in the event of continuation of the Agreement the Employee would have entered the employment of the acquirer by operation of law.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">18</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Other arrangements</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">Subject to the provisions in this Agreement, the arrangements related to employment conditions adopted by the Employer from time to time, as laid down in the Employee Handbook are applicable. A copy of these arrangements has been provided to the Employee. By signing this agreement, the Employee acknowledges to have received and understood the Employee Handbook and the Insider Trading Policy.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">19</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Employment costs regulation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">The conditions of employment costs regulation determined by the Employer apply. In this context, the Employer reserves the right at its sole discretion to modify certain fringe benefits, without any compensation in return.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">20</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Amendment clause</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">20.1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employer reserves the right to unilaterally amend the Agreement and the arrangements referred to in article 18 of this Agreement if it has such a serious interest in that respect entailing that the interests of the Employee must yield to that in accordance with standards of reasonableness and fairness.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">20.2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Employer reserves the right to unilaterally amend the Agreement and the arrangements referred to in article 18 of this Agreement in the event of a relevant amendment of the law.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">21</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Applicable law, no collective labour agreement</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">21.1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">This Agreement is governed by Dutch law.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">21.2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">The Agreement is not subject to any collective labour agreement.</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Paasheuvelweg 25a</font></p></td><td style="vertical-align:top;width:70.89%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Chamber of Commerce:</font></p></td><td style="vertical-align:top;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;">8</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">P.O. Box 22506</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">34275365</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">1100 DA Amsterdam, NL</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#ff6e00;">legal entity: uniQure biopharma B.V.</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">T: +31 20 240 6000</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">www.uniQure.com</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">F: +31 20 240 6020</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">info@uniQure.com</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="qure-20210630xex10d3001.jpg" alt="Graphic" style="display:inline-block;height:47.24pt;width:179.22pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">THIS AGREEMENT has been entered into on the date stated at the beginning of this Agreement</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">uniQure biopharma B.V.</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Employee</b></p></td></tr><tr><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Lilly Burggraaf</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Christian Klemt</p></td></tr><tr><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">Lilly Burggraaf</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">Christian Klemt</p></td></tr><tr><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">VP, Global Human Resources</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Paasheuvelweg 25a</font></p></td><td style="vertical-align:top;width:70.89%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">Chamber of Commerce:</font></p></td><td style="vertical-align:top;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;">9</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">P.O. Box 22506</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">34275365</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">1100 DA Amsterdam, NL</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#ff6e00;">legal entity: uniQure biopharma B.V.</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">T: +31 20 240 6000</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">www.uniQure.com</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">F: +31 20 240 6020</font></p></td><td colspan="2" style="vertical-align:top;width:76.64%;margin:0pt;padding:0pt;"><p style="color:#ff6e00;font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="font-size:10pt;">info@uniQure.com</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>qure-20210630xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 7/26/2021 08:02:08 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification of Chief Executive Officer</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Matthew Kapusta, certify that:</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">I have reviewed this Quarterly Report on Form&#160;10-Q of uniQure N.V.;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><div align="left"><table style="background-color:#ffffff;border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ MATTHEW KAPUSTA</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Kapusta</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 26, 2021</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>qure-20210630xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 7/26/2021 08:02:11 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification of Chief Financial Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Christian Klemt, certify that:</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of uniQure N.V.;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><div align="left"><table style="background-color:#ffffff;border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ CHRISTIAN KLEMT</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Christian Klemt</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Financial Officer</i></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer)</i></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 26, 2021</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>qure-20210630xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 7/26/2021 08:02:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with this Quarterly Report of uniQure N.V. (the &#8220;Company&#8221;) on&#160;Form&#160;10-Q&#160;for the period ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Matthew Kapusta, Chief Executive Officer, and Christian Klemt, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that:</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">the Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;"><font style="font-size:10pt;">2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><div align="left"><table style="background-color:#ffffff;border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ MATTHEW KAPUSTA</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Kapusta</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 26, 2021</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="background-color:#ffffff;border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ CHRISTIAN KLEMT</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Christian Klemt</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Financial Officer</i></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer)</i></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 26, 2021</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">A signed original of this written statement required by Section&#160;906 has been provided to uniQure N.V. and will be retained by uniQure N.V. and furnished to the SEC or its staff upon request.</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>qure-20210630xex2d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 qure-20210630xex2d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" 9@# 2(  A$! Q$!_\0
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MO:Q=>/-$,^J7LGFZE"9-T[$-F09R,T ?:5%%% !1110 4444 %%%% !1110
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MX,%UH.I12 XP;5^?H<<_A6E<_#[7M-\)7'B+5;.6PMDD2**.=2LDK,>NT\@
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MBK"\$V\UGX$\/VUS$\,\.G6Z21NN&1A&H(([$&MV@#BOB[_R2KQ!_P!<%_\
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M%>\6\1@MHH3*\IC0*9)#EGP,9..YK,\4:#!XF\,:CHUQC9=0E Q'W6ZJWX,
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>qure-20210630xex10d2001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 qure-20210630xex10d2001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "# 9(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#0!
MDZMXAL='(6=R96Y$:\G%0Z7XJT[5)Q C-'*?NJXQN^E>>>(9)9/$%Z9<Y$I
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MI7KIZ5Y%XD_Y&*^_ZZ?TKNSW^#'U.#(?X\O0N>"_^1DB_P!QOY5ZE7EO@O\
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M;"YL19- JP @A5XY%4/^$-T;_G@W_?57/(ZJ:Y9(B&?4FGSQ9=\/?\B]8?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>qure-20210630xex10d3001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 qure-20210630xex10d3001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ .\# 2(  A$! Q$!_\0
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MYOP_XHAO-6BLX=)@M?.SN>,C/ )]!GI6OXQ_Y%>[_P" ?^A"N&\(?\C19_\
M O\ T$UMCL35IXVG3B]';HNK,<#A:53 U*DEJK]7T1Z9J5P;33+JX'6.)F'U
M KQE%:655SEG8#)]2:]=\1''AW4,?\\&_E7E&GC.I6@/>9/_ $(5RYX^:M3A
MT_X)U9$E&C4GY_DCU_3=.M]+LH[:WC"JH&2!RQ]36!XWTN"?2'OUC N(""7
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'I.3NWJ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>qure-20210630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/26/2021 8:02:40 PM-->
<!--Modified on: 7/26/2021 8:02:40 PM-->
<xsd:schema targetNamespace="http://www.uniqure.com/20210630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:attributeFormDefault="unqualified" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:qure="http://www.uniqure.com/20210630" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.uniqure.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>40401 - Disclosure - Fair value measurement - Assets and liabilities measured on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>40501 - Disclosure - Accrued expenses and other current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity" id="StatementConsolidatedStatementsOfShareholdersEquity">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureGeneralBusinessInformation" id="DisclosureGeneralBusinessInformation">
        <link:definition>10101 - Disclosure - General business information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRisk" id="DisclosureCollaborationArrangementsAndConcentrationOfCreditRisk">
        <link:definition>10301 - Disclosure - Collaboration arrangements and concentration of credit risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10401 - Disclosure - Fair value measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>10501 - Disclosure - Accrued expenses and other current liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureLongTermDebt" id="DisclosureLongTermDebt">
        <link:definition>10601 - Disclosure - Long-term debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureShareholdersEquity" id="DisclosureShareholdersEquity">
        <link:definition>10701 - Disclosure - Shareholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>10801 - Disclosure - Share-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11001 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShare" id="DisclosureBasicAndDilutedEarningsPerShare">
        <link:definition>11101 - Disclosure - Basic and diluted earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11201 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30403 - Disclosure - Fair value measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>30503 - Disclosure - Accrued expenses and other current liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>30803 - Disclosure - Share-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareTables" id="DisclosureBasicAndDilutedEarningsPerShareTables">
        <link:definition>31103 - Disclosure - Basic and diluted earnings per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails" id="DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails">
        <link:definition>40301 - Disclosure - Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails" id="DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails">
        <link:definition>40402 - Disclosure - Fair value measurement - BMS warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureLongTermDebtDetails" id="DisclosureLongTermDebtDetails">
        <link:definition>40601 - Disclosure - Long-term debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureShareholdersEquityDetails" id="DisclosureShareholdersEquityDetails">
        <link:definition>40701 - Disclosure - Shareholders' equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails" id="DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails">
        <link:definition>40801 - Disclosure - Share-based compensation - Summary of share-based compensation expense and unrecognized costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails" id="DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails">
        <link:definition>40802 - Disclosure - Share-based compensation - Option activity and weighted-average assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails" id="DisclosureShareBasedCompensationRsuActivityDetails">
        <link:definition>40803 - Disclosure - Share-based compensation - RSU activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails" id="DisclosureShareBasedCompensationPsuActivityDetails">
        <link:definition>40804 - Disclosure - Share-based compensation - PSU activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails" id="DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails">
        <link:definition>40805 - Disclosure - Share-based compensation - Employee Share Purchase Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureOtherIncomeDetails" id="DisclosureOtherIncomeDetails">
        <link:definition>40901 - Disclosure - Other income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" id="DisclosureIncomeTaxesEffectiveTaxRateDetails">
        <link:definition>41001 - Disclosure - Income taxes - Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails" id="DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails">
        <link:definition>41101 - Disclosure - Basic and diluted earnings per share - Ordinary share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails" id="DisclosureBasicAndDilutedEarningsPerShareDetails">
        <link:definition>41102 - Disclosure - Basic and diluted earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureOtherIncome" id="DisclosureOtherIncome">
        <link:definition>10901 - Disclosure - Other income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.uniqure.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41201 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="qure-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="qure-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="qure-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="qure-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets" name="IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract" name="CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock" name="CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_PlanIn2014Member" name="PlanIn2014Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock" name="ScheduleOfPotentialDilutiveCommonSharesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember" name="RestrictedShareUnitsAndPerformanceShareUnitsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_BristolMyersSquibbMember" name="BristolMyersSquibbMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_ShareOption2012PlanMember" name="ShareOption2012PlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_The2014PlanMember" name="The2014PlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_EmployeeConsultantsAndDirectorsStockOptionsMember" name="EmployeeConsultantsAndDirectorsStockOptionsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent" name="AccrualsForServicesProvidedByVendorsNotYetBilledCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_VentureDebtLoanFacilityWithHerculesMember" name="VentureDebtLoanFacilityWithHerculesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_DebtInstrumentInterestRateDiscountRatePercentage" name="DebtInstrumentInterestRateDiscountRatePercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_DebtInstrumentBackEndFeeOne" name="DebtInstrumentBackEndFeeOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_DebtInstrumentBackEndFeePercentage" name="DebtInstrumentBackEndFeePercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_DebtInstrumentPercentageOfWorldwideCashReserves" name="DebtInstrumentPercentageOfWorldwideCashReserves" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_BmsWarrantsMember" name="BmsWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets" name="IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_CollaborativeArrangementLicenseRevenueMember" name="CollaborativeArrangementLicenseRevenueMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration" name="ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_LicenseRevenueFromRelatedPartyMember" name="LicenseRevenueFromRelatedPartyMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_CollaborativeRevenueMember" name="CollaborativeRevenueMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_CollaborativeRevenueFromRelatedPartyMember" name="CollaborativeRevenueFromRelatedPartyMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_EmployeeSharePurchasePlanMember" name="EmployeeSharePurchasePlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_NumberOfCollaborationTargets" name="NumberOfCollaborationTargets" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" name="SecondAmendedAndRestatedLoanAndSecurityAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_HerculesTechnologyGrowthCorp.Member" name="HerculesTechnologyGrowthCorp.Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_AmendedFacility2016Member" name="AmendedFacility2016Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_AmendedFacility2018Member" name="AmendedFacility2018Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_DebtInstrumentAggregateAmountOfEquityFinancing" name="DebtInstrumentAggregateAmountOfEquityFinancing" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_NumberOfWarrantTypes" name="NumberOfWarrantTypes" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_InitialResearchTerm" name="InitialResearchTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly" name="AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly" name="AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_UnauditedInterimFinancialInformationPolicyTextBlock" name="UnauditedInterimFinancialInformationPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_CslBehringCollaborationMember" name="CslBehringCollaborationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_RegulatoryAndCommercialMilestonePaymentsReceivable" name="RegulatoryAndCommercialMilestonePaymentsReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_AdditionalUnconditionalBorrowingCapacity" name="AdditionalUnconditionalBorrowingCapacity" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_UpfrontCashToReceiveUponClosingOfAgreement" name="UpfrontCashToReceiveUponClosingOfAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_OtherCurrentAssetsAndReceivables" name="OtherCurrentAssetsAndReceivables" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease" name="ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced" name="CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_CollaborationAgreementCashPayable" name="CollaborationAgreementCashPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_ThresholdPercentageOfNetProceeds" name="ThresholdPercentageOfNetProceeds" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_PercentageOfNetProceedsPayable" name="PercentageOfNetProceedsPayable" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_DerecognitionOfWarrantsMember" name="DerecognitionOfWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember" name="CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember" name="CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_AmendedFacility2021Member" name="AmendedFacility2021Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable" name="CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_GainLossOnRecognitionOfDerivatives" name="GainLossOnRecognitionOfDerivatives" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_AmendedFacility2018And2021Member" name="AmendedFacility2018And2021Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_SalesAgreementWithSvbLeerinkMember" name="SalesAgreementWithSvbLeerinkMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_PercentageOfGrossProceedsOfSharesSold" name="PercentageOfGrossProceedsOfSharesSold" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_NetProceedsFromIssuanceOfShares" name="NetProceedsFromIssuanceOfShares" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_DirectIncrementalLaborMember" name="DirectIncrementalLaborMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" name="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_OtherIncomeTextBlock" name="OtherIncomeTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_EmployeeRetentionCreditIncome" name="EmployeeRetentionCreditIncome" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_EquityMethodInvestmentSettlementIncome" name="EquityMethodInvestmentSettlementIncome" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_VectoryB.vMember" name="VectoryB.vMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi" name="DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii" name="DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="qure_CollaborationAgreementOtherPaymentsReceived" name="CollaborationAgreementOtherPaymentsReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>qure-20210630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/26/2021 8:02:40 PM-->
<!--Modified on: 7/26/2021 8:02:40 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.uniqure.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <calculationLink xlink:role="http://www.uniqure.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637629265584893845" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent_637629265584893845" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637629265584893845" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637629265584893845" xlink:to="us-gaap_OtherAssetsNoncurrent_637629265584893845" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637629265584893845" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637629265584893845" xlink:to="us-gaap_Goodwill_637629265584893845" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637629265584893845" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637629265584893845" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637629265584893845" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_637629265584893845" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637629265584893845" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_637629265584893845" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637629265584893845" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637629265584893845" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637629265584893845" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_637629265584893845" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637629265584893845" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_637629265584893845" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637629265584893845" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637629265584893845" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_OtherCurrentAssetsAndReceivables" xlink:label="qure_OtherCurrentAssetsAndReceivables_637629265584903699" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637629265584893845" xlink:to="qure_OtherCurrentAssetsAndReceivables_637629265584903699" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637629265584903699" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637629265584893845" xlink:to="us-gaap_PrepaidExpenseCurrent_637629265584903699" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637629265584903699" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637629265584893845" xlink:to="us-gaap_AccountsReceivableNetCurrent_637629265584903699" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637629265584903699" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637629265584893845" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637629265584903699" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637629265584903699" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637629265584903699" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637629265584903699" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637629265584903699" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637629265584903699" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637629265584903699" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637629265584903699" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637629265584903699" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637629265584903699" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637629265584903699" xlink:to="us-gaap_AdditionalPaidInCapital_637629265584903699" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637629265584913696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637629265584903699" xlink:to="us-gaap_CommonStockValue_637629265584913696" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637629265584913696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637629265584913696" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637629265584913696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637629265584913696" xlink:to="us-gaap_LiabilitiesNoncurrent_637629265584913696" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637629265584913696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637629265584913696" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637629265584913696" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637629265584913696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637629265584913696" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637629265584913696" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637629265584913696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637629265584913696" xlink:to="us-gaap_LongTermDebtNoncurrent_637629265584913696" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637629265584913696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637629265584913696" xlink:to="us-gaap_LiabilitiesCurrent_637629265584913696" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637629265584913696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637629265584913696" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637629265584913696" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637629265584913696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637629265584913696" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637629265584913696" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637629265584923696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637629265584913696" xlink:to="us-gaap_AccountsPayableCurrent_637629265584923696" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637629265584923696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637629265584923696" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637629265584923696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637629265584923696" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637629265584923696" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637629265584923696" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637629265584923696" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637629265584934147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637629265584923696" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637629265584934147" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637629265584934147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637629265584934147" xlink:to="us-gaap_InvestmentIncomeInterest_637629265584934147" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637629265584934147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637629265584934147" xlink:to="us-gaap_InterestExpense_637629265584934147" order="2" use="optional" weight="-1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637629265584934147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637629265584934147" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637629265584934147" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637629265584934147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637629265584934147" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637629265584934147" order="4" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637629265584934147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637629265584934147" xlink:to="us-gaap_OperatingIncomeLoss_637629265584934147" order="5" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses_637629265584934147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637629265584934147" xlink:to="us-gaap_OtherExpenses_637629265584934147" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637629265584934147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637629265584934147" xlink:to="us-gaap_OtherIncome_637629265584934147" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_637629265584934147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637629265584934147" xlink:to="us-gaap_CostsAndExpenses_637629265584934147" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637629265584944115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637629265584934147" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637629265584944115" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637629265584944115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637629265584934147" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637629265584944115" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_637629265584944115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637629265584934147" xlink:to="us-gaap_CostOfGoodsAndServicesSold_637629265584944115" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637629265584944115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637629265584934147" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637629265584944115" order="4" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637629265584944115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637629265584944115" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637629265584944115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent_637629265584944115" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265584944115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265584944115" order="1" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637629265584944115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265584944115" xlink:to="us-gaap_ProfitLoss_637629265584944115" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_637629265584954039" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265584944115" xlink:to="us-gaap_DepreciationAndAmortization_637629265584954039" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637629265584954039" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265584944115" xlink:to="us-gaap_ShareBasedCompensation_637629265584954039" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration" xlink:label="qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration_637629265584954039" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265584944115" xlink:to="qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration_637629265584954039" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_637629265584954039" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265584944115" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_637629265584954039" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_637629265584954039" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265584944115" xlink:to="us-gaap_OtherNoncashIncomeExpense_637629265584954039" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets" xlink:label="qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets_637629265584954039" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265584944115" xlink:to="qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets_637629265584954039" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637629265584954039" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265584944115" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637629265584954039" order="8" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_637629265584954039" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265584944115" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_637629265584954039" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637629265584954039" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637629265584954039" order="2" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_637629265584954039" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637629265584954039" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_637629265584954039" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637629265584964044" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637629265584954039" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637629265584964044" order="2" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637629265584964044" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637629265584964044" order="3" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637629265584964044" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637629265584964044" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637629265584964044" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637629265584964044" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637629265584964044" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637629265584964044" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637629265584964044" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637629265584964044" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637629265584964044" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637629265584964044" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637629265584964044" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637629265584964044" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637629265584964044" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637629265584964044" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair value measurement - Assets and liabilities measured on a recurring basis (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637629265584974053" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637629265584974053" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_637629265584974053" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilities_637629265584974053" order="1" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued expenses and other current liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent" xlink:label="qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent_637629265584974053" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent_637629265584974053" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637629265584974053" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637629265584974053" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637629265584974053" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_637629265584974053" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>qure-20210630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/26/2021 8:02:40 PM-->
<!--Modified on: 7/26/2021 8:02:41 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#StatementConsolidatedStatementsOfShareholdersEquity" roleURI="http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails" roleURI="http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails" roleURI="http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureLongTermDebtDetails" roleURI="http://www.uniqure.com/role/DisclosureLongTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareholdersEquityDetails" roleURI="http://www.uniqure.com/role/DisclosureShareholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensationRsuActivityDetails" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensationPsuActivityDetails" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureOtherIncomeDetails" roleURI="http://www.uniqure.com/role/DisclosureOtherIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureIncomeTaxesEffectiveTaxRateDetails" roleURI="http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails" roleURI="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureBasicAndDilutedEarningsPerShareDetails" roleURI="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <definitionLink xlink:role="http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637629265584974053" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637629265584974053" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_LicenseRevenueFromRelatedPartyMember" xlink:label="qure_LicenseRevenueFromRelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="qure_LicenseRevenueFromRelatedPartyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeRevenueMember" xlink:label="qure_CollaborativeRevenueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="qure_CollaborativeRevenueMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeRevenueFromRelatedPartyMember" xlink:label="qure_CollaborativeRevenueFromRelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="qure_CollaborativeRevenueFromRelatedPartyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637629265585024045" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637629265585024045" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" xlink:label="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="30803 - Disclosure - Share-based compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637629265585054299" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637629265585054299" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_PlanIn2014Member" xlink:label="qure_PlanIn2014Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="qure_PlanIn2014Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637629265585064080" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637629265585064080" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_BristolMyersSquibbMember" xlink:label="qure_BristolMyersSquibbMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="qure_BristolMyersSquibbMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637629265585074031" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637629265585074031" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeArrangementLicenseRevenueMember" xlink:label="qure_CollaborativeArrangementLicenseRevenueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="qure_CollaborativeArrangementLicenseRevenueMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_LicenseRevenueFromRelatedPartyMember" xlink:label="qure_LicenseRevenueFromRelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="qure_LicenseRevenueFromRelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeRevenueFromRelatedPartyMember" xlink:label="qure_CollaborativeRevenueFromRelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="qure_CollaborativeRevenueFromRelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeRevenueMember" xlink:label="qure_CollaborativeRevenueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="qure_CollaborativeRevenueMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637629265585084117" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637629265585084117" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CslBehringCollaborationMember" xlink:label="qure_CslBehringCollaborationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="qure_CslBehringCollaborationMember" priority="1" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="qure_BristolMyersSquibbMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_InitialResearchTerm" xlink:label="qure_InitialResearchTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_InitialResearchTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_NumberOfCollaborationTargets" xlink:label="qure_NumberOfCollaborationTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_NumberOfCollaborationTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced" xlink:label="qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease" xlink:label="qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_UpfrontCashToReceiveUponClosingOfAgreement" xlink:label="qure_UpfrontCashToReceiveUponClosingOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_UpfrontCashToReceiveUponClosingOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementOtherPaymentsReceived" xlink:label="qure_CollaborationAgreementOtherPaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_CollaborationAgreementOtherPaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_RegulatoryAndCommercialMilestonePaymentsReceivable" xlink:label="qure_RegulatoryAndCommercialMilestonePaymentsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_RegulatoryAndCommercialMilestonePaymentsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:label="qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" xlink:label="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair value measurement - Assets and liabilities measured on a recurring basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637629265585114099" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637629265585114099" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637629265585114099" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637629265585114099" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair value measurement - BMS warrants - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637629265585294083" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_637629265585294083" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember" xlink:label="qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember" xlink:label="qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637629265585294083" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637629265585294083" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DerecognitionOfWarrantsMember" xlink:label="qure_DerecognitionOfWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="qure_DerecognitionOfWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637629265585304043" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_637629265585304043" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_NumberOfWarrantTypes" xlink:label="qure_NumberOfWarrantTypes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_NumberOfWarrantTypes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_NumberOfCollaborationTargets" xlink:label="qure_NumberOfCollaborationTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_NumberOfCollaborationTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementCashPayable" xlink:label="qure_CollaborationAgreementCashPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_CollaborationAgreementCashPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ThresholdPercentageOfNetProceeds" xlink:label="qure_ThresholdPercentageOfNetProceeds" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_ThresholdPercentageOfNetProceeds" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_PercentageOfNetProceedsPayable" xlink:label="qure_PercentageOfNetProceedsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_PercentageOfNetProceedsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_GainLossOnRecognitionOfDerivatives" xlink:label="qure_GainLossOnRecognitionOfDerivatives" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="qure_GainLossOnRecognitionOfDerivatives" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureLongTermDebtDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Long-term debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637629265585314029" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637629265585314029" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637629265585314029" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637629265585314029" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_VentureDebtLoanFacilityWithHerculesMember" xlink:label="qure_VentureDebtLoanFacilityWithHerculesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="qure_VentureDebtLoanFacilityWithHerculesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_637629265585323762" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_637629265585323762" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AmendedFacility2016Member" xlink:label="qure_AmendedFacility2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="qure_AmendedFacility2016Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AmendedFacility2018Member" xlink:label="qure_AmendedFacility2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="qure_AmendedFacility2018Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AmendedFacility2021Member" xlink:label="qure_AmendedFacility2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="qure_AmendedFacility2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AmendedFacility2018And2021Member" xlink:label="qure_AmendedFacility2018And2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="qure_AmendedFacility2018And2021Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_637629265585333847" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_637629265585333847" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_637629265585333847" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_637629265585333847" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_HerculesTechnologyGrowthCorp.Member" xlink:label="qure_HerculesTechnologyGrowthCorp.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="qure_HerculesTechnologyGrowthCorp.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637629265585343733" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637629265585343733" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentInterestRateDiscountRatePercentage" xlink:label="qure_DebtInstrumentInterestRateDiscountRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="qure_DebtInstrumentInterestRateDiscountRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentBackEndFeePercentage" xlink:label="qure_DebtInstrumentBackEndFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="qure_DebtInstrumentBackEndFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AdditionalUnconditionalBorrowingCapacity" xlink:label="qure_AdditionalUnconditionalBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="qure_AdditionalUnconditionalBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentBackEndFeeOne" xlink:label="qure_DebtInstrumentBackEndFeeOne" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="qure_DebtInstrumentBackEndFeeOne" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentAggregateAmountOfEquityFinancing" xlink:label="qure_DebtInstrumentAggregateAmountOfEquityFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="qure_DebtInstrumentAggregateAmountOfEquityFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentPercentageOfWorldwideCashReserves" xlink:label="qure_DebtInstrumentPercentageOfWorldwideCashReserves" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="qure_DebtInstrumentPercentageOfWorldwideCashReserves" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly" xlink:label="qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly" xlink:label="qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtByMaturityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureShareholdersEquityDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Shareholders' equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_SalesAgreementWithSvbLeerinkMember" xlink:label="qure_SalesAgreementWithSvbLeerinkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="qure_SalesAgreementWithSvbLeerinkMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637629265585393763" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_637629265585393763" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637629265585403734" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637629265585403734" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DirectIncrementalLaborMember" xlink:label="qure_DirectIncrementalLaborMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="qure_DirectIncrementalLaborMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_PercentageOfGrossProceedsOfSharesSold" xlink:label="qure_PercentageOfGrossProceedsOfSharesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="qure_PercentageOfGrossProceedsOfSharesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_NetProceedsFromIssuanceOfShares" xlink:label="qure_NetProceedsFromIssuanceOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="qure_NetProceedsFromIssuanceOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Share-based compensation - Summary of share-based compensation expense and unrecognized costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_The2014PlanMember" xlink:label="qure_The2014PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="qure_The2014PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265585424106" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265585424106" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="qure_EmployeeConsultantsAndDirectorsStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="qure_EmployeeConsultantsAndDirectorsStockOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Share-based compensation - Option activity and weighted-average assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_The2014PlanMember" xlink:label="qure_The2014PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="qure_The2014PlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="qure_EmployeeConsultantsAndDirectorsStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="qure_EmployeeConsultantsAndDirectorsStockOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637629265585444041" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_637629265585444041" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637629265585454073" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637629265585454073" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice" xlink:label="qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Share-based compensation - RSU activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_The2014PlanMember" xlink:label="qure_The2014PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="qure_The2014PlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Share-based compensation - PSU activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_The2014PlanMember" xlink:label="qure_The2014PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="qure_The2014PlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Share-based compensation - Employee Share Purchase Plan - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeSharePurchasePlanMember" xlink:label="qure_EmployeeSharePurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="qure_EmployeeSharePurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureOtherIncomeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Other income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_637629265585574020" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_637629265585574020" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_VectoryB.vMember" xlink:label="qure_VectoryB.vMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="qure_VectoryB.vMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_OtherIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeRetentionCreditIncome" xlink:label="qure_EmployeeRetentionCreditIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="qure_EmployeeRetentionCreditIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EquityMethodInvestmentSettlementIncome" xlink:label="qure_EquityMethodInvestmentSettlementIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="qure_EquityMethodInvestmentSettlementIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_InvestmentOwnedBalanceShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Income taxes - Effective Tax Rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CslBehringCollaborationMember" xlink:label="qure_CslBehringCollaborationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="qure_CslBehringCollaborationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Basic and diluted earnings per share - Ordinary share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637629265585594023" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637629265585594023" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_RestrictedShareUnitsAndPerformanceShareUnitsMember" xlink:label="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ShareOption2012PlanMember" xlink:label="qure_ShareOption2012PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="qure_ShareOption2012PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeSharePurchasePlanMember" xlink:label="qure_EmployeeSharePurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="qure_EmployeeSharePurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Basic and diluted earnings per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_BmsWarrantsMember" xlink:label="qure_BmsWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="qure_BmsWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_RestrictedShareUnitsAndPerformanceShareUnitsMember" xlink:label="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_BristolMyersSquibbMember" xlink:label="qure_BristolMyersSquibbMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="qure_BristolMyersSquibbMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ShareOption2012PlanMember" xlink:label="qure_ShareOption2012PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="qure_ShareOption2012PlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeSharePurchasePlanMember" xlink:label="qure_EmployeeSharePurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="qure_EmployeeSharePurchasePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>qure-20210630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/26/2021 8:02:40 PM-->
<!--Modified on: 7/26/2021 8:02:40 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_OtherCurrentAssetsAndReceivables" xlink:label="qure_OtherCurrentAssetsAndReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_OtherCurrentAssetsAndReceivables" xlink:to="qure_OtherCurrentAssetsAndReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_OtherCurrentAssetsAndReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The balance of other current assets and receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_OtherCurrentAssetsAndReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets and receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_OtherCurrentAssetsAndReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets and receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, net of accumulated depreciation of $37.3 million as of June 30, 2021 and $35.2 million as of December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, 0.05 par value: 80,000,000 shares authorized as of June 30, 2021 and 60,000,000 shares authorized as of December 31, 2020 and 46,050,250 and 44,777,799 ordinary shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in-capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive (loss) / income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, par value (in euros per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of contract revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income / (loss) from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency gains / (losses), net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-operating gains, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income / (loss) before income tax expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income / (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive (loss) / gain:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive gain / (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per ordinary share - basic</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net income / (loss) per ordinary share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per ordinary share - diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net income / (loss) per ordinary share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares - basic</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average number of ordinary shares outstanding - diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive Income (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued in connection with offering</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" xlink:label="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" xlink:to="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in additional paid in capital (APIC) resulting from tax effect of prior years issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs, Tax Effect Prior Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax benefit past share issuance cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of share options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of share options (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Share-based Compensation, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted and performance share units distributed during the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Share-based Compensation, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted and performance share units distributed during the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares relating to employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares relating to employee stock purchase plan (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net income / (loss) to net cash generated from / used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization, Nonproduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration" xlink:label="qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration" xlink:to="qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of change in fair value of derivative financial instruments and contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change In Fair Value Of Derivative Financial Instruments And Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of derivative financial instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Gain (Loss) on Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized foreign exchange gains, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-cash items, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets" xlink:label="qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets" xlink:to="qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in accounts receivable, prepaid expenses and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable, Prepaid Expense and Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, prepaid expenses, and other current assets and receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses, other liabilities, and operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash generated from / (used) in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from loan increment, net of debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of ordinary shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issuance costs from issuance of ordinary shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of ordinary shares related to employee stock option and purchase plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash generated from financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency effect on cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase / (decrease) in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at the end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash related to leasehold and other deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental cash flow disclosures:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets" xlink:label="qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets" xlink:to="qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period for accounts payable and accrued liabilities under supplemental cash flow information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities Related to Non Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash increase in accounts payables and accrued expenses and other current liabilities related to purchases of intangible assets and property, plant, and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General business information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General business information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract" xlink:label="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract" xlink:to="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration arrangements and concentration of credit risk</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock" xlink:label="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock" xlink:to="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for collaboration arrangements and concentration of credit risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Arrangements and Concentration of Credit Risk Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration arrangements and concentration of credit risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_OtherIncomeDisclosureNonoperatingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income.</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_OtherIncomeTextBlock" xlink:label="qure_OtherIncomeTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_OtherIncomeTextBlock" xlink:to="qure_OtherIncomeTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_OtherIncomeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for other income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_OtherIncomeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_OtherIncomeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted earnings per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted earnings per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="qure_UnauditedInterimFinancialInformationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:to="qure_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policies for Unaudited interim financial information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited Interim Financial Information [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited interim financial information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assets and liabilities measured at fair value on recurring basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share-based compensation expense by classification included in consolidated statements of operations and comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of unrecognized compensation cost related to unvested awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of option activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted-average assumptions for fair value of option issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of RSUs activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Performance Shares Award Unvested Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of PSUs activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of bsic and diluted earnings per share</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock" xlink:label="qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock" xlink:to="qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of potential dilutive common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Potential Dilutive Common Shares [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potential dilutive common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration arrangements</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_InitialResearchTerm" xlink:label="qure_InitialResearchTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_InitialResearchTerm" xlink:to="qure_InitialResearchTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_InitialResearchTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial research term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_InitialResearchTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial research term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_InitialResearchTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial research term</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_NumberOfCollaborationTargets" xlink:label="qure_NumberOfCollaborationTargets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_NumberOfCollaborationTargets" xlink:to="qure_NumberOfCollaborationTargets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_NumberOfCollaborationTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of collaboration targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_NumberOfCollaborationTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Collaboration Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_NumberOfCollaborationTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration targets</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced" xlink:label="qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced" xlink:to="qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold number of collaboration targets that can be replaced under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Threshold Number Of Collaboration Targets That Can Be Replaced</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Threshold Number Of Collaboration Targets That Can Be Replaced</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease" xlink:label="qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease" xlink:to="qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold number of new collaboration targets in the field of cardiovascular disease under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Number Of New Collaboration Targets In The Field Of Cardiovascular Disease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Number Of New Collaboration Targets In The Field Of Cardiovascular Disease</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_UpfrontCashToReceiveUponClosingOfAgreement" xlink:label="qure_UpfrontCashToReceiveUponClosingOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_UpfrontCashToReceiveUponClosingOfAgreement" xlink:to="qure_UpfrontCashToReceiveUponClosingOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_UpfrontCashToReceiveUponClosingOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront cash to receive upon the closing of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_UpfrontCashToReceiveUponClosingOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront cash to receive upon the closing of the agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_UpfrontCashToReceiveUponClosingOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront cash to receive upon the closing of the agreement</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementOtherPaymentsReceived" xlink:label="qure_CollaborationAgreementOtherPaymentsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_CollaborationAgreementOtherPaymentsReceived" xlink:to="qure_CollaborationAgreementOtherPaymentsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_CollaborationAgreementOtherPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other payments related to transfer of licence received as of the effective date of the collaboration agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_CollaborationAgreementOtherPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Other Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_CollaborationAgreementOtherPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other payments received</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_RegulatoryAndCommercialMilestonePaymentsReceivable" xlink:label="qure_RegulatoryAndCommercialMilestonePaymentsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_RegulatoryAndCommercialMilestonePaymentsReceivable" xlink:to="qure_RegulatoryAndCommercialMilestonePaymentsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_RegulatoryAndCommercialMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of regulatory and commercial milestone payments to be received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_RegulatoryAndCommercialMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory And Commercial Milestone Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_RegulatoryAndCommercialMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory and commercial milestone payments received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax rate enacted in the Netherlands</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:label="qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:to="qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of threshold research, development and regulatory payment receivable under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Threshold Research, Development And Regulatory Milestone Payments Receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of derivative liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_NumberOfWarrantTypes" xlink:label="qure_NumberOfWarrantTypes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_NumberOfWarrantTypes" xlink:to="qure_NumberOfWarrantTypes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_NumberOfWarrantTypes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrant types are issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_NumberOfWarrantTypes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrant types</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_NumberOfWarrantTypes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrant types</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementCashPayable" xlink:label="qure_CollaborationAgreementCashPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_CollaborationAgreementCashPayable" xlink:to="qure_CollaborationAgreementCashPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_CollaborationAgreementCashPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of non-refundable, non-creditable cash payment to be made under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_CollaborationAgreementCashPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Cash Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_CollaborationAgreementCashPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Cash Payable</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ThresholdPercentageOfNetProceeds" xlink:label="qure_ThresholdPercentageOfNetProceeds" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_ThresholdPercentageOfNetProceeds" xlink:to="qure_ThresholdPercentageOfNetProceeds_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_ThresholdPercentageOfNetProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold percentage of net proceeds payable under the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_ThresholdPercentageOfNetProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Percentage Of Net Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_ThresholdPercentageOfNetProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Percentage Of Net Proceeds</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_PercentageOfNetProceedsPayable" xlink:label="qure_PercentageOfNetProceedsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_PercentageOfNetProceedsPayable" xlink:to="qure_PercentageOfNetProceedsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_PercentageOfNetProceedsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of net proceeds payable under the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_PercentageOfNetProceedsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Net Proceeds Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_PercentageOfNetProceedsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Net Proceeds Payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Fair Value, Gross Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of the derivative financial liability</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_GainLossOnRecognitionOfDerivatives" xlink:label="qure_GainLossOnRecognitionOfDerivatives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_GainLossOnRecognitionOfDerivatives" xlink:to="qure_GainLossOnRecognitionOfDerivatives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_GainLossOnRecognitionOfDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of gain (loss) o recognition of derivative liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_GainLossOnRecognitionOfDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) On Recognition Of Derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_GainLossOnRecognitionOfDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) from the recognition of the derivative financial liability</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent" xlink:label="qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent" xlink:to="qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for serviced provided by vendors not yet billed. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals for Services Provided by Vendors Not Yet Billed, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals for services provided by vendors-not yet billed</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel related accruals and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Line of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceed from drew down</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable interest rate basis</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentInterestRateDiscountRatePercentage" xlink:label="qure_DebtInstrumentInterestRateDiscountRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_DebtInstrumentInterestRateDiscountRatePercentage" xlink:to="qure_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual discount rate for interest rate under the debt agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Discount Rate Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentBackEndFeePercentage" xlink:label="qure_DebtInstrumentBackEndFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_DebtInstrumentBackEndFeePercentage" xlink:to="qure_DebtInstrumentBackEndFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_DebtInstrumentBackEndFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The back-end fee, expressed as a percentage of outstanding loan amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_DebtInstrumentBackEndFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Back-end Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_DebtInstrumentBackEndFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Back-end fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AdditionalUnconditionalBorrowingCapacity" xlink:label="qure_AdditionalUnconditionalBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_AdditionalUnconditionalBorrowingCapacity" xlink:to="qure_AdditionalUnconditionalBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_AdditionalUnconditionalBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional unconditional borrowing capacity from the loan as per Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_AdditionalUnconditionalBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional unconditional borrowing capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_AdditionalUnconditionalBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional unconditional borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentBackEndFeeOne" xlink:label="qure_DebtInstrumentBackEndFeeOne" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_DebtInstrumentBackEndFeeOne" xlink:to="qure_DebtInstrumentBackEndFeeOne_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_DebtInstrumentBackEndFeeOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of back-end fee which is due on October 2016 under debt arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_DebtInstrumentBackEndFeeOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Back-end Fee, One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_DebtInstrumentBackEndFeeOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Back-end fees due</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentAggregateAmountOfEquityFinancing" xlink:label="qure_DebtInstrumentAggregateAmountOfEquityFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_DebtInstrumentAggregateAmountOfEquityFinancing" xlink:to="qure_DebtInstrumentAggregateAmountOfEquityFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_DebtInstrumentAggregateAmountOfEquityFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate amount of equity financing as a result of extending the interest-only period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_DebtInstrumentAggregateAmountOfEquityFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Aggregate Amount Of Equity Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_DebtInstrumentAggregateAmountOfEquityFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount of Equity Financing</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency gain</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense recorded</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentPercentageOfWorldwideCashReserves" xlink:label="qure_DebtInstrumentPercentageOfWorldwideCashReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_DebtInstrumentPercentageOfWorldwideCashReserves" xlink:to="qure_DebtInstrumentPercentageOfWorldwideCashReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_DebtInstrumentPercentageOfWorldwideCashReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt covenant that specifies cash and cash equivalents of a minimum of 65% of the outstanding balance of principal due under Credit Facility are to be held in U.S. bank accounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_DebtInstrumentPercentageOfWorldwideCashReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Percentage of Worldwide Cash Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_DebtInstrumentPercentageOfWorldwideCashReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum cash and cash equivalents in U.S. bank accounts</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly" xlink:label="qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly" xlink:to="qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets pledged to secure facilities by directly or indirectly.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets pledged to secure facilities by directly or indirectly</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets pledged to secure facilities by directly or indirectly</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly" xlink:label="qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly" xlink:to="qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets not being pledged to secure facilities by directly or indirectly.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets not being pledged to secure facilities by directly or indirectly</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets not being pledged to secure facilities by directly or indirectly</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate maturities of loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_PercentageOfGrossProceedsOfSharesSold" xlink:label="qure_PercentageOfGrossProceedsOfSharesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_PercentageOfGrossProceedsOfSharesSold" xlink:to="qure_PercentageOfGrossProceedsOfSharesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_PercentageOfGrossProceedsOfSharesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of gross proceeds of shares sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_PercentageOfGrossProceedsOfSharesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Gross Proceeds of Shares Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_PercentageOfGrossProceedsOfSharesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of gross proceeds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_NetProceedsFromIssuanceOfShares" xlink:label="qure_NetProceedsFromIssuanceOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_NetProceedsFromIssuanceOfShares" xlink:to="qure_NetProceedsFromIssuanceOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_NetProceedsFromIssuanceOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of net proceeds from the issue of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_NetProceedsFromIssuanceOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Proceeds from Issuance of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_NetProceedsFromIssuanceOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Businesses, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash consideration paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in authorized shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding of fully vested share options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining period for recognition (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereof, fully vested and exercisable at end of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereof, outstanding and expected to vest at end of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereof, fully vested and exercisable at end of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice" xlink:label="qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice" xlink:to="qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and expected to vest under the stock option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding And Expected To Vest, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding and expected to vest at end of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total weighted average grant date fair value of options issued during the period (in $ millions)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from option sales during the period (in $ millions)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage per year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average assumptions used to estimate fair value of share options granted during year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected terms (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate, minimum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate, maximum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-vested at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-vested at beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant-date fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-vested at end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-vested at beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other disclosure</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total weighted average grant date fair value of RSUs granted during the period (in millions)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares available for issue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discounted rate for purchase of shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Equity Method Investments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Equity Method Investments [Line Items]</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeRetentionCreditIncome" xlink:label="qure_EmployeeRetentionCreditIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_EmployeeRetentionCreditIncome" xlink:to="qure_EmployeeRetentionCreditIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_EmployeeRetentionCreditIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of employee retention credit received U.S. Coronavirus Aid, Relief, and Economic Security Act.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_EmployeeRetentionCreditIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Retention Credit Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_EmployeeRetentionCreditIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee retention income</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EquityMethodInvestmentSettlementIncome" xlink:label="qure_EquityMethodInvestmentSettlementIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_EquityMethodInvestmentSettlementIncome" xlink:to="qure_EquityMethodInvestmentSettlementIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_EquityMethodInvestmentSettlementIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of settlement agreement income received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_EquityMethodInvestmentSettlementIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment, Settlement Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_EquityMethodInvestmentSettlementIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Owned, Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income taxes (benefits)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ShareBased payment arrangements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted earnings per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total potential dilutive ordinary shares</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage" xlink:label="qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage" xlink:to="qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Percentage</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi" xlink:label="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi" xlink:to="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of development milestones payable through Phase I/II.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Definitive Transaction Agreement, Development Milestone, Phase I and II</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii" xlink:label="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii" xlink:to="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of development milestones payable through Phase III.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Definitive Transaction Agreement, Development Milestone, Phase III</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and Services [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and Services [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License revenues</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_LicenseRevenueFromRelatedPartyMember" xlink:label="qure_LicenseRevenueFromRelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_LicenseRevenueFromRelatedPartyMember" xlink:to="qure_LicenseRevenueFromRelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_LicenseRevenueFromRelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to license revenue from related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_LicenseRevenueFromRelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Revenue From Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_LicenseRevenueFromRelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License revenues from related party</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeRevenueMember" xlink:label="qure_CollaborativeRevenueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_CollaborativeRevenueMember" xlink:to="qure_CollaborativeRevenueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_CollaborativeRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to collaborative revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_CollaborativeRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Revenue [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_CollaborativeRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration revenues</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeRevenueFromRelatedPartyMember" xlink:label="qure_CollaborativeRevenueFromRelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_CollaborativeRevenueFromRelatedPartyMember" xlink:to="qure_CollaborativeRevenueFromRelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_CollaborativeRevenueFromRelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to collaborative revenue from related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_CollaborativeRevenueFromRelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Revenue From Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_CollaborativeRevenueFromRelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration revenues from related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive (loss)/income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation Plans [Domain]</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_PlanIn2014Member" xlink:label="qure_PlanIn2014Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_PlanIn2014Member" xlink:to="qure_PlanIn2014Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_PlanIn2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2014 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_PlanIn2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan In2014 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_PlanIn2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2014 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_BristolMyersSquibbMember" xlink:label="qure_BristolMyersSquibbMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_BristolMyersSquibbMember" xlink:to="qure_BristolMyersSquibbMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_BristolMyersSquibbMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to a collaborative agreement the entity has with Bristol-Myers Squibb.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_BristolMyersSquibbMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bristol Myers Squibb [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_BristolMyersSquibbMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bristol Myers Squibb</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BMS arrangement</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeArrangementLicenseRevenueMember" xlink:label="qure_CollaborativeArrangementLicenseRevenueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_CollaborativeArrangementLicenseRevenueMember" xlink:to="qure_CollaborativeArrangementLicenseRevenueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_CollaborativeArrangementLicenseRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to collaboration license revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_CollaborativeArrangementLicenseRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement License Revenue [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_CollaborativeArrangementLicenseRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CslBehringCollaborationMember" xlink:label="qure_CslBehringCollaborationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_CslBehringCollaborationMember" xlink:to="qure_CslBehringCollaborationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_CslBehringCollaborationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Information pertaining to a collaborative agreement entity has with CSL Behring collaboration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_CslBehringCollaborationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Csl Behring Collaboration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_CslBehringCollaborationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CSL Behring collaboration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Plan Asset Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value hierarchy Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember" xlink:label="qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember" xlink:to="qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the scenario in which the the one time cash payment of 70 million is greater than five percent of net proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement If70 Million Is Greater Than Five Percent Of Net Proceeds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, If 70 Million Is Greater Than Five Percent Of Net Proceeds</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember" xlink:label="qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember" xlink:to="qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the scenario in which the the one time cash payment of 70 million is less than one percent of net proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement If70 Million Is Lesser Than One Percent Of Net Proceeds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, If 70 Million Is Lesser Than One Percent Of Net Proceeds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DerecognitionOfWarrantsMember" xlink:label="qure_DerecognitionOfWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_DerecognitionOfWarrantsMember" xlink:to="qure_DerecognitionOfWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_DerecognitionOfWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to derecognition of the warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_DerecognitionOfWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derecognition Of Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_DerecognitionOfWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derecognition Of Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncurrent Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt Issuances [Domain]</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_VentureDebtLoanFacilityWithHerculesMember" xlink:label="qure_VentureDebtLoanFacilityWithHerculesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_VentureDebtLoanFacilityWithHerculesMember" xlink:to="qure_VentureDebtLoanFacilityWithHerculesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_VentureDebtLoanFacilityWithHerculesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to venture debt loan facility with Hercules.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_VentureDebtLoanFacilityWithHerculesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Venture Debt Loan Facility With Hercules [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_VentureDebtLoanFacilityWithHerculesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Venture debt loan facility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Domain]</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AmendedFacility2016Member" xlink:label="qure_AmendedFacility2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_AmendedFacility2016Member" xlink:to="qure_AmendedFacility2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_AmendedFacility2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for 2016 Amended Facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_AmendedFacility2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended Facility2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_AmendedFacility2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016 Amended Facility</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AmendedFacility2018Member" xlink:label="qure_AmendedFacility2018Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_AmendedFacility2018Member" xlink:to="qure_AmendedFacility2018Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_AmendedFacility2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for 2018 Amended Facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_AmendedFacility2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended Facility2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_AmendedFacility2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Amended Facility</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AmendedFacility2021Member" xlink:label="qure_AmendedFacility2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_AmendedFacility2021Member" xlink:to="qure_AmendedFacility2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_AmendedFacility2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2021 Amended Facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_AmendedFacility2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended Facility2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_AmendedFacility2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Amended Facility</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AmendedFacility2018And2021Member" xlink:label="qure_AmendedFacility2018And2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_AmendedFacility2018And2021Member" xlink:to="qure_AmendedFacility2018And2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_AmendedFacility2018And2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for 2018 and 2021 Amended Facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_AmendedFacility2018And2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended Facility2018 And2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_AmendedFacility2018And2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 and 2021 Amended Facility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prime Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prime Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lender Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line Of Credit Facility Lender [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Lender [Domain]</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_HerculesTechnologyGrowthCorp.Member" xlink:label="qure_HerculesTechnologyGrowthCorp.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_HerculesTechnologyGrowthCorp.Member" xlink:to="qure_HerculesTechnologyGrowthCorp.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_HerculesTechnologyGrowthCorp.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Hercules Technology Growth Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_HerculesTechnologyGrowthCorp.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hercules Technology Growth Corp. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_HerculesTechnologyGrowthCorp.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hercules</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:to="qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Second Amended and Restated Loan and Security Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Amended And Restated Loan And Security Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Amended and Restated Loan and Security Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_SalesAgreementWithSvbLeerinkMember" xlink:label="qure_SalesAgreementWithSvbLeerinkMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_SalesAgreementWithSvbLeerinkMember" xlink:to="qure_SalesAgreementWithSvbLeerinkMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_SalesAgreementWithSvbLeerinkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Sales Agreement with SVB Leerink.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_SalesAgreementWithSvbLeerinkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Agreement With Svb Leerink [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_SalesAgreementWithSvbLeerinkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Agreement with SVB Leerink LLC</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DirectIncrementalLaborMember" xlink:label="qure_DirectIncrementalLaborMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_DirectIncrementalLaborMember" xlink:to="qure_DirectIncrementalLaborMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_DirectIncrementalLaborMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to direct incremental cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_DirectIncrementalLaborMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Direct Incremental Labor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_DirectIncrementalLaborMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Direct Incremental Labor</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative expense</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_The2014PlanMember" xlink:label="qure_The2014PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_The2014PlanMember" xlink:to="qure_The2014PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_The2014PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents share-based compensation plan approved at the general meeting of entity's shareholders on January 9, 2014.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_The2014PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The2014 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_The2014PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2014 Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation by Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="qure_EmployeeConsultantsAndDirectorsStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:to="qure_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Consultants And Directors Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted share units ("RSUs")</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance share units ("PSUs")</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Award Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One year from grant date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-executive directors</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeSharePurchasePlanMember" xlink:label="qure_EmployeeSharePurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_EmployeeSharePurchasePlanMember" xlink:to="qure_EmployeeSharePurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_EmployeeSharePurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to employee share purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_EmployeeSharePurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Share Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_EmployeeSharePurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment, Nonconsolidated Investee [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment Nonconsolidated Investee [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment, Nonconsolidated Investee [Domain]</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_VectoryB.vMember" xlink:label="qure_VectoryB.vMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_VectoryB.vMember" xlink:to="qure_VectoryB.vMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_VectoryB.vMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information relating to the  VectorY B.V</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_VectoryB.vMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vectory B.v [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_VectoryB.vMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VectorY B.V</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_RestrictedShareUnitsAndPerformanceShareUnitsMember" xlink:label="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember" xlink:to="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents restricted share units and performance share units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Share Units And Performance Share Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-vested and earned RSUs and PSUs</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ShareOption2012PlanMember" xlink:label="qure_ShareOption2012PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_ShareOption2012PlanMember" xlink:to="qure_ShareOption2012PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_ShareOption2012PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the 2012 Share Option Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_ShareOption2012PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Option2012 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_ShareOption2012PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Previous plan</label>
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_BmsWarrantsMember" xlink:label="qure_BmsWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="qure_BmsWarrantsMember" xlink:to="qure_BmsWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="qure_BmsWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BMS warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="qure_BmsWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bms Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="qure_BmsWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BMS Warrants</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>qure-20210630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/26/2021 8:02:40 PM-->
<!--Modified on: 7/26/2021 8:02:40 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.uniqure.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.uniqure.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.uniqure.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#StatementConsolidatedStatementsOfShareholdersEquity" roleURI="http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureGeneralBusinessInformation" roleURI="http://www.uniqure.com/role/DisclosureGeneralBusinessInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureCollaborationArrangementsAndConcentrationOfCreditRisk" roleURI="http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureFairValueMeasurement" roleURI="http://www.uniqure.com/role/DisclosureFairValueMeasurement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureLongTermDebt" roleURI="http://www.uniqure.com/role/DisclosureLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareholdersEquity" roleURI="http://www.uniqure.com/role/DisclosureShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensation" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureOtherIncome" roleURI="http://www.uniqure.com/role/DisclosureOtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureIncomeTaxes" roleURI="http://www.uniqure.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureBasicAndDilutedEarningsPerShare" roleURI="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureSubsequentEvents" roleURI="http://www.uniqure.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.uniqure.com/role/DisclosureFairValueMeasurementTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureBasicAndDilutedEarningsPerShareTables" roleURI="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails" roleURI="http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails" roleURI="http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureLongTermDebtDetails" roleURI="http://www.uniqure.com/role/DisclosureLongTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareholdersEquityDetails" roleURI="http://www.uniqure.com/role/DisclosureShareholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensationRsuActivityDetails" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensationPsuActivityDetails" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails" roleURI="http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureOtherIncomeDetails" roleURI="http://www.uniqure.com/role/DisclosureOtherIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureIncomeTaxesEffectiveTaxRateDetails" roleURI="http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails" roleURI="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureBasicAndDilutedEarningsPerShareDetails" roleURI="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="qure-20210630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.uniqure.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.uniqure.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637629265585633792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637629265585633792" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637629265585633792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637629265585633792" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637629265585633792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637629265585633792" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637629265585633792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637629265585633792" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637629265585644111" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637629265585644111" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637629265585644111" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637629265585644111" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637629265585644111" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry_637629265585644111" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637629265585644111" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637629265585644111" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637629265585644111" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637629265585644111" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637629265585644111" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637629265585644111" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637629265585644111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637629265585644111" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637629265585654494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637629265585654494" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637629265585654494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637629265585654494" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637629265585654494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637629265585654494" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637629265585654494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637629265585654494" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637629265585654494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637629265585654494" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637629265585654494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637629265585654494" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637629265585654494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637629265585654494" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637629265585654494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637629265585654494" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637629265585654494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637629265585654494" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637629265585654494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637629265585654494" order="27" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637629265585664011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_637629265585664011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637629265585664011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637629265585664011" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637629265585664011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637629265585664011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637629265585664011" xlink:to="us-gaap_AccountsReceivableNetCurrent_637629265585664011" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637629265585664011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637629265585664011" xlink:to="us-gaap_PrepaidExpenseCurrent_637629265585664011" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_OtherCurrentAssetsAndReceivables" xlink:label="qure_OtherCurrentAssetsAndReceivables_637629265585754118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637629265585664011" xlink:to="qure_OtherCurrentAssetsAndReceivables_637629265585754118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637629265585754118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637629265585664011" xlink:to="us-gaap_AssetsCurrent_637629265585754118" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637629265585754118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_637629265585754118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637629265585754118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637629265585754118" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637629265585754118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637629265585754118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637629265585754118" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637629265585754118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_637629265585754118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637629265585754118" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_637629265585754118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637629265585754118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637629265585754118" xlink:to="us-gaap_Goodwill_637629265585754118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_637629265585754118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637629265585754118" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_637629265585754118" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637629265585754118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637629265585754118" xlink:to="us-gaap_OtherAssetsNoncurrent_637629265585754118" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637629265585754118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637629265585754118" xlink:to="us-gaap_AssetsNoncurrent_637629265585754118" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637629265585764039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets_637629265585764039" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637629265585764039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637629265585764039" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637629265585764039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637629265585764039" xlink:to="us-gaap_AccountsPayableCurrent_637629265585764039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637629265585764039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637629265585764039" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637629265585764039" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637629265585764039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637629265585764039" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637629265585764039" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637629265585764039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637629265585764039" xlink:to="us-gaap_LiabilitiesCurrent_637629265585764039" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637629265585764039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637629265585764039" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637629265585764039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637629265585764039" xlink:to="us-gaap_LongTermDebtNoncurrent_637629265585764039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637629265585764039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637629265585764039" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637629265585764039" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637629265585764039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637629265585764039" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637629265585764039" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637629265585764039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637629265585764039" xlink:to="us-gaap_LiabilitiesNoncurrent_637629265585764039" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637629265585764039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities_637629265585764039" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637629265585774239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies_637629265585774239" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637629265585774239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_637629265585774239" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637629265585774239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637629265585774239" xlink:to="us-gaap_CommonStockValue_637629265585774239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637629265585774239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637629265585774239" xlink:to="us-gaap_AdditionalPaidInCapital_637629265585774239" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637629265585774239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637629265585774239" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637629265585774239" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637629265585774239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637629265585774239" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637629265585774239" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637629265585774239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637629265585774239" xlink:to="us-gaap_StockholdersEquity_637629265585774239" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637629265585774239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637629265585774239" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_636204300739190966" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637629265585784136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_636204300739190966" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637629265585784136" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637629265585784136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_636204300739190966" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637629265585784136" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637629265585784136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_636204300739190966" xlink:to="us-gaap_CommonStockSharesAuthorized_637629265585784136" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637629265585784136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_636204300739190966" xlink:to="us-gaap_CommonStockSharesIssued_637629265585784136" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637629265585784136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_636204300739190966" xlink:to="us-gaap_CommonStockSharesOutstanding_637629265585784136" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637629265585784136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_637629265585784136" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637629265585784136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637629265585784136" xlink:to="srt_ProductOrServiceAxis_637629265585784136" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637629265585784136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637629265585784136" xlink:to="srt_ProductsAndServicesDomain_637629265585784136" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember_637629265585784136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637629265585784136" xlink:to="us-gaap_LicenseMember_637629265585784136" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_LicenseRevenueFromRelatedPartyMember" xlink:label="qure_LicenseRevenueFromRelatedPartyMember_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637629265585784136" xlink:to="qure_LicenseRevenueFromRelatedPartyMember_637629265585793849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeRevenueMember" xlink:label="qure_CollaborativeRevenueMember_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637629265585784136" xlink:to="qure_CollaborativeRevenueMember_637629265585793849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeRevenueFromRelatedPartyMember" xlink:label="qure_CollaborativeRevenueFromRelatedPartyMember_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637629265585784136" xlink:to="qure_CollaborativeRevenueFromRelatedPartyMember_637629265585793849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637629265585784136" xlink:to="us-gaap_StatementLineItems_637629265585793849" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637629265585793849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_OperatingExpensesAbstract_637629265585793849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637629265585793849" xlink:to="us-gaap_CostOfGoodsAndServicesSold_637629265585793849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637629265585793849" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637629265585793849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637629265585793849" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637629265585793849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637629265585793849" xlink:to="us-gaap_CostsAndExpenses_637629265585793849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_OtherIncome_637629265585793849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_OtherExpenses_637629265585793849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_OperatingIncomeLoss_637629265585793849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637629265585793849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_InvestmentIncomeInterest_637629265585793849" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637629265585804011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_InterestExpense_637629265585804011" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637629265585804011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637629265585804011" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637629265585804011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637629265585804011" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637629265585804011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637629265585804011" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637629265585804011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637629265585804011" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637629265585804011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637629265585804011" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637629265585804011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637629265585804011" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637629265585804011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637629265585804011" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637629265585804011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637629265585804011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637629265585804011" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637629265585804011" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_637629265585804011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_EarningsPerShareBasicAbstract_637629265585804011" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637629265585804011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_637629265585804011" xlink:to="us-gaap_EarningsPerShareBasic_637629265585804011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_637629265585814041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_637629265585814041" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637629265585814041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637629265585814041" xlink:to="us-gaap_EarningsPerShareDiluted_637629265585814041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637629265585814041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637629265585814041" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637629265585814041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585793849" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637629265585814041" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637629265585814041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637629265585814041" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637629265585814041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637629265585814041" xlink:to="us-gaap_StatementEquityComponentsAxis_637629265585814041" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637629265585814041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637629265585814041" xlink:to="us-gaap_CommonStockMember_637629265585814041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637629265585814041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637629265585814041" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637629265585814041" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637629265585814041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637629265585814041" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637629265585814041" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637629265585814041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637629265585814041" xlink:to="us-gaap_RetainedEarningsMember_637629265585814041" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637629265585814041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637629265585814041" xlink:to="us-gaap_EquityComponentDomain_637629265585814041" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637629265585824022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637629265585814041" xlink:to="us-gaap_StatementLineItems_637629265585824022" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265585824022" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637629265585824022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_StockholdersEquity_637629265585824022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637629265585824022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_CommonStockSharesOutstanding_637629265585824022" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637629265585824022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637629265585824022" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637629265585824022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637629265585824022" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637629265585824022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637629265585824022" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637629265585824022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637629265585824022" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637629265585824022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637629265585824022" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" xlink:label="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears_637629265585824022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears_637629265585824022" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637629265585824022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637629265585824022" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637629265585824022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637629265585824022" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_637629265585834414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_637629265585834414" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_637629265585834414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_637629265585834414" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637629265585834414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637629265585834414" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_637629265585834414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_637629265585834414" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_637629265585834414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_637629265585834414" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637629265585834414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_StockholdersEquity_637629265585834414" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637629265585834414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637629265585824022" xlink:to="us-gaap_CommonStockSharesOutstanding_637629265585834414" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637629265585834414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637629265585834414" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637629265585834414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637629265585834414" xlink:to="us-gaap_ProfitLoss_637629265585834414" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637629265585834414" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637629265585844304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637629265585844304" xlink:to="us-gaap_DepreciationAndAmortization_637629265585844304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637629265585844304" xlink:to="us-gaap_ShareBasedCompensation_637629265585844304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration" xlink:label="qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637629265585844304" xlink:to="qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration_637629265585844304" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637629265585844304" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_637629265585844304" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637629265585844304" xlink:to="us-gaap_OtherNoncashIncomeExpense_637629265585844304" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637629265585834414" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637629265585844304" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets" xlink:label="qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637629265585844304" xlink:to="qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets_637629265585844304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637629265585844304" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637629265585844304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637629265585844304" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_637629265585844304" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637629265585834414" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637629265585844304" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637629265585844304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637629265585844304" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_637629265585844304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637629265585844304" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637629265585844304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637629265585844304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637629265585844304" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637629265585844304" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637629265585854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637629265585854098" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637629265585854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637629265585854098" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637629265585854098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637629265585854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637629265585854098" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637629265585854098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637629265585854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637629265585854098" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637629265585854098" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637629265585854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637629265585854098" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637629265585854098" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637629265585854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637629265585854098" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637629265585854098" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637629265585854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637629265585854098" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637629265585854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637629265585854098" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637629265585854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637629265585854098" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6376292655858540981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6376292655858540981" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637629265585854098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637629265585854098" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637629265585864105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent_637629265585864105" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637629265585864105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637629265585864105" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_637629265585864105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_637629265585864105" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637629265585864105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_637629265585864105" xlink:to="us-gaap_InterestPaidNet_637629265585864105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets" xlink:label="qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets_637629265585864105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_637629265585864105" xlink:to="qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets_637629265585864105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureGeneralBusinessInformation" xlink:type="extended" xlink:title="10101 - Disclosure - General business information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637629265585864105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_637629265585864105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of significant accounting policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637629265585864105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637629265585864105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRisk" xlink:type="extended" xlink:title="10301 - Disclosure - Collaboration arrangements and concentration of credit risk" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract" xlink:label="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock" xlink:label="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock_637629265585874156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract" xlink:to="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock_637629265585874156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10401 - Disclosure - Fair value measurement" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637629265585874156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637629265585874156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10501 - Disclosure - Accrued expenses and other current liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_637629265585874156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_637629265585874156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureLongTermDebt" xlink:type="extended" xlink:title="10601 - Disclosure - Long-term debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock_637629265585874156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock_637629265585874156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureShareholdersEquity" xlink:type="extended" xlink:title="10701 - Disclosure - Shareholders' equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637629265585874156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637629265585874156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="10801 - Disclosure - Share-based compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637629265585874156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637629265585874156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureOtherIncome" xlink:type="extended" xlink:title="10901 - Disclosure - Other income" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_OtherIncomeTextBlock" xlink:label="qure_OtherIncomeTextBlock_637629265585874156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="qure_OtherIncomeTextBlock_637629265585874156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11001 - Disclosure - Income taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637629265585884296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637629265585884296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShare" xlink:type="extended" xlink:title="11101 - Disclosure - Basic and diluted earnings per share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637629265585884296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637629265585884296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11201 - Disclosure - Subsequent events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637629265585884296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637629265585884296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of significant accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637629265585884296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637629265585884296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="qure_UnauditedInterimFinancialInformationPolicyTextBlock_637629265585884296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="qure_UnauditedInterimFinancialInformationPolicyTextBlock_637629265585884296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637629265585884296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637629265585884296" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637629265585884296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637629265585884296" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637629265585884296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637629265585884296" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair value measurement (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637629265585884296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637629265585884296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Accrued expenses and other current liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637629265585894122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="30803 - Disclosure - Share-based compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265585894122" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265585894122" xlink:to="us-gaap_PlanNameAxis_637629265585894122" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637629265585894122" xlink:to="us-gaap_PlanNameDomain_637629265585894122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_PlanIn2014Member" xlink:label="qure_PlanIn2014Member_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637629265585894122" xlink:to="qure_PlanIn2014Member_637629265585894122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265585894122" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265585894122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265585894122" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637629265585894122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265585894122" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_637629265585894122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265585894122" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_637629265585894122" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265585894122" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637629265585894122" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265585894122" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637629265585894122" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265585894122" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_637629265585894122" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265585894122" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_637629265585894122" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareTables" xlink:type="extended" xlink:title="31103 - Disclosure - Basic and diluted earnings per share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637629265585894122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637629265585894122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock" xlink:label="qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock_637629265585904115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract" xlink:label="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract_636207884144450466" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract_636207884144450466" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585904115" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585904115" xlink:to="dei_LegalEntityAxis_637629265585904115" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637629265585904115" xlink:to="dei_EntityDomain_637629265585904115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_BristolMyersSquibbMember" xlink:label="qure_BristolMyersSquibbMember_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637629265585904115" xlink:to="qure_BristolMyersSquibbMember_637629265585904115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585904115" xlink:to="us-gaap_TypeOfArrangementAxis_637629265585904115" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637629265585904115" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637629265585904115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637629265585904115" xlink:to="us-gaap_CollaborativeArrangementMember_637629265585904115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeArrangementLicenseRevenueMember" xlink:label="qure_CollaborativeArrangementLicenseRevenueMember_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember_637629265585904115" xlink:to="qure_CollaborativeArrangementLicenseRevenueMember_637629265585904115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585904115" xlink:to="srt_ProductOrServiceAxis_637629265585904115" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637629265585904115" xlink:to="srt_ProductsAndServicesDomain_637629265585904115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_LicenseRevenueFromRelatedPartyMember" xlink:label="qure_LicenseRevenueFromRelatedPartyMember_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637629265585904115" xlink:to="qure_LicenseRevenueFromRelatedPartyMember_637629265585904115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeRevenueFromRelatedPartyMember" xlink:label="qure_CollaborativeRevenueFromRelatedPartyMember_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637629265585904115" xlink:to="qure_CollaborativeRevenueFromRelatedPartyMember_637629265585904115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborativeRevenueMember" xlink:label="qure_CollaborativeRevenueMember_637629265585904115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637629265585904115" xlink:to="qure_CollaborativeRevenueMember_637629265585904115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637629265585914021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585904115" xlink:to="srt_CounterpartyNameAxis_637629265585914021" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637629265585914021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637629265585914021" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637629265585914021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CslBehringCollaborationMember" xlink:label="qure_CslBehringCollaborationMember_637629265585914021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637629265585914021" xlink:to="qure_CslBehringCollaborationMember_637629265585914021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_BristolMyersSquibbMember" xlink:label="qure_BristolMyersSquibbMember_637629265585914021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637629265585914021" xlink:to="qure_BristolMyersSquibbMember_637629265585914021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585904115" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_InitialResearchTerm" xlink:label="qure_InitialResearchTerm_637629265585914021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" xlink:to="qure_InitialResearchTerm_637629265585914021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_NumberOfCollaborationTargets" xlink:label="qure_NumberOfCollaborationTargets_637629265585914021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" xlink:to="qure_NumberOfCollaborationTargets_637629265585914021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced" xlink:label="qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced_637629265585914021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" xlink:to="qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced_637629265585914021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease" xlink:label="qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease_637629265585914021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" xlink:to="qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease_637629265585914021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637629265585914021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637629265585914021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_UpfrontCashToReceiveUponClosingOfAgreement" xlink:label="qure_UpfrontCashToReceiveUponClosingOfAgreement_637629265585914021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" xlink:to="qure_UpfrontCashToReceiveUponClosingOfAgreement_637629265585914021" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementOtherPaymentsReceived" xlink:label="qure_CollaborationAgreementOtherPaymentsReceived_637629265585914021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" xlink:to="qure_CollaborationAgreementOtherPaymentsReceived_637629265585914021" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637629265585924253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" xlink:to="us-gaap_AccountsReceivableNetCurrent_637629265585924253" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_RegulatoryAndCommercialMilestonePaymentsReceivable" xlink:label="qure_RegulatoryAndCommercialMilestonePaymentsReceivable_637629265585924253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" xlink:to="qure_RegulatoryAndCommercialMilestonePaymentsReceivable_637629265585924253" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637629265585924253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637629265585924253" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:label="qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable_637629265585924253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" xlink:to="qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable_637629265585924253" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears" xlink:label="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears_637629265585924253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585914021" xlink:to="qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears_637629265585924253" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair value measurement - Assets and liabilities measured on a recurring basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_636244948089998563" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637629265585924253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_636244948089998563" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637629265585924253" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637629265585924253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637629265585924253" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637629265585924253" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637629265585924253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637629265585924253" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637629265585924253" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637629265585924253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637629265585924253" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637629265585924253" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637629265585924253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637629265585924253" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637629265585924253" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637629265585934031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637629265585924253" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637629265585934031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637629265585934031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637629265585934031" xlink:to="us-gaap_FairValueInputsLevel1Member_637629265585934031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637629265585934031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637629265585934031" xlink:to="us-gaap_FairValueInputsLevel3Member_637629265585934031" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637629265585934031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637629265585924253" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637629265585934031" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_637629265585934031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637629265585934031" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_637629265585934031" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637629265585934031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637629265585934031" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637629265585934031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637629265585934031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637629265585934031" xlink:to="us-gaap_AssetsFairValueDisclosure_637629265585934031" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_637629265585934031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637629265585934031" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_637629265585934031" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_637629265585934031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_637629265585934031" xlink:to="us-gaap_DerivativeLiabilities_637629265585934031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_637629265585934031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_637629265585934031" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_637629265585934031" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair value measurement - BMS warrants - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585944091" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585944091" xlink:to="srt_StatementScenarioAxis_637629265585944091" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637629265585944091" xlink:to="srt_ScenarioUnspecifiedDomain_637629265585944091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember" xlink:label="qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637629265585944091" xlink:to="qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_637629265585944091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember" xlink:label="qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637629265585944091" xlink:to="qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember_637629265585944091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585944091" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637629265585944091" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637629265585944091" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637629265585944091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DerecognitionOfWarrantsMember" xlink:label="qure_DerecognitionOfWarrantsMember_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637629265585944091" xlink:to="qure_DerecognitionOfWarrantsMember_637629265585944091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585944091" xlink:to="us-gaap_BalanceSheetLocationAxis_637629265585944091" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637629265585944091" xlink:to="us-gaap_BalanceSheetLocationDomain_637629265585944091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637629265585944091" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_637629265585944091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637629265585944091" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585944091" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_NumberOfWarrantTypes" xlink:label="qure_NumberOfWarrantTypes_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585944091" xlink:to="qure_NumberOfWarrantTypes_637629265585944091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_NumberOfCollaborationTargets" xlink:label="qure_NumberOfCollaborationTargets_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585944091" xlink:to="qure_NumberOfCollaborationTargets_637629265585944091" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CollaborationAgreementCashPayable" xlink:label="qure_CollaborationAgreementCashPayable_637629265585944091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585944091" xlink:to="qure_CollaborationAgreementCashPayable_637629265585944091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ThresholdPercentageOfNetProceeds" xlink:label="qure_ThresholdPercentageOfNetProceeds_637629265585954009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585944091" xlink:to="qure_ThresholdPercentageOfNetProceeds_637629265585954009" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_PercentageOfNetProceedsPayable" xlink:label="qure_PercentageOfNetProceedsPayable_637629265585954009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585944091" xlink:to="qure_PercentageOfNetProceedsPayable_637629265585954009" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_637629265585954009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585944091" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_637629265585954009" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_GainLossOnRecognitionOfDerivatives" xlink:label="qure_GainLossOnRecognitionOfDerivatives_637629265585954009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637629265585944091" xlink:to="qure_GainLossOnRecognitionOfDerivatives_637629265585954009" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued expenses and other current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent" xlink:label="qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent_637629265585954009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent_637629265585954009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637629265585954009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637629265585954009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637629265585954009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent_637629265585954009" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637629265585954009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637629265585954009" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureLongTermDebtDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Long-term debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637629265585954009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637629265585954009" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637629265585954009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637629265585954009" xlink:to="us-gaap_SubsequentEventTypeAxis_637629265585954009" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637629265585954009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637629265585954009" xlink:to="us-gaap_SubsequentEventTypeDomain_637629265585954009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637629265585954009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637629265585954009" xlink:to="us-gaap_SubsequentEventMember_637629265585954009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637629265585954009" xlink:to="us-gaap_DebtInstrumentAxis_637629265585964045" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637629265585964045" xlink:to="us-gaap_DebtInstrumentNameDomain_637629265585964045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_VentureDebtLoanFacilityWithHerculesMember" xlink:label="qure_VentureDebtLoanFacilityWithHerculesMember_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637629265585964045" xlink:to="qure_VentureDebtLoanFacilityWithHerculesMember_637629265585964045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637629265585954009" xlink:to="us-gaap_CreditFacilityAxis_637629265585964045" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_637629265585964045" xlink:to="us-gaap_CreditFacilityDomain_637629265585964045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AmendedFacility2016Member" xlink:label="qure_AmendedFacility2016Member_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_637629265585964045" xlink:to="qure_AmendedFacility2016Member_637629265585964045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AmendedFacility2018Member" xlink:label="qure_AmendedFacility2018Member_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_637629265585964045" xlink:to="qure_AmendedFacility2018Member_637629265585964045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AmendedFacility2021Member" xlink:label="qure_AmendedFacility2021Member_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_637629265585964045" xlink:to="qure_AmendedFacility2021Member_637629265585964045" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AmendedFacility2018And2021Member" xlink:label="qure_AmendedFacility2018And2021Member_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_637629265585964045" xlink:to="qure_AmendedFacility2018And2021Member_637629265585964045" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637629265585954009" xlink:to="us-gaap_VariableRateAxis_637629265585964045" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_637629265585964045" xlink:to="us-gaap_VariableRateDomain_637629265585964045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_637629265585964045" xlink:to="us-gaap_PrimeRateMember_637629265585964045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637629265585954009" xlink:to="us-gaap_LineOfCreditFacilityAxis_637629265585964045" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis_637629265585964045" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_637629265585964045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_HerculesTechnologyGrowthCorp.Member" xlink:label="qure_HerculesTechnologyGrowthCorp.Member_637629265585964045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain_637629265585964045" xlink:to="qure_HerculesTechnologyGrowthCorp.Member_637629265585964045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637629265585974014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637629265585954009" xlink:to="us-gaap_TypeOfArrangementAxis_637629265585974014" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637629265585974014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637629265585974014" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637629265585974014" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_637629265585974014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637629265585974014" xlink:to="qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_637629265585974014" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637629265585974014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637629265585954009" xlink:to="srt_RangeAxis_637629265585974014" order="7" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637629265585974014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637629265585974014" xlink:to="srt_RangeMember_637629265585974014" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637629265585974014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637629265585974014" xlink:to="srt_MinimumMember_637629265585974014" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637629265585974014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637629265585954009" xlink:to="us-gaap_DebtInstrumentLineItems_637629265585974014" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit_637629265585974014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="us-gaap_LineOfCredit_637629265585974014" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit_637629265585974014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="us-gaap_ProceedsFromLinesOfCredit_637629265585974014" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637629265585974014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637629265585974014" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637629265585974014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637629265585974014" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentInterestRateDiscountRatePercentage" xlink:label="qure_DebtInstrumentInterestRateDiscountRatePercentage_637629265585974014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="qure_DebtInstrumentInterestRateDiscountRatePercentage_637629265585974014" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentBackEndFeePercentage" xlink:label="qure_DebtInstrumentBackEndFeePercentage_637629265585984020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="qure_DebtInstrumentBackEndFeePercentage_637629265585984020" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637629265585984020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637629265585984020" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AdditionalUnconditionalBorrowingCapacity" xlink:label="qure_AdditionalUnconditionalBorrowingCapacity_637629265585984020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="qure_AdditionalUnconditionalBorrowingCapacity_637629265585984020" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637629265585984020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637629265585984020" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentBackEndFeeOne" xlink:label="qure_DebtInstrumentBackEndFeeOne_637629265585984020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="qure_DebtInstrumentBackEndFeeOne_637629265585984020" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentAggregateAmountOfEquityFinancing" xlink:label="qure_DebtInstrumentAggregateAmountOfEquityFinancing_637629265585984020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="qure_DebtInstrumentAggregateAmountOfEquityFinancing_637629265585984020" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_637629265585984020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_637629265585984020" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax_637629265585984020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax_637629265585984020" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_637629265585984020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="us-gaap_InterestExpenseDebt_637629265585984020" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DebtInstrumentPercentageOfWorldwideCashReserves" xlink:label="qure_DebtInstrumentPercentageOfWorldwideCashReserves_637629265585994064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="qure_DebtInstrumentPercentageOfWorldwideCashReserves_637629265585994064" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly" xlink:label="qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly_637629265585994064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly_637629265585994064" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly" xlink:label="qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly_637629265585994064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly_637629265585994064" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_637629265585994064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637629265585974014" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_637629265585994064" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637629265585994064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_637629265585994064" xlink:to="us-gaap_LongTermDebt_637629265585994064" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureShareholdersEquityDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Shareholders' equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637629265585994064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable_637629265585994064" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637629265585994064" xlink:to="us-gaap_TypeOfArrangementAxis_637629265586004059" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637629265586004059" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637629265586004059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_SalesAgreementWithSvbLeerinkMember" xlink:label="qure_SalesAgreementWithSvbLeerinkMember_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637629265586004059" xlink:to="qure_SalesAgreementWithSvbLeerinkMember_637629265586004059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637629265585994064" xlink:to="srt_RangeAxis_637629265586004059" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637629265586004059" xlink:to="srt_RangeMember_637629265586004059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637629265586004059" xlink:to="srt_MaximumMember_637629265586004059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637629265585994064" xlink:to="us-gaap_StatementClassOfStockAxis_637629265586004059" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637629265586004059" xlink:to="us-gaap_ClassOfStockDomain_637629265586004059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637629265586004059" xlink:to="us-gaap_CommonStockMember_637629265586004059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637629265585994064" xlink:to="us-gaap_IncomeStatementLocationAxis_637629265586004059" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637629265586004059" xlink:to="us-gaap_IncomeStatementLocationDomain_637629265586004059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DirectIncrementalLaborMember" xlink:label="qure_DirectIncrementalLaborMember_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637629265586004059" xlink:to="qure_DirectIncrementalLaborMember_637629265586004059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637629265585994064" xlink:to="us-gaap_StatementLineItems_637629265586004059" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586004059" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637629265586004059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_PercentageOfGrossProceedsOfSharesSold" xlink:label="qure_PercentageOfGrossProceedsOfSharesSold_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586004059" xlink:to="qure_PercentageOfGrossProceedsOfSharesSold_637629265586004059" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586004059" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637629265586004059" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637629265586004059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586004059" xlink:to="us-gaap_SharePrice_637629265586004059" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_NetProceedsFromIssuanceOfShares" xlink:label="qure_NetProceedsFromIssuanceOfShares_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586004059" xlink:to="qure_NetProceedsFromIssuanceOfShares_637629265586014010" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586004059" xlink:to="us-gaap_AdditionalPaidInCapital_637629265586014010" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586004059" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637629265586014010" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586004059" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_637629265586014010" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Share-based compensation - Summary of share-based compensation expense and unrecognized costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636206981705201979" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636206981705201979" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586014010" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586014010" xlink:to="us-gaap_AwardTypeAxis_637629265586014010" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637629265586014010" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586014010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="qure_EmployeeConsultantsAndDirectorsStockOptionsMember_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586014010" xlink:to="qure_EmployeeConsultantsAndDirectorsStockOptionsMember_637629265586014010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586014010" xlink:to="us-gaap_RestrictedStockMember_637629265586014010" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586014010" xlink:to="us-gaap_PerformanceSharesMember_637629265586014010" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586014010" xlink:to="us-gaap_IncomeStatementLocationAxis_637629265586014010" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637629265586014010" xlink:to="us-gaap_IncomeStatementLocationDomain_637629265586014010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637629265586014010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637629265586014010" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637629265586014010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637629265586024107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637629265586014010" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637629265586024107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637629265586024107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586014010" xlink:to="us-gaap_PlanNameAxis_637629265586024107" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637629265586024107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637629265586024107" xlink:to="us-gaap_PlanNameDomain_637629265586024107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_The2014PlanMember" xlink:label="qure_The2014PlanMember_637629265586024107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637629265586024107" xlink:to="qure_The2014PlanMember_637629265586024107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586024107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586014010" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586024107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637629265586024107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586024107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637629265586024107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637629265586024107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586024107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637629265586024107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637629265586024107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586024107" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637629265586024107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637629265586024107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586024107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637629265586024107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637629265586024107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586024107" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637629265586024107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637629265586024107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586024107" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637629265586024107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Share-based compensation - Option activity and weighted-average assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636207636203244310" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586024107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636207636203244310" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586024107" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586024107" xlink:to="us-gaap_PlanNameAxis_637629265586034005" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637629265586034005" xlink:to="us-gaap_PlanNameDomain_637629265586034005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_The2014PlanMember" xlink:label="qure_The2014PlanMember_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637629265586034005" xlink:to="qure_The2014PlanMember_637629265586034005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586024107" xlink:to="us-gaap_VestingAxis_637629265586034005" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637629265586034005" xlink:to="us-gaap_VestingDomain_637629265586034005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637629265586034005" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637629265586034005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586024107" xlink:to="srt_TitleOfIndividualAxis_637629265586034005" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637629265586034005" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637629265586034005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637629265586034005" xlink:to="srt_DirectorMember_637629265586034005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586024107" xlink:to="us-gaap_AwardTypeAxis_637629265586034005" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637629265586034005" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586034005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="qure_EmployeeConsultantsAndDirectorsStockOptionsMember_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586034005" xlink:to="qure_EmployeeConsultantsAndDirectorsStockOptionsMember_637629265586034005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586024107" xlink:to="srt_RangeAxis_637629265586034005" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637629265586034005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637629265586034005" xlink:to="srt_RangeMember_637629265586034005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637629265586044106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637629265586034005" xlink:to="srt_MinimumMember_637629265586044106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637629265586044106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637629265586034005" xlink:to="srt_MaximumMember_637629265586044106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586044106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586024107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586044106" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637629265586044106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637629265586044106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637629265586044106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637629265586044106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637629265586044106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637629265586044106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637629265586044106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637629265586044106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_637629265586044106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_637629265586044106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637629265586044106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637629265586044106" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637629265586044106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6376292655860441061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6376292655860441061" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637629265586044106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637629265586044106" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637629265586044106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637629265586044106" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637629265586044106" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637629265586054116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637629265586054116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637629265586054116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637629265586054116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637629265586054116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637629265586054116" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637629265586054116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637629265586054116" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637629265586054116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637629265586054116" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6376292655860541161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6376292655860541161" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637629265586054116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637629265586054116" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice" xlink:label="qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice_637629265586054116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" xlink:to="qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice_637629265586054116" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637629265586054116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637629265586054116" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637629265586064004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637629265586064004" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637629265586064004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637629265586064004" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637629265586064004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637629265586064004" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637629265586064004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586044106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637629265586064004" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637629265586064004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637629265586064004" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637629265586064004" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637629265586064004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637629265586064004" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637629265586064004" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637629265586064004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637629265586064004" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637629265586064004" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637629265586064004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637629265586064004" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637629265586064004" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637629265586064004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637629265586064004" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637629265586064004" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637629265586074042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637629265586064004" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637629265586074042" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Share-based compensation - RSU activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636207656367473629" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586074042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636207656367473629" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586074042" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637629265586074042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586074042" xlink:to="srt_RangeAxis_637629265586074042" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637629265586074042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637629265586074042" xlink:to="srt_RangeMember_637629265586074042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637629265586074042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637629265586074042" xlink:to="srt_MinimumMember_637629265586074042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637629265586074042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637629265586074042" xlink:to="srt_MaximumMember_637629265586074042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637629265586074042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586074042" xlink:to="us-gaap_AwardTypeAxis_637629265586074042" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586074042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637629265586074042" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586074042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637629265586074042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586074042" xlink:to="us-gaap_RestrictedStockMember_637629265586074042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637629265586074042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586074042" xlink:to="us-gaap_PlanNameAxis_637629265586074042" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637629265586074042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637629265586074042" xlink:to="us-gaap_PlanNameDomain_637629265586074042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_The2014PlanMember" xlink:label="qure_The2014PlanMember_637629265586074042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637629265586074042" xlink:to="qure_The2014PlanMember_637629265586074042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586074042" xlink:to="srt_TitleOfIndividualAxis_637629265586084007" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637629265586084007" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637629265586084007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637629265586084007" xlink:to="srt_DirectorMember_637629265586084007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586074042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586084007" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586084007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637629265586084007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637629265586084007" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637629265586084007" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637629265586084007" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6376292655860840071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6376292655860840071" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586084007" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637629265586084007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637629265586084007" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637629265586084007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637629265586084007" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637629265586094004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637629265586094004" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637629265586094004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637629265586094004" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637629265586094004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586084007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637629265586094004" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637629265586094004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637629265586094004" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637629265586094004" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637629265586094004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637629265586094004" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637629265586094004" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Share-based compensation - PSU activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636207691108138445" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586094004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636207691108138445" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586094004" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637629265586094004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586094004" xlink:to="us-gaap_AwardTypeAxis_637629265586094004" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586094004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637629265586094004" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586094004" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637629265586094004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586094004" xlink:to="us-gaap_PerformanceSharesMember_637629265586094004" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637629265586094004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586094004" xlink:to="us-gaap_PlanNameAxis_637629265586094004" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637629265586094004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637629265586094004" xlink:to="us-gaap_PlanNameDomain_637629265586094004" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_The2014PlanMember" xlink:label="qure_The2014PlanMember_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637629265586094004" xlink:to="qure_The2014PlanMember_637629265586104042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586094004" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586104042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586104042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637629265586104042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637629265586104042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637629265586104042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637629265586104042" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6376292655861040421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6376292655861040421" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586104042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637629265586104042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637629265586104042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637629265586104042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637629265586104042" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6376292655861040421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6376292655861040421" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637629265586104042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637629265586104042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637629265586114030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637629265586114030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637629265586114030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637629265586104042" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637629265586114030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Share-based compensation - Employee Share Purchase Plan - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636765007527029525" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586114030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636765007527029525" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586114030" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637629265586114030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586114030" xlink:to="us-gaap_PlanNameAxis_637629265586114030" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637629265586114030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637629265586114030" xlink:to="us-gaap_PlanNameDomain_637629265586114030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeSharePurchasePlanMember" xlink:label="qure_EmployeeSharePurchasePlanMember_637629265586114030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637629265586114030" xlink:to="qure_EmployeeSharePurchasePlanMember_637629265586114030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637629265586114030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586114030" xlink:to="us-gaap_AwardTypeAxis_637629265586114030" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586114030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637629265586114030" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586114030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_637629265586114030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637629265586114030" xlink:to="us-gaap_EmployeeStockMember_637629265586114030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586114030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586114030" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586114030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637629265586114030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586114030" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637629265586114030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_637629265586114030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586114030" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_637629265586114030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637629265586154074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586114030" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637629265586154074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureOtherIncomeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Other income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_637629265586164075" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_637629265586164075" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_637629265586164075" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_637629265586164075" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_637629265586164075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_VectoryB.vMember" xlink:label="qure_VectoryB.vMember_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_637629265586164075" xlink:to="qure_VectoryB.vMember_637629265586164075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_637629265586164075" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_637629265586164075" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_637629265586164075" xlink:to="us-gaap_OtherIncome_637629265586164075" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeRetentionCreditIncome" xlink:label="qure_EmployeeRetentionCreditIncome_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_637629265586164075" xlink:to="qure_EmployeeRetentionCreditIncome_637629265586164075" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EquityMethodInvestmentSettlementIncome" xlink:label="qure_EquityMethodInvestmentSettlementIncome_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_637629265586164075" xlink:to="qure_EquityMethodInvestmentSettlementIncome_637629265586164075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_637629265586164075" xlink:to="us-gaap_InvestmentOwnedBalanceShares_637629265586164075" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Income taxes - Effective Tax Rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable_637629265586164075" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637629265586164075" xlink:to="srt_CounterpartyNameAxis_637629265586164075" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637629265586164075" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637629265586164075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_CslBehringCollaborationMember" xlink:label="qure_CslBehringCollaborationMember_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637629265586164075" xlink:to="qure_CslBehringCollaborationMember_637629265586164075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637629265586164075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637629265586164075" xlink:to="us-gaap_StatementLineItems_637629265586164075" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586164075" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637629265586174086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586164075" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637629265586174086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586164075" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637629265586174086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586164075" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_637629265586174086" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637629265586164075" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637629265586174086" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Basic and diluted earnings per share - Ordinary share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586174086" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586174086" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637629265586174086" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637629265586174086" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637629265586174086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637629265586174086" xlink:to="us-gaap_EmployeeStockOptionMember_637629265586174086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_RestrictedShareUnitsAndPerformanceShareUnitsMember" xlink:label="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637629265586174086" xlink:to="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_637629265586174086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586174086" xlink:to="us-gaap_PlanNameAxis_637629265586174086" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637629265586174086" xlink:to="us-gaap_PlanNameDomain_637629265586174086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ShareOption2012PlanMember" xlink:label="qure_ShareOption2012PlanMember_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637629265586174086" xlink:to="qure_ShareOption2012PlanMember_637629265586174086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeSharePurchasePlanMember" xlink:label="qure_EmployeeSharePurchasePlanMember_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637629265586174086" xlink:to="qure_EmployeeSharePurchasePlanMember_637629265586174086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586174086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637629265586174086" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586174086" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637629265586184089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586174086" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637629265586184089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637629265586184089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586174086" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637629265586184089" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_637629265586184089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586174086" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_637629265586184089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637629265586184089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637629265586174086" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637629265586184089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Basic and diluted earnings per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637629265586184089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637629265586184089" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637629265586184089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637629265586184089" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637629265586184089" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637629265586184089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637629265586184089" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637629265586184089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_BmsWarrantsMember" xlink:label="qure_BmsWarrantsMember_637629265586184089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637629265586184089" xlink:to="qure_BmsWarrantsMember_637629265586184089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637629265586184089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637629265586184089" xlink:to="us-gaap_EmployeeStockOptionMember_637629265586184089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_RestrictedShareUnitsAndPerformanceShareUnitsMember" xlink:label="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_637629265586184089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637629265586184089" xlink:to="qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_637629265586184089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637629265586184089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637629265586184089" xlink:to="srt_CounterpartyNameAxis_637629265586184089" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637629265586184089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637629265586184089" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637629265586184089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_BristolMyersSquibbMember" xlink:label="qure_BristolMyersSquibbMember_637629265586194098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637629265586184089" xlink:to="qure_BristolMyersSquibbMember_637629265586194098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637629265586194098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637629265586184089" xlink:to="us-gaap_PlanNameAxis_637629265586194098" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637629265586194098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637629265586194098" xlink:to="us-gaap_PlanNameDomain_637629265586194098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_ShareOption2012PlanMember" xlink:label="qure_ShareOption2012PlanMember_637629265586194098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637629265586194098" xlink:to="qure_ShareOption2012PlanMember_637629265586194098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_EmployeeSharePurchasePlanMember" xlink:label="qure_EmployeeSharePurchasePlanMember_637629265586194098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637629265586194098" xlink:to="qure_EmployeeSharePurchasePlanMember_637629265586194098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637629265586194098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637629265586184089" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637629265586194098" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637629265586194098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637629265586194098" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637629265586194098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.uniqure.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_637629265586194098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_637629265586194098" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage" xlink:label="qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage_637629265586194098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage_637629265586194098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi" xlink:label="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi_637629265586194098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi_637629265586194098" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="qure-20210630.xsd#qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii" xlink:label="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii_637629265586194098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii_637629265586194098" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>qure-20210630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:qure="http://www.uniqure.com/20210630"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="qure-20210630.xsd" xlink:type="simple"/>
    <context id="Duration_3_1_2021_To_3_1_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_orachVcrO0W16h4VtfgGfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_4_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_OssqgnSTskC6WxJuHZafpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyu1S0cqWU2xIkIh3ub-aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LAamd-jnaESPNk8ZipEekg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S1XNLHXDj0CmAF9NqjS7Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NCAjWMQk0EWYAF5NG6CWtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2hvGL0bx6EimerX1R8EITw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HOv4QC1gA0CfyEdcEjfcYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DsFKGwOurUui9rgpsgd2zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_L4tV3PEQJkC8fL3FzxLwNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_iSci5KSdxkuiCG7kJ4B7Rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OjQYcvlwLk6FKuTEnO6ixQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AJilnv7U0UKS6Pd__e9ntw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5Zz24Wjw0WmLw7GH5paxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0D6WZbsJ9EyfBMQ5KfZThg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tqrT9yrb-06NxeDkwo4JTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_98hRD2QNWkGhe45TCCi4eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nPdO4wtnvEWlpbuGGdBg-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B-LJE5DhoUS75c9QtNuw-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_w6u8-eqmkEiHOgU-Dd9xOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_kg7c_qm1bEy7UDtpE53ICA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XjeHbyUls0C0C2A5C4oucw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FiR-EdjoaE-NUqcozk-aQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8TmbfDxKjUKS_aB_XtU_QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_PuxofUyxYUyj1pHnYLQF2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_5Wm51a7LMUeByYsBhPlv-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_081a5t6cXUS5Pm3ISOEjBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_uJk1n3G3b0G2SAKAIt-9xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">qure:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_KP_4t1AgiEGnBsb8mhLMhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_YA8vUlYvg0e7cBJmuUUNoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_hyffprjeyUC_wzIZA8RTnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_5NV54NsdkEinwOnU-elbdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_YNaFty5MakKmr7kgK48vHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_Fwx05CDlmUWbLjlZZ48Tqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_yEL8uzvfzEuzep8u6-oSHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_l15cALnFH0u_MOExc4K0wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_hgABeo6nI0Sn_Cc_DbsdkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9_e4JUkm00245rwV5zhg_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2017_To_3_31_2017_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_7i4FeprKyk6MfKmRuuYBJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_PlanIn2014Member_-Uv1a7oNgUKp-nwzRoa6rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:PlanIn2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_jB8MZBGsWEasEDd9-gnQoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseMember_jHZhFitLrEOQNQKYgI7ZBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_7HYeLAkKd06-2u6h39LYwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_0j8VHpWGtkqyg1Eoh_-56w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_qure_CollaborativeArrangementLicenseRevenueMember_hIrNE1yg2EeFUIy3Z5A96A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:CollaborativeArrangementLicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseMember_9-058g41FkiUfUyhdRdA8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_iR-v-TBnd0evOoVwhDOfvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_9iY6fqOrEE6pUHvNw-CSpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_-pQINOMXokKJREGZdwpa4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_LicenseRevenueFromRelatedPartyMember_Ktoe6WsNfUut5PLrxfJPGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:LicenseRevenueFromRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_CollaborativeRevenueFromRelatedPartyMember_cprlgbYMcECa1gZndoHMVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueFromRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_J6tdEUumu0qt9JK5Mqjr8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_LicenseRevenueFromRelatedPartyMember_R4VI051DiE205Dp9r8_D5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:LicenseRevenueFromRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_CollaborativeRevenueFromRelatedPartyMember_qHipUZ-S2kSLqtPAsxvUgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">qure:CollaborativeRevenueFromRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30Oj847Y4U66T9RvHLydUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v04H0tAAR0aK-7lS6pBkDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MUECXMXIDUq79H4NmTlzIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FyQ6c103BEGWytFVswbKFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9yyiJreoCU29ZtH9tBKNqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rsNhF5HivUKK-feAZQNJXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qLQ5mvZzJUqhD9QUU80N6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XYYm-Buu4ECheKCzyils-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_MJTl_-uIN0WiFf9AUkk7rQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_YpwOrDxTvEiUCcfw64tNMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Hb9YyYVIVki_vUupPUugtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1_tWzno1-kmrzxYDHva6OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2016Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_931tErLp7EuUinvtjRhPIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-06</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_OAjMTWyJ8E-817Ww2pMKxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">qure:VectoryB.vMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_rsKxoYBI-UKgNQ9ydk4pHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_su0H_LmbCk-jIOvLYq58hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_CeTx4ptjcEaRDCkpZ_Y8fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_WvP6wlihOUS6tnrgQEZHWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_1sldxuu9EUKBKyfO334l3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_hv6WtwS-cEGRKyupdp3QwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_4CW_DXp0Ok6hoLPlu21sQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_q56A2rcme0OqndPdj4St-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9DvuX5iTKkaxcG2y02MZyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_VhK3MGv9eEWEY7B8EG-TcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">qure:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_qdkOPyY6VkGQRdYO2alqaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1TMDu79eQ0e28WbVBlbIAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_JOuPA4_0AkS3D-CstJPyIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_dtZW9N0cZUGKCdQgqHQtOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_4uX4YOxCI0Ku1yrWU3Qr-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_CfO51mljJ0eWh8ZOXwfRNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-06</instant>
        </period>
    </context>
    <context id="Duration_1_29_2021_To_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_1Xb1Y17A2U231__SZnvguA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-29</startDate>
            <endDate>2021-01-29</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2018_To_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_jJzGBF12x0arzA2m_P93oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-06</startDate>
            <endDate>2018-12-06</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_mgfIVNyUyFz4VtwWRMFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K-wgrSYcl0aXW5Oo0TuS1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_12u06vcwokqbZ_3H5sstHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v-LvwFQXTU-mEhIgrrFYHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_j3iYYSYmcUedzDpmYFlnzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cZati_nTb0C-UhhIBOUNCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_VrVcTXdK_ka4cFP6BumMkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7OFIcgQjGUKozaeCn_JOaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wAnsudVWJ0eStn1YOEaRPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fJtKgxuUvkyrzU-RtzqAcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kImN7dQ-PUeOCHGKL1wPsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_7LQNKgj-qUKqmDaRdvBRmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:ShareOption2012PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_sDADOxy2gkuHqUBfnjTovQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_aitVdVnE4k67WD71TFPNZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">qure:RestrictedShareUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_1bGUyXjk5Ee1HL6K4PJVRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:ShareOption2012PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_qf3KA5AywE6IX9nX9Nuxmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_Qy8ygST_9k-q-6WvPt0QgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">qure:RestrictedShareUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_Hg1BxwkRVUyQ6vANQg5uvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:ShareOption2012PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_2y8V3lT85USL1EXFTeWauA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_BmsWarrantsMember_lc-W0vqpCUOjhIwUvmVlTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">qure:BmsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_bIi4GQHMx0e79d3ltjcbDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">qure:RestrictedShareUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_9iYRZ8CW1k-TSh8NdyAR5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:ShareOption2012PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_g9VXfgfnr0G-HOsXC6wp3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_BmsWarrantsMember_AuiBBwndmkigvQN248BGAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">qure:BmsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_oT74WQam8EeTmP8aiGGhow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">qure:RestrictedShareUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_VqOyaS-XX0WhG4INMVMxnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_jQQMIKMldkWohZCXDVcmdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_2QyWUqSll0SvgxvLV-w2Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_J1hFmEl5jE2V8o1LwylINA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">qure:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_YS6DOwKX1k6x5P_vJL_MIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_Mt0t04auPESNygM01bISbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_Y_O-r5G3Y0WsfXY0g7W7Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_AG5JI3Sjjk21nqVDyvBZNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_2zEJuHZdn0KJM5hi1tu5YQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_UovYXxgpLUq_6ozAyB8paA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lLWpawwVD0SS1ZQfITt7dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">qure:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_qure_The2014PlanMember_YbJyX63qJUCF1-xqxcPn-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_ESty22Jv-0Sxj10FO4p7bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_Ew8hAizqJU-URTHYHt1zAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lwLmmaw8u0StuP6cZ9EnJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_fHzfNFAetEOpeFa4wvX2DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9G_kAneeM0SgziGdwfsbMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">qure:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_qure_The2014PlanMember_GDX-daUVNkiz9HBqranRrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_qure_DirectIncrementalLaborMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_MtE5A0KG6067RmXlMj46FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">qure:DirectIncrementalLaborMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_qure_DirectIncrementalLaborMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_H4D4ClXlxkaceIkX1aMBWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">qure:DirectIncrementalLaborMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eRp_lKNL2EODSNZA9eiuHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dR853wdTkmYUidJM4e8Yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_igOZK4wZWEOra8bKTcWHwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_eXzdB_wPDkSlyzIUnaikng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_24_2020_To_6_24_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_Ll8fzwuH2kqanQly9paw0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-24</startDate>
            <endDate>2020-06-24</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">qure:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">qure:The2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_24_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_qg5NvBFGdUO4WsF-xZGEIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-24</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_7EhntjUcpUyhyXRTh2k0Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">qure:CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">qure:DerecognitionOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_0kUnhi7n702ffhqbWEJJFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">qure:CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">qure:DerecognitionOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_1_2021_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_H93jbZY3yUCB1OwXUnoDlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_4_30_2021_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_98YVZPFE5kO5F_BzYuxpRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SalesAgreementWithSvbLeerinkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_wO4YQLjtzUyL7xfd70wfWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_Q_fLWImhIU-2TPyxON_IlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">qure:VectoryB.vMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_UIrDwGaqv0i6xXmaQYspcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">qure:VectoryB.vMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_Bf9nD-pPCUi6779uMq-cCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">qure:VectoryB.vMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_Eyl_r3-QvkyaUu52pRzIrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-06</instant>
        </period>
    </context>
    <context id="Duration_1_29_2021_To_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_VTx12u2MvECweTY9rrMN2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-29</startDate>
            <endDate>2021-01-29</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2018_To_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_Faze52U7JEmiziY1euKKaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-06</startDate>
            <endDate>2018-12-06</endDate>
        </period>
    </context>
    <context id="As_Of_5_31_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2016Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_Y21A5QNU90qnhAq2_ca6ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">qure:SecondAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_Lkz8BWrtm0OghqMAcJ8NmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">qure:HerculesTechnologyGrowthCorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_1_2020_dei_LegalEntityAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_y8tWzFCmok2XCsAFfg-1mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">qure:BristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-01</instant>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_6_24_2021_To_6_24_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_BpZu_RynUUeTx_oJ_rCgLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">qure:CslBehringCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_uevJahvpyU2rrC71LQx_GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2018And2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">qure:VentureDebtLoanFacilityWithHerculesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_axABhO3W6UGp87WAJu9rUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_kzh0NdwaSkOA9RR8biOrAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">qure:AmendedFacility2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-29</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_21_2021_woBf2SRzckevUj9Egzvr8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <instant>2021-07-21</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA">
        <measure>qure:item</measure>
    </unit>
    <unit id="Unit_Standard_EUR_8DR84qYcA0iepwyX32ILmw">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Divide_EUR_shares_ZsMCFKBuQUe6RFYLkqqOSA">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      id="Hidden_PPGYK1QCz0i7-ys18eOOgQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      id="Hidden_kVIVJMbKMUWyKwndLGdReQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="INF"
      id="Hidden_V30FJAMs5kyHjXPHAKDwBg"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44777799</us-gaap:CommonStockSharesIssued>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tc_xsybA4rD7kSBbCAyBuMJvA_2_1">0001590560</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tc_r3LHYjZWWU-xKGSC35PGQQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tc_MkQoYul5qEeDAM5rblI4hg_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tc_OEEgs8fJf0emzoRmZ6IjEg_5_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tc_Ef6trLJfJU696mbP67NjdA_6_1">false</dei:AmendmentFlag>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_yEL8uzvfzEuzep8u6-oSHg"
      id="Hidden_MCRGihcaXES2tnUHXX0Fgg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="INF"
      id="Hidden_iWDWSf8eDkasc3ZZLMhv3w"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">46050250</us-gaap:CommonStockSharesOutstanding>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_FeC79tuB60usbwxX-X6WCA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tc_G1kFeZhIUkyTEFIz12Dhsg_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_fYYqj917zEa0s4jb6AB1ZA">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tc_CBVXvHVHPk2GA_b8iZ0cSQ_7_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_P_QTZ6qlU0W90JMknNl4zA">001-36294</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_6UO6ZzEQJ0eDqVr-u1GDrg">uniQure N.V.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_Z9ue1jXMNUinMA9RS3YjMg">P7</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_3RRnejxdpUWlnD9-LM8bVw">Paasheuvelweg 25</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_yty5bPF-4EqSBhZTUP3lHw">1105 BP Amsterdam</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr__osiiDWRNEGy95z9gUMRJA">NL</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_pSfAri0UDk-vy_hpL1Fs3w">31</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_GqRF6zDEP0aqqKEU-4aFdw">20-240-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tc_Q0SC4VY2V0qSBX1t6MJE4A_2_0">Ordinary Shares, par value &#x20ac;0.05</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tc_cf62kM_KSEm9zT7pZD_wBA_2_2">QURE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tc_1hPHgz4UTkiXGd4ZsmH7AQ_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_D3NXsMaiIkWT6yp3_cK0rg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_gce2yyDwQEyPSRe_dRCwEQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_7UMd6y4cFUyJBSZvKDPFSg">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_OpVfcYRnukW6LUi3CFyQ5Q">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_GJhQZyptp0OZxxJm-lQK6A">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Narr_E6RllXKJukWaxfbnv7EEGw">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_7_21_2021_woBf2SRzckevUj9Egzvr8g"
      decimals="INF"
      id="Narr_GcopNX7aX0mW02NTQwkj3g"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">46073373</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_3IRJwkxARkCcE8ymyR_7OA_5_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">677330000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_lgSwLhU61kKs0N2baZLUEg_5_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">244932000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_7wsvJTFhuEWzOUVxqGCv_Q_6_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2705000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_pEV1WR1C6EykrY7OLBWj7g_6_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">6618000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_tTQe9OpKGkiIxQN3O9jEng_7_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">10861000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_c_mJsyfUV0S86HOSj20IWw_7_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">4337000</us-gaap:PrepaidExpenseCurrent>
    <qure:OtherCurrentAssetsAndReceivables
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_4lT93ruDzkSJJt15NQhQlQ_8_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3328000</qure:OtherCurrentAssetsAndReceivables>
    <qure:OtherCurrentAssetsAndReceivables
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_lwEbpNCWXkq3WmV6cKi44w_8_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3024000</qure:OtherCurrentAssetsAndReceivables>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_HwDFwTSAu0OdtkXVEWXX-w_9_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">694224000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_Psq7UmPNo0OobFVgUA2Mzw_9_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">258911000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-5"
      id="Narr_-TN6t1TkyES2EAVB4P5O8A"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">37300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-5"
      id="Narr_-D8_6VLUgUyiEa4AuEE0ug"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">35200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_OCc9EEORDUSa0GKed_aYpA_11_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">38371000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_H1LQ-HqaP0-aLwSS-l5PNg_11_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">32328000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_-4htlZFEIkmB0JihLp0g6g_12_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">26782000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_s7WE96G-x0-8z62gyfMXbw_12_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">26086000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_IzJZize-JUCmfV_bjTqwYw_13_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2637000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_pFyBxMFZ-EydYw9HEL18BA_13_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3361000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_Jgce3kE8AkOVkGNRV6j4VA_14_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">525000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_o_UZs0OsakKn-30Pyrsm2Q_14_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">542000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_-GRk9bRDb0mEj4ZWRLyXLA_15_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">15965000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_sSlYm__IwUOcffMxr_e9oA_15_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">16419000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_yj2gKl1puU2elgsYX7GCwQ_16_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5760000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_CT1DD6Yb20-etPUKQIU1Jg_16_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2748000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_fuwbdro7FUCdtJpLE43MJg_17_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">90040000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_YEQjBOv04kWXpFDpcHYcqw_17_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">81484000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_i1V9X-a1bUW6nb6PkZSP2Q_18_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">784264000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_7jpx6KeW4UqhBlSq4Bklxg_18_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">340395000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_4aKoaoYDj0K2dS5MiveelA_20_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">16817000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_Yf3aW9S1SE-Y8f5TKxC8yw_20_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3772000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_fpfrCU0ZpEyK2mGMD-9Brg_21_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">23526000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_G2d7pxtL2kypGMmeeNaCpg_21_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">18038000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_DPsvwUhZT0K8JMteS-L-HA_22_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5752000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_8CDd5hOHPkiHcplLM8q2VQ_22_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5524000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_kvoizeQbg0KJIW8d75W-Ug_23_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">46095000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_i3aTKIQMgEG4JoGCYdwnFw_23_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">27334000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_keH2bS1MBE2qJm0tW2O8wg_25_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">70780000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_Xweow8nd40-SXSfA3Qq8Jg_25_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">35617000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_x9Wi3A1nZkOUT2dbWDZ4Ag_26_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">30534000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_nw9DlVEofkCcr8FAQyGN8w_26_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">30403000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_f7bTbhT1iUKDGLrgzXBpow_27_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3247000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_pRB7Vzvw8UaAUdorD_stVA_27_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3136000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_ABdD7TkiSEeESFji0t55qA_28_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">104561000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_CBLz-eh-V02FYG0Kcx9soA_28_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">69156000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_rTIDlJCxtUi7hPtR4WYhjw_29_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">150656000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_1fdf4Hu9PUmmN11GLHBe8g_29_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">96490000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="INF"
      id="Narr_Zs7cfYx1DUyzyw0BjnOvGw"
      unitRef="Unit_Divide_EUR_shares_ZsMCFKBuQUe6RFYLkqqOSA">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="INF"
      id="Narr_1zM_bxo7q0SMf5DTgIdVlw"
      unitRef="Unit_Divide_EUR_shares_ZsMCFKBuQUe6RFYLkqqOSA">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="INF"
      id="Narr_3PcCyBTQAkazwiAEmi3KBQ"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="INF"
      id="Narr_GhEtx9rEuUyZ6K_y4Hnlcg"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="INF"
      id="Narr_0IX1BfUq-Eq6pjBvN3WY-g"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">46050250</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="INF"
      id="Narr_HeAOlTpuCkirtMn1gJ-tfQ"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44777799</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_s6Yz7trPfUG9-Iurmesv9g_32_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2788000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_nw9bU8xa30eO_ZV6ohqyog_32_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2711000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_fiNLTAe-S0CFfDdBoNOD0g_33_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1062234000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_weZxGmS3H0-CFQzeDLn7RQ_33_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1016018000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_YTv3VbVWg0WzM1QY5H8nKg_34_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-4595000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc__6LpVTd0B0qT7PcBJIgu9w_34_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">9907000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_NpzQESeUJEGJLINe4HmEaQ_35_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-426819000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_YTKNt2HFrkqKd5eF1QJiqA_35_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-784731000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_Na633EskiUm03fOLVCpnaw_36_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">633608000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_-RPejH8AiU-3x7qDteA_6w_36_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">243905000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_VzQDgiihWEOoBNEwdGgH8Q_37_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">784264000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_ELSD0qVn7UWjD7PZEsPe4A_37_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">340395000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseMember_jHZhFitLrEOQNQKYgI7ZBA"
      decimals="-3"
      id="Tc_T3kxTsDOXEOrTUwvpyg1Gg_4_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">462400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseMember_9-058g41FkiUfUyhdRdA8A"
      decimals="-3"
      id="Tc_hqS2xSAziUGK_Y8nIsAoIQ_4_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">462400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_LicenseRevenueFromRelatedPartyMember_Ktoe6WsNfUut5PLrxfJPGA"
      decimals="-3"
      id="Tc_XANQq4bPL02LHD-Pc5bvKA_5_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1530000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_LicenseRevenueFromRelatedPartyMember_R4VI051DiE205Dp9r8_D5A"
      decimals="-3"
      id="Tc_uYesz4XW10C6WUWhj9ABMw_5_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1577000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_0j8VHpWGtkqyg1Eoh_-56w"
      decimals="-3"
      id="Tc_ugRVXrhDfkm6iAqjtgQrmw_6_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1468000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_9iY6fqOrEE6pUHvNw-CSpw"
      decimals="-3"
      id="Tc_BfZuwOTdHUmsECXinW0-Vw_6_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1922000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_CollaborativeRevenueFromRelatedPartyMember_cprlgbYMcECa1gZndoHMVg"
      decimals="-3"
      id="Tc_MPZUrNZz7EakjRAaEcXSsw_7_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_qure_CollaborativeRevenueFromRelatedPartyMember_qHipUZ-S2kSLqtPAsxvUgg"
      decimals="-3"
      id="Tc_MOUHV9o9pUKXaIc4S_PL2Q_7_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">62000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_DNVXtiVevEeGqXuMHJotPw_8_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">463868000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_mBTYNTTYvUWxlTe_-KQxLA_8_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1535000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_Pa4StMi9IUmYsEOvljt08g_8_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">464322000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_y1mhCYCz6U60fCq2Xoek2Q_8_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1639000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_WqvH1bnVA0SLX7RhzqVckw_10_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">23178000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_fEHUvCqafUSz24MgINLj-A_10_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">23178000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_kie-rsGfxEWJgMq9LZcoLQ_11_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">32747000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_Fn5b7uGnAES1uq2m52ZKjA_11_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">28401000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_2kP_m-kmnU2J80Ox4zgXKg_11_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">64777000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_gBccFirykkKT-NaDA9z8dg_11_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">54414000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_E6s9VQ6zPEup2rSI0UWXxg_12_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">17299000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_R-CX7z01906Y6bT_71m1IQ_12_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">11511000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_WDIezqlRHUeHKxlPED64qQ_12_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">30300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_dAkyHdEwvUO7w3TtiQ85cw_12_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">20583000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_Ib8f1f9Vv0CoNTxmkEAfpw_13_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">73224000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_ot9VJU0H-kCRQoeYV_RVdg_13_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">39912000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_kbBYiCiKjUmXnoFpX5PjnQ_13_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">118255000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_o9S72fgybkG25FGjZ-7bpA_13_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">74997000</us-gaap:CostsAndExpenses>
    <us-gaap:OtherIncome
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_9a5fMonO7EWhJJglQf0mgw_14_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">7590000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_owEbLROBl0qtSv3pjqDgtA_14_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">669000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_gEwFQpwYm0CsXEcQhqLmUA_14_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">7942000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_aUIRyUZKO0ScVHRFd43q4g_14_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1526000</us-gaap:OtherIncome>
    <us-gaap:OtherExpenses
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_UeyPGsRz2kiVPWTApBG7Gw_15_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">226000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_tkMLUje7Fkuvi92JCCIm0A_15_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">500000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_G_Dv53eecU2-IHJgw9wneA_15_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">459000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_RrL6bco7WUq2ldUrVwz6Lw_15_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">839000</us-gaap:OtherExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_VwrYgpyswU2A60u59jIV_Q_16_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">398008000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_tkVMwAP73kOig9Xi3zBo3w_16_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-38208000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_s4QCR4vEnEySxFyWUBtTFw_16_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">353550000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_OZ7t2zZLAkWZhhLbPglyhg_16_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-72671000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_H4RPQA-QG0OnJD7-PuihFA_17_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">37000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_gYNUUSrbZkScg1uG95dqfA_17_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">81000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_2TT8PJJ57kKpkisgvY0_0w_17_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">77000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_pJqWtFFVQ0CrgC0ULh_FWA_17_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">903000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_51Ydi-_K3kCsa4PaklXeQg_18_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1902000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_Eqf-mBbHikmmrId81n9Eug_18_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">970000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_F3sulOuugE2VaNybZHRetQ_18_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3453000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_hlzN5_X2N0azh4ps-l6OoQ_18_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1945000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_yB6FzaJl10uZrAH9vUsy_Q_19_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">6583000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_W-34oK-J5UeBeTUdmKQkTQ_19_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-3645000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_Bsu-FucEOEqaqGzzQe9etA_19_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">11209000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_TvT0WhJFIUeR5DBYspDeiw_19_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">957000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_OEPTfJtWA0G436FNpeFMMQ_20_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">191000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_ialgCRiHN0-uufI4KGHShg_20_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2206000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_UFGywLSkHk-Wszrfcb5xlw_21_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">402726000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_AZIbLX_E_E-usGd-Yj-aUg_21_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-42551000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_r2PJK408yUShEY6Sb8XmNg_21_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">361383000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_hHrrivateEuK5O7LLrp5qA_21_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-70550000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_4msVsZkunUmPCjWJxosqYQ_22_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3258000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_nQ_LVqHSvUqWbd-uL5pjSw_22_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3471000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_GAQVjU2qKUmOrOKuuKtD8g_23_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">399468000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_CdX8iwy7mkClaxJuXkfkRg_23_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-42551000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_h3mJta2mDUqPTPgYIj64ZQ_23_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">357912000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_ydkYSGQ63kOAct_5R4BNkQ_23_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-70550000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_wWwswelg_EGx9ZH_RLjbpA_25_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-6942000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_fX2KliqamU61c0EbNyjCew_25_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">4647000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_1nPNfIsjkUGw456WYHYn9w_25_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-14502000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_1DcaS4MfnEaMm2Zqw83JxQ_25_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-630000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_F7O2QJXNWES97TckITbhvw_26_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">392526000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_f8fufD4giUOwFlLXz47zzg_26_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-37904000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_NCxv6EOSEUCRz2UmcGFBqQ_26_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">343410000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_NWuX973Pj0-PUXq5hd6_uw_26_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-71180000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="2"
      id="Tc_W-2YhiqQq0K7w6PXUgE7tg_28_3"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">8.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="2"
      id="Tc_YqJ84agnoEWZbh4iXEF-kg_28_6"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">-0.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="2"
      id="Tc_rozmvINuvEym4qYVegNY4Q_28_9"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">7.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="2"
      id="Tc_G00fKTxFJUmubNfdHe1rfg_28_12"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">-1.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="2"
      id="Tc_Z0tctxzfXUiBcb6_dCA-gg_30_3"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">8.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="2"
      id="Tc_Ww7myrheOUWmMGrZ6ghw6w_30_6"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">-0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="2"
      id="Tc_zhhU1rewpEuNq1m-IE8C-g_30_9"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">7.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="2"
      id="Tc_8QLWfLUe9E-G2Ldfg1StAg_30_12"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">-1.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="0"
      id="Tc_UMQt9WeLX0GMaSY3_oNgTA_31_3"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">46037900</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="0"
      id="Tc_7ZpJYvCAwUmV2WTCYvGSug_31_6"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44387463</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="0"
      id="Tc_IrslrnEOnUel8E1u_ev3ew_31_9"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">45754766</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="0"
      id="Tc_c1zMv3iEgkazIneCn9JK0Q_31_12"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44333460</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="0"
      id="Tc_1GczZ_eXRE24H7HRB4naNA_32_3"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">46929870</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="0"
      id="Tc_m6frIzpMPUiMLjpSmq4b-A_32_6"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44387463</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="0"
      id="Tc_BBBIrgvryE6U_OSzKx0xAw_32_9"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">46678835</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="0"
      id="Tc_TAQhGZNisUKpjCNBqEF8kQ_32_12"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44333460</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_j3iYYSYmcUedzDpmYFlnzA"
      decimals="INF"
      id="Tc_-SdSWX0IIkCUVRowbeEgtA_6_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44299596</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_j3iYYSYmcUedzDpmYFlnzA"
      decimals="-3"
      id="Tc_HOzkf5ibNEW-f3BZytbDxQ_6_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2683000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B-LJE5DhoUS75c9QtNuw-A"
      decimals="-3"
      id="Tc_fvc3BH55GkukddqLIOjnRg_6_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">992136000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_w6u8-eqmkEiHOgU-Dd9xOg"
      decimals="-3"
      id="Tc_LhCbokh_7k64t93liRZYbA_6_10"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-11966000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nPdO4wtnvEWlpbuGGdBg-w"
      decimals="-3"
      id="Tc_6cSZ0JjAQE-M8sGkpM8c2g_6_13"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-687706000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_kg7c_qm1bEy7UDtpE53ICA"
      decimals="-3"
      id="Tc_z6Sk5u20E0KUp5tl5LPoEA_6_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">295147000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qLQ5mvZzJUqhD9QUU80N6Q"
      decimals="-3"
      id="Tc_iF1qCL0cvkau0jtAogFoew_7_13"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-42551000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_phLwdG6o70qXjXxjth8K6w_7_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-42551000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MUECXMXIDUq79H4NmTlzIQ"
      decimals="-3"
      id="Tc_J-JbRheVIUu9Pj1KzbB5Cg_8_10"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">4647000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_Uux0Msn9AkeVP8dvQH-bnQ_8_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">4647000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyu1S0cqWU2xIkIh3ub-aw"
      decimals="INF"
      id="Tc_vxrpsKFl5EOugdiYctkIRw_9_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">139178</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyu1S0cqWU2xIkIh3ub-aw"
      decimals="-3"
      id="Tc_VJZsyEtdoEqCoxCMrsScOw_9_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eRp_lKNL2EODSNZA9eiuHg"
      decimals="-3"
      id="Tc_fF_ad3BatU6-DInJXo668w_9_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2461000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_y5m4MRN2C0Gl_vSf9pVrhQ_9_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2470000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyu1S0cqWU2xIkIh3ub-aw"
      decimals="INF"
      id="Tc_guJqe_7CQk2WF9IWLzc7zw_10_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">4427</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eRp_lKNL2EODSNZA9eiuHg"
      decimals="-3"
      id="Tc_6Q35pilQAEmDv8z_hkhueg_11_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5723000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_bPrbDkElikK9GKrEyHPgWQ_11_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5723000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyu1S0cqWU2xIkIh3ub-aw"
      decimals="INF"
      id="Tc_oeZKVbpE60-Pw4zLTepQlA_12_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">1204</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eRp_lKNL2EODSNZA9eiuHg"
      decimals="-3"
      id="Tc_dXgHDgiyOEG7H4Hav4g0LQ_12_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_bGVwmj0f50ujrMP39rAApw_12_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v-LvwFQXTU-mEhIgrrFYHg"
      decimals="INF"
      id="Tc_LFtRDqL0FkK5erWYm5UJwg_13_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44444405</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v-LvwFQXTU-mEhIgrrFYHg"
      decimals="-3"
      id="Tc_RN_4abTH3EKB5NHUHKuxkw_13_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2692000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tqrT9yrb-06NxeDkwo4JTg"
      decimals="-3"
      id="Tc_NXgzPnii1Umv6Z22cbm1Ug_13_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1000389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_98hRD2QNWkGhe45TCCi4eg"
      decimals="-3"
      id="Tc_sFyXuPyl-0mWaBeLq7FT8w_13_10"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-7319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0D6WZbsJ9EyfBMQ5KfZThg"
      decimals="-3"
      id="Tc_k3XpBPQgCkWy1QnMhAlElg_13_13"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-730257000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw"
      decimals="-3"
      id="Tc_8syMOzFa2EGqzpvR_MyEEQ_13_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">265505000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K-wgrSYcl0aXW5Oo0TuS1w"
      decimals="INF"
      id="Tc_gOenMsBtNE-1MrWRdvLMow_15_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">45924729</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K-wgrSYcl0aXW5Oo0TuS1w"
      decimals="-3"
      id="Tc_KyaLbKRqpE-yK0GegVCp1g_15_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2780000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DsFKGwOurUui9rgpsgd2zg"
      decimals="-3"
      id="Tc_TLQoD77XekyYe4NrusxrHQ_15_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1049850000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_L4tV3PEQJkC8fL3FzxLwNw"
      decimals="-3"
      id="Tc__BDm97TGH0aFm79Z0L4Z1g_15_10"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2347000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HOv4QC1gA0CfyEdcEjfcYQ"
      decimals="-3"
      id="Tc_XaTNG0-qDU6PWp8uIfyGMQ_15_13"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-826287000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_iSci5KSdxkuiCG7kJ4B7Rg"
      decimals="-3"
      id="Tc_sAh60NVwkkSKNVDF0Gh03Q_15_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">228690000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9yyiJreoCU29ZtH9tBKNqg"
      decimals="-3"
      id="Tc_cLeZG7C2gEmEAuJpqPUi5w_16_13"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">399468000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_PsVU-SR-6UC-ddeHMSDhwQ_16_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">399468000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30Oj847Y4U66T9RvHLydUA"
      decimals="-3"
      id="Tc_K2xW6n9cP0q8eFwkE8CDUA_17_10"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-6942000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_fKlyriJVk06-nT9WG-f0kQ_17_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-6942000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ"
      decimals="INF"
      id="Tc_n5VMj450zkee7mlTk2m1KA_18_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">61845</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ"
      decimals="-3"
      id="Tc_WTwwDJUpmECNZX_Wc3s3kw_18_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_axABhO3W6UGp87WAJu9rUA"
      decimals="-3"
      id="Tc_mNhNQQRWb0KaKZHtJb8G7g_18_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1862000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_9XgzYHWkLUilOLfxc43cfg_18_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1865000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_axABhO3W6UGp87WAJu9rUA"
      decimals="-3"
      id="Tc_mzdCcG8XrkqlIlT2pd5diA_19_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2977000</qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears>
    <qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_IML8jbGqUEy7mxSbu4HDZQ_19_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2977000</qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ"
      decimals="INF"
      id="Tc_04XMNbg_NkuDWMv3C7WMXQ_20_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">55194</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ"
      decimals="-3"
      id="Tc_Zzcj-d0vJ0qErdWeduyviw_20_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_axABhO3W6UGp87WAJu9rUA"
      decimals="-3"
      id="Tc_qzmTIo3yzUWOCyB_0y1q4A_20_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">515000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_7MgRNr5dCUGQfVqyJPvQvA_20_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">519000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ"
      decimals="INF"
      id="Tc_uhk2Wiw1ukiO3_OWfBf5rg_21_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">8482</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cBdqrEKPVkWDnkRs4OpsBQ"
      decimals="-3"
      id="Tc_wJH1hiWqOU-YYqdWNsSmUw_21_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_axABhO3W6UGp87WAJu9rUA"
      decimals="-3"
      id="Tc__XpdBoMx7kaHk9MXTlYLlA_21_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_axABhO3W6UGp87WAJu9rUA"
      decimals="-3"
      id="Tc_GmCFY2eFrk2Q-6qHB1RzoA_22_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">7031000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_lm6pZ3j7_0CLTgUT8iOhBA_22_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">7031000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_mgfIVNyUyFz4VtwWRMFw"
      decimals="INF"
      id="Tc_JzM3Bkhl20qFu_zjaTEFYw_23_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">46050250</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_mgfIVNyUyFz4VtwWRMFw"
      decimals="-3"
      id="Tc_w-G19QMACEqgrlgJMB2HsQ_23_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2788000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NCAjWMQk0EWYAF5NG6CWtw"
      decimals="-3"
      id="Tc_TT9KGMTk2EGDt3GjEGHhug_23_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1062234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2hvGL0bx6EimerX1R8EITw"
      decimals="-3"
      id="Tc_KT9JDNZRsEOFigjTJ4L6Bw_23_10"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-4595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S1XNLHXDj0CmAF9NqjS7Pg"
      decimals="-3"
      id="Tc_LK7-0EPP3kKaqxU65qNiBQ_23_13"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-426819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_-nSef5sdCECPFxJOr35BRQ_23_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">633608000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cZati_nTb0C-UhhIBOUNCQ"
      decimals="INF"
      id="Tc_PFosCwaa-kyVJoxzwM5YpQ_6_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">43711954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cZati_nTb0C-UhhIBOUNCQ"
      decimals="-3"
      id="Tc_kVQNGjUyGE63s0dZ97xWYQ_6_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2651000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FiR-EdjoaE-NUqcozk-aQg"
      decimals="-3"
      id="Tc_0clO6YQVeUikrivAwn-I8w_6_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">986803000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8TmbfDxKjUKS_aB_XtU_QQ"
      decimals="-3"
      id="Tc_dVKfy7t6HUKBkJkD1hAvXA_6_10"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-6689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XjeHbyUls0C0C2A5C4oucw"
      decimals="-3"
      id="Tc_JCpJHTB5PUKKRZTCD036kg_6_13"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-659707000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_VrVcTXdK_ka4cFP6BumMkQ"
      decimals="-3"
      id="Tc_zigJKVpgGkapNZl9nmd0Fw_6_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">323058000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XYYm-Buu4ECheKCzyils-Q"
      decimals="-3"
      id="Tc_ckjzdAvNH0q5RvyzHhM-Ng_7_13"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-70550000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_-bEPV5Jui0e5OFFgNCtdjw_7_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-70550000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FyQ6c103BEGWytFVswbKFQ"
      decimals="-3"
      id="Tc_U-DuKH1L_0OuBd9MTUOvqA_8_10"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-630000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_hVb5Bj1zSE-RNU4ue0ulbQ_8_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-630000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LAamd-jnaESPNk8ZipEekg"
      decimals="INF"
      id="Tc__Ow7-1mLEEGyh0ko2Qfpjg_9_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">203940</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LAamd-jnaESPNk8ZipEekg"
      decimals="-3"
      id="Tc_mxi8-Dp2BkSWXRWihz4obw_9_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">12000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dR853wdTkmYUidJM4e8Yg"
      decimals="-3"
      id="Tc_-LLfj-S26kiHbiAj3ibxfA_9_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3390000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_MZfratVIakm3LLmTjdZa4g_9_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3402000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LAamd-jnaESPNk8ZipEekg"
      decimals="INF"
      id="Tc_PgGkthpIbU6BANwVX0gBOA_10_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">525506</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LAamd-jnaESPNk8ZipEekg"
      decimals="-3"
      id="Tc_DhgE7m9RXkOxQHD_vK6YHQ_10_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">29000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dR853wdTkmYUidJM4e8Yg"
      decimals="-3"
      id="Tc_jhVM-Ei0OkG00rtzK95MBQ_10_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-29000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dR853wdTkmYUidJM4e8Yg"
      decimals="-3"
      id="Tc_wuSlLJvqyUumLMVAGa6t1Q_11_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">10078000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_k3YCfITWRU2pl2gAVx6tdA_11_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">10078000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LAamd-jnaESPNk8ZipEekg"
      decimals="INF"
      id="Tc_kqf3PvxyZkyv5RUjc8FxRw_12_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">3005</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dR853wdTkmYUidJM4e8Yg"
      decimals="-3"
      id="Tc_E_-e2C17HEy8dCVWjKB-8w_12_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">147000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_Ewvz_TYnLEuXwMfBJRdpew_12_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">147000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v-LvwFQXTU-mEhIgrrFYHg"
      decimals="INF"
      id="Tc_ubnQXPxNI06Jp9-0uxdHGg_13_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44444405</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v-LvwFQXTU-mEhIgrrFYHg"
      decimals="-3"
      id="Tc_XnbRPX35D0WULj_i0nZIxw_13_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2692000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tqrT9yrb-06NxeDkwo4JTg"
      decimals="-3"
      id="Tc_YvYIb5GzmkuyGOLyze2Y3g_13_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1000389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_98hRD2QNWkGhe45TCCi4eg"
      decimals="-3"
      id="Tc_HAE27zzjx0KRXkb7n-ewNw_13_10"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-7319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0D6WZbsJ9EyfBMQ5KfZThg"
      decimals="-3"
      id="Tc_GCNG3_d8S0iDSRMbBrMygw_13_13"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-730257000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw"
      decimals="-3"
      id="Tc_XwYe2ddzLUKaWJCrVa9Zgg_13_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">265505000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_12u06vcwokqbZ_3H5sstHw"
      decimals="INF"
      id="Tc_4EUx94J1qEy2blhJOXUWiw_15_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44777799</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_12u06vcwokqbZ_3H5sstHw"
      decimals="-3"
      id="Tc_9TqZNI2CyEGWw6Ua-sCJPg_15_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2711000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AJilnv7U0UKS6Pd__e9ntw"
      decimals="-3"
      id="Tc_mqYKnR9hJEmQ5GEtdYALBQ_15_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1016018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5Zz24Wjw0WmLw7GH5paxA"
      decimals="-3"
      id="Tc_VfI62c7LpE-Lv6mUSdTzjw_15_10"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">9907000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OjQYcvlwLk6FKuTEnO6ixQ"
      decimals="-3"
      id="Tc_ADiIr99On0Wr99pswrgYjg_15_13"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-784731000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_piObmh_7PEmoLPTXTumuMg_15_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">243905000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rsNhF5HivUKK-feAZQNJXQ"
      decimals="-3"
      id="Tc_ARLZpAy5C0CozMyqW7G1Cg_16_13"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">357912000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_X2VQ_4mzwkO6e91nbnwfog_16_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">357912000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v04H0tAAR0aK-7lS6pBkDA"
      decimals="-3"
      id="Tc_B2NimSkTXUSe8bTtEA4AFQ_17_10"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-14502000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc__x1ZQIOvI062wCYtvDAYtw_17_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-14502000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www"
      decimals="INF"
      id="Tc_oQU2KjuAKEaKyUNWFAbf9Q_18_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">921730</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www"
      decimals="-3"
      id="Tc_QkpzLSqmw0W-oqytqAM0GA_18_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">55000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg"
      decimals="-3"
      id="Tc_uEiumcHEFU69ztiD5dXYRw_18_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">29509000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_b1JssXak6kubiEeW5_ncQQ_18_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">29564000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg"
      decimals="-3"
      id="Tc_ZR1um7QGkEWd8aTm0kpSQQ_19_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2977000</qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears>
    <qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_Qs5WXkLzyEaX-f6PhZWSzQ_19_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2977000</qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www"
      decimals="INF"
      id="Tc_izHvm9CaL06UVfWxQracVw_20_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">71976</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www"
      decimals="-3"
      id="Tc_trJKZWAvWkWi4qKzgUKr6w_20_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg"
      decimals="-3"
      id="Tc_Rbu77uRpvkyJTq73vD1y5A_20_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">906000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_Up3hciRT-EaUeD1g3H3_iw_20_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">911000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www"
      decimals="INF"
      id="Tc_uQLUhQP6ikyadNi-pJovog_21_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">277571</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www"
      decimals="-3"
      id="Tc_IQ-sy-D7kEaqDvYeahUFVg_21_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">17000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg"
      decimals="-3"
      id="Tc_-hn3_8O6ZUOMJIEfYQW16g_21_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-17000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg"
      decimals="-3"
      id="Tc_4ZSJPUNEPk6NpZYe1tN40w_22_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">12792000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_T5OHl91R4kSiAa3q0ukM4w_22_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">12792000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bRNmPpyUdE6zTTHgN81Www"
      decimals="INF"
      id="Tc_vKBI7Zg8AUWMzVkSj0tg0Q_23_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">1174</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4MJazfe9kUaAf5SVwzaYCg"
      decimals="-3"
      id="Tc_CBGasfpkDE684MXkXql1WQ_23_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">49000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_udFx18BMO0O28E6itDY7LQ_23_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">49000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_mgfIVNyUyFz4VtwWRMFw"
      decimals="INF"
      id="Tc_c6nBvrfmYUu01IZ6R4sIAw_24_1"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">46050250</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_mgfIVNyUyFz4VtwWRMFw"
      decimals="-3"
      id="Tc_RtP52KOExUiMHTBvS2V3Vw_24_4"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2788000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NCAjWMQk0EWYAF5NG6CWtw"
      decimals="-3"
      id="Tc_8CpfDL2W_EKgk49PcNDInQ_24_7"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1062234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2hvGL0bx6EimerX1R8EITw"
      decimals="-3"
      id="Tc_i5xT-Ywz40qLWEZeNWRKSw_24_10"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-4595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S1XNLHXDj0CmAF9NqjS7Pg"
      decimals="-3"
      id="Tc_0jfbwmaDMEasT2ewZFWlXw_24_13"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-426819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_ORTMEz9mc0Ke7ze3mP6HvQ_24_16"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">633608000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_Li5n9BqvT0-_BRau1jxeOA_5_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">357912000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_5L6JZfwtLEm6vogX8u5JUQ_5_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-70550000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_uF8qnJkUX0yGDfSxbiL1Wg_7_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3667000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_j8oHb2C-GkiBbXjv858h5Q_7_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3505000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_DL6uAzLkbEeP7-W8jMw_5w_8_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">12792000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_Nj5hW0sqv0ylVE9x49L7KQ_8_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">10078000</us-gaap:ShareBasedCompensation>
    <qure:ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_ZOSM57BQ_k6gNmzt4ct6AA_9_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-2206000</qure:ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_qLw51KjaL0OxPpjuWeRSEg_10_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">12279000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_8fsbkZ-ZQ0q26g3lNfYZjw_10_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">908000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_i4_l5IpeoUu_cf5ROivffQ_11_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-539000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_cd2j11KVQkSn0UbgjT5mig_11_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1600000</us-gaap:OtherNoncashIncomeExpense>
    <qure:IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_BXtafurKzkyujAjYaM1XNw_13_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3355000</qure:IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets>
    <qure:IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_mUg8N3Z-NkSBlaaSvHzz1A_13_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-1050000</qure:IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_MIYDWk4YHUu_z-Kh2CJgBA_14_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">10444000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_XjbDYmAr_UG6oOexP73yYg_14_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-981000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_jsZG9ohjyk61Fh3XIDGVfg_15_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5486000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_wQXDHuVVT0u538uO6VyWIQ_15_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-1332000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_Ke-c7v8GVEm1Ajwe3Ft-DA_16_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">375206000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_BHgIMYj_m0u6uzqutu7eoA_16_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-62944000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_lshGgITxDkSAvLuDkZeWGA_18_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2214000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_qpaPdQf1PkuvnM39Ye9Zpw_19_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">6191000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_KeuDvlo2u0issf-wEsUIeA_19_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2392000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_0SkbFRVOMESXsOFyi5ZYYQ_20_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-6191000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_Y63evr950UaCTeILyuEOIw_20_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-4606000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_ZqUKueI90km2wQz90fyctA_22_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">34603000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_h-BP93NtNUaIttjH3I4CsQ_23_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">30899000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_SzzbOrZzEkqhvxInXnIluQ_24_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1334000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_ymUl5BCdO0-8pjiEWjvfsw_25_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">960000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_3JvXgktU80SCprt9_oJEDg_25_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3549000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_kkvVjF97AUy5QCeovpzg2w_26_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">65128000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_IQH2BiT56Ey66MoYshlQYA_26_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3549000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc__DNDvwlmqkeFAOK2FzUyww_27_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-1665000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_qVZ_4eureU-LqvBb4So75A_27_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">223000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_sjPlSKXXzUC9wP62_MASVg_28_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">432478000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_wjI3ClEpIUa9Zu7S9mtqdw_28_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-63778000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_syEZ2Y_8Uk6XWich0skGEw_29_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">247680000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_VrVcTXdK_ka4cFP6BumMkQ"
      decimals="-3"
      id="Tc_nVSqQB4PUUKhTPNeyWPOlw_29_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">380726000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_J2hibDdEOkSXhyqXftesAA_30_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">680158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw"
      decimals="-3"
      id="Tc_OxPiL86AAkiNhNLPu7C4wQ_30_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">316948000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_Jtm2ecuieEiXpR0WGkSuAQ_31_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">677330000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw"
      decimals="-3"
      id="Tc__wxWesMwMkubyiAMcSLj6w_31_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">314265000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_HMXFWpWRd0eKABFjjkkhOg_32_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2828000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw"
      decimals="-3"
      id="Tc_A5K6ngKgSEO9ReB8fUitjg_32_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2683000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_iEBI4IQOMEaumid1MWRTQw_33_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">680158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2020_zk1p4O9lH0aRrmhU9736cw"
      decimals="-3"
      id="Tc_qpAZA6f3pkSbN1xoRxCHjQ_33_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">316948000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_5du6LkAIYECGGrz2eAyANg_35_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2943000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_7o0H2NM9KUa9wJOUCUbr9w_35_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2545000</us-gaap:InterestPaidNet>
    <qure:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_R5CYImwdkEq9_HFgu05ryw_36_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3488000</qure:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets>
    <qure:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_1vsJqyjP2EOpaEk1IW6cVg_36_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1021000</qure:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_8Mq9JAvxNUGDEmt_SZS5iQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;1&lt;/b&gt;&lt;/span&gt;General business information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;uniQure (the &#x201c;Company&#x201d;) was incorporated on January 9, 2012 as a private company with limited liability (&lt;i style="font-style:italic;"&gt;besloten vennootschap met beperkte aansprakelijkheid&lt;/i&gt;) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company&#x2019;s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics (AMT) Holding N.V (&#x201c;AMT&#x201d;). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability (&lt;i style="font-style:italic;"&gt;naamloze vennootschap&lt;/i&gt;) and changed its legal name from uniQure B.V. to uniQure N.V.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 1pt 0pt 1pt;"&gt;&lt;span style="margin-left:0pt;margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company is registered in the trade register of the Chamber of Commerce (&lt;i style="font-style:italic;"&gt;Kamer van Koophandel&lt;/i&gt;) in Amsterdam, the Netherlands under number 54385229. The Company&#x2019;s headquarters are in Amsterdam, the Netherlands, and its registered office is located at Paasheuvelweg 25, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol &#x201c;QURE&#x201d;.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_ov7bFuILcES7CDVeW4rKTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;2&lt;/b&gt;&lt;/span&gt;Summary of significant accounting policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;2.1&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Basis of preparation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company prepared these unaudited consolidated financial statements in compliance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The unaudited consolidated financial statements are presented in U.S. dollars, except where otherwise indicated. Transactions denominated in currencies other than U.S. dollars are presented in the transaction currency with the U.S. dollar amount included in parenthesis, converted at the foreign exchange rate as of the transaction date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;2.2&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Unaudited interim financial information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the financial position, results of operations and changes in financial position for the period presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. The results of operations for the six months ended June 30, 2021, are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or for any other future year or interim period. The accompanying financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company&#x2019;s &lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm" style="-sec-extract:exhibit;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021&lt;/span&gt;&lt;/a&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;2.3&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;2.4&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Accounting policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      The principal accounting policies applied in the preparation of these unaudited consolidated financial statements are described in the Company&#x2019;s audited financial statements as of and for the year ended December 31, 2020, and the notes thereto, which are included in the Company&#x2019;s &lt;/span&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm" style="-sec-extract:exhibit;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021&lt;/span&gt;&lt;/a&gt;. There have been no material changes in the Company&#x2019;s significant accounting policies during the six months ended June 30, 2021 except as noted below. &lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company determined its revenue recognition policies related to the CSL Behring Agreement (defined below) when the CSL Behring Agreement became fully effective on May 6, 2021. Refer to Note 3 (&#x201c;Collaboration arrangements and concentration of credit risk&#x201d;) for further detail.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &lt;/span&gt;The Company for the first time recognized net income in the three and six months ended June 30, 2021. Net income / (loss) per ordinary share was calculated in accordance with ASC 260, Earnings Per Share. Refer to Note 11 (&#x201c;Basic and diluted earnings per share&#x201d;) for further detail. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;2.5&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Recent accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;There have been no new accounting pronouncements or changes to accounting pronouncements during the six months ended June 30, 2021, as compared to the recent accounting pronouncements described in Note 2.3.22 of the Company&#x2019;s &lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm" style="-sec-extract:exhibit;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Annual Report on Form 10-K for the year ended December 31, 2020&lt;/span&gt;&lt;/a&gt;, which could be expected to materially impact the Company&#x2019;s unaudited consolidated financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_JWe1WRCcZ0SJ_XKymTLfMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;2.1&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Basis of preparation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company prepared these unaudited consolidated financial statements in compliance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The unaudited consolidated financial statements are presented in U.S. dollars, except where otherwise indicated. Transactions denominated in currencies other than U.S. dollars are presented in the transaction currency with the U.S. dollar amount included in parenthesis, converted at the foreign exchange rate as of the transaction date.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <qure:UnauditedInterimFinancialInformationPolicyTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_iskgUAyBbkaW6qT3fxkfww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;2.2&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Unaudited interim financial information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the financial position, results of operations and changes in financial position for the period presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. The results of operations for the six months ended June 30, 2021, are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or for any other future year or interim period. The accompanying financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company&#x2019;s &lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm" style="-sec-extract:exhibit;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021&lt;/span&gt;&lt;/a&gt;.&lt;/p&gt;</qure:UnauditedInterimFinancialInformationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_ONLnhHa8r02K-T35tTv28Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;2.3&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_swB95WXlqUikie1EYGRMpA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;2.4&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Accounting policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      The principal accounting policies applied in the preparation of these unaudited consolidated financial statements are described in the Company&#x2019;s audited financial statements as of and for the year ended December 31, 2020, and the notes thereto, which are included in the Company&#x2019;s &lt;/span&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm" style="-sec-extract:exhibit;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021&lt;/span&gt;&lt;/a&gt;. There have been no material changes in the Company&#x2019;s significant accounting policies during the six months ended June 30, 2021 except as noted below. &lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company determined its revenue recognition policies related to the CSL Behring Agreement (defined below) when the CSL Behring Agreement became fully effective on May 6, 2021. Refer to Note 3 (&#x201c;Collaboration arrangements and concentration of credit risk&#x201d;) for further detail.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &lt;/span&gt;The Company for the first time recognized net income in the three and six months ended June 30, 2021. Net income / (loss) per ordinary share was calculated in accordance with ASC 260, Earnings Per Share. Refer to Note 11 (&#x201c;Basic and diluted earnings per share&#x201d;) for further detail. &lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_hTZv9IMilE6KxAcSQdE_fA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;2.5&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Recent accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;There have been no new accounting pronouncements or changes to accounting pronouncements during the six months ended June 30, 2021, as compared to the recent accounting pronouncements described in Note 2.3.22 of the Company&#x2019;s &lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm" style="-sec-extract:exhibit;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Annual Report on Form 10-K for the year ended December 31, 2020&lt;/span&gt;&lt;/a&gt;, which could be expected to materially impact the Company&#x2019;s unaudited consolidated financial statements. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <qure:CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_7yLf5xGe50Gnvor6-vOMnA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;Collaboration arrangements and concentration of credit risk&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;CSL Behring collaboration&lt;/span&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On June 24, 2020, (&#x201c;Signing&#x201d;), uniQure biopharma B.V., a wholly-owned subsidiary of uniQure N.V., entered into a commercialization and license agreement (the &#x201c;CSL Behring Agreement&#x201d;) with CSL Behring LLC, (&#x201c;CSL Behring&#x201d;), pursuant to which CSL Behring received exclusive global rights to etranacogene dezaparvovec, the Company&#x2019;s investigational gene therapy for patients with hemophilia B, (the &#x201c;Product&#x201d;). On May 6, 2021, the CSL Behring Agreement became fully effective (&#x201c;Closing&#x201d;) upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on May 5, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Pursuant to the CSL Behring Agreement, the Company has received a $450.0 million upfront cash payment and $12.4 million in other payments related to the transfer of the license, during the three and six months ended June 30, 2021. The Company is eligible to receive up to $1.6 billion in additional payments based on regulatory and commercial milestones. The CSL Behring Agreement also provides that the Company will be eligible to receive tiered double-digit royalties in a range of up to a low-twenties percent of net sales of the Product based on sales thresholds. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On Signing, the Company and CSL Behring entered into a development and commercial supply agreement, pursuant to which, among other things, the Company will supply the Product to CSL Behring at an agreed-upon price commensurate with the stand-alone selling price (&#x201c;SSP&#x201d;). The Company will be responsible for supplying development and commercial Product until such time that these capabilities may be transferred to CSL Behring or a designated contract manufacturing organization. The Company will be completing the HOPE-B clinical trial and the validation of the manufacturing process on behalf of CSL Behring, as well as provide further development services if requested by CSL Behring. Activities related to on-demand development services as well as activities related to the completing the HOPE-B clinical trial will be reimbursed by CSL Behring at an agreed full-time-employee rate (&#x201c;FTE-rate&#x201d;) and CSL Behring will also reimburse agreed third-party expenses incurred in relation to performing these activities. The validation of the manufacturing process as well as the development and validation of a next generation manufacturing process (&#x201c;Manufacturing Development Services&#x201d;) will be reimbursed through a future milestone payment. If completed after certain contractually agreed dates, the milestone payment will be reduced in accordance with a contractually agreed mechanism.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that CSL Behring is a customer in accordance with Topic 606. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company identified two material performance obligations related to the CSL Behring Agreement: &lt;/p&gt;&lt;div style="margin-top:6pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;"&gt;Sale of the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;"&gt;exclusive global rights to the Product (&#x201c;License&#x201d;); and&lt;/span&gt;&lt;/td&gt;&lt;td style="width:0.2pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;"&gt;Generate information to support the regulatory approval of the current and next generation manufacturing process of Product and to provide any such information generated to CSL Behring (&#x201c;Manufacturing Development&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;td style="width:0.2pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;These performance obligations are considered distinct from one another, as CSL Behring can benefit from the identified service either on its own or together with other resources that are readily available to CSL Behring, and as the performance obligation is separately identifiable from other performance obligations in the CSL Behring Agreement. The Company continued to develop the Product between Signing and Closing and performed certain reimbursable activities to fulfill the transfer of the global rights (&#x201c;Additional Covenants&#x201d; and together with the License the &#x201c;License Sale&#x201d;). The Additional Covenants are not considered distinct from the performance obligation to sell the license to CSL Behring as CSL Behring could not benefit from the Additional Covenants on their own, or have these activities be performed with readily available resources. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;The Company determined that the fixed upfront payment of &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$450.0&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt; million and the &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$12.4&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt; million that the Company received in relation to the Additional Covenants should be allocated to the License Sale. In addition, the Company concluded that variable milestone payments, sales milestone payments and royalties should be allocated to the License Sale performance obligation as well. The Company determined that the sale of the License was completed on May 6, 2021, when it transferred the License and CSL Behring assumed full responsibility for the development and commercialization of the Product. At Closing, the Company evaluated the amount of potential payments and the likelihood that the payments will be received. The Company utilized the most likely amount method to estimate the variable consideration to be included in the transaction price. Since the Company cannot control the achievement of regulatory and first commercial sales milestones, the Company concluded that the potential payments are constrained as of Closing. The Company determined that it will recognize revenue related to these payments only to the extent that it becomes probable that no significant reversal of recognized cumulative revenue will occur thereafter. The Company will include payments related to sales milestones in the transaction price when their achievement becomes probable, and it will include royalties on the sale of Product once these have been earned. The Company recognized &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$462.4&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt; million of revenues related to the License Sale in the three and six months ended June 30, 2021. The costs associated with fulfilling this performance obligation are presented as &#x201c;Cost of contract revenue&#x201d; with the exception of the cost incurred prior to the Closing, which had been presented as &#x201c;Research and development expenses&lt;/span&gt;&#x201d;. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;The Company determined that the variable milestone payment related to Manufacturing Development Services should be allocated to the Manufacturing Development performance obligation. The Company concluded that this milestone payment represents the SSP of the services based on the estimated cost of providing the services including a reasonable margin. The services related to Manufacturing Development will be provided between Closing and the completion of an agreed manufacturing development plan. The variable consideration will be reduced if the Company does not complete the development by pre-agreed dates. The Company utilized the most likely amount method to estimate the variable consideration to be included in the transaction price. Completion of Manufacturing Development is partially dependent on the timing of regulatory submissions by CSL Behring as well as regulatory approvals of the developed manufacturing processes. Since the Company cannot control the timing or outcome of any regulatory decisions, the Company concluded that it would recognize revenue related to this payment when it becomes probable that the milestone has been achieved. The Company did not recognize any revenue related to Manufacturing Development during the three and six months ended June 30, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;"&gt;The Company recognized $0.4 million of collaboration revenue in the three and six months ended June 30, 2021, compared to nil in the same periods in the prior year. &#160;The Company generates such collaboration revenue from services rendered in relation to completing the HOPE-B clinical trial on behalf of CSL Behring. CSL Behring may request &lt;span style="background-color:#ffffff;"&gt;additional development services or to request the Company to support the transfer of manufacturing to a party designated by CSL Behring. These collaboration services will be reimbursed at the pre-agreed FTE-rate. &lt;/span&gt;The Company concluded that these rights at Closing do not represent material rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt 0.2pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"/&gt;As of June 30, 2021, the Company has an accounts receivable of $1.3 million from CSL Behring. The Company collected the $2.1 million of accounts receivable related to reimbursable contract fulfillment costs that was outstanding as of December 31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Bristol-Myers Squibb collaboration&lt;/span&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In May 2015, the Company and Bristol-Myers Squibb (&#x201c;BMS&#x201d;) entered into a collaboration and license agreement and various related agreements with BMS (&#x201c;BMS CLA&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The initial four-year research term under the collaboration terminated on May 21, 2019. On December 1, 2020, the Company and BMS amended the BMS CLA (&#x201c;amended BMS CLA&#x201d;). Under the amended BMS CLA, BMS is limited to four Collaboration Targets. BMS may until November 30, 2021 replace up to two of these four Collaboration Targets with up to two new targets in the field of cardiovascular disease. The Company continues to be eligible to receive research, development, and regulatory milestone payments of up to $217.0 million for each Collaboration Target if defined milestones are achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;For as long as any of the four Collaboration Targets are being advanced, BMS may place a purchase order to be supplied with research, clinical and commercial supplies. Subject to the terms of the amended BMS CLA, BMS has the right to terminate the research, clinical and commercial supply relationships, and has certain remedies for failures of supply, up to and including technology transfer for any such failure that otherwise cannot be reasonably resolved. Both BMS and the Company may agree to a technology transfer of manufacturing capabilities pursuant to the terms of the amended BMS CLA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The amended BMS CLA does not extend the initial four-year research term. BMS may place purchase orders to provide limited services primarily related to analytical and development efforts in respect of the four Collaboration Targets. BMS may request such services for a period not to exceed the earlier of (i) the completion of all activities under a Research Plan and (ii) either (A) three years after the last replacement target has been designated by BMS during the one-year replacement period ending on November 30, 2021, or (B) November 30, 2023 if no replacement targets are designated. BMS continues to reimburse the Company for these services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company evaluated the impact of the amended BMS CLA in relation to its performance obligation to provide access to BMS to its technology and know-how in the field of gene therapy and to participate in joint steering committee and other governing bodies (&#x201c;License Revenue&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company determined that its remaining performance obligation under the amended BMS CLA was immaterial and recognized the remaining balance of unrecognized License Revenue as of November 30, 2020. The Company includes variable consideration related to any research, development, and regulatory milestone payments, in the transaction price once it is considered probable that including these payments in the transaction price would not result in the reversal of cumulative revenue recognized. Due to the significant uncertainty surrounding the development of gene-therapy product candidates and the dependence on BMS&#x2019;s performance and decisions, the Company does not generally consider this probable and did not record any License Revenue during the six months ended June 30, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"/&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; &#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="display:inline-block;width:18pt;"/&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</qure:CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock>
    <qure:UpfrontCashToReceiveUponClosingOfAgreement
      contextRef="Duration_6_24_2020_To_6_24_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_Ll8fzwuH2kqanQly9paw0w"
      decimals="-5"
      id="Narr_qeBq5bewL0WaqIoDJ0vOZA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">450000000.0</qure:UpfrontCashToReceiveUponClosingOfAgreement>
    <qure:CollaborationAgreementOtherPaymentsReceived
      contextRef="Duration_6_24_2021_To_6_24_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_BpZu_RynUUeTx_oJ_rCgLA"
      decimals="-5"
      id="Narr_Qd9v3K_CDk6nOM-54nkMCw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">12400000</qure:CollaborationAgreementOtherPaymentsReceived>
    <qure:RegulatoryAndCommercialMilestonePaymentsReceivable
      contextRef="As_Of_6_24_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_qg5NvBFGdUO4WsF-xZGEIA"
      decimals="-8"
      id="Narr_j455ffqOAUO-hx4syerFtw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1600000000</qure:RegulatoryAndCommercialMilestonePaymentsReceivable>
    <qure:UpfrontCashToReceiveUponClosingOfAgreement
      contextRef="Duration_6_24_2021_To_6_24_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_BpZu_RynUUeTx_oJ_rCgLA"
      decimals="-5"
      id="Narr_zLBWgS4wFkiRg8qGDeOzQA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">450000000.0</qure:UpfrontCashToReceiveUponClosingOfAgreement>
    <qure:CollaborationAgreementOtherPaymentsReceived
      contextRef="Duration_6_24_2021_To_6_24_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_BpZu_RynUUeTx_oJ_rCgLA"
      decimals="-5"
      id="Narr_Ug32I5hycUigE4BkUyw9eA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">12400000</qure:CollaborationAgreementOtherPaymentsReceived>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_iR-v-TBnd0evOoVwhDOfvA"
      decimals="-5"
      id="Narr_UA10CTDvRkeGAFfR7pOrRQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">462400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_7HYeLAkKd06-2u6h39LYwg"
      decimals="-5"
      id="Narr_TKneex5G1EG1m_7KPEtK7g"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">462400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_jB8MZBGsWEasEDd9-gnQoA"
      decimals="-5"
      id="Narr_CoQPzIbOlEuVv3QcFcvZLw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_J6tdEUumu0qt9JK5Mqjr8Q"
      decimals="-5"
      id="Narr_4jPSXZpSoU-KC-bhoDTkUA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_srt_ProductOrServiceAxis_qure_CollaborativeRevenueMember_-pQINOMXokKJREGZdwpa4A"
      decimals="-5"
      id="Narr_Cu_qPbqSiEuQbgLdce26wA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_igOZK4wZWEOra8bKTcWHwQ"
      decimals="-5"
      id="Narr_IzDlp9BElkGKHGQN0sKvcw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_eXzdB_wPDkSlyzIUnaikng"
      decimals="-5"
      id="Narr_EJ8lHqoBtkKQMzDLjCUGRw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2100000</us-gaap:AccountsReceivableNetCurrent>
    <qure:InitialResearchTerm
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_wO4YQLjtzUyL7xfd70wfWA"
      id="Narr_e2U8JeayAEaqEBGTRlCMUA">P4Y</qure:InitialResearchTerm>
    <qure:NumberOfCollaborationTargets
      contextRef="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ"
      decimals="INF"
      id="Narr_l9aA1khLOEOhy5a8p_GftA"
      unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA">4</qure:NumberOfCollaborationTargets>
    <qure:CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced
      contextRef="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ"
      decimals="INF"
      id="Narr_3BkZnptCbEqqFkAtwwt14g"
      unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA">2</qure:CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced>
    <qure:NumberOfCollaborationTargets
      contextRef="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ"
      decimals="INF"
      id="Narr_bFan7o1T40OKM8-dgDldrw"
      unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA">4</qure:NumberOfCollaborationTargets>
    <qure:ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease
      contextRef="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ"
      decimals="INF"
      id="Narr_D7yuICdGtkCYsUXZnRC5BQ"
      unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA">2</qure:ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease>
    <qure:CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable
      contextRef="As_Of_12_1_2020_dei_LegalEntityAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_y8tWzFCmok2XCsAFfg-1mw"
      decimals="-5"
      id="Narr_tNk0p-BbtUC7bs6Gt8m8eg"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">217000000.0</qure:CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable>
    <qure:NumberOfCollaborationTargets
      contextRef="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ"
      decimals="INF"
      id="Narr_o09lZevidky8SXEEC00ORA"
      unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA">4</qure:NumberOfCollaborationTargets>
    <qure:InitialResearchTerm
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_wO4YQLjtzUyL7xfd70wfWA"
      id="Narr_FXFy9B0LikKAs1adB66Qlw">P4Y</qure:InitialResearchTerm>
    <qure:NumberOfCollaborationTargets
      contextRef="Duration_12_1_2020_To_12_1_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tWQ5n8mTxUO1BZI4E8IcfQ"
      decimals="INF"
      id="Narr_7M56PzxgA0eWaTlSj7KeJg"
      unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA">4</qure:NumberOfCollaborationTargets>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_qure_CollaborativeArrangementLicenseRevenueMember_hIrNE1yg2EeFUIy3Z5A96A"
      decimals="-5"
      id="Narr_1q00us9C2k-bCHDdU3uc7Q"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_Lf8lze1oq0qlTklV9dA7YQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"&gt;4&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-size:5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;Fair value measurement&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company measures certain financial assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. U.S. GAAP requires disclosure of methodologies used in determining the reported fair values, and establishes a hierarchy of inputs used when available. The three levels of the fair value hierarchy are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 1 &#x2013; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 2 &#x2013; Valuations based on quoted prices for similar assets or liabilities in markets that are not active or models for which the inputs are observable, either directly or indirectly. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 3 &#x2013; Valuations that require inputs that reflect the Company&#x2019;s own assumptions that are both significant to the fair value measurement and are unobservable. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The carrying amount of cash and cash equivalents, accounts receivable, prepaid expenses, other assets, accounts payable, accrued expenses and other current liabilities reflected in the Consolidated balance sheets approximate their fair values due to their short-term maturities. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table sets forth the Company&#x2019;s assets and liabilities that are required to be measured at fair value on a recurring basis as of June 30, 2021, and December 31, 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&lt;br/&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&#160;in&#160;Consolidated&lt;br/&gt;balance&#160;sheets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="15" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:top;width:38.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 247,680&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 247,680&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Cash and cash equivalents; other non-current assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 247,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 247,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Derivative financial instruments &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Other non-current liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At June&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 680,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 680,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Cash and cash equivalents; other non-current assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 680,158&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 680,158&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Derivative financial instruments &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Other non-current liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company recognized no gains or losses related to changes in the fair market value of derivative financial instruments during the three and six months ended June 30, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 41pt;"&gt;Derivative financial instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 41pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company issued derivative financial instruments related to its collaboration with BMS. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.3pt;margin:0pt 0pt 0pt 5.75pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In 2015, the Company granted BMS two warrants that were subsequently terminated in connection with the amendment to the BMS CLA on December 1, 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On December 1, 2020, the Company and BMS agreed that upon the consummation of a change of control transaction of uniQure that occurs prior to December 1, 2026 or BMS&#x2019; delivery of a target cessation notice for all four Collaboration Targets, the Company (or its third party acquirer) shall pay to BMS a one-time, non-refundable, non-creditable cash payment of $70.0 million, provided that (x) if $70.0 million is greater than five percent (5.0%) of the net proceeds (as contractually defined) from such change of control transaction, the payment shall be an amount equal to five percent of such net proceeds, and (y) if $70.0 million is less than one percent of such net proceeds, the change of control payment shall be an amount equal to one percent of such net proceeds (&#x201c;CoC-payment&#x201d;). The Company has not consummated any change of control transaction as of June 30, 2021 that would obligate it to make a CoC-payment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company determined that the CoC-payment should be recorded as a derivative financial liability as of December 1, 2020 and that subsequent changes in the fair market value of this derivative financial liability should be recorded in profit and loss. The fair market value of the derivative financial liability is materially impacted by probability that market participants assign to the likelihood of the occurrence of a change of control transaction that would give rise to a CoC-payment. This probability represents an unobservable input. The Company determined the fair market value of the derivative financial liability by using a present value model based on expected cash flow. The expected cash flows are materially impacted by the probability that market participants assign to the likelihood of the occurrence of a change of control transaction within the biotechnology industry. The Company estimated this unobservable input using the best information available as of June 30, 2021 and December 31, 2020. The Company obtained reasonably available market information that it believed market participants would use in determining the likelihood of the occurrence of a change-of control transaction within the biotechnology industry. Selecting and evaluating market information involves considerable judgement and uncertainty. Based on all such information and its judgment the Company estimated that the fair market value of the derivative financial liability (presented within &#x201c;Other non-current liabilities&#x201d;) as of June 30, 2021 and December 31, 2020 was $2.6 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_vbWeB3OhLk6tVrPK5BqkVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&lt;br/&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&#160;in&#160;Consolidated&lt;br/&gt;balance&#160;sheets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="15" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:top;width:38.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 247,680&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 247,680&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Cash and cash equivalents; other non-current assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 247,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 247,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Derivative financial instruments &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Other non-current liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At June&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 680,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 680,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Cash and cash equivalents; other non-current assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 680,158&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 680,158&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Derivative financial instruments &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Other non-current liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fJtKgxuUvkyrzU-RtzqAcw"
      decimals="-3"
      id="Tc_H3Nivdjj8UmnotqR9oZZ_Q_5_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">247680000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kImN7dQ-PUeOCHGKL1wPsQ"
      decimals="-3"
      id="Tc_DNb8MOg18EOnkN6CUTkATA_5_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">247680000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fJtKgxuUvkyrzU-RtzqAcw"
      decimals="-3"
      id="Tc_kqDm60AHmU61BWvfWXmhwQ_6_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">247680000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kImN7dQ-PUeOCHGKL1wPsQ"
      decimals="-3"
      id="Tc_-M1Ui1AwIECls60k6N6rVA_6_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">247680000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_JOuPA4_0AkS3D-CstJPyIw"
      decimals="-3"
      id="Tc_l7XY-Zm9N0uTuUJUcxL9xA_8_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2645000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kImN7dQ-PUeOCHGKL1wPsQ"
      decimals="-3"
      id="Tc_81qieV1yok26otRujgrr8Q_8_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2645000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_JOuPA4_0AkS3D-CstJPyIw"
      decimals="-3"
      id="Tc_qgxhT9MjW0yjuLNiSy1ZDw_9_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2645000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kImN7dQ-PUeOCHGKL1wPsQ"
      decimals="-3"
      id="Tc_27pVzWpaTkyOCvIRNW-RSQ_9_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2645000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7OFIcgQjGUKozaeCn_JOaQ"
      decimals="-3"
      id="Tc_7G1bvDlxGkWNcmrroxSKTQ_12_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">680158000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_6_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wAnsudVWJ0eStn1YOEaRPQ"
      decimals="-3"
      id="Tc_Tq_TjM5PR0qzdETKqfGYhg_12_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">680158000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7OFIcgQjGUKozaeCn_JOaQ"
      decimals="-3"
      id="Tc_BK21Z1g7qUyOMZsRQdG0kg_13_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">680158000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_6_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wAnsudVWJ0eStn1YOEaRPQ"
      decimals="-3"
      id="Tc_lXXPPEtnw0Wq8IcjUTRQrA_13_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">680158000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1TMDu79eQ0e28WbVBlbIAg"
      decimals="-3"
      id="Tc_pLK8fpLp0EacS-lyAL6lbA_15_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2645000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_6_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wAnsudVWJ0eStn1YOEaRPQ"
      decimals="-3"
      id="Tc_Mq4A9qzN4UunIy6CarOm1Q_15_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2645000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1TMDu79eQ0e28WbVBlbIAg"
      decimals="-3"
      id="Tc_xY9aBqy5TkOYs8JSgvfM_A_16_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2645000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_6_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wAnsudVWJ0eStn1YOEaRPQ"
      decimals="-3"
      id="Tc_1IudQtn6DUyi6iylPtot7Q_16_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2645000</us-gaap:LiabilitiesFairValueDisclosure>
    <qure:GainLossOnRecognitionOfDerivatives
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="0"
      id="Narr_kNbCcRMUsU61xGddXFrQfg"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">0</qure:GainLossOnRecognitionOfDerivatives>
    <qure:GainLossOnRecognitionOfDerivatives
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="0"
      id="Narr_gR4YV1d2tkWPXADIaoJfig"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">0</qure:GainLossOnRecognitionOfDerivatives>
    <qure:NumberOfWarrantTypes
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="INF"
      id="Narr_teVcoXqq60yskdVTqgMiFg"
      unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA">2</qure:NumberOfWarrantTypes>
    <qure:NumberOfCollaborationTargets
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="INF"
      id="Narr_3hpLKh2sUUa8JP8ymDwtzg"
      unitRef="Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA">4</qure:NumberOfCollaborationTargets>
    <qure:CollaborationAgreementCashPayable
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-5"
      id="Narr_Qk4XdFPA9EmSaU0YZgGtWQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">70000000.0</qure:CollaborationAgreementCashPayable>
    <qure:CollaborationAgreementCashPayable
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-5"
      id="Narr_06Mzopoj6E-dK4vWfXLq6w"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">70000000.0</qure:CollaborationAgreementCashPayable>
    <qure:ThresholdPercentageOfNetProceeds
      contextRef="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_0kUnhi7n702ffhqbWEJJFw"
      decimals="0"
      id="Narr_0uY1iIqfiUiPj-mpEymafg"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">5</qure:ThresholdPercentageOfNetProceeds>
    <qure:ThresholdPercentageOfNetProceeds
      contextRef="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_0kUnhi7n702ffhqbWEJJFw"
      decimals="1"
      id="Narr_AZtyrA57DkuekA6i4H2e1g"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">5.0</qure:ThresholdPercentageOfNetProceeds>
    <qure:PercentageOfNetProceedsPayable
      contextRef="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_0kUnhi7n702ffhqbWEJJFw"
      decimals="0"
      id="Narr_FMtr8cmeGk-YFQYg2chkoQ"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">5</qure:PercentageOfNetProceedsPayable>
    <qure:CollaborationAgreementCashPayable
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-5"
      id="Narr_QTa0lF4D2UujgFoTqJPvvA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">70000000.0</qure:CollaborationAgreementCashPayable>
    <qure:ThresholdPercentageOfNetProceeds
      contextRef="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_7EhntjUcpUyhyXRTh2k0Nw"
      decimals="0"
      id="Narr_AGYIlZeZwEiAs_fhHQdq5g"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">1</qure:ThresholdPercentageOfNetProceeds>
    <qure:PercentageOfNetProceedsPayable
      contextRef="As_Of_6_30_2021_srt_StatementScenarioAxis_qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember_us-gaap_ClassOfWarrantOrRightAxis_qure_DerecognitionOfWarrantsMember_7EhntjUcpUyhyXRTh2k0Nw"
      decimals="0"
      id="Narr_NKGIqBUQI0Kwqo2jixCQ9w"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">1</qure:PercentageOfNetProceedsPayable>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="As_Of_6_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_dtZW9N0cZUGKCdQgqHQtOg"
      decimals="-5"
      id="Narr_ppY8MGS70UGFdQV2UxjC8w"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_4uX4YOxCI0Ku1yrWU3Qr-A"
      decimals="-5"
      id="Narr_S4aASXc7nEOuUOvIp41bdw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <qure:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_cY7tbaJVAUqoSFJqzqxBdQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;5&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;Accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accrued expenses and other current liabilities include the following items:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accruals for services provided by vendors-not yet billed&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,734&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,269&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel related accruals and liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,687&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liability&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,082&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 23,526&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 18,038&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</qure:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_o0Q0XfR5xEi5CQOPXGQFxA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accruals for services provided by vendors-not yet billed&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,734&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,269&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel related accruals and liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,687&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liability&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,082&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 23,526&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 18,038&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <qure:AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_WLTME-ISh0aZUPAYJwXlEQ_4_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">16734000</qure:AccrualsForServicesProvidedByVendorsNotYetBilledCurrent>
    <qure:AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_JesD44yksUOYXTeOdCZ9vg_4_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">8269000</qure:AccrualsForServicesProvidedByVendorsNotYetBilledCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_Jp9TcX76RUeN4YPLjw_xfw_5_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">6792000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_GzU_RazayECW5BZTzdBThA_5_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">7687000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_UusDTfVgEEWpylNdeIRZGQ_6_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2082000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-3"
      id="Tc_fBt1TTQ3OU2NuQbfpzcG8Q_7_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">23526000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_fWm4ihvS00G01RXPVLBZZw"
      decimals="-3"
      id="Tc_VZCtkNnplkCme7XVBwM3-A_7_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">18038000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb__JS9vld-_0eBE7oQndsAaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;6 &lt;/b&gt;&lt;/span&gt;&lt;span style="display:inline-block;width:18pt;"/&gt;&lt;b style="font-weight:bold;"&gt;Long-term debt&lt;/b&gt;&lt;span style="display:inline-block;width:4.51pt;"/&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"&gt;On June 14, 2013, the Company entered into a venture debt loan facility with Hercules Capital, Inc. (formerly known as Hercules Technology Growth Capital, Inc.) (&#x201c;Hercules&#x201d;), which was amended and restated on June 26, 2014, and again on May 6, 2016 (&#x201c;2016 Amended Facility&#x201d;). On December 6, 2018, the Company signed an amendment that both refinanced the then-existing $20.0 million 2016 Amended Facility and allowed the Company to draw down an additional $15.0 million (&#x201c;2018 Amended Facility&#x201d;). The 2018 Amended Facility extended the loan&#x2019;s maturity date from May 1, 2020 until June&#160;1, 2023.&#160;The interest-only period was initially extended from November&#160;2018 to January&#160;1, 2021 and was further extended to January 1, 2022 as a result of raising more than $90.0 million in equity financing in September 2019.&#160;The interest only period was again further extended to June 1, 2023 as a result of the January 2021 amendment (see below). &#160;The interest rate is adjustable and is the greater of (i)&#160;8.85% and (ii)&#160;8.85% plus the prime rate less 5.50% per annum. Under the 2018 Amended Facility, the Company owes a back-end fee of 4.95% of the outstanding debt. In addition, in May 2020 the Company paid a back-end fee of $1.0 million in relation to the 2016 Amended Facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;On January 29, 2021, the Company and Hercules amended the 2018 Amended Facility (&#x201c;2021 Amended Facility&#x201d;). Pursuant to the 2021 Amended Facility, Hercules agreed to an additional Facility of &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$100.0&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt; million (&#x201c;Tranche B&#x201d;), increasing the aggregate principal amount of the term loan facilities from &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$35.0&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;million to up to &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$135.0&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;million. On January 29, 2021, the Company drew down &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$35.0&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;million of the Tranche B. The Company may draw down the remaining &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$65.0&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;million under the Tranche B in a series of one or more advances of not less than &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$20.0&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;million each until December 15, 2021. Advances under Tranche B bear interest at a rate equal to the greater of (i)&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;8.25%&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt; or (ii)&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;8.25%&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt; plus the prime rate, less&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;3.25%&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt; per annum. The principal balance and all accrued but unpaid interest on advances under Tranche B is due on June 1, 2023, which date may be extended by the Company by up to two twelve-month periods. Advances under Tranche B may not be prepaid prior to July 29, 2021, following which the Company may prepay all such advances without charge. &lt;/span&gt;The Company owes a back-end fee of 4.85% of amounts outstanding under Tranche B. The back-end fee is reduced if prepayment occurs at an earlier date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"&gt;The amortized cost (including interest due presented as part of accrued expenses and other current liabilities) of the 2018 Amended Facility and 2021 Amended Facility was $71.3 million as of June 30, 2021, compared to $35.9 million amortized cost for the 2018 Amended Facility as of December 31, 2020, and is recorded net of discount and debt issuance costs. The foreign currency gain on the facilities in the three months ended June 30, 2021, was $0.9 million and the foreign currency loss on the facilities in the six months ended June 30, 2021, was $2.2 million, compared to a foreign currency gain of $0.7 million and $0.0 million during the same periods in 2020 for the 2018 Amended Facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"&gt;Interest expense associated with the 2018 Amended Facility and 2021 Amended Facility during the three and six months ended June 30, 2021, was $1.8 million and $3.4 million, compared to $0.9 million and $1.8 million, respectively, during the same periods in 2020 for the 2018 Amended Facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"&gt;As a covenant in the 2018 Amended Facility and 2021 Amended Facility, the Company has periodic reporting requirements and is required to keep a minimum cash balance deposited in bank accounts in the United States, equivalent to the lesser of (i) 65% of the outstanding balance of principal due or (ii) 100% of worldwide cash and cash equivalents. This restriction on cash and cash equivalents only relates to the location of the cash and cash equivalents, and such cash and cash equivalents can be used at the discretion of the Company. In combination with other covenants, the 2018 Amended Facility and 2021 Amended Facility restricts the Company&#x2019;s ability to, among other things, incur future indebtedness and obtain additional debt financing, to make investments in securities or in other companies, to transfer assets, to perform certain corporate changes, to make loans to employees, officers, and directors, and to make dividend payments and other distributions to its shareholders. The Company secured the facilities by directly or indirectly pledging its total assets of $784.3 million with the exception of $103.5 million of cash and cash equivalents and other current assets held by uniQure N.V.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"&gt;The 2018 Amended Facility and 2021 Amended Facility contain provisions that include the occurrence of a material adverse effect, as defined therein, which would entitle Hercules to declare all principal, interest and other amounts owed by the Company immediately due and payable. As of June 30, 2021, the Company was in material compliance with all covenants and provisions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCredit
      contextRef="As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2016Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_931tErLp7EuUinvtjRhPIg"
      decimals="-5"
      id="Narr_YAr44hBjREatKo-BsT71gw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">20000000.0</us-gaap:LineOfCredit>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_12_6_2018_To_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_Faze52U7JEmiziY1euKKaA"
      decimals="-5"
      id="Narr_yovk4G996E2EYkJeI1FhBA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">15000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <qure:DebtInstrumentAggregateAmountOfEquityFinancing
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_Lkz8BWrtm0OghqMAcJ8NmA"
      decimals="-5"
      id="Narr_Q5CAP3x3PEu-PfDVFqLVMQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">90000000.0</qure:DebtInstrumentAggregateAmountOfEquityFinancing>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_CfO51mljJ0eWh8ZOXwfRNQ"
      decimals="INF"
      id="Narr_zC1_IJjtCE2aZCRnRv8PyA"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0885</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_12_6_2018_To_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_jJzGBF12x0arzA2m_P93oA"
      decimals="4"
      id="Narr__4d8AoN2tk2zDQvgK2NvhA"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0885</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <qure:DebtInstrumentInterestRateDiscountRatePercentage
      contextRef="As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_Eyl_r3-QvkyaUu52pRzIrg"
      decimals="4"
      id="Narr_LPmP7MA6-0Kqp80KMpzGjg"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0550</qure:DebtInstrumentInterestRateDiscountRatePercentage>
    <qure:DebtInstrumentBackEndFeePercentage
      contextRef="Duration_12_6_2018_To_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_Faze52U7JEmiziY1euKKaA"
      decimals="4"
      id="Narr_HOX2g2sv7k-tVw5KcBLjwQ"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0495</qure:DebtInstrumentBackEndFeePercentage>
    <qure:DebtInstrumentBackEndFeeOne
      contextRef="As_Of_5_31_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2016Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_Y21A5QNU90qnhAq2_ca6ig"
      decimals="-5"
      id="Narr_7GSnrhAo3kiD0WTDxRcowQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1000000.0</qure:DebtInstrumentBackEndFeeOne>
    <qure:AdditionalUnconditionalBorrowingCapacity
      contextRef="As_Of_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_kzh0NdwaSkOA9RR8biOrAg"
      decimals="-5"
      id="Narr_aD6dNTBK50qzFYDddO_AEg"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">100000000.0</qure:AdditionalUnconditionalBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="As_Of_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_kzh0NdwaSkOA9RR8biOrAg"
      decimals="-5"
      id="Narr_cYjZYRLGCE-l2Gzash90mQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">35000000.0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_kzh0NdwaSkOA9RR8biOrAg"
      decimals="-5"
      id="Narr_QVLe67mZuEOimwDz82mGEA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">135000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="Duration_1_29_2021_To_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_VTx12u2MvECweTY9rrMN2w"
      decimals="-5"
      id="Narr_cwqq4qhoYU2h12TuLeHo4w"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">35000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCredit
      contextRef="As_Of_12_15_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1_tWzno1-kmrzxYDHva6OA"
      decimals="-5"
      id="Narr_81JPSqK3WU2JcbEwO8azKg"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">65000000.0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="As_Of_12_15_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Hb9YyYVIVki_vUupPUugtQ"
      decimals="-5"
      id="Narr_NJWLcrtZ3kO8KVGN0Na1AQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">20000000.0</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_kzh0NdwaSkOA9RR8biOrAg"
      decimals="4"
      id="Narr_IWIkxsXVzEWteApSV8njaQ"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0825</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_kzh0NdwaSkOA9RR8biOrAg"
      decimals="4"
      id="Narr_Ldp-4PqVKEWwqXcukhpKFg"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0825</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_29_2021_To_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_1Xb1Y17A2U231__SZnvguA"
      decimals="4"
      id="Narr_MLeRawGDg0-ObGUmVrfX8Q"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0325</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <qure:DebtInstrumentBackEndFeePercentage
      contextRef="Duration_1_29_2021_To_1_29_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2021Member_VTx12u2MvECweTY9rrMN2w"
      decimals="4"
      id="Narr_T9V6EBjm6UqZEqEWpEu-GQ"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0485</qure:DebtInstrumentBackEndFeePercentage>
    <us-gaap:LongTermDebt
      contextRef="As_Of_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_MJTl_-uIN0WiFf9AUkk7rQ"
      decimals="-5"
      id="Narr_Qxkr0xcrR0SrdNWNfWVkTQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">71300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_YpwOrDxTvEiUCcfw64tNMA"
      decimals="-5"
      id="Narr_XzLZN4SZKEec4v3Eaqk8pg"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">35900000</us-gaap:LongTermDebt>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_4CW_DXp0Ok6hoLPlu21sQg"
      decimals="-5"
      id="Narr_kTHdCm4TtUS21KLzNdhUsw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">900000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_1sldxuu9EUKBKyfO334l3g"
      decimals="-5"
      id="Narr_e9vKrVRLAkuo5yaB7Gc8nA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2200000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_hv6WtwS-cEGRKyupdp3QwA"
      decimals="-5"
      id="Narr_XbO-9ZyqbEaUadBq8s0xEw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">700000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_q56A2rcme0OqndPdj4St-Q"
      decimals="-5"
      id="Narr_Z55qWGXjaUCIECfqB-4ysA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">0.0</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_rsKxoYBI-UKgNQ9ydk4pHA"
      decimals="-5"
      id="Narr_LYmLQ5CwukSFe3k7A4NOzg"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1800000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_su0H_LmbCk-jIOvLYq58hA"
      decimals="-5"
      id="Narr_KV5xDQRoEEO9ry1YMPFGfw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3400000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_CeTx4ptjcEaRDCkpZ_Y8fw"
      decimals="-5"
      id="Narr_kICTi_puwkWCLzqz35UkoA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">900000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_WvP6wlihOUS6tnrgQEZHWg"
      decimals="-5"
      id="Narr_U5DkHVZaP0S00cD2Ov_o0A"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1800000</us-gaap:InterestExpenseDebt>
    <qure:DebtInstrumentPercentageOfWorldwideCashReserves
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_uevJahvpyU2rrC71LQx_GA"
      decimals="2"
      id="Narr_TSooilrhA0arjWk_PmocnA"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.65</qure:DebtInstrumentPercentageOfWorldwideCashReserves>
    <qure:AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_uevJahvpyU2rrC71LQx_GA"
      decimals="-5"
      id="Narr_WCkYZcSwUkCRRgVu6yTrXA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">784300000</qure:AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly>
    <qure:AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_CreditFacilityAxis_qure_AmendedFacility2018And2021Member_us-gaap_DebtInstrumentAxis_qure_VentureDebtLoanFacilityWithHerculesMember_uevJahvpyU2rrC71LQx_GA"
      decimals="-5"
      id="Narr_2QU3a3Hf9UmoDZrn8w0voQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">103500000</qure:AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_BFuTfI5sI06fp52TgQx_Zw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;7&lt;/b&gt;&lt;/span&gt;&lt;span style="display:inline-block;width:18pt;"/&gt;Shareholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On March 1, 2021, the Company entered into a Sales Agreement with SVB Leerink LLC (&#x201c;SVB Leerink&#x201d;) with respect to an at-the-market (&#x201c;ATM&#x201d;) offering program, under which the Company may, from time to time in its sole discretion, offer and sell through SVB Leerink, acting as agent, its ordinary shares, up to an aggregate offering price of $200.0 million. The Company will pay SVB Leerink a commission equal to 3% of the gross proceeds of the sales price of all ordinary shares sold through it as sales agent under the Sales Agreement. In March and April 2021, the Company issued 921,730 ordinary shares at a weighted average price of $33.52 per share, with net proceeds of $29.6 million, after deducting underwriting discounts and net of offering expenses. The Company defers direct, incremental costs associated to this offering, except for the commission costs to SVB Leerink, which are a reduction to additional paid-in capital, and will deduct these costs from additional paid-in capital in the consolidated balance sheets proportionately to the amount of proceeds raised. During the three and six months ended June 30, 2021, $0.3 million and $1.3 million of direct, incremental costs were deducted from additional paid-in capital. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Following the release of the valuation allowance related to the years 2011 to 2018, the Company recognized the tax benefits of share issuance costs incurred in 2014, 2015, 2017 and 2018. This resulted in an increase of additional paid-in capital of $3.0 million in the three and six months ended June 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_3_1_2021_To_3_1_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_orachVcrO0W16h4VtfgGfQ"
      decimals="-5"
      id="Narr_DEjLMJSrrk6XQJgcp9Z0PQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">200000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <qure:PercentageOfGrossProceedsOfSharesSold
      contextRef="Duration_3_1_2021_To_3_1_2021_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_H93jbZY3yUCB1OwXUnoDlA"
      decimals="2"
      id="Narr_eWev2cYlt0Os0CaEKYIBUw"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.03</qure:PercentageOfGrossProceedsOfSharesSold>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2021_To_4_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_OssqgnSTskC6WxJuHZafpw"
      decimals="0"
      id="Narr__nLDCRiWGUSSzOyJD0niRw"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">921730</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_4_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_PuxofUyxYUyj1pHnYLQF2Q"
      decimals="2"
      id="Narr_a1I8MVJOkUe2KHVOGRKRdg"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">33.52</us-gaap:SharePrice>
    <qure:NetProceedsFromIssuanceOfShares
      contextRef="Duration_3_1_2021_To_4_30_2021_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_98YVZPFE5kO5F_BzYuxpRQ"
      decimals="-5"
      id="Narr_P5kWIEjKAUeBx5JuVij7WA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">29600000</qure:NetProceedsFromIssuanceOfShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_qure_DirectIncrementalLaborMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_MtE5A0KG6067RmXlMj46FA"
      decimals="-5"
      id="Narr_47KmSZfMuUWNDdydq2TijA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_qure_DirectIncrementalLaborMember_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_H4D4ClXlxkaceIkX1aMBWQ"
      decimals="-5"
      id="Narr_G2uqob_9MEito8HOinG2Dg"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-5"
      id="Narr_0jpS3537dkq-YhrojRW_LA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3000000.0</qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears>
    <qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-5"
      id="Narr_tcOO1dq2JkGrOHhs_R0hMQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3000000.0</qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_sfOOhfWHk0KJqFWtG5TM5w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;8&lt;/b&gt;&lt;/span&gt;&lt;span style="display:inline-block;width:18pt;"/&gt;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;The Company&#x2019;s share-based compensation plans include the 2014 Amended and Restated Share Option Plan (the &#x201c;2014 Plan&#x201d;) and inducement grants under Rule 5653(c)(4) of the Nasdaq Global Select Market with terms similar to the 2014 Plan (together the &#x201c;2014 Plans&#x201d;). At the annual general meeting of shareholders in June 2021, the Company&#x2019;s shareholders approved amendments of the 2014 Plan, increasing the shares authorized for issuance by&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;4,000,000&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;to a total of&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;12,601,471&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;.&lt;/span&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background-color:#ffffff;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;2014 Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Share-based compensation expense recognized by classification included in the Consolidated statements of operations and comprehensive loss in relation to the 2014 Plans for the periods indicated below was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.25%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,286&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,889&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,960&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,735&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,825&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,714&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,775&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,054&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;Share-based compensation expense recognized by award type was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.25%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:22.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Award type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted share units&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,222&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,209&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,782&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,653&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Performance share units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 759&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,714&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,775&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,054&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of June 30, 2021, the unrecognized share-based compensation expense related to unvested awards under the 2014 Plans were:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrecognized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share-based&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;compensation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;period for &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;recognition&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Award type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.99&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted share units&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,960&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Performance share units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.58&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 60,607&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2.66&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company satisfies the exercise of share options and vesting of Restricted Share Units (&#x201c;RSUs&#x201d;) and Performance Share Units (&#x201c;PSUs&#x201d;) through newly issued ordinary shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Share options&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"&gt;Share options are priced on the date of grant and, except for certain grants made to non-executive directors, vest over a period of four years. The first 25% vests after one year from the initial grant date and the remainder vests in equal quarterly installments over years two, three and four. Certain grants to non-executive directors vest in full after one year. Any options that vest must be exercised by the tenth anniversary of the initial grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;       &lt;/span&gt;The following tables summarize option activity under the Company&#x2019;s 2014 Plans for the six months ended June 30, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;average &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ordinary shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,659,279&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 28.13&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 914,118&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36.36&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (74,397)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43.19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,093)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44.14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,976)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at June&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,417,931&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 30.29&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereof, fully vested and exercisable at June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,774,059&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.68&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereof, outstanding and expected to vest after June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,643,872&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39.58&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total weighted average grant date fair value of options issued during the period (in $ millions)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Proceeds from option sales during the period (in $ millions)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The fair value of each option issued is estimated at the respective grant date using the Hull &amp;amp; White option pricing model with the following weighted-average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.01%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assumptions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;75%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;70%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;75%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;70%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected terms&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;1.72% - 1.85%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;0.76% - 0.83%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;1.21% - 1.85%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;0.76% - 1.44%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Restricted share units (&#x201c;RSUs&#x201d;) &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the RSUs activity for the six months ended June 30, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;RSU&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;grant-date fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ordinary shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-vested at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 467,344&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 43.56&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 481,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (145,203)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,067)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42.86&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-vested at June&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 772,895&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 39.87&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total weighted average grant date fair value of RSUs granted during the period (in $ millions)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;RSUs vest over &lt;span style="-sec-ix-hidden:Hidden_MCRGihcaXES2tnUHXX0Fgg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;one&lt;/span&gt;&lt;/span&gt; to three years. RSUs granted to non-executive directors vest one year from the date of grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Performance share units (&#x201c;PSUs&#x201d;)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"&gt;The following table summarizes the PSUs activity for the six months ended June 30, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PSU&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;grant-date fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ordinary shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-vested at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 212,614&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 42.32&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (132,368)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33.09&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,916)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57.56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-vested at June&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 77,330&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 57.56&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.7pt 0pt 5pt;"&gt;The PSUs will vest on the third anniversary of the grant, subject to the grantee&#x2019;s continued employment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 5pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Employee Share Purchase Plan (&#x201c;ESPP&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 5.05pt;"&gt;&lt;span style="font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 5.05pt;"&gt;In June 2018, the Company&#x2019;s shareholders adopted and approved an ESPP allowing the Company to issue up to 150,000 ordinary shares. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code of 1986. Under the ESPP, employees are eligible to purchase ordinary shares through payroll deductions, subject to any plan limitations. The purchase price of the ordinary shares on each purchase date is equal to 85% of the lower of the closing market price on the offering date and the closing market price on the purchase date of each three-month offering period. During the six months ended June 30, 2021, 1,174 ordinary shares were issued under the ESPP compared to 3,005 during the same period in 2020. As of June 30, 2021, a total of 130,852 ordinary shares remain available for issuance under the ESPP plan compared to a total of 135,202 as of June 30, 2020.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg"
      decimals="INF"
      id="Narr_omEFn-5NfEGkAMzAQ02EhA"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_qdkOPyY6VkGQRdYO2alqaA"
      decimals="INF"
      id="Narr_RGqsI6rImEarilqs7PiReQ"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">12601471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_6kciBLw9rkuMdB7wxKi_oQ">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.25%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,286&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,889&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,960&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,735&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,825&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,714&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,775&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,054&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_2QyWUqSll0SvgxvLV-w2Sg"
      decimals="-3"
      id="Tc_2P7fpFBjAkigFUxdv5Ve3g_4_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3286000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_UovYXxgpLUq_6ozAyB8paA"
      decimals="-3"
      id="Tc_q5KeKD92MUmcxn_DPNhPKA_4_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2889000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_Y_O-r5G3Y0WsfXY0g7W7Ow"
      decimals="-3"
      id="Tc__FqELsGdEkOW3uuS4qIuPQ_4_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5960000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lwLmmaw8u0StuP6cZ9EnJw"
      decimals="-3"
      id="Tc_HLggcYf76EO70lMlwxmcmw_4_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5271000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_VqOyaS-XX0WhG4INMVMxnA"
      decimals="-3"
      id="Tc_jbaL7yytgUCDdBC0eu2_5g_5_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3735000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_AG5JI3Sjjk21nqVDyvBZNA"
      decimals="-3"
      id="Tc_Rn3iHWvOZEalvkuMS17xfQ_5_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2825000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_Mt0t04auPESNygM01bISbQ"
      decimals="-3"
      id="Tc_el0UQFcgjU6xHa8tAUjs-g_5_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">6815000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_ESty22Jv-0Sxj10FO4p7bw"
      decimals="-3"
      id="Tc_R9x89PucSEKBuSl2CeiALA_5_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">4783000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_YS6DOwKX1k6x5P_vJL_MIg"
      decimals="-3"
      id="Tc_E2UWM5lbZUaDYAXJ1cGU8g_6_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">7021000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_qure_The2014PlanMember_YbJyX63qJUCF1-xqxcPn-g"
      decimals="-3"
      id="Tc_yG7lrj2lBUi7I1WgfAdyBg_6_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5714000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg"
      decimals="-3"
      id="Tc_YMQouEtWVUygyRXOlja_9Q_6_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">12775000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_qure_The2014PlanMember_GDX-daUVNkiz9HBqranRrg"
      decimals="-3"
      id="Tc_4fJABhFa00akPpwAIHG4KA_6_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">10054000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_NqD693lSZ0uDFbRHAEI3XQ">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.25%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:22.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Award type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted share units&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,222&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,209&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,782&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,653&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Performance share units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 759&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,714&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,775&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,054&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw"
      decimals="-3"
      id="Tc_aWx6KZgGjUShkkBCZ5knmw_5_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A"
      decimals="-3"
      id="Tc_y6OOLGIZUUWLQWqihlXdpg_5_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2746000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="-3"
      id="Tc_hbkmSOyjXEuHxst9468tuA_5_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">6190000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9G_kAneeM0SgziGdwfsbMw"
      decimals="-3"
      id="Tc_msnu-wGROUCS4lo8jAhq-Q_5_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">4954000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_jQQMIKMldkWohZCXDVcmdw"
      decimals="-3"
      id="Tc_DGuX9KGboUizsG4ON0AKYA_6_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_2zEJuHZdn0KJM5hi1tu5YQ"
      decimals="-3"
      id="Tc_QZX10c6G9Umf0cbLLjwmUQ_6_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">2209000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A"
      decimals="-3"
      id="Tc_ajuTtVnwrEqaZom30C2ZXQ_6_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5782000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_Ew8hAizqJU-URTHYHt1zAA"
      decimals="-3"
      id="Tc_4ksAaFSfwkOw5SLXZF0fog_6_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_J1hFmEl5jE2V8o1LwylINA"
      decimals="-3"
      id="Tc_bLvRUliFgkOES8Zl1YirWQ_7_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">449000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lLWpawwVD0SS1ZQfITt7dg"
      decimals="-3"
      id="Tc_Sg6g0AzXcUe1tqYG9bqpow_7_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">759000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg"
      decimals="-3"
      id="Tc_glqCT3gHG0uMeAE2VUwFkg_7_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">803000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_fHzfNFAetEOpeFa4wvX2DQ"
      decimals="-3"
      id="Tc_Ew6XfU7uUkSSJ3w5WzhDBw_7_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1447000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_YS6DOwKX1k6x5P_vJL_MIg"
      decimals="-3"
      id="Tc_Ff1uA3T9oUSKO8_dMxV20Q_8_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">7021000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_qure_The2014PlanMember_YbJyX63qJUCF1-xqxcPn-g"
      decimals="-3"
      id="Tc_w-i1U3tWBUeq5CVDLXxd1A_8_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">5714000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg"
      decimals="-3"
      id="Tc_ZSlrF4HYOkiNKaJ097NWKA_8_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">12775000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_qure_The2014PlanMember_GDX-daUVNkiz9HBqranRrg"
      decimals="-3"
      id="Tc_kCWouMarUUqccGyjQznCow_8_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">10054000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_WvK8juhfgkC-Bb18Z3pcTw">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrecognized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share-based&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;compensation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;period for &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;recognition&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Award type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.99&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted share units&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,960&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Performance share units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.58&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 60,607&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2.66&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA"
      decimals="-3"
      id="Tc_bdjSKe7i5E2Gr9cT4Za4cQ_7_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">34855000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      id="Tc_la2PgnTZE0mZJA0d7GXjsQ_7_5">P2Y11M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9DvuX5iTKkaxcG2y02MZyQ"
      decimals="-3"
      id="Tc_znRwEkupJEWI5LNc4wq-Mg_8_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">24960000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A"
      id="Tc_npRmPCYLckSH-VYXW-pYLA_8_5">P2Y3M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_VhK3MGv9eEWEY7B8EG-TcA"
      decimals="-3"
      id="Tc_L-WZne6W1UyKylyhEuyD7A_9_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">792000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg"
      id="Tc_dx75Y5fk3EKzRU_spZUWaw_9_5">P0Y6M29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_qdkOPyY6VkGQRdYO2alqaA"
      decimals="-3"
      id="Tc_1WJMP3WmvUCf7KqAcOOORQ_10_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">60607000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg"
      id="Tc_LsDF0LfSSEa7MzAPOmKe4w_10_5">P2Y7M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg"
      id="Narr_l-c0we-IrkabMlqBFF99ow">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9_e4JUkm00245rwV5zhg_g"
      decimals="2"
      id="Narr_f7YxV8NOmEmGeMERag9UjA"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9_e4JUkm00245rwV5zhg_g"
      id="Narr_L6Wp5EOdRUyNufS8k0nBmA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_hgABeo6nI0Sn_Cc_DbsdkA"
      id="Narr_sserLgAMekuOTjqjV_sVZQ">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_PlanIn2014Member_-Uv1a7oNgUKp-nwzRoa6rg"
      id="Tb_mWRGwT3Rh06VnjXUTj0Mnw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;average &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ordinary shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,659,279&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 28.13&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 914,118&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36.36&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (74,397)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43.19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,093)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44.14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,976)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at June&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,417,931&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 30.29&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereof, fully vested and exercisable at June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,774,059&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.68&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereof, outstanding and expected to vest after June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,643,872&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39.58&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total weighted average grant date fair value of options issued during the period (in $ millions)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Proceeds from option sales during the period (in $ millions)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_uJk1n3G3b0G2SAKAIt-9xQ"
      decimals="INF"
      id="Tc_1EnZTtSpuk61P4zqEhiBhw_5_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">2659279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_uJk1n3G3b0G2SAKAIt-9xQ"
      decimals="2"
      id="Tc_7z6pOmVjq0-B6FFlQ1PnrQ_5_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">28.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="INF"
      id="Tc_E-4nJmJvi0uc-_HuAM1gtQ_6_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">914118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="2"
      id="Tc_c5xnMoGna06_P3GYVYHNfw_6_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">36.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="INF"
      id="Tc_JFo00EeGEECwPZ-PySKq-A_7_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">74397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="2"
      id="Tc_Mwtq_txULUewB_Ylb01OWw_7_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">43.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="INF"
      id="Tc_Ck6jsFKHukO5NFIN8APnLg_8_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">9093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="2"
      id="Tc_8ZVTUSmDVE6d6RMUUprk6g_8_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">44.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="INF"
      id="Tc_PhK9EdcDekSHizXUsNgONQ_9_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">71976</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="2"
      id="Tc_x_r5psU7lU6wZNtz0TRYtA_9_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">12.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA"
      decimals="INF"
      id="Tc_5addOm1fRkm6bEuky1ceeg_10_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">3417931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA"
      decimals="2"
      id="Tc_Vog--tO-vkGhq6Q0SxT1-Q_10_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">30.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA"
      decimals="INF"
      id="Tc_XjvNoKbvuUmfBeMsPNF7tA_11_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">1774059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA"
      decimals="2"
      id="Tc_7wF0tOsglUyDrAwTwDCGLg_11_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">21.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_TbtrCDVbW0yrByHtZEmdnA"
      decimals="INF"
      id="Tc_5DRU7txeXUqZS2GG6VM-fw_12_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">1643872</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <qure:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="2"
      id="Tc_QwCdz0_Go0aM_uK6Of6zCQ_12_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">39.58</qure:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-5"
      id="Tc_VDceGk7DyEKbpm50rKbFNQ_1_5"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">19400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-5"
      id="Tc_HYilKBzqeUaUuTxJsGOygg_2_5"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">900000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_-2Uafrh52k25BE9Gwn9qtg">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.01%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assumptions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;75%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;70%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;75%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;70%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected terms&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;1.72% - 1.85%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;0.76% - 0.83%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;1.21% - 1.85%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;0.76% - 1.44%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw"
      decimals="2"
      id="Tc_w_8ACX4wjk6kGcTXu-GlrA_3_2"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A"
      decimals="2"
      id="Tc_J95qlX6ioUmC2EkFhYFVKA_3_4"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="2"
      id="Tc_ktjd_gd-cU-Ct7r-rbw-Dg_3_6"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9G_kAneeM0SgziGdwfsbMw"
      decimals="2"
      id="Tc_tz2dctj7IE2APeyn-jJ5oQ_3_8"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw"
      id="Tc_rQ4GWt0NfkSNEBbElY2F-w_4_2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A"
      id="Tc_gIe43wNW90eg-GgQd2p6kg_4_4">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      id="Tc_IvdJl6RwWUWcGzJ0zt4opg_4_6">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9G_kAneeM0SgziGdwfsbMw"
      id="Tc_ly0CHvkVbk-vO-0pIymGnA_4_8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw"
      decimals="4"
      id="Narr_D1AI2o3NgUuUjIiBTQyNCw"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw"
      decimals="4"
      id="Narr_KMa8JXCr60acHnwcUFCuDw"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A"
      decimals="4"
      id="Narr_v4MLwW3BXkChJsPtA8WO3Q"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A"
      decimals="4"
      id="Narr_D8AEuUEjckK6SCgcrhW-jw"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="4"
      id="Narr_RJqwqPREA0yEdrH_U9Q98w"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="4"
      id="Narr_FViaKFFJi0iFmrmqka2N9w"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9G_kAneeM0SgziGdwfsbMw"
      decimals="4"
      id="Narr_4znFA0xymkeQakHbi8yzwQ"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.0076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_3-7W-9RlWEiC4pkgG5v5Tw"
      decimals="2"
      id="Tc_ZzQh4AxAw0CAeJ94isLP4g_6_2"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_eeAcFDtu4EqlvTOnWpYt-A"
      decimals="2"
      id="Tc_0lHlXtI0q061kltYBque4A_6_4"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_lM4NJA_JZEa4XqrUXy4m6w"
      decimals="2"
      id="Tc_0OR5iVDkMk6NAbm5PmN1sw_6_6"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_qure_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9G_kAneeM0SgziGdwfsbMw"
      decimals="2"
      id="Tc_Szct-SrpKEmmT-rNb5XMgg_6_8"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_GNuXQied-E-IXIyrstQFXg">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;RSU&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;grant-date fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ordinary shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-vested at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 467,344&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 43.56&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 481,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (145,203)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,067)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42.86&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-vested at June&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 772,895&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 39.87&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total weighted average grant date fair value of RSUs granted during the period (in $ millions)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_5NV54NsdkEinwOnU-elbdw"
      decimals="INF"
      id="Tc_iFiQT9C6ikCAX2i4l2SmLw_5_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">467344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_5NV54NsdkEinwOnU-elbdw"
      decimals="2"
      id="Tc_FC9v6YOydkqmyFes-oPwXA_5_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">43.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A"
      decimals="INF"
      id="Tc_RU1aIsheW0eGeQDRF7mTyA_6_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">481821</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A"
      decimals="2"
      id="Tc_4KdipQ4evkCWh5A0Lce4Vg_6_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">36.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A"
      decimals="INF"
      id="Tc_KoAdxtSWEUyO9HfgoD1JeA_7_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">145203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A"
      decimals="2"
      id="Tc_IPRR6UF0B0GTBveV69Qgig_7_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">39.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A"
      decimals="INF"
      id="Tc_H5QhCIpsRUyviNF8JG6REQ_8_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">31067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A"
      decimals="2"
      id="Tc_ULJkyRg9r0CGDSVQizMarA_8_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">42.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9DvuX5iTKkaxcG2y02MZyQ"
      decimals="INF"
      id="Tc_nY4YQPjd_UiSB0btLkZT0w_9_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">772895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_9DvuX5iTKkaxcG2y02MZyQ"
      decimals="2"
      id="Tc_ZgU3MC-vcUadmxQntQBzSA_9_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">39.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_mHghqwgQ_E2GRbZX7IfE-A"
      decimals="-4"
      id="Tc_LhnqSlPLkkWbj4_vKOn3BA_11_5"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">17600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_l15cALnFH0u_MOExc4K0wA"
      id="Narr_uA-cW7N-okSX87bHzJCIdg">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_3_1_2017_To_3_31_2017_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_7i4FeprKyk6MfKmRuuYBJQ"
      id="Narr_NSQLwitSxEeWxjT5hc2nwg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_jbotrJvJD0mooEVxhRGC2g">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PSU&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;grant-date fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ordinary shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-vested at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 212,614&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 42.32&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (132,368)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33.09&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,916)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57.56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-vested at June&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 77,330&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 57.56&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_YNaFty5MakKmr7kgK48vHQ"
      decimals="INF"
      id="Tc_fyUn_cz9f0SD9IY-SBLyFQ_5_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">212614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_YNaFty5MakKmr7kgK48vHQ"
      decimals="2"
      id="Tc_7ITaS6UdYUyWG6bGovRmmQ_5_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">42.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg"
      decimals="INF"
      id="Tc_OQkSXRFId0W01pGa64FNDA_6_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">132368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg"
      decimals="2"
      id="Tc_RGPCE_JhR0GJqq1snLMwgQ_6_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">33.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg"
      decimals="INF"
      id="Tc_e6jNT01BAkihg1-56L4_ug_7_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">2916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_znkPBi8N0UGsqt7A3b_tCg"
      decimals="2"
      id="Tc_h5dq0AKQwUehTOGaHhsAlg_7_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">57.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_VhK3MGv9eEWEY7B8EG-TcA"
      decimals="INF"
      id="Tc_vTVH1PhzeUKHtU-GFkziZA_8_2"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">77330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_VhK3MGv9eEWEY7B8EG-TcA"
      decimals="2"
      id="Tc_mMxXXhm-u0WALQXvtDz6_g_8_5"
      unitRef="Unit_Divide_USD_shares_atzGr-jA9ke4Oephad5_gw">57.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_hyffprjeyUC_wzIZA8RTnA"
      decimals="INF"
      id="Narr_7FK8v6DIbEa67JVV4GaUUA"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_Fwx05CDlmUWbLjlZZ48Tqw"
      decimals="INF"
      id="Narr_HJOXQM7kJkOLFHG92fKKLg"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_5Wm51a7LMUeByYsBhPlv-A"
      decimals="INF"
      id="Narr_fyNzPoVQxk2CP2zGpUeotA"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">1174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_081a5t6cXUS5Pm3ISOEjBQ"
      decimals="INF"
      id="Narr_2liUpjOlBU25zzyAxyu3nQ"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">3005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_KP_4t1AgiEGnBsb8mhLMhg"
      decimals="INF"
      id="Narr_kZpgLVd7KU6AS7KnOYuwRQ"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">130852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_YA8vUlYvg0e7cBJmuUUNoQ"
      decimals="INF"
      id="Narr_YFbPMbdqmEmsvt5dkteMTw"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">135202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <qure:OtherIncomeTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_rx9W5d2gfEqHEcVyNu5AwA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;9&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;Other income &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Other income during the three and six months ended June 30, 2021, was $7.6 million and $7.9 million, compared to $0.7 million and $1.5 million, respectively, during the same periods in 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Other income in 2020 and 2021 includes income from payments received from European authorities to subsidize the Company&#x2019;s research and development efforts in the Netherlands as well as income from subleasing part of the Amsterdam facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In addition, other income during the three and six months ended June 30, 2021 includes $1.3 million of employee retention credit received under the U.S. Coronavirus Aid, Relief, and Economic Security Act, as well as $3.0 million related to 69,899 shares in VectorY B.V. received in conjunction with a settlement agreement entered into in April 2021. No such income was recorded in 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"&gt;&lt;span style="font-weight:normal;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:normal;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</qure:OtherIncomeTextBlock>
    <us-gaap:OtherIncome
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-5"
      id="Narr_zCwNVRK3DkmlsHFXJoecFA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">7600000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-5"
      id="Narr_G1Hj8TNlyUmW9YhT61l0LA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">7900000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-5"
      id="Narr_tSdRzQhJaU2mh41JpQI_5Q"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">700000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-5"
      id="Narr_xpWL5sERi0KU1iPH9qzmeQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1500000</us-gaap:OtherIncome>
    <qure:EmployeeRetentionCreditIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-5"
      id="Narr_R7LtDewIPkaBvNfu42E3Nw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1300000</qure:EmployeeRetentionCreditIncome>
    <qure:EmployeeRetentionCreditIncome
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-5"
      id="Narr_pKDahN9gNUKBHGwoiDn3Ig"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">1300000</qure:EmployeeRetentionCreditIncome>
    <qure:EquityMethodInvestmentSettlementIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_Q_fLWImhIU-2TPyxON_IlA"
      decimals="-5"
      id="Narr_PDjQsUoCn0aFJ-M_OplNnw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3000000.0</qure:EquityMethodInvestmentSettlementIncome>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="As_Of_6_30_2021_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_OAjMTWyJ8E-817Ww2pMKxg"
      decimals="INF"
      id="Narr_8lI1NGVgJE-pnblPIdcGng"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">69899</us-gaap:InvestmentOwnedBalanceShares>
    <qure:EmployeeRetentionCreditIncome
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_Bf9nD-pPCUi6779uMq-cCQ"
      decimals="-5"
      id="Narr_pxzfW0JPHkKGtaQkBc63-w"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">0</qure:EmployeeRetentionCreditIncome>
    <qure:EmployeeRetentionCreditIncome
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_qure_VectoryB.vMember_UIrDwGaqv0i6xXmaQYspcQ"
      decimals="-5"
      id="Narr_6sEXduBIkUGazqqyQUa8ig"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">0</qure:EmployeeRetentionCreditIncome>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_jEG3tPPZZ0mZxKKWlIvqIQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;10&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;Income taxes &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company recorded $3.3 million in income tax expense in the three months ended June 30, 2021, and $3.5 million in the six months ended June 30, 2021. The Company recorded no income tax expense during the same periods in 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2020, the Company had recorded a full valuation allowance against its Dutch net deferred tax assets. On May 6, 2021, the CSL Behring Agreement became effective (refer to Note 3 &#x201c;Collaboration arrangements and concentration of credit risk&#x201d;). The Company recorded $462.4 million of license revenue related to closing the transaction. The Company intends to record such revenue in its Dutch tax return related to the 12-month period ended December 31, 2020. As such, the Company expects to file a return showing a taxable profit in the Netherlands in 2020, which would result in the consumption of substantially all of its Dutch net operating losses for the years 2011 to 2018. The Company&#x2019;s remaining Dutch net operating tax losses carried forward would relate to 2019. The Dutch government on June 4, 2021 enacted legislation, whereby such net operating tax losses can be carried forward indefinitely. The Company expects to continue incurring tax losses for the foreseeable future including 2021. As such, the Company retained its full valuation allowance related to the net deferred assets as of June 30, 2021. The adjustment to the Company&#x2019;s 2020 filing position resulting in the release and consumption of prior year net operating tax losses carried forward was treated as a discrete event in the three months ended June 30, 2021. The Company allocated part of the release to the tax benefit of share issuance cost incurred in 2014, 2015, 2017 and 2018. This resulted in an increase of additional paid-in capital as well as deferred tax expenses of $3.0 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company released its valuation allowance against the Company&#x2019;s deferred tax assets in the United States as of December 31, 2020. The Company recorded $0.2 million and $0.5 million deferred tax expense in relation to its operations in the United States during the three and six months ended June 30, 2021, respectively. The Company recorded a nil net deferred tax expense in the prior year as it had recorded a valuation allowance against its net deferred tax assets in the United States as of June 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The effective income tax rates of respectively -0.8% and -1.0% during the three and six months ended June 30, 2021, is substantially lower than the enacted rated of 25% in the Netherlands as the Company recorded a valuation allowance against its remaining net deferred tax assets in the Netherlands as of December 31, 2020, and June 30, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-5"
      id="Narr_mGNjQTBLNkSHLS1sU_tjBw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-5"
      id="Narr_vwDVU3czGEm_qjHrEasS1g"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-5"
      id="Narr_RvDt5BZcRkakXoRl6OVBQQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-5"
      id="Narr_ZbEVOZCYLUuhBr7B1zfGXA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_iR-v-TBnd0evOoVwhDOfvA"
      decimals="-5"
      id="Narr_CS9t0Ywak0-Cdg5IImNdRg"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">462400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-5"
      id="Narr_zoqk2R33YkS-8agMCB11gg"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">3000000.0</qure:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-5"
      id="Narr_6WdkeFjM0EmCzCpIsdGCaA"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">200000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-5"
      id="Narr_aadlNMzUO0qmmAdIsONqeQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-5"
      id="Narr_44s4QL_ky0yGgx15bMkapw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-5"
      id="Narr_qYzPBLrMJEG_XcA4cplFtQ"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="3"
      id="Narr_QxhmQstRh0y_OLMEb4rFhA"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.008</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="3"
      id="Narr_0hIaOr7b4UOBVRHNAlnQ9w"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.010</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="2"
      id="Narr_gmsfN-g-p0K6ibhDmQzb1Q"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="2"
      id="Narr_cnh_RNcnvUumUxET4gwueg"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_1DHVDgW-lk-n09U_Ev1uaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;11&lt;/b&gt;&lt;/span&gt;&lt;span style="display:inline-block;width:18pt;"/&gt;Basic and diluted earnings per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Basic net income / (loss) per ordinary share is computed by dividing net income / (loss) for the period by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per ordinary share are calculated by adjusting the weighted average number of ordinary shares outstanding, assuming conversion of all potentially dilutive ordinary shares. For the three months and six months ended June 30, 2021, dilutive net income per ordinary share is computed using the treasury method. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table provides the calculation of basic and diluted earnings per ordinary share: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.59%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:25.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income / (loss) attributable to ordinary shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 399,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42,551)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 357,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (70,550)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 399,468&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (42,551)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 357,912&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (70,550)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average number of ordinary shares outstanding - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,037,900&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,387,463&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,754,766&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,333,460&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options under 2014 Plans and previous plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 797,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 824,101&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Non-vested RSUs and PSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 92,681&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 98,514&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Employee share purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average number of ordinary shares outstanding - diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 46,929,870&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,387,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 46,678,835&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,333,460&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table presents ordinary share equivalents that were excluded from the calculation of diluted net income / (loss) per ordinary share for the three and six months ended June 30, 2021 and 2020 as the effect of their inclusion would have been anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:22.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Anti-dilutive ordinary share equivalents&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options under 2014 Plans and previous plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,634,766&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,893,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,607,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,893,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Non-vested RSUs and PSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 757,544&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 645,636&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 751,711&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 645,636&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Employee share purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,414&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,802&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;BMS warrants (derecognized as of December 1, 2020 - see Note 4, "Fair value measurement")&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,060,500&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,060,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total anti-dilutive ordinary share equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,393,724&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,600,123&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,361,343&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,603,143&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The anti-dilutive ordinary shares are presented without giving effect to the application of the treasury method or exercise prices that exceeded the price of the Company&#x2019;s ordinary shares as of June 30, 2020. In addition, the BMS warrants were not exercisable as of June 30, 2020. This would have resulted in a lower number of potentially dilutive ordinary shares as some stock option grants as well as the BMS warrants would have been excluded.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_DubeJnz8kkemIUFU7zulMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.59%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:25.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income / (loss) attributable to ordinary shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 399,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42,551)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 357,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (70,550)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 399,468&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (42,551)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 357,912&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (70,550)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average number of ordinary shares outstanding - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,037,900&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,387,463&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,754,766&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,333,460&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options under 2014 Plans and previous plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 797,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 824,101&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Non-vested RSUs and PSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 92,681&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 98,514&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Employee share purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average number of ordinary shares outstanding - diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 46,929,870&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,387,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 46,678,835&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,333,460&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_0NIxGwaDMk2EAFfuOCKp0Q_5_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">399468000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_c28d08SyHEKYi8biaA6X2Q_5_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-42551000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_7RbNzANvxkKAf0TK2cJnow_5_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">357912000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_Krhdm6mQHUG2EDb-7T8dtw_5_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-70550000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="-3"
      id="Tc_qWJisS7WJ0ul10drw0K3RQ_6_3"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">399468000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="-3"
      id="Tc_wv7mfFliwkijcCplkkb4oQ_6_6"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-42551000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-3"
      id="Tc_ChTZaLXDekCUExT9uwXcFg_6_9"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">357912000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="-3"
      id="Tc_GwwQssBdGUuMJhJJFIVwBA_6_12"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">-70550000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="INF"
      id="Tc_hWUjsla2oUGP-ddcUWO8AA_8_3"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">46037900</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="INF"
      id="Tc_s-zaCIYld0GLdzUiA1PMUg_8_6"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44387463</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="INF"
      id="Tc_6Xdh7VPKAEW_6Z2qlu2vhQ_8_9"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">45754766</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="INF"
      id="Tc_THsgIBv99EyTw1Klq3qWxA_8_12"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44333460</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_7LQNKgj-qUKqmDaRdvBRmg"
      decimals="INF"
      id="Tc_DJgrGjx6ik6kdjS8Z2o5bw_9_3"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">797165</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_1bGUyXjk5Ee1HL6K4PJVRA"
      decimals="INF"
      id="Tc_nrDPuxok8U-d8GpnIG5b2Q_9_9"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">824101</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_aitVdVnE4k67WD71TFPNZg"
      decimals="INF"
      id="Tc_cNa0E-3mcEaKCzrS1E-zPQ_10_3"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">92681</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_Qy8ygST_9k-q-6WvPt0QgQ"
      decimals="INF"
      id="Tc_jBAy0AMGE06fmCEEE3eZyw_10_9"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">98514</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_sDADOxy2gkuHqUBfnjTovQ"
      decimals="INF"
      id="Tc_vdUCIoQkZk-1tXec-4CbiQ_11_3"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">2124</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_qf3KA5AywE6IX9nX9Nuxmw"
      decimals="INF"
      id="Tc_XZTxCE0XOUi_xMEhl0Fgjg_11_9"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">1454</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="INF"
      id="Tc_mwbmsjS1MUGSBChSt59D5g_12_3"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">46929870</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="INF"
      id="Tc_nAhWjpOjHEq88r51VlJxPQ_12_6"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44387463</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="INF"
      id="Tc_hIGQeNBPh0GN0RE_sfGhVQ_12_9"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">46678835</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="INF"
      id="Tc_E6rlsaI5sUK8cRjNdfi7pg_12_12"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">44333460</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <qure:ScheduleOfPotentialDilutiveCommonSharesTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_3oGESuBQ0UankYV2nJYPWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:22.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Anti-dilutive ordinary share equivalents&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options under 2014 Plans and previous plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,634,766&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,893,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,607,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,893,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Non-vested RSUs and PSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 757,544&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 645,636&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 751,711&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 645,636&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Employee share purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,414&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,802&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;BMS warrants (derecognized as of December 1, 2020 - see Note 4, "Fair value measurement")&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,060,500&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,060,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total anti-dilutive ordinary share equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,393,724&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,600,123&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,361,343&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,603,143&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</qure:ScheduleOfPotentialDilutiveCommonSharesTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_7LQNKgj-qUKqmDaRdvBRmg"
      decimals="INF"
      id="Tc_8qDWzctaIEOWBbYqTU0T_Q_5_3"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">2634766</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_Hg1BxwkRVUyQ6vANQg5uvA"
      decimals="INF"
      id="Tc_GNVfi1y3_U-M9ppsbM4X5A_5_6"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">2893733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_1bGUyXjk5Ee1HL6K4PJVRA"
      decimals="INF"
      id="Tc_MhT9qY1J5UWDchIJ882mlw_5_9"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">2607830</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_9iYRZ8CW1k-TSh8NdyAR5g"
      decimals="INF"
      id="Tc_SMfBMv3TjkOH72dYg1XIsA_5_12"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">2893733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_aitVdVnE4k67WD71TFPNZg"
      decimals="INF"
      id="Tc__c_PHyzzGkmwQomaZQi78w_6_3"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">757544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_bIi4GQHMx0e79d3ltjcbDw"
      decimals="INF"
      id="Tc_Sm3pY3drX0W7XBst0TyN3w_6_6"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">645636</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_Qy8ygST_9k-q-6WvPt0QgQ"
      decimals="INF"
      id="Tc_f2JanXyeuU6wO-saIDVPbw_6_9"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">751711</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_RestrictedShareUnitsAndPerformanceShareUnitsMember_oT74WQam8EeTmP8aiGGhow"
      decimals="INF"
      id="Tc_vF60N_scxEmy24V40TsSBw_6_12"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">645636</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_sDADOxy2gkuHqUBfnjTovQ"
      decimals="INF"
      id="Tc_iE7czJHzq0upRUvuviqBSg_7_3"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">1414</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_2y8V3lT85USL1EXFTeWauA"
      decimals="INF"
      id="Tc__DwEjbFaaE6m9bVKLfCVCg_7_6"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">254</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_qf3KA5AywE6IX9nX9Nuxmw"
      decimals="INF"
      id="Tc_jx4LvGxdvUS2Mx7UiqRYXg_7_9"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">1802</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_g9VXfgfnr0G-HOsXC6wp3Q"
      decimals="INF"
      id="Tc_U7j7y70XaEO3bGET7YO8Fg_7_12"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">254</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_BmsWarrantsMember_lc-W0vqpCUOjhIwUvmVlTQ"
      decimals="INF"
      id="Tc_T2BXnPFzRE6_znUt3hW4PA_8_6"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">8060500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_qure_BristolMyersSquibbMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_qure_BmsWarrantsMember_AuiBBwndmkigvQN248BGAQ"
      decimals="INF"
      id="Tc_VEShOsj6yUqY5J8ELgwFAQ_8_12"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">8060500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ"
      decimals="INF"
      id="Tc_I-_cUyYPLEeJkMb6NizeDA_9_3"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">3393724</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2020_To_6_30_2020_AgoTZ_RTAkqmIiUEwr-hvg"
      decimals="INF"
      id="Tc_dkBNoYTBq0KY4fMeD11eSQ_9_6"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">11600123</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="INF"
      id="Tc_JxGdg7nkFkiFX0O-13zHWA_9_9"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">3361343</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_6_30_2020_FFfMLQI7W0qEToVGCoyKaQ"
      decimals="INF"
      id="Tc_AqslnEfjS0y-nY3nsieJ6w_9_12"
      unitRef="Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q">11603143</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      id="Tb_i3nPDoi0lkydoa0c2Wm4hg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;12&lt;/b&gt;&lt;/span&gt;&lt;span style="display:inline-block;width:18pt;"/&gt;Subsequent event&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt;Business combination&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On June 22, 2021, the Company announced that it entered into a definitive transaction agreement under which the Company will acquire Corlieve Therapeutics S.A.S. (&#x201c;Corlieve&#x201d;, together the &#x201c;Corlieve Transaction&#x201d;). The Corlieve Transaction has been approved by the Boards of both companies and does not require the Company&#x2019;s shareholder approval. The transaction is subject to customary closing conditions as well as review by the French Ministry of Economy, Finance and Recovery (Minist&#xe8;re de l&#x2019;Economie, des Finances et de la Relance) pursuant to articles L.151-3 and R.151-1 and seq. of the French Code Mon&#xe9;taire et Financier. Currently, the transaction is anticipated to be completed early in the third quarter of 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Corlieve Transaction strengthens the Company&#x2019;s pre-clinical program pipeline. Corlieve&#x2019;s lead gene therapy program employs miRNA silencing technology to target suppression of aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (&#x201c;TLE&#x201d;) and will be known as AMT-260. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Upon closing of the Corlieve Transaction, the Company expects to pay EUR 46.3 million in cash. The Company will fund the acquisition from its cash position. Corlieve&#x2019;s shareholders are eligible to receive the following additional payments of which up to 25% will be payable in the Company&#x2019;s ordinary shares at the Company&#x2019;s election: up to EUR 43.7 million in development milestones through Phase I/II and EUR 160.0 million in milestones associated with Phase III development and the approvals of AMT-260 in the U.S and European Union.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Corlieve Transaction is expected to be accounted for as a business combination, which requires that assets acquired and liabilities assumed be recognized at their fair value as of the acquisition date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 41.35pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:normal;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="-5"
      id="Narr_mTqeWLErMEm92CPkXoNksg"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">46300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <qure:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage
      contextRef="Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w"
      decimals="2"
      id="Narr_jDQKuCmXf02C0fwfvXEEuA"
      unitRef="Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw">0.25</qure:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage>
    <qure:DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-5"
      id="Narr_cHTjAEKYm0-VeCpTYGRbuw"
      unitRef="Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA">43700000</qure:DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi>
    <qure:DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii
      contextRef="As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A"
      decimals="-5"
      id="Narr_sseU76UdoEuN3FeCuNXNUg"
      unitRef="Unit_Standard_EUR_8DR84qYcA0iepwyX32ILmw">160000000.0</qure:DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740488114184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jul. 21, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">uniQure N.V.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">P7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Paasheuvelweg 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">1105 BP Amsterdam<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">NL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">20-240-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, par value &#8364;0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">QURE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,073,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001590560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740488238072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 677,330<span></span>
</td>
<td class="nump">$ 244,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="nump">2,705<span></span>
</td>
<td class="nump">6,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">10,861<span></span>
</td>
<td class="nump">4,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_OtherCurrentAssetsAndReceivables', window );">Other current assets and receivables</a></td>
<td class="nump">3,328<span></span>
</td>
<td class="nump">3,024<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">694,224<span></span>
</td>
<td class="nump">258,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net of accumulated depreciation of $37.3 million as of June 30, 2021 and $35.2 million as of December 31, 2020, respectively</a></td>
<td class="nump">38,371<span></span>
</td>
<td class="nump">32,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">26,782<span></span>
</td>
<td class="nump">26,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">3,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">15,965<span></span>
</td>
<td class="nump">16,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">5,760<span></span>
</td>
<td class="nump">2,748<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">90,040<span></span>
</td>
<td class="nump">81,484<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">784,264<span></span>
</td>
<td class="nump">340,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">16,817<span></span>
</td>
<td class="nump">3,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">23,526<span></span>
</td>
<td class="nump">18,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">5,752<span></span>
</td>
<td class="nump">5,524<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">46,095<span></span>
</td>
<td class="nump">27,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">70,780<span></span>
</td>
<td class="nump">35,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">30,534<span></span>
</td>
<td class="nump">30,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">3,247<span></span>
</td>
<td class="nump">3,136<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">104,561<span></span>
</td>
<td class="nump">69,156<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">150,656<span></span>
</td>
<td class="nump">96,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, 0.05 par value: 80,000,000 shares authorized as of June 30, 2021 and 60,000,000 shares authorized as of December 31, 2020 and 46,050,250 and 44,777,799 ordinary shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">2,788<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">1,062,234<span></span>
</td>
<td class="nump">1,016,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) / income</a></td>
<td class="num">(4,595)<span></span>
</td>
<td class="nump">9,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(426,819)<span></span>
</td>
<td class="num">(784,731)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">633,608<span></span>
</td>
<td class="nump">243,905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 784,264<span></span>
</td>
<td class="nump">$ 340,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_OtherCurrentAssetsAndReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The balance of other current assets and receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_OtherCurrentAssetsAndReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740491554808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation | $</a></td>
<td class="nump">$ 37.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">46,050,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,777,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">46,050,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,777,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740488062408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 463,868<span></span>
</td>
<td class="nump">$ 1,535<span></span>
</td>
<td class="nump">$ 464,322<span></span>
</td>
<td class="nump">$ 1,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of contract revenues</a></td>
<td class="num">(23,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(32,747)<span></span>
</td>
<td class="num">(28,401)<span></span>
</td>
<td class="num">(64,777)<span></span>
</td>
<td class="num">(54,414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="num">(17,299)<span></span>
</td>
<td class="num">(11,511)<span></span>
</td>
<td class="num">(30,300)<span></span>
</td>
<td class="num">(20,583)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="num">(73,224)<span></span>
</td>
<td class="num">(39,912)<span></span>
</td>
<td class="num">(118,255)<span></span>
</td>
<td class="num">(74,997)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">7,590<span></span>
</td>
<td class="nump">669<span></span>
</td>
<td class="nump">7,942<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expense</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="num">(459)<span></span>
</td>
<td class="num">(839)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income / (loss) from operations</a></td>
<td class="nump">398,008<span></span>
</td>
<td class="num">(38,208)<span></span>
</td>
<td class="nump">353,550<span></span>
</td>
<td class="num">(72,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,902)<span></span>
</td>
<td class="num">(970)<span></span>
</td>
<td class="num">(3,453)<span></span>
</td>
<td class="num">(1,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency gains / (losses), net</a></td>
<td class="nump">6,583<span></span>
</td>
<td class="num">(3,645)<span></span>
</td>
<td class="nump">11,209<span></span>
</td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating gains, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,206<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income / (loss) before income tax expense</a></td>
<td class="nump">402,726<span></span>
</td>
<td class="num">(42,551)<span></span>
</td>
<td class="nump">361,383<span></span>
</td>
<td class="num">(70,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(3,258)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,471)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income / (loss)</a></td>
<td class="nump">399,468<span></span>
</td>
<td class="num">(42,551)<span></span>
</td>
<td class="nump">357,912<span></span>
</td>
<td class="num">(70,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) / gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(6,942)<span></span>
</td>
<td class="nump">4,647<span></span>
</td>
<td class="num">(14,502)<span></span>
</td>
<td class="num">(630)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive gain / (loss)</a></td>
<td class="nump">$ 392,526<span></span>
</td>
<td class="num">$ (37,904)<span></span>
</td>
<td class="nump">$ 343,410<span></span>
</td>
<td class="num">$ (71,180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per ordinary share - basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income / (loss) per ordinary share</a></td>
<td class="nump">$ 8.68<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="nump">$ 7.82<span></span>
</td>
<td class="num">$ (1.59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per ordinary share - diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income / (loss) per ordinary share</a></td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="nump">$ 7.67<span></span>
</td>
<td class="num">$ (1.59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares - basic</a></td>
<td class="nump">46,037,900<span></span>
</td>
<td class="nump">44,387,463<span></span>
</td>
<td class="nump">45,754,766<span></span>
</td>
<td class="nump">44,333,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares - diluted</a></td>
<td class="nump">46,929,870<span></span>
</td>
<td class="nump">44,387,463<span></span>
</td>
<td class="nump">46,678,835<span></span>
</td>
<td class="nump">44,333,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 462,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=qure_LicenseRevenueFromRelatedPartyMember', window );">License revenues from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=qure_CollaborativeRevenueMember', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=qure_CollaborativeRevenueFromRelatedPartyMember', window );">Collaboration revenues from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=qure_LicenseRevenueFromRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=qure_LicenseRevenueFromRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=qure_CollaborativeRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=qure_CollaborativeRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=qure_CollaborativeRevenueFromRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=qure_CollaborativeRevenueFromRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740413143240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive (loss)/income</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 2,651<span></span>
</td>
<td class="nump">$ 986,803<span></span>
</td>
<td class="num">$ (6,689)<span></span>
</td>
<td class="num">$ (659,707)<span></span>
</td>
<td class="nump">$ 323,058<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">43,711,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Income (Loss) for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70,550)<span></span>
</td>
<td class="num">(70,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive Income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">3,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="nump">203,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Restricted and performance share units distributed during the period</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Restricted and performance share units distributed during the period (in shares)</a></td>
<td class="nump">525,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ordinary shares relating to employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ordinary shares relating to employee stock purchase plan (in shares)</a></td>
<td class="nump">3,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 2,692<span></span>
</td>
<td class="nump">1,000,389<span></span>
</td>
<td class="num">(7,319)<span></span>
</td>
<td class="num">(730,257)<span></span>
</td>
<td class="nump">265,505<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">44,444,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">$ 2,683<span></span>
</td>
<td class="nump">992,136<span></span>
</td>
<td class="num">(11,966)<span></span>
</td>
<td class="num">(687,706)<span></span>
</td>
<td class="nump">295,147<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">44,299,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Income (Loss) for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,551)<span></span>
</td>
<td class="num">(42,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive Income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">2,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="nump">139,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Restricted and performance share units distributed during the period (in shares)</a></td>
<td class="nump">4,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ordinary shares relating to employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ordinary shares relating to employee stock purchase plan (in shares)</a></td>
<td class="nump">1,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 2,692<span></span>
</td>
<td class="nump">1,000,389<span></span>
</td>
<td class="num">(7,319)<span></span>
</td>
<td class="num">(730,257)<span></span>
</td>
<td class="nump">265,505<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">44,444,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(784,731)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 2,711<span></span>
</td>
<td class="nump">1,016,018<span></span>
</td>
<td class="nump">9,907<span></span>
</td>
<td class="num">(784,731)<span></span>
</td>
<td class="nump">$ 243,905<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">44,777,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,777,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Income (Loss) for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,912<span></span>
</td>
<td class="nump">$ 357,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive Income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,502)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">29,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares (in shares)</a></td>
<td class="nump">921,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears', window );">Tax benefit past share issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="nump">71,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Restricted and performance share units distributed during the period</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Restricted and performance share units distributed during the period (in shares)</a></td>
<td class="nump">277,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ordinary shares relating to employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ordinary shares relating to employee stock purchase plan (in shares)</a></td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 2,788<span></span>
</td>
<td class="nump">1,062,234<span></span>
</td>
<td class="num">(4,595)<span></span>
</td>
<td class="num">(426,819)<span></span>
</td>
<td class="nump">$ 633,608<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">46,050,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,050,250<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">$ 2,780<span></span>
</td>
<td class="nump">1,049,850<span></span>
</td>
<td class="nump">2,347<span></span>
</td>
<td class="num">(826,287)<span></span>
</td>
<td class="nump">$ 228,690<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">45,924,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Income (Loss) for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,468<span></span>
</td>
<td class="nump">399,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive Income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,942)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares (in shares)</a></td>
<td class="nump">61,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears', window );">Tax benefit past share issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="nump">55,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Restricted and performance share units distributed during the period</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Restricted and performance share units distributed during the period (in shares)</a></td>
<td class="nump">8,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,031<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 2,788<span></span>
</td>
<td class="nump">$ 1,062,234<span></span>
</td>
<td class="num">$ (4,595)<span></span>
</td>
<td class="num">$ (426,819)<span></span>
</td>
<td class="nump">$ 633,608<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">46,050,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,050,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (426,819)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from tax effect of prior years issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740488046184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 357,912<span></span>
</td>
<td class="num">$ (70,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income / (loss) to net cash generated from / used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="nump">3,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">12,792<span></span>
</td>
<td class="nump">10,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration', window );">Change in fair value of derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Unrealized foreign exchange gains, net</a></td>
<td class="num">(12,279)<span></span>
</td>
<td class="num">(908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items, net</a></td>
<td class="nump">539<span></span>
</td>
<td class="num">(1,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets', window );">Accounts receivable, prepaid expenses, and other current assets and receivables</a></td>
<td class="num">(3,355)<span></span>
</td>
<td class="nump">1,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">10,444<span></span>
</td>
<td class="num">(981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses, other liabilities, and operating leases</a></td>
<td class="nump">5,486<span></span>
</td>
<td class="num">(1,332)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash generated from / (used) in operating activities</a></td>
<td class="nump">375,206<span></span>
</td>
<td class="num">(62,944)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(6,191)<span></span>
</td>
<td class="num">(2,392)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(6,191)<span></span>
</td>
<td class="num">(4,606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from loan increment, net of debt issuance costs</a></td>
<td class="nump">34,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of ordinary shares</a></td>
<td class="nump">30,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issuance costs from issuance of ordinary shares</a></td>
<td class="num">(1,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares related to employee stock option and purchase plans</a></td>
<td class="nump">960<span></span>
</td>
<td class="nump">3,549<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash generated from financing activities</a></td>
<td class="nump">65,128<span></span>
</td>
<td class="nump">3,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Currency effect on cash, cash equivalents and restricted cash</a></td>
<td class="num">(1,665)<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase / (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">432,478<span></span>
</td>
<td class="num">(63,778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">247,680<span></span>
</td>
<td class="nump">380,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of period</a></td>
<td class="nump">680,158<span></span>
</td>
<td class="nump">316,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">677,330<span></span>
</td>
<td class="nump">314,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash related to leasehold and other deposits</a></td>
<td class="nump">2,828<span></span>
</td>
<td class="nump">2,683<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">680,158<span></span>
</td>
<td class="nump">316,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="num">(2,943)<span></span>
</td>
<td class="num">(2,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets', window );">Non-cash increase in accounts payables and accrued expenses and other current liabilities related to purchases of intangible assets and property, plant, and equipment</a></td>
<td class="nump">$ 3,488<span></span>
</td>
<td class="nump">$ 1,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of change in fair value of derivative financial instruments and contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period for accounts payable and accrued liabilities under supplemental cash flow information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accounts receivable, prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740406519400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General business information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General business information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">General business information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">1</b></span>General business information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">uniQure (the &#8220;Company&#8221;) was incorporated on January 9, 2012 as a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company&#8217;s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics (AMT) Holding N.V (&#8220;AMT&#8221;). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability (<i style="font-style:italic;">naamloze vennootschap</i>) and changed its legal name from uniQure B.V. to uniQure N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 1pt 0pt 1pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is registered in the trade register of the Chamber of Commerce (<i style="font-style:italic;">Kamer van Koophandel</i>) in Amsterdam, the Netherlands under number 54385229. The Company&#8217;s headquarters are in Amsterdam, the Netherlands, and its registered office is located at Paasheuvelweg 25, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol &#8220;QURE&#8221;.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740406594984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">2</b></span>Summary of significant accounting policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.1</b></span><b style="font-weight:bold;">Basis of preparation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company prepared these unaudited consolidated financial statements in compliance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The unaudited consolidated financial statements are presented in U.S. dollars, except where otherwise indicated. Transactions denominated in currencies other than U.S. dollars are presented in the transaction currency with the U.S. dollar amount included in parenthesis, converted at the foreign exchange rate as of the transaction date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.2</b></span><b style="font-weight:bold;">Unaudited interim financial information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the financial position, results of operations and changes in financial position for the period presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. The results of operations for the six months ended June 30, 2021, are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or for any other future year or interim period. The accompanying financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company&#8217;s <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm" style="-sec-extract:exhibit;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021</span></a>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.3</b></span><b style="font-weight:bold;">Use of estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.4</b></span><b style="font-weight:bold;">Accounting policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">      The principal accounting policies applied in the preparation of these unaudited consolidated financial statements are described in the Company&#8217;s audited financial statements as of and for the year ended December 31, 2020, and the notes thereto, which are included in the Company&#8217;s </span><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm" style="-sec-extract:exhibit;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021</span></a>. There have been no material changes in the Company&#8217;s significant accounting policies during the six months ended June 30, 2021 except as noted below. <span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company determined its revenue recognition policies related to the CSL Behring Agreement (defined below) when the CSL Behring Agreement became fully effective on May 6, 2021. Refer to Note 3 (&#8220;Collaboration arrangements and concentration of credit risk&#8221;) for further detail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;"> </span>The Company for the first time recognized net income in the three and six months ended June 30, 2021. Net income / (loss) per ordinary share was calculated in accordance with ASC 260, Earnings Per Share. Refer to Note 11 (&#8220;Basic and diluted earnings per share&#8221;) for further detail. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.5</b></span><b style="font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There have been no new accounting pronouncements or changes to accounting pronouncements during the six months ended June 30, 2021, as compared to the recent accounting pronouncements described in Note 2.3.22 of the Company&#8217;s <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm" style="-sec-extract:exhibit;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Annual Report on Form 10-K for the year ended December 31, 2020</span></a>, which could be expected to materially impact the Company&#8217;s unaudited consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740406507144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration arrangements and concentration of credit risk<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract', window );"><strong>Collaboration arrangements and concentration of credit risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock', window );">Collaboration arrangements and concentration of credit risk</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Collaboration arrangements and concentration of credit risk</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">CSL Behring collaboration</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June 24, 2020, (&#8220;Signing&#8221;), uniQure biopharma B.V., a wholly-owned subsidiary of uniQure N.V., entered into a commercialization and license agreement (the &#8220;CSL Behring Agreement&#8221;) with CSL Behring LLC, (&#8220;CSL Behring&#8221;), pursuant to which CSL Behring received exclusive global rights to etranacogene dezaparvovec, the Company&#8217;s investigational gene therapy for patients with hemophilia B, (the &#8220;Product&#8221;). On May 6, 2021, the CSL Behring Agreement became fully effective (&#8220;Closing&#8221;) upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on May 5, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the CSL Behring Agreement, the Company has received a $450.0 million upfront cash payment and $12.4 million in other payments related to the transfer of the license, during the three and six months ended June 30, 2021. The Company is eligible to receive up to $1.6 billion in additional payments based on regulatory and commercial milestones. The CSL Behring Agreement also provides that the Company will be eligible to receive tiered double-digit royalties in a range of up to a low-twenties percent of net sales of the Product based on sales thresholds. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt;">On Signing, the Company and CSL Behring entered into a development and commercial supply agreement, pursuant to which, among other things, the Company will supply the Product to CSL Behring at an agreed-upon price commensurate with the stand-alone selling price (&#8220;SSP&#8221;). The Company will be responsible for supplying development and commercial Product until such time that these capabilities may be transferred to CSL Behring or a designated contract manufacturing organization. The Company will be completing the HOPE-B clinical trial and the validation of the manufacturing process on behalf of CSL Behring, as well as provide further development services if requested by CSL Behring. Activities related to on-demand development services as well as activities related to the completing the HOPE-B clinical trial will be reimbursed by CSL Behring at an agreed full-time-employee rate (&#8220;FTE-rate&#8221;) and CSL Behring will also reimburse agreed third-party expenses incurred in relation to performing these activities. The validation of the manufacturing process as well as the development and validation of a next generation manufacturing process (&#8220;Manufacturing Development Services&#8221;) will be reimbursed through a future milestone payment. If completed after certain contractually agreed dates, the milestone payment will be reduced in accordance with a contractually agreed mechanism.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that CSL Behring is a customer in accordance with Topic 606. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company identified two material performance obligations related to the CSL Behring Agreement: </p><div style="margin-top:6pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Sale of the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">exclusive global rights to the Product (&#8220;License&#8221;); and</span></td><td style="width:0.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:justify;">Generate information to support the regulatory approval of the current and next generation manufacturing process of Product and to provide any such information generated to CSL Behring (&#8220;Manufacturing Development&#8221;).</span></td><td style="width:0.2pt;"/></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">These performance obligations are considered distinct from one another, as CSL Behring can benefit from the identified service either on its own or together with other resources that are readily available to CSL Behring, and as the performance obligation is separately identifiable from other performance obligations in the CSL Behring Agreement. The Company continued to develop the Product between Signing and Closing and performed certain reimbursable activities to fulfill the transfer of the global rights (&#8220;Additional Covenants&#8221; and together with the License the &#8220;License Sale&#8221;). The Additional Covenants are not considered distinct from the performance obligation to sell the license to CSL Behring as CSL Behring could not benefit from the Additional Covenants on their own, or have these activities be performed with readily available resources. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">The Company determined that the fixed upfront payment of </span><span style="background-color:#ffffff;">$450.0</span><span style="background-color:#ffffff;"> million and the </span><span style="background-color:#ffffff;">$12.4</span><span style="background-color:#ffffff;"> million that the Company received in relation to the Additional Covenants should be allocated to the License Sale. In addition, the Company concluded that variable milestone payments, sales milestone payments and royalties should be allocated to the License Sale performance obligation as well. The Company determined that the sale of the License was completed on May 6, 2021, when it transferred the License and CSL Behring assumed full responsibility for the development and commercialization of the Product. At Closing, the Company evaluated the amount of potential payments and the likelihood that the payments will be received. The Company utilized the most likely amount method to estimate the variable consideration to be included in the transaction price. Since the Company cannot control the achievement of regulatory and first commercial sales milestones, the Company concluded that the potential payments are constrained as of Closing. The Company determined that it will recognize revenue related to these payments only to the extent that it becomes probable that no significant reversal of recognized cumulative revenue will occur thereafter. The Company will include payments related to sales milestones in the transaction price when their achievement becomes probable, and it will include royalties on the sale of Product once these have been earned. The Company recognized </span><span style="background-color:#ffffff;">$462.4</span><span style="background-color:#ffffff;"> million of revenues related to the License Sale in the three and six months ended June 30, 2021. The costs associated with fulfilling this performance obligation are presented as &#8220;Cost of contract revenue&#8221; with the exception of the cost incurred prior to the Closing, which had been presented as &#8220;Research and development expenses</span>&#8221;. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;"><span style="background-color:#ffffff;">The Company determined that the variable milestone payment related to Manufacturing Development Services should be allocated to the Manufacturing Development performance obligation. The Company concluded that this milestone payment represents the SSP of the services based on the estimated cost of providing the services including a reasonable margin. The services related to Manufacturing Development will be provided between Closing and the completion of an agreed manufacturing development plan. The variable consideration will be reduced if the Company does not complete the development by pre-agreed dates. The Company utilized the most likely amount method to estimate the variable consideration to be included in the transaction price. Completion of Manufacturing Development is partially dependent on the timing of regulatory submissions by CSL Behring as well as regulatory approvals of the developed manufacturing processes. Since the Company cannot control the timing or outcome of any regulatory decisions, the Company concluded that it would recognize revenue related to this payment when it becomes probable that the milestone has been achieved. The Company did not recognize any revenue related to Manufacturing Development during the three and six months ended June 30, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:6pt 0.2pt 12pt 0pt;">The Company recognized $0.4 million of collaboration revenue in the three and six months ended June 30, 2021, compared to nil in the same periods in the prior year. &#160;The Company generates such collaboration revenue from services rendered in relation to completing the HOPE-B clinical trial on behalf of CSL Behring. CSL Behring may request <span style="background-color:#ffffff;">additional development services or to request the Company to support the transfer of manufacturing to a party designated by CSL Behring. These collaboration services will be reimbursed at the pre-agreed FTE-rate. </span>The Company concluded that these rights at Closing do not represent material rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:36pt;margin:0pt 0.2pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"/>As of June 30, 2021, the Company has an accounts receivable of $1.3 million from CSL Behring. The Company collected the $2.1 million of accounts receivable related to reimbursable contract fulfillment costs that was outstanding as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Bristol-Myers Squibb collaboration</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In May 2015, the Company and Bristol-Myers Squibb (&#8220;BMS&#8221;) entered into a collaboration and license agreement and various related agreements with BMS (&#8220;BMS CLA&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The initial four-year research term under the collaboration terminated on May 21, 2019. On December 1, 2020, the Company and BMS amended the BMS CLA (&#8220;amended BMS CLA&#8221;). Under the amended BMS CLA, BMS is limited to four Collaboration Targets. BMS may until November 30, 2021 replace up to two of these four Collaboration Targets with up to two new targets in the field of cardiovascular disease. The Company continues to be eligible to receive research, development, and regulatory milestone payments of up to $217.0 million for each Collaboration Target if defined milestones are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For as long as any of the four Collaboration Targets are being advanced, BMS may place a purchase order to be supplied with research, clinical and commercial supplies. Subject to the terms of the amended BMS CLA, BMS has the right to terminate the research, clinical and commercial supply relationships, and has certain remedies for failures of supply, up to and including technology transfer for any such failure that otherwise cannot be reasonably resolved. Both BMS and the Company may agree to a technology transfer of manufacturing capabilities pursuant to the terms of the amended BMS CLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The amended BMS CLA does not extend the initial four-year research term. BMS may place purchase orders to provide limited services primarily related to analytical and development efforts in respect of the four Collaboration Targets. BMS may request such services for a period not to exceed the earlier of (i) the completion of all activities under a Research Plan and (ii) either (A) three years after the last replacement target has been designated by BMS during the one-year replacement period ending on November 30, 2021, or (B) November 30, 2023 if no replacement targets are designated. BMS continues to reimburse the Company for these services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company evaluated the impact of the amended BMS CLA in relation to its performance obligation to provide access to BMS to its technology and know-how in the field of gene therapy and to participate in joint steering committee and other governing bodies (&#8220;License Revenue&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company determined that its remaining performance obligation under the amended BMS CLA was immaterial and recognized the remaining balance of unrecognized License Revenue as of November 30, 2020. The Company includes variable consideration related to any research, development, and regulatory milestone payments, in the transaction price once it is considered probable that including these payments in the transaction price would not result in the reversal of cumulative revenue recognized. Due to the significant uncertainty surrounding the development of gene-therapy product candidates and the dependence on BMS&#8217;s performance and decisions, the Company does not generally consider this probable and did not record any License Revenue during the six months ended June 30, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"/> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> &#160;</span></span><span style="display:inline-block;width:18pt;"/> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaboration arrangements and concentration of credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740407888888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair value measurement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurement</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;">4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:5pt;font-weight:bold;">&#160;</b>Fair value measurement</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company measures certain financial assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. U.S. GAAP requires disclosure of methodologies used in determining the reported fair values, and establishes a hierarchy of inputs used when available. The three levels of the fair value hierarchy are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 1 &#8211; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 2 &#8211; Valuations based on quoted prices for similar assets or liabilities in markets that are not active or models for which the inputs are observable, either directly or indirectly. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 3 &#8211; Valuations that require inputs that reflect the Company&#8217;s own assumptions that are both significant to the fair value measurement and are unobservable. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The carrying amount of cash and cash equivalents, accounts receivable, prepaid expenses, other assets, accounts payable, accrued expenses and other current liabilities reflected in the Consolidated balance sheets approximate their fair values due to their short-term maturities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table sets forth the Company&#8217;s assets and liabilities that are required to be measured at fair value on a recurring basis as of June 30, 2021, and December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;prices<br/>in&#160;active<br/>markets<br/>(Level&#160;1)</b></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant<br/>other<br/>observable<br/>inputs<br/>(Level&#160;2)</b></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant<br/>unobservable<br/>inputs<br/>(Level&#160;3)</b></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:22.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification&#160;in&#160;Consolidated<br/>balance&#160;sheets</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"/></tr><tr><td style="vertical-align:top;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:top;width:38.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Assets:</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash, cash equivalents and restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247,680</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247,680</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash and cash equivalents; other non-current assets</p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Derivative financial instruments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other non-current liabilities</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">At June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 680,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 680,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash and cash equivalents; other non-current assets</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 680,158</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 680,158</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Derivative financial instruments </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other non-current liabilities</p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognized no gains or losses related to changes in the fair market value of derivative financial instruments during the three and six months ended June 30, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 41pt;">Derivative financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 41pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company issued derivative financial instruments related to its collaboration with BMS. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.3pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In 2015, the Company granted BMS two warrants that were subsequently terminated in connection with the amendment to the BMS CLA on December 1, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December 1, 2020, the Company and BMS agreed that upon the consummation of a change of control transaction of uniQure that occurs prior to December 1, 2026 or BMS&#8217; delivery of a target cessation notice for all four Collaboration Targets, the Company (or its third party acquirer) shall pay to BMS a one-time, non-refundable, non-creditable cash payment of $70.0 million, provided that (x) if $70.0 million is greater than five percent (5.0%) of the net proceeds (as contractually defined) from such change of control transaction, the payment shall be an amount equal to five percent of such net proceeds, and (y) if $70.0 million is less than one percent of such net proceeds, the change of control payment shall be an amount equal to one percent of such net proceeds (&#8220;CoC-payment&#8221;). The Company has not consummated any change of control transaction as of June 30, 2021 that would obligate it to make a CoC-payment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company determined that the CoC-payment should be recorded as a derivative financial liability as of December 1, 2020 and that subsequent changes in the fair market value of this derivative financial liability should be recorded in profit and loss. The fair market value of the derivative financial liability is materially impacted by probability that market participants assign to the likelihood of the occurrence of a change of control transaction that would give rise to a CoC-payment. This probability represents an unobservable input. The Company determined the fair market value of the derivative financial liability by using a present value model based on expected cash flow. The expected cash flows are materially impacted by the probability that market participants assign to the likelihood of the occurrence of a change of control transaction within the biotechnology industry. The Company estimated this unobservable input using the best information available as of June 30, 2021 and December 31, 2020. The Company obtained reasonably available market information that it believed market participants would use in determining the likelihood of the occurrence of a change-of control transaction within the biotechnology industry. Selecting and evaluating market information involves considerable judgement and uncertainty. Based on all such information and its judgment the Company estimated that the fair market value of the derivative financial liability (presented within &#8220;Other non-current liabilities&#8221;) as of June 30, 2021 and December 31, 2020 was $2.6 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740413380552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses and other current liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued expenses and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock', window );">Accrued expenses and other current liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Accrued expenses and other current liabilities</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities include the following items:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accruals for services provided by vendors-not yet billed</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,269</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel related accruals and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,687</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,082</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 23,526</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 18,038</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740408443624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">6 </b></span><span style="display:inline-block;width:18pt;"/><b style="font-weight:bold;">Long-term debt</b><span style="display:inline-block;width:4.51pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">On June 14, 2013, the Company entered into a venture debt loan facility with Hercules Capital, Inc. (formerly known as Hercules Technology Growth Capital, Inc.) (&#8220;Hercules&#8221;), which was amended and restated on June 26, 2014, and again on May 6, 2016 (&#8220;2016 Amended Facility&#8221;). On December 6, 2018, the Company signed an amendment that both refinanced the then-existing $20.0 million 2016 Amended Facility and allowed the Company to draw down an additional $15.0 million (&#8220;2018 Amended Facility&#8221;). The 2018 Amended Facility extended the loan&#8217;s maturity date from May 1, 2020 until June&#160;1, 2023.&#160;The interest-only period was initially extended from November&#160;2018 to January&#160;1, 2021 and was further extended to January 1, 2022 as a result of raising more than $90.0 million in equity financing in September 2019.&#160;The interest only period was again further extended to June 1, 2023 as a result of the January 2021 amendment (see below). &#160;The interest rate is adjustable and is the greater of (i)&#160;8.85% and (ii)&#160;8.85% plus the prime rate less 5.50% per annum. Under the 2018 Amended Facility, the Company owes a back-end fee of 4.95% of the outstanding debt. In addition, in May 2020 the Company paid a back-end fee of $1.0 million in relation to the 2016 Amended Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="background-color:#ffffff;">On January 29, 2021, the Company and Hercules amended the 2018 Amended Facility (&#8220;2021 Amended Facility&#8221;). Pursuant to the 2021 Amended Facility, Hercules agreed to an additional Facility of </span><span style="background-color:#ffffff;">$100.0</span><span style="background-color:#ffffff;"> million (&#8220;Tranche B&#8221;), increasing the aggregate principal amount of the term loan facilities from </span><span style="background-color:#ffffff;">$35.0</span><span style="background-color:#ffffff;">&#160;million to up to </span><span style="background-color:#ffffff;">$135.0</span><span style="background-color:#ffffff;">&#160;million. On January 29, 2021, the Company drew down </span><span style="background-color:#ffffff;">$35.0</span><span style="background-color:#ffffff;">&#160;million of the Tranche B. The Company may draw down the remaining </span><span style="background-color:#ffffff;">$65.0</span><span style="background-color:#ffffff;">&#160;million under the Tranche B in a series of one or more advances of not less than </span><span style="background-color:#ffffff;">$20.0</span><span style="background-color:#ffffff;">&#160;million each until December 15, 2021. Advances under Tranche B bear interest at a rate equal to the greater of (i)&#160;</span><span style="background-color:#ffffff;">8.25%</span><span style="background-color:#ffffff;"> or (ii)&#160;</span><span style="background-color:#ffffff;">8.25%</span><span style="background-color:#ffffff;"> plus the prime rate, less&#160;</span><span style="background-color:#ffffff;">3.25%</span><span style="background-color:#ffffff;"> per annum. The principal balance and all accrued but unpaid interest on advances under Tranche B is due on June 1, 2023, which date may be extended by the Company by up to two twelve-month periods. Advances under Tranche B may not be prepaid prior to July 29, 2021, following which the Company may prepay all such advances without charge. </span>The Company owes a back-end fee of 4.85% of amounts outstanding under Tranche B. The back-end fee is reduced if prepayment occurs at an earlier date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The amortized cost (including interest due presented as part of accrued expenses and other current liabilities) of the 2018 Amended Facility and 2021 Amended Facility was $71.3 million as of June 30, 2021, compared to $35.9 million amortized cost for the 2018 Amended Facility as of December 31, 2020, and is recorded net of discount and debt issuance costs. The foreign currency gain on the facilities in the three months ended June 30, 2021, was $0.9 million and the foreign currency loss on the facilities in the six months ended June 30, 2021, was $2.2 million, compared to a foreign currency gain of $0.7 million and $0.0 million during the same periods in 2020 for the 2018 Amended Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Interest expense associated with the 2018 Amended Facility and 2021 Amended Facility during the three and six months ended June 30, 2021, was $1.8 million and $3.4 million, compared to $0.9 million and $1.8 million, respectively, during the same periods in 2020 for the 2018 Amended Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">As a covenant in the 2018 Amended Facility and 2021 Amended Facility, the Company has periodic reporting requirements and is required to keep a minimum cash balance deposited in bank accounts in the United States, equivalent to the lesser of (i) 65% of the outstanding balance of principal due or (ii) 100% of worldwide cash and cash equivalents. This restriction on cash and cash equivalents only relates to the location of the cash and cash equivalents, and such cash and cash equivalents can be used at the discretion of the Company. In combination with other covenants, the 2018 Amended Facility and 2021 Amended Facility restricts the Company&#8217;s ability to, among other things, incur future indebtedness and obtain additional debt financing, to make investments in securities or in other companies, to transfer assets, to perform certain corporate changes, to make loans to employees, officers, and directors, and to make dividend payments and other distributions to its shareholders. The Company secured the facilities by directly or indirectly pledging its total assets of $784.3 million with the exception of $103.5 million of cash and cash equivalents and other current assets held by uniQure N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The 2018 Amended Facility and 2021 Amended Facility contain provisions that include the occurrence of a material adverse effect, as defined therein, which would entitle Hercules to declare all principal, interest and other amounts owed by the Company immediately due and payable. As of June 30, 2021, the Company was in material compliance with all covenants and provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740407886184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">7</b></span><span style="display:inline-block;width:18pt;"/>Shareholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 1, 2021, the Company entered into a Sales Agreement with SVB Leerink LLC (&#8220;SVB Leerink&#8221;) with respect to an at-the-market (&#8220;ATM&#8221;) offering program, under which the Company may, from time to time in its sole discretion, offer and sell through SVB Leerink, acting as agent, its ordinary shares, up to an aggregate offering price of $200.0 million. The Company will pay SVB Leerink a commission equal to 3% of the gross proceeds of the sales price of all ordinary shares sold through it as sales agent under the Sales Agreement. In March and April 2021, the Company issued 921,730 ordinary shares at a weighted average price of $33.52 per share, with net proceeds of $29.6 million, after deducting underwriting discounts and net of offering expenses. The Company defers direct, incremental costs associated to this offering, except for the commission costs to SVB Leerink, which are a reduction to additional paid-in capital, and will deduct these costs from additional paid-in capital in the consolidated balance sheets proportionately to the amount of proceeds raised. During the three and six months ended June 30, 2021, $0.3 million and $1.3 million of direct, incremental costs were deducted from additional paid-in capital. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Following the release of the valuation allowance related to the years 2011 to 2018, the Company recognized the tax benefits of share issuance costs incurred in 2014, 2015, 2017 and 2018. This resulted in an increase of additional paid-in capital of $3.0 million in the three and six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740406321000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">8</b></span><span style="display:inline-block;width:18pt;"/>Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">The Company&#8217;s share-based compensation plans include the 2014 Amended and Restated Share Option Plan (the &#8220;2014 Plan&#8221;) and inducement grants under Rule 5653(c)(4) of the Nasdaq Global Select Market with terms similar to the 2014 Plan (together the &#8220;2014 Plans&#8221;). At the annual general meeting of shareholders in June 2021, the Company&#8217;s shareholders approved amendments of the 2014 Plan, increasing the shares authorized for issuance by&#160;</span><span style="background-color:#ffffff;">4,000,000</span><span style="background-color:#ffffff;">&#160;to a total of&#160;</span><span style="background-color:#ffffff;">12,601,471</span><span style="background-color:#ffffff;">.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2014 Plans</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Share-based compensation expense recognized by classification included in the Consolidated statements of operations and comprehensive loss in relation to the 2014 Plans for the periods indicated below was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.25%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,286</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,889</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,960</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,271</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,825</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,783</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,714</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,775</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,054</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">Share-based compensation expense recognized by award type was as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.25%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:22.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Award type</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share options</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,746</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,954</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted share units</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,222</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,209</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,782</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,653</p></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance share units</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 449</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 759</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 803</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,447</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,714</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,775</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,054</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2021, the unrecognized share-based compensation expense related to unvested awards under the 2014 Plans were:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrecognized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share-based</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">period for </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;recognition&#160;&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Award type</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share options</p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.99</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted share units</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,960</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.25</p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance share units</p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.58</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 60,607</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2.66</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company satisfies the exercise of share options and vesting of Restricted Share Units (&#8220;RSUs&#8221;) and Performance Share Units (&#8220;PSUs&#8221;) through newly issued ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Share options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">Share options are priced on the date of grant and, except for certain grants made to non-executive directors, vest over a period of four years. The first 25% vests after one year from the initial grant date and the remainder vests in equal quarterly installments over years two, three and four. Certain grants to non-executive directors vest in full after one year. Any options that vest must be exercised by the tenth anniversary of the initial grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">       </span>The following tables summarize option activity under the Company&#8217;s 2014 Plans for the six months ended June 30, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise price</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,659,279</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28.13</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 914,118</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36.36</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (74,397)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43.19</p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,093)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44.14</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,976)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.65</p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,417,931</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 30.29</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereof, fully vested and exercisable at June&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,774,059</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.68</p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereof, outstanding and expected to vest after June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,643,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39.58</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total weighted average grant date fair value of options issued during the period (in $ millions)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.4</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from option sales during the period (in $ millions)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of each option issued is estimated at the respective grant date using the Hull &amp; White option pricing model with the following weighted-average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Assumptions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">75%</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">70%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">75%</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">70%</p></td></tr><tr><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected terms</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">10 years</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">10 years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">10 years</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">10 years</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">1.72% - 1.85%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0.76% - 0.83%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">1.21% - 1.85%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0.76% - 1.44%</p></td></tr><tr><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Restricted share units (&#8220;RSUs&#8221;) </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the RSUs activity for the six months ended June 30, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSU</b></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average</b></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant-date fair</b></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-vested at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 467,344</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 43.56</b></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 481,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36.50</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (145,203)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39.89</p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited </p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,067)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42.86</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-vested at June&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 772,895</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 39.87</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total weighted average grant date fair value of RSUs granted during the period (in $ millions)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.6</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">RSUs vest over <span style="-sec-ix-hidden:Hidden_MCRGihcaXES2tnUHXX0Fgg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">one</span></span> to three years. RSUs granted to non-executive directors vest one year from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Performance share units (&#8220;PSUs&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">The following table summarizes the PSUs activity for the six months ended June 30, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PSU</b></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average</b></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant-date fair</b></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-vested at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 212,614</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 42.32</b></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (132,368)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33.09</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,916)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57.56</p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-vested at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 77,330</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 57.56</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.7pt 0pt 5pt;">The PSUs will vest on the third anniversary of the grant, subject to the grantee&#8217;s continued employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Employee Share Purchase Plan (&#8220;ESPP&#8221;)</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 5.05pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 5.05pt;">In June 2018, the Company&#8217;s shareholders adopted and approved an ESPP allowing the Company to issue up to 150,000 ordinary shares. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code of 1986. Under the ESPP, employees are eligible to purchase ordinary shares through payroll deductions, subject to any plan limitations. The purchase price of the ordinary shares on each purchase date is equal to 85% of the lower of the closing market price on the offering date and the closing market price on the purchase date of each three-month offering period. During the six months ended June 30, 2021, 1,174 ordinary shares were issued under the ESPP compared to 3,005 during the same period in 2020. As of June 30, 2021, a total of 130,852 ordinary shares remain available for issuance under the ESPP plan compared to a total of 135,202 as of June 30, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740406617064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract', window );"><strong>Other income.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_OtherIncomeTextBlock', window );">Other income</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">9</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Other income </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other income during the three and six months ended June 30, 2021, was $7.6 million and $7.9 million, compared to $0.7 million and $1.5 million, respectively, during the same periods in 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other income in 2020 and 2021 includes income from payments received from European authorities to subsidize the Company&#8217;s research and development efforts in the Netherlands as well as income from subleasing part of the Amsterdam facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, other income during the three and six months ended June 30, 2021 includes $1.3 million of employee retention credit received under the U.S. Coronavirus Aid, Relief, and Economic Security Act, as well as $3.0 million related to 69,899 shares in VectorY B.V. received in conjunction with a settlement agreement entered into in April 2021. No such income was recorded in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:normal;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_OtherIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_OtherIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeDisclosureNonoperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740406543000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Income taxes </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recorded $3.3 million in income tax expense in the three months ended June 30, 2021, and $3.5 million in the six months ended June 30, 2021. The Company recorded no income tax expense during the same periods in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2020, the Company had recorded a full valuation allowance against its Dutch net deferred tax assets. On May 6, 2021, the CSL Behring Agreement became effective (refer to Note 3 &#8220;Collaboration arrangements and concentration of credit risk&#8221;). The Company recorded $462.4 million of license revenue related to closing the transaction. The Company intends to record such revenue in its Dutch tax return related to the 12-month period ended December 31, 2020. As such, the Company expects to file a return showing a taxable profit in the Netherlands in 2020, which would result in the consumption of substantially all of its Dutch net operating losses for the years 2011 to 2018. The Company&#8217;s remaining Dutch net operating tax losses carried forward would relate to 2019. The Dutch government on June 4, 2021 enacted legislation, whereby such net operating tax losses can be carried forward indefinitely. The Company expects to continue incurring tax losses for the foreseeable future including 2021. As such, the Company retained its full valuation allowance related to the net deferred assets as of June 30, 2021. The adjustment to the Company&#8217;s 2020 filing position resulting in the release and consumption of prior year net operating tax losses carried forward was treated as a discrete event in the three months ended June 30, 2021. The Company allocated part of the release to the tax benefit of share issuance cost incurred in 2014, 2015, 2017 and 2018. This resulted in an increase of additional paid-in capital as well as deferred tax expenses of $3.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company released its valuation allowance against the Company&#8217;s deferred tax assets in the United States as of December 31, 2020. The Company recorded $0.2 million and $0.5 million deferred tax expense in relation to its operations in the United States during the three and six months ended June 30, 2021, respectively. The Company recorded a nil net deferred tax expense in the prior year as it had recorded a valuation allowance against its net deferred tax assets in the United States as of June 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The effective income tax rates of respectively -0.8% and -1.0% during the three and six months ended June 30, 2021, is substantially lower than the enacted rated of 25% in the Netherlands as the Company recorded a valuation allowance against its remaining net deferred tax assets in the Netherlands as of December 31, 2020, and June 30, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740407866248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and diluted earnings per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">11</b></span><span style="display:inline-block;width:18pt;"/>Basic and diluted earnings per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Basic net income / (loss) per ordinary share is computed by dividing net income / (loss) for the period by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per ordinary share are calculated by adjusting the weighted average number of ordinary shares outstanding, assuming conversion of all potentially dilutive ordinary shares. For the three months and six months ended June 30, 2021, dilutive net income per ordinary share is computed using the treasury method. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table provides the calculation of basic and diluted earnings per ordinary share: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income / (loss) attributable to ordinary shares</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 399,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (42,551)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 357,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (70,550)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 399,468</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (42,551)</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 357,912</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (70,550)</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average number of ordinary shares outstanding - basic</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,037,900</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,387,463</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,754,766</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,333,460</p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options under 2014 Plans and previous plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 797,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 824,101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-vested RSUs and PSUs</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 92,681</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,514</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee share purchase plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average number of ordinary shares outstanding - diluted</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 46,929,870</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 44,387,463</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 46,678,835</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 44,333,460</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents ordinary share equivalents that were excluded from the calculation of diluted net income / (loss) per ordinary share for the three and six months ended June 30, 2021 and 2020 as the effect of their inclusion would have been anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:22.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Anti-dilutive ordinary share equivalents</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options under 2014 Plans and previous plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,634,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,893,733</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,607,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,893,733</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-vested RSUs and PSUs</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 757,544</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 645,636</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 751,711</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 645,636</p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee share purchase plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 254</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 254</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">BMS warrants (derecognized as of December 1, 2020 - see Note 4, "Fair value measurement")</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,060,500</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,060,500</p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total anti-dilutive ordinary share equivalents</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,393,724</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,600,123</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,361,343</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,603,143</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The anti-dilutive ordinary shares are presented without giving effect to the application of the treasury method or exercise prices that exceeded the price of the Company&#8217;s ordinary shares as of June 30, 2020. In addition, the BMS warrants were not exercisable as of June 30, 2020. This would have resulted in a lower number of potentially dilutive ordinary shares as some stock option grants as well as the BMS warrants would have been excluded.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740406394280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">12</b></span><span style="display:inline-block;width:18pt;"/>Subsequent event</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Business combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June 22, 2021, the Company announced that it entered into a definitive transaction agreement under which the Company will acquire Corlieve Therapeutics S.A.S. (&#8220;Corlieve&#8221;, together the &#8220;Corlieve Transaction&#8221;). The Corlieve Transaction has been approved by the Boards of both companies and does not require the Company&#8217;s shareholder approval. The transaction is subject to customary closing conditions as well as review by the French Ministry of Economy, Finance and Recovery (Minist&#232;re de l&#8217;Economie, des Finances et de la Relance) pursuant to articles L.151-3 and R.151-1 and seq. of the French Code Mon&#233;taire et Financier. Currently, the transaction is anticipated to be completed early in the third quarter of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Corlieve Transaction strengthens the Company&#8217;s pre-clinical program pipeline. Corlieve&#8217;s lead gene therapy program employs miRNA silencing technology to target suppression of aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (&#8220;TLE&#8221;) and will be known as AMT-260. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Upon closing of the Corlieve Transaction, the Company expects to pay EUR 46.3 million in cash. The Company will fund the acquisition from its cash position. Corlieve&#8217;s shareholders are eligible to receive the following additional payments of which up to 25% will be payable in the Company&#8217;s ordinary shares at the Company&#8217;s election: up to EUR 43.7 million in development milestones through Phase I/II and EUR 160.0 million in milestones associated with Phase III development and the approvals of AMT-260 in the U.S and European Union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Corlieve Transaction is expected to be accounted for as a business combination, which requires that assets acquired and liabilities assumed be recognized at their fair value as of the acquisition date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 41.35pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:normal;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740404904168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of preparation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.1</b></span><b style="font-weight:bold;">Basis of preparation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company prepared these unaudited consolidated financial statements in compliance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The unaudited consolidated financial statements are presented in U.S. dollars, except where otherwise indicated. Transactions denominated in currencies other than U.S. dollars are presented in the transaction currency with the U.S. dollar amount included in parenthesis, converted at the foreign exchange rate as of the transaction date.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_UnauditedInterimFinancialInformationPolicyTextBlock', window );">Unaudited interim financial information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.2</b></span><b style="font-weight:bold;">Unaudited interim financial information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the financial position, results of operations and changes in financial position for the period presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. The results of operations for the six months ended June 30, 2021, are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or for any other future year or interim period. The accompanying financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company&#8217;s <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm" style="-sec-extract:exhibit;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021</span></a>.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.3</b></span><b style="font-weight:bold;">Use of estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Accounting policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.4</b></span><b style="font-weight:bold;">Accounting policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">      The principal accounting policies applied in the preparation of these unaudited consolidated financial statements are described in the Company&#8217;s audited financial statements as of and for the year ended December 31, 2020, and the notes thereto, which are included in the Company&#8217;s </span><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm" style="-sec-extract:exhibit;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021</span></a>. There have been no material changes in the Company&#8217;s significant accounting policies during the six months ended June 30, 2021 except as noted below. <span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company determined its revenue recognition policies related to the CSL Behring Agreement (defined below) when the CSL Behring Agreement became fully effective on May 6, 2021. Refer to Note 3 (&#8220;Collaboration arrangements and concentration of credit risk&#8221;) for further detail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;"> </span>The Company for the first time recognized net income in the three and six months ended June 30, 2021. Net income / (loss) per ordinary share was calculated in accordance with ASC 260, Earnings Per Share. Refer to Note 11 (&#8220;Basic and diluted earnings per share&#8221;) for further detail. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.5</b></span><b style="font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There have been no new accounting pronouncements or changes to accounting pronouncements during the six months ended June 30, 2021, as compared to the recent accounting pronouncements described in Note 2.3.22 of the Company&#8217;s <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1590560/000155837021002186/qure-20201231x10k.htm" style="-sec-extract:exhibit;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Annual Report on Form 10-K for the year ended December 31, 2020</span></a>, which could be expected to materially impact the Company&#8217;s unaudited consolidated financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_UnauditedInterimFinancialInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policies for Unaudited interim financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_UnauditedInterimFinancialInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740407951128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair value measurement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured at fair value on recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;prices<br/>in&#160;active<br/>markets<br/>(Level&#160;1)</b></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant<br/>other<br/>observable<br/>inputs<br/>(Level&#160;2)</b></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant<br/>unobservable<br/>inputs<br/>(Level&#160;3)</b></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:22.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification&#160;in&#160;Consolidated<br/>balance&#160;sheets</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"/></tr><tr><td style="vertical-align:top;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:top;width:38.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Assets:</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash, cash equivalents and restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247,680</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247,680</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash and cash equivalents; other non-current assets</p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Derivative financial instruments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other non-current liabilities</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">At June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 680,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 680,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash and cash equivalents; other non-current assets</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 680,158</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 680,158</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Derivative financial instruments </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other non-current liabilities</p></td></tr><tr><td style="vertical-align:bottom;width:36.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740406569240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses and other current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued expenses and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accruals for services provided by vendors-not yet billed</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,269</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel related accruals and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,687</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,082</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 23,526</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 18,038</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740406263352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense by classification included in consolidated statements of operations and comprehensive loss</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.25%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,286</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,889</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,960</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,271</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,825</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,783</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,714</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,775</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,054</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.25%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:22.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Award type</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share options</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,746</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,954</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted share units</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,222</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,209</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,782</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,653</p></td></tr><tr><td style="vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance share units</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 449</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 759</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 803</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,447</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,714</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,775</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,054</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of unrecognized compensation cost related to unvested awards</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrecognized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share-based</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">period for </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;recognition&#160;&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Award type</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share options</p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.99</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted share units</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,960</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.25</p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance share units</p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.58</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 60,607</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2.66</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions for fair value of option issued</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Assumptions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">75%</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">70%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">75%</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">70%</p></td></tr><tr><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected terms</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">10 years</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">10 years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">10 years</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">10 years</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">1.72% - 1.85%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0.76% - 0.83%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">1.21% - 1.85%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0.76% - 1.44%</p></td></tr><tr><td style="vertical-align:top;width:46.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">0%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSUs activity</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSU</b></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average</b></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant-date fair</b></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-vested at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 467,344</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 43.56</b></p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 481,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36.50</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (145,203)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39.89</p></td></tr><tr><td style="vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited </p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,067)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42.86</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-vested at June&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 772,895</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 39.87</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total weighted average grant date fair value of RSUs granted during the period (in $ millions)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.6</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Summary of PSUs activity</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PSU</b></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average</b></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant-date fair</b></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-vested at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 212,614</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 42.32</b></p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (132,368)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33.09</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,916)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57.56</p></td></tr><tr><td style="vertical-align:top;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-vested at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 77,330</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 57.56</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=qure_PlanIn2014Member', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise price</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,659,279</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28.13</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 914,118</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36.36</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (74,397)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43.19</p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,093)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44.14</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,976)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.65</p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,417,931</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 30.29</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereof, fully vested and exercisable at June&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,774,059</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.68</p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereof, outstanding and expected to vest after June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,643,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39.58</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total weighted average grant date fair value of options issued during the period (in $ millions)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.4</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from option sales during the period (in $ millions)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=qure_PlanIn2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=qure_PlanIn2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740407888888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and diluted earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of bsic and diluted earnings per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income / (loss) attributable to ordinary shares</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 399,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (42,551)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 357,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (70,550)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 399,468</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (42,551)</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 357,912</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (70,550)</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average number of ordinary shares outstanding - basic</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,037,900</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,387,463</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,754,766</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,333,460</p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options under 2014 Plans and previous plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 797,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 824,101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-vested RSUs and PSUs</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 92,681</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,514</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee share purchase plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average number of ordinary shares outstanding - diluted</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 46,929,870</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 44,387,463</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 46,678,835</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 44,333,460</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock', window );">Schedule of potential dilutive common shares</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:22.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Anti-dilutive ordinary share equivalents</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options under 2014 Plans and previous plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,634,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,893,733</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,607,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,893,733</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-vested RSUs and PSUs</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 757,544</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 645,636</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 751,711</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 645,636</p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee share purchase plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 254</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 254</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">BMS warrants (derecognized as of December 1, 2020 - see Note 4, "Fair value measurement")</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,060,500</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,060,500</p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total anti-dilutive ordinary share equivalents</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,393,724</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,600,123</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,361,343</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,603,143</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of potential dilutive common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740412845416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 24, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2020 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 24, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_NumberOfCollaborationTargets', window );">Number of collaboration targets | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463,868<span></span>
</td>
<td class="nump">$ 1,535<span></span>
</td>
<td class="nump">$ 464,322<span></span>
</td>
<td class="nump">$ 1,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax rate enacted in the Netherlands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears', window );">Tax benefit past share issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=qure_CslBehringCollaborationMember', window );">CSL Behring collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_UpfrontCashToReceiveUponClosingOfAgreement', window );">Upfront cash to receive upon the closing of the agreement</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_CollaborationAgreementOtherPaymentsReceived', window );">Other payments received</a></td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_RegulatoryAndCommercialMilestonePaymentsReceivable', window );">Regulatory and commercial milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=qure_LicenseRevenueFromRelatedPartyMember', window );">License revenues from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=qure_CollaborativeRevenueFromRelatedPartyMember', window );">Collaboration revenues from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=qure_CollaborativeRevenueMember', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=qure_CollaborativeRevenueMember', window );">Collaboration revenues | CSL Behring collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">BMS arrangement | Bristol Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_InitialResearchTerm', window );">Initial research term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_NumberOfCollaborationTargets', window );">Number of collaboration targets | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced', window );">Collaboration Agreement, Threshold Number Of Collaboration Targets That Can Be Replaced | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease', window );">Threshold Number Of New Collaboration Targets In The Field Of Cardiovascular Disease | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=qure_CollaborativeArrangementLicenseRevenueMember', window );">License revenue | Bristol Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=qure_BristolMyersSquibbMember', window );">Bristol Myers Squibb | BMS arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable', window );">Collaboration Agreement, Threshold Research, Development And Regulatory Milestone Payments Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from tax effect of prior years issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_CollaborationAgreementOtherPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other payments related to transfer of licence received as of the effective date of the collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_CollaborationAgreementOtherPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold number of collaboration targets that can be replaced under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of threshold research, development and regulatory payment receivable under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_InitialResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_InitialResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_NumberOfCollaborationTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of collaboration targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_NumberOfCollaborationTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_RegulatoryAndCommercialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of regulatory and commercial milestone payments to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_RegulatoryAndCommercialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold number of new collaboration targets in the field of cardiovascular disease under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_UpfrontCashToReceiveUponClosingOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash to receive upon the closing of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_UpfrontCashToReceiveUponClosingOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=qure_CslBehringCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=qure_CslBehringCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=qure_LicenseRevenueFromRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=qure_LicenseRevenueFromRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=qure_CollaborativeRevenueFromRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=qure_CollaborativeRevenueFromRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=qure_CollaborativeRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=qure_CollaborativeRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=qure_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=qure_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=qure_CollaborativeArrangementLicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=qure_CollaborativeArrangementLicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=qure_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=qure_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740507757176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurement - Assets and liabilities measured on a recurring basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 680,158<span></span>
</td>
<td class="nump">$ 247,680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">680,158<span></span>
</td>
<td class="nump">247,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">2,645<span></span>
</td>
<td class="nump">2,645<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">2,645<span></span>
</td>
<td class="nump">2,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value hierarchy Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">680,158<span></span>
</td>
<td class="nump">247,680<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">680,158<span></span>
</td>
<td class="nump">247,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">2,645<span></span>
</td>
<td class="nump">2,645<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 2,645<span></span>
</td>
<td class="nump">$ 2,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740409360792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement - BMS warrants - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_NumberOfWarrantTypes', window );">Number of warrant types | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_NumberOfCollaborationTargets', window );">Number of Collaboration Targets | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_CollaborationAgreementCashPayable', window );">Collaboration Agreement, Cash Payable</a></td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_GainLossOnRecognitionOfDerivatives', window );">Gain (Loss) from the recognition of the derivative financial liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of the derivative financial liability</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember', window );">Collaboration Agreement, If 70 Million Is Greater Than Five Percent Of Net Proceeds | Derecognition Of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_ThresholdPercentageOfNetProceeds', window );">Threshold Percentage Of Net Proceeds</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_PercentageOfNetProceedsPayable', window );">Percentage Of Net Proceeds Payable</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember', window );">Collaboration Agreement, If 70 Million Is Lesser Than One Percent Of Net Proceeds | Derecognition Of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_ThresholdPercentageOfNetProceeds', window );">Threshold Percentage Of Net Proceeds</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_PercentageOfNetProceedsPayable', window );">Percentage Of Net Proceeds Payable</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_CollaborationAgreementCashPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-refundable, non-creditable cash payment to be made under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_CollaborationAgreementCashPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_GainLossOnRecognitionOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) o recognition of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_GainLossOnRecognitionOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_NumberOfCollaborationTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of collaboration targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_NumberOfCollaborationTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_NumberOfWarrantTypes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrant types are issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_NumberOfWarrantTypes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_PercentageOfNetProceedsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of net proceeds payable under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_PercentageOfNetProceedsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_ThresholdPercentageOfNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The threshold percentage of net proceeds payable under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_ThresholdPercentageOfNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=qure_DerecognitionOfWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=qure_DerecognitionOfWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740488285112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses and other current liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued expenses and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent', window );">Accruals for services provided by vendors-not yet billed</a></td>
<td class="nump">$ 16,734<span></span>
</td>
<td class="nump">$ 8,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Personnel related accruals and liabilities</a></td>
<td class="nump">6,792<span></span>
</td>
<td class="nump">7,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,082<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 23,526<span></span>
</td>
<td class="nump">$ 18,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for serviced provided by vendors not yet billed. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740403449160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 29, 2021</div></th>
<th class="th"><div>Dec. 06, 2018</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from loan increment, net of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=qure_AmendedFacility2016Member', window );">2016 Amended Facility | Hercules | Second Amended and Restated Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_DebtInstrumentBackEndFeeOne', window );">Back-end fees due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=qure_AmendedFacility2018Member', window );">2018 Amended Facility | Hercules</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_DebtInstrumentAggregateAmountOfEquityFinancing', window );">Aggregate amount of Equity Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Foreign currency loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=qure_AmendedFacility2018Member', window );">2018 Amended Facility | Hercules | Second Amended and Restated Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_DebtInstrumentBackEndFeePercentage', window );">Back-end fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from loan increment, net of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=qure_AmendedFacility2018Member', window );">2018 Amended Facility | Prime Rate | Hercules | Second Amended and Restated Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_DebtInstrumentInterestRateDiscountRatePercentage', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=qure_AmendedFacility2021Member', window );">2021 Amended Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding debt</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceed from drew down</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_DebtInstrumentBackEndFeePercentage', window );">Back-end fee (as a percent)</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_AdditionalUnconditionalBorrowingCapacity', window );">Additional unconditional borrowing capacity</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=qure_AmendedFacility2021Member', window );">2021 Amended Facility | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate basis</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=qure_AmendedFacility2018And2021Member', window );">2018 and 2021 Amended Facility | Hercules</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Foreign currency loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax', window );">Foreign currency gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=qure_VentureDebtLoanFacilityWithHerculesMember', window );">Venture debt loan facility | 2018 Amended Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Aggregate maturities of loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=qure_VentureDebtLoanFacilityWithHerculesMember', window );">Venture debt loan facility | 2018 Amended Facility | Hercules</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=qure_VentureDebtLoanFacilityWithHerculesMember', window );">Venture debt loan facility | 2018 and 2021 Amended Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_DebtInstrumentPercentageOfWorldwideCashReserves', window );">Minimum cash and cash equivalents in U.S. bank accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly', window );">Assets pledged to secure facilities by directly or indirectly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly', window );">Assets not being pledged to secure facilities by directly or indirectly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Aggregate maturities of loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=qure_VentureDebtLoanFacilityWithHerculesMember', window );">Venture debt loan facility | 2018 and 2021 Amended Facility | Hercules</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events. | 2021 Amended Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events. | 2021 Amended Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_AdditionalUnconditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional unconditional borrowing capacity from the loan as per Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_AdditionalUnconditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets not being pledged to secure facilities by directly or indirectly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets pledged to secure facilities by directly or indirectly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_DebtInstrumentAggregateAmountOfEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of equity financing as a result of extending the interest-only period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_DebtInstrumentAggregateAmountOfEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_DebtInstrumentBackEndFeeOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of back-end fee which is due on October 2016 under debt arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_DebtInstrumentBackEndFeeOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_DebtInstrumentBackEndFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The back-end fee, expressed as a percentage of outstanding loan amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_DebtInstrumentBackEndFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_DebtInstrumentInterestRateDiscountRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual discount rate for interest rate under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_DebtInstrumentInterestRateDiscountRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_DebtInstrumentPercentageOfWorldwideCashReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt covenant that specifies cash and cash equivalents of a minimum of 65% of the outstanding balance of principal due under Credit Facility are to be held in U.S. bank accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_DebtInstrumentPercentageOfWorldwideCashReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=qure_AmendedFacility2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=qure_AmendedFacility2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=qure_HerculesTechnologyGrowthCorp.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=qure_HerculesTechnologyGrowthCorp.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=qure_AmendedFacility2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=qure_AmendedFacility2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=qure_AmendedFacility2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=qure_AmendedFacility2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=qure_AmendedFacility2018And2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=qure_AmendedFacility2018And2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=qure_VentureDebtLoanFacilityWithHerculesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=qure_VentureDebtLoanFacilityWithHerculesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740491617448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,865<span></span>
</td>
<td class="nump">$ 29,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,062,234<span></span>
</td>
<td class="nump">1,062,234<span></span>
</td>
<td class="nump">$ 1,016,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=qure_SalesAgreementWithSvbLeerinkMember', window );">Sales Agreement with SVB Leerink LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_PercentageOfGrossProceedsOfSharesSold', window );">Percentage of gross proceeds</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_NetProceedsFromIssuanceOfShares', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=qure_SalesAgreementWithSvbLeerinkMember', window );">Sales Agreement with SVB Leerink LLC | Direct Incremental Labor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=qure_SalesAgreementWithSvbLeerinkMember', window );">Sales Agreement with SVB Leerink LLC | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in connection with offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">921,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=qure_SalesAgreementWithSvbLeerinkMember', window );">Sales Agreement with SVB Leerink LLC | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_NetProceedsFromIssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds from the issue of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_NetProceedsFromIssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_PercentageOfGrossProceedsOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds of shares sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_PercentageOfGrossProceedsOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=qure_SalesAgreementWithSvbLeerinkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=qure_SalesAgreementWithSvbLeerinkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=qure_DirectIncrementalLaborMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=qure_DirectIncrementalLaborMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740412944312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Summary of share-based compensation expense and unrecognized costs (Details) - 2014 Plan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares</a></td>
<td class="nump">12,601,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,601,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 7,021<span></span>
</td>
<td class="nump">$ 5,714<span></span>
</td>
<td class="nump">$ 12,775<span></span>
</td>
<td class="nump">$ 10,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="nump">60,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3,286<span></span>
</td>
<td class="nump">2,889<span></span>
</td>
<td class="nump">$ 5,960<span></span>
</td>
<td class="nump">5,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3,735<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
<td class="nump">6,815<span></span>
</td>
<td class="nump">4,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=qure_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3,350<span></span>
</td>
<td class="nump">2,746<span></span>
</td>
<td class="nump">$ 6,190<span></span>
</td>
<td class="nump">4,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding of fully vested share options</a></td>
<td class="nump">3,417,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,417,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,659,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 34,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted share units ("RSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
<td class="nump">$ 5,782<span></span>
</td>
<td class="nump">3,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="nump">24,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance share units ("PSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
<td class="nump">$ 803<span></span>
</td>
<td class="nump">$ 1,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=qure_The2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=qure_The2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=qure_EmployeeConsultantsAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=qure_EmployeeConsultantsAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740488419192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Option activity and weighted-average assumptions (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total weighted average grant date fair value of options issued during the period (in $ millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from option sales during the period (in $ millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=qure_The2014PlanMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used to estimate fair value of share options granted during year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=qure_The2014PlanMember', window );">2014 Plan | Share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,659,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of the period (in shares)</a></td>
<td class="nump">3,417,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,417,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Thereof, fully vested and exercisable at end of period (in shares)</a></td>
<td class="nump">1,774,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,774,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Thereof, outstanding and expected to vest at end of period (in shares)</a></td>
<td class="nump">1,643,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,643,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">$ 30.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Thereof, fully vested and exercisable at end of period (in dollars per share)</a></td>
<td class="nump">$ 21.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice', window );">Outstanding and expected to vest at end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used to estimate fair value of share options granted during year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum (as a percent)</a></td>
<td class="nump">1.72%<span></span>
</td>
<td class="nump">0.76%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">0.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum (as a percent)</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="nump">0.83%<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=qure_The2014PlanMember', window );">2014 Plan | Non-executive directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=qure_The2014PlanMember', window );">2014 Plan | One year from grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and expected to vest under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=qure_The2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=qure_The2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=qure_EmployeeConsultantsAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=qure_EmployeeConsultantsAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740507765320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - RSU activity (Details) - 2014 Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Other disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=qure_The2014PlanMember', window );">Non-executive directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Other disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted share units ("RSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,067)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant-date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested at beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Other disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total weighted average grant date fair value of RSUs granted during the period (in millions)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted share units ("RSUs") | Non-executive directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Other disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Restricted share units ("RSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Other disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Restricted share units ("RSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Other disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=qure_The2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=qure_The2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740488441688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - PSU activity (Details) - 2014 Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Other disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance share units ("PSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested at beginning of period (in shares) | shares</a></td>
<td class="nump">212,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(132,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(2,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested at end of period (in shares) | shares</a></td>
<td class="nump">77,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant-date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 42.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">33.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">57.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 57.56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=qure_The2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=qure_The2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740406462504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Employee Share Purchase Plan - Narrative (Details) - ESPP - Employee Stock [Member] - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for issue</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">130,852<span></span>
</td>
<td class="nump">135,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discounted rate for purchase of shares</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="nump">3,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=qure_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=qure_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740503615480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other Income</a></td>
<td class="nump">$ 7,590<span></span>
</td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">$ 7,942<span></span>
</td>
<td class="nump">$ 1,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_EmployeeRetentionCreditIncome', window );">Employee retention income</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=qure_VectoryB.vMember', window );">VectorY B.V</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_EmployeeRetentionCreditIncome', window );">Employee retention income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_EquityMethodInvestmentSettlementIncome', window );">Settlement Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Balance shares</a></td>
<td class="nump">69,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_EmployeeRetentionCreditIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of employee retention credit received U.S. Coronavirus Aid, Relief, and Economic Security Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_EmployeeRetentionCreditIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_EquityMethodInvestmentSettlementIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement agreement income received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_EquityMethodInvestmentSettlementIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=qure_VectoryB.vMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=qure_VectoryB.vMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740488493176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Effective Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (3,258)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,471)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax rate enacted in the Netherlands</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes (benefits)</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">463,868<span></span>
</td>
<td class="nump">$ 1,535<span></span>
</td>
<td class="nump">464,322<span></span>
</td>
<td class="nump">$ 1,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=qure_CslBehringCollaborationMember', window );">CSL Behring collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 462,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=qure_CslBehringCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=qure_CslBehringCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740488551720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and diluted earnings per share - Ordinary share (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Income (Loss) for the period</a></td>
<td class="nump">$ 399,468<span></span>
</td>
<td class="num">$ (42,551)<span></span>
</td>
<td class="nump">$ 357,912<span></span>
</td>
<td class="num">$ (70,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Shares Outstanding, Basic</a></td>
<td class="nump">46,037,900<span></span>
</td>
<td class="nump">44,387,463<span></span>
</td>
<td class="nump">45,754,766<span></span>
</td>
<td class="nump">44,333,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of ordinary shares outstanding - diluted</a></td>
<td class="nump">46,929,870<span></span>
</td>
<td class="nump">44,387,463<span></span>
</td>
<td class="nump">46,678,835<span></span>
</td>
<td class="nump">44,333,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Previous plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">ShareBased payment arrangements</a></td>
<td class="nump">797,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">824,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">ShareBased payment arrangements</a></td>
<td class="nump">2,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=qure_RestrictedShareUnitsAndPerformanceShareUnitsMember', window );">Non-vested and earned RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">ShareBased payment arrangements</a></td>
<td class="nump">92,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=qure_ShareOption2012PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=qure_ShareOption2012PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=qure_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=qure_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=qure_RestrictedShareUnitsAndPerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=qure_RestrictedShareUnitsAndPerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740409128648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and diluted earnings per share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Basic and diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive ordinary shares</a></td>
<td class="nump">3,393,724<span></span>
</td>
<td class="nump">11,600,123<span></span>
</td>
<td class="nump">3,361,343<span></span>
</td>
<td class="nump">11,603,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=qure_BmsWarrantsMember', window );">BMS Warrants | Bristol Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Basic and diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,060,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,060,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Previous plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Basic and diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive ordinary shares</a></td>
<td class="nump">2,634,766<span></span>
</td>
<td class="nump">2,893,733<span></span>
</td>
<td class="nump">2,607,830<span></span>
</td>
<td class="nump">2,893,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Basic and diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive ordinary shares</a></td>
<td class="nump">1,414<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">1,802<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=qure_RestrictedShareUnitsAndPerformanceShareUnitsMember', window );">Non-vested and earned RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Basic and diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive ordinary shares</a></td>
<td class="nump">757,544<span></span>
</td>
<td class="nump">645,636<span></span>
</td>
<td class="nump">751,711<span></span>
</td>
<td class="nump">645,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=qure_BmsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=qure_BmsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=qure_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=qure_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=qure_ShareOption2012PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=qure_ShareOption2012PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=qure_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=qure_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=qure_RestrictedShareUnitsAndPerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=qure_RestrictedShareUnitsAndPerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139740411722248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent events (Details) - 6 months ended Jun. 30, 2021<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="nump">$ 46.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage', window );">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi', window );">Definitive Transaction Agreement, Development Milestone, Phase I and II</a></td>
<td class="nump">$ 43.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii', window );">Definitive Transaction Agreement, Development Milestone, Phase III | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 160.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of development milestones payable through Phase I/II.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of development milestones payable through Phase III.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>qure_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MM;Z81!.T%"M>9^J;?/XHV@XU A.95<W_Z+FUQ1.4U)62>>L,"O*TV/[E+^U
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MR;RY7 L.LK4!/%])J=YN] >&W0>EQ3]02P,$%     @ @(#Z4DW)G1+( @
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M*S@!S#"%OP BM .LSSA7[X8^!NK_BOY_4$L#!!0    ( (" ^E+[ADJR!0<
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M"8R/[.,]R_B)HJ3CA;SS<D6L!O_:Y6-$G<^(. 0#_DR/'^Y X?S9[/'_GOV
M#-HE":WML0%[#T(FF2H+SSS?<?#M-N.]>GQ5FYXOF$<#+SB;/.^39L*P2]U#
M4 398I200U@,V/)HV($. F5=H*P>10<"G6UYD<@T7R'^JDIQR<M3"WUN9]6U
MTC<5I43B"2U4BA:J,EJ9;$RY>V&=$(I]C<GHM[ #3[W.4\_JZ3TO>5(LUDBM
M8E5NGU4?V:JN(#LZ((\]TQ5*?.9K[QZ D8 Y6 L,@'G,]S5K,0!S&<,,CM_O
MXO>M\<]5PU)O_S-:\5QE0E;SD"Q5W4U+667&,[=2X9M>89^$H48%!,,NUJD
M8-2ACJ-1 <"(XP84IB+HJ B.6//"6!!0V('I@:\6+-/"!F T#+&VL", AG%
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MC%EH[_4$L>N)G_49N&(C>5;B9\6;H$LXR]OH 17A.=4ZUC>P$)+1P&<>U4D
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MKXO'S[(;$&_Z2XMEU?Y'CYUM,$+IIJJ+5==8>;#*\NUC\M1-Q%X#+!P-2->
M& U(Z&A NP;4:,!<5V!= V9>P34&WC7@YABHHX'H&HAV[K>3U<[T-*F3LY.R
M>$1E8ZUZ:YZTR]6V5A.<Y4UDW=2E^C13[>JS\ZL_;JZ^7$X_WLZFZ.96/?P^
M^^/V!EU=H)O/'Z]GGZ^^3&?7-[^BV7^^7=[^#XW1MYLI>O?+>_0+RG)TNR@V
M59+/JY-)K;QI^IRDW94_;:],'%>^*N=9KH(958NDE% 'Y_X./L[G61.=R1*M
MDVP^5NZDR3JKDR70UW2@KS3=K#;+I)9S5-0+6:*T6*FMNFCVT ^)WBV+JGH_
MR7+UM@2ZG[V\>Q7V69K50"<7_DYN"VMH$[7:NR4GNR4G;3_,T<\G^9#E>98_
MJ"VY3/)4HJ1&4YE^0!3_"Y$ Q]!B;OL4;9_-<?7CC B.3R8_]A?,-HHC$06T
M;S:US<9"1''?:@99\3@,PK[=A6U'"0UXM#/KS1+=S1(]<);>J0#;QNK[%\W8
MMG^^YQ>C(<8Q9[!G;.<9:UM2AV>7>:H84BF'YG+[[#UZ=FU1+.>RK'Y%\J]-
M5O_T1 O?78U[Y^&R#7GT[DNS 9!"&5+; ZUEF15S:"-P:]3C,. \,!9MT*SG
MK-@Y*[S.7@%;]WD [0Z&3@9ANR*HZ>^ 4<_;<.=MZ/5V]B3+-%,+6=QO5P\5
MZ^9  P_3T(IR3(S=%UH^4AJ; P&,6$#@@42[@43'#61_ST"#BBQG2$!CYIC7
M>.=.['7G6E9UF:7-8:O0U,1JJ\":/;SU;I-G=87F66-VMVD/Y4W9;'5O:'^*
M[2/0.+/.8SM,]FQZH\&!1G3PZN,96HG.A7W/.5'[43B<W],7V.O\37/-<2/^
MYNW&5+LR:36E?&J>0S ][[K<=P8'01@9H3QHUG=9\Q'[ 7E959MV=E4X%WV5
MHL2THG@[M062J_6R^"G5*M1%^AVM-V6Z:,[EM>(%."QB^\M,F@T8]8>D88;]
M-/LGAC080C;P:!!PA^N:=ICY#Y=\;FB5?V]R1=Z@(2\)0$\8(%9B\[CLK(SP
M":@I1*: X3BDV-0KL%E N+7$MJ'24MPY51K5V,]J8ZH,P3(\;3:46?OG]$QS
M&?O!#&K.WY/R64$Y'!+ .D;47$>;S7%,,!7F,@(,5W),"',=(=9'81@(<QUM
M0Q)S]V[5N@#[A<&@]AR>.1OSC)$XYK'K0->LQ]$;R$^L88[]-#]4@&* P4RA
M#)NK-VC7SZXTKHD?UT>)4&+SEPD+#D-6?8\UHXF?T0<)T:ZO7I)GIH$VF D3
MY@* 5J%#^Y&][-9/[Z/%* '(2V/LTA-$PY?XX?L6^HT V28CKLC0\"5^^!ZC
MWHB--QX2:J[^@%7?88U ,I"NOI)V(S8;16P.R6O3'Y F)_&3\RV4&[%!ADG@
M*%,0C3$RD-\>KMR(G>8"RHW8=(.5&V (*3?8#%!N@*%/N1$-53*00?\]Y4;L
M1-JOW(C&+XG? /=4TY/ZZ?G"4BFU23@.(Z86UU'VTS"D?A@.E4?A%: V%4F(
MS?HHA3)6+ )LI+93P#".S<KG#+ R)Z&;+< [1F-7=% -6WIH+=E=)75,G$U=
MQD+U%YO'ZTLL^\/8J_72MPARC57JQ^JAFI;:L*0\C,T*X 6U$U_#KN^PQBKU
M8_4H34N!(B]F/+"\'K3K>ZW928]F)QB*=KK)N;F#P9POL&(5-!,.I%*-5.I'
MJD\-#$">VNQ267+H*F)3S2[J9]=M\H3N9*[.ZAJMDZKN1&WV[&I:5- 1?DZ!
MZF\<FL@=LNH[K;%&_5GE02D/M2N_5ES8V61L%0P@(^P %M/$9'YB'IWP,)NA
M(8Y#1X6 :8(R/T%?J_[.;(IA(US.&8!$[(@6IC''_)A[BPR.V7@C8<A#5WQH
MN#%_^GE,#L?L=!*3T!3B%X-F?9?W[G .\/&5LCAF<Y291[??IC\@S4_V^FGI
M8 #9&,4X=-ULUA!E?HCZLS@,>@+4;<,H,K<JD'4&@A#*##$,&(X9CXTC> ::
M$1&9Z=X%X)Z@5 2.0@_3=&8');R>+ Z>-J!H*P*E@ZR[YR^Q[(]!TYSY:3Y8
MJ8==CZ 5#\P5MUF. Q9'YOBF@*$*"S/] :S&$1$D,C4$Y!V)1.R:+*TBF%]%
M'%2HAR?.E@0JM D+7;>-N=8%/'B#I(9K[',_]@_^IHB-:AK'3)BW>8?M^@YK
MJG,_U8]*:KB-Z;&(F4G&0;.^SQKF_.@;N5!X=;WU$D)C4W* X9&PQ@-:.>H'
M7(.>'P_Z =QQF],"1\SETM[WG?RH/C:=X39^@71FR*KOM(8T'X#T(>D,M_G'
MS*"P6<HQ-\<"&;F.+0U1?N2WH@8#PH8B5_XX!!#71.1^(KY6.L-M*IGU0@X0
MSI$/< TM_OI?CQI<"QMK$8L<IY_02!/^5/>85$8 66Y@54B'K/H.:R:*@3NK
MAXMG 562+?$,6,'B&3"$Q#-H!HEGP- GGH6FL1BX;_OWQ+, JL.P>'Z)97\,
MFL[B+>K(0N-3^/'YPILEPBX+FXN[=6"R]T."YH<E2KXJ@5NAI;Q7+8,/H9JT
M<OM;C>V+NEBWORVX*^JZ6+5/%S)1XVP,U.?W15$_OVA^KK#[Q<S9_P%02P,$
M%     @ @(#Z4I V;7GJ!@  U1H  !@   !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6RE65%SFS@0_BL:SSVT,W&-),!V)\E,XK33WK1-ID[OGA60;5T!<1(D
MS?WZ6PD"& 1)VY<$\$KZ]M/N?BLX?9#JNSYP7J ?:9+IL]FA*/*WBX6.#CQE
M^HW,>0:_[*1*60&W:K_0N>(LMH/29$$\+URD3&2S\U/[[$:=G\JR2$3&;Q32
M99HR]7C)$_EP-L.SIP=?Q?Y0F >+\].<[?F6%]_R&P5WBV:66*0\TT)F2/'=
MV>P"O]W0P RP%G\)_J [U\BX<B?E=W/S,3Z;>0813WA4F"D8_+OG&YXD9B;
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M V<Q5\8 ?M])63S=F 6:+UGG_P-02P,$%     @ @(#Z4I?N6?_* @  $@8
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M73KMT(Y;M/P5M!VX--I7#DYU2>5S_Y29]?3R%;WC_$W \T9OPC#["'F6#][
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M\;Q#XK'BI4TV&/#]C'NS$D* _F]@\@=02P,$%     @ @(#Z4B'DZP+!!@
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MRA1FO>LQE?9W<^] R.=MGLIN-=]>5GZDUU>Y.YZW%6S3*Q. )5:GT4?)+@Q
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MKVOB%V=J?H5[:9PS)7_<* F%T (\7QGCXA<ZH'NG__6_ 5!+ P04    " "
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M02,&<BFF-60Z/06(0GD6#=Q'QM,<@ 9JEYF21=(\R:%556W<1M&>6RPT2',
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MC*[B/U=*(N7I /87SL7V@P1T[_)W_P%02P,$%     @ @(#Z4M&@9;>"!
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M&[*3 _B_LC8,"U$P3IOG?P%02P,$%     @ @(#Z4CZLT_XU"@  _2$  !D
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M(TO?F:6)3>I#P(FW%9WD.RN71W[JS$([GX:>&\S0=R03<T=C;T/Z! <@[C:
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M@!1O2YQ(R?$"?%]9;-2Z!S:P/>->_0=02P,$%     @ @(#Z4I +Q+K!!0
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M"&A*9\?J'DRZ9;"^&66'<D<FIU8,DX[<CK8NR8&=W%(%-8M$5:RLHO6>+HT
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M!JR/PZ%9R=S'B3_$R);^2: ',#:"G\$(M/EXX0U;L:4\?W^-MD0I8O?["#:
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MX]Z(?/=J[#;1->FEA@L-ETQ:5IA)[$4 WQ?.Q<U&#&R?[L?_ %!+ P04
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M9X8[$%@Z@,]I,VTNR$#[Y?+R'U!+ P04    " " @/I2G*GY"A #  "=#
M&0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6SM5VU/VS 0_BNG;)I ZDB:
MME!!6PG*T#8-C0';/KO)I;%P[&([E/W[G9TTA+<B),0V:5]J^WSWW+M[&2V5
MOC YHH7K0D@S#G)K%[MA:)(<"V:VU (EW61*%\S24<]#L]#(4B]4B#".HNVP
M8%P&DY&GG>C)2)56<(DG&DQ9%$S_.D"AEN.@&ZP(IWR>6T<()Z,%F^,9VN^+
M$TVGL$%)>8'2<"5!8S8.]KN[!WW'[QE^<%R:UAZ<)S.E+MSA4SH.(F<0"DRL
M0V"T7.$4A7! 9,9EC1DT*IU@>[]"/_*^DR\S9G"JQ$^>VGP<# -(,6.EL*=J
M^1%K?P8.+U'"^%]85KP[.P$DI;&JJ(7)@H++:F77=1Q: L/H$8&X%HB]W94B
M;^4ALVPRTFH)VG$3FMMX5[TT&<>E2\J9U73+2<Y.CAC7<,5$B5 @,Z5&BKB%
MC7,V$V@V1Z$E)8XU3&K @PHP?@1P&XZ5M+F!#S+%]+9\2,8U%L8K"P_BM8"?
M2[D%O:@#<11WU^#U&H]['J_W+(_7 /<;X+X'[C\"?$8-DY8"067 C$%K@,D4
M!&<S+KCE:%8*4V 6LAL[?'TGI=9<SEV-<?-0W-=K?_=F&$>]/?C3Z[=267)P
MH7E"#I_QN>093QC55'M_KBP3,!44)T_R'<HE3)4T2O"4.8S'5&P0H\U5:2B\
M9O/>];Z%0TRPF*&&7M?73?3J8=CW!;#[ZGJGS.0=2.@7\++D5%]4W%4A:C26
MLN(BZ^]7(F\A[N]TMH=1B^)VW7AO+>6NE%/M%=W5O@?*YI0,J>1[5^7N@:D;
MI*J#^O#2!JW6+S<=^/H).41-<7!_/9!QR63"R6$N*15EX5/SD&#;KZ?H<6>[
M/WB"^O5>_-NO4I6$-N69<;^EZ^ZYU9;TE&/SE/]OR74M277<Z0Z&S\S$7:D7
M;,F7,>C?:LF7*/^_H/4>FFW"ULA8H)[[P=A HDIIJ^FQH3:S]WXU<MZP5X/[
M,=-SBAX(S$@TVMH9!*"K8;@Z6+7P ^A,61IG_3:G[P?4CH'N,T4C0WUP"IHO
MDLEO4$L#!!0    ( (" ^E*W8'XFG@(  %@&   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;*U5;4_;,!#^*Z=LFD#J2.KT#=96HK!IFX14 =L^N\FU
ML7#LSG9:^N]W=MJ0#>B'B2^Q?;Y[GKNS_62\U>;!%H@.'DNI["0JG%M?Q+'-
M"BRY/=-K5+2SU*;DCI9F%=NU09Z'H%+&+$D&<<F%BJ;C8)N;Z5A73@J%<P.V
M*DMN=C.4>CN)NM'!<"M6A?.&>#I>\Q7>H?NQGAM:Q0U*+DI45F@%!I>3Z+)[
M,>MY_^#P4^#6MN;@*UEH_> 7W_))E/B$4&+F/ *G88-7**4'HC1^[S&CAM('
MMN<']"^A=JIEP2U>:?E+Y*Z81*,(<ESR2KI;O?V*^WKZ'B_3TH8O;&O?_GD$
M666=+O?!E$$I5#WRQWT?6@&CY)4 M@]@(>^:*&1YS1V?CHW>@O'>A.8GH=00
M3<D)Y0_ESAG:%13GII=99BK, 1_IF"U:X"H'[0HTQ&X,*@=2\(60P@G:/;GG
M"XGV=!P[(O<0<;8GFM5$[!6B =QHY0H+GU6.^=_Q,27=9,X.F<_84<#OE3J#
M-.D 2UCW"%[:="(->.F;=.((8:\A[ 7"WBN$=_3 \DHBZ"5=SO\GKYMUG.O#
MNQ%+TD_P5B,U'T/S#X9KS+!<4+II]\GH3\9_DF?Q)T*!*W1EJ4Y["J'W7%H@
ME0&+9B,RZL':Z(V@RP*+'6Q0Y=K8CTH[V)%642LD[1SPWD-WT!FFO99AU&&#
M<YBCL5HIE*0@DCL*X0<NW^+VW?XW1P(\9\^LP\Y@-(0KNLN&%*4!V+W8JBY[
MWCK6248,[K7CLI4M2SM]-FC7,^HDZ>BE:Q:W7GN)9A4TS4*F*^7JA]]8&]F\
MK-7BR;W6W!MN5D)9D+BDT.1LV(_ U#I6+YQ>!^U8:$=*%*8%23\:[T#[2ZW=
M8>$)FI_)] ]02P,$%     @ @(#Z4A,XK 6-!@  #QH  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&ULU5E9;]LX$/XKA+=9-( B2]3=30(D;?<"V@9)
MCV=%HFVBDN@E*3O97[]#RKHL6W$.=-$72QP//P[);PY2IVO&OXL%(1+=Y5DA
MSB8+*9=OIE.1+$@>"Y,M20'_S!C/8PE-/I^*)2=QJCOEV11;EC_-8UI,SD^U
M[(J?G[)29K0@5QR),L]C?G]),K8^F]B36G!-YPNI!-/STV4\)S=$?EE><6A-
M&Y24YJ00E!6(D]G9Y,)^<VECU4%K?*5D+3KO2$WEEK'OJO%7>C:QE$4D(XE4
M$#$\5N0MR3*%!';\LP&=-&.JCMWW&OUW/7F8S&TLR%N6?:.I7)Q-P@E*R2PN
M,WG-UG^2S80\A9>P3.A?M-[H6A.4E$*R?-,9+,AI43WCN\U"'-(!;SKHA9A6
M VDKW\4R/C_E;(VXT@8T]:*GJGN#<;10NW(C.?Q+H9\\OUG$G)RH>:4H83EL
MMHCU<KW^'-]F1!R?3B4,HY2GR0;RLH+$>R!]]($5<B'0^R(E:;__%,QK;,2U
MC9=X%/#OLC"18QD(6]@>P7.:.3L:SWGDG$>@W0;:U=#N/FCPFK3,"&(S)/8M
M+;E3[P3=WJ,DBX6@,YI4_] BR4I8-'B!+H5@&4UC"6TAX0'.((5"!I_DNH-
M<5&!<[)0KK(B*&-"[-JT<<-__27$EO,;^E'/SPM.",HKHA!%% 3;3/0VUSHW
M].X!#44(]6/U)9V&-1CY-:RM7+!2P-*)XWWB:R)(S).%7N"4K"!\+=7Z-_JO
MD&/@T.^TL1&&4:?M&9%O]=HXL-$-!"!:S TT)P7L8J8'B%-P;2JDVE78PFV3
M'2-PO($4QL-#J6^$]E#J&D'HH,],PH"M18'172UE86"[G;:-C2#PN@++L#QW
MQ$^\QD^\%_.3760>1__19/Y92'VQCGF*Y/UR2+&7?NH8"X&JBE)=IW&\KE,
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M;2,*>IYC0R7K;4]TM^LXAFL'1N3T4I-EX@B*/BA^V,Q LS++[E'M@U"?;#9
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MO. '_#^B)FS5A+6:\(":*3935N5 Y(+,7JNQB<MQ!;_\E/IN\"OYKY[W*P5
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M /ZA@*  !#;0G)D-:T04&?0$7R)AK+4WL[#:6+2.AJ8FC0]*Z%.J<6IP0ZA
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M4;YCRH[B:WNS7W*EWPFVF>FW'P@CH.=3SM6N8Q:H7Y.3_P!02P,$%     @
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MQ[L6/R:5'Q.G'[>"+RF-)5@)GI8H@22)WBM'89P<8/2]J!WBM((X=4)$/@S
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M'8L.\,(P#/Q)M.]8_\1FPV@Y%[DYMW*,UQ<I]VNCOZ&*JF#<?;5SZ)"<X33
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M-$6(XI*W>%%\D]]BWG.E>)H_KBF)J3 3].\KSM7+BS%07;5?_@=02P,$%
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M/C02(=8WILF7">28=^@:B%R)*<NQD$.V,OF: 8XT*,],Q[(",\<I,48#/??
M1@.Z$5E*X($AOLESS/Z,(:.[H6$;AXE9NDJ$FC!'@S5>P1S$T_J!R9%9L41I
M#H2GE" &\="XM6^F?66O#7ZFL.-'WT@I65#ZK 9WT="P5$"0P5(H!BQ?6YA
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MF#*0ZS&EXC!0#JI>=/074$L#!!0    ( (" ^E)BI$-@]0,  !H.   9
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MR D"IQ6["#UH0P]Z0_^NNY\D>'+ 3'9S\+4JU[)8Z;:FGX-OE>!"EJ&LXX]
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M10B@,2JWC933J9*TTK#RJ!N6=L*$N(.'\6NVQ;W(-G+:@HS*IFD%U4U'XSK
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M(XY@"D #AD11M0_N[$?A:I\*U_^0#7\#4$L#!!0    ( (" ^E*7BKL<P
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MVS6I5=D<_%GW5V#V!5!+ 0(4 Q0    ( (" ^E('04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    " " @/I2^X9*L@4'   -'P  &
M    @('R%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M@(#Z4LX\C>S,"   /3,  !@              ("!+1X  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( (" ^E*0-FUYZ@8  -4:   8
M          " @2\G  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " " @/I2E^Y9_\H"   2!@  &               @(%/+@  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ @(#Z4B'DZP+!!@  NA(
M !@              ("!3S$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( (" ^E)6];>@! \  -\O   8              " @48X  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " " @/I29)*P?T4)
M  #='P  &0              @(& 1P  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( (" ^E(RA8LZI (  - &   9              "
M@?Q0  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ @(#Z
M4K^?:>#9"   HQ<  !D              ("!UU,  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " " @/I2T:!EMX($  !Y"@  &0
M        @('G7   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( (" ^E(^K-/^-0H  /TA   9              " @:!A  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ @(#Z4IFTU'Q> P  E <
M !D              ("!#&P  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " " @/I2TO_@QGX%  #O#@  &0              @(&A;P
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( (" ^E*0"\2Z
MP04  /<3   9              " @59U  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ @(#Z4CR;<"-,!0  Q@L  !D
M ("!3GL  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "
M@/I2BK,'J!D'  #%%   &0              @('1@   >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( (" ^E*<J?D*$ ,  )T,   9
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M970R-"YX;6Q02P$"% ,4    " " @/I2//9K3Q(#  !%"P  &0
M    @(&%GP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M (" ^E+DF$=-P@,  %D.   9              " @<ZB  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ @(#Z4J\G85R( @  >@8  !D
M             ("!QZ8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " " @/I26Y&IU8D&   /(@  &0              @(&&J0  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( (" ^E(:"0,5MP,
M ",,   9              " @4:P  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ @(#Z4M5"\DTW!0  _1<  !D              ("!
M-+0  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " " @/I2
M[QG;R6X&  !V'P  &0              @(&BN0  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( (" ^E*EZ74$9 0  (X2   9
M      " @4?   !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ @(#Z4CT\P/\X P  =@H  !D              ("!XL0  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " " @/I2IHA -K "  !S!P
M&0              @(%1R   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( (" ^E(KZQ+]_ (  +,)   9              " @3C+  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ @(#Z4L^-=N8B
M P  EPH  !D              ("!:\X  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " " @/I28J1#8/4#   :#@  &0
M@('$T0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ("
M^E+X,:$S<@,  +@-   9              " @?#5  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ @(#Z4MYTI%VL @  I 8  !D
M         ("!F=D  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    " " @/I2(?8N138#   N$P  #0              @ %\W   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( (" ^E*7BKL<P    !,"   +
M  "  =W?  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (" ^E*<=WB_P ,  'H:
M   /              "  <;@  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" " @/I20+O#+8<!  "\%P  &@              @ &SY   >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " " @/I2_WEJDI\!   =&
M$P              @ %RY@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..+P O , ,  !"Z      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>174</ContextCount>
  <ElementCount>307</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - General business information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureGeneralBusinessInformation</Role>
      <ShortName>General business information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Collaboration arrangements and concentration of credit risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRisk</Role>
      <ShortName>Collaboration arrangements and concentration of credit risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair value measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>Fair value measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Accrued expenses and other current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued expenses and other current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Long-term debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureLongTermDebt</Role>
      <ShortName>Long-term debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Shareholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureShareholdersEquity</Role>
      <ShortName>Shareholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Share-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Other income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureOtherIncome</Role>
      <ShortName>Other income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Basic and diluted earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShare</Role>
      <ShortName>Basic and diluted earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair value measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>Fair value measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.uniqure.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Accrued expenses and other current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued expenses and other current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Share-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.uniqure.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Basic and diluted earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareTables</Role>
      <ShortName>Basic and diluted earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair value measurement - Assets and liabilities measured on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair value measurement - Assets and liabilities measured on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Fair value measurement - BMS warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails</Role>
      <ShortName>Fair value measurement - BMS warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Accrued expenses and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued expenses and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Long-term debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureLongTermDebtDetails</Role>
      <ShortName>Long-term debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.uniqure.com/role/DisclosureLongTermDebt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Shareholders' equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureShareholdersEquityDetails</Role>
      <ShortName>Shareholders' equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.uniqure.com/role/DisclosureShareholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Share-based compensation - Summary of share-based compensation expense and unrecognized costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails</Role>
      <ShortName>Share-based compensation - Summary of share-based compensation expense and unrecognized costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Share-based compensation - Option activity and weighted-average assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share-based compensation - Option activity and weighted-average assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Share-based compensation - RSU activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails</Role>
      <ShortName>Share-based compensation - RSU activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Share-based compensation - PSU activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails</Role>
      <ShortName>Share-based compensation - PSU activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40805 - Disclosure - Share-based compensation - Employee Share Purchase Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails</Role>
      <ShortName>Share-based compensation - Employee Share Purchase Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Other income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureOtherIncomeDetails</Role>
      <ShortName>Other income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.uniqure.com/role/DisclosureOtherIncome</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Income taxes - Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails</Role>
      <ShortName>Income taxes - Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Basic and diluted earnings per share - Ordinary share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails</Role>
      <ShortName>Basic and diluted earnings per share - Ordinary share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Basic and diluted earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>Basic and diluted earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="qure-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.uniqure.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.uniqure.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="qure-20210630x10q.htm">qure-20210630x10q.htm</File>
    <File>qure-20210630.xsd</File>
    <File>qure-20210630_cal.xml</File>
    <File>qure-20210630_def.xml</File>
    <File>qure-20210630_lab.xml</File>
    <File>qure-20210630_pre.xml</File>
    <File>qure-20210630xex10d1.htm</File>
    <File>qure-20210630xex10d2.htm</File>
    <File>qure-20210630xex10d3.htm</File>
    <File>qure-20210630xex2d1.htm</File>
    <File>qure-20210630xex31d1.htm</File>
    <File>qure-20210630xex31d2.htm</File>
    <File>qure-20210630xex32d1.htm</File>
    <File>qure-20210630xex3d1.htm</File>
    <File>qure-20210630xex4d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "qure-20210630x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 174,
   "dts": {
    "calculationLink": {
     "local": [
      "qure-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "qure-20210630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "qure-20210630x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "qure-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "qure-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "qure-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 390,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 5,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 10
   },
   "keyCustom": 40,
   "keyStandard": 267,
   "memberCustom": 26,
   "memberStandard": 22,
   "nsprefix": "qure",
   "nsuri": "http://www.uniqure.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Fair value measurement",
     "role": "http://www.uniqure.com/role/DisclosureFairValueMeasurement",
     "shortName": "Fair value measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "qure:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Accrued expenses and other current liabilities",
     "role": "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued expenses and other current liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "qure:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Long-term debt",
     "role": "http://www.uniqure.com/role/DisclosureLongTermDebt",
     "shortName": "Long-term debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Shareholders' equity",
     "role": "http://www.uniqure.com/role/DisclosureShareholdersEquity",
     "shortName": "Shareholders' equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Share-based compensation",
     "role": "http://www.uniqure.com/role/DisclosureShareBasedCompensation",
     "shortName": "Share-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "qure:OtherIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Other income",
     "role": "http://www.uniqure.com/role/DisclosureOtherIncome",
     "shortName": "Other income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "qure:OtherIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Income taxes",
     "role": "http://www.uniqure.com/role/DisclosureIncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Basic and diluted earnings per share",
     "role": "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShare",
     "shortName": "Basic and diluted earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Subsequent events",
     "role": "http://www.uniqure.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of significant accounting policies (Policies)",
     "role": "http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Fair value measurement (Tables)",
     "role": "http://www.uniqure.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "Fair value measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "qure:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Accrued expenses and other current liabilities (Tables)",
     "role": "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued expenses and other current liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "qure:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Share-based compensation (Tables)",
     "role": "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables",
     "shortName": "Share-based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Basic and diluted earnings per share (Tables)",
     "role": "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareTables",
     "shortName": "Basic and diluted earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "qure:NumberOfCollaborationTargets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details)",
     "role": "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
     "shortName": "Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_6_24_2021_To_6_24_2021_srt_CounterpartyNameAxis_qure_CslBehringCollaborationMember_BpZu_RynUUeTx_oJ_rCgLA",
      "decimals": "-5",
      "lang": null,
      "name": "qure:UpfrontCashToReceiveUponClosingOfAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wAnsudVWJ0eStn1YOEaRPQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Fair value measurement - Assets and liabilities measured on a recurring basis (Details)",
     "role": "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "shortName": "Fair value measurement - Assets and liabilities measured on a recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wAnsudVWJ0eStn1YOEaRPQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "qure:NumberOfWarrantTypes",
      "reportCount": 1,
      "unitRef": "Unit_Standard_item_8tAhAmp0n0aKr-pwSfk9bA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Fair value measurement - BMS warrants - Narrative (Details)",
     "role": "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails",
     "shortName": "Fair value measurement - BMS warrants - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "qure:GainLossOnRecognitionOfDerivatives",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ",
      "decimals": "0",
      "lang": null,
      "name": "qure:GainLossOnRecognitionOfDerivatives",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "qure:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "qure:AccrualsForServicesProvidedByVendorsNotYetBilledCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Accrued expenses and other current liabilities (Details)",
     "role": "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued expenses and other current liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "qure:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "qure:AccrualsForServicesProvidedByVendorsNotYetBilledCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Long-term debt (Details)",
     "role": "http://www.uniqure.com/role/DisclosureLongTermDebtDetails",
     "shortName": "Long-term debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_12_6_2018_us-gaap_CreditFacilityAxis_qure_AmendedFacility2016Member_us-gaap_LineOfCreditFacilityAxis_qure_HerculesTechnologyGrowthCorp.Member_us-gaap_TypeOfArrangementAxis_qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember_931tErLp7EuUinvtjRhPIg",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Shareholders' equity (Details)",
     "role": "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails",
     "shortName": "Shareholders' equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_3_1_2021_To_3_1_2021_us-gaap_TypeOfArrangementAxis_qure_SalesAgreementWithSvbLeerinkMember_H93jbZY3yUCB1OwXUnoDlA",
      "decimals": "2",
      "lang": null,
      "name": "qure:PercentageOfGrossProceedsOfSharesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.uniqure.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_41K6eacn2kKBEUPZlfWK2A",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_qdkOPyY6VkGQRdYO2alqaA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Share-based compensation - Summary of share-based compensation expense and unrecognized costs (Details)",
     "role": "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails",
     "shortName": "Share-based compensation - Summary of share-based compensation expense and unrecognized costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_YS6DOwKX1k6x5P_vJL_MIg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Share-based compensation - Option activity and weighted-average assumptions (Details)",
     "role": "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
     "shortName": "Share-based compensation - Option activity and weighted-average assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Share-based compensation - RSU activity (Details)",
     "role": "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails",
     "shortName": "Share-based compensation - RSU activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_5NV54NsdkEinwOnU-elbdw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_PlanNameAxis_qure_The2014PlanMember_nzw4N2cW0ESs40KfjRmwsg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40804 - Disclosure - Share-based compensation - PSU activity (Details)",
     "role": "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
     "shortName": "Share-based compensation - PSU activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_qure_The2014PlanMember_YNaFty5MakKmr7kgK48vHQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_hyffprjeyUC_wzIZA8RTnA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40805 - Disclosure - Share-based compensation - Employee Share Purchase Plan - Narrative (Details)",
     "role": "http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails",
     "shortName": "Share-based compensation - Employee Share Purchase Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_qure_EmployeeSharePurchasePlanMember_hyffprjeyUC_wzIZA8RTnA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherIncome",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Other income (Details)",
     "role": "http://www.uniqure.com/role/DisclosureOtherIncomeDetails",
     "shortName": "Other income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "qure:EmployeeRetentionCreditIncome",
       "p",
       "qure:OtherIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ",
      "decimals": "-5",
      "lang": null,
      "name": "qure:EmployeeRetentionCreditIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Income taxes - Effective Tax Rate (Details)",
     "role": "http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails",
     "shortName": "Income taxes - Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Basic and diluted earnings per share - Ordinary share (Details)",
     "role": "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails",
     "shortName": "Basic and diluted earnings per share - Ordinary share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_qure_ShareOption2012PlanMember_7LQNKgj-qUKqmDaRdvBRmg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "qure:ScheduleOfPotentialDilutiveCommonSharesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Basic and diluted earnings per share (Details)",
     "role": "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails",
     "shortName": "Basic and diluted earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "qure:ScheduleOfPotentialDilutiveCommonSharesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_gCCz-szMj0-DoDt0gm3M_Q",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Subsequent events (Details)",
     "role": "http://www.uniqure.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": "2",
      "lang": null,
      "name": "qure:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_HRUiLqh140aV48l4HRJvlw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_qDm6EZ2Ptk-GBjt_Z1j-pQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cZati_nTb0C-UhhIBOUNCQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY",
     "role": "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cZati_nTb0C-UhhIBOUNCQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_OAjbLdXoPEyBBUwX_XyMlA",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - General business information",
     "role": "http://www.uniqure.com/role/DisclosureGeneralBusinessInformation",
     "shortName": "General business information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of significant accounting policies",
     "role": "http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "qure:CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Collaboration arrangements and concentration of credit risk",
     "role": "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRisk",
     "shortName": "Collaboration arrangements and concentration of credit risk",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "qure-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_kwjby91j0kqBksocnF1d8w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "qure:CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 50,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "qure_AccrualsForServicesProvidedByVendorsNotYetBilledCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for serviced provided by vendors not yet billed. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accruals for Services Provided by Vendors Not Yet Billed, Current",
        "terseLabel": "Accruals for services provided by vendors-not yet billed"
       }
      }
     },
     "localname": "AccrualsForServicesProvidedByVendorsNotYetBilledCurrent",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accrued expenses and other current liabilities.",
        "label": "Accrued Expenses and Other Current Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "qure_AdditionalUnconditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional unconditional borrowing capacity from the loan as per Agreement.",
        "label": "Additional unconditional borrowing capacity",
        "terseLabel": "Additional unconditional borrowing capacity"
       }
      }
     },
     "localname": "AdditionalUnconditionalBorrowingCapacity",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from tax effect of prior years issuance costs.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs, Tax Effect Prior Years",
        "terseLabel": "Tax benefit past share issuance cost"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_AmendedFacility2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for 2016 Amended Facility.",
        "label": "Amended Facility2016 [Member]",
        "terseLabel": "2016 Amended Facility"
       }
      }
     },
     "localname": "AmendedFacility2016Member",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_AmendedFacility2018And2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for 2018 and 2021 Amended Facility.",
        "label": "Amended Facility2018 And2021 [Member]",
        "terseLabel": "2018 and 2021 Amended Facility"
       }
      }
     },
     "localname": "AmendedFacility2018And2021Member",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_AmendedFacility2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for 2018 Amended Facility.",
        "label": "Amended Facility2018 [Member]",
        "terseLabel": "2018 Amended Facility"
       }
      }
     },
     "localname": "AmendedFacility2018Member",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_AmendedFacility2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2021 Amended Facility.",
        "label": "Amended Facility2021 [Member]",
        "terseLabel": "2021 Amended Facility"
       }
      }
     },
     "localname": "AmendedFacility2021Member",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets not being pledged to secure facilities by directly or indirectly.",
        "label": "Assets not being pledged to secure facilities by directly or indirectly",
        "terseLabel": "Assets not being pledged to secure facilities by directly or indirectly"
       }
      }
     },
     "localname": "AssetsNotBeingPledgedToSecureFacilitiesByDirectlyOrIndirectly",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets pledged to secure facilities by directly or indirectly.",
        "label": "Assets pledged to secure facilities by directly or indirectly",
        "terseLabel": "Assets pledged to secure facilities by directly or indirectly"
       }
      }
     },
     "localname": "AssetsPledgedToSecureFacilitiesByDirectlyOrIndirectly",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_BmsWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMS warrants.",
        "label": "Bms Warrants [Member]",
        "terseLabel": "BMS Warrants"
       }
      }
     },
     "localname": "BmsWarrantsMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to a collaborative agreement the entity has with Bristol-Myers Squibb.",
        "label": "Bristol Myers Squibb [Member]",
        "terseLabel": "Bristol Myers Squibb"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails",
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Percentage"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "qure_ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of change in fair value of derivative financial instruments and contingent consideration.",
        "label": "Change In Fair Value Of Derivative Financial Instruments And Contingent Consideration",
        "terseLabel": "Change in fair value of derivative financial instruments"
       }
      }
     },
     "localname": "ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_CollaborationAgreementCashPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-refundable, non-creditable cash payment to be made under the collaboration agreement.",
        "label": "Collaboration Agreement, Cash Payable",
        "terseLabel": "Collaboration Agreement, Cash Payable"
       }
      }
     },
     "localname": "CollaborationAgreementCashPayable",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the scenario in which the the one time cash payment of 70 million is greater than five percent of net proceeds.",
        "label": "Collaboration Agreement If70 Million Is Greater Than Five Percent Of Net Proceeds [Member]",
        "terseLabel": "Collaboration Agreement, If 70 Million Is Greater Than Five Percent Of Net Proceeds"
       }
      }
     },
     "localname": "CollaborationAgreementIf70MillionIsGreaterThanFivePercentOfNetProceedsMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the scenario in which the the one time cash payment of 70 million is less than one percent of net proceeds.",
        "label": "Collaboration Agreement If70 Million Is Lesser Than One Percent Of Net Proceeds [Member]",
        "terseLabel": "Collaboration Agreement, If 70 Million Is Lesser Than One Percent Of Net Proceeds"
       }
      }
     },
     "localname": "CollaborationAgreementIf70MillionIsLesserThanOnePercentOfNetProceedsMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_CollaborationAgreementOtherPaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other payments related to transfer of licence received as of the effective date of the collaboration agreement",
        "label": "Collaboration Agreement Other Payments Received",
        "terseLabel": "Other payments received"
       }
      }
     },
     "localname": "CollaborationAgreementOtherPaymentsReceived",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold number of collaboration targets that can be replaced under the collaboration agreement.",
        "label": "Collaboration Agreement, Threshold Number Of Collaboration Targets That Can Be Replaced",
        "terseLabel": "Collaboration Agreement, Threshold Number Of Collaboration Targets That Can Be Replaced"
       }
      }
     },
     "localname": "CollaborationAgreementThresholdNumberOfCollaborationTargetsThatCanBeReplaced",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "qure_CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of threshold research, development and regulatory payment receivable under the collaboration agreement.",
        "label": "Collaboration Agreement, Threshold Research, Development And Regulatory Milestone Payments Receivable"
       }
      }
     },
     "localname": "CollaborationAgreementThresholdResearchDevelopmentAndRegulatoryMilestonePaymentsReceivable",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Collaboration arrangements and concentration of credit risk"
       }
      }
     },
     "localname": "CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureAbstract",
     "nsuri": "http://www.uniqure.com/20210630",
     "xbrltype": "stringItemType"
    },
    "qure_CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaboration arrangements and concentration of credit risk.",
        "label": "Collaboration Arrangements and Concentration of Credit Risk Disclosure [Text Block]",
        "terseLabel": "Collaboration arrangements and concentration of credit risk"
       }
      }
     },
     "localname": "CollaborationArrangementsAndConcentrationOfCreditRiskDisclosureTextBlock",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRisk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "qure_CollaborativeArrangementLicenseRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to collaboration license revenue.",
        "label": "Collaborative Arrangement License Revenue [Member]",
        "terseLabel": "License revenue"
       }
      }
     },
     "localname": "CollaborativeArrangementLicenseRevenueMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_CollaborativeRevenueFromRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to collaborative revenue from related party.",
        "label": "Collaborative Revenue From Related Party [Member]",
        "terseLabel": "Collaboration revenues from related party"
       }
      }
     },
     "localname": "CollaborativeRevenueFromRelatedPartyMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_CollaborativeRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to collaborative revenue.",
        "label": "Collaborative Revenue [Member]",
        "terseLabel": "Collaboration revenues"
       }
      }
     },
     "localname": "CollaborativeRevenueMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_CslBehringCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Information pertaining to a collaborative agreement entity has with CSL Behring collaboration.",
        "label": "Csl Behring Collaboration [Member]",
        "terseLabel": "CSL Behring collaboration"
       }
      }
     },
     "localname": "CslBehringCollaborationMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_DebtInstrumentAggregateAmountOfEquityFinancing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of equity financing as a result of extending the interest-only period.",
        "label": "Debt Instrument, Aggregate Amount Of Equity Financing",
        "terseLabel": "Aggregate amount of Equity Financing"
       }
      }
     },
     "localname": "DebtInstrumentAggregateAmountOfEquityFinancing",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_DebtInstrumentBackEndFeeOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of back-end fee which is due on October 2016 under debt arrangement.",
        "label": "Debt Instrument, Back-end Fee, One",
        "terseLabel": "Back-end fees due"
       }
      }
     },
     "localname": "DebtInstrumentBackEndFeeOne",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_DebtInstrumentBackEndFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The back-end fee, expressed as a percentage of outstanding loan amount.",
        "label": "Debt Instrument, Back-end Fee Percentage",
        "terseLabel": "Back-end fee (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBackEndFeePercentage",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "qure_DebtInstrumentInterestRateDiscountRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual discount rate for interest rate under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Discount Rate Percentage",
        "terseLabel": "Discount rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDiscountRatePercentage",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "qure_DebtInstrumentPercentageOfWorldwideCashReserves": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt covenant that specifies cash and cash equivalents of a minimum of 65% of the outstanding balance of principal due under Credit Facility are to be held in U.S. bank accounts.",
        "label": "Debt Instrument, Percentage of Worldwide Cash Reserves",
        "terseLabel": "Minimum cash and cash equivalents in U.S. bank accounts"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfWorldwideCashReserves",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of development milestones payable through Phase I/II.",
        "label": "Definitive Transaction Agreement, Development Milestone, Phase I and II"
       }
      }
     },
     "localname": "DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of development milestones payable through Phase III.",
        "label": "Definitive Transaction Agreement, Development Milestone, Phase III"
       }
      }
     },
     "localname": "DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_DerecognitionOfWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to derecognition of the warrants.",
        "label": "Derecognition Of Warrants [Member]",
        "terseLabel": "Derecognition Of Warrants"
       }
      }
     },
     "localname": "DerecognitionOfWarrantsMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_DirectIncrementalLaborMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to direct incremental cost.",
        "label": "Direct Incremental Labor [Member]",
        "terseLabel": "Direct Incremental Labor"
       }
      }
     },
     "localname": "DirectIncrementalLaborMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_EmployeeConsultantsAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee Consultants And Directors Stock Options [Member]",
        "terseLabel": "Share options"
       }
      }
     },
     "localname": "EmployeeConsultantsAndDirectorsStockOptionsMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_EmployeeRetentionCreditIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of employee retention credit received U.S. Coronavirus Aid, Relief, and Economic Security Act.",
        "label": "Employee Retention Credit Income",
        "terseLabel": "Employee retention income"
       }
      }
     },
     "localname": "EmployeeRetentionCreditIncome",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_EmployeeSharePurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents information pertaining to employee share purchase plan.",
        "label": "Employee Share Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeSharePurchasePlanMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails",
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_EquityMethodInvestmentSettlementIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlement agreement income received.",
        "label": "Equity Method Investment, Settlement Income",
        "terseLabel": "Settlement Income"
       }
      }
     },
     "localname": "EquityMethodInvestmentSettlementIncome",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_GainLossOnRecognitionOfDerivatives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) o recognition of derivative liability.",
        "label": "Gain (Loss) On Recognition Of Derivatives",
        "terseLabel": "Gain (Loss) from the recognition of the derivative financial liability"
       }
      }
     },
     "localname": "GainLossOnRecognitionOfDerivatives",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_HerculesTechnologyGrowthCorp.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Hercules Technology Growth Corp.",
        "label": "Hercules Technology Growth Corp. [Member]",
        "terseLabel": "Hercules"
       }
      }
     },
     "localname": "HerculesTechnologyGrowthCorp.Member",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period for accounts payable and accrued liabilities under supplemental cash flow information.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities Related to Non Current Assets",
        "terseLabel": "Non-cash increase in accounts payables and accrued expenses and other current liabilities related to purchases of intangible assets and property, plant, and equipment"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accounts receivable, prepaid expenses and other current assets.",
        "label": "Increase (Decrease) in Accounts Receivable, Prepaid Expense and Other Current Assets",
        "negatedLabel": "Accounts receivable, prepaid expenses, and other current assets and receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_InitialResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial research term.",
        "label": "Initial research term",
        "terseLabel": "Initial research term"
       }
      }
     },
     "localname": "InitialResearchTerm",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "qure_LicenseRevenueFromRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to license revenue from related party.",
        "label": "License Revenue From Related Party [Member]",
        "terseLabel": "License revenues from related party"
       }
      }
     },
     "localname": "LicenseRevenueFromRelatedPartyMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_NetProceedsFromIssuanceOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net proceeds from the issue of shares.",
        "label": "Net Proceeds from Issuance of Shares",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceOfShares",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_NumberOfCollaborationTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of collaboration targets.",
        "label": "Number of Collaboration Targets",
        "terseLabel": "Number of collaboration targets"
       }
      }
     },
     "localname": "NumberOfCollaborationTargets",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "qure_NumberOfWarrantTypes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrant types are issued.",
        "label": "Number of warrant types",
        "terseLabel": "Number of warrant types"
       }
      }
     },
     "localname": "NumberOfWarrantTypes",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "qure_OtherCurrentAssetsAndReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The balance of other current assets and receivables.",
        "label": "Other current assets and receivables",
        "terseLabel": "Other current assets and receivables"
       }
      }
     },
     "localname": "OtherCurrentAssetsAndReceivables",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_OtherIncomeTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income.",
        "label": "Other Income [Text Block]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncomeTextBlock",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureOtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "qure_PercentageOfGrossProceedsOfSharesSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of gross proceeds of shares sold.",
        "label": "Percentage of Gross Proceeds of Shares Sold",
        "terseLabel": "Percentage of gross proceeds"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsOfSharesSold",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "qure_PercentageOfNetProceedsPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of net proceeds payable under the arrangement.",
        "label": "Percentage Of Net Proceeds Payable",
        "terseLabel": "Percentage Of Net Proceeds Payable"
       }
      }
     },
     "localname": "PercentageOfNetProceedsPayable",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "qure_PlanIn2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2014 Plan.",
        "label": "Plan In2014 [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "PlanIn2014Member",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_RegulatoryAndCommercialMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of regulatory and commercial milestone payments to be received.",
        "label": "Regulatory And Commercial Milestone Payments Receivable",
        "terseLabel": "Regulatory and commercial milestone payments received"
       }
      }
     },
     "localname": "RegulatoryAndCommercialMilestonePaymentsReceivable",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_RestrictedShareUnitsAndPerformanceShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents restricted share units and performance share units.",
        "label": "Restricted Share Units And Performance Share Units [Member]",
        "terseLabel": "Non-vested and earned RSUs and PSUs"
       }
      }
     },
     "localname": "RestrictedShareUnitsAndPerformanceShareUnitsMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails",
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_SalesAgreementWithSvbLeerinkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Sales Agreement with SVB Leerink.",
        "label": "Sales Agreement With Svb Leerink [Member]",
        "terseLabel": "Sales Agreement with SVB Leerink LLC"
       }
      }
     },
     "localname": "SalesAgreementWithSvbLeerinkMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_ScheduleOfPotentialDilutiveCommonSharesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of potential dilutive common shares.",
        "label": "Schedule of Potential Dilutive Common Shares [Table Text Block]",
        "terseLabel": "Schedule of potential dilutive common shares"
       }
      }
     },
     "localname": "ScheduleOfPotentialDilutiveCommonSharesTableTextBlock",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "qure_SecondAmendedAndRestatedLoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Second Amended and Restated Loan and Security Agreement.",
        "label": "Second Amended And Restated Loan And Security Agreement [Member]",
        "terseLabel": "Second Amended and Restated Loan and Security Agreement [Member]"
       }
      }
     },
     "localname": "SecondAmendedAndRestatedLoanAndSecurityAgreementMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and expected to vest under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding And Expected To Vest, Weighted Average Exercise Price",
        "terseLabel": "Outstanding and expected to vest at end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExpectedToVestWeightedAverageExercisePrice",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "qure_ShareOption2012PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2012 Share Option Plan.",
        "label": "Share Option2012 Plan [Member]",
        "terseLabel": "Previous plan"
       }
      }
     },
     "localname": "ShareOption2012PlanMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails",
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_The2014PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents share-based compensation plan approved at the general meeting of entity's shareholders on January 9, 2014.",
        "label": "The2014 Plan [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "The2014PlanMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold number of new collaboration targets in the field of cardiovascular disease under the collaboration agreement.",
        "label": "Threshold Number Of New Collaboration Targets In The Field Of Cardiovascular Disease",
        "terseLabel": "Threshold Number Of New Collaboration Targets In The Field Of Cardiovascular Disease"
       }
      }
     },
     "localname": "ThresholdNumberOfNewCollaborationTargetsInFieldOfCardiovascularDisease",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "qure_ThresholdPercentageOfNetProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold percentage of net proceeds payable under the arrangement.",
        "label": "Threshold Percentage Of Net Proceeds",
        "terseLabel": "Threshold Percentage Of Net Proceeds"
       }
      }
     },
     "localname": "ThresholdPercentageOfNetProceeds",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "qure_UnauditedInterimFinancialInformationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policies for Unaudited interim financial information.",
        "label": "Unaudited Interim Financial Information [Policy Text Block]",
        "terseLabel": "Unaudited interim financial information"
       }
      }
     },
     "localname": "UnauditedInterimFinancialInformationPolicyTextBlock",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "qure_UpfrontCashToReceiveUponClosingOfAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront cash to receive upon the closing of the agreement.",
        "label": "Upfront cash to receive upon the closing of the agreement",
        "terseLabel": "Upfront cash to receive upon the closing of the agreement"
       }
      }
     },
     "localname": "UpfrontCashToReceiveUponClosingOfAgreement",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "qure_VectoryB.vMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information relating to the  VectorY B.V",
        "label": "Vectory B.v [Member]",
        "terseLabel": "VectorY B.V"
       }
      }
     },
     "localname": "VectoryB.vMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "qure_VentureDebtLoanFacilityWithHerculesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to venture debt loan facility with Hercules.",
        "label": "Venture Debt Loan Facility With Hercules [Member]",
        "terseLabel": "Venture debt loan facility"
       }
      }
     },
     "localname": "VentureDebtLoanFacilityWithHerculesMember",
     "nsuri": "http://www.uniqure.com/20210630",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r52",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails",
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Non-executive directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r205",
      "r207",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r364",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r205",
      "r207",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r364",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r161",
      "r194",
      "r195",
      "r334",
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r161",
      "r194",
      "r195",
      "r334",
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r196",
      "r205",
      "r207",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r364",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r196",
      "r205",
      "r207",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r364",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails",
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r181",
      "r206",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r164",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r28",
      "r165",
      "r166"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r55",
      "r56",
      "r57",
      "r352",
      "r371",
      "r372"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) / income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r57",
      "r58",
      "r100",
      "r101",
      "r102",
      "r280",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated other comprehensive (loss)/income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r29",
      "r243"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails",
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income / (loss) to net cash generated from / used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r208",
      "r210",
      "r246",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r185",
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r210",
      "r236",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total potential dilutive ordinary shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails",
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails",
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails",
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r94",
      "r150",
      "r153",
      "r159",
      "r169",
      "r275",
      "r281",
      "r298",
      "r338",
      "r350"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r48",
      "r94",
      "r169",
      "r275",
      "r281",
      "r298"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r94",
      "r169",
      "r275",
      "r281",
      "r298"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r211",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r285",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r35",
      "r89"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r83",
      "r89",
      "r91"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r83",
      "r303"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase / (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r92",
      "r94",
      "r116",
      "r120",
      "r121",
      "r123",
      "r125",
      "r133",
      "r134",
      "r135",
      "r169",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r191",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "BMS arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaboration arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r180",
      "r342",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value (in euros per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Ordinary shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Ordinary shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Ordinary shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares, 0.05 par value: 80,000,000 shares authorized as of June 30, 2021 and 60,000,000 shares authorized as of December 31, 2020 and 46,050,250 and 44,777,799 ordinary shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r61",
      "r63",
      "r64",
      "r67",
      "r344",
      "r357"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive gain / (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r70",
      "r334"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "negatedLabel": "Cost of contract revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r339",
      "r340",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable interest rate basis"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Long-Term Debt Issuances [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r97",
      "r186",
      "r187",
      "r188",
      "r189",
      "r312",
      "r313",
      "r315",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r95",
      "r257",
      "r262",
      "r263",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes (benefits)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r87",
      "r176"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r49",
      "r53",
      "r287",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Fair value of the derivative financial liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Unrealized foreign exchange gains, net"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r50",
      "r51",
      "r297"
     ],
     "calculation": {
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r68",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r113",
      "r116",
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r345",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic net income / (loss) per ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings per ordinary share - basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r68",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r116",
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r345",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net income / (loss) per ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Earnings per ordinary share - diluted"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Currency effect on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r253",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Tax rate enacted in the Netherlands"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Personnel related accruals and liabilities"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average remaining period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails",
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r132",
      "r170",
      "r185",
      "r190",
      "r240",
      "r241",
      "r242",
      "r258",
      "r259",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r0",
      "r94",
      "r169",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r0",
      "r94",
      "r169",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r290",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r289",
      "r290",
      "r292",
      "r293",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r197",
      "r198",
      "r203",
      "r204",
      "r290",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Fair value hierarchy Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r290",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Plan Asset Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r294",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r175",
      "r335"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainBeforeTax": {
     "auth_ref": [
      "r301",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain, before Tax",
        "terseLabel": "Foreign currency gain"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency gains / (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionLossBeforeTax": {
     "auth_ref": [
      "r301",
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.",
        "label": "Foreign Currency Transaction Loss, before Tax",
        "terseLabel": "Foreign currency loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r173",
      "r174",
      "r337"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r150",
      "r152",
      "r155",
      "r158",
      "r160",
      "r336",
      "r343",
      "r347",
      "r359"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income / (loss) before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails",
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails",
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r260",
      "r266",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r111",
      "r112",
      "r149",
      "r252",
      "r261",
      "r267",
      "r360"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses, other liabilities, and operating leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (decrease) in shareholders' equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "ShareBased payment arrangements"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r65",
      "r148",
      "r311",
      "r314",
      "r346"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r74",
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense recorded"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r81",
      "r84",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid",
        "negatedLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r73",
      "r147"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Balance shares"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureOtherIncomeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r94",
      "r154",
      "r169",
      "r276",
      "r281",
      "r282",
      "r298"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r94",
      "r169",
      "r298",
      "r341",
      "r354"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r94",
      "r169",
      "r276",
      "r281",
      "r282",
      "r298"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r23",
      "r24",
      "r94",
      "r169",
      "r276",
      "r281",
      "r282",
      "r298"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r23",
      "r340",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "verboseLabel": "Outstanding debt"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r39",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line Of Credit Facility Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r23",
      "r182",
      "r340",
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt.",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "verboseLabel": "Aggregate maturities of loan"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r136",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "General business information"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureGeneralBusinessInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash generated from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r83",
      "r85",
      "r88"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash generated from / (used) in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r113",
      "r114",
      "r122",
      "r125",
      "r150",
      "r152",
      "r155",
      "r158",
      "r160"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Income (Loss) for the period",
        "totalLabel": "Net income / (loss)"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r150",
      "r152",
      "r155",
      "r158",
      "r160"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income / (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General business information"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r273",
      "r274",
      "r279"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r60",
      "r63",
      "r273",
      "r274",
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive Income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive (loss) / gain:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r72",
      "r362"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "negatedLabel": "Other expense"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureOtherIncomeDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeDisclosureNonoperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income."
       }
      }
     },
     "localname": "OtherIncomeDisclosureNonoperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r41"
     ],
     "calculation": {
      "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense).",
        "terseLabel": "Other non-operating gains, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Share issuance costs from issuance of ordinary shares"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r76",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Cash consideration paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails",
      "http://www.uniqure.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Purchases of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance share units (\"PSUs\")"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r211",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails",
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Stock-Based Compensation Plans [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails",
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r171",
      "r172"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Proceeds from issuance of ordinary shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of ordinary shares related to employee stock option and purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "verboseLabel": "Proceeds from loan increment, net of debt issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r78",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options",
        "terseLabel": "Proceeds from option sales during the period (in $ millions)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r79",
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceed from drew down"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r59",
      "r62",
      "r82",
      "r94",
      "r103",
      "r111",
      "r112",
      "r150",
      "r152",
      "r155",
      "r158",
      "r160",
      "r169",
      "r273",
      "r277",
      "r278",
      "r283",
      "r284",
      "r298",
      "r347"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r178",
      "r355"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net.",
        "terseLabel": "Property, plant and equipment, net of accumulated depreciation of $37.3 million as of June 30, 2021 and $35.2 million as of December 31, 2020, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r249",
      "r376"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r20",
      "r91",
      "r375"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "verboseLabel": "Restricted cash related to leasehold and other deposits"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted share units (\"RSUs\")"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r190",
      "r243",
      "r353",
      "r370",
      "r372"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r170",
      "r240",
      "r241",
      "r242",
      "r258",
      "r259",
      "r367",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r145",
      "r146",
      "r151",
      "r156",
      "r157",
      "r161",
      "r162",
      "r163",
      "r193",
      "r194",
      "r334"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementBmsWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of bsic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r210",
      "r235",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense by classification included in consolidated statements of operations and comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r0",
      "r94",
      "r168",
      "r169",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured at fair value on recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r211",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]",
        "terseLabel": "Summary of RSUs activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r216",
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted-average assumptions for fair value of option issued"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]",
        "terseLabel": "Schedule of unrecognized compensation cost related to unvested awards"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense.",
        "negatedLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation.",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Discounted rate for purchase of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Other disclosure"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested at end of period (in shares)",
        "periodStartLabel": "Non-vested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested at end of period (in dollars per share)",
        "periodStartLabel": "Non-vested at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "verboseLabel": "Total weighted average grant date fair value of RSUs granted during the period (in millions)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions used to estimate fair value of share options granted during year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, minimum (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in authorized shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Authorized shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Ordinary shares available for issue"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Thereof, fully vested and exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Thereof, fully vested and exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r218",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of the period (in shares)",
        "periodStartLabel": "Outstanding at beginning of the period (in shares)",
        "verboseLabel": "Outstanding of fully vested share options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r209",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Stock-Based Compensation by Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationEmployeeSharePurchasePlanNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationPsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationRsuActivityDetails",
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseAndUnrecognizedCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "One year from grant date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.",
        "label": "Share-based Compensation, Performance Shares Award Unvested Activity [Table Text Block]",
        "terseLabel": "Summary of PSUs activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage per year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r231",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected terms (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "verboseLabel": "Thereof, outstanding and expected to vest at end of period (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total weighted average grant date fair value of options issued during the period (in $ millions)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r92",
      "r94",
      "r116",
      "r120",
      "r121",
      "r123",
      "r125",
      "r133",
      "r134",
      "r135",
      "r169",
      "r185",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r47",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r132",
      "r170",
      "r185",
      "r190",
      "r240",
      "r241",
      "r242",
      "r258",
      "r259",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails",
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r132",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails",
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r26",
      "r27",
      "r185",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of ordinary shares relating to employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r185",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of ordinary shares (in shares)",
        "verboseLabel": "Shares issued in connection with offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross",
        "terseLabel": "Restricted and performance share units distributed during the period (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r185",
      "r190",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of share options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r26",
      "r27",
      "r185",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of ordinary shares relating to employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r185",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of ordinary shares",
        "verboseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Gross",
        "terseLabel": "Restricted and performance share units distributed during the period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r185",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of share options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r32",
      "r33",
      "r94",
      "r167",
      "r169",
      "r298"
     ],
     "calculation": {
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r190",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r310",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent events."
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r310",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r310",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureCollaborationArrangementsAndConcentrationOfCreditRiskBmsCollaborationNarrativeDetails",
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails",
      "http://www.uniqure.com/role/DisclosureShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureShareBasedCompensationOptionActivityAndWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r115",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares - diluted",
        "verboseLabel": "Weighted-average number of ordinary shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r113",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.uniqure.com/role/DisclosureBasicAndDilutedEarningsPerShareOrdinaryShareDetails",
      "http://www.uniqure.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r377": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r378": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r379": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r381": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r382": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001558370-21-009246-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-009246-xbrl.zip
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M1 ],97$K,F0CN++-J$VU[97K15397EO8IUM4\H@PE[0A=ER?6C?^H2SRI>:
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M;OU+:^&&EJ?D1$X?"%['PES)P04"AVP[FD<\5U'F2U5SJWA_")'WQ3E7'"\
M7!RQ:EC^IDJ6DF6RQA"BO@OS1X8$ &9T:;4M2*NE2Q@C>ER\0O&_MYG@A5@,
M1X'GW03XEX5EGD3M42!8K\)!.WJH0?-'[8(K78:[#2'L_4J*:':U[J(&C4^I
MG6M1)Z&Z"X0U5@'OU$A"X^*V/4[MGZXH&VQI@&.1CA!VCA5PM BJT/CZ%D(B
M)7O1"CC^UL,ES81)PDB3K$ \]J8#-''A%+@E)*(:+6+OMCPB"J'#GS5Y0+_X
M+_+34*&^$#(SJ]J9Y6/;$@;'&Y22'-[I#"')TQR+=] U7K=M$[9*QH'$)9D"
MEOV?O=_'RQJPK U>?/^10?E/9.%M[IJ9 D)VZ1XR8(8H+=$&7(GQW^(':LCU
M*\*V2Z0!627&@9##:M@,2#!OB1#$:JX"*5 .!"(=UK2M:+<@Q+(L?*#G*Y:7
MY2@]&HB\5].J046 ELA%(MM5"4:!X4"DS!I7%FT2C4([)(;0\\X3;XA2BK@A
M2JH0QB08Q8\%L@9\G4A##$Q/"R*EMP)1,T\I:"*I4KOK!^58F_2#<B5LF&(L
M$,F_ABV8 OV62$2L;J5XE#)?JM% Y..9MEXJ M0<#5_X4?04 R0!\&?]S_VS
MWE%O,R2+AF>C'G&]V;-3X_;^$8_\_X#'O-LSY$0>DKWAFWXC_6*Y:?-H+?F[
MWTP\E.'RU8W?A-*(GQF=B]Z"$C<!%$=?-6?3JS^+- #MO@)(&=6]W0A(C+U(
MR$3$!A1+7X+<V=#R#^>G7[[ B9[78X$0%1,N?S;MK7_:/SF7/\BRVP9"U)-8
M0-8^]5V@P6T7\Y2F3&?>Y86+5C!P@^&EE9$ELYFLSE:U-9)U0X+UYCD^<4LH
MXG%8Z%_#27(:_Q>E!]^#QS=/%-T+VN9G[L:L\OD@1.Z9EM/*B09._ZU136/$
MH*:'PEW2I19H&FLQ73CN%TMF!/BJ+2ZKM<("(5[1M!S72E"X,O[-Q^OUN8W,
M0\!K@".'TY5H2NP>(T.(GC0M?WN0!ZXTB8F6OO\=V*'[0F'7%*;R T,(M6QF
M[UB$.FT0I31!TC@Q/WQ,2$*B>?Q=:;':9Q(((9WUB=@^E&J#N&4O 4F(79N7
MD:$(?*/,)1SQ2M68]BP0 DR;T6G:I (G<4*TZ,EH$N YBYZ,[Y$X3M]6NP M
M8:MP @A!K(;DK$(J-7:OEWJ[.>LI&O@4+8J$'^+DQ'*)D>.&(Y?\O)B33+\'
M"\</\5VQ["ZOV(7@>?^L?[)](9@9MF>EX.E9/KLC3$'4"R8]F\/4PQ0HVOOB
M_HDV28]PU%O#UOM' EUK+A4S[VIO\8:_]"#^.56ZF12[7:QN(GUU2%84(\A^
M/PU>J)B[,;'H']LTHE_]=8>FEG?M4RE:"BX6A2T@WBM6S5RFF83([VVPM#D4
MSRZ\W=K]N>%K1(5$K2B:A1<T.;-W:Q_/^Y_[S5\3:I)8B(.)^\$+:C7"P+M?
M(DR>_H[<YV?Y/:&\;9/WA3+I6-\4RL$&L(T=TPF&DY1N4\2)2-HVH-AE5R9&
M%7L.&0 P<Q=12XR;NI*6[BA @E"4HIR))=9%\*VR-FL%/M'#PDGSELPTNX5(
M Y  F4K+J2:I[@0AT*:D:&=+U*C1-+%SD<UYY]KL;;D1>D%^)*Y96*(_!$85
MD\#UOD</0</^/8+#U%*CG[:7&?WJKT<<.)$=#G$2$R'8"\F;-; -DMVX&]T&
MR2G0+-<83@DX1'A.RVG;\"XF3_ZV2"_"P(26RRY6]BKJ"/%"48\6#I=R[5:L
M7Y-:K9#HK)59,7R,VQEM/NCT;C+J38\;.EC5Q1,]'D"H1;P_S<T=D II_LL@
M8J\K+QB[)3DN\F8-V&M9A))Q>RVF0$-<&Z%%DD\WF&*4O/.2A4]JOS7Z K#G
M*OE<L48#HT/F5_;4_?G\A#UAU;2KH7(>"K$T8J"(=X%F+*DU<YFKL%'J#DUO
MU+1E<&.VU(@5.G8VM!\JCS3H*X<*C-Q=3H92M5,TEZMD@E2R*/JJ=A[UIR])
M=. M8Y7EC1!!E.2S,<)SD>83-H.0 &2*^7*LC1> 7+TTF%'%8PM/42BLYJAN
M#R&[Q2B3U.@;YU8V+&UE@L:T#V%U-E30C6=6>&GY%_2@N/ L>Z?4GH'Q(>2:
M&)6&:LEE7'IV 'M OT2PW?HW+O(<"KB%'3=XL8@=>1:^<@FKZR*2FZI&AI!1
M8E1BJB(4M-CKE,?O,O#Y<]0_W'!V&=%-[QSA6]_V(O8ZQ8 01/]SQM:K9*-8
M:B0(:2*F=X:E"&-<IWQ;4"K04Y!%9N-@A&Q$L?NV"/Q+NGNDP PG:[4HTALZ
MO2%D9AC5#3K$:&BGP5\E2#(!2 *BQD9"TAU"+D0#^P0)-:"I]H%M,Q=' B$[
M43Z@\#+"BD<\U%T@U.<VK:S5%#"^>D=HRAX/"O"2YZO,YZPRM.7=NQZBUL)'
M6:D3)$.4'@5$U6VCB[D,5:"MZ?C]@/6C,G2K,+)"Q,J)^+;KN;&>"F\0I3)[
MA\ *(X9OIK%DZ5<R,H@ZW:951"64:MKCL/)67='-J1<L>-"G[VR6B*;&,3D;
MB!+?3;HC]J)>]Q)-TR_1R$IY&Q6I!MZI,931>V.YF)>7OD<6^\S%GYZ3.9WN
M7.N9ZMS0123YV1GZ5/SIAHV>O-@#?$0OA_=\-X>7 =![81#TYAL0Z \Q%#R1
MU]O L6KD]%C&;P^O@.D],VC:DK6[IGI!4L<RBS.45R7K5CA^$_NP-?@7RY18
MWF#T=X1\6Y3(J]433H)OY7*0WDD5H@6 7;=(!:VA5%:]+=032-*7ADP+F:A"
M\="9F(E&.CDY[T.J9VR.L4*T@?*:K'64,LVK6%<(.40: IW'UET$(3'Q8KG^
M\T^7'JKI46AYQ\Y"Q<RLLC.<C.NZ+*V2')#8GI;/7:"U-;9B#'@&N(# YZYI
M.;YOD<MML= F.0_>7-_ZBR@D'.&38E9:U .J<<Z5;R%C11@"Y=F9-L_.&N%9
MG@6NDF=G$'FVQQ9CQ^5HP+%S!R%@W BQA-*R_X:OK>]<Q)BO";%QNPZ>"0^4
MDL4IY/<#I5!,B5 !.D"[P6914NS^G?[#GA9\L;R,EMV@(&&]1G\(^X#"$IZI
MP5(<1VCLE>*KNY)AK.!2[%/@!(U=*7VDKX6+=H:07&)<%1<E!C0)N$*8*AAV
MQYS"0,)P25L(>E9/D-.,DR %C4]J!$NM4!@JMCSG\K #%;)P,2<_>#&VD)0L
M+W[>/RT<FL JA_]*INN*AH,O&EZNF@2++>0P/-G(MZBP2XJV2-K!"3(P7[5%
M0H*&RH"L@/CFDP6RW8F+'&G9#T5; &59E"*X)KX<A38S(.--/_URWO]\UOR-
MPOY,$:)57X3R[>13_][U//K=+?F*$44%CV>6?T-7_"-5+"S_9O* PD<<V @Y
MXB*]!L9ONFQ+KLCF1!.7Q;NA0/4,N'<L+Y)#._2K%X+"HS==Q*92$2B,-;2#
MT*5G$3*<))OI(1ZYTYFJU+ZB/9S@CWK*[2M( 96QR@  90\@01VYXIK+($!1
M&Y6R".3^J6JVU;:;ND+)V[ELU#4L"LN8TP&"4Z^ N*U-7@XZT*S8A>7%3^HA
M%-XECV@KC)B\^5NIE9Y/":!<5:I'50<@!BQ/4O.8 \A\5<B>C%X_ZY_WSP$9
MKVI8)D01 !=Y^0VF1N*J#)E[/$7X67XW""8O7T33S,O'"0"_NB*E79'2.HJ4
MKBJS)5L_]JB5LA)FMAV$J]!:*F!FT>[JE'9U2G.=L2P0[=%:ZA7_R'1ZHQ5%
M,S2HKTQHXLZUIBCCT17Q+K_/VRGM*26!<<Y)9E:LN;P>AUQ8LQ !H#E\-F%F
MZ^B@X60W]FR9&WJ7U_V0RVWJ4\/XTOU*J7(7$,)C1S?^QPTP0K5;I-?!5]<L
M0H3&8OCN G_*2OE?H>=0+T[OXVX)(3;844A'ZSETN+8$X3'4;WU"CVB<IXHH
M.F'+)K3L4_1,> 6$\/H%Q8<<A5==VAI.:)R"!YF#O0P3 )9/ )O2Z:IH#\0E
MGB-E.8P!Y!"OC#597_')>?\44'9]%>P2(@B/@TH/N*0M!+=WKB JF 3(U9W5
MU@K+(VH()QJIH-$1(0&."=(W%?.; [$V<J&2,\/L6Y=-L02TE=F/3=7;%\EY
M]3N=EO[+X+@++/_&LOE)F;U(\B?3$Y[D&E6W,P2KDB=VZY.H!E[0_$J7&#EN
MN()8%0<K: @G>*B@R1$A 8X)ZH!(85,@ID8N3'(F #(S>[(AJX-/V0<XYJ4\
M:X1H&:D$/^<.L=7LI_V3CW)3HF@,P72H1&E39%V.@_FR^SMS?]8A]F<(22U[
M$OMS<\0^%9>GRVL,(GRA%+%/JZD]5UR8![ZC2>:=/B""#DJ*]A8JT':=WRWL
MLCT:>\Q&L>?<;=; CE/"F8([SET4@)%?N<T1-02RUY2)D(SX@/:9>Y _NQD[
M._M\_@G.'K,<2X0H >#2(Z;X,S"53O&=5A!VGW(!2[-B!W0 1+]S?19=7-0I
M(6_>@*&0!)\5-!1R5("RY8YM.K!2?^5W V),\L0NCU%9I Z78:#-3Y5,K-XH
M28XN*__P&-DS/_""Z?(K#GZ%L\L +][+3R^%ND$P144%<7V8*809M/,,NW >
M3E(1; J;)6G;@,&2Q-T6-%@2/ !P8S?0T!+'%BIW=MJC +%E2EG,U)G51="$
M_GMB[]XZB0>#/TM*6/DIA]VCT8]/K((JT^.KE BY2BP[$@0M65)BUTJS+.Z&
M]6BA8FHCAJ>D]&#JMP;THR0Z/4<_;L'=)%6%BV7G5P!U '=D($-(<^?3:DF9
MW32>GWTZ Y#47Y2\0N ;HO@])=0\FDMIOO5[T[7U! *R(O 6I  V1UGM=9>3
M&2]MW5R2>PX"\FBIEC]VDCY)%3B^P[B:U6!6%GAH)[Q5@N -18]!2G)8H6@/
MX197@R\*3* Q*8O5+5W1F&Z$F8N;U[1-9>@64G?J 2!<#Y?6A6K48/.5/Z;Q
MM,#(<H9^^JKCI!!75=TA)*N7YJD*,>,A+G+Q8IF,0>3SOZ4+L.08$-+4"_"K
M)'8U,^W"LG]>^\X-TF*3N!>$+/)RC!'C TTCBMSJ]]8K.VM<!!@'OUQ_>FDM
MZ"_2D@!Z0T#()B^YF<Q'SGP H..X\8#??.:I2S[DL4JS;ZT\^K+?HBN.%;2E
ME]X/WQ(2L7I[PTDZW[_ D4#6L5Y71K_2PX$,I\;,V-#7LE^\>;T,*._BR,>D
M9K(/IE.,IBSR:\[V,L,)>WHR7-ZX/I4)NJ#S.9$_0KW,*>_2*(4<-#UW$V#D
M3OU+7AO47J9NH5C1E0LTH;^/K5>)LBO<NUZ>[N\.*8Q8>_C)"NF4Y^=6[WKY
MN;]?I#!BT/BY.D%>ORZ03Y!BXR%L62^?]O=U")&HV<:EB\;]"+#G_'(=Q(HT
MCA!!6%*K2WN(>CE3J5>C ';FSUK\A=Y'#SE3Y(P#'ON DC.@B\C%\LK%R Z]
MY1#?TG-'_+?PX%5NH'K9MZ?OHR2.-3'Q(0@O$-T<5<;,T@/6R]3R_H\J<(5F
MZ-*GR8OEO17&L4PYCXOG=*J7H>6=)47Q@<RT BR"$8973-)D;&FPVN33S,*(
MU2!&F,0'2[V:DY]V:TZFA_R/'N*#MJ7RY/H%4^73S5N-NKCQ?9]A%E*]"QGO
M0L8K#AFW/$36H<RLR-+3R_,=0ICV5(2'%^@%P0;M'0I> ,\N[+O,&ZM2]=9%
M?!]8Q'=R4RR//\[^#CG^. LI $N[7D;)ZYQ/86#_5!79EK>'4WXN?^NC0 ,
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M?\HO"OY&&:.,LZ6-2GOV\43[L+FVL ]F;.%E?RIFR$I,/9PJ<.#19#:-6>Z
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M^CH]8"?M/&Y5>?U.ZTB58;<NJ%(A-TVL4C:4>A1Y2FBEKI+)HZ8IX95YB^D
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M2Y5!"P]8A'5N%L<41@NHH!9C%O4[,1*C=R( '+"Z&Z/?C33 (-1#"?LWR\S
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M%[6"^=/$\U!\P?@3K^_K+4*BRBZFCVBSG1YV&[8U[-#, S@8&3%I_05R#0P
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MX9E8A%4T"STYY/LW2;+;\-_UQK9!3":(<\.-VH9Y_3E,#/\T**H;"RMUJ(_
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M 9P(NX(I?,=O555IP@/LV.TR&YG@S'AME#I!D]>:4_:1LJ85^GM>TM3CF$*
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M8R^WPD64I++7 P:2!(I].@TF!AI#Z $.3;2HU?]R=L&<;J +=[4I?YJ,DDE
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M?XY.\ZL^]E.>8PU8P>0\F_1/6K0QVPY?4P'Z/F*2XTGA?DT^DPWP[R[&J<\
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M+8[9#\!&-%,]U,$*QNR80T!#38&9IGM&Q+W8Z0//R:!Y>%%(QWG-;K]J'Z#
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M#<VG-HYUW5]C(WE1CN1%,9*M9CZ8U[G6>_7OPEWB&+O14\C>E"H4:EC*M'4
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M%QO 'V^ZJHOG(\YNV?11=;)^5L V^&(ROZSQ(FQ.H>M& ;@/]C"'PH9]77?
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MHD)_?5,ROR$_D5_FO\KZ_L?_!U!+ P04    " " @/I2,K%6"2Y#   Y!@4
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MIA2XTB-SF?C]&H:]&<V1)^-'WH:1:?7OP'_S1"1M$+7/GB1*>8"J1"H(* S
MEN\8'?CDE!#EH$$JF;S^'EW8.;B80&<2\=LQN9Q,3",&J8&.<:>FX%+SG5WJ
M0*;X-=17*(YAC=W\&=F B4KXZITF$J?84O.@<;\/BGV  &<JZ/JE%[GQW[&N
MIE(;'2&).-FE)D(3E9)SUQ;,/^]=ZP%P<:.L5E$C5T/HOSK"!F9II28CTV Q
MDYW.?3,^T,K^QO-][Z?MSF^-%?P--AD>3Q,=89$PT:6F*N.>$./"12W+3OKU
MW47;YND_:/S@JML18M276>J."7>";_&+Y\<@B- ;$>-9/HT)PRJZO&)'>%-3
MX)0TUY+V7+@70YQSD['+-2F!Q3L">R4QLPVVOAXN@@GKT7SN@SD*Y%VBR?9X
M=O\C@I][L%W(<.@2Z?#36N@N(RI)GI%$DX<BQ(PC#YX/[+F;Y/,RU[FC?Y0E
M]@;,X.^GQ@=F,&&LW1$BB9 Z(Y&<_5I%._EXA:!TP]5)5*A],"2B2YV12,X^
MK:)-_VP'*4W13)C"EI3L&#E8)<R((&>G5=1BMZB+_',)OWN^8_VT+8 >8IE
MD'Q,9G?.)HK*NA[V+[JRSUI-](PG<O991<UO1T$ PN#% =8<6%,OCA@$Z1Z0
M#8*;]9WM S-TUF/_T;72OY?ND%1IJ$N<$:> C#ER=FC%,N?9"V\ G+T+8U#%
M!KO'))&*R!@E9X-6T3(JOYUTL_YFA$FL,SF)+KE21UA40]B,*74W;G%[<(KR
MHS)LTN)W)S7@004DR70@@B\)^TT4@<2DXJ\+J$OTAAST5,D&$U]J\<O]U.+Y
M)O^]!^)&VY)@_#7TS#\+ZH##"BW1.*V2DIRV*)2*EFN\6$@[(V8#HY"WEBZ0
MOIG&A5[WO.CWA_USU6F(Z7#L8\@N&@.4BO:)E-_TU )^=B3W62!"=N4747 W
M/0WTK$EVQQ#E9'U]?WL"P(<U";<ZJ;6T(X ($'?6>A6UH)P*#=[6U )Z+M=/
M%Z6QE./R+FHJA86NX1(TNFE/:: >_J)F_O?Z <CD*MGDT!/$ZDN=6\<(@O$L
M7C:0WNC!E=<&[%KS9S[Q-$[[G>L^.>GW7D%]@63"9!]31A$[8M"WWG+IN;&P
MQ/717CGM<&?$K01P)M$Z@O>C:WI+L+&1)_0EA!'>A1-J:,>!2DZ<5T!]4]-B
M)"%Z=&(=[0#FQ8H9;9T]/2Z,)CY5A?+XL23QXZB>C]_4()5O"]!,CKV:M,IA
M%CQ#?Z)D4=DOJ!T)ZLW)R7+I==-4X(D:NM,"K+O(1_$9 ';)^LUP(O ,?L:_
MP=.!H:Z^#"&#7<:2JN(V=1!=<W3(!P9^];T@R.X]P2DR.C0.7KVM4O/#!%/%
M]A.AIJQ2TZRH>JBWW"82353T'SN5V\\; ?(*RJHB["JA(/8@R5]\V\1&0&P*
M=(@%9)FD)CX1%8[_#,+R.[$)E\O&"$J5HBX&P_Y \>V+:J-#%2FE3BL5C0O;
MR_8OAFT]NK?&R@Z13.61%.6EV\^)*@)*S6>BZ';?R/K?* CC0(.IAU%&;G3,
MS.;6"T+<Y*%.DUTBEF M,*1<5K12?3'6F9SFC\CVP4T4H-2& 0CB>3B&)[1J
MW>%")4D%)3;!32PW$P[9,=(W1@"L6V^)+CO&C;U&RZ7AK].1=^_7Z;7(D6M]
M=WU@>G/7_@N5@';!%V%]A8FP/D$QTE;/S'T3_2KI5<^;]0)<*9!TK6>X5B_*
M=0Z6@KUK2ZCV5B/C65[Q$^"@+)*QIF-%Q1K(N$L)Y:[7*#2 B]/^Q?75X+)_
M?MH?7%]>*UKWF M@10[ D3,?F'>SWI9)!1K]-'R+&#@NJGWMG*,$ I2LT*2J
M3]\(]Z3C\"N$H]U"&>WH(1>YDND751OZHEU=0UNI7>O%,=QG8TE^UE3&I[3C
M'IT+F+V@)A2C_*02LY%TOUPYWAK !8D;1$YH))'HR4&LYP?QTF6\PM_%J-:(
M=MQIC <[VU5B-*><7&(<(GIMRK=-.(V@Q[:5ECW2JHJ")!R+*=F> /[,\Y=H
M=R79ZR4__5Q>^LB@:BJ2\.B 1L%X(B(M=>!2PY-S7MTT=HE)MR!-#;C!BQ4S
MVCK/B85-6P!4] )-W, [<+P5DC_=WZ1-8F@UVT(4WKE));D[0IA7X, VYU^!
M"WS#@4H864O;M=$666B_@U0/Y/D+5QM%99X.!_W+]I.HO@:Z,O%-)W>$64J^
MB'9D:'I:0E6&OG?^F#;[2)-]#>"FJA^/&$$BY4,#9G]MN@"GD(I( OS^V5XA
M;4$C(+"SL\4FDW+8&MK*Q_FM)]J%C]H-:T>EIMV])!5*#1/5]40*IZKG"%EX
M%F0YBL(%%.0OL'M70=IW]".Y'-()9#>7*B6X:>4YR&IK;AOMUQ3M\5\\&D!3
M2NWB6\TC)VX<6,10/5Q "E/EPR5H#?U(?<JY;6XW/08?1V$0&JYEN_/$@D4[
M6]QW#I?!S:A2T(2:&@C=+-VS (]7X+_;)B94^MESWT$ 742LM6#JA8:3_SV*
MJGSVPG^!<+()1L;07MKW#I?^S:I4ZF6TKAE!<G_WP?/3'Z%R@Z8MH[031W-1
MJ&>I-_C4W:A)AM.1&=KOZ+$&U_H=V/,%4B(<](PY& 5!M$R&7-XK-*<<5VB2
M;O2,M!_Q-9F?:4].C*0K/6/;E^.%F9KW)2[C_YZ=#H=GA=/_XX49VJ:P!GY7
M @%*9NA2U:?O%8I:1]]GPW[_O)-G(=2#5*PR](>Z\M&W!G!3U<]W]$W'K/5'
MWQJ!1D" [^A;%]C$V.5O<!IONW."!\Z5T [<IATP31?ZAD"G/2>ZWT(9[;"F
MZ1Z+ELZ^5^JF?,QN: #02,8N.929HP5=B<'DX$7)JR=QF!X(F:)M@_$,/1'[
M;EN1X6 >WRDMIQWX38T ?!II+ 2U&N+H7:EX 8OV=Q;V:NK=NR%Z&[-L=*C0
M@C8LX4.-@G8%F5OL)K)+S-B'A(H%](:\ G1%,C (JR?6_,$D]9*8'-"0P*X-
M?9^OZ%02$PVX1^="A?@,48I1[J$T3F*B 7<:X\'.?I<8S2DG5_6I3H4G2'6@
M2X,K'[(6"#$O[7F]5/&4E:SA$C2Z:8K?;)?\>FG^]T7AAY"X%XH!)(!2A) N
M1YM!K/X$;;M I,K1D2OJK;D?J9 ^JE:?DE0H-09/U\4N>R#\Q'.<!\]'OY1_
M@2'W,?WH+H=^ GG.K\_C=4EM[^VTF?'\1)1J!03U"C* 5?(\5VCXH2X/J=35
MWU<?;8\\NDDP.^G=# E?.IJ"2%-@5;"@.3SN8INJAP=K:@]B-0-V&$'292J4
M9 @E7SH:@DA#8%5PW>O,UXDAN&".(N>[,C&Z_UC9?G*P+-D02KYT- 21AL"J
MX+I7G2F&P/T<L2!#(+VNFC\$NO\ OFD'^#PIW T=:<S\S"V[_NK>1*:PM*7S
M%IW6L8-#)GDS^A6TC9FL9._=?3-HZ3HV=1UHGUFJ&>Q]Y^CJQ<Y86-1+>)-4
MQ I6U7QE<^N6K+LWC.XV.0R*J?1(AB#^:T=SV#.'AI0L^>%6E48A!KZ=[!39
M9//%MTV H)TU=?S%V)'NF)+"H[$ZNNYB:L6&5*O6B(IHG@\'@[9:CEA"*[.T
M4D :.)33=4V/#90I/<J186CB>G T-F'&)AF4@QS/:#HM.2Q286^<W3@:76-&
M)P*9@TR<3%-LR>F4"LOC[,;1\AJS/!'(2'T6I;V6EZA-L=UQ=.)H=0U:75U<
MNI@R^E#W3;ISI-N5C9,F#H%UW3=A/SU48&2,7S\.90H.DZN.876/F 6-89@\
M$P*1&[D6>OG'A#J:>B@!'8<!*>W+T9QHYJ0?/(*.JLN-:]#.Z(W?XG/^;,[]
M8-C^;X83 =SK(;(^=S2GIF([N!!(+>9:C^%(4 9UWS,!L(('B#>*#C9<,[MD
M'GQWH;R/\ =N:+^C+$#E-$"Y@> ZU70BA&\^E!AC-E*_643N8MCO#X^V4VH[
MS<.0'3;WNV1!E5U0_)\TS? $ 1M +X0T#J$5/>"0OG6T&.FC#;?Z,TN1DRV@
M;>'E>?4E(S5Q1B;H$T>[D+Y'P*KUS!P.*VH"I[7--#7WMAL<HK^!<.%9GN/-
MUY3WQQKX<G>,I[&XV9K*/<CP!AY=9OLEOWDH9;<#Y9H8H?!]:/8O=\=$:C)7
ML@UQ:%]JCB:5YSE5)JTD74Z!OQ2^*T;]X-%BR!;3G-*E1K&V[>"S3(43._CS
MP0?@T84RP@DN<CEI>M8F1AS"YX]&U,RPPPN!U/E;9TTJ29:KS*22SQ]-2J%)
M$2"0&G?:!9/*!OH[]*(1<*VF%T3Y[QZ-J-GE$%7W4B-(VV8]V=W_D679B1Z2
M@[)1!$'U[;_P>:OD?;&(VN6P/SP]6HP:K4M-;+XYKOG'ESRH3U#HY,>[/TT5
MLH=KY-HH#NFSZ2V3[]W9@>EX ?Q9N<(F030R0^@HPO4=" W;V1SI)SP"'R'T
M(%ONA^B)/#C@]J_Z9[V3WK9Y^(_X"R?Q^K-GYKX!?S5Y_=XSTN_T_I9^Z>^P
MT:7C!@2=H6^B!C\I\"1;V<:S@LK0@X!(BT$8[*VX \K&?+U&(3,O3ON7%^?P
MS\OA)?S'M2(O*^JU IQ/E?,:@@8>5 (!2IRC5/41]E!5O=O$]PJ7!C20B]"6
M$70M,* I9BHG\Q4NA8C2-5R"!D&&-C_@5/T5+AT )/2K""%=CC:#6/T5KG:!
M2)6C(Z]P;5_YK/0R\P$-ENS:(%!#]_V/-KW,K 'WZ%RHL#<A2C%Z#C/<G)T
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M-?7"L+KP$-Z(D--*$2'' !!] D!JGNZQ18&(^(AVKDM(*(@TS1SC012<8&O
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MT(F;=LRQA=+&/D#.8&06M*["$Z9T#OJ/+PF6Z;3M/_X_4$L#!!0    ( ("
M^E*^ZFYBO"\# "%C'P 5    <75R92TR,#(Q,#8S,'@Q,'$N:'1M[+UI<^)(
MTR[\_42<_Z#3SWF>>R;>QJU]<<_T"1:!,?LB%G]1E*02R @)M+#XU[]5 FS
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M<K6ZT:W0P!Z#V(+F*VLK"RRO!>P0IN;W?UXA:0%/[\^+< +M#>=T7R;OC,+
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MRS;\_9, CD'\12_:J"';0-]KMQB#J'Q4%-V$:[%\#EZ*XD>5B"H)_("02,(
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M[#_7C*^^\68\1^/5=CR:$]J ZV$]$1FQ<TJN[P7V$ ([CNMR&2;;)3"1'-Q
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MQ@S0'H,B\A1U+G\3.A40,^X&,VZ\7N6-7H8T9GS\.&[PUF"\6#0F;6-U6!@
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M><,R [X6<.X[N*L_Q9EU:]'J=+J#"5K7ZN.*7YNP9<8 .!-75;/TN3NI(-;
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M:I\CCF\?7%Z[@5\>6=Z>!K6(IJZ[WNE-SF5!(F6,ZS1Y0=P:[LJH-0MXQ>L
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M8G.+81\^&9VG$3F>C.VL_21VF8'5[>=7[" ]1X]&WC_V]+JE/1 /G8)7S_&
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M?J]_V/;$(-=MZ+9%/D<U\%7N.HJWHFZAESCJB?><]5O#ULC B_-B8-"SUR%
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M^B93MBX;6M'*!M[ $%WR1C,I:D-;%I/5SE2U5V92;GSR9<C[Z$*HHQKWU'@
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MEB.7;!I!#/_K'X&(R4N<K!<GZ\7B'B?KQ<EZL;C'R7IQLMZ9)^N]E?=U)O1
M-9KMI"AW0([LTW>T9 1^*PX2OX-W3UY(H;PF<#W'4#V@)> RHHLD\,RB;+W
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M$D"C*4ZC"6[W&X3&IC@!-L]J#/P&@,*EZ!PKZ8!4!%[A94)/[8T#3@8 <!Q
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MP-* =JC<T8$\_&O2G$\ZWW-NJI1ZUR&=8*6C_^*U5P[V)0L'JC@&?/<=&,T
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MFB*XZPOX[^W&'<L!L$\K%,2W'0 [EP +-=BB^S+<?F]0O#^V-6);XRIMC>^
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M^9DT^-(9>HT-"0UDG,B%Y?JZ#M<#,A]\)9H3,)_G TPS&9$9]'>H6P [J:"
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M&]:VLN-9UVW;0[QS1T2#Q8=2L+W?'A.^C>B&6=>.]LSLGUGILZA#\N %K&(
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M*V7'06+Z;)M!I$0\_AE*50= T$LXAFMNHO](FW3?"<\D>+(QBOWS?]#5E[;
ML)_;0K?Q8!N."RUMV*FUP*V0*QC@F+D]!IN0.P3]X.3(<?2X15G/Z^_^E?@W
M-/G=_R +>R\U%Y_]4.41.KSA'0X I%O9!,7!=D79L:#(NHDZ;*:%OKTOC22Y
M$4>4J:7BCFK&R$=-@_7742_PRX_)7>)[;?IS=Z7"P6V9#HYMP1_50+V/YRT.
MVKV94*P8(Y$K+=)JJZ&)DAX;$Y]C3+!O-2::0 5[A&!G#;_>LKA48#U Q2SX
MMA=G$L7RUA0-9=B]^-R;B=@-HF X$.@\[_C.*PNZ:W-@<*1NZ5N*VIS5B>-X
M7Q;'V^+R:[M+7<=I-[%C[YG3HY S7(W0F[Z_,N\I0_'-N];7>**W'6@[)VDX
MFF)2+/6U!VEPQMH.F4UO<5ETB^(VDZWI6<QCFY#&YC:AC>@VR"_+.KLH )8H
M6#/;X9*S6L5*1T_4''[NA1,UN+3+QLL=W%.@HIY/7/![_<.SJ_K7:[5TT6KB
M.GPO5H+B)E]4+^B%LS+K,,/6&4KDWGY!''_]0Q^JG'3.'?Z U?1=A7Y>W\&C
M!SLCLW/J3?Y#G8?+M&4QJ]M+%G8^$9.G0SM S0JH#,6L/6&;4P_(367UUQ;8
MS>8$MV*@8\!P:\9GNR'W@1LHG/!ETIXC5X;K*ZZA&>&)L^UCWS<)'"9\/J.N
M!D>0X0X9GMH/8\LJ"@$GY&<WR79AB4.>D><R$\@<W7ZD7,X^#VGK#\_#BM8)
MV/X^8G&0,:' M#KR7>1NZ0<'4G'@#S-(@%+-96B2HWH/&EC)D ?.[!E0;PZR
M!<.:H;AT'X\8-K13)@*1ETU)"#R: 1C#^88"!.?[9F<JH)&G^>IF\+>)VHXC
MZ.;]GJ3-1,%-<FN2$OXDS%B%W,C8S6B8R\96:'[K..Z=['C)E@K!-MFT(;K;
MB33<2.&^Z'J)XAARX5F(HFD5YY.2 L^M75GLVD41*^TAI:UOB>R+:[Q;'V(@
MN\^R+"?^]54E_3B)8K9J^JU_<1U/RB(["#BH@MNR"J4OO3!<"7$Y*>N.PN[O
M;+85S-FE\BBEK^;^'65.9:LQ6@H3>4[L5@9EWUH/L#/1H1'FH5L!VG8SF(\.
M%.Y0X&OZ9OHVI?ZX@"%6X<XO34%FRBI@7B:Z\K1HY^Z)6:V7_O4/PQ*WT1OO
M$U <1GAR@[<&=_=,Y"56001U7[X,Y/8RD!]:ALRDYTO-I=7I@/9"LN\E)]LO
MI_]L&7;)^WK*:P@$Z\'TN.'B: ?7H:$),[HD97,F9]4J29:QS$IV_NL?$D=O
M7UH&:&8'B;WA$D2<]/C(D/Y<+2/<B6ZV/0%O=Z_NE>@ 4,%Q,6E\O \/#@H&
M^NVSI6!][]=G*-^TSU9GF7Q!Z]28KIM/+GH%L;B[ZJFWKGHS.(5I.TMLHZWW
M_HHQ@ONA;8'=I4=<>;/XPM;B#QF6U?5I+=VI)0<+QET")^^AQ;_EHFNO/*\]
MLC'"+7<C (KL!L<QG$W?UJ5^PMXAZ0FZMZZ=='!#A5-A(P?/S-! F'ZW#;]S
MV WL6S@@!'"S1YPHN+,NJ<$'H/5@+^41SJY#'4]@FP/3*2PP<F)DSY/>')4M
M MA;KH:',E XP)5'8',*+N0(SP,-_HJDV$7%B=P?LL=B!W*8:$7>4NP?,>60
M$N_NK$A<MF5BC^-J8 9&]F0#^5N2Y:)[W9;///< %[U!B9*PT?6A2Q0=N8E*
M5MC2]H+#%K9[A=)!K>!56A+3N8F#"N;@[EBNCP]//M>N0I #9P=5OW$!U*#@
MA+;ZS!!;K?HS[VP?D'0H7_ M+A9V1&J#+N+R92_/R+KSR&&*1@7). YXK?4)
M6@4J9->;U-,QY(K*,VZ'WM?M<>/#2U EX<K)H8,.NTU1.JVOPQ_\\+'GTF&'
MQQ,6_UIO W>UNIC,)%0X-<@_ [N ^K].[)C)V >X19-W7P>! IUE0?JH@($\
MTG'"VW.WL4-Y#M I+G>-*EOAK^?Y@\(^@\L"84+'F<( %]!1EMN-X6Q98Q:Y
M[,"VDAH8X_C;H1:W>B ?_#X:UIMFY5DDC+$")3S2PQWIQ$9)$BU[$L#&[24(
MC_9N#I.WQ23Z8.<4^W9K^'T8D#=O7+<--<C1DG@7?$XU-H*+OK$?/L@41-:.
MC7 5)V4'@T.-;.8AD)&W+O/65.),Z3T%V&U&AB"^\,)R"?C#PXVNIZ.R\]?<
M5MNM<"FWK./(0JPK^,GKTTZ;[6Z]2=XFBOIVZ3N4<)M0P\-F:W7R@\(.P20C
M[W>(4I'6MOH -?UP.%D^W.P8H*B-X8X_,^/@+?O"F^HLH^2:2]K1@KIXU"8/
M>!OSD$\SR#_#P+NM6[C>I0J;M\=!Q<O]Q6O;$T--< 3W0J3CPA+74W'B>IRX
M?M:)Z\?C4>^(7E&?MFA?"$T&^H*AH_Q?;[Z5<QGNU1B';&44>E??EH;W.T"J
MP^+.!<(6+-[;PGF?.W>[H(CWF?VP%>I5<B0O;=_[K1L+<# ;94N\U@@3#&TW
MXK@51OP5B=,='=G^2#XC=OEOXS^OQ JWU3Z*QCK^OX^MR)OPX"TB_^N?ECS:
MG)%;P\/WXM;;^GDDV+%M8ZXI:#GPDZUYYM^(U6[0;W?U@I4F;JDM^=H)CIY>
MQ?8"P]RU:]AUJ5A0OM\#.W4PH-PB_P-*%0I2LYZ=?1-D7D,)#[5R?4$@LLO>
M9H?!+Z[U 9O_&S<@KB2!?1C;70G;BWHJ7K7GM@JH_9EJ'=[@2&I[ASL] >"B
M!.!M$HB)@@M>I (HEQGE9\&E<8**/9 9P57#YX61B2I;V,V&G2\[Z00R<M-8
M0#>\]>%BL$U$0I=) AC8/X.H&<HRG%O(^^39?5Q<.K". C^> US;=]2UHQAU
M#!4'085-Y)ELC.300[SK$<)'O-<E<@Z,$-EF;G 6"HR>F1)N+!AC$/QX87J,
M(R</=EUB&TX97&6 !737V0R\.<K$#/VE@8,FB+ %=V@&74#NN-"/L/9(X,YN
MN9O@"W1_I".?P:$ S>[NM*E6^.SHS]HS8,F0C(?*$ZKH]I*@=L(-++$57%]_
MA+;L74_GH>8W16I>%+ CZX;0"80C7"<_[+MO]R02YRJB]T7D\F#O@NB]X2"A
MO$%2B;-E]YU:R"WSO#1X<J)BN9'=VR\X2'0ZW#ATQF<3Q<$[_B:*N_9D01D\
MQ.&.O.>GAGL_&'5?E3/=?HN9YTVCV4]-"SE06S5>C+J_<TTVT>&U[SY>TV\)
MX7?Z-%5D!TNU8_1%)F-VEG,!I%\(X?_IFD;BL)L4F#U7_XO(^5R^2QZM;Y8(
MG]_>(? -->L <^1FEFUGZDQV@BTYXAIW;\+@;/0O0>V434SXC9UZ:;\)PQ&[
MF_HAW'.WS-5UP_/PJ$,0#;#W,L[P 4:X'>U$Y+:^O1^JP35KPIC/<\@PN)MF
MG<?_<KQPG36X&^N^3:2]-=W870H B;X?7EP$UA5G4:GP]85)NQ,>[,?H@JB!
M;6]-R^:AYUA&(%6[,^I[<!RK\&5CV_6"QI;K%X\A";'QPJW+U(2QPU! UE1B
M(Z1*]&#X=I%;'*"]A:0++?>.!,I62$T\QPYHAJP.###;U'+<RWX(CAIN1ZIW
MY=(]*N%XB@[,:$B_89>QE 6'YL-U.BZ+1A@VVIQ[W#IZN^W><[?6!M>X#)4"
M8BLNFQ2VI0!TYA$'5I6 :J,_6/;.R6ST!LA'1\'T;,Y;JO[8'ZUOU KZ@+MF
MJ]!R#([R8\_^@2#RNOKFH>RC_0E^<7TW1X0AF=M>Q/TQK2_)V7WU,X1L*I &
M&KYF[G8H.^[V@2IT+'-?N+>FY%PVS,-'23ZR7QK-Y"S9SE@: 68U^V$^R-7T
MV?OWR_4)S68@,'E(U;-A@+,+278VC*85\2+!KJ"[AN'_:VUY<7CK3)-$MIV;
M-4U02.?U)C^I.<W&IDC-IT\L\^D3R]\]@7+:+&D$EZ1\;D +Y:=Y_^03VRY9
M "S8 BD6R+'$E^JB5^+[D&ARATG))[&4[1IH>_&*G>W\W0>\VSA#P\452EP;
M(KFWMNM"HSI(;3#<%YG"3DUWB-B;2@*NMRX.A[-IPOZOK>R-81U4J-C:HU%W
MGA,N(*1A%TFPG:RW[" +?R!KFZK)D0XTX4>X-L=^^LHZJ2-<B_4-4)^9Y/9A
M(Q5YZ+["3'V96FZ+U>OY(L?XY<O?/BQ"$<_1+E,P#K!=5.\O6/+ V]5JU=?2
MLTE.VJ0S8B$+Z9,62!>^^P5Y8#>'=S=)4FL@0"F50'8AU\?3A=<FZ.GFV3?-
MV)H AAY?;>/YVO9V;>=)A2D^FURG79?RMB!/1K*USC(Z2 @CB30[IX83FHW+
M/'L;LA[AT@J^X26YG;1S%@0VNS-7+T\^@BVX\02G<S4P 5C=UD(!.X03^W;(
MK>LKX>4N;B0%[3E'ZT!X8)-/&TY@9.G": ":PC<1\'7WG(3M>[@$!Y:+Y?;+
MT6Z'^WJ4;B..A]7U%7:,IRO,P0JMM,-$>#=O"QT<P3 <LLT]'J@9@1_R^>7!
M("(=>'D=_R2Y_@Q=C_NH_@);_C+Z^_DL#7TW- QJ3K@Y;'WW^1LS$#*P\(O#
M3*K2RQ3<KBB[8DX3DGVK89^>-V?M1GU55&HCT7^8T0TUK\YZY?FO?XACAT8P
MR]D^ ;R6[7>RL9N= A%?; ,1VT+PL0,@?RP$]YRGB1UH+A-33[@OL97IT$$U
MO%\4 E35 @G"W'8TN/M_E10PPWKKL3=IV9UD*9M4!G:N;7;27VX]G<.2)">-
M8K56>;3-TGU3+/2T^41FCNGE-RU)UI>F=67:,D2_H?3+F@HH;@Z7Q#)&KUM=
M:T7$EZF$!:*?:T,B^P(5 KF%E@/)$7]OH_(Z%.\&4?K#:HX#:UNLT-+ @53Q
M-^7!OY3M?[M#1-"9AC"5/_%6RV#K:-/!7/[ R%JWNDTF]C(CM@.LNP0GN%0<
M)\YO':?8/VD01.!W9W+3BP/IYVMWX3,/76?WWQZJA1;U-,*WA=%?>>/TA=PW
MY"2A'?&<)A@\>_M"(9,+RTT6XMSD.#?Y/'*3PQ) A" H J50$J/IA,2D5%J2
M.8J74B1@59Z@6)U1P]I X3<4CB84@28E( NZQ"@I71)(@9?4%"TKC)Y2*9K=
M_4:*4@B>HF2)4$D@,8P@2RE-XR6:80 />$8 ,K?[#9:4!4;C:(D5- 'V2M%A
MA[24Q)&L)E,ZS],<V/T&0Z3@, @@40+/!-\0%)F1-)95%9I6&8*0][X!&$#Q
M<'>G"16.0V7AH 5-AIL]H^LRRS(,SSQ717IG'O<9968?]5U]0KV^0"[3V-[>
MX\_;VQ:R2F5K75QM7=I@+>5?=:#Z4V(*_5JOQ,Q[7;'FR"FEU%:[=_-CM/BX
M;126?-PZ,UT%7C9(8CS(M8JKW&@B9,2162C=%1I5PBW-5'QZFG[9",(D:'^C
MW]J51Z.P8AK\]&LFGZ0DFOPX=0:/*RTCS>LYLS5:KHH=2S9,Z\\##^^>??$^
M-;J;VAG/+#4JJUQYF.T4FO/P@NLC)N@A0=]RKNRDSVV<\J&3'U/!( R 61.*
MX-N^A\_XAIXO^(9(B;SO/F5WI(#\T;RN-U6'RC@&M$E&R<H2.&ZB-?4-13E%
MF:CC1\R+038%19!L](SYP2%L:NE66IM3GI$B2SOURPX66 I.H4)CR7]V?&_^
M&M8A@J_8?ETB6T['5SK_R8VB!LZ+^//BB,?Q+Q03+"6!D(30%V*6U%Y.0$W?
MJIB(O[O^ZX[W8.NAL)%YC7EJE(?>JK,L\PM=XXFYWDU'?0::[^SY#'#26#$8
M_#IZUP;.> L< =5)W0-YF1;EJ9@IM)NC; 5Y9G3;=Y+(B-\_3(HRAH(P( J&
M;=6>VI7Y(%(F;^4K41CC2 &7S-H@W^8R@(CJ07&'@["T<(L+Q7^C#NN_[:M%
MHK/IT=XC-_@'X_^Q]YW-J2/;HM]?U?L/U+[WO)JI,C[*8<Z]NTI$8W(.7U2*
M("0D4"#]^M?=$A@0]K:]C<'>.G5FQD"KU;URKU[! [PX,_PW^03!\)G(^<)$
MF,TQ&Y/*;GJ^:NLF+S_K%"0.7%!/'ZY)1WZ_2=O<K+/NUO',J$3EN9*B'UE!
MI5KA-:XH1%: 'L"D=?U(XW< YVF^MU?#V &E6;PDX.:D4L_7)QM:XN9B4?<C
M2HOKX>,*D-&\]PB#T%D3%JNHP7IF2'_NNC.X&C"&E5V1GP2[[\7N^4C3SJZ"
MS4O([P![)RO9&:T5XD(]2PUDQAS9<S\KYQ>+@BGXJY6/4^,?/_V5$R>&?8N9
M!*&?QJYR0;)9!^]06+U<Y=+J.&>I[NI-[!K:, DK_A[F8DP'C*5S6"S9!4.S
M5(!B $C#64H>[![AY@R@KCWM+(YS["8H9=6B;V:'7G<PLEM9.M-\A@EA?7<_
M0FSDZM?A"]%MW=$K818.?.?Y#*9]N^@S9;EVML7=H4O]+NIBN;^C/Q.KO2_3
M=;&3<$17JF:(%6TL67E86'/S622UX?S^MI"=.28QR'I"01^G\=D[ZS'^0K;O
M#,6#< '!5I_JR+VF=-SA\=NOF=@\G9'];I:5/:;H<S-. Y*>P-F7ZC?"2'1-
M@I5ASX@6&'BS:^-S$, +0^?V(1/)^>A52RW :EW )G9"KP3JQ!XERR<B^[.4
MK8/QUDA;&JJYX=J#?#Z+8?76VVQC1/RRAIQ+ZA)&!*IW>W,Y-(HE6.M.F4BP
MQ;2KA@V"@"!&5>*,I^S#G0C>WZ2>*Z&'ZG&U WFJ*?N2N/#,MP_:.GOXFD3)
MM.BN"3VV.R9&.>*O>O=F?PWL38RY%^H'./539NM,4V'$/>I@)!E6X(;5&</'
M[W8E'6&T_CX\T=>4B>U8SGCS=",+G]]GE$<3A0X]E->[,E!Q/#M,"GT*;]R@
MC$T+!6YEG,B/LPM+W.E#B!?D[PFO><^]/G8A?%2(;WY2D?@E\"?2\/7>HA/0
M/45UHI26$(F)1^E9CU)A4-CP&:QBF&7!PR4UPS!-:_5JC]+]B= Z%EG>8:V'
MG1]G'^PP=X&P=HV=@ A=/)(M61M_+TR. M=UL./0G(5Y<%I8%#W1?9^J^]@J
MS32VZ[& :7VI8[6G;%E['+_3+[0+MT$">T\72(SOJN5#3H;ATVM%BUR+@/B
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M$_FK*,4*6&O("G7[XIS YB>V/^TJ\^YFLAFT.A/"Q&J?J1*%XK!DC;31*F\
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MNU3)5NY3?T'C4'.M3<H$AC@J7KH?V7DJ3%=TG168Y.C9O_>%5'=/[&JSW:6
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M8P/1/P>ZRU&1N#9@\6]4AW;_=C1]S5D>9)*B]0(F>)3L0'(WAV\)BW#"J?3
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ML'V@>R6,Q3D:Q_B3?3# (N&!6B,UJ C1LY1*BSS&R0I0:CJMG^(#5S6, 28
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M)/?Q-BN.XFH-L *PVUD@O50,2"7 QD T 3-*)*$Y"$Q$8"J2IW,SPW;'9K4
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MM2CG,+XR[ZD3DA#F4,+JMN!%8\W67/#?F::AV_"==S\*3H5>S;#K_&D8T3&
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M& ;-4R(6L21%M(-$(5IC555A=9GL(\"C3,FL M!DJ%@ 9:1'D!L4DR0PL"?
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M@VG%+:K327MH)''9KU6R(KB$-$VL*OI*%+DKBG_M5/\BL)?XU0\"H(LUM1\
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M%/(_49"^G+A?3MQ?.'$_+6E^#;*G7+DTZ[#)KI7JW_BU("%UJFR=%,L1A:-
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MH@2=B<Q*HWF9@F\I D9@-@"O K8*L!A995@>P?]P]!L4)X.*H4'#RC![5A?
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M\4*WL/#\H)[MGD9#UJ]V8Q7I:^:8C93^L&ZLJY;UU*5WU2%W_;5;(^R%$B=
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M%<_36P+^GV_0XN=IF%\D_#PD_%!:_-,5M ^KQ<6&6GE(5*9SJY@PJ%:1T6Z
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M9-?T#,'-)%AJ6''O.:?8U^)2@F#?K^7;'D<&U: <M$OM-%5MI*HWB*.35A:
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MS[L#=_3/Y'UIG7RTW^Z-? QL^3W=U7N.OMGIKJY.[?K*.NY:%FPK="B2=M?
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MI,NK;I!,RF.<VS"%'2 P?ND^VNL6;]6HTCCBZJY(_*Z9[P+YJDJ=M17+IM?
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ME7X ZCAE*(71"0KYM,SR0E'*23*=9B$#]YX8'V@KX>2R@+,(TXVG(.)3\):
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M/8D938%<[;/>6C(1[J/".$[6WDYSX3@&V&DHA"4E@E48]H%JT=-[S+^> /L
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ME&"IU%/"()3C.-; @W$:XE6N08G:AH)MC(]!V1CDOA*YZN_^><ZFCX5)=@Z
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M8-M*$3\Z/]RQ([.YG>?W;-VX/_RP-3'A3F'<#X7AVCW/NT<*8VL89#LTR,Z
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MT\-HO^ #'0]T/' -//"*)9,2_M>K.$#2(A"<"#' [V QP%\S(%CX80KP AX
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MERA825TP]#F1+IZA 'GU#Z^R<6WSO&AR138!@$KZ!N%9>:8)2C\,YE%&,B"
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M]9/EQVPBO>EFHI,ZSO?%V2HP *(LWZY[13K>N3^\(ZH0Q2TVJM8@G*N^&]C
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M!=HFBQ.(9HU5.X]5YRBN\Z3$567'&V($T/-( !->WJQ\<*]%/@CFE8V#00#
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M!XSF+L%E2PV7C@IND KTC@JN@0IV6SE2:N>LT);)0:K A5";OL;@:,'3T"N
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MKHY'5BT(C9. $B:IT%0RQF,I!$<RC+0(#72&D%AN$6L=!YPJ&1,52T95*,.
M<TECC(SO,Q;$:+D%#F+J"YU(GZ)0,A0P&>D 2<%% H\;94*UW$+$1- 0^Q*+
M) $Z#(>',961T3CVXRB.66M4)N$^T3J2R$1,,N,',L2,2A\)7\$K!4M:E$-7
M"!-XA(5  HLHL(G[6NI$(XSB@,#/RRUX(F),?2R545@R >,3E'&I2 PT,)^$
M)&A1;A0PA&H9^;$"RHF0$0\I\"JFC'!":!*VYH,EE A@)Q(F@*'Y5*H8QQ)%
M,?)-1 +%DE8+;8(PQ :F@G"@(X3Y$$DL0V!KC)5@BK2XJY7MQAB8#PZ\"E@
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M<V?&,[,VO<4SKU6^@OLRSPU-=?6&S'-CSYW,!, X&U!"CC+=/=9[K)\TZ\6
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MW0[./&^/6M#5+*+=#M3T<9G3,^$BA8$,L#5D9R4,78O/=4,ZNL:5BXQ:^H,
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M$/R =2E.$:C:%(;Y+9NJ4>VJO+@,Q1K7^>27!TYPG>)1Z;BXNQ.<#2C9VS7
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M,QA%(A((21SKT&8 "66D8WB;YA0+$5/1SGT2$X&9]F$L-/(E YLK%06H8*"
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MFIZ9ZJR$/49>=V0U^]P/:QFQT@Q\X[VK@GM?#[T_?H4Y^O"]N^52G^*P%U]
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MHCA0BK?JM/@*.$^!Z(B$=E0P%2%&(>"* 9<8)N"3++=(D**^B; ,HMC.AZ\
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M59D6"QAI%\E@0 L#QKM,@.GL=C9V#J=%GDNJZ=)0Q2::+CVY)M-64A/K4N.
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MUFUIZ6,WY\JN^T';6/>YU,]VD%:39.,E33QH5!YJ"G6YNBW=TT64?EZ8RNT
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MKQ+C ^64R,A$0'G(D6\B 7QLM1"(8EL?3\9(8&BAA!0A!A;')(Z4"",=M4L
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M.Z22V9-7Y+=,WT).K^J,+&Y05R/UD,VF[Y/TBXG7R45#A=16I)3MY3!:=0T
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M!0NYBGC$HE;A7<I\3KC/9(03>(=&@12^3J2A":=^@ 6C8KD%$H3XH18RYF!
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M9O[PV.39_"&LT'D^AYD_.'D[LR?PK]GLP8,'I\?&SFQO5 ]G\Q-SD;U]E#V
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M].YPT:Z^YCWGZ6$ORQ*=A5=V7=5$ZOD+?!C,DH/_8G\%MA$!I60#?[*97<W
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M)(YK_6;1 5DBA#\FDE<<]FBL?8<?,CA:O%N3[XKO.6:$O]8AX6 &(TZD8+%
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M2]PQRS/8FK#^1;/@!0=G/E]&@K;I,61O^)D!V(;B_<'XKRC+%^*_V+(&%<R
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MPUG;T-HA9L]9 U/#0>EC]T48GVS 1#*X;ZG0BO760>..9;*PJVJ] ./%)$_
MQJD=;(U6>5\^?W-P='YTF/SB/"4.>LBDQ:X%9XSM5*V/A)65KZ:,GT">.7[[
MIDK*#I1QU1:YMZ&SBBQK7M*,G=1?GOT?#4]MM8'1U+5M#6*;5>0'YO8?9FWJ
MZPJL<O(%3HZ.'Z8<?BFKC@2$]-;2E$)Q0&*S_2EJ];DB.U#0EY=_.U.[/S-U
MO=% #HSYX*7).PQTP@OP8:F&/M?%==7J,3Y,?H=U)\,2<Z@@X]M'0&?%+>>H
M&2FP0Z9QN@;I16B/<@8U?+E !H1G/SQ[Q@-(V:">63"]^T'WF0VM48K9,-
M/ FY8,:(Z&*G0K%=3-/  97,<$&>2>R4P,53J3\VHNX*5@;;EX;B/*AL @H8
MC$Q; E(0_>ND^#63F[,(AQ]33Z<KY^:ZDLDZ;\<-J>I:C*U('Y-[6!QI+VI?
M[LOA$IP"B ]&6U10MG/R@0@EV(9^76">A9Y.&HE]L.7&C2MV/$RV("D*/>>@
M!DK<&2'9$9=MZ[)&9LC0[)[3_X&J 2FV7E_N\&U=1HBM#*\]7&2*',-P]-0F
M1KFH)@E:5YH@A;0].42/A NO0#E>\OX(EZA[ECW<,ROB&8?>@Y/:N_IARYP:
M ,71@$3!SN5Q9@D4P(%]7W I&\:Z#DA;!5$O"HER(ZT*;!@KUHXT3M6 !H:W
MJ#V CKI[FWN_ZV&C46(9'0Z*S.IKUN6CXZ""9&=Q='0V#"<#&NQMHV_+YTF5
M&%";KPLBP<#CFS-G)5S$-7T0CL9R>: X*!0!J]FFAS?-;'N#NB[JFAH=5A0B
M\R?>IQ,6E>J+L6_7%!G!#D<^#3[BJ_<.;5EX&>P\B\&4JW*Y"=2V)J!PP6'A
M-/,P N2(4Z+OZ6>B>"!*3-1Q^=&J6JU+,2U%T<9F*EB 5>HP^KP^PXV1U58#
M6&[*/3J?:BW@<<#0<(0I++;,W;<V#8 ",<7#L3 ]1E6XC$F.A8'NBN-+FE)?
MO;>Z4\M?.9!G:/D?/IDEDBUEZS-:*4DV68%AN38."Z:YE"' ?$[>'Q_]>]/%
M.T)K_/#PK%\L@QZVUL3T*U.J-:SJ\2FHX6[]'\E5]L.[*[I1I)AR6?C,'JT,
M7QZ>%+=%XU"L&1^>#2_0H&;!'66-+E*INK7OHC1 U!A]R^:-[=#VC1%AC@SI
M,'H73@:%_R><YG//3O6T6I%2"1TW]]K/O"NLP^.U&9_>7S UQ$IVMSIB47<X
MVA+Z34=WEPT$,M="PU0^Y1)!O8[:CU"U^Z)I+H-5<RE3M^*W)5GA%5U#S$Y\
MDA#ECDYRV![4V!8-N\;YWEMB1IBN46)3,C$E4 ZV&=?*\YKOCCR!)X:90H$$
M]OGM2"KR"@:,MT=0PN6,"'U/WD.KU'@4=S/[R\:%6&HKP+"2)BVB%ON&G8>\
M(-%>D I0U8%9:&*AV^)S^>M.<U]QP[^4;^!+?WY^><@'FO-;VL6Z-3,G@U"#
M(JC!O3;L;<: 6$-3.N4#F#+<"?7.COD&O7R9Y%I@[1&+P49U)IX/HK9_6*E.
MG_EJ->K[1Q>P5S0PCHVQKI9%M@EU,6L "0?VT7!!<?J*%-6ZWE>+PFV:$Q,)
MGFT"!]=57$11J#BE'<G'+<=#NO%8KD?J-SA7Q.:BTUV^MU[<P_+3LCU[H[:<
MP[>D$L&XF"'TMT65A2H#IQ=$G/5@:S4!777!$]2>%X<HB)$<I[N<PEWEBH%]
M$8>_=3!?VUW]!G-Z#Z><WI33FW)Z'Y33^\4T6!8%1T/OH30AH=?4AE0[(3-N
M@2I$T7CHMG]EI=@&39+GF%3".,^EID?>2*74=QAQ/#EZ_.KYY1OZY_'C[R6Y
M)!&3H (5M1#E6K0PZN6K9\]_3AKDM[;Z2;!RTEV%H&HNP:Z1!SLWZ&%&"9XJ
MLC@$8B@$KG'<P11+:+W1*/%5*[['._ >%TB2RJ&+\0$1MM#VPJ5]BP^J9^QL
M2"T=T79 =H.H[#&LK,4*'R]1P1:/2U7\"12/^#?1UHM4D)$9B6(D2MN%XC"Y
M# ?G+3__9? "^4<K4D,X?@IM-9HG)+,.O(B\D$^I),V3O.ZN CP.%&<,Y&"4
M0Q"7T1PHYO8 HR/P%@*9<698<)WW0;9\]2QW&5-"FW(**XL ^#D-$X/D..G1
ME:>ISGEOL8 2!RL0#W[,(/L[*>W#G:<$.DTYO>M4I1):JKV=8T!FW!J#,HB_
M6 ?4@["TN>6T*.7TK0=FY FPO>07*P14+U9DV_#A1X?+A:Y]E\N60G',< 4.
M+:S-NBJB%L3P14%=M :(.7"<LQ5*:SDB2[A7_3/0%TD\!$LN;XP08^I0$P?Y
M:9G88?)RQYDI8BEMUE8"/NA31LK*(=++4]!GG==FQ:%W%GA?:1ML?R35Y$.+
MJ8GUBE)K6^'N4@S0+W6X:9@+'Z\./A1-@=6(JB[D>7ET96A/@UPM,#^7#+M=
M/U&$?4%!6>W]UW1$=+',^002!38O!CIM[98#NB\J_Q>W@1+F6597128S"!.X
MO"*L-X;ZM&$]3O?XR)(6DM&\J@TA;&V_ZE...YC,Z4*L<>Q*E< PRQ*Z.@R^
M[7L80!=4M4LJ,2V#P7J$Y9I:3G!I8*7HSZNJ:;E4A+UK THN(J2*3NMK?G;3
MN_7BA0A^W+HB/J\9]/HP=N7X\2-%91*,K>-?9J8IL!'!FM(!]?CCZXX\2BQ_
MF?KX1\^U%*&&2\<#:>(BG? [_C!I<,Q]=XUA'/R%,EAP 9#W8'5CYD7=M#I"
M_>7X$'5K<7:B1/38YYWT2M 8!B^I[4J0W!H)*F&0/(C "#BIA-AVV1FIUQ^G
M%X^;W5KRJL+KI]'Z8]&RQ7N0M[)=- 316JT1CX&M!)!J_@LCGKJ^0WG>WJB,
MGX([A(R(X2G8YDVPCJ#SGHZ9= &@#YH:8G:"P0"F=QMM:>_DPR6:916A^6-D
MB&+*7)JOQ2]TP6^E'$*\RT8>O;37> =E,# ,IO&>BX+A/ $S#$A1'+@8)@_R
MW>@K4'GW.\MV0B _' PM-XQYF<H+0?#6=(&P63$P;,<(-GQDV/53C+D[SIL9
M\72X[(:%CZ\ [1KK@WFR/,)?<=0<T@H#K?B.'!P#OD.<PV2:!KT%C3J-X2C*
M):U[&$6*0U7&M7NYS;CU4!2=.\!EI>W #K=4SB-J56>$</D"50[-G5II$EN0
M$3LNQ^Y6,^.F0E6G4A0Q*LFP\H-1<Q2:"M!@>B,;0UZCU% ZY?$EL]34K[_U
M_"?_]J_'YT>/>__Y\"#$[U&]KB^UU$H&N)%A[M(7Q-T-<2>63TBM04 (JP:S
MHUV!G1_)NE@C=@B=^A"2:?^+?2_+!)206I5<I\"H.J@8/W YP$L-2JEIZFYE
MZ$ZM?'$T)[@B9C66]CLU>,$K&KN\YD88!ZM*+F/4[HQMC.V"GHO5"41)U&K=
M2;QOOA6W=2V%OH(W>+EO?XI;IYV=5SF]N)5!3F&*XYS-8?*SOTPX518*JO0K
M"YL7RQZMM<PB[7GNVUX.#W=CC4Y%T;I6T'%[])7VI[K%"N==!K=J\$Y-4D0.
M+ H0-]RZ]!"'P0C@&J\:F%F&!^9W.][(3A7:V#$='6#)*_&7T8:-EH/'7(U>
MR[0T0=J"S#XM@2C]3E#ZEUJHM#J(F\C[_5(J OV6OU&4<K"OM72=P!3<^7+"
M-C=9!%. BLO!!NL373]B46H 3;K0XG8O?Y.'GC!U:DG3H$_?C6;I:%8^L:<1
M:@GBN:(&7^=I)#F("F9!965UD7VC6:!'4Q9HR@)-6: /[NQRE@6J$J>[2.;H
M(GEG \NB"$P"$"MXK"T;VXR;<7MG5OUN'6##+J.(2VM@&.24%X1I0: JZ*VX
M6;OZNJTK%1%]+AAU<:D-$%(9M@21J>$^P1\EY41_R;"MH27;](W/NX "N\'X
M^SRZ#93 8FT982"\/6C8<G\%I?Q^[QS=XTW18*Z%K8)X8CN-9[+UHEDS_@PX
MAQCS5FGACF@U%>BV8BP&Q>@81=DX3/ZSNH'KLW8W+MW[SKB+IK%E\-J3?OO0
M75&@!T:B@!MW-- [P<7GXHL6.[UY<R*1(+(2'$A3!/$*3!J&+Z* M3:(4] )
MKII4NUPVG(4(89-\B1Y>T]QZ#]9VQ]"(=(*E[GYD0>XP<S5!"49'@@ PR9;B
ML&@#OZ%)C _)-_+'<\)T!!6W4-JE"_$R"L09^@<8QR#HB\ VI - F:)Q:W<+
M5D-FUBS=0WP&/TRF=8$O4IB/88)F-NK3=Q*&1TI,>EU0+U(=Q@\9R 4W:HML
MJ@'N+/@[;(/$O.BT8JZ9H1.RKE'[%G??OR,R;177P@WS UZ<WK4Z#!Z%6#RM
MEIUQX>?>1"8__ K\3;H$%/@',>[49M:$?T1*U&0U]AG2?3E G\%?M*$RHW A
M@P3*"T@ UR'%Z!8@B3$K/5#AV@(5W00>WF08:]N%H+5W5_7+P6+) 2O*^9(:
M."G!ERU-L9*3'6T&=ON4Z,L'=ZK^38V5*R/AY;AEC=QU$0;.*&C>3A)1[8;U
M/@$A8_DT?K.6+ ,K=N(XHO4.WRS8A!1@">*CG'UO?=2/:)HIHNM)J[34?'MK
MS#!Z2H2%O?"##EI9<'H<3+Y/ 2RDJI%JV'&H/M'F:\2%:?#Y+GOHRXL="9B>
M#%>@ZIKO4?]6I15>-O?T3K(BU/PZ^HC]:=NY%!2OD48$NA=]N7F^C75;JI3'
M>+JPGX CU%J)^AWU[F/J[$#3_U6OU3K<LN\I<;ZSA]D:L;ST%)CQ@5*9!HT%
M'DDRW#)FN%!\[\JQ<"1,*#3QRB?4.;SR$ 2,RUT+3>S2+3/DG@L,PMX"RK4Y
M6+Q:;&_?! 5Z0V ?Q,;[3K-%.*$@V*1ST^MV?%K?IRXUR5$9BOV0 J'^VGYP
M1VKGP2FNECE?Q(YP= M56QI<11%TG=Q+=.##QN+!79,ZN$7-L?9UFE:9K%OM
MV(.;KIAM!3]+0Z4R*.&7?52^@RK&I-\F'XQ)C_!X"OL=\5O.W6;NBN!J@0F;
MXIA]X:H]6OH5A<@D=+G%+>!6DG+C;7<1,6G')O5,#8R!X?LIA?>WHBSM@8K[
M<,OJ*:/\[<JY!L7R*H]@ZQ?451_$@WMM8?" 'XAVR%R5%1(2NG@H=ZUL>]W,
M4O$9,L/G45&;WCFC4*4HQK[M?+4&O<".JW>*MW"GCMOLFJ!L[+;OA?Z$7M.B
M;8/$AMAY;HU<M\V>67*WBH$OIL/K[?CT*-TF%/Z3<#MAYVC5HIF1(1;GE3.\
MJY(15.!WN-](B(O[;6#-6^N2M6.2=2BIS!=\P>V4VPCU6BI=^-X4A[,J PF5
M&?3[.5')6KEP'>JJFCG.0 *KBJQY3)SQ +<@ZMXF\\[?'4A^H,RQ-X0P@[
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MLR$(,VXSB&!4]8A-@7Y7BBW9R17MZGB*W7$6-=X^[#\I1)URE@K?>-0'782
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M %O@I><VA$[P_KFI:QS]2FDF^%&H,PG;G:-"6UVB_4= >-HOE/JV\0[&T$W
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MO*]%F(6KTJ/&LPZ4T #VO*^"6MANZQA\VZ[&,]_*V!GRJV5F#N%U$[-$=BI
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M<'#&Y2WXJJ"4:EO[^$M7:QG4D7)ON[;\F,SD"+=-(:BB5;[GH+83KG3P?&Q
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M:TCII&/BGTCA)W;), P 8@^JTR@U D,KB[C2:XPEEV1<.JA#2'IFW,G"[+8
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MC: 2,3U['QF[^4@9SAY\.6*($D@=FA2_<M"#!*!Z-41AXT!@ZBU\Y6I!DB?
ME "]2ARL!M])IX=@^$<X3@)3RJTE'$M?CN<A+$44B"N\F .^OM$\<XB0-8=/
M'XY^DLO'*1N+RF4NIO4WZVP(<G#?+/>M#MV6HWG388SY)[<A=3C&)XF1.EJT
MX K6L3^SYR_%7\S*6;.D/H/8.< W5F!!:>2# 4O."0*^&1E[XJI1)!(WT]PW
MJR/V[1@)CX!T5&41J$!-* E8 6N=FBTJ*D8)L@ XTH+>AS(?Z]08%JMOK@Z>
M3CYO6$2A6T+@$/DE)9O:UMRXHG!O (^C R1W,+*I'5LUX5M!,M%+Y32I,F+3
M*?'>8X.)#]T:G,$TB#.\E,(;I.NN0'JR1<1,(V]! )N@DE8$8P$X4.HXPBI,
M09MT /8"*D^T!5DK;$8D.ME >41B!!!\1A4(*IB(1 #%+=;W50\1"IY^((!?
M&GX$FEX,RJ2'G?=ADH&>'0T#!\/ P7X,'/Q&.-.?'A&\WIH&5_^G!R.OB_,:
M5]NPGK:E=A9[#ZND+(MK"OIG_LZ*9F=TF@M.5/^C%F7+AU=>!)Q*56]#L8CL
MD"![G&KY]LZ[1[ZXL+:465!N5[$<MUF9'O=>J&%S]Y%1D=ENHM6MA!252ASA
M(50 *N"UR3CL6C9YG:USU]IQYKR#YH!<_1_*!?575ZTPF=:S,JM<+#;7[/]H
MSR>VI=VC,(TC:>J_W2UD3+)!YN;Z@N.1R^@+\]^U7_VY%*1](-7(5V36E^?/
M/UF1F2QNY$E).Z_)R!4MGV[/E,1K56$=)(LM^IN;0U,?H5PZ[*6^.=6*KG>&
MY) A_<DYS[$D0<<X6U%2?W:(I^U^^4LUBEC>M\'DL)NO"/<-@DW:U^@&8R'-
MR]0(06WQ2<-L4%G3V0;_&Q@"\"<\?GC4':.WMB 1M L^9"@XD(9&IVCX2S(G
MTKI((*[Q W&8XR\DW;=KM_*+"&\7E$;XPN'H+6IB+^\S2OG,1( M;TX;)!0N
M<I7DC58WNK,DQ%0=^M[I[O ^L>[WNKS3O=)Y)XPJI#]$X@K3\,CG3-\POD#,
MJ V?]YO,N>R5NRQJ8#/ &1G("BZ1P*H3S0+YA5_7JZ*,LXC4B\.%R:)R-S]/
MU"@469.@'FYA2AZ^)NZ%VKE%CG5G-C#PIZG)#FD/>Z6L8CHYZ3:$'$!9)$R+
M91K:;T<$IDX,0,I"/NUPSU2ZDJVRNAI3&A>*6\NI.5"0!=V>QK?2:]"+2#%?
MKUQJ<PZ\W-N-*7%O\0*/: Z(./:8(9[T:F?&H$]8O$FJH@VFA-?[%2*7O:VI
MK0U^]:*!VWN9]7^3$IJ@8WJ#4&;,?XPWGPI#=%^*K9UG7GG=G'?+;7T$H?#B
MLE3MU%0C\-A>72[]@_J[0^TRYGOC]X39*("C#<-)D&Y#USQ,QTI7>X1 WG<W
MV]#NU;[71<FE:W'?R%,#4<?UJE4JH"V!@S"#W* )Z3A+S*M8K"7010@AK]+]
MAE-FWJ7$QQW:/TRK8%$19Z<<;LJMYDE&ZACQ$U=UIC>BA;9+P\=4] [E97$!
MT0U$&2[*D-F2UYUJ%1)65)X83(;!Y(ZVWE9_4*:! 9,;8N :E +<'T7^-I3)
M#8:V\$4:6>WNA_OHE4(%15LT4W-O[%((#@O&Q>;F--E]WC!R$BCX@AZ(T+U&
MQ)$+EX/GP(E3V+&Q>EAZ0=!D-M!!K,*.#H=96V8>QK.!59IVFT1K8XG-AX9A
MMYL;NA]6K9HR:K3H&IW=M:S]D81WT=-KG8$+9V [M=]VW.K&)74*+.XE<7J:
M!H66\SO/F'-'$^58X@K50&ROK#)RN?K4+\15MIZ$4/X,8":)?3EE+]%[QF8#
MKWJ(JRL"H)? 09DIZ8[$#!0#86L#!^&%FV)E4Z^;6LH7&=ZR+KQKB/&#&JZ.
M9!R.GFG1#FPT$:^@L[X$FX0BY=\GKM:U2J5C&=IFZ%B#V 9S3' -\')[,='Y
M=,L3P4' ^DF87J+XQ>\[*%=^05#="^^S8F@ *(CM+W$^R RZ]K"<DLZ%9VXI
MW1'XP_,BSXJM)M).BZ@CC=HH==&!;Y]SU<S]!QZ57O5 *Q?'0^5BJ%S\H2L7
MUH"IGSD?3;.B;7N!(#>984\')CH%'I_9%X&IN!HM_"KZGXQ54R(9SG8+"1VD
M39F50+C&* 98).@$0B>@?ZB-7T3P?YPT*)*;[!]Q2>U0TN+<99SQMN2ZXD -
MZ<XT:+%*4N.N.%E=)4OE9TZJZ'*=8*GE]K]X+ROJO]&A!@C^CGA=\"ZN7A0I
MTQ*ZI)9^'OCPHED"#D*1X@(S?@*A3".PP?O#MX=PI\/1&P35E53?7,=WLX!&
M9+A <^"(2RB/YK65=U&32VDJ1%KX\&TFH>_Q*_IB1Q,F_JLILRJ5$7BP<?5F
MS0 -A._DG[A:8-JK]D[%\6/_@JMZ4;&5I"EAABS:C C7A=P6TUM,#6I;6A(^
MK K>!!9)X%U;.'P\<&BP1Q5Z<[*RJJGH_T&:\"'8H<4L@P?4^0)Z9^!E]+JQ
MK2NA0Q^(%K='406F)-,M\73+.<";5%5#N5^,^<8C#!&0@4[C A2X<2O)'#*4
M(7R1TX!-;:TSS2$Y/QP>Y"ABC00D-/9*)*1A(L8T\-2..4/M:>SO#=P2U112
MEZ,:C=>H^4:C_5V^C8WBMR4C_%H_#Y!>G,DV40NIA;(SJ3CO?(@/2SNKTCU
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M#E/('J_0D=,IM)9?#Q>!S&M0'MUP=+>'JNJDXA6H/I""8$;YR'Y05Q*XH*M
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MM#!4\^LZ6PK1LQG)## 9,9=WZ!C'5"_,R3"AP!AC[ -N!8*(\BH#Y7OE9HJ
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M,D([54QS9K8%.)U-(1F+\&Z8?!*C2DZ R@OTQ=E+0+/;)=&A&71(05RT]Y*
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M:#)U,^_2/NF<SK,7'Q?^'G5U,7ET=/SX;#B5MSZ59W<_E;+XPV&\U6%\ZZC
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MRE4'KS_F;C-Z1K!"DZ.CR9<1F.VEI1Z1.3ZZ29_1?]\A &6>%]<XV=R'<1K
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MZ?^\C%M2QK'V+>6:"KGUYA"/3S>W,REV4"8:K8>,"R"JDD(" 8=+Q#H-,CG
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MV-_-S.I!,V6VF&#Z&T(PMI&6844H$(;8T9;X?K/9X@[7'0"]4%(BV90GN*]
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M-3@P'SA[\,!9SP?.?.#,!\Z>.'!VO-Z!LY,J7:2$HW3MZ_4IWJXEOC2;4*"
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MSH)M#EGT-3)'S QUY^[#-NNC:#] V.;5FH=MSMFI])MQ*G''5]0P@A.@;U!
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MT^!K.A8)#)@^P8'/C'G.>PW-M;QDX6TZF-6(5MF/WLS_4*B]$'_#4+?%C5C
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MJBB>P*PQO 8/[*NDA'AW*ZGQ;\SI#AOG#3_3SGFKC;!C*SC):R;048?V 7H
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M51";L2XY%]M:J8.)>'18"GZ+6[GPS#RF]8*[PGQ_20K_)*Z#WJM.<'APV%N
MA3AW_KU7W>/>VLY_6?UZR<4 TZ-WO+:+P?+G7,D,)"6\,OU?.[#BG4[&S:)D
MI5;B@\CE_8_#6DWZ4<_"6JW$#S_?? BL!X>MED?W"WC_Q!/Z)]YX_X3W3VRW
M?^(D2>15<!+L!?]*^\$'J<-,36K.[ >:CK-U(4'(+<=\GMYIL6B@52.%!2O=
M:U_ITQ&"77VID%R^# 8JE%FP<_KERX,[)IQ9_+?0N1I<S[C0$>,].#8^]*]R
MDF8N_LSIQR\4-NL3WAXW <5@P,E8PYI$8MP)/A/V%O9#T2:T][N\@D?D")OR
MZ<0DK2R<-M=E]>NUS@3"@>5:OWXZIY+52RP7-@UV5 4I9YT]57)+2ODD6.R)
M<7.\O89LT^'TI.L@' D%8X0OD*PLV@R5@LEPA"GSL8.YTW'>0)EZ!C5')"*^
M)J7([1[4#?XSPNCA[.NQB@WS!?#DBIQ3!FP9 <*&S!P!N_LGF1+Q@KUO=EO4
M]8VP\[SN<)Q',2PCR+0\W<,:MB%[/C)JSH.E;CQ?B<!_&2R7Z;]3ZY$T(+0W
MW- X#>ULVHFC&YQ@43;E_4QDJ&#_J_VF@?%R<A-(D_5JQ_#V:?2=)7F,(Q4>
M,@;95 8.C[LM'3%J@OI-]^BX_9S31RK!BNVW>^:RQFQ+E>50'D?O,%H?B^NW
M*B&-I0\;^KWNEFMV77@WAF&Q''Q#(W7?2<)_-C2-Z_GFU>%+NYX@:V#4MAKE
M].'/P.FGTP ;,N5RR 2&C0SHM$H;L>W,\(Y<WI9U=!Z2=\PJ'RX-= _,7LY<
M]:#$R*_9-GJ\H/W%?8JR8HC)'CJG5"Y*'L&/+!M$^13#4N!7:@P[J'/88*2$
M$ 9,>YHCM1K2P#(LF84$9\6Y;\PW*14&%%'E)(Q1.JP1>*8F&)-,3(HL9=FV
MT(C?_7OO_L=$LXR&+2+$'$Q:10X2"DS,,2(JDC$H^73="-2,X*]"E.(K1 QL
MSN-#6!Q75LY"[-53BQZ2ZY6]\@SX&E%L"'^0SN&IYU&HYRRYE(P"0,V#<;=5
MXB(J/<I&R['2R'5 E+FB"'G%/&GB]]K9Z^.[;?8'/MF<3!\9)$'"(&)E@V ;
ML%/\!#Z0@FL9HG2:F#^M&N!PB,X<?:!#=0T&&>(&EH*4A^LY+DN43HTTZ@3_
M9C[5";Y6,@6?<%J))B]B'IUP3C%$V4\S4;42_[<C0+CVPMI5J"V0U03VN$23
M63$\)HP&^Y63K@F3 M46J"[1 X2 LI2E8=/E7C$Q,@OU;)0X5.I6HF]:4C7M
M&+ NG5Z6I<!/$KF/H.#F]QG*(_W8,<AW9'?8[>!EBI6;?<4<<6BU8#LT-<:2
M.ENX;BI$J-XM17U)CV0\V(O5 )-Y<YEHOOOTY/P$,P_SL+OKB?.QN5I?Y"&2
M!!8SX*I?82-0*ND"YB1R0;N9IR'M6$:.(UWC8&.P_5.\]>++N=DVOVF/L6DG
MC"=H)%$&QT].2>4H+5$MC9=FP( 0#ZV%6-=1)5<H\5YS ?#.V></0 !GG\[Q
MG_>_XR'^=$(_)?<6^0IB!Q@%?ILI.<"//J1A40);D)=($F/Z38H86)69,S!-
MNI,9!'$&QM V&?_:5 T"J0XS,?8R[;%D6H(6AJTLM&P>C:2!L72)-LE2*C\Q
M!K/?D\?:DSQ3_<)UYW.!9KD=R,!-#0Y5F'%A*?84C6/)A>=H!LN,H _])CW\
M)GU!=Z.4UD"<U>UQ,Q*NRS5=G(IH*-G[U.1NCB[F.ARYEI#;]91;K?, V>:8
MFG?APQ!_#KL7^HU^),5J0'Z #NJ^7!I/?SDN K;;635V',4F+*6O=2['FCW0
MH&MQ =M8"KQU4,3!_Y77P;G,"-L9Z>4LB9#1IAD(X/][?O: XMXKWX]#(^\+
M%=.)[</1A'OWPEA@@Z,J:II+T&&('&(I(F =[CD'53TK5,X>@XE#"6PL\N?X
M$TABI"9@=X%I";9FD^GH@OJ6(*N 54@2ADQXU W?QMVN^P$T["RVL[+ I#-N
M@!(5F]5@F5!CDTA<8_@V(BR(DE XMA1=TNX_DN.Q[!R34CFLNFQ5Y!;$K1XX
M08:I8AF2J$6 RV0PH+D7LY3B"P>?+S'OZ, GYOG$/)^8=Q6\#_8L"%"V5V)3
MUZJSFZ C)YBG'<O@L-?!GARB&QPNN8(KQP9ZS\ &[GOF+U,5W73D]_MI= W_
MC/)Q_//_!U!+ P04    " " @/I2_ =3C1T(  !:+@  &    '%U<F4M,C R
M,3 V,S!X97@Q,&0R+FAT;>U:>7/CMA7_*JAV4MLSXB7;:X6R/>,KV>WL)JZM
M;2=_@B0D(@8)+@!*5B8?ON\!E$3)\F:;NFNKM6<DB\3Q#OS>!>#X+YYW5>:T
M3%E&W@T_?B"93.N"E8:DBE$#;Z?<Y&0HJXJ6Y"-3B@M!SA7/QHR0[_TH\D._
M?^AYI\<PU44S1I8Q.0IZ;X->V(M(V(_#7AQ&Y/HCV?TTO-BSO2]_OAC^<GWE
MJ%Y_.O_P_H)TO"#XY_Y%$%P.+UW#@0_CAHJ6FALN2RJ"X.JG#NGDQE1Q$$RG
M4W^Z[TLU#H8W06X*<1 (*37S,Y-U3H_Q#7PSFIT>%\Q0DN94:69..I^&/WA]
MZ&&X$>ST.)C_=WT3F<U.CS,^(=K,!#OI%%2->>D96<7[864&,#* YK4^]]Z4
M9R:/HS#\;E#1+./EV!-L9.)#O]]?OE)\G"_>22=:K)B@AD\8SMV:-16,JCB1
M)A^L$]@TLIJ/&\G2>"-:<#&+=RZHX(GB.]V==TQ,F.$IA=\:U.IIIOAH9V"[
M:_X;@[E!/L/NC0>#QC [,CMP"H@;V9,5*FY8#YKLXY19\1(I,NA[=9_SA!L2
MA7[O.$A ;]63<;G*%#9NX"N"U@G7P(3@9A;G/,M8"?W_^J;?"_<'QP'V?1ZV
MH)478Z)5>M+Y7"OFH;V$;_?#>W8?A5DO#"/_UVK<(50 9']4M,IYVIE/EG%=
M"3J+>2EXR;Q$R/1ND#OE'_3\MT"@0<M^Y+\];%#[?-)^Y2(@]BWR3CIH.FBC
M-!%L/FDB5<:4ETHA:*59//_19@M%;Q2!-I-""[BT58M$?E?M,5PJ#,T+"2OX
M9'/*$Z90&Z*Q"_ %3?<CL.2#[]J*:":>*^7;:+IM=U^IZ\!D7R5A[\"/#K^Y
MA,FCXG5._P8D& 0BFLT67L5*$]A%VY:%^U]8IXN<LQ%Y5Q>0(=PP+6N5,DU^
M'HUXRM3KPCRC ?U9@>Q2!=;MSO.<E\+?MP_1'^F,1$==@K%Y"\+GMU?0-8>R
M@!$@(7][5= #MJ8Y-\S3%4U97$&.-X4T#H;<7,6$W/*,D0_,&*;(V5@Q9DLO
M4.;5YQKD()#RE4:_*G4#ZBZA+"(.>MU7!6U0T&V=_,I20XPDYY(JJ,I'Y)(K
M>"65)K2JE)Q002CTR!DIH> #X(UK0968$9WF+*L%U/)UR?\.I0GYR?^'WTQ4
M,."T'!,Z0MSB:';/TAIK421B<JY;:*8EA,<E+]@]E04TI:X=1K"B$G)FGZI:
MZ1I CUUGD$JTV^AB3KLI,><LX;*"LKZ@Y!QX[*YRO(OT<#UZX>!"%A4M9_8I
M&NRY^312&J.=(;UX"Z#DRB%7!YUTP@Y)F1!-.K%X1G_3/*]G74V-TW^8A/Q!
M-H-[ C:E:7FT4EI_]OB<3ZI$+Y'&R")NO<$MF<=4.Z=V.RN@;-BQZHSZ7\S@
M7A#W;6,>3@'V,^\'/F%DF,M:HU7M]@Z[81CN@=UJHWB*6V_:R/0.3<!H9XL0
MF!WLR>[-[2>]UP5C3'."O\D$QJ$A@ROP%#64@ $S"JW-R!%7&MT#F F8<0G$
ME::*L\74SFXR:M@?))&OF/W_P^P91(/*!@7PL.#7TYQJ1F[99!.4CQHH T)X
M215$('#I;!W#79+3B0T])<8<E7*8L0+H SX7?5,A-?:Q,S2MR 0T(5*QF\5M
M8PD-CW-;D( @0DD%.I$V9HXP"LT@V]!=%W=DR;S/-548_!J2#;.+.<J6^2P-
M9_;0;&QTQ%>*%927"[:7<S64(";#K'1IJ@G5$&:S6F&GY0S9DJF%=5M1!DCJ
MU4A?C73-2,$(JDK8M JR08=, -"0E2WKC$)GG2M1@Y=D5 OQ;Z#=_S+^GCS?
M(O./Q<^75='H;;$W_&+S^BL,T$ZG4SR,2]A*TMS.?I'?Z&@ V3@L;P;9 2[F
M#2R?/:7KA=$!N;5.\CTDXR4>(9%K0<ONPBN!XRFT(R/A64W1WRHV$C:91\=G
MH"O6!'-0X$C;M1F+SZDL,WM2I?&G 2\%U+E#S2;Z"_*MA-V*L:#&7'GLM+ H
M"[2_!=G[<Q2"RR@W1XPK_V 9DIG5](8*$1Y6*JE2&B*HJ_APC0S!'//1NK$I
M$GWR?M2B,*)<V(JKH'=LZ1TT3F>C\1>FZ@)!C(Y.@@S7'!!-QA+BM&)4@W@C
MZ7 '*<2R&F6;:TB0' J^]=*THK-Y5:HA4U%X-/X*JZ_>U?H%-#K'&(/@SC&C
MP%49U0:1U#9<O>*W-ME[)05/L=Q AP" 30$0D!OYA)Q!/8,!U5T*F,_7RH9<
M-,*T;6V#81=QS,M4U)GK*VT**2?<.L@$K&)OZ5B55-970K9E[S60'.S#QC+G
M)!&,C6@-#TC-";F ZCK$D)BV[O#!;DEWR9K+-F4-5L<+;BR@N^W!]M@?N()I
M(;4NQS:S10>KI' N=&D)VP#A[3OX/0R?_]1WQ=,#>!C 8M;],V=4+TT::Q0N
M9SE+[Z >@%@P9EF\.8G<RB5[XE/&[15N>Y>P<QKH@*Q<1]CVA7,B/7:LM^7K
M]5\PN28R-45X5-T3#8E+1MZ$]F]+A=_>)5Z['?0?+2KNH[SD%7W\^/VEW^1X
M<']VY:9K>UMK_V&"]O377'$#@JFY6+V#UN[1!ADA^90J?I,>''X?1= XKY1_
MOZ94YZR>,#%E8]([I.3W* H/SZ_)6:&!0$:+ATIPW[E:I+HTO1LK69>9UQ!J
M<-=2T6I#D_3B'5Q[&;1Y#E>VM=R%X^9-^P[R^NWFBHZ9ET!-?>?9,]Z83B3/
MFB7H]_W>P<(^W+O0;O*Z6]/V&O;IOP!02P,$%     @ @(#Z4B.CO?P<*P
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M%[_C7,]$<2>2I9BRX1GOL*/! (SJ5^^.O2<=H83:+OZ(#T2&ZW+\#(=N8=3
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MQ6?%A1&#0/69T N56F<.?AG!4BI8Z153&?S*M4J)ZF%8WC:P^7%1C,&6*^W
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M%1D"A&U8X4/.B<I231[AJ6!'+]_^JSL%FHQFN9S&@B4"Y*G\/3X.U-=*??N
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MUD'<34Y0C]4V93V] W,J,!,UKE[T:U9\>?2J*5\.S GH_(#.#^C\/P<Z?WC
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M'X2S?SKUXA?5"=6T^3$&&KO\RSJ).<?@F&NIV_"O!N.K+>%6S\0;UYY8G>A
M8DI26(.AP=MVC,<Q65%R'D],:I<3^-C!:64<BRG5>Z#*$67B!MU:0QM;%"Z5
M)B>4.\Z=IDYOTV&#CJE,3?F J!S(5K3QI C3PLH)V0V!-<"]&%YT^I>CSFCD
MTM;>I&4N.:H!M@80QC<6/,,\SLK/NS#1%Q&WB?KO7/#J^T1# V@X@(8#:#B
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M#0N;V7TQ>B- N .$>SLV-D"X#P7"?<B8WP#A/JCM#!#N .$^-+8-$.Y#W=D
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M#EI\,=-LU&&G7ZUM:X"(!XAX@(@'B/A#(>(7!XQ*#!#Q@]K. !$/$/%#8]L
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MO91GNH&9T0%;G@=\) 8</:"UAD.,5('CF\/B,F ./M))6GB?4SCD\/?..AP
MBKF7IW$4JB@307D7E7>1S+1G<+/#W0HW#DX1J'S_Y+W4<0R'87GJDBQ4P<@'
M20C*0A26N'=X7C8TUY7./$P6]_5W.O+>A>:2V8*4%MID/ED[F)6N _P4U[(1
M]CT'7@0-;17VC=IK?HE]+.O %_=) A)EWM'=T_X>D"=K*H?U5.L'HQ#^ [$W
M\*YBNX$.L@>:?Z9)?*73Q -UW0?*@4P&\TUE,[X!ZW??COX2Q"6:=W"K:!B)
M'MG=@/#Y:&;%KUQ%,TMHT6H(JMT0E#HZZ4_W#_VC9\_F%AN A()+5)9S"72"
M#X^-0).'\ RQR3>( C;VJB.5X':Z6[8!6<>S_/JM(6LOUP6N$)0Y^'I09JCP
M>:$&6S:&U=VCP# @><=WK\!310$7"U"*+^C[Q06XO]-HIGWKTY:5T$, _)D&
M9"0].?0/GS_U!G .EQK&<.]:JHI12X= NQ+,DWP)5<7'<S =16 ,//&/GA[!
M_&$1Y.((4".EDZ8' [Y,D;>0&4_B-$?Y@O97#P[BP=/]EZ!R+[=5CKZ.8X%6
MI:($1\-=LAMP[R?2D8VB3SP,K:F:MTQ[!5E2OTR.GOK/'A_6MGTI FZ#_'FU
MNOSQ@=5$7T1N0_M16##*\Q(]&D#4M"SR O[1Y$?\+J_<<$.@.8X1!#K/T6^'
MP]"C<&PF>")K]\M2V[H9YXG#]LLSSE+SMY/.R\G\0\\8[*0EV$3%8O";!W<Q
ML&,Y$17:NE;T%^ 3^HC8*X);WSBL?,^Z.HBC+D[?GG[XYZNSC][9AQ-R-@'=
M)D(ZCP DX,6+_#R7!6I*\,=K#1\#17V>1#H E0=YMEB.\9X_VS_RWNL0Z>*=
MD"+NO<Y W/NPV\'U3027@.^]?^T=[C][LK_</7;_\OOB[3]7L;7H7LLT"X1
MX@+*$"9'8L*1F&AVJ^/VP@N\=["12:XK"MZO%71_O&I6;%A'K O:%7@9Q0Z
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M!3.);\(8:<&!4=_@1'#^&_R2_F@TK7/*YW5R$V5IPM%2F,H S!K.'L#!DW(
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MH*XP+9EA^!77N%4">!-7V7R:3A_[?VM;W,Q'-!%4('MVG(VWKAW]91*G4>%
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M<@CW=%)+L[+* K?]18BF=&Q<HIP35A3H6F)ARY^8G#,2X26']&H)7' D H2
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MNG<RNX6KWD6< KB45M?8RKR<S#_ZK'>(\)MPJ,AW+1M4I!-;\/G;(_CA75[
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M4W0+'6LGA#]U3\2 HGS5(RMRR3!-0\(K5WF>!A%%IZR14(VQ:0ZXLI1<D0F
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M)^]/D"=5K3&3YDKAF$NBJ,D5/@^KP90+KG5JI/[!Y*R\ZQWT#MS:N[DBQ.X
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MZI1WZU^_D2YK:QQ\R=P%=0,#3&&4P2,I_&N210GVDP8=;DPHV:1] .MA&*J
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MD/<N5<FW;37?G;D[SEPGXS:WW^F@F*Y1AMXU<?FQV8+Q^C#)-,U7;_%#=UZ
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MP'8#026"!SZ7X;!R&6'_D:H=F:BR^"=/ $3A,+(-$S&1J70J2=QN9J9G5I3
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MG&->2%.J>Y!9#5NI,2W2JNHM^$Q.L//DNE*GG=!F.^S3J&.:!%Q^MPEQ<HM
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MMC2P=ADHUYJ9.#7?>*$8=-#E>X.RW/HK&\\P7G*#>+\(5K<6SZH4K5IS%TF
MJ$V  R.U%)*6";6BNHX5@22D@[H*)IG:Z1C+]@-\*59V '>0GYH:W%/[-ZOX
MI=0-"FG!>Y1:28'?[+9&"T 5!.,$1Z3X0EF,THP3S>>K<<U/I<J*ER>0*+1
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ME_N/(F*SGV74C@]I@:QD,6_)N4=>*2I/((%@9)%3#$L!1LI1DL+^FOM)IN!
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M!RFIG3C7/EOBG,0GO_ODXI,C+,J.J'I6F3SCO<(<H4?>+&^S]HO?5JM'>]2
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M,K-FQ/W.JYP$P:DMD1JR7;_BH^B*#K38GV9TLJTW<-QD >>]J[0+IR(!$J1
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MB7$N*NA?)4D.:[M0VS?W")_$F3H!@Y,G7E6(P!7"YG(]2)]3$+1707!['-)
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MYMY?T_@<9GT,=\5#I XN/ESN%BN@M69YIG^HR@ZVS8-N>+_/#4NX"7KHR.F
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M',1,PP9'3XU!A34IO<0QP6$H#.EQ%A,+ #-\+[*;I%C-LWV*./7#ITA6$-1
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ME\1": BK:VJ7+.L</0*2?VW<<NY*%%V$';\@)2&\)ZQEQO-+(0UF.L>M;:C
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M\,=5R%XI<:Q1GQ4V]&B1?]E:X,?,NX[A,9:39_QR4UEDKBM_: \P6*@%'Z7
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M(WBL,(T]C7/I/0=\\E\=_UAGJX)&I2@4=;Y!N'K5-6A[R5@LV @W2 QT0[Q
MS3".>0TC1P6=/CZ/\@5*3<W+*9^88[-FX10")YY2M6O'<)JBH83X0YKV_NMO
M^8XE<]'(Q]%[75006ER&(WI%1RTF 0Q48M,M''"&8WB>BY[FR#*I:VP)P'/3
MACF]F(7M;]K)V(O*(&,-S17,P7@$(S<7G]T;/_MR+C[/Q>>Y^'PNQ>>_O+/U
M]?&=K:1\#RN$79:'!--?[PBF9=\T4L"9(#*SE9P%/I)Z41-L8 . JWP^*KOU
M@OB<4D_(QGY-6@L;(BLJTDWLI_0OKO.XHCV,4H$)U68VU1WFQ'H@7L\.IX^
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M&.'K+H%O0Y:)OK[(I?XT3N&C3!A<3A(FB[XY&H$AX+ZF:DJL+8'$1^19-1"
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M%;/\BMLMF17JV'U&F:P =COK7OUE-M%WQZ=C>/$<'"CBU#W<7DO;(X>R0G#
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M:(&;BF,"$PELJJ;)&<R7<J2(DM&^NMJCZ+%T\$R_N.IJ0;XC>62ZZS:2.-
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MX,8@_C803!/IA^.<WVI][J-<+[&U.9I$_<%A]2;%C<J 6$>8&LUGM]BZ"ID
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M&B&TUI+)^(";,"8Z"MDNW$T/C.)@@4T/3YI,B>_5(DW+H!5(PP3V6L32(JM
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M,[43<0U/M@'J8N.@UIK89>[? 4]HW-)XYU]L;I*;"7!,<2KU[@5HEP(TW%B
M+FV$H=BP&;8/TC*@(C-%Y5V),4CS0R+-5;WO,/1@X?2Y>Z:@S'+:&,C-%9D3
MPR5?JER#J+3O G+F1JKDS4!9;K%3S+4>:U!.X/2KUHL5-GGZ":,MW?(W:K?(
ME!0N 5A.)._.8\E6"\92P4;6QUS5WR^_C_<U@87'A,@-V3A$R? U0?(%@\[
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M4;O^!$18AF>IS0'\4M$@3*JTK-V![X!A2*PNR^HW].6MD@97VKHFH54U+:_
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M3P"R9:/SL ,"D+<P ]0$G*);;[P!2.WKI&W_QK-4@NJS8&&:(Q6*^-X$+TT
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MHP( B1>:1H3>6??GJ32!UV7,<"3#;V$VCC#>Q[2U""()%L2>R]\0,H98[U'
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M> $>OT[]8),L!3*"PP=KRGM'@CI"5T/_9@(TZJIEL=,O!YD8SZC)33[P9(?
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MP606)1BT=GH\K/89I2ES<W!X8$V A3,:T^'$Q!2M#7TD.0,J-%6M,"C#'4S
M2=8(J\P*2AF/BWZ\;^9XY6QM."\TN;6)H?TB_:CS%0];0?Z^YR:0;B)J( 'W
MKCC+%3<2=DU4J X>;A.S&DDT1O@;ZBFY5#;\9N.^:@T]&MRQ'Q@]V->%SM3F
M<AXLR%,W%8PK<6Z5 IF]AT$XZ#<G9=.^C*72:@YK4](X3N_RW[AS;93E!7?[
M@87/\M68/SV(=_ V'*)*%F^$M1PIU'4M-&ZBG/K/@7 J4<!%G*+%V>>+6KRF
MSUK$'A[+S7A1L:IP@V]79U7#QH]+;_569P=6YW3[5N?Z8]D*_E;8N\H76@0K
M%8W>S20D3\\HK67V@!QWB66J5*_RDD-I)$8BUXX&5N@%;)JJ$0KG>+UJ+3)L
MI 46+CK1*GT.>FF>2@,,?B?&;;-EKJ26_WT*?#E.I@ZDVZ-#.2TQ%^4"CAWV
M"4MR\HH\L*)IMYF4GCGP/F-R34##*D^G5W==&%G#%R3UC7TQB#UD_1A!]-.*
M[E=4@K\LA.X(TP$H0['W+H7X9$E*/DFM&(#5KZN&L=E,??HND-X*J]-3W6;S
M>&L08@EW2.,CL^)HBB6)^K'MH%+.68R#D@VR#'1(7F8:!2Z-_AA_DK4WW6FE
MX%B4<1'-..I%!@F"TO3:3_I8R4/0+[S<NMHZ0JD69DC;D;_QAJ9%SK%N@33U
M+A51UCU(DA19CT HG>H9NV<58QE4URJLT3B83Z9850OF'=Z(6N^DU&V(RVK'
MUM!]M@+A=Q5M)>CA(-%@:79[!)(M!U65U=?0%_@\E1;*@UEH03A]3Y/_" T2
MI@CU451\2PFR #'%S'5B[F,-_L [D4+J6[+$=?]*34\6Y6X3K_:3)HT$S:WD
M#4G;P>6WL.FXCEJWC#225$'6"00IY55P!9K7)&=1EPM:K/(4-'!EO?>->*<7
M!QDF[C3CZ='Q4=Z)\U[T)A6*-J(]L-:2"R?2:2^..A%'OVQ='%U2G)7U:AM9
M<\*U'U3@H$+[*ZG#Z"@I]B@R9=DXCA(Z"G"H8PJ\D+XMDS"A_4HFLO00%7N"
M:;?X@1)@R=K05R7XAO KBDRR-85W1DAT_6SDJ1=C\EJ"2S!O23H#X0R/XO"0
MM/4=:VB'\Z94NB95*VKX8J2@IL^D&? $Z>\T/H*.NQB-TH7.@H@:\;1LSHE:
M;>/)5((FTNQV>KX$9%Y!86 7WW0"6[,VS2E-5ZKFT"F4P2(^0S2D&QN"IP"F
M)YH^6,N8YGFDQZ@B@O@!SQWMNH@FF*Q,WD5J6K#U;Q:--2<'Q[&H=R%LM"P-
M:,=QSUU/9L0)8]HWP**7(J?-@;8['!Y&]@2::8L >]+D&)G)2F840]AY2*_Z
M)YB(^43NA[I8GMGX,+9BOT6S<B8/L[H#@Z(Y#>[8*C8CZ#$/V\0\/.LQ#SWF
MH<<\/';,@Y1H":0Z-P2A(KG9?"8@N[A+E.UB_4QJ#JN1.&2"%(T+I3]![8[!
MP2!G"D2!E"4L$_&]F=R)F?SKULUD<+$S59WV-DQ"S.($V'^ZC<U\+K!IM&TL
MY@;841W50_R*,]2N' (.2J7X#&&H6,=PK:"R;,K;',HUL*SNVDR>?5;R9=>1
MX%,%EIV:>2D,&W%3RE8B E%FRI"E@%L;2T&.KFO.Y8=LJV/$[E]EQ*:DL)HR
MF2G9QUSWQ^9BVA2[K.*8@M4LR?UA[^2PO^JB?.*2)#BE%E7!3=N":+6-*69-
M#L\XFE.J0R&8)!ED<7<S8B8#$TZP"%5$AQ.PHCS3*+HNJ;PC\YB<1  2XF]1
M17"8S;' DI\ 7DF8U\JF==S.G%2.#]%HK$%+GD;>3G,EHT0H9W.%$AF58&K2
M0."@H(/%3,?X;' C;]-,(ND3+(N5/PT9,SSC-LJ*4CO77#^6WT3S#6BK^W/8
MR3E\O?5S^/[\C^'%V<G9>^]T\*75\?MP<ND-WE\,AQ^'9U?>Y8?!Z:GW=NCQ
MC8;'WMM_>H.S8^_H_.SRZN(S?(!_G9Q=#2\^70ROAOAO;W!T='YQ/#@[&GI?
M3JX^P$V'?,G9X!0'<NF=OZ,/+Z\&5T/\XVSXQ?OG^<7OOG=R<3&\_#0\NCKY
M8Z@N._IP?G)$?]&//UV<G!V=?#H=KKK/X-*[.O=P].=PQ87W<7 % [B$!YP=
MG7X^QBF1C_!W?PQ.3XY/KO[IJQ>#YY^?^=[P[-WYQ=%P\/;DE+[]-+R #S[2
MJ^&+7\ T'9\,+_L#T\F!.7RZ]1/SWU;LZ8WW![9M?@->9:8*I3ZA]Y)C,G'=
M84+G$8O9 IMD_P%,5YRW9VTHGR1U+A5([5"9S9K0I<@P!?@A.=RD< ;9**K
M-4]0W7+(%DS/HQO0T,P1@<Y[B,XA:5!D[0CDURG6O*/)0)9H8"+6*05_&5"B
MK\57B I-1L;U=&8<?">T7U,N\&MSKR#)[S"^BC\M[E)[9+7?XWQE$_LFAEV-
MS)E4AZQE2G(,G]N_D =5[R-& J>FT*"@\(NZ"R7$84YU[D%]7IU+%8!70Y[8
M1>M$[!=',WQK?,08[HJVSBAE+AFI3*NLHHKNWFN]Y;6$)HP#QI6I8*IC-&VL
M!^B-^!X<S=O NX37^#><';"X^%?PK^M2&BB1E=3TXV%R'4?Y#?_"OB*XP]ZU
M[FYW$Y*..^8:M706J'01J5:"#-/50C;-]U4P:^ZA89JJL/=F^.X20G',\!4T
MH'$4D&^9>!QDS5T'$9.?E1!<Z$EWV3.I1@%['2UD6B:^X )N?IU$VL@>N@F
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MS15;I(WP- R2-N5#)%7I:,E1XBRE4N\2D?VP/SF[8#=XU82-F3V27(T$*PQ
M3,]X+B^?/!]<7O"_V5:$KS\&<"OOT/>>/7UVZ.V]@\_YBK-4EN#Y\^=/GKU\
M_NN+U_O\P1[E-R0;VNZY/O\KS1A08&4@3>6296 .F*()Q/%M$,6J49=^ZWU?
MQ".>7T6TF?&2U.S8%X<OI?TMEM?@V>>FAMS7."#K.TI*8LL(\BCW-7TT\_GK
M6H<];@?=%=%K>S)77\FP9CTHC+;-*U4%&YHMAU.TX&6;9^$3)LXBCE!926IH
MJS]FVW^FF4S,ALUY!K'?,VK7D"6Y_E2GUQ7[&(XH!;,B4]R[5B8OLSJ_$T';
MDBL-76LAK>.9E)'_X((PFQV"\M0=V"G?)364N<+3BUQ;3?*ANJ)8L61?R=\*
MWFBUKO,[G)1/9H27^ETV(32N2]14R=%5C\!I4(P: ANIV6I2H]>DA&H#HBA:
MB^NLJD0T!0F?4:CVV<KXPZ8E=\@GY[-^,.^HR$L,N8C@,>;"AIJ7.;91]/:H
MTNLNPXL2U3;6H3W.]QUS*,.T._.&KIPWZB^[<OO@&21<BVDL;\%)=,.^BMQO
MJ(*ES;[Z48R.D=M;\T3,+[3AC7Q)8!=*:TG;L+8X:.V/J76Y.5SE?(+ &\(;
M9-C<  0:#$B:>LM[TI1:QKR(.D3.*>""'$*"$2P3=U'2YM6=[E6".I?7FZ0S
M!LY-&DR&MRE6_L$B'*OF-C1>EQ&>JWDU([QJ2EK=CC<D0$=PE8<Q+F^DK&[^
M+4]"JF9(2*C6+(A]##2H,+B&PWV-*Y"4JIIU$BSR&B5W]6SDS<<#[RG[W;2,
M6+?OM=*C5VSZZ9*E,FSAV(<5!O9C10K99=84P<A^Z -8]=-T*ZHQW2KZASZH
M=[(Z<;*>[[:3]05D_R0+[H*X59<,V(Y":I\FBH*:V+S!]L>]NL0ZMM%D#991
MLQ"P&@V0[Z%JQN]DR(R%S.QPTI+'LR'+QCG57A<"#H7_74=46EU7WB1J%)6M
MY1@M"W"LE6K]@>ODP+W8[0/G:"WB89FTY?<_J5MM:YV+BLK^K?,]^/)%)SOP
MU<[LO[U@WUNQ]VKKBI:19?V-B&]Z"A9:D3.Y1IFK#C"-82"X1MC,39R@3(HH
MULF!"AW+FL"6C?&W SU=Q,%_>6QQ<-]J>K]F(1F1+\R?LWG!G.<1_HDU!1P6
MQ_6YTRI9UU@@!$"9TZ9DU5XT9/^#G3A5G1KW)&+GFM'B_.Y;UKGXHU(VHFZN
MW%.J3N N3DYX@[YQZ$A<VDSVQ;K/?O[UI,UH,VF#]LUTX>Q"=JPX/09KOL2&
M4AX8!FD'$J2N9WA6&G04A,02&A7%Y&W8$,/<>VL]@5H.SG7D:(R\2G@U!YPQ
MN#$\4N4 )!95:0P.&TN&F#U27L,NH7F/'#H)W@T9?ZRKJARPNDIO62@^6Q_'
ML5\\7_KF5!ATM*](>/'L,X.M,E#S(IV+0*B.LC9"7P:.!SVW-,!JT:%8N_!U
MC%W;N"D:!(&O7C9"MB7]"%6")GO%I=!NGO!J2]0W=K[6B8P8EW\4FMPMW$9V
M>RX9Y)6[&Q]),K"O^]\J2._7'J37@_1ZD-Y#@_26U/TO,99J=L1$4R?"4AF#
M("6JI.V;Z,9E>-'"95 FK"B6RYLPGBX+'Y-JF:16"R>.B7.2G/M.+H6S-&K_
MW@K>OA4\KO897KDAHJEB3\6\Q[3,DBBGQE:M3&%&W=%>1:.,^JJ:5H4Q&YG$
MZ,E6[S4GC*W6IM);GF 5H57!KDT=GS$30EHQ3N<+JTM5HP6J>T,9X]I%"&@H
M +8%IRO'8#O9B>REP $EA/,5:32! .R;Q+FJ\,?<DTXCP:N(N;42+^&^B;_J
M5>@^^"J:<I0#M^I%G!?8]RL ##LAR:VUL$@>(R;9PKILWXE;KQRZV@FK)$*N
M\1C?.]^^F6]V:<QO%54I;V??WK"^VI248>6]B.RD.GJQT.S"V/J3G W,] =C
ME'^!="1&T2&J:DW\/;U+>/S6@&J9QQ8=AHG>@GY$<ER]JZ.R2?'DH:)0#9A"
M14.<A)$57$8=_1H>OQ]<>/D"I,%L-V3U%L@1=DE83S82UFO":BJK8_S8Q4J7
ME;%PLA'-#LT4"&<4ER#&ORX4$"@.[HR\LAW=7#6'%(3'"N^RX5SQ.6^@/@G&
M(AZHUXY@%H4ZV+I/$B*!.THI=+<GX"LJ!%^8Z$CBS=J188 97J6<S9I.M9)U
M[FMO<M;5W. +?0W#>8/LK,4?="2;25;<3IQ+U!]'P',G!+X$\[BW<11A[YN8
MMVI_@? ,,R8-2G$5-1*C*3"JNY)'A<4(91%+N0]3S\!>R0R[1'E6CN;*XO6]
MO86,!S[^$^<)% A:M"C]@F]Z$G70:M/AJ-O:]ULQ'/AT[]\R(FFTIK*C,E%P
MTG3K@3FW'KCO5%EC6W'SI:/=[P5\!P(^W$C 2Y"N8GNOD.&^ISKA(MKXCC#,
MMDW'?C-G,LBHBG+GB%%W<M75>ZF<4(9<1LT>F(KJNHPE,U;H%K.^X7E'Z%5*
MO=M1M-#)$&%Y [ZB$_R4#DZ(Z,+.27&AFZ+[J^0<W1YOLWIZ<D9V:TGJJ] *
MO@AF!S-4<B9\C4!$C12;8@<&'#HU2<"X<L&-(Q:5:RIS2I=--!A8PL!TI=%6
MV#V8V@;<6 /(]8_PO,^B/&9V(B$4<C-FEA*T,V=S(HKE)LXUC\Z8G?"BN1N7
MU_Z2R*R5@?RF*+LUD7GJF;:2RZY1:L:RW5>G361Z&,QJ=JZ,=ZX46+XN6F\]
M6;;#AKOA03=#+[D[D-S3+6 7<-,MVY'&?M<[)\8_J6X$.<O.@GP2_,M['Z<C
MV&F788S*_R/&@B5[J#U?W8/%,NM#%9_%0$N.+'@@%D+I;(FB] G\] FZP 7"
M(?#3&=^;4_.%Z@<S!Z&+[?MB3[Y/E:G"N2WL "L?Y!&L6I YWL741LYG(=]7
MO2C<( O 'J6B@WZ3;W^37__838ZTF9)BD$8_*BI,OJ,5?%X7P$M!64LKQ(G)
MO[HIB\HCFJT3^-G2W+:+_2=92V,WD3!?A]*(F$]2R2M,)#L-LK\K,,=M;.)=
MPCF^W&V<X_ ;@@[: 1L'% GEZS'FR7V_&FLP':K5J40P*[RU:+;:*#:K<'Q'
M0&-KCAJ><4=,2%*32C%#LO"Q@#64DZ^G3BAWK<FH2H\502Z^*2JZ0HD@3#Q(
MPV=Z %\RP][/<-HS#F*Q/;JH7-0XN/IRXA%#%!K[-AR)EMB&JC 9I5E"3?/T
MKP^6!VVPZUT>H6!4):N- Q&68GR<QJNHI-Z8S &D/)8P>4Z7X,\S*M21%+4T
MPE41KL;&@@9%TVP '52KS>;!@K9OQ%WEK&.Q3CSC-,##J!EY[7WI1$RGT5C%
MXD+8)>D"IT8.%"ZS[I8M<T#U5J5)><D=U00&25)BV4 /EMD>6.95#Y;IP3(]
M6&9'P3*MFV0$(+BMW'!%D(*^%F!)E.1EALI[OWHM+P$ILRDQ9N<:JYVO*'1*
M$Q57K?O$>$,[K4T7;N8E:R^XP>D5\AU;<2_W??%?]GNEB073M;WXH 0)1?[4
MO\I46MISZK;W.[KQ.W[9;;_CRA2\;,01HTW2NN?048^/9ZTZ7-.QW?J(O%\/
MV@#KQ&8VK/R2N-X11TN\ U4#%?HUG#G)/#;A?84- 5431QCD81(")>*DS-1*
M:^LMLZ+J]3=O+Y#<*"E?5S:O(W<@!XL2\B$5@+OMBW3LYHVW-](/ 0\0W@'V
M<"2  (S&PWB-VW";QF GH#0%29%(N@U'8?P)L!=JJOWPQ8OEV3+3R@B#^]A1
M"']"G8546$JGXVQ(0S!)YX7QIBZ'1[ZW-U;9Y) Z0?,[P,A!-R7B =V$C)9P
M$V@PK>#9L$.4A2HSXF.?YG$8Q^(JV?I$)Y<YCSVQUPIGS619B#KAH2:EYBA2
M[VW&V?&!A9EHAG"95M-2N<T%@^EM*.5=IO,A.( AMYE1Q%/R'??1%O:GIEJ-
M)2< 53J?GC9RE@3')3;9PFFRR[_5 9XT0+VL['YO G1C ORZVR8 4CVB$4G,
M0D(P=F(\IU9=LRU4KHKP\(94N64Z>[8_5C^ -K+',8.K)TCP.V20%TO5B:;C
M:DF@4"T8U^K"M]6>H7*Q,[@@/&%\U2@L"RF*-%7?7G [.?(I(/( ?$V0(1R.
M# MV-@+LV8HZ-4I<,C*9BIRQ'#-P"/J3W,U)?K7;)WDPP:'.N"CO<?25_O%U
M%CO4UPQLV4TRIR>U]LQ&E%#A>TJF//86PUI>R7!LQ"57-)$(8S.RJFD8V'6P
MBE*I+.+.6I=Z;9R[K;#@3=,X3N]4N$@SX2EGIL[!+%'!?#T>:I921"?8WI!9
MTZ@QDTO6]E'M+EPR.Q/R%_&CK;,S7H$$"0OO&)[8GJ"RL?B[NI12[^(ZLNL1
M9Y'%P\WA85+?NHAB*@2&VG3H9)H^@F552IO,+<R5"<\V]'[MHI+Q5>N !N(_
M%@^N[GY2%3?:3,6Q"D+&110A\TR0Z%PB&/T/$G*>8_=FQ#MJ]:1@;1)QNLH(
MX4CTZ=$,^]UR)F:.U!>:\,5"_52/ I[8S45QNPM!."J"?2'$I5>\Y\@M65<C
MIZ+LM\1;A/2?\T.FDA#K"R(X6IK>P@MFF)? +K?PM3K;DVAJ2(H3+ ^\X3H9
M?:,E:T/0<@7ESD)5VV9!#RXKM8W.B"Q>S"":,)6R@NN"!YBD'F+!LNUJ3#*)
MJAO$T!0)5L(N\K@)%:S1BOCD-N/DUJRBW'O]X#'OPZ<MAC *87IW3N96QMEI
M(YH>IV%P&J][G$:/T^AQ&@^-T]A*.\?CW[QWYQ<?O?-WV-+Q[.B#=_GA_.**
M/[RZ&)Q=OAM>>(/W%\.NVY)M D)YJ!YES8.VE$6T:D78A(\*N-<8C]PEW#(H
MT'#[!"(L]]Z1U0,F4M1KMJUHME^?]IJMUVR]9GMHS?;]OL%__-?)F??EY.IL
M>'GI??DPO!B>OY-,($Q\L:#E";_!;''AIMUFC\HLL)BO]H644Y?((ZI^FW)+
M"Z&''RUL^+DJG$;B!/R1<'/^&VE@*+2E^24H:#F-,B3+&"%:01@PM^"#_6C_
M"O<-+=O__0\4&W#/@H(?2FRR^ ')& ?S//Q-_<,>%BZM"$?<;WC4D$K,D48L
M[VQ91)L&'_4D#A9I6?R&<,F*K"FT^);[\^;X/\5$?7X+!S\:![%L/9;)<I>7
M_\N>+7FZFCGKO%CW1@3I%+2TFC+U]Y.[+)C_QK+Z#J9DK0P5Y4 /5I<&HSR-
M8==M1:"VVA>;JG[Y_\6D[90_>W7P_$4_[5U/^R^_'/S2[_8?..U_+S*4/C3_
M(/+R>0#R\=E_M%F+Y\_7'(%MS, J"TF%C\\._K",AA^XN;:]I&T7\3$NW'W?
MLU^Z?NEVYY7ZI?LIENY[;>JM1+0H&/"Z_I)VR.7I!JK^!QJS6UC'O^=_]SX&
M!3B5=][OP1P\Z> OL_WN)SG$0Q43]'#^#6LAHHFGPGB/8QXV6MIEKUQD09(C
MLUA2/)+7WESZR+MC</*!U_KMXK=[2I1=>(=?:N'SOZK8V36MARC+J(C#^^ZN
M3D=Z=!.%4V](X50LRSKGT.E?9O/TUFZ_=#OXGOW2]4NW.Z^TV=*!6;0[H=25
MJ)O+X>GI\.*R95#5O->#+]ZZ5_MI%_>''\H=6M1^T?I%ZQ=MU]YGO:=I7NS1
MO%2+=WD(9[1U><JCVFV5%^DWW^/;?#^; .RW9+\E^RW9;\E^2_9;LM^2_9;L
MM^1NKEF_)?LMN6-KUF_)?DONV)K]A;;DSH>--\B^?3@_/1Y>>!?#3Q?#R^'9
MU>#JY(_AH\_%]<*F%S;]ENRW9+\E^RWY<VU)YFI($U5LGTZ]W\ML%GB?@JQ(
MPBS_2V[,OU,-_'])\>FN;+%'1OQRV"GQR_>RO-RFT60=R<O?1^ED ?^Y*6;Q
M?_U_4$L#!!0    ( (" ^E(VW'N4H0@  &4[   8    <75R92TR,#(Q,#8S
M,'AE>#,Q9#$N:'1M[5MM<]LV$OXK.&?:V#.2*%EVXE".9QS'G>9:ITY.N<Y]
M!(FEB#%$L  H6??K;Q>@)$I^OZ09VY$_R!*P !;@\V!?"!S^H]T^+7)>I"#8
MK\.SWYG0:36&PK'4 '=8.I4N9T-=EKQ@9V",5(J],U*,@+$WG5ZOT^T<[+?;
M1X?8U4G=1A<Q>QWMOHIVN[L]UCV(N[MQ]X"=G['M+\.3'2_]_H^3X7_.3\.H
MYU_>_?[AA&VUH^C/_DD4O1^^#Q5[G6Z/#0TOK'12%UQ%T>G'+;:5.U?&432=
M3CO3?D>;433\'.5NK/8BI;6%CG!BZ^B02O 3N#@Z'(/C+,VYL>#>;GT9_M(^
M0 DGG8*CPVC^/\@F6LR.#H6<,.MF"MYNC;D9R:+M=!GWNZ4;8,L(J]=D+MM3
M*5P>][K=GP8E%T(6H[:"S&%)I[^_+#-RE"\+=9A<;$!Q)R= O3?Z315P$R?:
MY8/U(:YK6<[;9;IP[8R/I9K%+X=R#)9]A"G[K,>\>-D*)?C?@I'9RX&7MO*_
M@%WC!!U<NC97<H2=D[*#L )Q/?ED99 I^/DD6@FL/+W,92+=SR]ZK[J#?J_3
M.XP27*[R6ZFVJ@E5SKN=2(LC*^EF<2Z%@ (%?GYQL-OM#PXC$EQ3(^'IQ<CH
MJA#M5"MMXA>9_QM\JZ5+D4E@'K!V)V"<S&3*Z;$RG;&37$+&3B\AK>@!LS\R
MK 5S=4G_GKFL:!Z>Z'<?]D.+G7'G<FS]&R\KZWB+I7Z=9LSEW,7/<R'ZMT)]
M3;VMHUZGAGA0[GE_WKX4'UC.D2H&)A*F:(Y<+BW[5'&#7%0S]AE*;1P:*?:+
M-N/08:_;_D1TJPKYJ3+ /G;^W?F>>\:CA]?N!E[SI7C'K?=QV'C&+@H]58#.
M4"N@S 1L"8V/H=#H16%C+@O&BQEBRYD*L%OTD;R+A7CC;(R_C.2*93S%(L/T
M6#KF=)"[(E! "M9R,R.1,;\ '+?1I\4R@<K@D(KL"HU! JDTZ->A&'IZ%C41
M8-@TEVG.;$4?R_930/B'3F@"8VG1_2"G)7B"!FP)J5>0^BU1-2UPFA-L)E@R
M:R[#AD -U/0W!+J30, R62!$">U+2+:0/2B.U:91+XL,=^_@)\DB597 /A'V
M#?RUD#*2=OP244N$(R)B^+)@5 UFNS8TDE9XO[I%$I5" :211JS[X:S7)^4V
M9YG24SOGF(&1M YC%<<X%0:]4<M6@RIVKLP5;3=L:4!D;\.6^5(,5Z!%X4SO
M]<#6?*C]8-J>=8@,/.@^,&[ PQOA*A,%!$,&R*E$29N3.(F-T321>:+?0MI4
M:4O.#QDMHU7 >6ET"@*++=M&6 M G@3LGEYB-%V,@!VC/?A<*;"U+]7G[=[^
M-NR$G]1);U^$HAW?IZ2HJ A,HY$8F8\& 0,A2*N'#9E='3+#(6GNZP1%"7(2
MXPWIEDC;YCO/BG6WS_8]6 S1$5?> [H;_BURSE)>V?LW(2\I 01P/5+PNW1E
ML ,T!Y2N(".#4E#X?BB<79JGIHD+&1YD1.UX+;'<JLT?54HT5:B+U4H*GXFS
M56*ED-Q(FH ,[J$WN@7U5%ERV?Q68KU_YTV2MH *.32!U*C$N$FFE>)D27%:
M7HFEZX<M@B/9]'_Q6P(DB,8.VX/8&+<FSY(?EV?WWOJOT.W^1N/>K$.F3J0@
M,G&K"TYVDELD(D5)Q#!NQ!SMR#_)0VZ1_+WKAB7N>V)XS"\R>->YM,$<7]83
M*BM3(N>L]T_35!OA%?#QU@@*=#L54@]KH"1.DPC&DH%>R'U9HAW<$*Q)L/1Y
M$>P^-#N=<%7Y/9\P"%F&@8V<('KL-0'*PHN\APT+/Z^/63RKL"':'QLBHT17
M[F8-[F-E^4(:*.S+[LXSL&0>4/J- L)*H#X;4C1)(9X7*>ZP.@%I5Q%+F;@Z
MB/ UU]+B ;:&/#:=II4A7#;<HVMZ'6OKL)Q>"F%?-L6._@I9:;9]0Y,,"896
M8$VZ5CQ%V/LD(N47BVJAUT[0*N=VX4N2_?"$!.$-JU^/VNC-F)(7H.J,XII\
MZZN7:$/"!BSW-WF-K\MK^#<[8D[NUG+K)TO4)-C2"A!%'N!V7@FP%JIQ#+*<
M-G;AZ?D"['(\ELX!W&)G$XV^)-4+B?KY3K:1AFC6+)E-_$^AWGSO@+\JB>K[
M?:(J4I]TW-FD*G[85,6QPN !@QE_,@#E*".62D#HUO[9(F4P!7Y!#E<()KS+
MY<,@_V)IGL!^$"'JZ#[D$Z^Q&%Q@0PL+@W$C>>K@"9L@ S#&:06OSZ++9ZLQ
M/GN<L)],;:BO3?4/2&)#A!\UEW",SEMF<-MM(2S!6PH$MG]/63.@%7P?64RT
MF@ Y0 4?U:];36U<8%PJ/0.LG>8Z6!2^PB_DPS?Q#CN/ *ETD,P?1GJ[12?1
MZ,B;3W3<I4R"% 5#A8J7%N+YE^:XKW"P/)Q?HI-IM!RXT*LGWTBAU6-O5-(X
MQ$8:F;DZ=6^]@'PG%B>[R!] %[@^5^5T67>Q]Z:S=_!3<_;U8'/V- [2-3JG
M)T8O[^;GQ.:_VU/#RSC!G>ZB/<45N/-PWJ*>)U:KRL& S@A>G6(X+5A_.G&O
MN>UWNOO/=&I[^YV])SFWR!G":W.2-U+H_P?MUQ^4O&5'6'M&#U?_+ES^#<<\
MW\WB;Z-[#;QZ=TNT<WH<]SHX"O-O3=B+KO_[OM.+;,3.CH?#7T__9+\=GW_Y
MU_!X.=VG KG;K-!3Q-RW5/_._>X[Z/]4</2T8?3<4+1V]'H#IPV<ONJ^AEP-
M[NA[+!VJEM+UAYMN.\BCIP>\V^^JK#[C>]Y<>0* ?8RS?GQ WSX/;^ZYNHKV
MG:<)]\T^^YC@]\]*S=CNJQ:C*YAK8(I\!F@>UCZ22WG-2#LW-R]V'9XU+D6N
M5M39@EU41,D"VO7O>4"W<AVS+EJYC;E^T[/D(VB'S +/')B83[04]9-]_:;3
M7P23H:CKTP;A JF_D7KT/U!+ P04    " " @/I2RA4XC: (  !=.P  &
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MP$^1PAL/S%:,%ZH8(>Q\AA@[PM0QIVGU5MW^!GW2_-37-;;LSO3J#W^181[
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MKG],#RQB'2PS6C\<@QAPT"TS@V$;F"C?UY'GPF:0SO&2O!\4/IYCL!R^<T5
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M&_GICH7*&R;RIT$&50 4NBRO0%E<A!81AJ(L>T[.+<)A\T ^^<\F8IYO[(1
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M?XN5][9=ZKS]_/;SV\]O/[_]_/;SV\]O/[_]_#8TOQVK CC=5P'LJP"^^RJ
M=K)^IY9F-(7^&[G2.3H]U2U2AXL#0N>+HZZ:0JM K)>$CAMB+RKN*EB&PGD-
M/K0E/K.Y_L+MM +OKG='0POMEWNR-X8R3K?<$F;S,_KXKP\.-8:Y.W+>WOSQ
M_O[F-^?3[;L_W]Z___BADX;S.R]FH^4)5,[AQ]+&N@<(WL9IU&2K-H=&V;JQ
ME=1T 0P_:XL@JCL2E:5%JB'Y<+I;/6*:P(>%2JL20Z4=,_42'4HAB0@FA7P4
M-)!ZR=:@@)69B><,%Z918<52,3V0#'L[(1:79RK*/TSG&>4M@;G*<U@#SD7+
M#&%D!\/+K&9](Z NVY6/G)N%,P["X-"0$!AX/9@WJ<]].Q]#U1T^P88D^"YQ
MH8VK?J=PH8WHA/)2:8#)-?/4DOHKI$K'TN#9O!I9AZMQ;K:%:RLA32)X$GA7
M'$*!EVF 2^-110F;[(@UR/6-0>1K] )<SITBJFCN"P1#AEE'97V@5UMG$2$C
MREC^ ME$E2#JKS1,5F*8Z"S):R,!W8#!UV'3C#.[&6[/\UKK 'L WVZ<QAIU
M@&\UOA.66>IJR$SKUMYY2Y7/W=6:C-:NTCCM17N##4SD7\W66VZI:56.$*[8
MNC$4C39AZJ ;^<9!5F4S5AFT[H%ZQ8<9RIT:!ZY6O*BA852>.4YO1UR&%<<A
MJ&!&OX,V/U!P58UUQS?3B?J]/-[\4AE92[WZ:5KTH"!P;9^HQ$P1/@45><WY
MP8SI@%6SL>D9KB.+^KN??CRY>E/AMT#I[*9&\*H56V!T:050]O-M]J!(<-TI
MH(U=+JXVM8&1S%CA2JRFQL8FXQ2M:CZOF\I4L!?:8-@]X<VO7V^L@>#PM*>]
M35:;Q1^XNY*QF4E98"2PL2-2:<-7464G?U(,1R>JQYP? /&ZG35^LP0;-N =
M=59A,2RV(=Y0(/ELRVF7S<_H_M/-A[M?;C]UX!^!2+7C<'<H4@UY+WN*Y6PT
MJBN+L^V[1\NG[VIS:)2C7Y <JA"3ZC;/<F'=\S:19^G=3MI@^YQ]%VD6#+@6
M)4BP#.GXJ?:VX5-JRR&_8OO=C)U8)%EL5 3>P(FQJEX[&?*1J]^U"YYA'[0G
M0K4HL(D_FW)Y&H-PV45^BE228(VE^P7$PY?> ]=LU?,/26'XNL5?Y1Q%!3%F
M8Y>*2,;U(+.)X^P&69S5H]I\C#GP)<"K#R/$:63D *43\3SZ1CAN.*=A4>TV
M'.0F.B6#SX&.U0UF=;$;!J@1V'% _ZKX%8T!"8LG$^? DVGT) 0NU5<T.CWL
MO(C.'@+OI':^B)@Y+K;@+:/T+H]YLUA];>56:O%$3\5S7SQ?JX"@:6,_=+\8
MG-;12.,!%X&9&CQK&3TJCC?!JU!YY*GVIHT[D_6JY'>>O_!,2,I5EF..,^&"
M H-3.T958<6ZR(2DSQ3FPR(1#Z @IT<MP"_7>X>5A[A=)&D^[N9A?L\\T&=[
M!.@> ;I'@&Y)66PN/M625;TS,(:S[P;&,$>T+J6#LCW<$"Y0\?8L17JIF/X-
M/!67+&%CC8/Y8$@,<H)+-M&KW2; H"9#@C)@PH_)Z'5!Q28:^H.\*!:+&LMQ
M:]9/S8AAY@>19&0J)]>CDRNB'":H W%D&BH((DWYYEL9UP/L/)V<*Q$W%&W>
MTF &5,!N/NFP#>"PE56+1'<=XAJ6"T]@Z?=R8:[S+0?N-CZA3[?_>']W?_OI
M[LCYX[?;=_^X/7+^O+MU;CZ\<VX__//C__Q^^^'>H3E;M]WJ?8;F+G3@-6;?
ME&N[[\%CE+K3Y$&.HU1]J:>,=DFDSZSMYK??W1+5^$5=C9]O/\"S?'=+ZQPL
M\E1@4\8 PH.*P0+M!JS31LKW5,?H=\(N./\N8H8+@#HO-,1 $R&2B'%FSALM
M?09X S:$X-^J\ID'4;[(N;$E$)$LB6VP3(,\T&9(_60FC(K ^DKG'.6CP*4.
M4H(1!O92$76JN># HM+630@3XT <1B\'V8#@@QQ('0:2HT+$7I54OH$W##.-
ML>]AE&7'[9/65&]T!S&.0D%Q(5J(7#,V0T.28=WY@S<MZJPO((Q*%%MP'[10
MH]3?^0;S%B1@/Y?/^7?AXMQ6F/DUG"@0,_!,B/Z*Y9P6 2&4)VFD@^_8UX31
MW13#UN!L6-1(^082ZH*D@F.#'U+WDGF$W>],^%\ORL*BQD[A)F;:L):Z$^Z6
M'/C>=IBR5+NBA&^?7G0#$T$_GIKP&.)#[&1+T-.%>GM!5TW&GBXJ5#*X4;(5
MZ,8-"J,E 6Z%@?!DAW!Y^+AWG^>3>JI0SU?0KS).3-BHU$=E+/,@$C:/)=Y+
M..I!4X":1*S$0PI"NMPRH$M@5Y4H8T77&*V"X:=XE+QOF&66YU[CT  ,M3%$
MQ7)@]2"U-1>Y6&U 3J]J%D1. !=XUVOYZ^+J[&RE6>J4=]L.6H6^^>QX8E]Z
M?61!7'MB]]8.R"5=?\+N@JYB(R741!MJ"L:0W1-7'>(<*3H,UTT9C>'(X'/(
MT,A* (E<@/QX'30.V3F![\A;68K\LQT2H'F- JB4L>&4-,*$G.'QB'W_AG=Q
MB3\V(5L=6J#MNAQ;8.%=L-S,$G[Y9ZC@EOC6%#'>CUO,Z#=1)YU=O41A8ME0
MWJ/,1F'Z,*6TA"M0TIY B<:A?,1T14U\J!CQ,\X7Q'8J?3:"GL+L,"W' \UU
MKJ4:%;TYRW#7<G=O34(=P2H"IU4C:W(0N:7_=IS=A#V%O/& ;0O *>BK(D!X
MIKPXR5!!U 5!@Y8*W"V\<\RLUQ/9!LI]1C"C RHF"N1S&W"."K'-974E\4<-
M G&\.DJGU*^2:/')OPLCJKLMM$I%T). C1[,!D]INFXF/L:R\Z]$,JX[LI9:
MQ1>:K1!K<=8MOHU.$:!,6MB0D3>_NY#W:&FK$=65!09POGV_K6D65HU;FX(M
M<5/>ZKH(=5^V@;ON+3C6&@$XV;5 MV46>ALS'3<"-YV-R6DQ3!IL.R%J3[HI
M]<9A%@]/CI,M&$]:0DI*7W]FT_I:3/>POO["^L[WL+X]K&\/Z]MQ6-]I&Y5]
MO34'K"'5D^\@Y?4^+X]1<:,Y,##-\2BQ2K8G.'W"G4H=!04?L5AC\XC!69VZ
M*D1H!T[*315U<IJ0?$6?B&V/VKVR-I/D8,DL\LK'=T3U Q+?C@%L8XSL@; T
M6,!;]Z4V8P&;P#Z&&TV;R=3G I9:(-$+R?NG#JM%P027GSXS/"WDE76#.;BZ
MLC5KW(!G;^LLV2F<T6H)P(^%=NI\^SFME4"9R[%.?6H.>R^$8M8>$/^Y&A2S
M,UW:2@?3#BE-5ZKB;C0A>D&5N_Y$7@HJ-&=R]GMW9^9J#TCZ6C=7FP6M(Q-V
M0<YR:;-6PQE>O&)G:Z>=I'Y7E.8;63H[9O8VZ>CES-ZZ[/X[6< =FA"72QJ/
MV !AO)3Q>+'E$J7-S^CO'V\^O>ND=4,+&&[LW-!A==#:'M5%'^S1AFFLX5)1
M1O^:B@MTK+:+C&E;1F=73+ZK>.@-F\Y%'XJ#-C"/>H=Y8M\)Q$,%!KWC-EF'
M)-&;$*WM.S3KSR-''+%@4:$(L]H7X6>WQ%.EP-9ZIR+I)F'$92C%8SZ$P:'M
M.+S%N'"+#,+/[,_D0^']FNY1/JKA+A:DV@N7ULP!X(C!/]C9@P!MY%U19=E2
MM^T&DE##:F+MBC.\N%@(UFP(0'_$'BF!2%+D^#90/E<@ZKMAENUT1&NCN0AB
MP[JS=Y9>>PV=JBZVKT&:9K$&&Z>V=L1\CHA3#G[$:3R7 0$0&X/(#0\)-4 C
M1'CY47DJGJDX%OY.M\SJL&9MN/X.V8LN"FO/ [>O15M3T[:7&6IZ)6#I9<RX
M[*:&6[QMC17W/& VY6)X[]LVH<U)=1M4WR.;F]+/&-;%;C%]+PAB!Q:)1CO.
M+F YXV<FRH,E1'\FOB#/J5V<0=9]*>*JH6;L$5@I6%C@1FJ<U3%O ?YY7.^?
MW5P#<L&M.Q:\#0LARGU#PY6271K"LD)"@2;U0(41!5YVX87S1!.BFN<LJ$Z$
M2BXP5?8Y)'"M5BR/82+1"(R3:A.L[,BLTB,NL"]0F6!3LY<CY[V]TYB9CM<P
MGQ6$*Y!/A1,[* $YMO0V+E1%5R3B\ENH6N^SGCB%SH9CY %V_;10E5^F5;5L
M)GGSDH(QEE\OYP1HC0FU7.!7+J5JPE##0[O\MLQ<X:%A<HM;U<F >8I!C=4_
MA">)->.XR@;,#IL]G2)K;/:LS9Y??=C9653RBXQR_,!A4.Q<_RY)P\%+P3XS
M.2W*#CSYRK/>H]>WB5Z_V*/7]^CU/7I]Q]'K9U:"M4T$T/OH2UG[#:$OM5.H
M!NLL;BK=D!JV?8I(/VGK0ULI>>:FR=!%-\ TM.Z)1=]53[$6H!7];#C?T(T+
M5\?6P<5KS^)?4^PXDC<+G3!57N:)$.Q'$\K XK ''M!.9X=P$OI^^*28_ADF
M@[R#-8/]FIG2'G);W>PPCL:VQ<850/X$)"&,PXF@WA_,;H#RGC6TSPKH9404
M:P7&'@_&JIN1VL(IW#LEF_L,+'$>(L/J8 43;8DA>%;45V4L8ME5$O?<RAS[
M?6Y""Y99'\EQ6EUFS3&^;UUJS$X(]Y_(.,[B-WE0CYE(\_5779EQBTNS*:7I
M_,+<B;CSZ?&*F<QXA'SY $\2GIXR5^)E2ANC(WQ8OQYW&PH.979USSS,0LS&
M W& A_7&41--K:+C.-5[\ W&T@^QWS%C<6,8$S>I'S!+>TX9!F8 =Z\W;1;C
ME-K2(S*W_ZJGG4Q"#_'PN&9/[9KG?+<TCV4612.7N8GR7!?3-H"WIV;IS$'$
M!\KM)$PCY^#TE?,,#F$5M)&CV\OF<T0T<[$#I_@*0?"H;LP5ZZ%-R1S!A(_W
M<<$9;K @2&$Y5&-WG-D@,B4=[,-!)E,:HD-A"_J4_H1+D=++;[J5K,2P'H3.
M8W.5H-[5T>G*+_:F_ )T90UHCNSU+N#;S-MT9.1"3A5FY$7BR0'EA6F+1'>?
M=V(LATB9;[E [:GEJPV&HM8T4?_JR/%-6R&WH#9W2Q%99F'+HMGQ7;3=^KK7
M":%2J >=AH=4- _+K2T]1WXY.>6UCL@O7K7?3GP["FMD29N-&M-F5XLR0 U6
M\ TR!H7PW&N)L%I31]/19G0]'!W7>]S0"^8\$>;('N%ZK63(JIEFRR,Z7?"(
M5M?J525,+8V662 'XS2A)P*?:9E^U>3U8BL#VD<Q$W9P\@K$,DBFL=Y(11$*
M1O9Y:66@[9^(+\B/.YG !0?V_'%Q=U"%O@*\$A]E7!Q\=2,9L,6L#\4C=0M3
M1J6BF<R])\W)A1&7C1KP/%3H<00@Y$M49LT*1(\$GFEILIF3\ !/D"V/<(Y-
MTM- <1M7X;IAJET=,CM<=I>$[@,[XP>R&\*YSR/V*(]XN<\C[O.(^SSBCN<1
M3PAPU@+A>?_B* L@F9>[X[XTHY<";820=5]P**CM"^?^M-E3M8:F9."2,>,5
M##2+W5,Q9MC^R*V>/-21&S:%P_$^\NM<5?%B;9:9_?MTSEB0H;C:'?ENF,5[
MMF[EHTY'4#0.G"X*&F'[(L%*DVW>6O%9*0PTT*F#)PPYAF7C?X:4V"I(A)M4
M0HO7G4CL13N]7D87-CW?3U5VH.K]-/LJK0U36*ZH(^>KQUR-G('C)B(8OS-!
M[Y*B-\+%/%66?V;G4>O6=&YR/!,5Q8G%QZ7^>-3WM^XGIP$)+"^70>%BLY B
MJ9RF"D('DTG5X]_L]%KHK$9X7:5WH'9H*33,0:VNN F<KS-"Y9Z/Q&4D$?@L
MHN?,^L@7#F48XCFBTL>%) #7N<\*(S"E\&F0J,)2<S&+2GPP!/#&=?BBJ=).
MDY#&P$C>]&0%D-DW[)ZKO00L2PL9' #*BI\^1N$X+2Y=&<=X\$R*.(TXN*;+
M+SPY48$B'2FB2 3\GMJ(1U4?)[>K@0>ZL.V*]7EB2(ZRA]@$0[<NP18E&%W#
M\+Z$45RWX*Y=M-*?JC.%.#PZ6YNI;_O6P29FD3M%G6VEK0B.#6;9TD,OJ,1E
MBN4MA7(]V$XW,0W8E +0IYT)3@L!HDX%9T5V4 O?!0A.#R1G_7G /N_B5JP#
MC(,M&#:-&),+6]N3%[;AHFU93M&F ?733,<.+GJ""])+)-!)F"8&/&@>!?78
M#,GM!],O>9(ZFU9RF>  5T8!-R@OF9$EOPPQ2FC.')R]<CSQ'&>8I/R"VBXM
M6%$2>Z@YGIH00B]AZT+/CSPX@>2%@;=31"I=$62NM#8NFIA4MEY+TC@-"W&<
M90[T9YFRY.U4R2)UT4?$=R(HY>U4* 2\EDS[;BCE6JI;LHEP/SWBB]UJP]4P
MBQH2Q-0M68DAP"]LD$72G:;5)*I/4524B*/QI*L\>>2\1U8";E4XJ!S"?0LU
M@ *Q)^1AVN$E73&=[#Y_SVK,<)Y=TK?/=K+^/!IEO:D2@@'!KDW)-LG[N"KO
M.RZG_8.O-N9_=ZXGS$MM7S,!+:; %A- H1@^@CX^7$EH+4I:]Z(W5\'D,P8:
MJ65O&B!N3B/FL_ @'3N Q52^?Y8G@9.C-,X0XS2,O#RG=+>F8>TVNU4/J^$:
M2[)/=JGHM"E:/L&\5R9469>#O'0!8^9K"/K,9.B*2RR3=T1C4]8928Z8F*FR
M,B.GFE69FMMS0#^[?T!^9WT,=-62<XM&FH:@ZD(_C0J'-82U,\)4Y+ :R/MI
M4X+%@B)M;9T='UO+L'>(^'-Y"466>6%;9SU=95::_-H$+)ZJIOR,Y"S%+/9+
M#.=M0)1-5_ 21ME\:(M9&4'<HY3[BU*^VJ.4]RCE/4IYQU'*EZU$J!&FO+T=
MW\*QMVH<L0?-]]J86+%7!3$/R!@%2<74SS?TE?N,!C B?:2;X5F*ID,YK$T5
M5*6OS47B(BN2#1F=SL- 5R1K*H2U>)1;JHRL&BW%D%?99+D<+D*[+'@?MJ>[
M$-V8M6AXD:1J01VX[:4M?F.6EYV_L9]^'%Z<O%EUW.PF;7:4[2A)&WG%3H6<
MUT^M[%2/R,8ZY$S;D-0910=^?$G4D.P 2VXSS@FFL]"]3,%5YPYW>)[^#-EI
MT_%,)4MPQVDX<%4C8@@ "6C%'-'QNU +?CE<!"UH+'1F/J(B_XV$O29-RKSC
MII WIRI:\/@Y+5!HEFD#6&;@ C>")1DI08^<3M*5RV(F Z^&DMQ4=.6DM;8J
MW?616S[C<PD_5DZ+K9-Z-<W"$F*Q3*$YQ*)C=7$7V?ZKM@CBMDG3M '#_>S[
M--SU'E'19YKZ!]XP<D(@6038]<R7KBL6Q\_-Q5I4QH*U@RK6L"F%X>\XB5*F
M,AB8C2Q#4W64[FE-N+LC&>49K"4&5F:RLQY88>W,[;X$V^,V&QG-Q\PF_T>%
M[G5Y2A)W_SDZ&AJVPH 5OE2>(!+@'8$P[K9 ;[=8=B/:NH_X@+4G=BO<:3D'
M2*PV5/Y$;BUUTP:Q1/8H4M 'PU=$*%4G8V,>*Y7$A<+SF+*, >8E\1-9XJ;*
M>:D(V%5*9@K8'32C9F:!6UJ.P*T^@Z_262WY55M0F?ZE'1<LA9XF'E=RK^M"
MC\Q4S%.KYDAD@%U=) Q3N]HYX2P)NHXJ%46]'(_,F%ZGU*.>$^H@Q<SNR@E\
M_3O(\\17?!J""^ J";O]Y /J,*AVNBDK,L>:84+:X)(H&TNT>(7UH@,=J\IX
M(7(XN^%_72%HU>8RVW5F5UO#P(UL0UOW2=N9&FXF,Q6D"2.ZK%94O@%\D;#3
MU$S^A;D]Q/DTP#K-??.J_/(:T"&9).=2GN44<NC+,/??7RGN7<O!8%JIJVD$
M*5SJ^.UJ<,+WQ4=/2DP_EJ+.,[4TR+M-UJIY /8:X2]2,ENK&T94)2-%F:C&
MW*/QND?.'7/;T!5R+G$0O?R-Y6! K;+M?N&FPF6GMASBVM&R\^YLYN'1Q=7Z
MX;*M,U$W3F/=>!GSQ Q@[\:D-^_\##]%0O4XB13'(3J(IYWJ*/>_=_7,>2^#
M9^M5S]1ASHMY*U"W\9DU2":;@)I 1I,</1E&5>GX:H:6I&E2()Z8!Q39?=$(
M-LD)K4S))/9U(X0X#ETE#$DQARW8%?0$44?@/\UCMLQ4YYALB72Z;B+B+TS$
M"B8T+#]9:]? X^P^!Z7=ME(.2G]FVX7-RMU#!?L+%1P>[[&">ZS@'BNX)6VQ
M9:0 9EN7:K=LX57(01.\Y:G(%"BY(M T\,Q)+F"%,E70LB"RS14G?7^9V%4+
M_<Y[D)9:=Q;_:L:A-1IKUF!],>-*]!,4T7Q(?1WQ]*2@"J:\Z&Z&^2DN%403
MD@*+&-4,HP<1J+C0>!ULLT!2E1)'0C'G%7,<-=)+89#%-[62X@_TNA'4_2*_
M+/-SS BY)&-+0P8]=P=?\ND1G4]Q4\HOFX'KB"?5997YS!J*TP=-YNGB_O(9
M@B<?<09AK826.BM-;(EV88L ZM57?Q_3>*N7^38U>N5E32WA_&?G$49:#]<5
ML81F59#_-T'%4' 38S><R]IVMF#1#7G1L9(EYVU14UKN&]*? 7>U"EL@88-%
MN$5JW^6#_PO691]SBFM/K%R1GY<PT%9:WLM4HI$A<E8@R^2MLW D'D/I[W@Q
MOS5^BM\7BGE?*DSH_3[33SH)BR^ \KS]/-VZLVC:9S3EKII)T-B:'OWEX@X\
M1P44LR-C+I)_I=@$("/HE5]EY*JXIK\[:R;:2I> 7CI'"\+J6\_AK#V+?^G,
MX3R2GU,/+'BF@3)^@)C/?1@2"@W)+KLD+'-QH_\TJ#E06G[9Z=)U$,8)L]5+
M%(V:2K^!!_B'<YR8Q53@=2"3E3M%(F13V*$\ZJA&*)! )&E.YO(VAX?0,LK@
M(0/=(A@OC78/'$/PJHZ:&+2"X< >!MUA.-8G#17;I@S=P"10JI((;CCAXI:R
ME*'<S2,DO7;)A-??XM(H'(1+T*'VE 2Q>NZ(N+8M&>R*U-**M5F@#BV<E@?C
M[8O@VI/00A5AS2^F'?,NBZ8!)"@W;%)QZ(N85*X;@BNH:^1TK*6@*(5SEXYC
MY2FRL<D\R38([J>N^6_"J B_(R#?)$4Q]Q6)Z(/6]"C4 2\/P>E5Z9D/XZF:
M\TTK1^,7E08SQC/(!Z_5>G&^.$R)J#[:28I[AL(V" G% W5:54_Z#?JY7:TY
M6Y'73BG^=2,T!^[6U]RZ4R"SQ@431W>=X3;$6?F[*"!EV;[0J-6,KIB:!/.A
M9N'Q0L,@3\K=:$P1)7BQA[PYZ.TE3F=90#MF7F07\5Y*LVE-&0,>^LHC3JJQ
M\$GHXRE87'P?^74.GPEP0*@+KXQYV>AVJ*5+^=1!60//;KB]^PWW3(TK5M;@
M!672$?O5T-I;;P/UF5VYV$N6-2[+<7Q!S<?'6UMN&Y[.)].-^T4.K,UYOY8"
MA$U@RGJILJTAFXM=@I0M"-EHM#)7C1$;YE-HYE632.MU+!+ID RNXOF,7EF#
M1[H[SF<D400S"E.!Y1YH62?ZHIJE^B!N8A;X7"B:77PKN*\:HD!_9L-]Z<6U
MAWWU&/8UW,.^]K"O/>QKMV%?Y6J8)OJKE[K,6-VAC-5=49E?2-"0 7OK%NYW
M)!5[>5<SFR$.>2YIW/YS&[BOT[:J5GN8VVA,,5]\!\"O<CY9=[PHI(!UHG?@
M/$TE!;,P6Q FCIS-_? YAQUEWFQ6'] LI.:9J:7&R'_B@=<8 % NVH+S*'13
MC&?)5W YM=*4#>_1,D/%^C%JX:2"%!?66,2\7HM=E1B7UHFC?G792BJ\0Y;J
M56B4+N#'6A=VN>UUMS2-DG4*%G>H6$[8NF]^VA)BJ$,96K[?8:/ZOMR^>[Z)
MB=1(,[(V,GFI+&'#PS1!C@M"V6J*N(Z0$*=M$>WN3@ ?Q>W[L!:J!=@5@HM&
MQJ)!*8)D.6H)7#.:%[S_(A=%B$1'SWEA8Q%GSJ2(S(KD$>%N9[+^_6'5-@#'
MO.PE3'HC<,SJ@IBD$5G*5#++1;1<+RNX4$'$FEH 9'2J9B\5Q8K 0[=P_%GC
ME1<<.RCS2W"2C<(YW,J%=X8:QV>;P,VVR.PZLS1L7;DWLAZV#D]N:6YU+KLQ
MD5F'CZ:?/<<ZBIR-W1>O7+4"Y#G9KERNZD9=]5,$U_&CW@>>G#%ZA;1G"<+>
MA6]U1I[AYMD.;8JT.WS?!HBFKK;O;K4SM3^Y#_>[-(&M'JDO-/XJ9OC7$P%G
MF4K=]\,G#"-EI!615+-Q&NF8KIM&%%#""B*T;K'(T,+EW1'<]K*-#/[HDK![
MW;SMU5JTVF!7/4#;KCT)=HT$<@6B8+AAS" D<*&\E/,% CRE";7Y$P\":9 =
MUQ=J%F.\4Y(A*=R$*H F0OFI9IW'MO:F96!#J04W #1 2%.^SF+N/S/25SZJ
M,(VQ\H,96#*?;V88TG0T]J<?3Z[>Q(23!P>Q,\!O&R;LZ**[&E?.J2PK0E85
MUP?([_JS0$'TQ$P\L%Q.5 "_S,4S2XH1N9C8Y.+49]98$OV"Y!O!KQ2+IV!W
M@*AW))3M9 % -W<GE#8>[=7VW1Y@8C<PBR;M#,ZZ%)&NM"GAR*/0E=*CR%E&
MA0#?,_1)!8^ACYZ6R/0L"6^S-3'( VCRJRLS'MKB?>:1@DDJA%>I&=/MS\%J
M27GOH+W"81@Y:/[P*0#3!BR<R5:ZN%BH69IP5-K$:=Y.AQ90QSV"?G,++@BI
M."7QF9V,,HG:IJ,/*GI"C,$/QC:_Q.80ZL>><-Y1E"NI-K>%M4 F"3M8_QBF
MF\PX;^N:8MTI".U?N&$:)=2]HMJL641CE40Z#HC;EOX[C(AJM1A2I_PU;'^@
M35 ,D<#$3V/$FQA*%2X=8<B^;??3"D37M.2<SZX(B$Y]*K" 2S):!>/^RI^D
M_B8R_^'\?V622%]]_O)JL'+N'ZL* GQ$5%D62?<+^6X;&-=8/F$[IRB47Z0?
MAO$WX1)0E-@6=E-8Z;C\-S T>#7@USXXC^B,?D[&0D2KCTY["P.P=%YT=[G$
M2,%K#U/?(U%]5/(I2_2HR$UG,545Y=D?@6XRR$X:"!>W(9I]J;("S_!@Q]*D
M0F;/I&[DY#(+%>$?;^#^G=AAE\>ME'B#'7:R,ZI5[KQJY=QCG!BG ,12@6;T
MPSANU'-H:KFPDT?LK(+6 Z\YC:ADR/ TT2>2M>]<*(_:O"VXV1:L)2UI)7-)
M?V:SEXR\[X'G/0:>C_; \SWP? \\WUG@^=6\BCL_MZCCHY-3#3V_^J8^#';W
M$SFC<+L:2QE403B-'LA2%FK9)&6G964#>:&3LXI34]O/P58E5#-[\MYR;OP
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M9I.G4RE!-=E#[$&/)&U=(DC:$M<>%I4V\EF=;C^+M_8LFL55"C;'T?_\=M=
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M)&FIR-G F:D@360W-/AM]%3H)=]9HQH\VR5,8<,L[JUDS9K&%=59LW;+:-+
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M#%NQY#OL"K.\ #5&;WH:#M]H[*9(=Y5+8!?-84KX,"T8)02D_LP&@#3BN0=
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M8E95W.W[L";*CL]M2(6K[:<G5A&K\R7!"K^H #O3@-9ZEB)ZL[#96S=5)K;
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M*<]O4PNUU!^W?S@H7+]-AML.@4 :IH%<K%FP "%UQ3T5Q3(+A^7N$7&WEFF
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M8U#I. L$(_[NF*$C^O% Q$D6Y,3B*0/>T,) VB7<Z^PSL4H, "&\P:+4EX:
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MO_?Z"LT>NYUAE 9BD06=$1.,'GVL5CP0A[\5!5O(.SX:M.!$F-#LYIS?((-
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M?8ZG!3:M($]X;*JC71F5:8V(%A3VB :8S.)X755)UC2WC#$3V<Y-'O(P95_
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M4$L! A0#%     @ @(#Z4LE]F4/T"P  =9P  !4              ( !!!
M '%U<F4M,C R,3 V,S!?8V%L+GAM;%!+ 0(4 Q0    ( (" ^E*+O80HHBH
M +D< P 5              "  2L<  !Q=7)E+3(P,C$P-C,P7V1E9BYX;6Q0
M2P$"% ,4    " " @/I2L+6^V8%B  #/=P8 %0              @ $ 1P
M<75R92TR,#(Q,#8S,%]L86(N>&UL4$L! A0#%     @ @(#Z4C*Q5@DN0P
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M,RYH=&U02P$"% ,4    " " @/I2A);_CNM, 0#HEPH %P
M@ %HH 0 <75R92TR,#(Q,#8S,'AE>#)D,2YH=&U02P$"% ,4    " " @/I2
M-MQ[E*$(  !E.P  &               @ &([04 <75R92TR,#(Q,#8S,'AE
M>#,Q9#$N:'1M4$L! A0#%     @ @(#Z4LH5.(V@"   73L  !@
M     ( !7_8% '%U<F4M,C R,3 V,S!X97@S,60R+FAT;5!+ 0(4 Q0    (
M (" ^E)!UB#(B 8  %4Z   8              "  37_!0!Q=7)E+3(P,C$P
M-C,P>&5X,S)D,2YH=&U02P$"% ,4    " " @/I2C,%<K[I1  "E @, %P
M            @ 'S!08 <75R92TR,#(Q,#8S,'AE>#-D,2YH=&U02P$"% ,4
M    " " @/I2P.D)8TP[  "'D $ %P              @ 'B5P8 <75R92TR
G,#(Q,#8S,'AE>#1D,2YH=&U02P4&      \ #P !!   8Y,&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
